---
title: 'Preclinical pharmacology of alogabat: a novel GABA**DOI:** 10.3389/fphar.2025.1626078'
authors:
- GiuseppeCecere
- Theresa MBallard
- FredericKnoflach
- MichaelHoner
- Joerg FHipp
- PilarGarces
- ThomasMueggler
- "BasilK\xFCnnecke"
- AndreasBruns
- Eric PPrinssen
- PhilippSchoenenberger
- PhilippJanz
- RogerRedondo
- BarbaraBiemans
- HennerKnust
- "Andr\xE9sOlivares-Morales"
- AlessandroBrigo
- Jan MichaelSchulz
- DanielBertrand
- MichaelSaxe
- Eoin CO'Connor
- Maria-ClemenciaHernandez
journal: Frontiers in pharmacology
doi: 10.3389/fphar.2025.1626078
publication_date: ''
source: Processed from scraped content
processing_date: '2025-10-21T22:15:07.306832'
content_type: research_paper
conditions:
- adhd
- asd
- related_disorders
topics:
- neurochemistry
- comorbidity
categories:
- adhd
- asd
- related-disorders
- neurochemistry
- comorbidity
reading_level: academic
audience:
- professional
- researcher
patient_friendly: false
search_priority: standard
keywords:
- cognitive
search_tags:
- asd
- adhd
- related_disorders
- peer-reviewed
- comorbidity
- academic
- research
- neurochemistry
---

# Preclinical pharmacology of alogabat: a novel GABA**DOI:** 10.3389/fphar.2025.1626078

**Authors:** GiuseppeCecere, Theresa MBallard, FredericKnoflach, MichaelHoner, Joerg FHipp, PilarGarces, ThomasMueggler, BasilKünnecke, AndreasBruns, Eric PPrinssen, PhilippSchoenenberger, PhilippJanz, RogerRedondo, BarbaraBiemans, HennerKnust, AndrésOlivares-Morales, AlessandroBrigo, Jan MichaelSchulz, DanielBertrand, MichaelSaxe, Eoin CO'Connor, Maria-ClemenciaHernandez

**Journal:** Frontiers in pharmacology

**DOI:** 10.3389/fphar.2025.1626078

## Abstract

Alterations in the GABAergic system contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder (ASD) and Angelman syndrome (AS), particularly in cases involving large deletions in the 15q11-13 region. Positive modulation of GABA
Alogabat was assessed for binding and functional activity at GABA
Alogabat is a potent positive allosteric modulator of GABA
Alogabat showed beneficial effects in mouse models relevant to neurodevelopmental disorders and anti-seizure activity at doses that did not produce cognitive, sedative, or motoric side effects.

Alogabat was assessed for binding and functional activity at GABA
Alogabat is a potent positive allosteric modulator of GABA
Alogabat showed beneficial effects in mouse models relevant to neurodevelopmental disorders and anti-seizure activity at doses that did not produce cognitive, sedative, or motoric side effects.## Full Text## Abstract
| crossref full text | google scholar ali, a. b., and thomson, a. m. (2008). synaptic alpha 5 subunit-containing gabaa receptors mediate ipsps elicited by dendrite-preferring cells in rat neocortex. cereb. cortex 18, 1260–1271. doi:10.1093/cercor/bhm160 pubmed abstract | crossref full text | google scholar american psychiatric association (2008). diagnostic and statistical manual of mental disorders . 5th ed. washington: american psychiatric association . google scholar ballard, t. m., knoflach, f., prinssen, e., borroni, e., vivian, j. a., basile, j., et al. (2009). ro4938581, a novel cognitive enhancer acting at gabaa alpha5 subunit-containing receptors. psychopharmacol. berl. 202, 207–223. doi:10.1007/s00213-008-1357-7 pubmed abstract | crossref full text | google scholar ballard, t. m., woolley, m. l., prinssen, e., huwyler, j., porter, r., and spooren, w. (2005). the effect of the mglu5 receptor antagonist mpep in rodent tests of anxiety and cognition: a comparison. psychopharmacol. berl. 179, 218–229. doi:10.1007/s00213-005-2211-9 pubmed abstract | crossref full text | google scholar banerjee, a., garcia-oscos, f., roychowdhury, s., galindo, l. c., hall, s., kilgard, m. p., et al. (2013). impairment of cortical gabaergic synaptic transmission in an environmental rat model of autism. int. j. neuropsychopharmacol. 16, 1309–1318. doi:10.1017/s1461145712001216 pubmed abstract | crossref full text | google scholar bourgeron, t. (2015). from the genetic architecture to synaptic plasticity in autism spectrum disorder. nat. rev. neurosci. 16, 551–563. doi:10.1038/nrn3992 pubmed abstract | crossref full text | google scholar braat, s., and kooy, r. f. (2015). the gabaa receptor as a therapeutic target for neurodevelopmental disorders. neuron 86, 1119–1130. doi:10.1016/j.neuron.2015.03.042 pubmed abstract | crossref full text | google scholar bruns, a., kunnecke, b., risterucci, c., moreau, j. l., and von kienlin, m. (2009). validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological mri in rats. magn. reson med. 61, 1451–1458. doi:10.1002/mrm.21779 pubmed abstract | crossref full text | google scholar buettelmann, b., cecere, g., fasching, b., groebke zbinden, k., hernandez, m.-c., knust, h., et al. (2018). preparation of new isoxazolyl ether derivatives as gabaa α5 receptor positive allosteric modulators (pams) . copyright © 2025 american chemical society acs . available online at: https://worldwide.espacent.com/patent/search/family/057530563/publication/wo2018104419a1?q=wo2018104419a1 google scholar buiting, k. (2010). prader-willi syndrome and angelman syndrome. am. j. med. genet. c semin. med. genet. 154c, 365–376. doi:10.1002/ajmg.c.30273 pubmed abstract | crossref full text | google scholar chao, h. t., chen, h., samaco, r. c., xue, m., chahrour, m., yoo, j., et al. (2010). dysfunction in gaba signalling mediates autism-like stereotypies and rett syndrome phenotypes. nature 468, 263–269. doi:10.1038/nature09582 pubmed abstract | crossref full text | google scholar davenport, c. m., rajappa, r., katchan, l., taylor, c. r., tsai, m. c., smith, c. m., et al. (2021). relocation of an extrasynaptic gaba(a) receptor to inhibitory synapses freezes excitatory synaptic strength and preserves memory. neuron 109, 123–134 e4. doi:10.1016/j.neuron.2020.09.037 pubmed abstract | crossref full text | google scholar delong, r. (2007). gaba(a) receptor alpha5 subunit as a candidate gene for autism and bipolar disorder: a proposed endophenotype with parent-of-origin and gain-of-function features,with or without oculocutaneous albinism. autism 11, 135–147. doi:10.1177/1362361307075705 pubmed abstract | crossref full text | google scholar delorey, t. m. (2005). gabrb3 gene deficient mice: a potential model of autism spectrum disorder. int. rev. neurobiol. 71, 359–382. doi:10.1016/s0074-7742(05)71015-1 pubmed abstract | crossref full text | google scholar delorey, t. m., sahbaie, p., hashemi, e., homanics, g. e., and clark, j. d. (2008). gabrb3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: a potential model of autism spectrum disorder. behav. brain res. 187, 207–220. doi:10.1016/j.bbr.2007.09.009 pubmed abstract | crossref full text | google scholar dhossche, d., applegate, h., abraham, a., maertens, p., bland, l., bencsath, a., et al. (2002). elevated plasma gamma-aminobutyric acid (gaba) levels in autistic youngsters: stimulus for a gaba hypothesis of autism. med. sci. monit. 8, pr1–pr6. pubmed abstract | google scholar di nanni, n., bersanelli, m., cupaioli, f. a., milanesi, l., mezzelani, a., and mosca, e. (2019). network-based integrative analysis of genomics, epigenomics and transcriptomics in autism spectrum disorders. int. j. mol. sci. 20, 3363. doi:10.3390/ijms20133363 pubmed abstract | crossref full text | google scholar dufour, b. d., mcbride, e., bartley, t., juarez, p., and martinez-cerdeno, v. (2023). distinct patterns of gabaergic interneuron pathology in autism are associated with intellectual impairment and stereotypic behaviors. autism 27, 1730–1745. doi:10.1177/13623613231154053 pubmed abstract | crossref full text | google scholar fatemi, s. h., halt, a. r., stary, j. m., kanodia, r., schulz, s. c., and realmuto, g. r. (2002). glutamic acid decarboxylase 65 and 67 kda proteins are reduced in autistic parietal and cerebellar cortices. biol. psychiatry 52, 805–810. doi:10.1016/s0006-3223(02)01430-0 pubmed abstract | crossref full text | google scholar friedman, h., greenblatt, d. j., peters, g. r., metzler, c. m., charlton, m. d., harmatz, j. s., et al. (1992). pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. clin. pharmacol. ther. 52, 139–150. doi:10.1038/clpt.1992.123 pubmed abstract | crossref full text | google scholar fritschy, j. m., benke, d., johnson, d. k., mohler, h., and rudolph, u. (1997). gabaa-receptor alpha-subunit is an essential prerequisite for receptor formation in vivo . neuroscience 81, 1043–1053. doi:10.1016/s0306-4522(97)00244-3 pubmed abstract | crossref full text | google scholar frohlich, j., miller, m. t., bird, l. m., garces, p., purtell, h., hoener, m. c., et al. (2019a). electrophysiological phenotype in angelman syndrome differs between genotypes. biol. psychiatry 85, 752–759. doi:10.1016/j.biopsych.2019.01.008 pubmed abstract | crossref full text | google scholar frohlich, j., reiter, l. t., saravanapandian, v., distefano, c., huberty, s., hyde, c., et al. (2019b). mechanisms underlying the eeg biomarker in dup15q syndrome. mol. autism 10, 29. doi:10.1186/s13229-019-0280-6 pubmed abstract | crossref full text | google scholar frye, r. e., casanova, m. f., fatemi, s. h., folsom, t. d., reutiman, t. j., brown, g. l., et al. (2016). neuropathological mechanisms of seizures in autism spectrum disorder. front. neurosci. 10, 192. doi:10.3389/fnins.2016.00192 pubmed abstract | crossref full text | google scholar fukuda, t., itoh, m., ichikawa, t., washiyama, k., and goto, y. (2005). delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of mecp2-deficient mice. j. neuropathol. exp. neurol. 64, 537–544. doi:10.1093/jnen/64.6.537 pubmed abstract | crossref full text | google scholar gaetz, w., bloy, l., wang, d. j., port, r. g., blaskey, l., levy, s. e., et al. (2014). gaba estimation in the brains of children on the autism spectrum: measurement precision and regional cortical variation. neuroimage 86, 1–9. doi:10.1016/j.neuroimage.2013.05.068 pubmed abstract | crossref full text | google scholar han, s., tai, c., jones, c. j., scheuer, t., and catterall, w. a. (2014). enhancement of inhibitory neurotransmission by gabaa receptors having α2,3-subunits ameliorates behavioral deficits in a mouse model of autism. neuron 81, 1282–1289. doi:10.1016/j.neuron.2014.01.016 pubmed abstract | crossref full text | google scholar han, s., tai, c., westenbroek, r. e., yu, f. h., cheah, c. s., potter, g. b., et al. (2012). autistic-like behaviour in scn1a+/- mice and rescue by enhanced gaba-mediated neurotransmission. nature 489, 385–390. doi:10.1038/nature11356 pubmed abstract | crossref full text | google scholar hipp, j. f., knoflach, f., comley, r., ballard, t. m., honer, m., trube, g., et al. (2021). basmisanil, a highly selective gaba a -α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man. sci. rep. 11, 7700. doi:10.1038/s41598-021-87307-7 pubmed abstract | crossref full text | google scholar hogart, a., wu, d., lasalle, j. m., and schanen, n. c. (2010). the comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. neurobiol. dis. 38, 181–191. doi:10.1016/j.nbd.2008.08.011 pubmed abstract | crossref full text | google scholar hu, x., rocco, b. r., fee, c., and sibille, e. (2019). cell type-specific gene expression of alpha 5 subunit-containing gamma-aminobutyric acid subtype a receptors in human and mouse frontal cortex. mol. neuropsychiatry 4, 204–215. doi:10.1159/000495840 pubmed abstract | crossref full text | google scholar hvoslef-eide, m., nilsson, s. r., saksida, l. m., and bussey, t. j. (2016). cognitive translation using the rodent touchscreen testing approach. curr. top. behav. neurosci. 28, 423–447. doi:10.1007/7854_2015_5007 pubmed abstract | crossref full text | google scholar kalsner, l., and chamberlain, s. j. (2015). prader-willi, angelman, and 15q11-q13 duplication syndromes. pediatr. clin. north am. 62, 587–606. doi:10.1016/j.pcl.2015.03.004 pubmed abstract | crossref full text | google scholar koh, m. t., rosenzweig-lipson, s., and gallagher, m. (2013). selective gaba(a) α5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. neuropharmacology 64, 145–152. doi:10.1016/j.neuropharm.2012.06.023 pubmed abstract | crossref full text | google scholar lim, c. s., kim, h., yu, n. k., kang, s. j., kim, t., ko, h. g., et al. (2017). enhancing inhibitory synaptic function reverses spatial memory deficits in shank2 mutant mice. neuropharmacology 112, 104–112. doi:10.1016/j.neuropharm.2016.08.016 pubmed abstract | crossref full text | google scholar luk, h. m., and lo, i. f. (2016). angelman syndrome in hong kong chinese: a 20 years' experience. eur. j. med. genet. 59, 315–319. doi:10.1016/j.ejmg.2016.05.003 pubmed abstract | crossref full text | google scholar luscher, b., maguire, j. l., rudolph, u., and sibille, e. (2023). gaba(a) receptors as targets for treating affective and cognitive symptoms of depression. trends pharmacol. sci. 44, 586–600. doi:10.1016/j.tips.2023.06.009 pubmed abstract | crossref full text | google scholar mcfarlane, h. g., kusek, g. k., yang, m., phoenix, j. l., bolivar, v. j., and crawley, j. n. (2008). autism-like behavioral phenotypes in btbr t+tf/j mice. genes brain behav. 7, 152–163. doi:10.1111/j.1601-183x.2007.00330.x pubmed abstract | crossref full text | google scholar mcnaughton, n., and morris, r. g. (1987). chlordiazepoxide, an anxiolytic benzodiazepine, impairs place navigation in rats. behav. brain res. 24, 39–46. doi:10.1016/0166-4328(87)90034-9 pubmed abstract | crossref full text | google scholar mendez, m. a., horder, j., myers, j., coghlan, s., stokes, p., erritzoe, d., et al. (2013). the brain gaba-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)c]ro15-4513 positron emission tomography study. neuropharmacology 68, 195–201. doi:10.1016/j.neuropharm.2012.04.008 pubmed abstract | crossref full text | google scholar mermer, f., poliquin, s., rigsby, k., rastogi, a., shen, w., romero-morales, a., et al. (2021). common molecular mechanisms of slc6a1 variant-mediated neurodevelopmental disorders in astrocytes and neurons. brain 144, 2499–2512. doi:10.1093/brain/awab207 pubmed abstract | crossref full text | google scholar mertz, l. g., christensen, r., vogel, i., hertz, j. m., nielsen, k. b., gronskov, k., et al. (2013). angelman syndrome in denmark. birth incidence, genetic findings, and age at diagnosis. am. j. med. genet. a 161a, 2197–2203. doi:10.1002/ajmg.a.36058 pubmed abstract | crossref full text | google scholar mesbah-oskui, l., penna, a., orser, b. a., and horner, r. l. (2017). reduced expression of α5gaba a receptors elicits autism-like alterations in eeg patterns and sleep-wake behavior. neurotoxicol teratol. 61, 115–122. doi:10.1016/j.ntt.2016.10.009 pubmed abstract | crossref full text | google scholar mohler, h. (2011). the rise of a new gaba pharmacology. neuropharmacology 60, 1042–1049. doi:10.1016/j.neuropharm.2010.10.020 pubmed abstract | crossref full text | google scholar mori, t., mori, k., fujii, e., toda, y., miyazaki, m., harada, m., et al. (2012). evaluation of the gabaergic nervous system in autistic brain: (123)i-iomazenil spect study. brain dev. 34, 648–654. doi:10.1016/j.braindev.2011.10.007 pubmed abstract | crossref full text | google scholar myers, j. f., comley, r. a., and gunn, r. n. (2017). quantification of [ 11 c]ro15-4513 gaba a α5 specific binding and regional selectivity in humans. j. cereb. blood flow. metab. 37, 2137–2148. doi:10.1177/0271678x16661339 pubmed abstract | crossref full text | google scholar nakamura, t., arima-yoshida, f., sakaue, f., nasu-nishimura, y., takeda, y., matsuura, k., et al. (2016). px-rics-deficient mice mimic autism spectrum disorder in jacobsen syndrome through impaired gabaa receptor trafficking. nat. commun. 7, 10861. doi:10.1038/ncomms10861 pubmed abstract | crossref full text | google scholar orefice, l. l., zimmerman, a. l., chirila, a. m., sleboda, s. j., head, j. p., and ginty, d. d. (2016). peripheral mechanosensory neuron dysfunction underlies tactile and behavioral deficits in mouse models of asds. cell 166, 299–313. doi:10.1016/j.cell.2016.05.033 pubmed abstract | crossref full text | google scholar penagarikano, o., abrahams, b. s., herman, e. i., winden, k. d., gdalyahu, a., dong, h., et al. (2011). absence of cntnap2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. cell 147, 235–246. doi:10.1016/j.cell.2011.08.040 pubmed abstract | crossref full text | google scholar percie du sert, n., hurst, v., ahluwalia, a., alam, s., avey, m. t., baker, m., et al. (2020). the arrive guidelines 2.0: updated guidelines for reporting animal research. plos biol. 18, e3000410. doi:10.1371/journal.pbio.3000410 pubmed abstract | crossref full text | google scholar perez, s. m., mccoy, a. m., prevot, t. d., mian, m. y., carreno, f. r., frazer, a., et al. (2023). hippocampal α5-gaba(a) receptors modulate dopamine neuron activity in the rat ventral tegmental area. biol. psychiatry glob. open sci. 3, 78–86. doi:10.1016/j.bpsgos.2021.12.010 pubmed abstract | crossref full text | google scholar pirker, s., schwarzer, c., wieselthaler, a., sieghart, w., and sperk, g. (2000). gaba(a) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. neuroscience 101, 815–850. doi:10.1016/s0306-4522(00)00442-5 pubmed abstract | crossref full text | google scholar pizzarelli, r., and cherubini, e. (2011). alterations of gabaergic signaling in autism spectrum disorders. neural plast. 2011, 297153. doi:10.1155/2011/297153 pubmed abstract | crossref full text | google scholar porjesz, b., almasy, l., edenberg, h. j., wang, k., chorlian, d. b., foroud, t., et al. (2002). linkage disequilibrium between the beta frequency of the human eeg and a gabaa receptor gene locus. proc. natl. acad. sci. u. s. a. 99, 3729–3733. doi:10.1073/pnas.052716399 pubmed abstract | crossref full text | google scholar puts, n. a. j., wodka, e. l., harris, a. d., crocetti, d., tommerdahl, m., mostofsky, s. h., et al. (2017). reduced gaba and altered somatosensory function in children with autism spectrum disorder. autism res. 10, 608–619. doi:10.1002/aur.1691 pubmed abstract | crossref full text | google scholar robertson, c. e., ratai, e. m., and kanwisher, n. (2016). reduced gabaergic action in the autistic brain. curr. biol. 26, 80–85. doi:10.1016/j.cub.2015.11.019 pubmed abstract | crossref full text | google scholar rojas, d. c., singel, d., steinmetz, s., hepburn, s., and brown, m. s. (2014). decreased left perisylvian gaba concentration in children with autism and unaffected siblings. neuroimage 86, 28–34. doi:10.1016/j.neuroimage.2013.01.045 pubmed abstract | crossref full text | google scholar rubenstein, j. l., and merzenich, m. m. (2003). model of autism: increased ratio of excitation/inhibition in key neural systems. genes brain behav. 2, 255–267. doi:10.1034/j.1601-183x.2003.00037.x pubmed abstract | crossref full text | google scholar sanders, s. j. (2015). first glimpses of the neurobiology of autism spectrum disorder. curr. opin. genet. dev. 33, 80–92. doi:10.1016/j.gde.2015.10.002 pubmed abstract | crossref full text | google scholar schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2018). dendrite-targeting interneurons control synaptic nmda-receptor activation via nonlinear α5-gaba a receptors. nat. commun. 9, 3576. doi:10.1038/s41467-018-06004-8 pubmed abstract | crossref full text | google scholar schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2019). enhanced dendritic inhibition and impaired nmdar activation in a mouse model of down syndrome. j. neurosci. 39, 5210–5221. doi:10.1523/jneurosci.2723-18.2019 pubmed abstract | crossref full text | google scholar serwanski, d. r., miralles, c. p., christie, s. b., mehta, a. k., li, x., and de blas, a. l. (2006). synaptic and nonsynaptic localization of gabaa receptors containing the alpha5 subunit in the rat brain. j. comp. neurol. 499, 458–470. doi:10.1002/cne.21115 pubmed abstract | crossref full text | google scholar sieghart, w. (2006). structure, pharmacology, and function of gabaa receptor subtypes. adv. pharmacol. 54, 231–263. doi:10.1016/s1054-3589(06)54010-4 pubmed abstract | crossref full text | google scholar sitnikova, e., rutskova, e., and smirnov, k. (2023). alpha2-adrenergic receptors as a pharmacological target for spike-wave epilepsy. int. j. mol. sci. 24, 1477. doi:10.3390/ijms24021477 pubmed abstract | crossref full text | google scholar smit, d. j. a., wright, m. j., meyers, j. l., martin, n. g., ho, y. y. w., malone, s. m., et al. (2018). genome-wide association analysis links multiple psychiatric liability genes to oscillatory brain activity. hum. brain mapp. 39, 4183–4195. doi:10.1002/hbm.24238 pubmed abstract | crossref full text | google scholar souza, a. j., freitas, i. s., sharmin, d., cook, j. m., guimaraes, f. s., and gomes, f. v. (2024). an alpha 5-gaba(a) receptor positive allosteric modulator attenuates social and cognitive deficits without changing dopamine system hyperactivity in rats exposed to valproic acid in utero. autism res. 17, 1534–1544. doi:10.1002/aur.3178 pubmed abstract | crossref full text | google scholar sur, c., fresu, l., howell, o., mckernan, r. m., and atack, j. r. (1999). autoradiographic localization of alpha5 subunit-containing gabaa receptors in rat brain. brain res. 822, 265–270. doi:10.1016/s0006-8993(99)01152-x pubmed abstract | crossref full text | google scholar traub, r. d. w. m., and jefferys, j. g. r. (1999). fast oscillations in cortical circuits . the mit press . google scholar van lier, h., drinkenburg, w. h., van eeten, y. j., and coenen, a. m. (2004). effects of diazepam and zolpidem on eeg beta frequencies are behavior-specific in rats. neuropharmacology 47, 163–174. doi:10.1016/j.neuropharm.2004.03.017 pubmed abstract | crossref full text | google scholar visser, s. a., wolters, f. l., gubbens-stibbe, j. m., tukker, e., van der graaf, p. h., peletier, l. a., et al. (2003). mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of gabaa receptor modulators: in vitro-in vivo correlations. j. pharmacol. exp. ther. 304, 88–101. doi:10.1124/jpet.102.042341 pubmed abstract | crossref full text | google scholar vithlani, m., terunuma, m., and moss, s. j. (2011). the dynamic modulation of gaba(a) receptor trafficking and its role in regulating the plasticity of inhibitory synapses. physiol. rev. 91, 1009–1022. doi:10.1152/physrev.00015.2010 pubmed abstract | crossref full text | google scholar warrier, v., baron-cohen, s., and chakrabarti, b. (2013). genetic variation in gabrb3 is associated with asperger syndrome and multiple endophenotypes relevant to autism. mol. autism 4, 48. doi:10.1186/2040-2392-4-48 pubmed abstract | crossref full text | google scholar whittington, m. a., traub, r. d., kopell, n., ermentrout, b., and buhl, e. h. (2000). inhibition-based rhythms: experimental and mathematical observations on network dynamics. int. j. psychophysiol. 38, 315–336. doi:10.1016/s0167-8760(00)00173-2 pubmed abstract | crossref full text | google scholar xie, x. h., and tietz, e. i. (1991). chronic benzodiazepine treatment of rats induces reduction of paired-pulse inhibition in ca1 region of in vitro hippocampus. brain res. 561, 69–76. doi:10.1016/0006-8993(91)90750-p pubmed abstract | crossref full text | google scholar zurek, a. a., kemp, s. w., aga, z., walker, s., milenkovic, m., ramsey, a. j., et al. (2016). α5gabaa receptor deficiency causes autism-like behaviors. ann. clin. transl. neurol. 3, 392–398. doi:10.1002/acn3.303 pubmed abstract | crossref full text | google scholar keywords: autism spectrum disorder, angelman syndrome, gaba a , gaba a -α5, positron emission tomography (pet), electroencephalography, pharmacological mri, biomarker citation: cecere g, ballard tm, knoflach f, honer m, hipp jf, garces p, mueggler t, künnecke b, bruns a, prinssen ep, schoenenberger p, janz p, redondo r, biemans b, knust h, olivares-morales a, brigo a, schulz jm, bertrand d, saxe m, o’connor ec and hernandez m-c (2025) preclinical pharmacology of alogabat: a novel gaba a -α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gaba a signaling. front. pharmacol. 16:1626078. doi: 10.3389/fphar.2025.1626078 received: 09 may 2025; accepted: 18 june 2025; published: 21 july 2025. edited by: agenor limon , university of texas medical branch at galveston, united states reviewed by: hansen wang , university of toronto, canada junzhan jing , baylor college of medicine, united states azar omrani , boehringer ingelheim, germany copyright © 2025 cecere, ballard, knoflach, honer, hipp, garces, mueggler, künnecke, bruns, prinssen, schoenenberger, janz, redondo, biemans, knust, olivares-morales, brigo, schulz, bertrand, saxe, o’connor and hernandez. this is an open-access article distributed under the terms of the creative commons attribution license (cc by). the use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. no use, distribution or reproduction is permitted which does not comply with these terms. *correspondence: maria-clemencia hernandez, bwfyawety2xlbwvuy2lhlmhlcm5hbmrlekbyb2nozs5jb20= † these authors have contributed equally to this work ‡ present address: theresa m. ballard, galwyn (uk) ltd., dartmouth, united kingdom barbara biemans, b2discovery llc, riehen, switzerland michael saxe, translational in vivo sciences, biogen, cambridge, ma, united states disclaimer: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. download article download pdf readcube epub xml share on export citation endnote reference manager simple text file bibtex 2,218 total views 442 downloads citation numbers are available from dimensions view article impact view altmetric score share on edited by a l agenor limon reviewed by j j junzhan jing a o azar omrani h w hansen wang table of contents abstract 1 introduction 2 materials and methods 3 results 4 discussion 5 conclusion data availability statement ethics statement author contributions funding acknowledgments conflict of interest generative ai statement publisher’s note supplementary material abbreviations references export citation endnote reference manager simple text file bibtex check for updates frontiers' impact articles published with frontiers have received 12 million total citations your research is the real superpower - learn how we maximise its impact through our leading community journals explore our impact metrics supplementary material download article download download pdf readcube epub xml guidelines author guidelines services for authors policies and publication ethics editor guidelines fee policy explore articles research topics journals how we publish outreach frontiers forum frontiers policy labs frontiers for young minds frontiers planet prize connect help center emails and alerts contact us submit career opportunities follow us © 2025 frontiers media s.a. all rights reserved privacy policy | terms and conditions [["shallowreactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverrendered":13,"path":14,"pinia":15},["shallowreactive",3],{},["reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","frontiers articles","https://article-pages-2024.frontiersin.org/",["set"],["shallowreactive",12],{},true,"/journals/pharmacology/articles/10.3389/fphar.2025.1626078/full",["reactive",16],{"main":17,"user":511,"article":512,"articlehub":968,"mainheader":972},{"ibar":18,"footer":264,"newslettercomponent":-1,"snackbaritem":346,"toggleshowsnackbar":347,"contentfuljournal":348,"graphjournal":412,"settingsfeaturesswitchers":416,"templatetogglebanner":417,"tenantconfig":476},{"tenantlogo":19,"journallogo":19,"aboutus":20,"submiturl":113,"showsubmitbutton":13,"journal":114,"sectionterm":195,"aboutjournal":196,"mainlinks":245,"journallinks":252,"helpcenterlink":261},"",[21,38,47,71,87],{"title":22,"links":23},"who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"arialabel":28},"mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"arialabel":28},"history","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"arialabel":28},"leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"arialabel":28},"awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"impact and progress",[41,44],{"text":42,"url":43,"target":27,"arialabel":28},"frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"arialabel":28},"our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"arialabel":28},"how we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"arialabel":28},"open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"arialabel":28},"peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"arialabel":28},"research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"arialabel":28},"research topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"arialabel":28},"fair² data management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"arialabel":28},"fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"services",[74,78,81,84],{"text":75,"url":76,"target":77,"arialabel":28},"societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"arialabel":28},"national consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"arialabel":28},"institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"arialabel":28},"collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"more from frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"arialabel":93},"frontiers forum","https://forum.frontiersin.org/","this link will take you to the frontiers forum website",{"text":95,"url":96,"target":27,"arialabel":28},"frontiers planet prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"arialabel":100},"press office","https://pressoffice.frontiersin.org/","this link will take you to the frontiers press office website",{"text":102,"url":103,"target":27,"arialabel":104},"sustainability","https://www.frontiersin.org/about/sustainability","link to information about frontiers' sustainability",{"text":106,"url":107,"target":77,"arialabel":108},"career opportunities","https://careers.frontiersin.org/","this link will take you to the frontiers careers website",{"text":110,"url":111,"target":27,"arialabel":112},"contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=1&fieldid=62&specialtyid=0&entitytype=2&entityid=176",{"id":115,"name":116,"slug":117,"sections":118},176,"frontiers in pharmacology","pharmacology",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191],{"id":120,"name":121,"slug":122},182,"cardiovascular and smooth muscle pharmacology","cardiovascular-and-smooth-muscle-pharmacology",{"id":124,"name":125,"slug":126},199,"drug metabolism and transport","drug-metabolism-and-transport",{"id":128,"name":129,"slug":130},202,"drugs outcomes research and policies","drugs-outcomes-research-and-policies",{"id":132,"name":133,"slug":134},184,"ethnopharmacology","ethnopharmacology",{"id":136,"name":137,"slug":138},183,"experimental pharmacology and drug discovery","experimental-pharmacology-and-drug-discovery",{"id":140,"name":141,"slug":142},186,"gastrointestinal and hepatic pharmacology","gastrointestinal-and-hepatic-pharmacology",{"id":144,"name":145,"slug":146},188,"inflammation pharmacology","inflammation-pharmacology",{"id":148,"name":149,"slug":150},178,"integrative and regenerative pharmacology","integrative-and-regenerative-pharmacology",{"id":152,"name":153,"slug":154},26,"neuropharmacology","neuropharmacology",{"id":156,"name":157,"slug":158},196,"obstetric and pediatric pharmacology","obstetric-and-pediatric-pharmacology",{"id":160,"name":161,"slug":162},2186,"pharmacoepidemiology","pharmacoepidemiology",{"id":164,"name":165,"slug":166},198,"pharmacogenetics and pharmacogenomics","pharmacogenetics-and-pharmacogenomics",{"id":168,"name":169,"slug":170},192,"pharmacology of anti-cancer drugs","pharmacology-of-anti-cancer-drugs",{"id":172,"name":173,"slug":174},2216,"pharmacology of infectious diseases","pharmacology-of-infectious-diseases",{"id":176,"name":177,"slug":178},179,"pharmacology of ion channels and channelopathies","pharmacology-of-ion-channels-and-channelopathies",{"id":180,"name":181,"slug":182},195,"predictive toxicology","predictive-toxicology",{"id":184,"name":185,"slug":186},1357,"renal pharmacology","renal-pharmacology",{"id":188,"name":189,"slug":190},190,"respiratory pharmacology","respiratory-pharmacology",{"id":192,"name":193,"slug":194},1251,"translational pharmacology","translational-pharmacology","sections",[197,221],{"title":198,"links":199},"scope",[200,203,206,209,212,215,218],{"text":201,"url":202,"target":27,"arialabel":28},"field chief editors","https://www.frontiersin.org/journals/pharmacology/about#about-editors",{"text":204,"url":205,"target":27,"arialabel":28},"mission & scope","https://www.frontiersin.org/journals/pharmacology/about#about-scope",{"text":207,"url":208,"target":27,"arialabel":28},"facts","https://www.frontiersin.org/journals/pharmacology/about#about-facts",{"text":210,"url":211,"target":27,"arialabel":28},"journal sections","https://www.frontiersin.org/journals/pharmacology/about#about-submission",{"text":213,"url":214,"target":27,"arialabel":28},"open access statement","https://www.frontiersin.org/journals/pharmacology/about#about-open",{"text":216,"url":217,"target":27,"arialabel":28},"copyright statement","https://www.frontiersin.org/journals/pharmacology/about#copyright-statement",{"text":219,"url":220,"target":27,"arialabel":28},"quality","https://www.frontiersin.org/journals/pharmacology/about#about-quality",{"title":222,"links":223},"for authors",[224,227,230,233,236,239,242],{"text":225,"url":226,"target":27,"arialabel":28},"why submit?","https://www.frontiersin.org/journals/pharmacology/for-authors/why-submit",{"text":228,"url":229,"target":27,"arialabel":28},"article types","https://www.frontiersin.org/journals/pharmacology/for-authors/article-types",{"text":231,"url":232,"target":27,"arialabel":28},"author guidelines","https://www.frontiersin.org/journals/pharmacology/for-authors/author-guidelines",{"text":234,"url":235,"target":27,"arialabel":28},"editor guidelines","https://www.frontiersin.org/journals/pharmacology/for-authors/editor-guidelines",{"text":237,"url":238,"target":27,"arialabel":28},"publishing fees","https://www.frontiersin.org/journals/pharmacology/for-authors/publishing-fees",{"text":240,"url":241,"target":27,"arialabel":28},"submission checklist","https://www.frontiersin.org/journals/pharmacology/for-authors/submission-checklist",{"text":243,"url":244,"target":27,"arialabel":28},"contact editorial office","https://www.frontiersin.org/journals/pharmacology/for-authors/contact-editorial-office",[246,249],{"text":247,"url":248,"target":27,"arialabel":28},"all journals","https://www.frontiersin.org/journals",{"text":250,"url":251,"target":27,"arialabel":28},"all articles","https://www.frontiersin.org/articles",[253,256,258],{"text":254,"url":255,"target":27,"arialabel":28},"articles","articles",{"text":63,"url":257,"target":27,"arialabel":28},"research-topics",{"text":259,"url":260,"target":27,"arialabel":28},"editorial board","editors",{"text":262,"url":263,"target":77,"arialabel":262},"help center","https://helpcenter.frontiersin.org",{"blocks":265,"sociallinks":319,"copyright":343,"termsandconditionsurl":344,"privacypolicyurl":345},[266,280,290,304],{"title":267,"links":268},"guidelines",[269,271,274,277,279],{"text":231,"url":270,"target":27,"arialabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":272,"url":273,"target":27,"arialabel":28},"services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":275,"url":276,"target":27,"arialabel":28},"policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":234,"url":278,"target":27,"arialabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"arialabel":28},{"title":281,"links":282},"explore",[283,284,287,289],{"text":254,"url":251,"target":27,"arialabel":28},{"text":285,"url":286,"target":27,"arialabel":28},"research topics ","https://www.frontiersin.org/research-topics",{"text":288,"url":248,"target":27,"arialabel":28},"journals",{"text":51,"url":52,"target":27,"arialabel":28},{"title":291,"links":292},"outreach",[293,296,299,303],{"text":294,"url":92,"target":77,"arialabel":295},"frontiers forum ","frontiers forum website",{"text":297,"url":298,"target":77,"arialabel":28},"frontiers policy labs ","https://policylabs.frontiersin.org/",{"text":300,"url":301,"target":77,"arialabel":302},"frontiers for young minds","https://kids.frontiersin.org/","frontiers for young minds journal",{"text":95,"url":96,"target":27,"arialabel":28},{"title":305,"links":306},"connect",[307,308,312,315,318],{"text":262,"url":263,"target":77,"arialabel":262},{"text":309,"url":310,"target":77,"arialabel":311},"emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","subscribe to frontiers emails",{"text":313,"url":111,"target":27,"arialabel":314},"contact us ","subscribe to newsletter",{"text":316,"url":317,"target":27,"arialabel":28},"submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"arialabel":28},[320,328,333,338],{"link":321,"type":324,"color":325,"icon":326,"size":327,"hiddentext":13},{"text":322,"url":323,"target":77,"arialabel":322},"frontiers facebook","https://www.facebook.com/frontiersin","link","grey","facebook","medium",{"link":329,"type":324,"color":325,"icon":332,"size":327,"hiddentext":13},{"text":330,"url":331,"target":77,"arialabel":28},"frontiers twitter","https://twitter.com/frontiersin","twitter",{"link":334,"type":324,"color":325,"icon":337,"size":327,"hiddentext":13},{"text":335,"url":336,"target":77,"arialabel":28},"frontiers linkedin","https://www.linkedin.com/company/frontiers","linkedin",{"link":339,"type":324,"color":325,"icon":342,"size":327,"hiddentext":13},{"text":340,"url":341,"target":77,"arialabel":28},"frontiers instagram","https://www.instagram.com/frontiersin_","instagram","frontiers media s.a. all rights reserved","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":349,"identifier":115,"name":116,"slug":117,"banner":350,"description":405,"mission":406,"palette":407,"impactfactor":408,"citescore":409,"citations":410,"showtagline":28,"twitter":411},"journal",[351],{"id":352,"src":353,"name":354,"tags":355,"type":363,"width":364,"height":365,"idhash":366,"archive":367,"brandid":368,"limited":367,"filesize":369,"ispublic":370,"original":371,"copyright":372,"extension":373,"thumbnails":375,"datecreated":383,"description":384,"orientation":385,"usercreated":386,"watermarked":367,"datemodified":383,"datepublished":387,"ecsarchivefiles":388,"propertyoptions":389,"property_channel":394,"property_sub-type":396,"property_asset_type":398,"activeoriginalfocuspoint":400,"property_office_department":403},"754e12a9-443f-4ea8-ab01e0811e45131d","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/webimage-9d720582-24ad-4d2e-9205ab9d241919da.jpg","fphar_main visual_purple_website",[356,357,358,359,360,361,362],"pain","medical","pharmaceutical","antibiotic","concept","capsule","treatment","image",5844,3896,"79b643019a2651e0",0,"22c10171-81b3-4da6-99342f272a32e8bb",8675243,1,"https://brand.frontiersin.org/m/79b643019a2651e0/original/fphar_main-visual_purple_website.jpeg","copyright (c) 2017 marian weyo/shutterstock. no use without permission.",[374],"jpeg",{"mini":376,"thul":377,"webimage":353,"guidelines":378,"websitejpg_xl":379,"websitewebp_l":380,"websitewebp_m":381,"websitewebp_xl":382},"https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/mini-97eef455-249b-43bd-9d8f02fee86046d3.jpg","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/thul-b2dbd910-1ddf-4ed3-b1500df973953144.jpg","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/guidelines-fphar_main visual_purple_website.png","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitejpg_xl-fphar_main visual_purple_website.jpg","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitewebp_l-fphar_main visual_purple_website.webp","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitewebp_m-fphar_main visual_purple_website.webp","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitewebp_xl-fphar_main visual_purple_website.webp","2022-06-27t10:00:45z","pills tablets capsule or medicament freely laid on glass background.","landscape","caroline sutter","2022-06-27t09:27:09z",[],[390,391,392,393],"414fb2d4-2283-43fd-be14e534eca67928","6c18119b-14bd-4951-b437696f4357bd33","7c692885-db25-4858-b1fb4ff47b241e9b","d88c0047-ec30-4506-a7df28a4d765e1cf",[395],"frontiersin_org",[397],"main_visual",[399],"photography",{"x":401,"y":402},2922,1948,[404],"publishing","the world's most cited pharmacology and pharmacy journal, advancing global pharmacological discoveries to prevent and treat human disease.","\u003cp>frontiers in pharmacology is an interdisciplinary journal that publishes research on the interactions between drugs and living beings to prevent and cure human disease.\u003c/p>\n\n\u003cp>led by field chief editor heike wulff (university of california, davis, us), frontiers in pharmacology explores basic and clinical pharmacology, medicinal chemistry, pharmacy, and toxicology to clarify the fundamental processes of disease treatment and drug effects. indexed in pubmed central (pmc), scopus, web of science (scie), and the doaj, the journal welcomes academic, industrial, and clinical work focused on pharmacology.\u003c/p>\n\n\u003cp>topics include, but are not limited to:\u003c/p>\n\u003cul>\n \u003cli>cardiovascular and smooth muscle pharmacology\u003c/li>\n \u003cli>drug metabolism and transport\u003c/li>\n \u003cli>drugs outcomes research and policies\u003c/li>\n \u003cli>elsi in science and genetics\u003c/li>\n \u003cli>ethnopharmacology\u003c/li>\n \u003cli>experimental pharmacology and drug discovery\u003c/li>\n \u003cli>gastrointestinal and hepatic pharmacology\u003c/li>\n \u003cli>inflammation pharmacology\u003c/li>\n \u003cli>integrative and regenerative pharmacology\u003c/li>\n \u003cli>neuropharmacology\u003c/li>\n \u003cli>obstetric and pediatric pharmacology\u003c/li>\n \u003cli>pharmacoepidemiology\u003c/li>\n \u003cli>pharmacogenetics and pharmacogenomics\u003c/li>\n \u003cli>pharmacology of anti-cancer drugs\u003c/li>\n \u003cli>pharmacology of infectious diseases\u003c/li>\n \u003cli>pharmacology of ion channels and channelopathies\u003c/li>\n \u003cli>predictive toxicology\u003c/li>\n \u003cli>renal pharmacology\u003c/li>\n \u003cli>respiratory pharmacology\u003c/li>\n \u003cli>translational pharmacology.\u003c/li>\n\u003c/ul>\n\n\u003cp>all submissions to the journal involving natural products, including plant extracts or preparations, must adhere to \u003ci>'the four pillars of ethnopharmacology'\u003c/i> to be considered for peer review, regardless of the specialty section, as a baseline standard for sample characterization. these are a set of mandatory guidelines designed to maintain the scientific, cultural, and ethical integrity of the journal, and describe what the leading journals in the field consider as the basic aspects of good research (full conphymp statement available \u003ca href=\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.953205/full\" target=\"_blank\">here\u003c/a>, conphymp statement overview \u003ca href=\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1338710/full\" target=\"_blank\">here\u003c/a>, and ga-tool \u003ca href=\"https://ga-online.org/best-practice/\" target=\"_blank\">here\u003c/a>). please refer to the \u003ca href=\"https://assets.ctfassets.net/41vi7p4898pd/63dcrrxgncg4b1stfayeh8/1b87b9a742b0610ace5b19fd11f62359/four_pillars_ethnopharmacology_2025.pdf\" target=\"_blank\">full version\u003c/a> of these guidelines before submitting a manuscript to the journal.\u003c/p> \n\u003cp>to be considered for publication in frontiers in pharmacology, studies incorporating complementary or alternative medicine must be based on a set of data linked to local or traditional uses that can be evaluated pharmacologically. a clear and plausible set of pharmacological data must be generated in these studies. similarly, the journal endorses protocols including a minimum of 2 cell-lines in vitro as an evidential basis to demonstrate proposed anti-cancer effects in all relevant studies submitted to all specialty sections in the journal.\u003c/p>\n\u003cp>isolated data mining studies using disproportionality analyses of databases containing spontaneously reported adverse events, frequently lead to misinterpretation due to various reporting biases, lack of structured control, and insufficient demographic details. presenting such analyses in isolation typically does not yield clinically actionable safety findings without the broader context of a comprehensive signal evaluation. to ensure rigor and relevance, all submissions to the journal must be complemented by a proper systematic review and/or thorough analyses of reported cases, and adhere to the readus-pv guidelines (\u003ca href=\"https://www.equator-network.org/reporting-guidelines/the-reporting-of-a-disproportionality-analysis-for-drug-safety-signal-detection-using-individual-case-safety-reports-in-pharmacovigilance-readus-pv-development-and-statement/\" target=\"_blank\">the reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance\u003c/a>). authors are expected to ensure compliance with the corresponding \u003ca href=\"https://readus-statement.org/wp-content/uploads/2024/03/readus-checklist.pdf\" target=\"_blank\">checklist\u003c/a> before proceeding with submission to the journal. full publication of the readus-pv guidelines is available \u003ca href=\"https://pmc.ncbi.nlm.nih.gov/articles/pmc11116242/pdf/40264_2024_article_1421.pdf\" target=\"_blank\">here\u003c/a>.\u003c/p>\n\n\u003cp>frontiers’ journals require that manuscripts primarily comprising computational studies of public data, such as nhanes or mendelian randomization studies, must include appropriate validation. please refer to the \u003ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology:~:text=complaints%20and%20allegations.-,standards%20for%20research%20methodology,-experiments\">frontiers standards for research methodology policy\u003c/a>, for more information. manuscripts not adhering to these standards will not be considered.\u003cp>\n\n\u003cp>further unique criteria for the conception and review of submissions may apply, where appropriate, for individual specialty sections.\u003c/p>\n\n\u003cp>the journal welcomes submissions that support and advance the \u003ca href=\"https://www.globalgoals.org/goals/\" target=\"_blank\">un sustainable development goals\u003c/a> (sdgs), notably the \u003ca href=\"https://www.globalgoals.org/goals/3-good-health-and-well-being/\" target=\"_blank\">sdg 3: good health and well-being\u003c/a>.\u003c/p>\n\n\u003cp>manuscripts that focus solely on clinical trials, patient management, or conventional therapies without a focus on pharmacological research are not suitable for publication in this journal. additionally, studies that are purely statistical or predictive in nature, without providing novel insights into pharmacological mechanisms or drug development, are not within the scope of this journal.\u003c/p>\n\n\u003cp>frontiers in pharmacology is committed to advancing developments in the field of pharmacological discoveries by allowing unrestricted access to articles and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.\u003c/p>\n\n\u003cb>\u003cp>ethics information\u003c/p>\u003c/b>\n\u003cp>research involving human subjects should comply with the ethical guidelines outlined in the \u003ca href= https://www.wma.net/policies-post/wma-declaration-of-helsinki/” target=”_blank”>world medical association’s declaration of helsinki\u003c/a>.\u003c/p>\n\u003cp>similarly, authors are required to specify the institutional and national standards adhered to for the care and use of laboratory animals. transparent and accurate reporting of animal studies is required, with references to guidelines such as \u003ca href=\"https://arriveguidelines.org/arrive-guidelines\" target=\"_blank\">arrive\u003c/a> and \u003ca href=\"https://nc3rs.org.uk/sites/default/files/2022-01/the%20improve%20guidelines%20%28poster%29.pdf\" target=\"_blank\"> improve\u003c/a>.\u003c/p>\n\u003cp>extended information on research ethics can be found under the frontiers policies and publication ethics page.\u003c/p>","purple","5.6","6.3","531663","@frontpharmacol",{"id":115,"name":116,"slug":117,"abbreviation":413,"isonline":13,"isopenforsubmissions":13,"citescore":414,"impactfactor":415},"fphar",8.9,4.8,{"displaytitlepilllabels":13,"displayrelatedarticlesbox":13,"showeditors":13,"showreviewers":13,"showloopimpactlink":13,"enablefigshare":347,"usexmlimages":13},{"ispublic":13,"allowcompanyusers":347,"whitelistemails":418,"enablealljournals":13,"whitelistjournals":440},[419,420,421,422,423,424,425,426,427,424,428,429,430,431,432,433,434,435,436,437,438,439],"y2fybg9zlmxvcmnhqgzyb250awvyc2lulm9yzw==","zgfuawvslmx1ekbmcm9udgllcnnpbi5vcmc=","bgf1cmeudgvuyubmcm9udgllcnnpbi5vcmc=","cmfmywvslnjpyw5jag9aznjvbnrpzxjzaw4ub3jn","amftzxmuc21hbgxib25lqgzyb250awvyc2lulm9yzw==","znjhbi5tb3jlbm9aznjvbnrpzxjzaw4ub3jn","c2ftdwvslmzlcm5hbmrlekbmcm9udgllcnnpbi5vcmc=","ymfyymfyys5jyxjjyw5naxvaznjvbnrpzxjzaw4ub3jn","axzhbi5zyw50yw1hcmlhqgzyb250awvyc2lulm9yzw==","ahvllnryyw5aznjvbnrpzxjzaw4ub3jn","z29uy2fsby52yxjnyxnaznjvbnrpzxjzaw4ub3jn","bhvjawuuc2vubkbmcm9udgllcnnpbi5vcmc=","bg9ybi5mcmfzzxjaznjvbnrpzxjzaw4ub3jn","zwxzys5jyxjyb25aznjvbnrpzxjzaw4ub3jn","bwfhcnrlbi52yw5kawpja0bmcm9udgllcnnpbi5vcmc=","ymluzgh1lmtyaxnobmfuqgzyb250awvyc2lulm9yzw==","bwf0dghldy5hdhr3yxrlcnnaznjvbnrpzxjzaw4ub3jn","z2l1bglhlnzhbhnly2noaubmcm9udgllcnnpbi5vcmc=","zmfiawfulmrlbgxhbw9ydgvaznjvbnrpzxjzaw4ub3jn","dmlqyxlhbi5wcebwaxrzb2x1dglvbnmuy29t","z3vpbgxhdw1llnnldxjhdebmcm9udgllcnnpbi5vcmc=",[441,442,443,444,445,446,370,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,115,469,470,471,472,473,474,475],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,451,141,1335,2655,1238,604,698,1547,1440,403,1239,755,2136,609,1534,{"spaceid":370,"name":370,"availablejournalpages":477,"announcement":481},[255,260,257,478,479,480],"volumes","about","community-reviewers",{"__typename":482,"sys":483,"preheader":42,"title":485,"description":486,"image":487,"link":509},"announcement",{"id":484},"5ittnttqgazppgh6rx0alm","articles published with frontiers have received 12 million total citations","your research is the real superpower - learn how we maximise its impact through our leading community journals",[488],{"archive":367,"brandid":368,"copyright":28,"datecreated":489,"datemodified":490,"datepublished":491,"description":28,"extension":492,"filesize":494,"height":495,"id":496,"ispublic":367,"limited":367,"name":497,"orientation":385,"original":28,"thumbnails":498,"type":363,"watermarked":367,"width":505,"videopreviewurls":506,"tags":507,"textmetaproperties":508,"src":499},"2025-06-18t12:58:01z","2025-06-18t14:15:34z","2025-06-18t12:57:32z",[493],"png",1365026,920,"7c5269c4-3c83-4591-951a74d15b95daea","impact metrics banner for article pages",{"webimage":499,"thul":500,"mini":501,"websitewebp_l":502,"websitewebp_m":503,"guidelines":504},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/websitewebp_l/impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/websitewebp_m/impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/guidelines/impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":510,"url":43,"target":27,"arialabel":28},"explore our impact metrics",{"loggeduserinfo":-1},{"currentarticle":513,"ispreviewpage":347,"hassupplementaldata":347,"showcrossmarkwidget":13,"articletemplate":758,"currentarticlepagemetainfo":759,"xmlparsedarticlecontent":-1,"xmlparsingerror":-1},{"id":514,"doi":515,"title":516,"acceptancedate":517,"receptiondate":518,"publicationdate":519,"lastmodifieddate":520,"ispublished":13,"abstract":521,"researchtopic":28,"articletype":522,"stage":525,"keywords":527,"authors":536,"editors":682,"reviewers":690,"journal":712,"section":719,"impactmetrics":721,"volume":724,"articlevolume":725,"relatedarticles":726,"ispublishedv2":13,"contents":727,"files":731},1626078,"10.3389/fphar.2025.1626078","preclinical pharmacology of alogabat: a novel gabaa-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gabaa signaling","2025-06-18t08:27:15.000z","2025-05-09t23:15:40.000z","2025-07-21t00:00:00.000z","2025-10-21t02:34:53.269z","backgroundalterations in the gabaergic system contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder (asd) and angelman syndrome (as), particularly in cases involving large deletions in the 15q11–13 region. positive modulation of gabaa-α5 receptors may provide a novel therapeutic approach without the typical side effects associated with non-selective gabaa positive allosteric modulators such as diazepam.methodsalogabat was assessed for binding and functional activity at gabaa-α5β3γ2 receptors in vitro and in electrophysiological studies using hippocampal slices. in vivo studies in rodents included receptor occupancy (ro) using a selective gabaa-α5 tracer (autoradiography), pharmacological mri, and electroencephalography (eeg). alogabat was evaluated for its effects on the repetitive behavior phenotype in btbr and contactin-associated protein-like 2 (cntnap2−/−) knockout mice, seizure models, cognitive performance in rats, and rotarod performance following combination treatment with diazepam.resultsalogabat is a potent positive allosteric modulator of gabaa-α5 receptors, with binding and functional selectivity. receptor occupancy studies provided direct proof of dose-dependent target engagement. functional circuit modulation was demonstrated by dose-dependent regional perfusion changes in pharmacological mri and changes in eeg theta- and beta-band power in rats. at >50% gabaa-α5 receptor occupancy, alogabat normalized elevated self-grooming behavior in both cntnap2−/− and btbr mice and exhibited antiepileptic activity in rats. alogabat did not impair cognition in wildtype rats at gabaa-α5 receptor occupancy up to 75%, although impairment occurred at higher doses, probably due to increased activity at other receptor subtypes and/or saturation of α5 receptors. alogabat did not worsen diazepam-induced impairment on the rotarod test.conclusionalogabat showed beneficial effects in mouse models relevant to neurodevelopmental disorders and anti-seizure activity at doses that did not produce cognitive, sedative, or motoric side effects.",{"id":523,"name":524},24,"original research",{"id":526,"name":19},18,[528,529,530,531,532,533,534,535],"biomarker","autism spectrum disorder","electroencephalography","positron emission tomography (pet)","angelman syndrome","gabaa","gabaa-α5","pharmacological mri",[537,546,554,560,566,573,580,587,594,600,606,612,617,623,629,635,643,650,656,664,668,675],{"id":538,"firstname":539,"middlename":19,"lastname":540,"givennames":541,"iscorresponding":347,"isprofilepublic":13,"userid":538,"email":-1,"affiliations":542},3088634,"giuseppe","cecere","giuseppe ",[543],{"organizationname":544,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"medicinal chemistry","switzerland",{"id":547,"firstname":548,"middlename":19,"lastname":549,"givennames":550,"iscorresponding":347,"isprofilepublic":13,"userid":547,"email":-1,"affiliations":551},3064665,"theresa m.","ballard","theresa m. ",[552],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"neuroscience and rare diseases",{"id":367,"firstname":555,"middlename":19,"lastname":556,"givennames":557,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":558},"frederic","knoflach","frederic ",[559],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":561,"middlename":19,"lastname":562,"givennames":563,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":564},"michael","honer","michael ",[565],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":567,"firstname":568,"middlename":19,"lastname":569,"givennames":570,"iscorresponding":347,"isprofilepublic":13,"userid":567,"email":-1,"affiliations":571},81732,"joerg f.","hipp","joerg f. ",[572],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":574,"firstname":575,"middlename":19,"lastname":576,"givennames":577,"iscorresponding":347,"isprofilepublic":13,"userid":574,"email":-1,"affiliations":578},2412410,"pilar","garces","pilar ",[579],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":581,"firstname":582,"middlename":19,"lastname":583,"givennames":584,"iscorresponding":347,"isprofilepublic":13,"userid":581,"email":-1,"affiliations":585},13967,"thomas","mueggler","thomas ",[586],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":588,"firstname":589,"middlename":19,"lastname":590,"givennames":591,"iscorresponding":347,"isprofilepublic":13,"userid":588,"email":-1,"affiliations":592},577428,"basil","künnecke","basil ",[593],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":595,"middlename":19,"lastname":596,"givennames":597,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":598},"andreas","bruns","andreas ",[599],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":601,"middlename":19,"lastname":602,"givennames":603,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":604},"eric p.","prinssen","eric p. ",[605],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":607,"middlename":19,"lastname":608,"givennames":609,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":610},"philipp","schoenenberger","philipp ",[611],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":613,"firstname":607,"middlename":19,"lastname":614,"givennames":609,"iscorresponding":347,"isprofilepublic":13,"userid":613,"email":-1,"affiliations":615},2424959,"janz",[616],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":618,"middlename":19,"lastname":619,"givennames":620,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":621},"roger","redondo","roger ",[622],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":624,"middlename":19,"lastname":625,"givennames":626,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":627},"barbara","biemans","barbara ",[628],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":630,"middlename":19,"lastname":631,"givennames":632,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":633},"henner","knust","henner ",[634],{"organizationname":544,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":636,"firstname":637,"middlename":19,"lastname":638,"givennames":639,"iscorresponding":347,"isprofilepublic":13,"userid":636,"email":-1,"affiliations":640},2264913,"andrés","olivares-morales","andrés ",[641],{"organizationname":642,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"pharmaceutical sciences",{"id":644,"firstname":645,"middlename":19,"lastname":646,"givennames":647,"iscorresponding":347,"isprofilepublic":13,"userid":644,"email":-1,"affiliations":648},1172717,"alessandro","brigo","alessandro ",[649],{"organizationname":642,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":651,"middlename":19,"lastname":652,"givennames":653,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":654},"jan michael","schulz","jan michael ",[655],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":657,"firstname":658,"middlename":19,"lastname":659,"givennames":660,"iscorresponding":347,"isprofilepublic":13,"userid":657,"email":-1,"affiliations":661},157846,"daniel","bertrand","daniel ",[662],{"organizationname":663,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"hiqscreen sàrl",{"id":367,"firstname":561,"middlename":19,"lastname":665,"givennames":563,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":666},"saxe",[667],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":669,"firstname":670,"middlename":19,"lastname":671,"givennames":672,"iscorresponding":347,"isprofilepublic":13,"userid":669,"email":-1,"affiliations":673},2733790,"eoin c.","o’connor","eoin c. ",[674],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":676,"firstname":677,"middlename":19,"lastname":678,"givennames":679,"iscorresponding":347,"isprofilepublic":13,"userid":676,"email":-1,"affiliations":680},2269471,"maria-clemencia","hernandez","maria-clemencia ",[681],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},[683],{"id":684,"firstname":685,"middlename":19,"lastname":686,"givennames":687,"iscorresponding":347,"isprofilepublic":13,"userid":684,"email":-1,"affiliations":688},52072,"agenor","limon","agenor ",[689],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},[691,698,705],{"id":692,"firstname":693,"middlename":19,"lastname":694,"givennames":695,"iscorresponding":347,"isprofilepublic":13,"userid":692,"email":-1,"affiliations":696},1285968,"junzhan","jing","junzhan ",[697],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},{"id":699,"firstname":700,"middlename":19,"lastname":701,"givennames":702,"iscorresponding":347,"isprofilepublic":13,"userid":699,"email":-1,"affiliations":703},1380630,"azar","omrani","azar ",[704],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},{"id":706,"firstname":707,"middlename":19,"lastname":708,"givennames":709,"iscorresponding":347,"isprofilepublic":13,"userid":706,"email":-1,"affiliations":710},39673,"hansen","wang","hansen ",[711],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},{"id":115,"slug":117,"name":116,"shortname":713,"electronicissn":714,"field":715,"specialtyid":28,"journalsectionpaths":717},"front. pharmacol.","1663-9812",{"id":716,"domainid":370},62,[718],{"section":719},{"id":152,"name":153,"slug":154,"specialtyid":720},762,{"views":722,"downloads":723,"citations":367},2218,442,16,"volume 16 - 2025",[],{"titlehtml":728,"fulltexthtml":729,"menuhtml":730},"preclinical pharmacology of alogabat: a novel gaba\u003csub>a\u003c/sub>-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gaba\u003csub>a\u003c/sub> signaling","\u003cdiv class=\"journalabstract\">\u003ca id=\"h1\" name=\"h1\">\u003c/a>\u003cdiv class=\"authors\">\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/3088634\" class=\"user-id-3088634\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/3088634/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"giuseppe cecere&#x;\">giuseppe cecere\u003c/a>\u003csup>1\u003c/sup>\u003csup>†\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/3064665\" class=\"user-id-3064665\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/3064665/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"theresa m. ballard&#x;&#x;\">theresa m. ballard\u003c/a>\u003csup>2\u003c/sup>\u003csup>&#x02020;\u003c/sup>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"frederic knoflach&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">frederic knoflach\u003csup>2\u003c/sup>\u003csup>&#x02020;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"michael honer\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">michael honer\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/81732\" class=\"user-id-81732\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/81732/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"joerg f. hipp\">joerg f. hipp\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2412410\" class=\"user-id-2412410\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2412410/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"pilar garces\">pilar garces\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/13967\" class=\"user-id-13967\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/13967/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"thomas mueggler\">thomas mueggler\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/577428\" class=\"user-id-577428\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/577428/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"basil k&#xfc;nnecke\">basil k&#x000fc;nnecke\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"andreas bruns\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">andreas bruns\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"eric p. prinssen\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">eric p. prinssen\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"philipp schoenenberger\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">philipp schoenenberger\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2424959\" class=\"user-id-2424959\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2424959/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"philipp janz\">philipp janz\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"roger redondo\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">roger redondo\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"barbara biemans&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">barbara biemans\u003csup>2\u003c/sup>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"henner knust\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">henner knust\u003csup>1\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2264913\" class=\"user-id-2264913\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2264913/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"andr&#xe;s olivares-morales\">andr&#x000e9;s olivares-morales\u003c/a>\u003csup>3\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/1172717\" class=\"user-id-1172717\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1172717/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"alessandro brigo\">alessandro brigo\u003c/a>\u003csup>3\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"jan michael schulz\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">jan michael schulz\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/157846\" class=\"user-id-157846\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/157846/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"daniel bertrand\">daniel bertrand\u003c/a>\u003csup>4\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"michael saxe&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">michael saxe\u003csup>2\u003c/sup>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2733790\" class=\"user-id-2733790\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2733790/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"eoin c. o&#x;connor\">eoin c. o&#x02019;connor\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2269471\" class=\"user-id-2269471\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2269471/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"maria-clemencia hernandez&#xa;\">maria-clemencia hernandez\u003c/a>\u003csup>2\u003c/sup>&#x0002a;\u003c/span>\u003c/div>\u003cul class=\"notes\">\u003cli>\u003cspan>\u003csup>1\u003c/sup>\u003c/span>medicinal chemistry, roche pharmaceutical research and early development, roche innovation center basel, basel, switzerland\u003c/li>\u003cli>\u003cspan>\u003csup>2\u003c/sup>\u003c/span>neuroscience and rare diseases, roche pharmaceutical research and early development, roche innovation center basel, basel, switzerland\u003c/li>\u003cli>\u003cspan>\u003csup>3\u003c/sup>\u003c/span>pharmaceutical sciences, roche pharmaceutical research and early development, roche innovation center basel, basel, switzerland\u003c/li>\u003cli>\u003cspan>\u003csup>4\u003c/sup>\u003c/span>hiqscreen s&#x000e0;rl, v&#x000e9;senaz, switzerland\u003c/li>\u003c/ul>\u003cp class=\"mb0\">\u003cb>background:\u003c/b> alterations in the gabaergic system contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder (asd) and angelman syndrome (as), particularly in cases involving large deletions in the 15q11&#x02013;13 region. positive modulation of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors may provide a novel therapeutic approach without the typical side effects associated with non-selective gaba\u003csub>a\u003c/sub> positive allosteric modulators such as diazepam.\u003c/p>\u003cp class=\"mb0\">\u003cb>methods:\u003c/b> alogabat was assessed for binding and functional activity at gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 receptors \u003cem>in vitro\u003c/em> and in electrophysiological studies using hippocampal slices. \u003cem>in vivo\u003c/em> studies in rodents included receptor occupancy (ro) using a selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 tracer (autoradiography), pharmacological mri, and electroencephalography (eeg). alogabat was evaluated for its effects on the repetitive behavior phenotype in btbr and contactin-associated protein-like 2 (cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup>) knockout mice, seizure models, cognitive performance in rats, and rotarod performance following combination treatment with diazepam.\u003c/p>\u003cp class=\"mb0\">\u003cb>results:\u003c/b> alogabat is a potent positive allosteric modulator of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors, with binding and functional selectivity. receptor occupancy studies provided direct proof of dose-dependent target engagement. functional circuit modulation was demonstrated by dose-dependent regional perfusion changes in pharmacological mri and changes in eeg theta- and beta-band power in rats. at &#x0003e;50% gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor occupancy, alogabat normalized elevated self-grooming behavior in both cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> and btbr mice and exhibited antiepileptic activity in rats. alogabat did not impair cognition in wildtype rats at gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor occupancy up to 75%, although impairment occurred at higher doses, probably due to increased activity at other receptor subtypes and/or saturation of &#x003b1;5 receptors. alogabat did not worsen diazepam-induced impairment on the rotarod test.\u003c/p>\u003cp class=\"mb0\">\u003cb>conclusion:\u003c/b> alogabat showed beneficial effects in mouse models relevant to neurodevelopmental disorders and anti-seizure activity at doses that did not produce cognitive, sedative, or motoric side effects.\u003c/p>\u003cdiv class=\"clear\">\u003c/div>\u003c/div>\u003cdiv class=\"journalfulltext\">\u003ca id=\"h2\" name=\"h2\">\u003c/a>\u003ch2>1 introduction\u003c/h2>\u003cp class=\"mb15\">alterations in the gabaergic system, the main inhibitory neurotransmitter system in the brain, may contribute to the pathophysiology of neurodevelopmental disorders (ndds), such as autism spectrum disorder (asd) and angelman syndrome (as). asd is a complex, heterogeneous ndd with both genetic and environmental factors (\u003ca href=\"#b7\">bourgeron, 2015\u003c/a>) contributing to aberrant changes in brain growth, neuronal development, and functional connectivity (\u003ca href=\"#b18\">dhossche et al., 2002\u003c/a>; \u003ca href=\"#b55\">pizzarelli and cherubini, 2011\u003c/a>; \u003ca href=\"#b8\">braat and kooy, 2015\u003c/a>; \u003ca href=\"#b58\">robertson et al., 2016\u003c/a>). asd is characterized by two core domains: impairments in social interaction and communication and the presence of repetitive or restricted behaviors, interests, or activities (\u003ca href=\"#b3\">american psychiatric association, 2008\u003c/a>). there are a range of comorbid conditions, including irritability, depression, anxiety, attention deficits, obsessive-compulsive symptoms, seizures, and sleep disruption. as is a rare genetic ndd with a prevalence of 1 in 12,000 to 20,000 births (\u003ca href=\"#b38\">luk and lo, 2016\u003c/a>; \u003ca href=\"#b44\">mertz et al., 2013\u003c/a>). individuals with as often present with autistic features, severe intellectual disability, microcephaly, speech impairment, bursts of laughter, sleep problems, movement disorders, and epilepsy (\u003ca href=\"#b12\">buiting, 2010\u003c/a>; \u003ca href=\"#b35\">kalsner and chamberlain, 2015\u003c/a>).\u003c/p>\u003cp class=\"mb15\">gaba\u003csub>a\u003c/sub> receptors are ligand-gated chloride channels. there are 19 genes encoding gaba\u003csub>a\u003c/sub> receptor subunits that assemble as pentamers, with the most common stoichiometry being two &#x003b1;, two &#x003b2;, and one &#x003b3; subunit. gaba\u003csub>a\u003c/sub> subunit combinations give rise to functional, circuit, and behavioral specificity (\u003ca href=\"#b65\">sieghart, 2006\u003c/a>; \u003ca href=\"#b73\">vithlani et al., 2011\u003c/a>). gaba\u003csub>a\u003c/sub> receptors that contain the &#x003b1;5 subunit (gaba\u003csub>a\u003c/sub>-&#x003b1;5) are of particular interest due to their restricted pattern of expression and unique physiological and pharmacological properties (\u003ca href=\"#b69\">sur et al., 1999\u003c/a>; \u003ca href=\"#b46\">mohler, 2011\u003c/a>). in humans, gaba\u003csub>a\u003c/sub> receptors containing the &#x003b1;5 subunit are preferentially localized in the hippocampus, prefrontal cortex, nucleus accumbens, amygdala, insular cortex, anterior cingulate, and cingulate cortex&#x02014;key regions believed to be involved in the neuropathology and pathophysiology of asd (\u003ca href=\"#b42\">mendez et al., 2013\u003c/a>; \u003ca href=\"#b48\">myers et al., 2017\u003c/a>). the \u003cem>gabra5\u003c/em> gene has been proposed as a candidate gene for asd (\u003ca href=\"#b15\">delong, 2007\u003c/a>; \u003ca href=\"#b45\">mesbah-oskui et al., 2017\u003c/a>; \u003ca href=\"#b74\">warrier et al., 2013\u003c/a>; \u003ca href=\"#b19\">di nanni et al., 2019\u003c/a>), suggesting decreased gabaergic inhibition in a subpopulation of autistic individuals. mutations involving the gaba\u003csub>a\u003c/sub> receptor subunit genes \u003cem>gabra5\u003c/em>, \u003cem>gabrb3\u003c/em>, and \u003cem>gabrg3\u003c/em> (encoding the &#x003b1;5, &#x003b2;3, and &#x003b3;3 subunits) found on chromosomal region 15q11&#x02013;q13 have been associated with ndds including as, epilepsy, and prader&#x02013;willi syndrome in addition to asd (\u003ca href=\"#b32\">hogart et al., 2010\u003c/a>; \u003ca href=\"#b61\">sanders, 2015\u003c/a>). as is predominantly caused by the loss of function of the maternally inherited \u003cem>ube3a\u003c/em> gene; however, approximately 75% of individuals with as carry a large deletion of the maternal 15q11&#x02013;q13 chromosomal region. clinical studies have shown that individuals with as who have large deletions (deletion as) exhibit more severe symptoms than those in whom \u003cem>ube3a\u003c/em> is the only gene affected, suggesting that the \u003cem>gabra5\u003c/em>, \u003cem>gabrb3\u003c/em>, and \u003cem>gabrg3\u003c/em> genes are relevant to the etiology of the disease.\u003c/p>\u003cp class=\"mb15\">imaging studies using pet and magnetic resonance spectroscopy have shown reduced gaba\u003csub>a\u003c/sub> receptor binding in the superior and medial frontal cortex (\u003ca href=\"#b47\">mori et al., 2012\u003c/a>) and reduced gaba levels in individuals with asd (\u003ca href=\"#b58\">robertson et al., 2016\u003c/a>; \u003ca href=\"#b28\">gaetz et al., 2014\u003c/a>; \u003ca href=\"#b59\">rojas et al., 2014\u003c/a>; \u003ca href=\"#b57\">puts et al., 2017\u003c/a>). postmortem studies have shown reduced numbers of inhibitory interneurons (\u003ca href=\"#b20\">dufour et al., 2023\u003c/a>), reduced expression of gaba\u003csub>a\u003c/sub> receptor subunits (\u003ca href=\"#b16\">delorey, 2005\u003c/a>; \u003ca href=\"#b1\">abrahams and geschwind, 2008\u003c/a>), and reduced levels of the gaba-synthesizing enzymes such as glutamic acid decarboxylase (gad) 65 and 67 (\u003ca href=\"#b21\">fatemi et al., 2002\u003c/a>). there is increasing evidence from genetic, environmental, and phenotypic rodent models relevant to asd indicating that gabaergic circuit dysfunctions contribute to autism-like phenotypes (\u003ca href=\"#b27\">fukuda et al., 2005\u003c/a>; \u003ca href=\"#b13\">chao et al., 2010\u003c/a>; \u003ca href=\"#b6\">banerjee et al., 2013\u003c/a>). such deficits may result from multiple causes, including a reduced number of gabaergic interneurons, altered interneuron function, impaired gaba\u003csub>a\u003c/sub> receptor trafficking to the membrane, reduced expression of gaba\u003csub>a\u003c/sub> receptor subunits, and reduced gaba uptake function of gat-1 in neurons (\u003ca href=\"#b49\">nakamura et al., 2016\u003c/a>; \u003ca href=\"#b50\">orefice et al., 2016\u003c/a>; \u003ca href=\"#b43\">mermer et al., 2021\u003c/a>). supportive evidence is provided by the observation of autism-like behaviors in both gaba\u003csub>a\u003c/sub>-&#x003b1;5 and &#x003b2;3 subunit knockout mice (\u003ca href=\"#b77\">zurek et al., 2016\u003c/a>; \u003ca href=\"#b17\">delorey et al., 2008\u003c/a>). regarding possible therapeutic approaches, enhancement of the gaba\u003csub>a\u003c/sub> receptor activity by non-selective benzodiazepines has been shown to ameliorate autism-like behavioral deficits in mouse models; however, due to sedation that is likely mediated by the activation of the gaba\u003csub>a\u003c/sub>-&#x003b1;1 subtype, very narrow therapeutic margins were observed (\u003ca href=\"#b30\">han et al., 2012\u003c/a>; \u003ca href=\"#b29\">han et al., 2014\u003c/a>; \u003ca href=\"#b37\">lim et al., 2017\u003c/a>). interestingly, a recent study showed that a gaba\u003csub>a\u003c/sub>-&#x003b1;5 positive allosteric modulator (pam), sh-053-2&#x02032;f-r-ch3, attenuated social and cognitive deficits in male rats exposed to valproic acid \u003cem>in utero\u003c/em>, a rat model relevant to autism (\u003ca href=\"#b68\">souza et al., 2024\u003c/a>).\u003c/p>\u003cp class=\"mb15\">the aim of the current study was to determine whether a selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 pam, alogabat (also known as ro7017773 or rg7816), would produce beneficial effects in animal models relevant to autism-like repetitive behavior&#x02014;specifically btbr mice (\u003ca href=\"#b40\">mcfarlane et al., 2008\u003c/a>) and contactin-associated protein-like 2 [cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup>] homozygous knockout mice (\u003ca href=\"#b51\">penagarikano et al., 2011\u003c/a>)&#x02014;and anti-seizure activity, without the typical side effects of non-selective gaba\u003csub>a\u003c/sub> pams, such as sedation and cognitive impairment. furthermore, target engagement was assessed by \u003cem>in vivo\u003c/em> receptor occupancy (ro) and pharmacological mri (phmri) in rodents, and an electroencephalography (eeg) study in rats was undertaken to identify a putative pharmacodynamic readout for future clinical trials.\u003c/p>\u003ca id=\"h3\" name=\"h3\">\u003c/a>\u003ch2>2 materials and methods\u003c/h2>\u003cp class=\"mb15\">further information for each method listed below can be found in the \u003ca href=\"#sm1\">supplementary material\u003c/a>.\u003c/p>\u003ca id=\"h3-1\" name=\"h3-1\">\u003c/a>\u003ch3 class=\"pt0\">2.1 materials\u003c/h3>\u003cp class=\"mb0\">alogabat [ro7017773; c\u003csub>21\u003c/sub>h\u003csub>23\u003c/sub>n\u003csub>5\u003c/sub>o\u003csub>4\u003c/sub>; 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl) methoxy)-n-(tetrahydropyran-4-yl)pyridazine-3-carboxamide (iupac name); molecular weight: 409.44&#x000a0;gmol\u003csup>&#x02212;1\u003c/sup>] was synthesized at f.hoffmann-la roche ag, switzerland [\u003ca href=\"#f1\">figure 1a\u003c/a>; see example 8 in \u003ca href=\"#b10\">buettelmann et al., 2018\u003c/a>]. the discovery of alogabat and the related chemical series will be disclosed in future publications. diazepam, l-655,708, [\u003csup>3\u003c/sup>h]flumazenil, [\u003csup>3\u003c/sup>h]l-655,708, and [\u003csup>3\u003c/sup>h]ro0154513 were synthesized at f.hoffmann-la roche ag, switzerland.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 1\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" name=\"figure1\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" alt=\"www.frontiersin.org\" id=\"f1\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 1\u003c/b>. \u003cem>in vitro\u003c/em> pharmacology of alogabat. \u003cb>(a)\u003c/b> chemical structure of alogabat (ro7017773; c21h23n5o4); 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl) methoxy)-n-(tetrahydropyran-4-yl)pyridazine-3-carboxamide (iupac name); molecular weight, 409.44&#x000a0;gmol\u003csup>&#x02212;1\u003c/sup>. \u003cb>(b)\u003c/b> concentration-response curves of alogabat in [\u003csup>3\u003c/sup>h]flumazenil competition-binding assays with membranes expressing different rat recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (\u003cem>n\u003c/em> &#x0003d; 10&#x02013;20/concentration). \u003cb>(c)\u003c/b> concentration-response curves of the effects of alogabat in hek293 cells expressing different rat recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (\u003cem>n\u003c/em> &#x0003d; 4&#x02013;5/concentration). data in the graphs are shown as the mean (symbols) &#x000b1; sem (error bars). error bars smaller than the symbol size are not shown. \u003cb>(d)\u003c/b> isoguvacine concentration-response curves obtained in the presence and absence of alogabat in rat hippocampal slices. the points represent the mean values &#x000b1; sem of three slices. the sigmoidal curves were fit through these points. \u003cb>(e)\u003c/b> the ppi of ps was measured in the absence (control) and presence of alogabat at 0.3&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 3 slices) and 1&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 6 slices). ps1 and ps2 are the responses induced by the first and second stimulus, respectively. the data are normalized to the amplitude of ps1 and presented as the mean &#x000b1; sem.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h3-2\" name=\"h3-2\">\u003c/a>\u003ch3 class=\"pt0\">2.2 \u003cem>in vitro\u003c/em> experiments\u003c/h3>\u003ca id=\"h7-2-1\" name=\"h7-2-1\">\u003c/a>\u003ch4>2.2.1 gaba\u003csub>a\u003c/sub> receptor radioligand binding assays\u003c/h4>\u003cp class=\"mb0\">the affinity of alogabat for rat and human gaba\u003csub>a\u003c/sub> receptors containing &#x003b1;5, &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits was measured by [\u003csup>3\u003c/sup>h]flumazenil competition-binding assays with membranes expressing different rat recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (\u003cem>n\u003c/em> &#x0003d; 10&#x02013;20/concentration) and for human &#x003b1;4 and &#x003b1;6 by [\u003csup>3\u003c/sup>h]ro0154513, as previously described (\u003ca href=\"#b4\">ballard et al., 2009\u003c/a>; \u003ca href=\"#b31\">hipp et al., 2021\u003c/a>).\u003c/p>\u003ca id=\"h7-2-2\" name=\"h7-2-2\">\u003c/a>\u003ch4>2.2.2 gaba\u003csub>a\u003c/sub> receptor electrophysiological studies\u003c/h4>\u003cp class=\"mb0\">alogabat was tested for functional activity on four different cloned rat and human gaba\u003csub>a\u003c/sub> receptor subtypes (\u003ca href=\"#b10\">buettelmann et al., 2018\u003c/a>), namely, &#x003b1;1&#x003b2;2&#x003b3;2, &#x003b1;2&#x003b2;3&#x003b3;2, &#x003b1;3&#x003b2;3&#x003b3;2, and &#x003b1;5&#x003b2;3&#x003b3;2. ion currents were induced by gaba concentrations that evoked approximately 20% of the maximal response (\u003cem>n\u003c/em> &#x0003d; 4&#x02013;5/concentration). the following concentrations of gaba were used: 1&#x000a0;&#x000b5;m for &#x003b1;1&#x003b2;2&#x003b3;2, 10&#x000a0;&#x000b5;m &#x003b1;2&#x003b2;3&#x003b3;2, 10&#x000a0;&#x000b5;m for &#x003b1;3&#x003b2;3&#x003b3;2, and 3&#x000a0;&#x000b5;m for &#x003b1;5&#x003b2;3&#x003b3;2 receptor subtype.\u003c/p>\u003cp class=\"mb0\">alogabat was also tested for functional activity on native gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors in rat hippocampal slices: modulation of isoguvacine-induced population spikes (\u003ca href=\"#b4\">ballard et al., 2009\u003c/a>) and paired-pulse inhibition (ppi) (\u003ca href=\"#b76\">xie and tietz, 1991\u003c/a>). population spikes (pss) were recorded every 30&#x000a0;s by the stimulation of the schaffer collaterals, and isoguvacine was applied consecutively and in increasing concentrations for at least 4&#x000a0;min to the slices (control). after the washout of isoguvacine, alogabat (300&#x000a0;nm) was added to the bath perfusion, and a new isoguvacine concentration-response curve was obtained (alogabat). the ps amplitudes were normalized to the control ps obtained before the first application of isoguvacine and were fitted individually for each slice (\u003cem>n\u003c/em> &#x0003d; 3 slices).\u003c/p>\u003cp class=\"mb0\">the ppi of ps was measured in the absence (control) and presence of alogabat at 0.3&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 3 slices from one animal) and 1&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 6 slices from two animals). the paired-pulse protocol consisted of two stimuli timely spaced by 20&#x000a0;ms, which were applied at the schaffer collaterals in rat hippocampal slices. we used a low number of animals based on our experience with the assay, which is highly robust and reproducible, and in alignment with our commitment to reducing the number of animals used.\u003c/p>\u003ca id=\"h7-2-3\" name=\"h7-2-3\">\u003c/a>\u003ch4>2.2.3 selectivity screening\u003c/h4>\u003cp class=\"mb0\">the selectivity of alogabat (10&#x000a0;&#x000b5;m) over more than 70 receptors was assessed by radioligand binding studies conducted using eurofins cerep sa (celle l&#x000e9;vescault, france), following the methods described on \u003ca href=\"http://www.eurofinsdiscoveryservices.com/\">www.eurofinsdiscoveryservices.com\u003c/a>.\u003c/p>\u003ca id=\"h3-3\" name=\"h3-3\">\u003c/a>\u003ch3 class=\"pt0\">2.3 \u003cem>in vivo\u003c/em> experiments\u003c/h3>\u003ca id=\"h7-3-1\" name=\"h7-3-1\">\u003c/a>\u003ch4>2.3.1 ethics approval\u003c/h4>\u003cp class=\"mb0\">experiments performed at f.hoffmann-la roche ag (basel, switzerland) complied with the swiss federal and cantonal laws on animal research and aaalac regulations and received prior approval from the cantonal veterinary office. the eeg study was conducted at brains online (ca, united states) in accordance with the guide for the care and use of laboratory animals (national research council 2011) after gaining approval from the institutional animal care and use committee. the pentylenetetrazole (ptz) and maximal electroshock (mes) tests were conducted at vivocore inc., canada, which is a facility licensed by the ontario ministry of agriculture, food, and rural affairs and accredited by the canadian council on animal care. all \u003cem>in vivo\u003c/em> studies are reported in compliance with the arrive guidelines (\u003ca href=\"#b52\">percie du sert et al., 2020\u003c/a>).\u003c/p>\u003ca id=\"h7-3-2\" name=\"h7-3-2\">\u003c/a>\u003ch4>2.3.2 animals\u003c/h4>\u003cp class=\"mb0\">all animals were group-housed in holding rooms at controlled temperature and humidity under a 12&#x000a0;h light/dark cycle and were allowed to acclimate for at least 7&#x000a0;days. twenty-six male wistar rats (charles river, germany; &#x0223c;160&#x000a0;g) and sixteen male cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (bred at roche basel; 18&#x02013;22&#x000a0;g) were used in receptor occupancy studies. thirty-two male fischer rats (charles river, germany) were assessed in mri experiments (&#x0223c;250&#x000a0;g). seventeen male wistar rats (envigo, united states) were assessed in eeg experiments. one hundred male btbr mice (bred in roche basel) were assessed in grooming and open-field tests (n &#x0003d; 60, &#x0223c;30&#x000a0;g) and for digging behavior (n &#x0003d; 40, &#x0223c;30&#x000a0;g). fifty-seven male cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (bred in roche basel; 5&#x02013;6&#x000a0;weeks) and wildtype littermates (n &#x0003d; 15) were assessed in grooming and open-field tests. one hundred male sprague&#x02013;dawley rats (charles river, canada) were used to evaluate antiepileptic effects in the ptz (70&#x02013;100&#x000a0;g, n &#x0003d; 40) and mes (&#x0003c;50&#x000a0;g n &#x0003d; 60) tests. forty-eight male sprague&#x02013;dawley rats (charles river, france) were used in the rotarod test (&#x0223c;170&#x02013;200&#x000a0;g). one hundred and forty-one male lister hooded (lh) rats (charles river, germany) were used in the cognition tests: 5-choice serial reaction time (5-csrt) task (n &#x0003d; 11, &#x0223c;400&#x000a0;g); continuous performance test (cpt; n &#x0003d; 11, &#x0223c;400&#x000a0;g); paired associates learning (pal) task (n &#x0003d; 12, &#x0223c;400&#x000a0;g); context fear conditioning (n &#x0003d; 67, &#x0223c;250&#x000a0;g); and morris water maze (n &#x0003d; 40, 350&#x02013;400&#x000a0;g).\u003c/p>\u003ca id=\"h7-3-3\" name=\"h7-3-3\">\u003c/a>\u003ch4>2.3.3 alogabat treatment\u003c/h4>\u003cp class=\"mb0\">alogabat was formulated in 2% hydroxypropyl cellulose in water (or 0.3% tween 80 in saline for \u003cem>in vivo\u003c/em> occupancy and grooming/digging experiments). the administration volume was 10&#x000a0;ml/kg (mice) and 5&#x000a0;ml/kg (rats). each dose was expressed as the weight of the base. alogabat was administered with a pre-treatment time of 30&#x000a0;min in mice and 60&#x000a0;min in rats (except for the eeg study), based on pharmacokinetic data indicating the time of maximal drug plasma concentration. treatment groups were assigned randomly. dose groups were provided as coded vials to allow blinded assessment during the conduct of each experiment. to minimize potential confounders regarding the time of day for behavioral testing, animals were split into separate cohorts (balanced for treatment groups) and tested during the same period.\u003c/p>\u003ca id=\"h7-3-4\" name=\"h7-3-4\">\u003c/a>\u003ch4>2.3.4 receptor occupancy studies\u003c/h4>\u003ch5>2.3.4.1 \u003cem>in vivo\u003c/em> occupancy in rats\u003c/h5>\u003cp class=\"mb0\">male wistar rats (n &#x0003d; 26, &#x0223c;160&#x000a0;g) were administered vehicle or alogabat (0.3, 1, 3, 10, 30, and 100&#x000a0;mg/kg, intraperitoneally [i.p.], n &#x0003d; 3/group) or the gaba\u003csub>a\u003c/sub>-&#x003b1;5 blocker l-655,708 at 10&#x000a0;mg/kg i.p. (n &#x0003d; 2). fifteen minutes later, the gaba\u003csub>a\u003c/sub>-&#x003b1;5 radioligand [\u003csup>3\u003c/sup>h]ro0154513 was administered intravenously (i.v.) to assess ro (\u003ca href=\"#b4\">ballard et al., 2009\u003c/a>; \u003ca href=\"#b31\">hipp et al., 2021\u003c/a>). non-specific binding was determined by pre-treatment with the established gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor blocker l-655,708 (10&#x000a0;mg/kg i.p.; n &#x0003d; 2).\u003c/p>\u003ch5>2.3.4.2 \u003cem>ex vivo\u003c/em> occupancy in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h5>\u003cp class=\"mb0\">cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (\u003ca href=\"#b51\">penagarikano et al., 2011\u003c/a>) (n &#x0003d; 16, 18&#x02013;22&#x000a0;g) were administered the vehicle or alogabat (30, 60, and 100&#x000a0;mg/kg) i.p. (n &#x0003d; 4/group), and ro was assessed in brain sections with the highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 radioligand, [\u003csup>3\u003c/sup>h]l-655,708, 30&#x000a0;min post-administration.\u003c/p>\u003ca id=\"h7-3-5\" name=\"h7-3-5\">\u003c/a>\u003ch4>2.3.5 pharmacological mri in rats\u003c/h4>\u003cp class=\"mb0\">male fischer rats (n &#x0003d; 32, &#x0223c;250&#x000a0;g) were administered vehicle or alogabat (3, 10, and 30&#x000a0;mg/kg) i.p. (n &#x0003d; 8/dose). phmri was performed under medetomidine sedation in a small-animal scanner (4.7t/40&#x000a0;cm; bruker biospin, germany), and blood perfusion was analyzed according to previously published procedures (\u003ca href=\"#b9\">bruns et al., 2009\u003c/a>). fifteen minutes after drug treatment, rats were initially anesthetized using isoflurane (4%) in the carrier gas composed of oxygen and air (1:5), supplied to the spontaneously breathing animals in an inhalation box. upon the induction of anesthesia, a subcutaneous (s.c.) bolus injection of 0.2&#x000a0;mg/kg (1&#x000a0;ml/kg) of medetomidine prepared from 1:5 diluted dormilan\u003csup>&#x000ae;\u003c/sup> was administered, and the animal was transferred onto a rat cradle for inserting an s.c. catheter and starting continuous infusion of 1:10 diluted dormilan\u003csup>&#x000ae;\u003c/sup> (medetomidine) at a dose of 0.1&#x000a0;mg/kg/h (1&#x000a0;ml/kg/h). the head was immobilized in a stereotaxic frame. respiratory rate, body temperature, and o\u003csub>2\u003c/sub> and co\u003csub>2\u003c/sub> levels in inhaled and exhaled air were continuously monitored using a powerlab data acquisition system (adinstruments, spechbach, germany). body temperature was maintained at 37&#x000b0;c with a feedback-regulated electric heating blanket. immediately after the last imaging assessment, rats were euthanized by decapitation under anesthesia, and plasma samples were collected at approximately 40&#x000a0;min post-administration of alogabat. images were processed and analyzed using in-house developed software written in idl (rsi, boulder, co, united states) and matlab (the mathworks inc., natick, ma, united states).\u003c/p>\u003ca id=\"h7-3-6\" name=\"h7-3-6\">\u003c/a>\u003ch4>2.3.6 eeg in rats\u003c/h4>\u003cp class=\"mb0\">male wistar rats (n &#x0003d; 17) were surgically prepared with wireless implanted transmitters to enable simultaneous recording of eeg, hippocampal (ca3) local field potential (lfp), and emg. rats were anesthetized using isoflurane (2%, 800&#x000a0;ml/min o2). bupivacaine/epinephrine was used for local analgesia, while finadyne or carprofen was used for peri-/post-operative analgesia. amoxicillin was used as an antibiotic. the animals were placed in a stereotaxic frame (kopf instruments, united states). a subcutaneous pocket was created near the dorsal flank, into which a transmitter (f50-eee, data sciences international, physio tel f50-eee small animal cns telemetry; three bipolar channels, biopotential lead, outer diameter 0.3&#x000a0;mm) was inserted. the transmitter included three bipolar channels: channel 1 (eeg): two screws in the left hemisphere (frontal: 11&#x000a0;mm anterior and 2.5&#x000a0;mm lateral to bregma; central: 3&#x000a0;mm anterior and 3.5&#x000a0;mm lateral to lambda); channel 2 (lfp): a single wire electrode targeting the ca3 region of the right hippocampus; and channel 3 (emg): electrodes placed in the neck muscle for recording emg activity, aiding in sleep stage classification.\u003c/p>\u003cp class=\"mb0\">after a 2-week recovery, rats were administered the vehicle or alogabat (10&#x000a0;mg/kg) using a cross-over design (1-week interval). if the setup allowed, the positive control diazepam (2&#x000a0;mg/kg) was assessed. all drugs were administered i.v. via an implanted cannula so that brain exposure was expected within a few minutes of administration. eeg spectral power was analyzed quantitatively up to 1&#x000a0;h post-administration. only animals with clean eeg recordings were included in the analysis. eeg data in the awake state were used for the analyses reported in this study. we first investigated the effects on power over predefined theta and beta power ranges, defined \u003cem>a priori\u003c/em> as 6&#x02013;10&#x000a0;hz and 20&#x02013;30&#x000a0;hz, respectively, based on previous studies with gabaa drugs (\u003ca href=\"#b72\">visser et al., 2003\u003c/a>; \u003ca href=\"#b71\">van lier et al., 2004\u003c/a>). then, we evaluated frequency-specific effects across the 2&#x02013;128&#x000a0;hz range.\u003c/p>\u003ca id=\"h7-3-7\" name=\"h7-3-7\">\u003c/a>\u003ch4>2.3.7 grooming behavior and open-field test in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h4>\u003cp class=\"mb0\">male btbr mice (n &#x0003d; 60, &#x0223c;30&#x000a0;g) were pre-treated with the vehicle or alogabat at 30, 60, 90, and 120&#x000a0;mg/kg i.p. (n &#x0003d; 12/dose). male cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (n &#x0003d; 57, 5&#x02013;6&#x000a0;weeks) and wildtype littermates (n &#x0003d; 15) received sub-chronic treatment (8&#x02013;10&#x000a0;days) with the vehicle or alogabat at 30, 60, and 100&#x000a0;mg/kg i.p. (n &#x0003d; 14&#x02013;15/dose). spontaneous locomotor activity was assessed in both groups of mice for 1&#x000a0;h in an open field (42 &#x000d7; 42 &#x000d7; 30.5&#x000a0;cm; 20 lux at the center of the arena) with a small amount of sawdust bedding. movement of the animal was detected by interruptions in an array of photobeams from horizontally located infrared sources placed around the open field, measured using a versamax system (accuscan instruments inc., columbus, oh, united states). activity was measured as the distance traveled (cm).\u003c/p>\u003cp class=\"mb0\">one week later, each mouse was placed into a type-ii cage (21.5 &#x000d7; 15.5 &#x000d7; 13.0&#x000a0;cm; 40 lux) for 5&#x000a0;min habituation, and then the cumulative time (s) spent grooming during 10&#x000a0;min was recorded manually by a blinded observer. distance traveled (cm) during the session was measured using a video tracking system (ethovision, noldus information technology, netherlands). plasma samples were collected from btbr mice 1&#x000a0;week after testing and 30&#x000a0;min after treatment (\u003cem>n\u003c/em> &#x0003d; 6/dose). plasma samples were collected from cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice 1&#x000a0;day later and 30&#x000a0;min after treatment (\u003cem>n\u003c/em> &#x0003d; 4/dose).\u003c/p>\u003ca id=\"h7-3-8\" name=\"h7-3-8\">\u003c/a>\u003ch4>2.3.8 digging behavior in btbr mice\u003c/h4>\u003cp class=\"mb0\">a separate group of male btbr mice (n &#x0003d; 40, &#x0223c;30&#x000a0;g) were pre-treated with vehicle or alogabat at 30, 60, and 100&#x000a0;mg/kg i.p. (n &#x0003d; 10/dose) and were placed into a small circular dish (d &#x0003d; 10&#x000a0;cm) filled with fresh thick sawdust located in the middle of a clean type-ii cage (21.5 &#x000d7; 15.5 &#x000d7; 13.0&#x000a0;cm; 40 lux). the cumulative time (s) spent digging over 5&#x000a0;min was recorded manually by a blinded observer. the distance traveled (cm) and speed were also measured in the arena, outside the dish (ethovision, noldus information technology, netherlands). plasma samples were collected immediately after the digging test, i.e., 35&#x02013;40&#x000a0;min post-administration (\u003cem>n\u003c/em> &#x0003d; 3/dose).\u003c/p>\u003ca id=\"h7-3-9\" name=\"h7-3-9\">\u003c/a>\u003ch4>2.3.9 evaluation of antiepileptic effects in rats\u003c/h4>\u003cp class=\"mb0\">vehicle or alogabat (5, 15, or 30&#x000a0;mg/kg) was administered p.o. (n &#x0003d; 8/dose) and assessed for seizures induced by (1) subcutaneous (s.c.) ptz and (2) the maximum electrical stimulus (mes) model in male sprague&#x02013;dawley rats (ptz: 70&#x02013;100&#x000a0;g, n &#x0003d; 40; mes: &#x0003c;50&#x000a0;g n &#x0003d; 60, charles river, canada). diazepam (synthesized at f.hoffmann-la roche ag) was included in each experiment as a positive control and administered at 3&#x000a0;mg/kg i.p., 30&#x000a0;min prior to testing. immediately following testing, a terminal blood sample was collected under anesthesia.\u003c/p>\u003ch5>2.3.9.1 pentylenetetrazole test\u003c/h5>\u003cp class=\"mb0\">following the designated pre-treatment time, ptz was administered at 75&#x000a0;mg/kg s.c. animals were transferred to a single cage and monitored closely for the onset of clonic seizure, and the percentage of each group showing seizures was recorded. protection was defined as the complete absence of clonic seizure, including forelimb clonus, over the 30&#x000a0;min observation period.\u003c/p>\u003ch5>2.3.9.2 maximal electroshock test\u003c/h5>\u003cp class=\"mb0\">following the designated pre-treatment time, rats received maximal electroshock (mes: 150&#x000a0;ma, 0.2&#x000a0;s duration, 60&#x000a0;hz) via corneal electrodes moistened with saline (shock simulator type 221; harvard apparatus). due to inconsistency in responses by rats to this type of stimuli, all test animals (n &#x0003d; 60) were subjected to two screening sessions on two separate days, and 40 rats were selected based on their reliability to have tonic seizures. drug testing was conducted on the third day, during which the rats received the standard maximal electroshock, and the presence or absence of a tonic seizure was recorded and expressed as the percentage of animals in each group that showed seizures. protection was defined as the absence of a full tonic seizure within 15&#x000a0;s of stimulus delivery.\u003c/p>\u003ca id=\"h7-3-10\" name=\"h7-3-10\">\u003c/a>\u003ch4>2.3.10 combination with diazepam on rotarod performance in rats\u003c/h4>\u003cp class=\"mb0\">forty-eight male sprague&#x02013;dawley rats (&#x0223c;170&#x02013;200&#x000a0;g) were pre-trained to the rotarod (47750 rota-rod ng, ugo basile) at 8&#x000a0;rpm for 120&#x000a0;s. one day later, rats were administered alogabat (or vehicle) p.o., 30&#x000a0;min prior to diazepam or vehicle i.p., and they were assessed on the rotarod 30&#x000a0;min later. each rat was given three attempts to remain on the rotarod, with a maximum duration of 120&#x000a0;s per attempt. treatment groups (n &#x0003d; 8/group) consisted of alogabat alone (30&#x000a0;mg/kg), diazepam alone (5&#x000a0;mg/kg), or alogabat at 3, 10, and 30&#x000a0;mg/kg in combination with diazepam (5&#x000a0;mg/kg). the maximum time (s) spent on the rotarod was recorded. after the completion of rotarod testing, animals were euthanized under isoflurane anesthesia for plasma sample collection at approximately 70&#x000a0;min post-administration of alogabat.\u003c/p>\u003ca id=\"h7-3-11\" name=\"h7-3-11\">\u003c/a>\u003ch4>2.3.11 cognition testing in rats\u003c/h4>\u003ch5>2.3.11.1 operant and touchscreen cognition tests\u003c/h5>\u003cp class=\"mb0\">separate groups of male lister hooded (lh) rats (&#x0223c;400&#x000a0;g) were pre-trained in the operant and touch screen tests, as described in \u003ca href=\"#sm1\">supplementary material\u003c/a>. the 5-csrt task (n &#x0003d; 11) is a test of attention. the primary parameter is the total percentage of correct responses. continuous performance test (cpt; n &#x0003d; 11) assesses sustained attention. the primary parameter is the discrimination sensitivity index (d prime), which is a ratio based on the rate at which rats make correct and incorrect responses. the paired associates learning (pal) task (n &#x0003d; 12) assesses visual&#x02013;spatial memory. the primary parameter is the total percentage of correct responses. a latin-squares design was used to assess the vehicle and doses of alogabat (3, 10, and 30&#x000a0;mg/kg p.o.). rats were tested twice weekly with at least a 2-day interval between test sessions. rats were trained between test days to maintain baseline performance.\u003c/p>\u003ch5>2.3.11.2 context fear conditioning\u003c/h5>\u003cp class=\"mb0\">two cohorts of male lh rats (&#x0223c;250&#x000a0;g; n &#x0003d; 67) were assessed for context fear conditioning (cfc) in two experiments: (1) vehicle or alogabat at 10 and 30&#x000a0;mg/kg (n &#x0003d; 9/dose); (2) vehicle or alogabat at 1, 3, and 10&#x000a0;mg/kg (n &#x0003d; 10/dose) administered p.o., 60&#x000a0;min prior to the acquisition session. rats were placed into a novel test chamber (45&#x000a0;cm &#x000d7; 45&#x000a0;cm &#x000d7; 46.5&#x000a0;cm) with a grid floor and clear plastic walls (tse-systems gmbh, germany). during the acquisition session, a 2-min habituation phase was followed by the delivery of a mild foot shock (0.8&#x000a0;ma for 1&#x000a0;s) applied through the grid floor. following a 1&#x000a0;min interval, a second foot shock was delivered. the animals remained in the chambers for a further 30&#x000a0;s. one day later, the animals were returned to the same test chamber for a 5-min period without any foot shock. rodents respond to danger in a species-specific manner by freezing, i.e., the animals will withhold all movement, except for respiration, to avoid detection. the amount of freezing behavior was measured by the computer as the time spent immobile (minimum threshold of 1&#x000a0;s) and was expressed as the percentage of time spent freezing during the 5-min session. following cfc, plasma samples were collected 1&#x02013;2&#x000a0;days later from rats pre-treated with the same dose at 60&#x000a0;min post-administration (\u003cem>n\u003c/em> &#x0003d; 4/dose).\u003c/p>\u003ch5>2.3.11.3 morris water maze\u003c/h5>\u003cp class=\"mb0\">male lh rats (350&#x02013;400&#x000a0;g) were pre-treated with vehicle or 10 or 30&#x000a0;mg/kg alogabat p.o. (n &#x0003d; 10/dose) once daily during cued acquisition (visible platform; three trials per day for 2&#x000a0;days), followed by a 2-day interval and then spatial acquisition (hidden platform; three trials per day for 4&#x000a0;days) in the morris water maze (mwm; computer tracking system hvs image ltd., united kingdom) (\u003ca href=\"#b5\">ballard et al., 2005\u003c/a>). twenty-four hours later, the platform was removed, and the rats were pre-treated with vehicle or alogabat and allowed to swim in the maze for 60&#x000a0;s (probe trial) to assess the retention/spatial memory of the platform position, expressed as the percentage of distance traveled in each quadrant. for the mwm, plasma samples were collected immediately after the last trial on the 12th day of treatment at approximately 70&#x000a0;min post-administration (\u003cem>n\u003c/em> &#x0003d; 4&#x02013;5/dose).\u003c/p>\u003ca id=\"h7-3-12\" name=\"h7-3-12\">\u003c/a>\u003ch4>2.3.12 plasma sampling and analysis\u003c/h4>\u003cp class=\"mb0\">rodents were deeply anesthetized with 5% isoflurane, and blood was collected following decapitation with a guillotine or via cardiac puncture (ptz and mes). during eeg experiments, blood was collected from a cannula in the right femoral artery. blood samples were centrifuged in edta-coated eppendorf tubes (4,000&#x000a0;rpm, 4&#x000b0;c, 5&#x000a0;min), and plasma was collected, immediately frozen, and stored at &#x02212;80&#x000b0;c. samples were analyzed for the concentration of alogabat using qualified liquid chromatography coupled to tandem mass spectrometry (lc-ms/ms) assays.\u003c/p>\u003ca id=\"h7-3-13\" name=\"h7-3-13\">\u003c/a>\u003ch4>2.3.13 statistical analysis\u003c/h4>\u003cp class=\"mb0\">sample sizes were determined based on historical data for each experiment within each laboratory.\u003c/p>\u003ch5>2.3.13.1 eeg\u003c/h5>\u003cp class=\"mb0\">linear mixed-effects models (lmms) were used since these can account for incomplete datasets, which was the case in this study. specific contrasts were derived and tested using t-tests within the model using satterthwaite approximation for degrees of freedom. models were derived for each compound individually: y &#x0223c; compound &#x0002b; (1&#x0007c;animal). the significance of differences in the peak frequency was assessed using random permutation tests (10,000).\u003c/p>\u003ch5>2.3.13.2 phmri\u003c/h5>\u003cp class=\"mb0\">analysis was performed with jmp (sas institute inc., cary, united states) and matlab (the mathworks inc., natick, ma, united states). global (whole-brain) absolute-perfusion values from the vehicle and the three dose groups were tested for a linear trend across the four doses using a one-way anova framework. the same analysis was applied roi-wise to the normalized-perfusion values. multiple testing across the single rois was accounted for by controlling the false discovery rate (fdr) at 10% using the benjamini&#x02013;hochberg approach. to also obtain an overall activation&#x02013;strength metric, normalized-perfusion values of each dose group were compared roi-wise to those of the vehicle group using welch&#x02019;s t-test without multiple-testing correction. the number of significantly modulated rois at each dose was then taken as a measure of &#x0201c;pattern strength.&#x0201d; the mean and the upper 95% confidence limit of the corresponding chance levels were estimated via random group-label permutations (100,000 runs per group). significance levels of the actual pattern strengths were determined based on the distributions obtained through the permutation procedure.\u003c/p>\u003ch5>2.3.13.3 behavior\u003c/h5>\u003cp class=\"mb0\">all statistical analyses were performed using prism (graphpad software). one-factor anova was used for between-group comparison (i.e., dose), with repeated measures for within-subject comparison (i.e., time bins and platform quadrants). dunnett&#x02019;s test was used for \u003cem>post hoc\u003c/em> comparisons. student&#x02019;s unpaired two-tailed t-test was used when two groups were compared. the chi-square test was used to compare the percentage of groups. rotarod data were analyzed using a non-parametric kruskal&#x02013;wallis test, followed by dunn&#x02019;s multiple comparison test. statistical significance was predetermined as \u003cem>p\u003c/em> &#x0003c; 0.05.\u003c/p>\u003ca id=\"h4\" name=\"h4\">\u003c/a>\u003ch2>3 results\u003c/h2>\u003ca id=\"h4-1\" name=\"h4-1\">\u003c/a>\u003ch3 class=\"pt0\">3.1 binding affinity for gaba\u003csub>a\u003c/sub> receptors containing &#x003b1;5 and other &#x003b1; subunits\u003c/h3>\u003cp class=\"mb0\">the aim of these radioligand binding studies was to determine the binding selectivity of alogabat at the rat and human gaba\u003csub>a\u003c/sub> receptors containing &#x003b1;5 compared to &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits. alogabat had a high affinity for gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 receptors in rats (ki 7.9&#x000a0;nm), with approximately 37-, 26-, and 18-fold selectivity compared to gaba\u003csub>a\u003c/sub> &#x003b1;1&#x003b2;3&#x003b3;2, &#x003b1;2&#x003b2;3&#x003b3;2, and &#x003b1;3&#x003b2;3&#x003b3;2, respectively (\u003ca href=\"#f1\">figure 1b\u003c/a>; see \u003ca href=\"#sm1\">supplementary table s1\u003c/a>). alogabat had a similar pharmacological profile in human recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (see \u003ca href=\"#sm1\">supplementary table s1\u003c/a>).\u003c/p>\u003ca id=\"h4-2\" name=\"h4-2\">\u003c/a>\u003ch3 class=\"pt0\">3.2 functional activity at recombinant and native gaba\u003csub>a\u003c/sub> receptors\u003c/h3>\u003cp class=\"mb0\">we undertook electrophysiological studies in hek293 cells and oocytes to assess the functional activity of alogabat on cloned rat and human gaba\u003csub>a\u003c/sub> receptor subtypes containing &#x003b1;5, &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits. alogabat enhanced gaba-evoked responses of rat and human &#x003b1;5-containing receptors by 167% (\u003ca href=\"#f1\">figure 1c\u003c/a>) and 72% (see \u003ca href=\"#sm1\">supplementary table s2\u003c/a>), respectively. the maximum amount of potentiation was slightly lower at human receptors. this may be due to the different expression systems used, i.e., hek293 cells for rat receptors and \u003cem>xenopus\u003c/em> oocytes for human receptors. at the highest concentrations tested, alogabat potentiated other receptor subtypes to a much lesser extent than &#x003b1;5-containing receptors. the potency of alogabat was comparable between gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors containing either &#x003b3;2 or &#x003b3;3 subunits, i.e., gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 and gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;3 receptors (see \u003ca href=\"#sm1\">supplementary figure s1\u003c/a>).\u003c/p>\u003cp class=\"mb0\">at native gaba\u003csub>a\u003c/sub> receptors in rat hippocampal slices, alogabat positively modulated gabaergic inhibition of ca1 pyramidal cells, as shown by a leftward shift of the concentration-dependent inhibition of the population spike by isoguvacine (\u003ca href=\"#f1\">figure 1d\u003c/a>) and enhanced paired-pulse inhibition of the population spike during field potential recordings (\u003ca href=\"#f1\">figure 1e\u003c/a>). together, these results confirm the binding selectivity of alogabat and demonstrate that alogabat is a functionally selective pam of gaba-evoked responses.\u003c/p>\u003ca id=\"h4-3\" name=\"h4-3\">\u003c/a>\u003ch3 class=\"pt0\">3.3 selectivity data\u003c/h3>\u003cp class=\"mb0\">we assessed alogabat in radioligand binding studies with more than 70 receptors and showed that alogabat at 10&#x000a0;&#x000b5;m had over 917-fold binding selectivity for the gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 receptor subtype against all other targets tested (see \u003ca href=\"#sm1\">supplementary table s3\u003c/a>).\u003c/p>\u003ca id=\"h4-4\" name=\"h4-4\">\u003c/a>\u003ch3 class=\"pt0\">3.4 receptor occupancy in wistar rats and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h3>\u003cp class=\"mb0\">the main objective of these studies was to visualize and quantify gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro by alogabat. alogabat decreased the specific binding of the gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor-specific radioligand [\u003csup>3\u003c/sup>h]ro0154513 in the hippocampus of rats in a dose-dependent manner. the highest dose of alogabat (100&#x000a0;mg/kg i.p.) reduced specific binding by 100%, i.e., to the same binding level as that of 10&#x000a0;mg/kg l-655,708 (\u003ca href=\"#f2\">figure 2a\u003c/a>). a total plasma concentration of 669&#x000a0;ng/ml and a total brain concentration of 208&#x000a0;ng/g were required to produce half-maximal gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro (ec\u003csub>50\u003c/sub>) in the hippocampus in rats. in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice, estimated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro based on the \u003cem>ex vivo\u003c/em> study with [\u003csup>3\u003c/sup>h]l-655,708 was 43%, 46%, and 71% at doses of 30, 60, and 100&#x000a0;mg/kg i.p., respectively (\u003ca href=\"#f2\">figure 2b\u003c/a>). in addition, the rat occupancy curve was used to calculate ro related to plasma exposure for all \u003cem>in vivo\u003c/em> experiments described in this manuscript below (also refer to \u003ca href=\"#sm1\">supplementary tables s4&#x02013;s5\u003c/a>).\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 2\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" name=\"figure2\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" alt=\"www.frontiersin.org\" id=\"f2\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 2\u003c/b>. receptor occupancy and phmri signature of alogabat following acute administration. \u003cb>(a)\u003c/b> concentration-dependent blockade of [\u003csup>3\u003c/sup>h]ro0154513 binding by alogabat in wistar rats: with increasing concentrations from the different doses (0.3&#x02013;100&#x000a0;mg/kg i.p., n &#x0003d; 3/dose) of alogabat (vehicle &#x0003d; without pre-treatment, n &#x0003d; 3). \u003cb>(b)\u003c/b> representative autoradiograms of alogabat \u003cem>ex vivo\u003c/em> occupancy in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice via \u003cem>in vitro\u003c/em> incubation of the highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor radioligand [\u003csup>3\u003c/sup>h]l-655,708 to sagittal brain sections. the cntnap2&#x02212;/&#x02212; mice were treated with vehicle and 30, 60, or 100&#x000a0;mg/kg i.p. alogabat (n &#x0003d; 4/dose). \u003cb>(c)\u003c/b> trend of normalized-perfusion response pattern strength increasing with dose, given as numbers (&#x000b1; 95% confidence intervals) of significantly (de-)activated regions of interest (rois) following the administration of alogabat (n &#x0003d; 8/dose) to fischer (f344) rats under medetomidine sedation. &#x0201c;chance level&#x0201d; &#x0003d; mean (black dotted line) and 95th percentile (gray dotted line) derived from the permutation test. significant deviations in the number of modulated rois from the chance level are denoted by &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 (uncorrected). ro is the calculated receptor occupancy for gaba\u003csub>a\u003c/sub>-&#x003b1;5 from measured plasma concentrations at each dose. \u003cb>(d)\u003c/b> sagittal schematic of rat brain showing rois with a significant dose-dependent modulation (linear trend of normalized perfusion). rois passing false discovery rate control at 10% are shown, with roi outlines indicating uncorrected significance level (no outline, \u003cem>p\u003c/em> &#x0003c; 0.05; dotted outline, \u003cem>p\u003c/em> &#x0003c; 0.01; and solid outline, \u003cem>p\u003c/em> &#x0003c; 0.001). roi abbreviations: acbsh, nucleus accumbens shell; amg, amygdala; drn, dorsal raphe nucleus; hpcfi, fimbria hippocampi; insc, insular cortex; lc, locus coeruleus; m1, primary motor cortex; mpfc/cg, medial prefrontal, cingulate cortex; pir, piriform (entorhinal) cortex; prh, perirhinal cortex; s1, primary somatosensory cortex; sn, substantia nigra; th, thalamus; vc, visual cortex.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h4-5\" name=\"h4-5\">\u003c/a>\u003ch3 class=\"pt0\">3.5 pharmacological mri signature in rats\u003c/h3>\u003cp class=\"mb0\">the purpose of this study was to evaluate the effects of alogabat on regional neural activity. blood perfusion, measured quantitatively by phmri, was taken as a proxy for neural activity. the administration of a single dose of alogabat at 3&#x02013;30&#x000a0;mg/kg i.p. in rats resulted in moderate but consistent and dose-dependent changes in neural activity patterns compared to treatment with the vehicle (\u003ca href=\"#f2\">figure 2c\u003c/a>). significant dose-dependent modulation of normalized perfusion by alogabat was observed in limbic brain regions, i.e., the nucleus accumbens (shell), amygdala, and hippocampus (fimbria); in several cortical brain regions, the thalamus and brainstem nuclei; and in the substantia nigra (\u003ca href=\"#f2\">figure 2d\u003c/a>). a linear dose effect was also observed on whole-brain absolute perfusion. alogabat target engagement in brain tissue ranged from 54% to 84% ro.\u003c/p>\u003ca id=\"h4-6\" name=\"h4-6\">\u003c/a>\u003ch3 class=\"pt0\">3.6 eeg signature in rats\u003c/h3>\u003cp class=\"mb0\">the aim of this study was to determine whether alogabat induces a characteristic eeg signature that could be used as a translational pharmacodynamic marker. as a first step and based on previous findings on the eeg effects of gaba\u003csub>a\u003c/sub> drugs (\u003ca href=\"#b71\">van lier et al., 2004\u003c/a>; \u003ca href=\"#b72\">visser et al., 2003\u003c/a>; \u003ca href=\"#b22\">friedman et al., 1992\u003c/a>), we investigated eeg spectral power change in the theta (6&#x02013;10&#x000a0;hz) and beta (20&#x02013;30&#x000a0;hz) frequency bands. alogabat, administered as 10&#x000a0;mg/kg i.v. (5&#x000a0;min infusion), significantly increased eeg beta-band activity by 21% &#x000b1; 11% relative to the baseline (mean &#x000b1; sd) and decreased theta-band activity by 32% &#x000b1; 19% (\u003ca href=\"#f3\">figures 3a,b\u003c/a>). frequency-resolved changes confirmed a decrease in theta power (approximately 6&#x02013;10&#x000a0;hz) and revealed broader beta and gamma modulation (approximately 20&#x02013;50&#x000a0;hz) (\u003ca href=\"#f3\">figures 3c&#x02013;e\u003c/a>). the calculated ro after the application of alogabat was 77%&#x02013;85% for gaba\u003csub>a\u003c/sub>-&#x003b1;5 (see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). the overall spectral pattern was qualitatively similar to that of diazepam; however, the peak frequency in the beta frequency range was higher for alogabat (32&#x000a0;hz for alogabat vs. 22.6&#x000a0;hz for diazepam; \u003cem>p\u003c/em> &#x0003d; 0.006, random permutation test), and its amplitude was greater for diazepam (142% &#x000b1; 44% increase for diazepam vs. 27% &#x000b1; 16% increase for alogabat; \u003cem>p\u003c/em> &#x0003c; 0.001). this is likely related to the high binding and functional selectivity of alogabat for &#x003b1;5-containing gaba\u003csub>a\u003c/sub> receptors compared to the non-selective profile of diazepam.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 3\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" name=\"figure3\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" alt=\"www.frontiersin.org\" id=\"f3\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 3\u003c/b>. pharmacodynamic effect of alogabat on eeg spectral power. \u003cb>(a,b)\u003c/b> modulations of vehicle (\u003cem>n\u003c/em> &#x0003d; 12), alogabat 10&#x000a0;mg/kg (\u003cem>n\u003c/em> &#x0003d; 9), and diazepam 2&#x000a0;mg/kg (\u003cem>n\u003c/em> &#x0003d; 7, positive control) in the beta (20&#x02013;30&#x000a0;hz) and theta (6&#x02013;10&#x000a0;hz) power. \u003cb>(c&#x02013;e)\u003c/b> effects of individual compounds and vehicle on the eeg power spectrum. each individual recording is displayed as a light gray line, and the group average and its 95% confidence intervals are shown as colored bands. for all panels, power averaged over 0.2&#x02013;1&#x000a0;h post dosing is shown relative to pre-dosing baseline average over &#x02212;1 to &#x02212;0.2&#x000a0;h before dosing. statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05 versus vehicle (linear mixed-effects models followed by t-tests).\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h4-7\" name=\"h4-7\">\u003c/a>\u003ch3 class=\"pt0\">3.7 repetitive behaviors in mouse models relevant to asd\u003c/h3>\u003cp class=\"mb0\">the inbred mouse strain btbr and the cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mouse show abnormalities in core asd behavioral domains, such as repetitive behaviors. self-grooming and digging are more elevated in the btbr mouse than in other strains, i.e., c57bl/6j (\u003ca href=\"#b40\">mcfarlane et al., 2008\u003c/a>), and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice show more elevated grooming than their wildtype littermates (\u003ca href=\"#b51\">penagarikano et al., 2011\u003c/a>). the aim of the following experiments was to determine whether alogabat has a specific effect on repetitive behaviors independent of potential effects on overall locomotor activity. we assessed the effects of subchronic treatment on cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice to exclude potential tolerance to the effects of alogabat.\u003c/p>\u003ca id=\"h8-7-1\" name=\"h8-7-1\">\u003c/a>\u003ch4>3.7.1 open field in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h4>\u003cp class=\"mb0\">in btbr mice, acute administration of alogabat (30&#x02013;120&#x000a0;mg/kg i.p.) had no effect on the total activity over 1&#x000a0;h measured in an open field [f(4,55) &#x0003d; 2.04], although during the first 10&#x000a0;min, alogabat at 90 and 120&#x000a0;mg/kg significantly reduced the distance traveled [f(4,55) &#x0003d; 9.623, \u003cem>p\u003c/em> &#x0003c; 0.001, \u003ca href=\"#f4\">figure 4a\u003c/a>]. there was also no effect of sub-chronic alogabat (30&#x02013;100&#x000a0;mg/kg i.p.) on the total activity over 1&#x000a0;h in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice [f(3,53) &#x0003d; 0.98]. during the first 5&#x000a0;min, 100&#x000a0;mg/kg reduced the distance traveled in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice to the same level as vehicle-treated wildtype mice (\u003ca href=\"#f4\">figure 4b\u003c/a>). alogabat did not induce a major impairment of locomotor activity in the open field.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 4\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" name=\"figure4\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" alt=\"www.frontiersin.org\" id=\"f4\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 4\u003c/b>. effect of alogabat on repetitive behaviors in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. \u003cb>(a)\u003c/b> alogabat was administered i.p. 30&#x000a0;min prior to the assessment of locomotor activity in an open-field test in btbr mice: distance traveled (cm) per 5&#x000a0;min time bin (\u003cem>line graph\u003c/em>) and in 1&#x000a0;h total (\u003cem>bar chart inset\u003c/em>). \u003cb>(b)\u003c/b> alogabat was administered i.p. once daily for 2&#x02013;3&#x000a0;days, and on the test day, it was administered 30&#x000a0;min prior to testing cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice in an open field: distance traveled (cm) per 5&#x000a0;min time bin (\u003cem>line graph\u003c/em>) and in 1&#x000a0;h total (\u003cem>bar chart insert\u003c/em>). in btbr mice, on a separate test day, alogabat was administered i.p. 30&#x000a0;min prior to the grooming test: \u003cb>(c)\u003c/b> duration (s) of grooming behavior and \u003cb>(e)\u003c/b> distance (cm) traveled during the 10&#x000a0;min period in the test chamber. in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice, alogabat was administered i.p. once daily for 8&#x02013;10&#x000a0;days, and on the test day, it was administered 30&#x000a0;min prior to the grooming test: \u003cb>(d)\u003c/b> duration (s) of grooming behavior and \u003cb>(f)\u003c/b> distance traveled during the 10&#x000a0;min period in the test chamber. data are presented as individual points (circles) and mean &#x000b1; sem (btbr: \u003cem>n\u003c/em> &#x0003d; 12/group; cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup>: \u003cem>n\u003c/em> &#x0003d; 14&#x02013;15/group). statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. vehicle (veh)-treated btbr or cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. &#x000a7;&#x000a7;&#x000a7;\u003cem>p\u003c/em> &#x0003c; 0.001 vehicle-treated wildtype (wt-v) mice vs. vehicle (v)-treated cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. alogabat was administered i.p. 30&#x000a0;min prior to the assessment of digging behavior in btbr mice: \u003cb>(g)\u003c/b> duration (s) of digging behavior, \u003cb>(h)\u003c/b> distance traveled (cm), and \u003cb>(i)\u003c/b> speed (cm/s) during the 5&#x000a0;min period in the test chamber. data are presented as individual points (circles) and mean &#x000b1; sem (\u003cem>n\u003c/em> &#x0003d; 12/group). statistics: &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01 and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. vehicle-treated btbr mice. ro is the calculated receptor occupancy for gaba\u003csub>a\u003c/sub>-&#x003b1;5 from the measured plasma concentrations at each dose.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h8-7-2\" name=\"h8-7-2\">\u003c/a>\u003ch4>3.7.2 grooming behavior in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h4>\u003cp class=\"mb0\">acute administration of alogabat in btbr mice dose-dependently attenuated grooming behavior at 60, 90, and 120&#x000a0;mg/kg i.p. [f(4,55) &#x0003d; 6.946, \u003cem>p\u003c/em> &#x0003d; 0.0001, \u003ca href=\"#f4\">figure 4c\u003c/a>] without reducing locomotor activity in the same test arena (\u003ca href=\"#f4\">figure 4e\u003c/a>). in contrast, doses of 60 and 90&#x000a0;mg/kg increased the distance traveled [f(4,55) &#x0003d; 3.454, \u003cem>p\u003c/em> &#x0003c; 0.05]. alogabat had a specific effect on grooming behavior at plasma concentrations corresponding to calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 45%&#x02013;70% (see \u003ca href=\"#sm1\">supplementary table s4\u003c/a>).\u003c/p>\u003cp class=\"mb0\">sub-chronic administration of alogabat in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice attenuated grooming behavior at 60 and 100&#x000a0;mg/kg i.p. [f(3,53) &#x0003d; 10.57, \u003cem>p\u003c/em> &#x0003c; 0.0001, \u003ca href=\"#f4\">figure 4d\u003c/a>], with no effect on locomotor activity measured in the same test arena [f(3,53) &#x0003d; 0.74, \u003ca href=\"#f4\">figure 4f\u003c/a>]. alogabat had a specific effect on repetitive grooming behavior at plasma concentrations that correspond with calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro of 52%&#x02013;79% (see \u003ca href=\"#sm1\">supplementary table s4\u003c/a>).\u003c/p>\u003ca id=\"h8-7-3\" name=\"h8-7-3\">\u003c/a>\u003ch4>3.7.3 digging behavior in btbr mice\u003c/h4>\u003cp class=\"mb0\">there was no effect of acute alogabat administration on digging behavior at doses up to 100&#x000a0;mg/kg i.p. [f(3,36) &#x0003d; 0.8, \u003ca href=\"#f4\">figure 4g\u003c/a>], corresponding to a calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro level of 67% (see \u003ca href=\"#sm1\">supplementary table s4\u003c/a>). alogabat at 100&#x000a0;mg/kg reduced the distance traveled [f(3,36) &#x0003d; 12.1, \u003cem>p\u003c/em> &#x0003c; 0.001, \u003ca href=\"#f4\">figure 4h\u003c/a>] and speed [f(3,36) &#x0003d; 11.5, \u003cem>p\u003c/em> &#x0003c; 0.001, \u003ca href=\"#f4\">figure 4i\u003c/a>] in the same arena.\u003c/p>\u003ca id=\"h4-8\" name=\"h4-8\">\u003c/a>\u003ch3 class=\"pt0\">3.8 anticonvulsant activity in rats\u003c/h3>\u003cp class=\"mb0\">the purpose of these experiments was to evaluate the antiepileptic properties of alogabat against seizures induced by ptz and the mes model. alogabat administered in combination with a convulsant dose of ptz completely blocked seizures at 15 and 30&#x000a0;mg/kg (\u003ca href=\"#f5\">figure 5a\u003c/a>), which corresponds to calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 71% and 77% (see \u003ca href=\"#sm1\">supplementary table s5\u003c/a>). meanwhile, in the mes test, alogabat at 5&#x000a0;mg/kg (57% ro, see \u003ca href=\"#sm1\">supplementary table s5\u003c/a>) showed a significant reduction in the percent of rats that had tonic seizures (\u003ca href=\"#f5\">figure 5b\u003c/a>); there was only a tendency for reduction at 15&#x000a0;mg/kg (\u003cem>p\u003c/em> &#x0003d; 0.1) and 30&#x000a0;mg/kg (\u003cem>p\u003c/em> &#x0003d; 0.06). the positive control, diazepam, significantly reduced the percentage of rats that had seizures in both the ptz and mes tests.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 5\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" name=\"figure5\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" alt=\"www.frontiersin.org\" id=\"f5\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 5\u003c/b>. evaluation of alogabat for effects on anticonvulsant, motor, and cognitive tests. alogabat was administered p.o. 60&#x000a0;min prior to the following behavior tests. assessment of potential anticonvulsant activity in \u003cb>(a)\u003c/b> ptz and \u003cb>(b)\u003c/b> mes tests in rats. diazepam (dzp) at 3&#x000a0;mg/kg i.p. was included as a positive control. data are presented as individual points (circles) and the percentage of rats per group showing seizures (\u003cem>n\u003c/em> &#x0003d; 8/group). \u003cb>(c)\u003c/b> time (s) spent on the rotarod at 16&#x000a0;rpm in rats administered alogabat alone (30&#x000a0;mg/kg, gray bar with black outline) or alogabat at 3, 10, and 30&#x000a0;mg/kg co-administered with diazepam at 5&#x000a0;mg/kg i.p. (gray bars with red outline) compared with vehicle (open bar) or diazepam (open bar with red outline). data are presented as individual points (circles) and median &#x000b1; interquartile range (n &#x0003d; 8/group). assessment of cognition in rats: \u003cb>(d)\u003c/b> attention in the 5-choice serial reaction time (5-csrt) task; \u003cb>(e)\u003c/b> sustained attention in the touchscreen continuous performance test (cpt); \u003cb>(f)\u003c/b> visual&#x02013;spatial memory in the touchscreen pal task. cfc at \u003cb>(g)\u003c/b> 10 and 30&#x000a0;mg/kg; \u003cb>(h)\u003c/b> 1, 3, and 10&#x000a0;mg/kg. spatial learning and memory in the mwm: alogabat was administered once daily for 11&#x000a0;days prior to the probe trial. \u003cb>(i)\u003c/b> percentage of distance traveled in all four quadrants: vehicle; 10&#x000a0;mg/kg; 30&#x000a0;mg/kg. data are presented as individual points (circles) and mean &#x000b1; sem for pal (\u003cem>n\u003c/em> &#x0003d; 12/dose; within-subjects), 5-csrt and cpt (\u003cem>n\u003c/em> &#x0003d; 11/dose, within-subjects), cfc (\u003cem>n\u003c/em> &#x0003d; 9&#x02013;10/group), and mwm (\u003cem>n\u003c/em> &#x0003d; 10/group). statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. vehicle (veh or 0)-treated rats; mwm statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. percentage of distance in the platform quadrant. ro is the calculated receptor occupancy of alogabat for gaba\u003csub>a\u003c/sub>-&#x003b1;5 from measured plasma concentrations at each dose.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h4-9\" name=\"h4-9\">\u003c/a>\u003ch3 class=\"pt0\">3.9 combination with diazepam on rotarod performance in rats\u003c/h3>\u003cp class=\"mb0\">classical benzodiazepines, such as diazepam, are known to induce sedation and ataxia, which can be measured by the rotarod task in rodents. the aim of this experiment was to determine whether alogabat affects rotarod performance when administered alone and, second, whether alogabat modulates the sedative/motor effect of diazepam on rotarod performance when given in combination. diazepam at 5&#x000a0;mg/kg i.p. significantly impaired rotarod performance. alogabat (3&#x02013;30&#x000a0;mg/kg p.o.) co-administered with diazepam did not worsen the effects of diazepam on rotarod performance (\u003ca href=\"#f5\">figure 5c\u003c/a>). alogabat administered alone at 30&#x000a0;mg/kg p.o. did not differ from vehicle-treated rats, corresponding to a calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro level of 88% (see \u003ca href=\"#sm1\">supplementary table s5\u003c/a>).\u003c/p>\u003ca id=\"h4-10\" name=\"h4-10\">\u003c/a>\u003ch3 class=\"pt0\">3.10 evaluation of cognition in rats\u003c/h3>\u003cp class=\"mb0\">since non-selective gaba\u003csub>a\u003c/sub> pams, such as diazepam, have been shown to impair cognition (\u003ca href=\"#b5\">ballard et al., 2005\u003c/a>), the aim of the following experiments was to study the potential effects of acute administration of alogabat on cognition in rats. this included attention in the 5-csrt task and associative (fear) memory in cfc. we also assessed visual&#x02013;spatial memory (pal task) and attention (cpt) in a touchscreen system, which provides a translational approach for assessing cognition (\u003ca href=\"#b34\">hvoslef-eide et al., 2016\u003c/a>). chronic treatment with alogabat was also assessed on spatial learning and memory in the mwm.\u003c/p>\u003cp class=\"mb0\">in the 5-csrt task, alogabat at 30&#x000a0;mg/kg induced a small but statistically significant reduction in percent correct (3%; within-subjects comparison; f(3,30) &#x0003d; 5.6, \u003cem>p\u003c/em> &#x0003c; 0.01; \u003ca href=\"#f5\">figure 5d\u003c/a>). however, alogabat did not impair attention in cpt (f(2,20) &#x0003d; 0.3; \u003ca href=\"#f5\">figure 5e\u003c/a>) or visual&#x02013;spatial memory in the pal task (f(2,22) &#x0003d; 2.6; \u003ca href=\"#f5\">figure 5f\u003c/a>).\u003c/p>\u003cp class=\"mb0\">in the cfc test, alogabat was administered before the acquisition session to determine whether there was an effect on learning the association between foot shock and the surrounding context. in the first experiment, alogabat impaired cfc at 10 and 30&#x000a0;mg/kg, corresponding to calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 75% and 81% (f(2,24) &#x0003d; 10.99, \u003cem>p\u003c/em> &#x0003c; 0.001; \u003ca href=\"#f5\">figure 5g\u003c/a>). a second experiment was undertaken to explore lower doses, and it showed that alogabat did not significantly impair cfc at 1, 3, and 10&#x000a0;mg/kg (f(3,36) &#x0003d; 0.9; \u003ca href=\"#f5\">figure 5h\u003c/a>), corresponding to the calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 35%, 56%, and 72%. this suggests that the dose of 10&#x000a0;mg/kg is approximately the threshold level for the impairment of cfc and is likely dependent on the level of ro achieved per subject.\u003c/p>\u003cp class=\"mb0\">in the mwm test, chronic administration of alogabat at 10 and 30&#x000a0;mg/kg did not significantly impair the acquisition of the hidden platform position (see \u003ca href=\"#sm1\">supplementary figure s2\u003c/a>). twenty-four hours later, the platform was removed, and the rats were allowed to swim in the maze for 60&#x000a0;s (probe trial) to assess memory-retention of the platform position. the groups receiving vehicle [f(3,27) &#x0003d; 8, \u003cem>p\u003c/em> &#x0003c; 0.001] and 10&#x000a0;mg/kg [f(3,27) &#x0003d; 7, \u003cem>p\u003c/em> &#x0003c; 0.01] had learned the spatial position of the platform, as shown by their preference for the platform quadrant (\u003ca href=\"#f5\">figure 5i\u003c/a>). however, rats that received 30&#x000a0;mg/kg alogabat showed impaired spatial memory of the platform position during the probe trial [f(3,27) &#x0003d; 3, p &#x0003d; 0.08; \u003ca href=\"#f5\">figure 5i\u003c/a>], and gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro was estimated to be 79%. in summary, alogabat impaired context and spatial memory at gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro above 70%.\u003c/p>\u003ca id=\"h5\" name=\"h5\">\u003c/a>\u003ch2>4 discussion\u003c/h2>\u003ca id=\"h5-1\" name=\"h5-1\">\u003c/a>\u003ch3 class=\"pt0\">4.1 \u003cem>in vitro\u003c/em> and \u003cem>in vivo\u003c/em> characterization of alogabat\u003c/h3>\u003cp class=\"mb0\">alogabat was shown to be a potent and functionally selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor pam \u003cem>in vitro\u003c/em>. the functional activity of alogabat was confirmed at native gaba\u003csub>a\u003c/sub> receptors in rat hippocampal slices. \u003cem>in vivo\u003c/em> binding experiments demonstrated dose-dependent target engagement of alogabat in rats and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. the highest specific binding was observed in the hippocampus, which is consistent with the known distribution of the gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor subtype in rodents (\u003ca href=\"#b54\">pirker et al., 2000\u003c/a>). phmri studies in rats demonstrated dose-dependent perfusion changes, indicating circuit modulation by alogabat. there were consistent changes in the neural activity pattern across dose groups, with modulation of neural activity in, among others, the medial prefrontal cortex, cingulate cortex, motor cortex, perirhinal cortex, nucleus accumbens shell, amygdala, hippocampus fimbria, and substantia nigra.\u003c/p>\u003ca id=\"h5-2\" name=\"h5-2\">\u003c/a>\u003ch3 class=\"pt0\">4.2 eeg signature\u003c/h3>\u003cp class=\"mb0\">acute administration of alogabat in rats induced an eeg signature characterized by a power decrease in theta and an increase in the beta frequency range, which was qualitatively similar to the eeg signature of non-selective gaba\u003csub>a\u003c/sub> pams such as diazepam (\u003ca href=\"#b71\">van lier et al., 2004\u003c/a>; \u003ca href=\"#b72\">visser et al., 2003\u003c/a>; \u003ca href=\"#b22\">friedman et al., 1992\u003c/a>). the lower magnitude of induced eeg beta-band power by alogabat compared to diazepam is likely attributed to its &#x003b1;5-selectivity, resulting in an overall lower magnitude of gaba\u003csub>a\u003c/sub> receptor modulation. this eeg signature of alogabat is qualitatively a mirror image of the eeg signature of basmisanil, a highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 negative allosteric modulator (nam), which we recently found to induce an increase in the theta power and a decrease in the beta-band eeg power in healthy volunteers (\u003ca href=\"#b31\">hipp et al., 2021\u003c/a>). furthermore, the eeg signature of alogabat is in agreement with the link between beta-band activity and single-nucleotide polymorphisms (snps) in gaba\u003csub>a\u003c/sub> receptor genes (\u003ca href=\"#b56\">porjesz et al., 2002\u003c/a>; \u003ca href=\"#b67\">smit et al., 2018\u003c/a>) and ndds (dup15q syndrome, as) involving gene copy number variations of \u003cem>gabrb3, gabra5\u003c/em>, and \u003cem>gabrg3\u003c/em> (\u003ca href=\"#b24\">frohlich et al., 2019a\u003c/a>; \u003ca href=\"#b25\">frohlich et al., 2019b\u003c/a>). gaba\u003csub>a\u003c/sub> receptor-related changes in beta-band activity are believed to reflect the modulation of recurrent excitatory&#x02013;inhibitory feedback loops in the cortical tissue (\u003ca href=\"#b75\">whittington et al., 2000\u003c/a>; \u003ca href=\"#b70\">traub and jefferys, 1999\u003c/a>). for the administered doses, the calculated receptor occupancies were in the range of 77%&#x02013;84% for &#x003b1;5-containing receptors and 22%&#x02013;34% for &#x003b1;1-containing receptors (with different pam effects (e\u003csub>max\u003c/sub>) at &#x003b1;5 vs. &#x003b1;1). thus, at the studied doses, alogabat has some effect on &#x003b1;1-containing receptors, and further work is needed to systematically study lower doses of alogabat, including those &#x0003c;70% ro without the impairment of cognition in wt rats, to confirm whether the modulation of &#x003b1;5-containing receptors alone is sufficient to induce the described eeg effect. nonetheless, eeg theta- and beta-band power are promising candidates for translational mechanistic biomarkers of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor function and could be used in the further development of alogabat.\u003c/p>\u003ca id=\"h5-3\" name=\"h5-3\">\u003c/a>\u003ch3 class=\"pt0\">4.3 behavioral effects of alogabat in animal models relevant to asd\u003c/h3>\u003cp class=\"mb0\">we assessed the effects of alogabat in two different mouse models relevant to asd, one phenotypic and one genetic. acute administration of alogabat significantly and dose-dependently attenuated excessive grooming, but not digging, behavior in btbr mice. sub-chronic administration of alogabat significantly attenuated elevated grooming behavior in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. efficacy in these different models was linked to gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro above 50%. despite initial findings of a transiently decreased activity in an open-field test, alogabat increased the activity of btbr mice and had no effect on the activity of cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice during the grooming test, supporting the specific effect of alogabat on repetitive grooming. we have tested additional compounds with similar properties, e.g., ro7015738, and have confirmed that gaba\u003csub>a\u003c/sub>-&#x003b1;5 pams reduce repetitive behaviors in these mouse models (\u003ca href=\"#b10\">buettelmann et al., 2018\u003c/a>). these results align well with recently published data showing that gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor deficiency causes autism-like behaviors in mice, including increased grooming and reduced social contacts (\u003ca href=\"#b77\">zurek et al., 2016\u003c/a>), and with sh-053-2&#x02032;f-r-ch3, a gaba\u003csub>a\u003c/sub>-&#x003b1;5 pam, which was recently shown to have positive effects on social and cognitive deficits in a rat model of autism (\u003ca href=\"#b68\">souza et al., 2024\u003c/a>). our data are valuable in providing information on the ro required for \u003cem>in vivo\u003c/em> effects on repetitive behavior. however, it should be noted that this effect may not directly translate to all individuals with asd as it is a heterogeneous disorder, whereas these mouse models exhibit specific genetic or phenotypic deficits.\u003c/p>\u003ca id=\"h5-4\" name=\"h5-4\">\u003c/a>\u003ch3 class=\"pt0\">4.4 anticonvulsant effects of alogabat\u003c/h3>\u003cp class=\"mb0\">it has been proposed that the reduction of gabaergic inhibitory activity results in hyperexcitability of minicolumn circuits, explaining some of the symptomatology observed in some ndds, including the high incidence of seizures and auditory&#x02013;tactile hypersensitivity (\u003ca href=\"#b60\">rubenstein and merzenich, 2003\u003c/a>; \u003ca href=\"#b26\">frye et al., 2016\u003c/a>). in the current study, we demonstrated that alogabat exhibits an anticonvulsant profile with activity comparable to the benzodiazepine drug class in acutely induced seizure models (electrical and chemical). alogabat had a small effect on seizures in the mes test, whereas in the ptz test, alogabat was shown to completely block seizures at calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro &#x0003e;70%. since ptz is a gaba\u003csub>a\u003c/sub> antagonist, this supports the assessment of alogabat for anticonvulsant activity in disorders where there is dysfunction of the gabaergic system. furthermore, in a separate eeg study, we observed that one out of eight rats had frequent spike-and-wave discharge (swd) activity, which was alleviated following treatment with alogabat (see \u003ca href=\"#sm1\">supplementary figures s3a&#x02013;s3c\u003c/a>; methods in \u003ca href=\"#sm1\">supplementary material\u003c/a>). to better understand the temporal dynamics of swd occurrence and the suppressing effect of alogabat, we performed a follow-up study on three additional rats that showed pronounced swd. both 3 and 10&#x000a0;mg/kg alogabat substantially reduced the number of swds within the first 3&#x000a0;h of recording, when the same rats showed increased swd numbers in the vehicle control condition (see \u003ca href=\"#sm1\">supplementary figures s3d&#x02013;s3f\u003c/a>), which corresponds to the calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro level of 30%&#x02013;46% (see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). from a circuit perspective, the consensus is that such epileptic activity is generated by dysregulated thalamocortical circuitry, with abnormal interactions between reticular thalamic neurons and thalamic relay cells acting as the trigger and cortical circuits serving as the generator (\u003ca href=\"#b66\">sitnikova et al., 2023\u003c/a>). considering that in rats, &#x003b1;5-subunit-containing gaba\u003csub>a\u003c/sub> receptors are enriched in the cortex and hippocampus (\u003ca href=\"#b64\">serwanski et al., 2006\u003c/a>; \u003ca href=\"#b33\">hu et al., 2019\u003c/a>), mediating dendritic inhibition on pyramidal neurons (\u003ca href=\"#b2\">ali and thomson, 2008\u003c/a>; \u003ca href=\"#b62\">schulz et al., 2018\u003c/a>), we hypothesize that alogabat could suppress swd generation by enhancing the inhibition of cortical pyramidal neurons. however, more systematic work is required to confirm that alogabat can prevent swd activity.\u003c/p>\u003ca id=\"h5-5\" name=\"h5-5\">\u003c/a>\u003ch3 class=\"pt0\">4.5 assessment of non-specific behavioral effects\u003c/h3>\u003cp class=\"mb0\">non-selective gaba\u003csub>a\u003c/sub> pams, such as diazepam and chlordiazepoxide, are effective anxiolytics in clinical use but have also been shown to impair cognition in rodents and humans. gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors are believed to play a major role in cognition since they are predominantly expressed in the hippocampus in rats, where they regulate nmdar-dependent synaptic plasticity underlying learning and memory processes (\u003ca href=\"#b62\">schulz et al., 2018\u003c/a>; \u003ca href=\"#b23\">fritschy et al., 1997\u003c/a>; \u003ca href=\"#b63\">schulz et al., 2019\u003c/a>; \u003ca href=\"#b14\">davenport et al., 2021\u003c/a>). moreover, it has been proposed that gaba\u003csub>a\u003c/sub> pams may induce memory impairment by modulating hippocampal function (\u003ca href=\"#b41\">mcnaughton and morris, 1987\u003c/a>). therefore, alogabat was evaluated in several rodent tests of cognition to determine whether a selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 pam would induce cognitive impairment following acute administration in rats. there was no effect of alogabat up to 70% gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro on cognition (visual&#x02013;spatial memory, attention, context fear conditioning, spatial learning, and memory). cognitive impairment was only observed at high doses (&#x0003e;70% ro) and supra-therapeutic levels of alogabat in associative (fear) learning (cfc) and spatial memory in the mwm in wildtype rats. the impairment at high doses is likely linked to the loss of selectivity toward gaba\u003csub>a\u003c/sub> &#x003b1;1, &#x003b1;2, and &#x003b1;3 receptor subtypes (&#x003b1;1 ro was calculated as 19%&#x02013;25% at these doses; see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). in addition to the loss of selectivity, we cannot exclude the possibility that these effects may be a consequence of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor saturation, i.e., excessive &#x003b1;5 activity in wildtype subjects may be detrimental. the cognitive impairment observed in wildtype rats may translate to healthy human subjects; however, our focus is on the effect of &#x003b1;5 pams in disease conditions with impaired gaba\u003csub>a\u003c/sub> signaling and impaired cognition, where our hypothesis is that an &#x003b1;5 pam would have beneficial effects.\u003c/p>\u003cp class=\"mb0\">alogabat had no effect on social approach/avoidance, the elevated plus maze, and the vogel conflict test in rats at ro levels up to 80% (see \u003ca href=\"#sm1\">supplementary figure s4\u003c/a> and methods in \u003ca href=\"#sm1\">supplementary material\u003c/a>), suggesting that alogabat does not exhibit an anxiolytic-like effect in rodents. this might be explained by the low expression of gaba\u003csub>a\u003c/sub>-&#x003b1;5 in the amygdala, a key node controlling anxiety-like behaviors. potential anxiolytic effects of alogabat in humans cannot be excluded as this receptor subtype is much more abundant in the human amygdala. since benzodiazepines, such as diazepam, are frequently used to treat anxiety and seizures in ndds, it was important to establish that alogabat at relevant therapeutic doses in mouse models did not worsen the sedative/motor-impairing effects of diazepam in the rotarod test. alogabat did not worsen diazepam-induced motor impairment; on the contrary, in combination, it reduced the motor impairments, which is more likely due to the more localized and precise inhibitory effect, counterbalancing the broader suppression of neuronal activity by diazepam, or due to lower intrinsic activity at &#x003b1;1 receptors compared to diazepam. we have previously shown that a gaba\u003csub>a\u003c/sub>-&#x003b1;5 nam, which binds at the benzodiazepine binding site of the receptor, does not decrease the anxiolytic activity of chlordiazepoxide (see \u003ca href=\"#sm1\">supplementary figure s5\u003c/a>); therefore, it is unlikely that alogabat will interfere with the anxiolytic effect of the classical benzodiazepines.\u003c/p>\u003ca id=\"h6\" name=\"h6\">\u003c/a>\u003ch2>5 conclusion\u003c/h2>\u003cp class=\"mb15\">multiple lines of evidence point to deficits in gabaergic signaling in epilepsy and ndds, such as asd and deletion as, with a prominent role attributed to gaba\u003csub>a\u003c/sub> receptors, including the gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor subtype. the current data for alogabat showed robust dose-dependent efficacy on repetitive behaviors in two disease-relevant mouse models and anti-seizure activity in the ptz rat model at gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro above 50%. our \u003cem>in vivo\u003c/em> occupancy measurements using the selective &#x003b1;5 tracer l-655,708 were highly valuable for understanding plasma and csf exposures (as a surrogate of free brain concentration) and their relationship to \u003cem>in vivo\u003c/em> effects. we observed that there was a 34-fold shift between the csf concentration of alogabat in the \u003cem>in vivo\u003c/em> occupancy study and that of alogabat \u003cem>in vitro\u003c/em> binding data (ki value). the receptor occupancy of alogabat correlates well with pd effects (\u003cem>in vivo\u003c/em> effects) and is consistent across the different studies/species (see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). this finding highlights the importance of using pet tracers in drug development.\u003c/p>\u003cp class=\"mb15\">our data suggest that gaba\u003csub>a\u003c/sub>-&#x003b1;5 pams may have potential benefits in individuals with autistic features and in conditions with clinical and nonclinical manifestations of cortical hyperexcitability and epilepsy. however, alogabat is unlikely to work across all ndds and should be utilized as a precision medicine to target a specific subgroup of the ndd population with deficient gaba\u003csub>a\u003c/sub> pathway signaling, or specifically gaba\u003csub>a\u003c/sub>-&#x003b1;5. interestingly, recent data suggest that gaba\u003csub>a\u003c/sub>-&#x003b1;5 pams may also have therapeutic potential in schizophrenia, alzheimer&#x02019;s disease, and depression (\u003ca href=\"#b53\">perez et al., 2023\u003c/a>; \u003ca href=\"#b39\">luscher et al., 2023\u003c/a>; \u003ca href=\"#b36\">koh et al., 2013\u003c/a>). with regard to the current status of alogabat, good-laboratory practice (glp) toxicology and safety pharmacology studies in rats and minipigs showed an overall benign safety profile, which supported its clinical investigations in phase-1 studies in healthy volunteers and phase-2 trials in asd and deletion as patients (nct03507569, nct03774576, nct03847987, nct04299464, nct05630066, and eudract&#x00023;2019-003524-20). the outcome of these studies, including pet, eeg, and effects on cognition, will be reported in the future.\u003c/p>\u003ca id=\"h7\" name=\"h7\">\u003c/a>\u003ch2>data availability statement\u003c/h2>\u003cp class=\"mb15\">the original contributions presented in the study are included in the article/\u003ca href=\"#sm1\">supplementary material\u003c/a>, further inquiries can be directed to the corresponding author.\u003c/p>\u003ca id=\"h8\" name=\"h8\">\u003c/a>\u003ch2>ethics statement\u003c/h2>\u003cp class=\"mb0\">experiments performed at f. hoffmann-la roche ag (basel, switzerland) complied with swiss federal and cantonal laws on animal research and aaalac regulations and received prior approval from the cantonal veterinary office. the eeg study was conducted at brains online (ca, united states) in accordance with the guide for the care and use of laboratory animals (national research council 2011) after receiving approval from the institutional animal care and use committee. the ptz and mes tests were conducted at vivocore inc., canada, which is a facility licensed by the ontario ministry of agriculture, food, and rural affairs and accredited by the canadian council on animal care. all \u003cem>in vivo\u003c/em> studies are reported in compliance with the arrive guidelines (\u003ca href=\"#b52\">percie du sert et al., 2020\u003c/a>). the study was conducted in accordance with the local legislation and institutional requirements.\u003c/p>\u003ca id=\"h9\" name=\"h9\">\u003c/a>\u003ch2>author contributions\u003c/h2>\u003cp class=\"mb0\">gc: supervision, writing - original draft, investigation, formal analysis. tmb: formal analysis, investigation, writing - review and editing, methodology. fk: formal analysis, writing - original draft, investigation, methodology. mh: writing - original draft, investigation, methodology, formal analysis. jfh: data curation, visualization, methodology, writing - original draft, formal analysis. pg: methodology, data curation, formal analysis, writing - original draft. tm: investigation, writing - original draft, formal analysis, methodology. bk: investigation, writing - original draft, methodology, formal analysis. anb: formal analysis, writing - original draft, data curation. epp: writing - original draft, methodology, investigation. ps: methodology, investigation, writing - original draft, formal analysis. pj: writing - original draft, formal analysis. rr: methodology, writing - original draft, investigation, formal analysis. bb: methodology, investigation, writing - original draft. hk: methodology, writing - original draft, investigation. ao-m: writing - original draft, formal analysis, methodology. alb: methodology, writing - original draft, investigation. jms: investigation, formal analysis, writing - original draft. db: methodology, writing - original draft, investigation. ms: writing - original draft, methodology, investigation. eco&#x00027;c: investigation, writing - original draft, methodology. m-ch: investigation, conceptualization, writing - review and editing, supervision, writing - original draft, methodology.\u003c/p>\u003ca id=\"h10\" name=\"h10\">\u003c/a>\u003ch2>funding\u003c/h2>\u003cp class=\"mb0\">the author(s) declare that financial support was received for the research and/or publication of this article. the funding was provided by f. hoffmann-la roche ag switzerland.\u003c/p>\u003ca id=\"h11\" name=\"h11\">\u003c/a>\u003ch2>acknowledgments\u003c/h2>\u003cp class=\"mb03\">the authors thank gregoire friz, maria karg, and judith lengyel (molecular biology and binding assays); v&#x000e9;ronique graf, rachel haab, and marie-claire pflimlin (\u003cem>in vitro\u003c/em> electrophysiology); brigitte algeyer, severine bandinelli, sean durkin, audrey genet, marie haman, martine maco, and roger wyler (behavioral pharmacology); and stephanie sch&#x000f6;ppenthau, s&#x000e9;bastien debilly, and thomas bielser (\u003cem>in vivo\u003c/em> phmri). the rat ptz and mes studies were carried out under the scientific guidance of dr guy higgins, intervivo solutions, and coordinated by leo silenieks at vivocore inc., ontario, canada. the rat eeg data acquisition was undertaken by brains on-line llc, south san francisco, united states, and the data analysis was undertaken by pg, vanessa keeney, and andr&#x000e9;s olivares at roche.\u003c/p>\u003ca id=\"h12\" name=\"h12\">\u003c/a>\u003ch2>conflict of interest\u003c/h2>\u003cp class=\"mb0\">authors gc, tmb, fk, mh, jfh, pg, tm, bk, ab, epp, ps, pj, rr, bb, hk, ao-m, ab, jms, ms, eco&#x00027;c, and m-ch were employed by f. hoffmann-la roche ag switzerland. all employees (former and current) may be eligible for stock and stock options. author db was employed by hiqscreen s&#x000e0;rl.\u003c/p>\u003ca id=\"h13\" name=\"h13\">\u003c/a>\u003ch2>generative ai statement\u003c/h2>\u003cp class=\"mb15\">the author(s) declare that no generative ai was used in the creation of this manuscript.\u003c/p>\u003ca id=\"h14\" name=\"h14\">\u003c/a>\u003ch2>publisher&#x02019;s note\u003c/h2>\u003cp class=\"mb15\">all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.\u003c/p>\u003ca id=\"h15\" name=\"h15\">\u003c/a>\u003ch2>supplementary material\u003c/h2>\u003cp class=\"mb15\" id=\"sm1\">the supplementary material for this article can be found online at: \u003ca href=\"https://www.frontiersin.org/articles/10.3389/fphar.2025.1626078/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fphar.2025.1626078/full&#x00023;supplementary-material\u003c/a>\u003c/p>\u003ca id=\"h16\" name=\"h16\">\u003c/a>\u003ch2>abbreviations\u003c/h2>\u003cp class=\"mb15\">as, angelman syndrome; asd, autism spectrum disorder; cfc, context fear conditioning; cntnap2, contactin-associated protein-like 2; cpt, continuous performance test; 5-csrt, 5-choice serial reaction time; eeg, electroencephalography; gaba, gamma-aminobutyric acid; gad, glutamic acid decarboxylase; i.p., intraperitoneally; i.v., intravenously; lfp, local field potential; mes, maximum electrical stimulus; mwm, morris water maze; ndds, neurodevelopmental disorders; pal, paired associates learning; pam, positive allosteric modulator; phmri, pharmacological magnetic resonance imaging; p.o, per os; ptz, pentylenetetrazole; ro, receptor occupancy; pet, positron emission tomography.\u003c/p>\u003ca id=\"h17\" name=\"h17\">\u003c/a>\u003ch2>references\u003c/h2>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b1\" id=\"b1\">\u003c/a>abrahams, b. s., and geschwind, d. h. (2008). advances in autism genetics: on the threshold of a new neurobiology. \u003cem>nat. rev. genet.\u003c/em> 9, 341&#x02013;355. doi:10.1038/nrg2346\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/18414403/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nrg2346\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=advances+in+autism+genetics:+on+the+threshold+of+a+new+neurobiology&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b2\" id=\"b2\">\u003c/a>ali, a. b., and thomson, a. m. (2008). synaptic alpha 5 subunit-containing gabaa receptors mediate ipsps elicited by dendrite-preferring cells in rat neocortex. \u003cem>cereb. cortex\u003c/em> 18, 1260&#x02013;1271. doi:10.1093/cercor/bhm160\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17951598/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1093/cercor/bhm160\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=synaptic+alpha+5+subunit-containing+gabaa+receptors+mediate+ipsps+elicited+by+dendrite-preferring+cells+in+rat+neocortex&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\" style=\"margin-bottom:0.5em;\">\u003cp class=\"referencescopy1\">\u003ca name=\"b3\" id=\"b3\">\u003c/a>american psychiatric association (2008). \u003cem>diagnostic and statistical manual of mental disorders\u003c/em>. 5th ed. washington: \u003cspan class=\"publisher-name\">american psychiatric association\u003c/span>. \u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=american+psychiatric+association+%2c+diagnostic+and+statistical+manual+of+mental+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b4\" id=\"b4\">\u003c/a>ballard, t. m., knoflach, f., prinssen, e., borroni, e., vivian, j. a., basile, j., et al. (2009). ro4938581, a novel cognitive enhancer acting at gabaa alpha5 subunit-containing receptors. \u003cem>psychopharmacol. berl.\u003c/em> 202, 207&#x02013;223. doi:10.1007/s00213-008-1357-7\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/18936916/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1007/s00213-008-1357-7\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=ro4938581%2c+a+novel+cognitive+enhancer+acting+at+gabaa+alpha5+subunit-containing+receptors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b5\" id=\"b5\">\u003c/a>ballard, t. m., woolley, m. l., prinssen, e., huwyler, j., porter, r., and spooren, w. (2005). the effect of the mglu5 receptor antagonist mpep in rodent tests of anxiety and cognition: a comparison. \u003cem>psychopharmacol. berl.\u003c/em> 179, 218&#x02013;229. doi:10.1007/s00213-005-2211-9\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/15739074/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1007/s00213-005-2211-9\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+effect+of+the+mglu5+receptor+antagonist+mpep+in+rodent+tests+of+anxiety+and+cognition:+a+comparison&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b6\" id=\"b6\">\u003c/a>banerjee, a., garcia-oscos, f., roychowdhury, s., galindo, l. c., hall, s., kilgard, m. p., et al. (2013). impairment of cortical gabaergic synaptic transmission in an environmental rat model of autism. \u003cem>int. j. neuropsychopharmacol.\u003c/em> 16, 1309&#x02013;1318. doi:10.1017/s1461145712001216\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23228615/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1017/s1461145712001216\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=impairment+of+cortical+gabaergic+synaptic+transmission+in+an+environmental+rat+model+of+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b7\" id=\"b7\">\u003c/a>bourgeron, t. (2015). from the genetic architecture to synaptic plasticity in autism spectrum disorder. \u003cem>nat. rev. neurosci.\u003c/em> 16, 551&#x02013;563. doi:10.1038/nrn3992\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26289574/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nrn3992\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=from+the+genetic+architecture+to+synaptic+plasticity+in+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b8\" id=\"b8\">\u003c/a>braat, s., and kooy, r. f. (2015). the gabaa receptor as a therapeutic target for neurodevelopmental disorders. \u003cem>neuron\u003c/em> 86, 1119&#x02013;1130. doi:10.1016/j.neuron.2015.03.042\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26050032/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuron.2015.03.042\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+gabaa+receptor+as+a+therapeutic+target+for+neurodevelopmental+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b9\" id=\"b9\">\u003c/a>bruns, a., kunnecke, b., risterucci, c., moreau, j. l., and von kienlin, m. (2009). validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological mri in rats. \u003cem>magn. reson med.\u003c/em> 61, 1451&#x02013;1458. doi:10.1002/mrm.21779\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/19358231/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/mrm.21779\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=validation+of+cerebral+blood+perfusion+imaging+as+a+modality+for+quantitative+pharmacological+mri+in+rats&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\" style=\"margin-bottom:0.5em;\">\u003cp class=\"referencescopy1\">\u003ca name=\"b10\" id=\"b10\">\u003c/a>buettelmann, b., cecere, g., fasching, b., groebke zbinden, k., hernandez, m.-c., knust, h., et al. (2018). \u003cem>preparation of new isoxazolyl ether derivatives as gabaa &#x003b1;5 receptor positive allosteric modulators (pams)\u003c/em>. \u003cspan class=\"publisher-name\">copyright &#x000a9; 2025 american chemical society acs\u003c/span>. available online at: \u003ca href=\"https://worldwide.espacent.com/patent/search/family/057530563/publication/wo2018104419a1?q=wo2018104419a1\">https://worldwide.espacent.com/patent/search/family/057530563/publication/wo2018104419a1?q&#x0003d;wo2018104419a1\u003c/a>\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=â buettelmannâ bcecereâ gfaschingâ bgroebke+zbindenâ khernandezâ m-cknustâ het+al+2018+preparation+of+new+isoxazolyl+ether+derivatives+as+gabaa+î±5+receptor+positive+allosteric+modulators+pams+copyright+â©+2025+american+chemical+society+acs+available+online+at:+https://worldwideespacentcom/patent/search/family/057530563/publication/wo2018104419a1?q=wo2018104419a1&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b12\" id=\"b12\">\u003c/a>buiting, k. (2010). prader-willi syndrome and angelman syndrome. \u003cem>am. j. med. genet. c semin. med. genet.\u003c/em> 154c, 365&#x02013;376. doi:10.1002/ajmg.c.30273\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/20803659/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/ajmg.c.30273\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=prader-willi+syndrome+and+angelman+syndrome&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b13\" id=\"b13\">\u003c/a>chao, h. t., chen, h., samaco, r. c., xue, m., chahrour, m., yoo, j., et al. (2010). dysfunction in gaba signalling mediates autism-like stereotypies and rett syndrome phenotypes. \u003cem>nature\u003c/em> 468, 263&#x02013;269. doi:10.1038/nature09582\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21068835/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nature09582\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=dysfunction+in+gaba+signalling+mediates+autism-like+stereotypies+and+rett+syndrome+phenotypes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b14\" id=\"b14\">\u003c/a>davenport, c. m., rajappa, r., katchan, l., taylor, c. r., tsai, m. c., smith, c. m., et al. (2021). relocation of an extrasynaptic gaba(a) receptor to inhibitory synapses freezes excitatory synaptic strength and preserves memory. \u003cem>neuron\u003c/em> 109, 123&#x02013;134 e4. doi:10.1016/j.neuron.2020.09.037\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/33096025/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuron.2020.09.037\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=relocation+of+an+extrasynaptic+gabaa+receptor+to+inhibitory+synapses+freezes+excitatory+synaptic+strength+and+preserves+memory&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b15\" id=\"b15\">\u003c/a>delong, r. (2007). gaba(a) receptor alpha5 subunit as a candidate gene for autism and bipolar disorder: a proposed endophenotype with parent-of-origin and gain-of-function features,with or without oculocutaneous albinism. \u003cem>autism\u003c/em> 11, 135&#x02013;147. doi:10.1177/1362361307075705\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17353214/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1177/1362361307075705\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa+receptor+alpha5+subunit+as+a+candidate+gene+for+autism+and+bipolar+disorder:+a+proposed+endophenotype+with+parent-of-origin+and+gain-of-function+features%2cwith+or+without+oculocutaneous+albinism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b16\" id=\"b16\">\u003c/a>delorey, t. m. (2005). gabrb3 gene deficient mice: a potential model of autism spectrum disorder. \u003cem>int. rev. neurobiol.\u003c/em> 71, 359&#x02013;382. doi:10.1016/s0074-7742(05)71015-1\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/16512358/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0074-7742(05)71015-1\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabrb3+gene+deficient+mice:+a+potential+model+of+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b17\" id=\"b17\">\u003c/a>delorey, t. m., sahbaie, p., hashemi, e., homanics, g. e., and clark, j. d. (2008). gabrb3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: a potential model of autism spectrum disorder. \u003cem>behav. brain res.\u003c/em> 187, 207&#x02013;220. doi:10.1016/j.bbr.2007.09.009\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17983671/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.bbr.2007.09.009\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabrb3+gene+deficient+mice+exhibit+impaired+social+and+exploratory+behaviors%2c+deficits+in+non-selective+attention+and+hypoplasia+of+cerebellar+vermal+lobules:+a+potential+model+of+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b18\" id=\"b18\">\u003c/a>dhossche, d., applegate, h., abraham, a., maertens, p., bland, l., bencsath, a., et al. (2002). elevated plasma gamma-aminobutyric acid (gaba) levels in autistic youngsters: stimulus for a gaba hypothesis of autism. \u003cem>med. sci. monit.\u003c/em> 8, pr1&#x02013;pr6.\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/12165753/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=elevated+plasma+gamma-aminobutyric+acid+gaba+levels+in+autistic+youngsters:+stimulus+for+a+gaba+hypothesis+of+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b19\" id=\"b19\">\u003c/a>di nanni, n., bersanelli, m., cupaioli, f. a., milanesi, l., mezzelani, a., and mosca, e. (2019). network-based integrative analysis of genomics, epigenomics and transcriptomics in autism spectrum disorders. \u003cem>int. j. mol. sci.\u003c/em> 20, 3363. doi:10.3390/ijms20133363\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/31323926/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.3390/ijms20133363\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=network-based+integrative+analysis+of+genomics%2c+epigenomics+and+transcriptomics+in+autism+spectrum+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b20\" id=\"b20\">\u003c/a>dufour, b. d., mcbride, e., bartley, t., juarez, p., and martinez-cerdeno, v. (2023). distinct patterns of gabaergic interneuron pathology in autism are associated with intellectual impairment and stereotypic behaviors. \u003cem>autism\u003c/em> 27, 1730&#x02013;1745. doi:10.1177/13623613231154053\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/36935610/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1177/13623613231154053\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=distinct+patterns+of+gabaergic+interneuron+pathology+in+autism+are+associated+with+intellectual+impairment+and+stereotypic+behaviors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b21\" id=\"b21\">\u003c/a>fatemi, s. h., halt, a. r., stary, j. m., kanodia, r., schulz, s. c., and realmuto, g. r. (2002). glutamic acid decarboxylase 65 and 67 kda proteins are reduced in autistic parietal and cerebellar cortices. \u003cem>biol. psychiatry\u003c/em> 52, 805&#x02013;810. doi:10.1016/s0006-3223(02)01430-0\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/12372652/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0006-3223(02)01430-0\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=glutamic+acid+decarboxylase+65+and+67+kda+proteins+are+reduced+in+autistic+parietal+and+cerebellar+cortices&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b22\" id=\"b22\">\u003c/a>friedman, h., greenblatt, d. j., peters, g. r., metzler, c. m., charlton, m. d., harmatz, j. s., et al. (1992). pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. \u003cem>clin. pharmacol. ther.\u003c/em> 52, 139&#x02013;150. doi:10.1038/clpt.1992.123\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/1505149/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/clpt.1992.123\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=pharmacokinetics+and+pharmacodynamics+of+oral+diazepam:+effect+of+dose%2c+plasma+concentration%2c+and+time&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b23\" id=\"b23\">\u003c/a>fritschy, j. m., benke, d., johnson, d. k., mohler, h., and rudolph, u. (1997). gabaa-receptor alpha-subunit is an essential prerequisite for receptor formation \u003cem>in vivo\u003c/em>. \u003cem>neuroscience\u003c/em> 81, 1043&#x02013;1053. doi:10.1016/s0306-4522(97)00244-3\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/9330366/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0306-4522(97)00244-3\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa-receptor+alpha-subunit+is+an+essential+prerequisite+for+receptor+formation+in+vivo&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b24\" id=\"b24\">\u003c/a>frohlich, j., miller, m. t., bird, l. m., garces, p., purtell, h., hoener, m. c., et al. (2019a). electrophysiological phenotype in angelman syndrome differs between genotypes. \u003cem>biol. psychiatry\u003c/em> 85, 752&#x02013;759. doi:10.1016/j.biopsych.2019.01.008\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/30826071/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.biopsych.2019.01.008\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=electrophysiological+phenotype+in+angelman+syndrome+differs+between+genotypes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b25\" id=\"b25\">\u003c/a>frohlich, j., reiter, l. t., saravanapandian, v., distefano, c., huberty, s., hyde, c., et al. (2019b). mechanisms underlying the eeg biomarker in dup15q syndrome. \u003cem>mol. autism\u003c/em> 10, 29. doi:10.1186/s13229-019-0280-6\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/31312421/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1186/s13229-019-0280-6\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=mechanisms+underlying+the+eeg+biomarker+in+dup15q+syndrome&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b26\" id=\"b26\">\u003c/a>frye, r. e., casanova, m. f., fatemi, s. h., folsom, t. d., reutiman, t. j., brown, g. l., et al. (2016). neuropathological mechanisms of seizures in autism spectrum disorder. \u003cem>front. neurosci.\u003c/em> 10, 192. doi:10.3389/fnins.2016.00192\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27242398/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.3389/fnins.2016.00192\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=neuropathological+mechanisms+of+seizures+in+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b27\" id=\"b27\">\u003c/a>fukuda, t., itoh, m., ichikawa, t., washiyama, k., and goto, y. (2005). delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of mecp2-deficient mice. \u003cem>j. neuropathol. exp. neurol.\u003c/em> 64, 537&#x02013;544. doi:10.1093/jnen/64.6.537\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/15977646/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1093/jnen/64.6.537\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=delayed+maturation+of+neuronal+architecture+and+synaptogenesis+in+cerebral+cortex+of+mecp2-deficient+mice&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b28\" id=\"b28\">\u003c/a>gaetz, w., bloy, l., wang, d. j., port, r. g., blaskey, l., levy, s. e., et al. (2014). gaba estimation in the brains of children on the autism spectrum: measurement precision and regional cortical variation. \u003cem>neuroimage\u003c/em> 86, 1&#x02013;9. doi:10.1016/j.neuroimage.2013.05.068\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23707581/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuroimage.2013.05.068\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gaba+estimation+in+the+brains+of+children+on+the+autism+spectrum:+measurement+precision+and+regional+cortical+variation&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b29\" id=\"b29\">\u003c/a>han, s., tai, c., jones, c. j., scheuer, t., and catterall, w. a. (2014). enhancement of inhibitory neurotransmission by gabaa receptors having &#x003b1;2,3-subunits ameliorates behavioral deficits in a mouse model of autism. \u003cem>neuron\u003c/em> 81, 1282&#x02013;1289. doi:10.1016/j.neuron.2014.01.016\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/24656250/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuron.2014.01.016\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=enhancement+of+inhibitory+neurotransmission+by+gabaa+receptors+having+î±2%2c3-subunits+ameliorates+behavioral+deficits+in+a+mouse+model+of+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b30\" id=\"b30\">\u003c/a>han, s., tai, c., westenbroek, r. e., yu, f. h., cheah, c. s., potter, g. b., et al. (2012). autistic-like behaviour in scn1a&#x0002b;/- mice and rescue by enhanced gaba-mediated neurotransmission. \u003cem>nature\u003c/em> 489, 385&#x02013;390. doi:10.1038/nature11356\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22914087/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nature11356\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=autistic-like+behaviour+in+scn1a+/-+mice+and+rescue+by+enhanced+gaba-mediated+neurotransmission&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b31\" id=\"b31\">\u003c/a>hipp, j. f., knoflach, f., comley, r., ballard, t. m., honer, m., trube, g., et al. (2021). basmisanil, a highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man. \u003cem>sci. rep.\u003c/em> 11, 7700. doi:10.1038/s41598-021-87307-7\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/33833333/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/s41598-021-87307-7\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=basmisanil%2c+a+highly+selective+gabaa-î±5+negative+allosteric+modulator:+preclinical+pharmacology+and+demonstration+of+functional+target+engagement+in+man&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b32\" id=\"b32\">\u003c/a>hogart, a., wu, d., lasalle, j. m., and schanen, n. c. (2010). the comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. \u003cem>neurobiol. dis.\u003c/em> 38, 181&#x02013;191. doi:10.1016/j.nbd.2008.08.011\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/18840528/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.nbd.2008.08.011\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+comorbidity+of+autism+with+the+genomic+disorders+of+chromosome+15q112-q13&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b33\" id=\"b33\">\u003c/a>hu, x., rocco, b. r., fee, c., and sibille, e. (2019). cell type-specific gene expression of alpha 5 subunit-containing gamma-aminobutyric acid subtype a receptors in human and mouse frontal cortex. \u003cem>mol. neuropsychiatry\u003c/em> 4, 204&#x02013;215. doi:10.1159/000495840\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/30815456/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1159/000495840\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=cell+type-specific+gene+expression+of+alpha+5+subunit-containing+gamma-aminobutyric+acid+subtype+a+receptors+in+human+and+mouse+frontal+cortex&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b34\" id=\"b34\">\u003c/a>hvoslef-eide, m., nilsson, s. r., saksida, l. m., and bussey, t. j. (2016). cognitive translation using the rodent touchscreen testing approach. \u003cem>curr. top. behav. neurosci.\u003c/em> 28, 423&#x02013;447. doi:10.1007/7854_2015_5007\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27305921/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1007/7854_2015_5007\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=cognitive+translation+using+the+rodent+touchscreen+testing+approach&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b35\" id=\"b35\">\u003c/a>kalsner, l., and chamberlain, s. j. (2015). prader-willi, angelman, and 15q11-q13 duplication syndromes. \u003cem>pediatr. clin. north am.\u003c/em> 62, 587&#x02013;606. doi:10.1016/j.pcl.2015.03.004\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26022164/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.pcl.2015.03.004\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=prader-willi%2c+angelman%2c+and+15q11-q13+duplication+syndromes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b36\" id=\"b36\">\u003c/a>koh, m. t., rosenzweig-lipson, s., and gallagher, m. (2013). selective gaba(a) &#x003b1;5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. \u003cem>neuropharmacology\u003c/em> 64, 145&#x02013;152. doi:10.1016/j.neuropharm.2012.06.023\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22732440/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2012.06.023\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=selective+gabaa+î±5+positive+allosteric+modulators+improve+cognitive+function+in+aged+rats+with+memory+impairment&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b37\" id=\"b37\">\u003c/a>lim, c. s., kim, h., yu, n. k., kang, s. j., kim, t., ko, h. g., et al. (2017). enhancing inhibitory synaptic function reverses spatial memory deficits in shank2 mutant mice. \u003cem>neuropharmacology\u003c/em> 112, 104&#x02013;112. doi:10.1016/j.neuropharm.2016.08.016\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27544825/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2016.08.016\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=enhancing+inhibitory+synaptic+function+reverses+spatial+memory+deficits+in+shank2+mutant+mice&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b38\" id=\"b38\">\u003c/a>luk, h. m., and lo, i. f. (2016). angelman syndrome in hong kong chinese: a 20 years&#x00027; experience. \u003cem>eur. j. med. genet.\u003c/em> 59, 315&#x02013;319. doi:10.1016/j.ejmg.2016.05.003\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27174604/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.ejmg.2016.05.003\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=angelman+syndrome+in+hong+kong+chinese:+a+20+years'+experience&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b39\" id=\"b39\">\u003c/a>luscher, b., maguire, j. l., rudolph, u., and sibille, e. (2023). gaba(a) receptors as targets for treating affective and cognitive symptoms of depression. \u003cem>trends pharmacol. sci.\u003c/em> 44, 586&#x02013;600. doi:10.1016/j.tips.2023.06.009\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/37543478/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.tips.2023.06.009\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa+receptors+as+targets+for+treating+affective+and+cognitive+symptoms+of+depression&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b40\" id=\"b40\">\u003c/a>mcfarlane, h. g., kusek, g. k., yang, m., phoenix, j. l., bolivar, v. j., and crawley, j. n. (2008). autism-like behavioral phenotypes in btbr t&#x0002b;tf/j mice. \u003cem>genes brain behav.\u003c/em> 7, 152&#x02013;163. doi:10.1111/j.1601-183x.2007.00330.x\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17559418/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1111/j.1601-183x.2007.00330.x\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=autism-like+behavioral+phenotypes+in+btbr+t+tf/j+mice&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b41\" id=\"b41\">\u003c/a>mcnaughton, n., and morris, r. g. (1987). chlordiazepoxide, an anxiolytic benzodiazepine, impairs place navigation in rats. \u003cem>behav. brain res.\u003c/em> 24, 39&#x02013;46. doi:10.1016/0166-4328(87)90034-9\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/3580114/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/0166-4328(87)90034-9\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=chlordiazepoxide%2c+an+anxiolytic+benzodiazepine%2c+impairs+place+navigation+in+rats&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b42\" id=\"b42\">\u003c/a>mendez, m. a., horder, j., myers, j., coghlan, s., stokes, p., erritzoe, d., et al. (2013). the brain gaba-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)c]ro15-4513 positron emission tomography study. \u003cem>neuropharmacology\u003c/em> 68, 195&#x02013;201. doi:10.1016/j.neuropharm.2012.04.008\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22546616/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2012.04.008\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+brain+gaba-benzodiazepine+receptor+alpha-5+subtype+in+autism+spectrum+disorder:+a+pilot+%5b11c%5dro15-4513+positron+emission+tomography+study&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b43\" id=\"b43\">\u003c/a>mermer, f., poliquin, s., rigsby, k., rastogi, a., shen, w., romero-morales, a., et al. (2021). common molecular mechanisms of slc6a1 variant-mediated neurodevelopmental disorders in astrocytes and neurons. \u003cem>brain\u003c/em> 144, 2499&#x02013;2512. doi:10.1093/brain/awab207\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/34028503/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1093/brain/awab207\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=common+molecular+mechanisms+of+slc6a1+variant-mediated+neurodevelopmental+disorders+in+astrocytes+and+neurons&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b44\" id=\"b44\">\u003c/a>mertz, l. g., christensen, r., vogel, i., hertz, j. m., nielsen, k. b., gronskov, k., et al. (2013). angelman syndrome in denmark. birth incidence, genetic findings, and age at diagnosis. \u003cem>am. j. med. genet. a\u003c/em> 161a, 2197&#x02013;2203. doi:10.1002/ajmg.a.36058\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23913711/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/ajmg.a.36058\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=angelman+syndrome+in+denmark+birth+incidence%2c+genetic+findings%2c+and+age+at+diagnosis&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b45\" id=\"b45\">\u003c/a>mesbah-oskui, l., penna, a., orser, b. a., and horner, r. l. (2017). reduced expression of &#x003b1;5gaba\u003csub>a\u003c/sub> receptors elicits autism-like alterations in eeg patterns and sleep-wake behavior. \u003cem>neurotoxicol teratol.\u003c/em> 61, 115&#x02013;122. doi:10.1016/j.ntt.2016.10.009\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27793660/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.ntt.2016.10.009\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=reduced+expression+of+î±5gabaa+receptors+elicits+autism-like+alterations+in+eeg+patterns+and+sleep-wake+behavior&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b46\" id=\"b46\">\u003c/a>mohler, h. (2011). the rise of a new gaba pharmacology. \u003cem>neuropharmacology\u003c/em> 60, 1042&#x02013;1049. doi:10.1016/j.neuropharm.2010.10.020\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21035473/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2010.10.020\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+rise+of+a+new+gaba+pharmacology&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b47\" id=\"b47\">\u003c/a>mori, t., mori, k., fujii, e., toda, y., miyazaki, m., harada, m., et al. (2012). evaluation of the gabaergic nervous system in autistic brain: (123)i-iomazenil spect study. \u003cem>brain dev.\u003c/em> 34, 648&#x02013;654. doi:10.1016/j.braindev.2011.10.007\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22099869/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.braindev.2011.10.007\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=evaluation+of+the+gabaergic+nervous+system+in+autistic+brain:+123i-iomazenil+spect+study&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b48\" id=\"b48\">\u003c/a>myers, j. f., comley, r. a., and gunn, r. n. (2017). quantification of [\u003csup>11\u003c/sup>c]ro15-4513 gaba\u003csub>a\u003c/sub>&#x003b1;5 specific binding and regional selectivity in humans. \u003cem>j. cereb. blood flow. metab.\u003c/em> 37, 2137&#x02013;2148. doi:10.1177/0271678x16661339\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27466376/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1177/0271678x16661339\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=quantification+of+%5b11c%5dro15-4513+gabaaî±5+specific+binding+and+regional+selectivity+in+humans&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b49\" id=\"b49\">\u003c/a>nakamura, t., arima-yoshida, f., sakaue, f., nasu-nishimura, y., takeda, y., matsuura, k., et al. (2016). px-rics-deficient mice mimic autism spectrum disorder in jacobsen syndrome through impaired gabaa receptor trafficking. \u003cem>nat. commun.\u003c/em> 7, 10861. doi:10.1038/ncomms10861\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26979507/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/ncomms10861\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=px-rics-deficient+mice+mimic+autism+spectrum+disorder+in+jacobsen+syndrome+through+impaired+gabaa+receptor+trafficking&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b50\" id=\"b50\">\u003c/a>orefice, l. l., zimmerman, a. l., chirila, a. m., sleboda, s. j., head, j. p., and ginty, d. d. (2016). peripheral mechanosensory neuron dysfunction underlies tactile and behavioral deficits in mouse models of asds. \u003cem>cell\u003c/em> 166, 299&#x02013;313. doi:10.1016/j.cell.2016.05.033\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27293187/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.cell.2016.05.033\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=peripheral+mechanosensory+neuron+dysfunction+underlies+tactile+and+behavioral+deficits+in+mouse+models+of+asds&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b51\" id=\"b51\">\u003c/a>penagarikano, o., abrahams, b. s., herman, e. i., winden, k. d., gdalyahu, a., dong, h., et al. (2011). absence of cntnap2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. \u003cem>cell\u003c/em> 147, 235&#x02013;246. doi:10.1016/j.cell.2011.08.040\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21962519/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.cell.2011.08.040\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=absence+of+cntnap2+leads+to+epilepsy%2c+neuronal+migration+abnormalities%2c+and+core+autism-related+deficits&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b52\" id=\"b52\">\u003c/a>percie du sert, n., hurst, v., ahluwalia, a., alam, s., avey, m. t., baker, m., et al. (2020). the arrive guidelines 2.0: updated guidelines for reporting animal research. \u003cem>plos biol.\u003c/em> 18, e3000410. doi:10.1371/journal.pbio.3000410\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/32663219/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1371/journal.pbio.3000410\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+arrive+guidelines+20:+updated+guidelines+for+reporting+animal+research&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b53\" id=\"b53\">\u003c/a>perez, s. m., mccoy, a. m., prevot, t. d., mian, m. y., carreno, f. r., frazer, a., et al. (2023). hippocampal &#x003b1;5-gaba(a) receptors modulate dopamine neuron activity in the rat ventral tegmental area. \u003cem>biol. psychiatry glob. open sci.\u003c/em> 3, 78&#x02013;86. doi:10.1016/j.bpsgos.2021.12.010\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/36712569/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.bpsgos.2021.12.010\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=hippocampal+î±5-gabaa+receptors+modulate+dopamine+neuron+activity+in+the+rat+ventral+tegmental+area&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b54\" id=\"b54\">\u003c/a>pirker, s., schwarzer, c., wieselthaler, a., sieghart, w., and sperk, g. (2000). gaba(a) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. \u003cem>neuroscience\u003c/em> 101, 815&#x02013;850. doi:10.1016/s0306-4522(00)00442-5\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/11113332/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0306-4522(00)00442-5\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa+receptors:+immunocytochemical+distribution+of+13+subunits+in+the+adult+rat+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b55\" id=\"b55\">\u003c/a>pizzarelli, r., and cherubini, e. (2011). alterations of gabaergic signaling in autism spectrum disorders. \u003cem>neural plast.\u003c/em> 2011, 297153. doi:10.1155/2011/297153\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21766041/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1155/2011/297153\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=alterations+of+gabaergic+signaling+in+autism+spectrum+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b56\" id=\"b56\">\u003c/a>porjesz, b., almasy, l., edenberg, h. j., wang, k., chorlian, d. b., foroud, t., et al. (2002). linkage disequilibrium between the beta frequency of the human eeg and a gabaa receptor gene locus. \u003cem>proc. natl. acad. sci. u. s. a.\u003c/em> 99, 3729&#x02013;3733. doi:10.1073/pnas.052716399\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/11891318/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1073/pnas.052716399\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=linkage+disequilibrium+between+the+beta+frequency+of+the+human+eeg+and+a+gabaa+receptor+gene+locus&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b57\" id=\"b57\">\u003c/a>puts, n. a. j., wodka, e. l., harris, a. d., crocetti, d., tommerdahl, m., mostofsky, s. h., et al. (2017). reduced gaba and altered somatosensory function in children with autism spectrum disorder. \u003cem>autism res.\u003c/em> 10, 608&#x02013;619. doi:10.1002/aur.1691\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27611990/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/aur.1691\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=reduced+gaba+and+altered+somatosensory+function+in+children+with+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b58\" id=\"b58\">\u003c/a>robertson, c. e., ratai, e. m., and kanwisher, n. (2016). reduced gabaergic action in the autistic brain. \u003cem>curr. biol.\u003c/em> 26, 80&#x02013;85. doi:10.1016/j.cub.2015.11.019\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26711497/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.cub.2015.11.019\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=reduced+gabaergic+action+in+the+autistic+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b59\" id=\"b59\">\u003c/a>rojas, d. c., singel, d., steinmetz, s., hepburn, s., and brown, m. s. (2014). decreased left perisylvian gaba concentration in children with autism and unaffected siblings. \u003cem>neuroimage\u003c/em> 86, 28&#x02013;34. doi:10.1016/j.neuroimage.2013.01.045\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23370056/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuroimage.2013.01.045\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=decreased+left+perisylvian+gaba+concentration+in+children+with+autism+and+unaffected+siblings&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b60\" id=\"b60\">\u003c/a>rubenstein, j. l., and merzenich, m. m. (2003). model of autism: increased ratio of excitation/inhibition in key neural systems. \u003cem>genes brain behav.\u003c/em> 2, 255&#x02013;267. doi:10.1034/j.1601-183x.2003.00037.x\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/14606691/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1034/j.1601-183x.2003.00037.x\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=model+of+autism:+increased+ratio+of+excitation/inhibition+in+key+neural+systems&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b61\" id=\"b61\">\u003c/a>sanders, s. j. (2015). first glimpses of the neurobiology of autism spectrum disorder. \u003cem>curr. opin. genet. dev.\u003c/em> 33, 80&#x02013;92. doi:10.1016/j.gde.2015.10.002\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26547130/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.gde.2015.10.002\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=first+glimpses+of+the+neurobiology+of+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b62\" id=\"b62\">\u003c/a>schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2018). dendrite-targeting interneurons control synaptic nmda-receptor activation \u003cem>via\u003c/em> nonlinear &#x003b1;5-gaba\u003csub>a\u003c/sub> receptors. \u003cem>nat. commun.\u003c/em> 9, 3576. doi:10.1038/s41467-018-06004-8\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/30177704/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/s41467-018-06004-8\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=dendrite-targeting+interneurons+control+synaptic+nmda-receptor+activation+via+nonlinear+î±5-gabaa+receptors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b63\" id=\"b63\">\u003c/a>schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2019). enhanced dendritic inhibition and impaired nmdar activation in a mouse model of down syndrome. \u003cem>j. neurosci.\u003c/em> 39, 5210&#x02013;5221. doi:10.1523/jneurosci.2723-18.2019\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/31000585/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1523/jneurosci.2723-18.2019\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=enhanced+dendritic+inhibition+and+impaired+nmdar+activation+in+a+mouse+model+of+down+syndrome&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b64\" id=\"b64\">\u003c/a>serwanski, d. r., miralles, c. p., christie, s. b., mehta, a. k., li, x., and de blas, a. l. (2006). synaptic and nonsynaptic localization of gabaa receptors containing the alpha5 subunit in the rat brain. \u003cem>j. comp. neurol.\u003c/em> 499, 458&#x02013;470. doi:10.1002/cne.21115\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/16998906/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/cne.21115\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=synaptic+and+nonsynaptic+localization+of+gabaa+receptors+containing+the+alpha5+subunit+in+the+rat+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b65\" id=\"b65\">\u003c/a>sieghart, w. (2006). structure, pharmacology, and function of gabaa receptor subtypes. \u003cem>adv. pharmacol.\u003c/em> 54, 231&#x02013;263. doi:10.1016/s1054-3589(06)54010-4\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17175817/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s1054-3589(06)54010-4\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=structure%2c+pharmacology%2c+and+function+of+gabaa+receptor+subtypes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b66\" id=\"b66\">\u003c/a>sitnikova, e., rutskova, e., and smirnov, k. (2023). alpha2-adrenergic receptors as a pharmacological target for spike-wave epilepsy. \u003cem>int. j. mol. sci.\u003c/em> 24, 1477. doi:10.3390/ijms24021477\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/36674992/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.3390/ijms24021477\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=alpha2-adrenergic+receptors+as+a+pharmacological+target+for+spike-wave+epilepsy&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b67\" id=\"b67\">\u003c/a>smit, d. j. a., wright, m. j., meyers, j. l., martin, n. g., ho, y. y. w., malone, s. m., et al. (2018). genome-wide association analysis links multiple psychiatric liability genes to oscillatory brain activity. \u003cem>hum. brain mapp.\u003c/em> 39, 4183&#x02013;4195. doi:10.1002/hbm.24238\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/29947131/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/hbm.24238\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=genome-wide+association+analysis+links+multiple+psychiatric+liability+genes+to+oscillatory+brain+activity&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b68\" id=\"b68\">\u003c/a>souza, a. j., freitas, i. s., sharmin, d., cook, j. m., guimaraes, f. s., and gomes, f. v. (2024). an alpha 5-gaba(a) receptor positive allosteric modulator attenuates social and cognitive deficits without changing dopamine system hyperactivity in rats exposed to valproic acid in utero. \u003cem>autism res.\u003c/em> 17, 1534&#x02013;1544. doi:10.1002/aur.3178\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/39169698/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/aur.3178\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=an+alpha+5-gabaa+receptor+positive+allosteric+modulator+attenuates+social+and+cognitive+deficits+without+changing+dopamine+system+hyperactivity+in+rats+exposed+to+valproic+acid+in+utero&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b69\" id=\"b69\">\u003c/a>sur, c., fresu, l., howell, o., mckernan, r. m., and atack, j. r. (1999). autoradiographic localization of alpha5 subunit-containing gabaa receptors in rat brain. \u003cem>brain res.\u003c/em> 822, 265&#x02013;270. doi:10.1016/s0006-8993(99)01152-x\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/10082908/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0006-8993(99)01152-x\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=autoradiographic+localization+of+alpha5+subunit-containing+gabaa+receptors+in+rat+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\" style=\"margin-bottom:0.5em;\">\u003cp class=\"referencescopy1\">\u003ca name=\"b70\" id=\"b70\">\u003c/a>traub, r. d. w. m., and jefferys, j. g. r. (1999). \u003cem>fast oscillations in cortical circuits\u003c/em>. \u003cspan class=\"publisher-name\">the mit press\u003c/span>. \u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=â traubâ r+d+w+mjefferysâ j+g+r+1999+fast+oscillations+in+cortical+circuits+the+mit+press&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b71\" id=\"b71\">\u003c/a>van lier, h., drinkenburg, w. h., van eeten, y. j., and coenen, a. m. (2004). effects of diazepam and zolpidem on eeg beta frequencies are behavior-specific in rats. \u003cem>neuropharmacology\u003c/em> 47, 163&#x02013;174. doi:10.1016/j.neuropharm.2004.03.017\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/15223295/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2004.03.017\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=effects+of+diazepam+and+zolpidem+on+eeg+beta+frequencies+are+behavior-specific+in+rats&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b72\" id=\"b72\">\u003c/a>visser, s. a., wolters, f. l., gubbens-stibbe, j. m., tukker, e., van der graaf, p. h., peletier, l. a., et al. (2003). mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of gabaa receptor modulators: in vitro-in vivo correlations. \u003cem>j. pharmacol. exp. ther.\u003c/em> 304, 88&#x02013;101. doi:10.1124/jpet.102.042341\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/12490579/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1124/jpet.102.042341\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=mechanism-based+pharmacokinetic/pharmacodynamic+modeling+of+the+electroencephalogram+effects+of+gabaa+receptor+modulators:+in+vitro-in+vivo+correlations&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b73\" id=\"b73\">\u003c/a>vithlani, m., terunuma, m., and moss, s. j. (2011). the dynamic modulation of gaba(a) receptor trafficking and its role in regulating the plasticity of inhibitory synapses. \u003cem>physiol. rev.\u003c/em> 91, 1009&#x02013;1022. doi:10.1152/physrev.00015.2010\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21742794/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1152/physrev.00015.2010\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+dynamic+modulation+of+gabaa+receptor+trafficking+and+its+role+in+regulating+the+plasticity+of+inhibitory+synapses&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b74\" id=\"b74\">\u003c/a>warrier, v., baron-cohen, s., and chakrabarti, b. (2013). genetic variation in gabrb3 is associated with asperger syndrome and multiple endophenotypes relevant to autism. \u003cem>mol. autism\u003c/em> 4, 48. doi:10.1186/2040-2392-4-48\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/24321478/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1186/2040-2392-4-48\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=genetic+variation+in+gabrb3+is+associated+with+asperger+syndrome+and+multiple+endophenotypes+relevant+to+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b75\" id=\"b75\">\u003c/a>whittington, m. a., traub, r. d., kopell, n., ermentrout, b., and buhl, e. h. (2000). inhibition-based rhythms: experimental and mathematical observations on network dynamics. \u003cem>int. j. psychophysiol.\u003c/em> 38, 315&#x02013;336. doi:10.1016/s0167-8760(00)00173-2\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/11102670/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0167-8760(00)00173-2\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=inhibition-based+rhythms:+experimental+and+mathematical+observations+on+network+dynamics&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b76\" id=\"b76\">\u003c/a>xie, x. h., and tietz, e. i. (1991). chronic benzodiazepine treatment of rats induces reduction of paired-pulse inhibition in ca1 region of \u003cem>in vitro\u003c/em> hippocampus. \u003cem>brain res.\u003c/em> 561, 69&#x02013;76. doi:10.1016/0006-8993(91)90750-p\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/1797351/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/0006-8993(91)90750-p\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=chronic+benzodiazepine+treatment+of+rats+induces+reduction+of+paired-pulse+inhibition+in+ca1+region+of+in+vitro+hippocampus&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b77\" id=\"b77\">\u003c/a>zurek, a. a., kemp, s. w., aga, z., walker, s., milenkovic, m., ramsey, a. j., et al. (2016). &#x003b1;5gabaa receptor deficiency causes autism-like behaviors. \u003cem>ann. clin. transl. neurol.\u003c/em> 3, 392&#x02013;398. doi:10.1002/acn3.303\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27231709/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/acn3.303\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=î±5gabaa+receptor+deficiency+causes+autism-like+behaviors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003c/div>\u003cdiv class=\"thinlinem20\">\u003c/div>\u003cdiv class=\"abstractsummary\">\u003cp>\u003cspan>keywords:\u003c/span> autism spectrum disorder, angelman syndrome, gaba\u003csub>a\u003c/sub>, gaba\u003csub>a\u003c/sub>-&#x003b1;5, positron emission tomography (pet), electroencephalography, pharmacological mri, biomarker\u003c/p>\u003cp>\u003cspan>citation:\u003c/span> cecere g, ballard tm, knoflach f, honer m, hipp jf, garces p, mueggler t, k&#x000fc;nnecke b, bruns a, prinssen ep, schoenenberger p, janz p, redondo r, biemans b, knust h, olivares-morales a, brigo a, schulz jm, bertrand d, saxe m, o&#x02019;connor ec and hernandez m-c (2025) preclinical pharmacology of alogabat: a novel gaba\u003csub>a\u003c/sub>-&#x003b1;5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gaba\u003csub>a\u003c/sub> signaling. \u003cem>front. pharmacol.\u003c/em> 16:1626078. doi: 10.3389/fphar.2025.1626078\u003c/p>\u003cp id=\"timestamps\">\u003cspan>received:\u003c/span> 09 may 2025; \u003cspan>accepted:\u003c/span> 18 june 2025;\u003cbr>\u003cspan>published:\u003c/span> 21 july 2025.\u003c/p>\u003cdiv>\u003cp>edited by:\u003c/p> \u003ca href=\"https://loop.frontiersin.org/people/52072/overview\">agenor limon\u003c/a>, university of texas medical branch at galveston, united states\u003c/div>\u003cdiv>\u003cp>reviewed by:\u003c/p> \u003ca href=\"https://loop.frontiersin.org/people/39673/overview\">hansen wang\u003c/a>, university of toronto, canada\u003cbr>\u003ca href=\"https://loop.frontiersin.org/people/1285968/overview\">junzhan jing\u003c/a>, baylor college of medicine, united states\u003cbr>\u003ca href=\"https://loop.frontiersin.org/people/1380630/overview\">azar omrani\u003c/a>, boehringer ingelheim, germany\u003c/div>\u003cp>\u003cspan>copyright\u003c/span> &#x000a9; 2025 cecere, ballard, knoflach, honer, hipp, garces, mueggler, k&#x000fc;nnecke, bruns, prinssen, schoenenberger, janz, redondo, biemans, knust, olivares-morales, brigo, schulz, bertrand, saxe, o&#x02019;connor and hernandez. this is an open-access article distributed under the terms of the \u003ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">creative commons attribution license (cc by).\u003c/a> the use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. no use, distribution or reproduction is permitted which does not comply with these terms.\u003c/p>\u003cp>\u003cspan>&#x0002a;correspondence:\u003c/span> maria-clemencia hernandez, \u003ca id=\"encmail\">bwfyawety2xlbwvuy2lhlmhlcm5hbmrlekbyb2nozs5jb20=\u003c/a>\u003c/p>\u003cp>\u003cspan>\u003csup>&#x02020;\u003c/sup>\u003c/span>these authors have contributed equally to this work\u003c/p>\u003cp>\u003cspan>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cb>present address:\u003c/b> theresa m. ballard, galwyn (uk) ltd., dartmouth, united kingdom\u003cbr>barbara biemans, b2discovery llc, riehen, switzerland\u003cbr>michael saxe, translational in vivo sciences, biogen, cambridge, ma, united states\u003c/p>\u003cdiv class=\"clear\">\u003c/div>\u003c/div>","\u003cul class=\"flyoutjournal\">\u003cli>\u003ca href=\"#h1\">abstract\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h2\">1 introduction\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h3\">2 materials and methods\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h4\">3 results\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h5\">4 discussion\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h6\">5 conclusion\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h7\">data availability statement\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h8\">ethics statement\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h9\">author contributions\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h10\">funding\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h11\">acknowledgments\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h12\">conflict of interest\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h13\">generative ai statement\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h14\">publisher&#x02019;s note\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h15\">supplementary material\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h16\">abbreviations\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h17\">references\u003c/a>\u003c/li>\u003c/ul>",[732,740,746,752],{"name":733,"fileserverpackageentryid":734,"fileserverid":735,"fileserverversionnumber":736,"type":737},"fphar-16-1626078.xml","fphar-16-1626078-r1/fphar-16-1626078.xml","1626078/xml",2,{"code":738,"name":739},"nlm_xml","xml",{"name":741,"fileserverpackageentryid":19,"fileserverid":742,"fileserverversionnumber":736,"type":743},"epub.epub","1626078/epub",{"code":744,"name":745},"epub","epub",{"name":747,"fileserverpackageentryid":19,"fileserverid":748,"fileserverversionnumber":736,"type":749},"publishers-proof.pdf","1626078/publishers-proof",{"code":750,"name":751},"pdf","pdf",{"name":753,"fileserverpackageentryid":19,"fileserverid":754,"fileserverversionnumber":370,"type":755},"supplementary file 1.docx","1626078/supplementary-file/1",{"code":756,"name":757},"supplementary_material","docx","v3",{"title":760,"link":761,"meta":765,"script":956},"frontiers | preclinical pharmacology of alogabat: a novel gabaa-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gabaa signaling",[762],{"rel":763,"href":764},"canonical","https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1626078/full",[766,769,772,774,777,781,784,788,791,794,797,799,801,803,805,807,810,813,815,818,820,822,825,828,831,834,837,841,845,848,851,854,856,859,861,864,866,869,871,874,876,879,881,884,886,889,891,894,896,899,901,904,906,909,911,914,916,919,922,925,927,930,932,935,938,941,943,946,948,951,953],{"hid":767,"property":767,"name":767,"content":768},"description","backgroundalterations in the gabaergic system contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder (asd) and...",{"hid":770,"property":770,"name":771,"content":760},"og:title","title",{"hid":773,"property":773,"name":767,"content":768},"og:description",{"hid":775,"name":775,"content":776},"keywords","biomarker,autism spectrum disorder,electroencephalography,positron emission tomography (pet),angelman syndrome,gabaa,gabaa-α5,pharmacological mri",{"hid":778,"property":778,"name":779,"content":780},"og:site_name","site_name","frontiers",{"hid":782,"property":782,"name":363,"content":783},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg",{"hid":785,"property":785,"name":786,"content":787},"og:type","type","article",{"hid":789,"property":789,"name":790,"content":764},"og:url","url",{"hid":792,"name":792,"content":793},"twitter:card","summary_large_image",{"hid":795,"name":795,"content":796},"citation_volume","16",{"hid":798,"name":798,"content":116},"citation_journal_title",{"hid":800,"name":800,"content":780},"citation_publisher",{"hid":802,"name":802,"content":713},"citation_journal_abbrev",{"hid":804,"name":804,"content":714},"citation_issn",{"hid":806,"name":806,"content":515},"citation_doi",{"hid":808,"name":808,"content":809},"citation_firstpage","1626078",{"hid":811,"name":811,"content":812},"citation_language","english",{"hid":814,"name":814,"content":516},"citation_title",{"hid":816,"name":816,"content":817},"citation_keywords","biomarker; autism spectrum disorder; electroencephalography; positron emission tomography (pet); angelman syndrome; gabaa; gabaa-α5; pharmacological mri",{"hid":819,"name":819,"content":521},"citation_abstract",{"hid":821,"name":821,"content":524},"citation_article_type",{"hid":823,"name":823,"content":824},"citation_pdf_url","https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1626078/pdf",{"hid":826,"name":826,"content":827},"citation_xml_url","https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1626078/xml",{"hid":829,"name":829,"content":830},"citation_fulltext_world_readable","yes",{"hid":832,"name":832,"content":833},"citation_online_date","2025/06/18",{"hid":835,"name":835,"content":836},"citation_publication_date","2025/07/21",{"hid":838,"name":839,"content":840},"citation_author_0","citation_author","cecere, giuseppe ",{"hid":842,"name":843,"content":844},"citation_author_institution_0","citation_author_institution","medicinal chemistry, switzerland",{"hid":846,"name":839,"content":847},"citation_author_1","ballard, theresa m. ",{"hid":849,"name":843,"content":850},"citation_author_institution_1","neuroscience and rare diseases, switzerland",{"hid":852,"name":839,"content":853},"citation_author_2","knoflach, frederic ",{"hid":855,"name":843,"content":850},"citation_author_institution_2",{"hid":857,"name":839,"content":858},"citation_author_3","honer, michael ",{"hid":860,"name":843,"content":850},"citation_author_institution_3",{"hid":862,"name":839,"content":863},"citation_author_4","hipp, joerg f. ",{"hid":865,"name":843,"content":850},"citation_author_institution_4",{"hid":867,"name":839,"content":868},"citation_author_5","garces, pilar ",{"hid":870,"name":843,"content":850},"citation_author_institution_5",{"hid":872,"name":839,"content":873},"citation_author_6","mueggler, thomas ",{"hid":875,"name":843,"content":850},"citation_author_institution_6",{"hid":877,"name":839,"content":878},"citation_author_7","künnecke, basil ",{"hid":880,"name":843,"content":850},"citation_author_institution_7",{"hid":882,"name":839,"content":883},"citation_author_8","bruns, andreas ",{"hid":885,"name":843,"content":850},"citation_author_institution_8",{"hid":887,"name":839,"content":888},"citation_author_9","prinssen, eric p. ",{"hid":890,"name":843,"content":850},"citation_author_institution_9",{"hid":892,"name":839,"content":893},"citation_author_10","schoenenberger, philipp ",{"hid":895,"name":843,"content":850},"citation_author_institution_10",{"hid":897,"name":839,"content":898},"citation_author_11","janz, philipp ",{"hid":900,"name":843,"content":850},"citation_author_institution_11",{"hid":902,"name":839,"content":903},"citation_author_12","redondo, roger ",{"hid":905,"name":843,"content":850},"citation_author_institution_12",{"hid":907,"name":839,"content":908},"citation_author_13","biemans, barbara ",{"hid":910,"name":843,"content":850},"citation_author_institution_13",{"hid":912,"name":839,"content":913},"citation_author_14","knust, henner ",{"hid":915,"name":843,"content":844},"citation_author_institution_14",{"hid":917,"name":839,"content":918},"citation_author_15","olivares-morales, andrés ",{"hid":920,"name":843,"content":921},"citation_author_institution_15","pharmaceutical sciences, switzerland",{"hid":923,"name":839,"content":924},"citation_author_16","brigo, alessandro ",{"hid":926,"name":843,"content":921},"citation_author_institution_16",{"hid":928,"name":839,"content":929},"citation_author_17","schulz, jan michael ",{"hid":931,"name":843,"content":850},"citation_author_institution_17",{"hid":933,"name":839,"content":934},"citation_author_18","bertrand, daniel ",{"hid":936,"name":843,"content":937},"citation_author_institution_18","hiqscreen sàrl, switzerland",{"hid":939,"name":839,"content":940},"citation_author_19","saxe, michael ",{"hid":942,"name":843,"content":850},"citation_author_institution_19",{"hid":944,"name":839,"content":945},"citation_author_20","o’connor, eoin c. ",{"hid":947,"name":843,"content":850},"citation_author_institution_20",{"hid":949,"name":839,"content":950},"citation_author_21","hernandez, maria-clemencia ",{"hid":952,"name":843,"content":850},"citation_author_institution_21",{"hid":954,"name":954,"content":955},"dc.identifier","doi:10.3389/fphar.2025.1626078",[957,960,962,964,966],{"src":958,"body":13,"type":959,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":961,"body":13,"type":959,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/mathjax.js?config=tex-mml-am_chtml",{"src":963,"body":13,"type":959,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":965,"body":13,"type":959,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fphar.2025.1626078?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":967,"body":13,"type":959,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articlehubslug":19,"articlehubpage":969,"articlehubarticleslist":970,"canjournalhasarticlehub":347,"articledoilist":971},{},[],[],{"title":19,"image":-1,"breadcrumbs":973,"linkscollection":974,"metricscollection":976},[],{"total":367,"items":975},[],{"total":367,"items":977},[]] window.__nuxt__={};window.__nuxt__.config={public:{isdevmode:false,appname:"article-pages-2024",baseurl:"https://www.frontiersin.org",domain:"frontiersin.org",loopurl:"https://loop.frontiersin.org",ssmaindomain:"frontiersin.org",contentfulurl:"https://graphql.contentful.com/content/v1/spaces",spaceid:1,spacename:"frontiers",livespaceid:1,tenantlogourl:"",frontiersgraphurl:"https://apollo-federation-gateway.frontiersin.org",registrationapiurl:"https://onboarding-ui.frontiersin.org",emaildigestapiurl:"https://api-email-digest.frontiersin.org",journalfilesapiurl:"https://files-journal-api.frontiersin.org",searchapiurl:"https://search-api.frontiersin.org",productionforumapiurl:"https://production-forum-api-v2.frontiersin.org",gtmserverurl:"https://tag-manager.frontiersin.org",gtmid:"gtm-m322fv2",gtmauth:"owvbwxfajr21yqv1fe1caq",gtmpreview:"env-1",figsharepluginurl:"https://widgets.figshare.com/static/figshare.js",figshareapiurl:"https://api.figshare.com/v2/collections/search",figsharetimeout:3000,crossmarkpublisheddate:"2015/08/24",googlerecaptchasitekey:"6ldg3i0uaaaaaoc4quh35ubhgjotehp_stxhgr_v",googlerecaptchakeyname:"frontiersrecaptchav2",faviconsize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantfavicon-frontiers.png",faviconsize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantfavicon-frontiers.png",faviconsize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantfavicon-frontiers.png",faviconsize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantfavicon-frontiers.png",faviconsize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantfavicon-frontiers.png",socialmediaimg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/guidelines-frontiers_logo_1200x628_1-91to1.png",linkedarticlecopytext:"'{\"articletypecopytext\":[{\"articletypeid\":0,\"originalarticlecopytext\":\"part of this article's content has been mentioned in:\",\"linkedarticlecopytext\":\"this article mentions parts of:\"},{\"articletypeid\":122,\"originalarticlecopytext\":\"parts of this article's content have been modified or rectified in:\",\"linkedarticlecopytext\":\"this article is an erratum on:\"},{\"articletypeid\":129,\"originalarticlecopytext\":\"parts of this article's content have been modified or rectified in:\",\"linkedarticlecopytext\":\"this article is an addendum to:\"},{\"articletypeid\":128,\"originalarticlecopytext\":\"a correction has been applied to this article in:\",\"linkedarticlecopytext\":\"this article is a correction to:\"},{\"articletypeid\":134,\"originalarticlecopytext\":\"a retraction of this article was approved in:\",\"linkedarticlecopytext\":\"this article is a retraction of:\"},{\"articletypeid\":29,\"originalarticlecopytext\":\"a commentary has been posted on this article:\",\"linkedarticlecopytext\":\"this article is a commentary on:\"},{\"articletypeid\":30,\"originalarticlecopytext\":\"a commentary has been posted on this article:\",\"linkedarticlecopytext\":\"this article is a commentary on:\"}],\"articleidcopytext\":[]}'\n",acceptedarticleexcludedjournalids:"'[2766,979]'\n",articletypeconfigurablelabel:"\u003c\u003carticle-type:uppercase>> article",settingsfeaturesswitchers:"'{\"displaytitlepilllabels\":true,\"displayrelatedarticlesbox\":true,\"showeditors\":true,\"showreviewers\":true,\"showloopimpactlink\":true,\"enablefigshare\":false,\"usexmlimages\":true}'\n",journalswitharticlehub:"'{\"strings\":[\"science\"]}'\n",terminologysettings:"'{\"terms\":[{\"sequencenumber\":1,\"key\":\"frontiers\",\"tenantterm\":\"frontiers\",\"frontiersdefaultterm\":\"frontiers\",\"category\":\"customer\"},{\"sequencenumber\":2,\"key\":\"submission_system\",\"tenantterm\":\"submission system\",\"frontiersdefaultterm\":\"submission system\",\"category\":\"product\"},{\"sequencenumber\":3,\"key\":\"public_pages\",\"tenantterm\":\"public pages\",\"frontiersdefaultterm\":\"public pages\",\"category\":\"product\"},{\"sequencenumber\":4,\"key\":\"my_frontiers\",\"tenantterm\":\"my frontiers\",\"frontiersdefaultterm\":\"my frontiers\",\"category\":\"product\"},{\"sequencenumber\":5,\"key\":\"digital_editorial_office\",\"tenantterm\":\"digital editorial office\",\"frontiersdefaultterm\":\"digital editorial office\",\"category\":\"product\"},{\"sequencenumber\":6,\"key\":\"deo\",\"tenantterm\":\"deo\",\"frontiersdefaultterm\":\"deo\",\"category\":\"product\"},{\"sequencenumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantterm\":\"digital editorial office for chiefs\",\"frontiersdefaultterm\":\"digital editorial office for chiefs\",\"category\":\"product\"},{\"sequencenumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantterm\":\"digital editorial office for eof\",\"frontiersdefaultterm\":\"digital editorial office for eof\",\"category\":\"product\"},{\"sequencenumber\":9,\"key\":\"editorial_office\",\"tenantterm\":\"editorial office\",\"frontiersdefaultterm\":\"editorial office\",\"category\":\"product\"},{\"sequencenumber\":10,\"key\":\"eof\",\"tenantterm\":\"eof\",\"frontiersdefaultterm\":\"eof\",\"category\":\"product\"},{\"sequencenumber\":11,\"key\":\"research_topic_management\",\"tenantterm\":\"research topic management\",\"frontiersdefaultterm\":\"research topic management\",\"category\":\"product\"},{\"sequencenumber\":12,\"key\":\"review_forum\",\"tenantterm\":\"review forum\",\"frontiersdefaultterm\":\"review forum\",\"category\":\"product\"},{\"sequencenumber\":13,\"key\":\"accounting_office\",\"tenantterm\":\"accounting office\",\"frontiersdefaultterm\":\"accounting office\",\"category\":\"product\"},{\"sequencenumber\":14,\"key\":\"aof\",\"tenantterm\":\"aof\",\"frontiersdefaultterm\":\"aof\",\"category\":\"product\"},{\"sequencenumber\":15,\"key\":\"publishing_office\",\"tenantterm\":\"publishing office\",\"frontiersdefaultterm\":\"publishing office\",\"category\":\"product\"},{\"sequencenumber\":16,\"key\":\"production_office\",\"tenantterm\":\"production office forum\",\"frontiersdefaultterm\":\"production office forum\",\"category\":\"product\"},{\"sequencenumber\":17,\"key\":\"pof\",\"tenantterm\":\"pof\",\"frontiersdefaultterm\":\"pof\",\"category\":\"product\"},{\"sequencenumber\":18,\"key\":\"book_office_forum\",\"tenantterm\":\"book office forum\",\"frontiersdefaultterm\":\"book office forum\",\"category\":\"product\"},{\"sequencenumber\":19,\"key\":\"bof\",\"tenantterm\":\"bof\",\"frontiersdefaultterm\":\"bof\",\"category\":\"product\"},{\"sequencenumber\":20,\"key\":\"aira\",\"tenantterm\":\"aira\",\"frontiersdefaultterm\":\"aira\",\"category\":\"product\"},{\"sequencenumber\":21,\"key\":\"editorial_board_management\",\"tenantterm\":\"editorial board management\",\"frontiersdefaultterm\":\"editorial board management\",\"category\":\"product\"},{\"sequencenumber\":22,\"key\":\"ebm\",\"tenantterm\":\"ebm\",\"frontiersdefaultterm\":\"ebm\",\"category\":\"product\"},{\"sequencenumber\":23,\"key\":\"domain\",\"tenantterm\":\"domain\",\"frontiersdefaultterm\":\"domain\",\"category\":\"taxonomy\"},{\"sequencenumber\":24,\"key\":\"journal\",\"tenantterm\":\"journal\",\"frontiersdefaultterm\":\"journal\",\"category\":\"taxonomy\"},{\"sequencenumber\":25,\"key\":\"section\",\"tenantterm\":\"section\",\"frontiersdefaultterm\":\"section\",\"category\":\"taxonomy\"},{\"sequencenumber\":26,\"key\":\"domains\",\"tenantterm\":\"domains\",\"frontiersdefaultterm\":\"domains\",\"category\":\"taxonomy\"},{\"sequencenumber\":27,\"key\":\"specialty_section\",\"tenantterm\":\"specialty section\",\"frontiersdefaultterm\":\"specialty section\",\"category\":\"taxonomy\"},{\"sequencenumber\":28,\"key\":\"specialty_journal\",\"tenantterm\":\"specialty journal\",\"frontiersdefaultterm\":\"specialty journal\",\"category\":\"taxonomy\"},{\"sequencenumber\":29,\"key\":\"journals\",\"tenantterm\":\"journals\",\"frontiersdefaultterm\":\"journals\",\"category\":\"taxonomy\"},{\"sequencenumber\":30,\"key\":\"sections\",\"tenantterm\":\"sections\",\"frontiersdefaultterm\":\"sections\",\"category\":\"taxonomy\"},{\"sequencenumber\":31,\"key\":\"specialty_sections\",\"tenantterm\":\"specialty sections\",\"frontiersdefaultterm\":\"specialty sections\",\"category\":\"taxonomy\"},{\"sequencenumber\":32,\"key\":\"specialty_journals\",\"tenantterm\":\"specialty journals\",\"frontiersdefaultterm\":\"specialty journals\",\"category\":\"taxonomy\"},{\"sequencenumber\":33,\"key\":\"manuscript\",\"tenantterm\":\"manuscript\",\"frontiersdefaultterm\":\"manuscript\",\"category\":\"core\"},{\"sequencenumber\":34,\"key\":\"manuscripts\",\"tenantterm\":\"manuscripts\",\"frontiersdefaultterm\":\"manuscripts\",\"category\":\"core\"},{\"sequencenumber\":35,\"key\":\"article\",\"tenantterm\":\"article\",\"frontiersdefaultterm\":\"article\",\"category\":\"core\"},{\"sequencenumber\":36,\"key\":\"articles\",\"tenantterm\":\"articles\",\"frontiersdefaultterm\":\"articles\",\"category\":\"core\"},{\"sequencenumber\":37,\"key\":\"article_type\",\"tenantterm\":\"article type\",\"frontiersdefaultterm\":\"article type\",\"category\":\"core\"},{\"sequencenumber\":38,\"key\":\"article_types\",\"tenantterm\":\"article types\",\"frontiersdefaultterm\":\"article types\",\"category\":\"core\"},{\"sequencenumber\":39,\"key\":\"author\",\"tenantterm\":\"author\",\"frontiersdefaultterm\":\"author\",\"category\":\"label (role)\"},{\"sequencenumber\":40,\"key\":\"authors\",\"tenantterm\":\"authors\",\"frontiersdefaultterm\":\"authors\",\"category\":\"label (role)\"},{\"sequencenumber\":41,\"key\":\"authoring\",\"tenantterm\":\"authoring\",\"frontiersdefaultterm\":\"authoring\",\"category\":\"core\"},{\"sequencenumber\":42,\"key\":\"authored\",\"tenantterm\":\"authored\",\"frontiersdefaultterm\":\"authored\",\"category\":\"core\"},{\"sequencenumber\":43,\"key\":\"accept\",\"tenantterm\":\"accept\",\"frontiersdefaultterm\":\"accept\",\"category\":\"process\"},{\"sequencenumber\":44,\"key\":\"accepted\",\"tenantterm\":\"accepted\",\"frontiersdefaultterm\":\"accepted\",\"category\":\"process\"},{\"sequencenumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantterm\":\"assistant field chief editor\",\"frontiersdefaultterm\":\"assistant field chief editor\",\"description\":\"an editorial role on a field journal that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantterm\":\"assistant specialty chief editor\",\"frontiersdefaultterm\":\"assistant specialty chief editor\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantterm\":\"assistant specialty chief editors\",\"frontiersdefaultterm\":\"assistant specialty chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":48,\"key\":\"associate_editor\",\"tenantterm\":\"associate editor\",\"frontiersdefaultterm\":\"associate editor\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":49,\"key\":\"specialty_chief_editor\",\"tenantterm\":\"specialty chief editor\",\"frontiersdefaultterm\":\"specialty chief editor\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":50,\"key\":\"specialty_chief_editors\",\"tenantterm\":\"specialty chief editors\",\"frontiersdefaultterm\":\"specialty chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":51,\"key\":\"chief_editor\",\"tenantterm\":\"chief editor\",\"frontiersdefaultterm\":\"chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":52,\"key\":\"chief_editors\",\"tenantterm\":\"chief editors\",\"frontiersdefaultterm\":\"chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":53,\"key\":\"call_for_participation\",\"tenantterm\":\"call for participation\",\"frontiersdefaultterm\":\"call for participation\",\"category\":\"process\"},{\"sequencenumber\":54,\"key\":\"citation\",\"tenantterm\":\"citation\",\"frontiersdefaultterm\":\"citation\",\"category\":\"misc.\"},{\"sequencenumber\":55,\"key\":\"citations\",\"tenantterm\":\"citations\",\"frontiersdefaultterm\":\"citations\",\"category\":\"misc.\"},{\"sequencenumber\":56,\"key\":\"contributor\",\"tenantterm\":\"contributor\",\"frontiersdefaultterm\":\"contributor\",\"category\":\"label (role)\"},{\"sequencenumber\":57,\"key\":\"contributors\",\"tenantterm\":\"contributors\",\"frontiersdefaultterm\":\"contributors\",\"category\":\"label (role)\"},{\"sequencenumber\":58,\"key\":\"corresponding_author\",\"tenantterm\":\"corresponding author\",\"frontiersdefaultterm\":\"corresponding author\",\"category\":\"label (role)\"},{\"sequencenumber\":59,\"key\":\"corresponding_authors\",\"tenantterm\":\"corresponding authors\",\"frontiersdefaultterm\":\"corresponding authors\",\"category\":\"label (role)\"},{\"sequencenumber\":60,\"key\":\"decline\",\"tenantterm\":\"decline\",\"frontiersdefaultterm\":\"decline\",\"category\":\"process\"},{\"sequencenumber\":61,\"key\":\"declined\",\"tenantterm\":\"declined\",\"frontiersdefaultterm\":\"declined\",\"category\":\"process\"},{\"sequencenumber\":62,\"key\":\"reject\",\"tenantterm\":\"reject\",\"frontiersdefaultterm\":\"reject\",\"category\":\"process\"},{\"sequencenumber\":63,\"key\":\"rejected\",\"tenantterm\":\"rejected\",\"frontiersdefaultterm\":\"rejected\",\"category\":\"process\"},{\"sequencenumber\":64,\"key\":\"publish\",\"tenantterm\":\"publish\",\"frontiersdefaultterm\":\"publish\",\"category\":\"core\"},{\"sequencenumber\":65,\"key\":\"published\",\"tenantterm\":\"published\",\"frontiersdefaultterm\":\"published\",\"category\":\"core\"},{\"sequencenumber\":66,\"key\":\"publication\",\"tenantterm\":\"publication\",\"frontiersdefaultterm\":\"publication\",\"category\":\"core\"},{\"sequencenumber\":67,\"key\":\"peer_review\",\"tenantterm\":\"peer review\",\"frontiersdefaultterm\":\"peer review\",\"category\":\"peer review process\"},{\"sequencenumber\":68,\"key\":\"peer_reviewed\",\"tenantterm\":\"peer reviewed\",\"frontiersdefaultterm\":\"peer reviewed\",\"category\":\"peer review process\"},{\"sequencenumber\":69,\"key\":\"initial_validation\",\"tenantterm\":\"initial validation\",\"frontiersdefaultterm\":\"initial validation\",\"category\":\"peer review process\"},{\"sequencenumber\":70,\"key\":\"editorial_assignment\",\"tenantterm\":\"editorial assignment\",\"frontiersdefaultterm\":\"editorial assignment\",\"category\":\"peer review process\"},{\"sequencenumber\":71,\"key\":\"independent_review\",\"tenantterm\":\"independent review\",\"frontiersdefaultterm\":\"independent review\",\"category\":\"peer review process\"},{\"sequencenumber\":72,\"key\":\"interactive_review\",\"tenantterm\":\"interactive review\",\"frontiersdefaultterm\":\"interactive review\",\"category\":\"peer review process\"},{\"sequencenumber\":73,\"key\":\"review\",\"tenantterm\":\"review\",\"frontiersdefaultterm\":\"review\",\"category\":\"peer review process\"},{\"sequencenumber\":74,\"key\":\"reviewing\",\"tenantterm\":\"reviewing\",\"frontiersdefaultterm\":\"reviewing\",\"category\":\"peer review process\"},{\"sequencenumber\":75,\"key\":\"reviewer\",\"tenantterm\":\"reviewer\",\"frontiersdefaultterm\":\"reviewer\",\"category\":\"label (role)\"},{\"sequencenumber\":76,\"key\":\"reviewers\",\"tenantterm\":\"reviewers\",\"frontiersdefaultterm\":\"reviewers\",\"category\":\"label (role)\"},{\"sequencenumber\":77,\"key\":\"review_finalized\",\"tenantterm\":\"review finalized\",\"frontiersdefaultterm\":\"review finalized\",\"category\":\"peer review process\"},{\"sequencenumber\":78,\"key\":\"final_decision\",\"tenantterm\":\"final decision\",\"frontiersdefaultterm\":\"final decision\",\"category\":\"peer review process\"},{\"sequencenumber\":79,\"key\":\"final_validation\",\"tenantterm\":\"final validation\",\"frontiersdefaultterm\":\"final validation\",\"category\":\"peer review process\"},{\"sequencenumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantterm\":\"recommend to accept manuscript\",\"frontiersdefaultterm\":\"accept manuscript\",\"category\":\"process\"},{\"sequencenumber\":81,\"key\":\"fee\",\"tenantterm\":\"fee\",\"frontiersdefaultterm\":\"fee\",\"category\":\"accounting\"},{\"sequencenumber\":82,\"key\":\"fees\",\"tenantterm\":\"fees\",\"frontiersdefaultterm\":\"fees\",\"category\":\"accounting\"},{\"sequencenumber\":83,\"key\":\"guest_associate_editor\",\"tenantterm\":\"guest associate editor\",\"frontiersdefaultterm\":\"guest associate editor\",\"category\":\"label (role)\"},{\"sequencenumber\":84,\"key\":\"guest_associate_editors\",\"tenantterm\":\"guest associate editors\",\"frontiersdefaultterm\":\"guest associate editors\",\"category\":\"label (role)\"},{\"sequencenumber\":85,\"key\":\"in_review\",\"tenantterm\":\"in review\",\"frontiersdefaultterm\":\"in review\",\"category\":\"peer review process\"},{\"sequencenumber\":86,\"key\":\"institutional_member\",\"tenantterm\":\"institutional partner\",\"frontiersdefaultterm\":\"institutional partner\",\"category\":\"accounting\"},{\"sequencenumber\":87,\"key\":\"institutional_membership\",\"tenantterm\":\"institutional partnership\",\"frontiersdefaultterm\":\"institutional partnership\",\"category\":\"accounting\"},{\"sequencenumber\":88,\"key\":\"article_processing_charge\",\"tenantterm\":\"article processing charge\",\"frontiersdefaultterm\":\"article processing charge\",\"category\":\"accounting\"},{\"sequencenumber\":89,\"key\":\"article_processing_charges\",\"tenantterm\":\"article processing charges\",\"frontiersdefaultterm\":\"article processing charges\",\"category\":\"accounting\"},{\"sequencenumber\":90,\"key\":\"apcs\",\"tenantterm\":\"apcs\",\"frontiersdefaultterm\":\"apcs\",\"category\":\"accounting\"},{\"sequencenumber\":91,\"key\":\"apc\",\"tenantterm\":\"apc\",\"frontiersdefaultterm\":\"apc\",\"category\":\"accounting\"},{\"sequencenumber\":92,\"key\":\"received\",\"tenantterm\":\"received\",\"frontiersdefaultterm\":\"received\",\"description\":\"date manuscript was received on.\",\"category\":\"core\"},{\"sequencenumber\":93,\"key\":\"transferred\",\"tenantterm\":\"transferred\",\"frontiersdefaultterm\":\"transferred\",\"category\":\"core\"},{\"sequencenumber\":94,\"key\":\"transfer\",\"tenantterm\":\"transfer\",\"frontiersdefaultterm\":\"transfer\",\"category\":\"core\"},{\"sequencenumber\":95,\"key\":\"research_topic\",\"tenantterm\":\"research topic\",\"frontiersdefaultterm\":\"research topic\",\"category\":\"core\"},{\"sequencenumber\":96,\"key\":\"research_topics\",\"tenantterm\":\"research topics\",\"frontiersdefaultterm\":\"research topics\",\"category\":\"core\"},{\"sequencenumber\":97,\"key\":\"topic_editor\",\"tenantterm\":\"topic editor\",\"frontiersdefaultterm\":\"topic editor\",\"category\":\"label (role)\"},{\"sequencenumber\":98,\"key\":\"review_editor\",\"tenantterm\":\"community reviewer\",\"frontiersdefaultterm\":\"review editor\",\"category\":\"label (role)\"},{\"sequencenumber\":99,\"key\":\"title\",\"tenantterm\":\"title\",\"frontiersdefaultterm\":\"title\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":100,\"key\":\"running_title\",\"tenantterm\":\"running title\",\"frontiersdefaultterm\":\"running title\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":101,\"key\":\"submit\",\"tenantterm\":\"submit\",\"frontiersdefaultterm\":\"submit\",\"category\":\"process\"},{\"sequencenumber\":102,\"key\":\"submitted\",\"tenantterm\":\"submitted\",\"frontiersdefaultterm\":\"submitted\",\"category\":\"process\"},{\"sequencenumber\":103,\"key\":\"submitting\",\"tenantterm\":\"submitting\",\"frontiersdefaultterm\":\"submitting\",\"category\":\"process\"},{\"sequencenumber\":104,\"key\":\"t_e\",\"tenantterm\":\"te\",\"frontiersdefaultterm\":\"te\",\"category\":\"label (role)\"},{\"sequencenumber\":105,\"key\":\"topic\",\"tenantterm\":\"topic\",\"frontiersdefaultterm\":\"topic\",\"category\":\"process\"},{\"sequencenumber\":106,\"key\":\"topic_summary\",\"tenantterm\":\"topic summary\",\"frontiersdefaultterm\":\"topic summary\",\"category\":\"process\"},{\"sequencenumber\":107,\"key\":\"figure\",\"tenantterm\":\"figure\",\"frontiersdefaultterm\":\"figure\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":108,\"key\":\"figures\",\"tenantterm\":\"figures\",\"frontiersdefaultterm\":\"figures\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":109,\"key\":\"editorial_file\",\"tenantterm\":\"editorial file\",\"frontiersdefaultterm\":\"editorial file\",\"category\":\"core\"},{\"sequencenumber\":110,\"key\":\"editorial_files\",\"tenantterm\":\"editorial files\",\"frontiersdefaultterm\":\"editorial files\",\"category\":\"core\"},{\"sequencenumber\":111,\"key\":\"e_book\",\"tenantterm\":\"e-book\",\"frontiersdefaultterm\":\"e-book\",\"category\":\"core\"},{\"sequencenumber\":112,\"key\":\"organization\",\"tenantterm\":\"organization\",\"frontiersdefaultterm\":\"organization\",\"category\":\"core\"},{\"sequencenumber\":113,\"key\":\"institution\",\"tenantterm\":\"institution\",\"frontiersdefaultterm\":\"institution\",\"category\":\"core\"},{\"sequencenumber\":114,\"key\":\"reference\",\"tenantterm\":\"reference\",\"frontiersdefaultterm\":\"reference\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":115,\"key\":\"references\",\"tenantterm\":\"references\",\"frontiersdefaultterm\":\"references\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":116,\"key\":\"sce\",\"tenantterm\":\"sce\",\"frontiersdefaultterm\":\"sce\",\"description\":\"abbreviation for specialty chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":117,\"key\":\"submission\",\"tenantterm\":\"submission\",\"frontiersdefaultterm\":\"submission\",\"category\":\"process\"},{\"sequencenumber\":118,\"key\":\"submissions\",\"tenantterm\":\"submissions\",\"frontiersdefaultterm\":\"submissions\",\"category\":\"process\"},{\"sequencenumber\":119,\"key\":\"editing\",\"tenantterm\":\"editing\",\"frontiersdefaultterm\":\"editing\",\"category\":\"process\"},{\"sequencenumber\":120,\"key\":\"in_preparation\",\"tenantterm\":\"in preparation\",\"frontiersdefaultterm\":\"in preparation\",\"category\":\"process\"},{\"sequencenumber\":121,\"key\":\"country_region\",\"tenantterm\":\"country/region\",\"frontiersdefaultterm\":\"country/region\",\"description\":\"because of political issues, some of the country listings are actually classified as `regions` and we need to include this. however other clients may not want to do this.\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":122,\"key\":\"countries_regions\",\"tenantterm\":\"countries/regions\",\"frontiersdefaultterm\":\"countries/regions\",\"description\":\"because of political issues, some of the country listings are actually classified as `regions` and we need to include this. however other clients may not want to do this.\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":123,\"key\":\"specialty\",\"tenantterm\":\"specialty\",\"frontiersdefaultterm\":\"specialty\",\"category\":\"core\"},{\"sequencenumber\":124,\"key\":\"specialties\",\"tenantterm\":\"specialties\",\"frontiersdefaultterm\":\"specialties\",\"category\":\"core\"},{\"sequencenumber\":125,\"key\":\"associate_editors\",\"tenantterm\":\"associate editors\",\"frontiersdefaultterm\":\"associate editors\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":126,\"key\":\"reviewed\",\"tenantterm\":\"reviewed\",\"frontiersdefaultterm\":\"reviewed\",\"category\":\"peer review process\"},{\"sequencenumber\":127,\"key\":\"institutional_members\",\"tenantterm\":\"institutional partners\",\"frontiersdefaultterm\":\"institutional partners\",\"category\":\"accounting\"},{\"sequencenumber\":128,\"key\":\"institutional_memberships\",\"tenantterm\":\"institutional partnerships\",\"frontiersdefaultterm\":\"institutional partnerships\",\"category\":\"accounting\"},{\"sequencenumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantterm\":\"assistant field chief editors\",\"frontiersdefaultterm\":\"assistant field chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":130,\"key\":\"publications\",\"tenantterm\":\"publications\",\"frontiersdefaultterm\":\"publications\",\"category\":\"process\"},{\"sequencenumber\":131,\"key\":\"ae_accepted\",\"tenantterm\":\"recommended acceptance\",\"frontiersdefaultterm\":\"accepted\",\"category\":\"process\"},{\"sequencenumber\":132,\"key\":\"field_journal\",\"tenantterm\":\"field journal\",\"frontiersdefaultterm\":\"field journal\",\"category\":\"taxonomy\"},{\"sequencenumber\":133,\"key\":\"field_journals\",\"tenantterm\":\"field journals\",\"frontiersdefaultterm\":\"field journals\",\"category\":\"taxonomy\"},{\"sequencenumber\":134,\"key\":\"program_manager\",\"tenantterm\":\"program manager\",\"frontiersdefaultterm\":\"program manager\",\"category\":\"label (role)\"},{\"sequencenumber\":135,\"key\":\"journal_manager\",\"tenantterm\":\"journal manager\",\"frontiersdefaultterm\":\"journal manager\",\"category\":\"label (role)\"},{\"sequencenumber\":136,\"key\":\"journal_specialist\",\"tenantterm\":\"journal specialist\",\"frontiersdefaultterm\":\"journal specialist\",\"category\":\"label (role)\"},{\"sequencenumber\":137,\"key\":\"program_managers\",\"tenantterm\":\"program managers\",\"frontiersdefaultterm\":\"program managers\",\"category\":\"label (role)\"},{\"sequencenumber\":138,\"key\":\"journal_managers\",\"tenantterm\":\"journal managers\",\"frontiersdefaultterm\":\"journal managers\",\"category\":\"label (role)\"},{\"sequencenumber\":139,\"key\":\"journal_specialists\",\"tenantterm\":\"journal specialists\",\"frontiersdefaultterm\":\"journal specialists\",\"category\":\"label (role)\"},{\"sequencenumber\":140,\"key\":\"cover_letter\",\"tenantterm\":\"manuscript contribution to the field\",\"frontiersdefaultterm\":\"manuscript contribution to the field\",\"category\":\"process\"},{\"sequencenumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantterm\":\"recommended to accept manuscript\",\"frontiersdefaultterm\":\"accepted manuscript\",\"category\":\"process\"},{\"sequencenumber\":142,\"key\":\"recommend_for_rejection\",\"tenantterm\":\"recommend for rejection\",\"frontiersdefaultterm\":\"recommend for rejection\",\"category\":\"process\"},{\"sequencenumber\":143,\"key\":\"recommended_for_rejection\",\"tenantterm\":\"recommended for rejection\",\"frontiersdefaultterm\":\"recommended for rejection\",\"category\":\"process\"},{\"sequencenumber\":144,\"key\":\"ae\",\"tenantterm\":\"ae\",\"frontiersdefaultterm\":\"ae\",\"description\":\"associate editor - board member\",\"category\":\"label (role)\"},{\"sequencenumber\":145,\"key\":\"re\",\"tenantterm\":\"re\",\"frontiersdefaultterm\":\"re\",\"description\":\"review editor\",\"category\":\"label (role)\"},{\"sequencenumber\":146,\"key\":\"rev\",\"tenantterm\":\"rev\",\"frontiersdefaultterm\":\"rev\",\"description\":\"reviewer\",\"category\":\"label (role)\"},{\"sequencenumber\":147,\"key\":\"aut\",\"tenantterm\":\"aut\",\"frontiersdefaultterm\":\"aut\",\"description\":\"author\",\"category\":\"label (role)\"},{\"sequencenumber\":148,\"key\":\"coraut\",\"tenantterm\":\"coraut\",\"frontiersdefaultterm\":\"coraut\",\"description\":\"corresponding author\",\"category\":\"label (role)\"},{\"sequencenumber\":149,\"key\":\"saut\",\"tenantterm\":\"saut\",\"frontiersdefaultterm\":\"saut\",\"description\":\"submitting author\",\"category\":\"label (role)\"},{\"sequencenumber\":150,\"key\":\"coaut\",\"tenantterm\":\"coaut\",\"frontiersdefaultterm\":\"coaut\",\"description\":\"co-author\",\"category\":\"label (role)\"},{\"sequencenumber\":151,\"key\":\"tsof\",\"tenantterm\":\"tsof\",\"frontiersdefaultterm\":\"tsof\",\"description\":\"typesetter\",\"category\":\"label (role)\"},{\"sequencenumber\":152,\"key\":\"typesetting_office\",\"tenantterm\":\"typesetting office\",\"frontiersdefaultterm\":\"typesetting office\",\"category\":\"product\"},{\"sequencenumber\":153,\"key\":\"config\",\"tenantterm\":\"config\",\"frontiersdefaultterm\":\"config\",\"description\":\"configuration office role\",\"category\":\"label (role)\"},{\"sequencenumber\":154,\"key\":\"jm\",\"tenantterm\":\"jm\",\"frontiersdefaultterm\":\"jm\",\"description\":\"journal manager\",\"category\":\"label (role)\"},{\"sequencenumber\":155,\"key\":\"rte\",\"tenantterm\":\"rte\",\"frontiersdefaultterm\":\"rte\",\"description\":\"research topic editor\",\"category\":\"label (role)\"},{\"sequencenumber\":156,\"key\":\"organizations\",\"tenantterm\":\"organizations\",\"frontiersdefaultterm\":\"organizations\",\"category\":\"core\"},{\"sequencenumber\":157,\"key\":\"publishing\",\"tenantterm\":\"publishing\",\"frontiersdefaultterm\":\"publishing\",\"category\":\"core\"},{\"sequencenumber\":158,\"key\":\"acceptance\",\"tenantterm\":\"acceptance\",\"frontiersdefaultterm\":\"acceptance\",\"category\":\"process\"},{\"sequencenumber\":159,\"key\":\"preferred_associate_editor\",\"tenantterm\":\"preferred associate editor\",\"frontiersdefaultterm\":\"preferred associate editor\",\"category\":\"label (role)\"},{\"sequencenumber\":160,\"key\":\"topic_editors\",\"tenantterm\":\"topic editors\",\"frontiersdefaultterm\":\"topic editors\",\"category\":\"label (role)\"},{\"sequencenumber\":161,\"key\":\"institutions\",\"tenantterm\":\"institutions\",\"frontiersdefaultterm\":\"institutions\",\"category\":\"core\"},{\"sequencenumber\":162,\"key\":\"author(s)\",\"tenantterm\":\"author(s)\",\"frontiersdefaultterm\":\"author(s)\",\"category\":\"label (role)\"},{\"sequencenumber\":163,\"key\":\"figure(s)\",\"tenantterm\":\"figure(s)\",\"frontiersdefaultterm\":\"figure(s)\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":164,\"key\":\"co-authors\",\"tenantterm\":\"co-authors\",\"frontiersdefaultterm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"label (role)\"},{\"sequencenumber\":165,\"key\":\"editorial_board_members\",\"tenantterm\":\"editorial board members\",\"frontiersdefaultterm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"label (role)\"},{\"sequencenumber\":166,\"key\":\"editorial_board\",\"tenantterm\":\"editorial board\",\"frontiersdefaultterm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"product\"},{\"sequencenumber\":167,\"key\":\"co-authorship\",\"tenantterm\":\"co-authorship\",\"frontiersdefaultterm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"misc.\"},{\"sequencenumber\":168,\"key\":\"role_id_1\",\"tenantterm\":\"registration office\",\"frontiersdefaultterm\":\"registration office\",\"category\":\"user role\"},{\"sequencenumber\":169,\"key\":\"role_id_2\",\"tenantterm\":\"editorial office\",\"frontiersdefaultterm\":\"editorial office\",\"category\":\"user role\"},{\"sequencenumber\":170,\"key\":\"role_id_7\",\"tenantterm\":\"field chief editor\",\"frontiersdefaultterm\":\"field chief editor\",\"category\":\"user role\"},{\"sequencenumber\":171,\"key\":\"role_id_8\",\"tenantterm\":\"assistant field chief editor\",\"frontiersdefaultterm\":\"assistant field chief editor\",\"category\":\"user role\"},{\"sequencenumber\":172,\"key\":\"role_id_9\",\"tenantterm\":\"specialty chief editor\",\"frontiersdefaultterm\":\"specialty chief editor\",\"category\":\"user role\"},{\"sequencenumber\":173,\"key\":\"role_id_10\",\"tenantterm\":\"assistant specialty chief editor\",\"frontiersdefaultterm\":\"assistant specialty chief editor\",\"category\":\"user role\"},{\"sequencenumber\":174,\"key\":\"role_id_11\",\"tenantterm\":\"associate editor\",\"frontiersdefaultterm\":\"associate editor\",\"category\":\"user role\"},{\"sequencenumber\":175,\"key\":\"role_id_12\",\"tenantterm\":\"guest associate editor\",\"frontiersdefaultterm\":\"guest associate editor\",\"category\":\"user role\"},{\"sequencenumber\":176,\"key\":\"role_id_13\",\"tenantterm\":\"review editor\",\"frontiersdefaultterm\":\"review editor\",\"category\":\"user role\"},{\"sequencenumber\":177,\"key\":\"role_id_14\",\"tenantterm\":\"reviewer\",\"frontiersdefaultterm\":\"reviewer\",\"category\":\"user role\"},{\"sequencenumber\":178,\"key\":\"role_id_15\",\"tenantterm\":\"author\",\"frontiersdefaultterm\":\"author\",\"category\":\"user role\"},{\"sequencenumber\":179,\"key\":\"role_id_16\",\"tenantterm\":\"corresponding author\",\"frontiersdefaultterm\":\"corresponding author\",\"category\":\"user role\"},{\"sequencenumber\":180,\"key\":\"role_id_17\",\"tenantterm\":\"submitting author\",\"frontiersdefaultterm\":\"submitting author\",\"category\":\"user role\"},{\"sequencenumber\":181,\"key\":\"role_id_18\",\"tenantterm\":\"co-author\",\"frontiersdefaultterm\":\"co-author\",\"category\":\"user role\"},{\"sequencenumber\":182,\"key\":\"role_id_20\",\"tenantterm\":\"production office\",\"frontiersdefaultterm\":\"production office\",\"category\":\"user role\"},{\"sequencenumber\":183,\"key\":\"role_id_22\",\"tenantterm\":\"typesetting office (typesetter)\",\"frontiersdefaultterm\":\"typesetting office (typesetter)\",\"category\":\"user role\"},{\"sequencenumber\":184,\"key\":\"role_id_24\",\"tenantterm\":\"registered user\",\"frontiersdefaultterm\":\"registered user\",\"category\":\"user role\"},{\"sequencenumber\":185,\"key\":\"role_id_35\",\"tenantterm\":\"job office\",\"frontiersdefaultterm\":\"job office\",\"category\":\"user role\"},{\"sequencenumber\":186,\"key\":\"role_id_41\",\"tenantterm\":\"special event administrator\",\"frontiersdefaultterm\":\"special event administrator\",\"category\":\"user role\"},{\"sequencenumber\":187,\"key\":\"role_id_42\",\"tenantterm\":\"special event reviewer\",\"frontiersdefaultterm\":\"special event reviewer\",\"category\":\"user role\"},{\"sequencenumber\":188,\"key\":\"role_id_43\",\"tenantterm\":\"submit abstract\",\"frontiersdefaultterm\":\"submit abstract\",\"category\":\"user role\"},{\"sequencenumber\":189,\"key\":\"role_id_52\",\"tenantterm\":\"events office\",\"frontiersdefaultterm\":\"events office\",\"category\":\"user role\"},{\"sequencenumber\":190,\"key\":\"role_id_53\",\"tenantterm\":\"event administrator\",\"frontiersdefaultterm\":\"event administrator\",\"category\":\"user role\"},{\"sequencenumber\":191,\"key\":\"role_id_89\",\"tenantterm\":\"content management office\",\"frontiersdefaultterm\":\"content management office\",\"category\":\"user role\"},{\"sequencenumber\":192,\"key\":\"role_id_98\",\"tenantterm\":\"accounting office\",\"frontiersdefaultterm\":\"accounting office\",\"category\":\"user role\"},{\"sequencenumber\":193,\"key\":\"role_id_99\",\"tenantterm\":\"projects\",\"frontiersdefaultterm\":\"projects\",\"category\":\"user role\"},{\"sequencenumber\":194,\"key\":\"role_id_103\",\"tenantterm\":\"configuration office\",\"frontiersdefaultterm\":\"configuration office\",\"category\":\"user role\"},{\"sequencenumber\":195,\"key\":\"role_id_104\",\"tenantterm\":\"beta user\",\"frontiersdefaultterm\":\"beta user\",\"category\":\"user role\"},{\"sequencenumber\":196,\"key\":\"role_id_106\",\"tenantterm\":\"wfconf\",\"frontiersdefaultterm\":\"wfconf\",\"category\":\"user role\"},{\"sequencenumber\":197,\"key\":\"role_id_107\",\"tenantterm\":\"rt management beta user\",\"frontiersdefaultterm\":\"rt management beta user\",\"category\":\"user role\"},{\"sequencenumber\":198,\"key\":\"role_id_108\",\"tenantterm\":\"deo beta user\",\"frontiersdefaultterm\":\"deo beta user\",\"category\":\"user role\"},{\"sequencenumber\":199,\"key\":\"role_id_109\",\"tenantterm\":\"search beta user\",\"frontiersdefaultterm\":\"search beta user\",\"category\":\"user role\"},{\"sequencenumber\":200,\"key\":\"role_id_110\",\"tenantterm\":\"journal manager\",\"frontiersdefaultterm\":\"journal manager\",\"category\":\"user role\"},{\"sequencenumber\":201,\"key\":\"role_id_111\",\"tenantterm\":\"myfrontiers beta user\",\"frontiersdefaultterm\":\"myfrontiers beta user\",\"category\":\"user role\"},{\"sequencenumber\":202,\"key\":\"role_id_21\",\"tenantterm\":\"copy editor\",\"frontiersdefaultterm\":\"copy editor\",\"category\":\"user role\"},{\"sequencenumber\":203,\"key\":\"role_id_1_abr\",\"tenantterm\":\"rof\",\"frontiersdefaultterm\":\"rof\",\"category\":\"user role\"},{\"sequencenumber\":204,\"key\":\"role_id_2_abr\",\"tenantterm\":\"eof\",\"frontiersdefaultterm\":\"eof\",\"category\":\"user role\"},{\"sequencenumber\":205,\"key\":\"role_id_7_abr\",\"tenantterm\":\"fce\",\"frontiersdefaultterm\":\"fce\",\"category\":\"user role\"},{\"sequencenumber\":206,\"key\":\"role_id_8_abr\",\"tenantterm\":\"afce\",\"frontiersdefaultterm\":\"afce\",\"category\":\"user role\"},{\"sequencenumber\":207,\"key\":\"role_id_9_abr\",\"tenantterm\":\"sce\",\"frontiersdefaultterm\":\"sce\",\"category\":\"user role\"},{\"sequencenumber\":208,\"key\":\"role_id_10_abr\",\"tenantterm\":\"asce\",\"frontiersdefaultterm\":\"asce\",\"category\":\"user role\"},{\"sequencenumber\":209,\"key\":\"role_id_11_abr\",\"tenantterm\":\"ae\",\"frontiersdefaultterm\":\"ae\",\"category\":\"user role\"},{\"sequencenumber\":210,\"key\":\"role_id_12_abr\",\"tenantterm\":\"gae\",\"frontiersdefaultterm\":\"gae\",\"category\":\"user role\"},{\"sequencenumber\":211,\"key\":\"role_id_13_abr\",\"tenantterm\":\"re\",\"frontiersdefaultterm\":\"re\",\"category\":\"user role\"},{\"sequencenumber\":212,\"key\":\"role_id_14_abr\",\"tenantterm\":\"rev\",\"frontiersdefaultterm\":\"rev\",\"category\":\"user role\"},{\"sequencenumber\":213,\"key\":\"role_id_15_abr\",\"tenantterm\":\"aut\",\"frontiersdefaultterm\":\"aut\",\"category\":\"user role\"},{\"sequencenumber\":214,\"key\":\"role_id_16_abr\",\"tenantterm\":\"coraut\",\"frontiersdefaultterm\":\"coraut\",\"category\":\"user role\"},{\"sequencenumber\":215,\"key\":\"role_id_17_abr\",\"tenantterm\":\"saut\",\"frontiersdefaultterm\":\"saut\",\"category\":\"user role\"},{\"sequencenumber\":216,\"key\":\"role_id_18_abr\",\"tenantterm\":\"coaut\",\"frontiersdefaultterm\":\"coaut\",\"category\":\"user role\"},{\"sequencenumber\":217,\"key\":\"role_id_20_abr\",\"tenantterm\":\"pof\",\"frontiersdefaultterm\":\"pof\",\"category\":\"user role\"},{\"sequencenumber\":218,\"key\":\"role_id_22_abr\",\"tenantterm\":\"tsof\",\"frontiersdefaultterm\":\"tsof\",\"category\":\"user role\"},{\"sequencenumber\":219,\"key\":\"role_id_24_abr\",\"tenantterm\":\"ru\",\"frontiersdefaultterm\":\"ru\",\"category\":\"user role\"},{\"sequencenumber\":220,\"key\":\"role_id_35_abr\",\"tenantterm\":\"jof\",\"frontiersdefaultterm\":\"jof\",\"category\":\"user role\"},{\"sequencenumber\":221,\"key\":\"role_id_41_abr\",\"tenantterm\":\"se-adm\",\"frontiersdefaultterm\":\"se-adm\",\"category\":\"user role\"},{\"sequencenumber\":222,\"key\":\"role_id_42_abr\",\"tenantterm\":\"se-rev\",\"frontiersdefaultterm\":\"se-rev\",\"category\":\"user role\"},{\"sequencenumber\":223,\"key\":\"role_id_43_abr\",\"tenantterm\":\"se-aut\",\"frontiersdefaultterm\":\"se-aut\",\"category\":\"user role\"},{\"sequencenumber\":224,\"key\":\"role_id_52_abr\",\"tenantterm\":\"evof\",\"frontiersdefaultterm\":\"evof\",\"category\":\"user role\"},{\"sequencenumber\":225,\"key\":\"role_id_53_abr\",\"tenantterm\":\"ev-adm\",\"frontiersdefaultterm\":\"ev-adm\",\"category\":\"user role\"},{\"sequencenumber\":226,\"key\":\"role_id_89_abr\",\"tenantterm\":\"comof\",\"frontiersdefaultterm\":\"comof\",\"category\":\"user role\"},{\"sequencenumber\":227,\"key\":\"role_id_98_abr\",\"tenantterm\":\"aof\",\"frontiersdefaultterm\":\"aof\",\"category\":\"user role\"},{\"sequencenumber\":228,\"key\":\"role_id_99_abr\",\"tenantterm\":\"projects\",\"frontiersdefaultterm\":\"projects\",\"category\":\"user role\"},{\"sequencenumber\":229,\"key\":\"role_id_103_abr\",\"tenantterm\":\"config\",\"frontiersdefaultterm\":\"config\",\"category\":\"user role\"},{\"sequencenumber\":230,\"key\":\"role_id_104_abr\",\"tenantterm\":\"beta\",\"frontiersdefaultterm\":\"beta\",\"category\":\"user role\"},{\"sequencenumber\":231,\"key\":\"role_id_106_abr\",\"tenantterm\":\"wfconf\",\"frontiersdefaultterm\":\"wfconf\",\"category\":\"user role\"},{\"sequencenumber\":232,\"key\":\"role_id_107_abr\",\"tenantterm\":\"rtbeta\",\"frontiersdefaultterm\":\"rtbeta\",\"category\":\"user role\"},{\"sequencenumber\":233,\"key\":\"role_id_108_abr\",\"tenantterm\":\"deobeta\",\"frontiersdefaultterm\":\"deobeta\",\"category\":\"user role\"},{\"sequencenumber\":234,\"key\":\"role_id_109_abr\",\"tenantterm\":\"searchbeta\",\"frontiersdefaultterm\":\"searchbeta\",\"category\":\"user role\"},{\"sequencenumber\":235,\"key\":\"role_id_110_abr\",\"tenantterm\":\"jm\",\"frontiersdefaultterm\":\"jm\",\"category\":\"user role\"},{\"sequencenumber\":236,\"key\":\"role_id_111_abr\",\"tenantterm\":\"mfbeta\",\"frontiersdefaultterm\":\"mfbeta\",\"category\":\"user role\"},{\"sequencenumber\":237,\"key\":\"role_id_21_abr\",\"tenantterm\":\"coped\",\"frontiersdefaultterm\":\"coped\",\"category\":\"user role\"},{\"sequencenumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantterm\":\"editorial board\",\"frontiersdefaultterm\":\"editorial board\",\"description\":\"this is the label for the review editorial board\",\"category\":\"label\"},{\"sequencenumber\":239,\"key\":\"field_chief_editor\",\"tenantterm\":\"field chief editor\",\"frontiersdefaultterm\":\"field chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":240,\"key\":\"field_chief_editors\",\"tenantterm\":\"field chief editors\",\"frontiersdefaultterm\":\"field chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":241,\"key\":\"editor\",\"tenantterm\":\"editor\",\"frontiersdefaultterm\":\"editor\",\"category\":\"label (role)\"},{\"sequencenumber\":242,\"key\":\"editors\",\"tenantterm\":\"editors\",\"frontiersdefaultterm\":\"editors\",\"category\":\"label (role)\"},{\"sequencenumber\":243,\"key\":\"board\",\"tenantterm\":\"board\",\"frontiersdefaultterm\":\"board\",\"category\":\"label\"},{\"sequencenumber\":244,\"key\":\"boards\",\"tenantterm\":\"boards\",\"frontiersdefaultterm\":\"boards\",\"category\":\"label\"},{\"sequencenumber\":245,\"key\":\"article_collection\",\"tenantterm\":\"article collection\",\"frontiersdefaultterm\":\"article collection\",\"category\":\"label\"},{\"sequencenumber\":246,\"key\":\"article_collections\",\"tenantterm\":\"article collections\",\"frontiersdefaultterm\":\"article collections\",\"category\":\"label\"},{\"sequencenumber\":247,\"key\":\"handling_editor\",\"tenantterm\":\"handling editor\",\"frontiersdefaultterm\":\"associate editor\",\"description\":\"this terminology key is for the person assigned to edit a manuscript. it is a label for the temporary handling editor assignment.\",\"category\":\"label (role)\"},{\"sequencenumber\":248,\"key\":\"handling_editors\",\"tenantterm\":\"handling editors\",\"frontiersdefaultterm\":\"associate editors\",\"description\":\"this terminology key is for the person assigned to edit a manuscript. it is a label for the temporary handling editor assignment.\",\"category\":\"label (role)\"},{\"sequencenumber\":249,\"key\":\"ae_accept\",\"tenantterm\":\"recommend acceptance\",\"frontiersdefaultterm\":\"accept\",\"category\":\"process\"},{\"sequencenumber\":250,\"key\":\"rtm\",\"tenantterm\":\"rtm\",\"frontiersdefaultterm\":\"rtm\",\"category\":\"product\"},{\"sequencenumber\":251,\"key\":\"frontiers_media_sa\",\"tenantterm\":\"frontiers media s.a\",\"frontiersdefaultterm\":\"frontiers media s.a\",\"category\":\"customer\"},{\"sequencenumber\":252,\"key\":\"review_editors\",\"tenantterm\":\"community reviewers\",\"frontiersdefaultterm\":\"review editors\",\"category\":\"label (role)\"},{\"sequencenumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantterm\":\"chief editor\",\"frontiersdefaultterm\":\"chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantterm\":\"chief editors\",\"frontiersdefaultterm\":\"chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":255,\"key\":\"call_for_papers\",\"tenantterm\":\"call for papers\",\"frontiersdefaultterm\":\"call for papers\",\"category\":\"label\"},{\"sequencenumber\":256,\"key\":\"calls_for_papers\",\"tenantterm\":\"calls for papers\",\"frontiersdefaultterm\":\"calls for papers\",\"category\":\"label\"},{\"sequencenumber\":257,\"key\":\"supervising_editor\",\"tenantterm\":\"supervising editor\",\"frontiersdefaultterm\":\"supervising editor\",\"description\":\"a chief or assistant chief editor who is assigned to a manuscript to supervise.\",\"category\":\"role\",\"externalkey\":\"supervising_editor\"},{\"sequencenumber\":258,\"key\":\"supervising_editors\",\"tenantterm\":\"supervising editors\",\"frontiersdefaultterm\":\"supervising editors\",\"description\":\"a chief or assistant chief editor who is assigned to a manuscript to supervise.\",\"category\":\"role\",\"externalkey\":\"supervising_editors\"},{\"sequencenumber\":259,\"key\":\"reviewer_endorse\",\"tenantterm\":\"endorse\",\"frontiersdefaultterm\":\"endorse\",\"category\":\"label\"},{\"sequencenumber\":260,\"key\":\"reviewer_endorsed\",\"tenantterm\":\"endorsed\",\"frontiersdefaultterm\":\"endorsed\",\"category\":\"label\"},{\"sequencenumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantterm\":\"endorse publication\",\"frontiersdefaultterm\":\"endorse publication\",\"category\":\"label\"},{\"sequencenumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantterm\":\"endorsed publication\",\"frontiersdefaultterm\":\"endorsed publication\",\"category\":\"label\"},{\"sequencenumber\":263,\"key\":\"editor_role\",\"tenantterm\":\"editor role\",\"frontiersdefaultterm\":\"editor role\",\"category\":\"label\"},{\"sequencenumber\":264,\"key\":\"editor_roles\",\"tenantterm\":\"editor roles\",\"frontiersdefaultterm\":\"editor roles\",\"category\":\"label\"},{\"sequencenumber\":265,\"key\":\"editorial_role\",\"tenantterm\":\"editorial role\",\"frontiersdefaultterm\":\"editorial role\",\"category\":\"label\"},{\"sequencenumber\":266,\"key\":\"editorial_roles\",\"tenantterm\":\"editorial roles\",\"frontiersdefaultterm\":\"editorial roles\",\"category\":\"label\"},{\"sequencenumber\":267,\"key\":\"call_for_paper\",\"tenantterm\":\"call for paper\",\"frontiersdefaultterm\":\"call for paper\",\"category\":\"label\"},{\"sequencenumber\":268,\"key\":\"research_topic_abstract\",\"tenantterm\":\"manuscript summary\",\"frontiersdefaultterm\":\"manuscript summary\",\"category\":\"process\"},{\"sequencenumber\":269,\"key\":\"research_topic_abstracts\",\"tenantterm\":\"manuscript summaries\",\"frontiersdefaultterm\":\"manuscript summaries\",\"category\":\"process\"},{\"sequencenumber\":270,\"key\":\"submissions_team_manager\",\"tenantterm\":\"journal manager\",\"frontiersdefaultterm\":\"content manager\",\"category\":\"process\"},{\"sequencenumber\":271,\"key\":\"submissions_team\",\"tenantterm\":\"journal team\",\"frontiersdefaultterm\":\"content team\",\"category\":\"process\"},{\"sequencenumber\":272,\"key\":\"topic_coordinator\",\"tenantterm\":\"topic coordinator\",\"frontiersdefaultterm\":\"topic coordinator\",\"category\":\"process\"},{\"sequencenumber\":273,\"key\":\"topic_coordinators\",\"tenantterm\":\"topic coordinators\",\"frontiersdefaultterm\":\"topic coordinators\",\"category\":\"process\"},{\"sequencenumber\":274,\"key\":\"frontiers_journal_team\",\"tenantterm\":\"frontiers journal team\",\"frontiersdefaultterm\":\"frontiers journal team\",\"category\":\"label (role)\"},{\"sequencenumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantterm\":\"rt:ic submission\",\"frontiersdefaultterm\":\"rt:ic submission\",\"category\":\"label (role)\"},{\"sequencenumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantterm\":\"rt:ic submission participant\",\"frontiersdefaultterm\":\"rt:ic submission participant\",\"category\":\"label (role)\"}]}'\n",impactgtmid:"gtm-njf2ml9b",impactgtmauth:"fyo-7nodm9w37qgfms03sa",impactgtmpreview:"env-1",impactgooglemapsapikey:"aizasyctehx2eu8pwfi86gw9fi00ftcykk6ifr8",qualtricsv4tov3:"'{\"enabled\":true,\"interceptid\":\"si_er0e2ze69oz8yn4\",\"projectid\":\"zn_cloy77jhkpc8gai\",\"brandid\":\"frontiersin\"}'\n",qualtricsumux:"'{\"enabled\":false,\"interceptid\":\"si_89fphy3etxqbwtu\",\"projectid\":\"zn_cloy77jhkpc8gai\",\"brandid\":\"frontiersin\"}'\n",qualtricscontinuousbrand:"'{\"enabled\":true,\"interceptid\":\"si_9zut94ut81fcrh4\",\"projectid\":\"zn_cloy77jhkpc8gai\",\"brandid\":\"frontiersin\"}'\n",defaultarticletemplate:"v3"},app:{baseurl:"/",buildid:"f2d5b6d8-d01c-4534-90b9-d659f10f17ca",buildassetsdir:"ap-2024/_nuxt",cdnurl:""}}## Introduction
alterations in the gabaergic system, the main inhibitory neurotransmitter system in the brain, may contribute to the pathophysiology of neurodevelopmental disorders (ndds), such as autism spectrum disorder (asd) and angelman syndrome (as). asd is a complex, heterogeneous ndd with both genetic and environmental factors ( bourgeron, 2015 ) contributing to aberrant changes in brain growth, neuronal development, and functional connectivity ( dhossche et al., 2002 ; pizzarelli and cherubini, 2011 ; braat and kooy, 2015 ; robertson et al., 2016 ). asd is characterized by two core domains: impairments in social interaction and communication and the presence of repetitive or restricted behaviors, interests, or activities ( american psychiatric association, 2008 ). there are a range of comorbid conditions, including irritability, depression, anxiety, attention deficits, obsessive-compulsive symptoms, seizures, and sleep disruption. as is a rare genetic ndd with a prevalence of 1 in 12,000 to 20,000 births ( luk and lo, 2016 ; mertz et al., 2013 ). individuals with as often present with autistic features, severe intellectual disability, microcephaly, speech impairment, bursts of laughter, sleep problems, movement disorders, and epilepsy ( buiting, 2010 ; kalsner and chamberlain, 2015 ). gaba a receptors are ligand-gated chloride channels. there are 19 genes encoding gaba a receptor subunits that assemble as pentamers, with the most common stoichiometry being two &#x003b1;, two &#x003b2;, and one &#x003b3; subunit. gaba a subunit combinations give rise to functional, circuit, and behavioral specificity ( sieghart, 2006 ; vithlani et al., 2011 ). gaba a receptors that contain the &#x003b1;5 subunit (gaba a -&#x003b1;5) are of particular interest due to their restricted pattern of expression and unique physiological and pharmacological properties ( sur et al., 1999 ; mohler, 2011 ). in humans, gaba a receptors containing the &#x003b1;5 subunit are preferentially localized in the hippocampus, prefrontal cortex, nucleus accumbens, amygdala, insular cortex, anterior cingulate, and cingulate cortex&#x02014;key regions believed to be involved in the neuropathology and pathophysiology of asd ( mendez et al., 2013 ; myers et al., 2017 ). the gabra5 gene has been proposed as a candidate gene for asd ( delong, 2007 ; mesbah-oskui et al., 2017 ; warrier et al., 2013 ; di nanni et al., 2019 ), suggesting decreased gabaergic inhibition in a subpopulation of autistic individuals. mutations involving the gaba a receptor subunit genes gabra5 , gabrb3 , and gabrg3 (encoding the &#x003b1;5, &#x003b2;3, and &#x003b3;3 subunits) found on chromosomal region 15q11&#x02013;q13 have been associated with ndds including as, epilepsy, and prader&#x02013;willi syndrome in addition to asd ( hogart et al., 2010 ; sanders, 2015 ). as is predominantly caused by the loss of function of the maternally inherited ube3a gene; however, approximately 75% of individuals with as carry a large deletion of the maternal 15q11&#x02013;q13 chromosomal region. clinical studies have shown that individuals with as who have large deletions (deletion as) exhibit more severe symptoms than those in whom ube3a is the only gene affected, suggesting that the gabra5 , gabrb3 , and gabrg3 genes are relevant to the etiology of the disease. imaging studies using pet and magnetic resonance spectroscopy have shown reduced gaba a receptor binding in the superior and medial frontal cortex ( mori et al., 2012 ) and reduced gaba levels in individuals with asd ( robertson et al., 2016 ; gaetz et al., 2014 ; rojas et al., 2014 ; puts et al., 2017 ). postmortem studies have shown reduced numbers of inhibitory interneurons ( dufour et al., 2023 ), reduced expression of gaba a receptor subunits ( delorey, 2005 ; abrahams and geschwind, 2008 ), and reduced levels of the gaba-synthesizing enzymes such as glutamic acid decarboxylase (gad) 65 and 67 ( fatemi et al., 2002 ). there is increasing evidence from genetic, environmental, and phenotypic rodent models relevant to asd indicating that gabaergic circuit dysfunctions contribute to autism-like phenotypes ( fukuda et al., 2005 ; chao et al., 2010 ; banerjee et al., 2013 ). such deficits may result from multiple causes, including a reduced number of gabaergic interneurons, altered interneuron function, impaired gaba a receptor trafficking to the membrane, reduced expression of gaba a receptor subunits, and reduced gaba uptake function of gat-1 in neurons ( nakamura et al., 2016 ; orefice et al., 2016 ; mermer et al., 2021 ). supportive evidence is provided by the observation of autism-like behaviors in both gaba a -&#x003b1;5 and &#x003b2;3 subunit knockout mice ( zurek et al., 2016 ; delorey et al., 2008 ). regarding possible therapeutic approaches, enhancement of the gaba a receptor activity by non-selective benzodiazepines has been shown to ameliorate autism-like behavioral deficits in mouse models; however, due to sedation that is likely mediated by the activation of the gaba a -&#x003b1;1 subtype, very narrow therapeutic margins were observed ( han et al., 2012 ; han et al., 2014 ; lim et al., 2017 ). interestingly, a recent study showed that a gaba a -&#x003b1;5 positive allosteric modulator (pam), sh-053-2&#x02032;f-r-ch3, attenuated social and cognitive deficits in male rats exposed to valproic acid in utero , a rat model relevant to autism ( souza et al., 2024 ). the aim of the current study was to determine whether a selective gaba a -&#x003b1;5 pam, alogabat (also known as ro7017773 or rg7816), would produce beneficial effects in animal models relevant to autism-like repetitive behavior&#x02014;specifically btbr mice ( mcfarlane et al., 2008 ) and contactin-associated protein-like 2 [cntnap2 &#x02212;/&#x02212; ] homozygous knockout mice ( penagarikano et al., 2011 )&#x02014;and anti-seizure activity, without the typical side effects of non-selective gaba a pams, such as sedation and cognitive impairment. furthermore, target engagement was assessed by in vivo receptor occupancy (ro) and pharmacological mri (phmri) in rodents, and an electroencephalography (eeg) study in rats was undertaken to identify a putative pharmacodynamic readout for future clinical trials. 2 materials and methods further information for each method listed below can be found in the supplementary material . 2.1 materials alogabat [ro7017773; c 21 h 23 n 5 o 4 ; 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl) methoxy)-n-(tetrahydropyran-4-yl)pyridazine-3-carboxamide (iupac name); molecular weight: 409.44&#x000a0;gmol &#x02212;1 ] was synthesized at f.hoffmann-la roche ag, switzerland [ figure 1a ; see example 8 in buettelmann et al., 2018 ]. the discovery of alogabat and the related chemical series will be disclosed in future publications. diazepam, l-655,708, [ 3 h]flumazenil, [ 3 h]l-655,708, and [ 3 h]ro0154513 were synthesized at f.hoffmann-la roche ag, switzerland. figure 1 figure 1 . in vitro pharmacology of alogabat. (a) chemical structure of alogabat (ro7017773; c21h23n5o4); 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl) methoxy)-n-(tetrahydropyran-4-yl)pyridazine-3-carboxamide (iupac name); molecular weight, 409.44&#x000a0;gmol &#x02212;1 . (b) concentration-response curves of alogabat in [ 3 h]flumazenil competition-binding assays with membranes expressing different rat recombinant gaba a receptor subtypes ( n &#x0003d; 10&#x02013;20/concentration). (c) concentration-response curves of the effects of alogabat in hek293 cells expressing different rat recombinant gaba a receptor subtypes ( n &#x0003d; 4&#x02013;5/concentration). data in the graphs are shown as the mean (symbols) &#x000b1; sem (error bars). error bars smaller than the symbol size are not shown. (d) isoguvacine concentration-response curves obtained in the presence and absence of alogabat in rat hippocampal slices. the points represent the mean values &#x000b1; sem of three slices. the sigmoidal curves were fit through these points. (e) the ppi of ps was measured in the absence (control) and presence of alogabat at 0.3&#x000a0;&#x000b5;m ( n &#x0003d; 3 slices) and 1&#x000a0;&#x000b5;m ( n &#x0003d; 6 slices). ps1 and ps2 are the responses induced by the first and second stimulus, respectively. the data are normalized to the amplitude of ps1 and presented as the mean &#x000b1; sem. 2.2 in vitro experiments 2.2.1 gaba a receptor radioligand binding assays the affinity of alogabat for rat and human gaba a receptors containing &#x003b1;5, &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits was measured by [ 3 h]flumazenil competition-binding assays with membranes expressing different rat recombinant gaba a receptor subtypes ( n &#x0003d; 10&#x02013;20/concentration) and for human &#x003b1;4 and &#x003b1;6 by [ 3 h]ro0154513, as previously described ( ballard et al., 2009 ; hipp et al., 2021 ). 2.2.2 gaba a receptor electrophysiological studies alogabat was tested for functional activity on four different cloned rat and human gaba a receptor subtypes ( buettelmann et al., 2018 ), namely, &#x003b1;1&#x003b2;2&#x003b3;2, &#x003b1;2&#x003b2;3&#x003b3;2, &#x003b1;3&#x003b2;3&#x003b3;2, and &#x003b1;5&#x003b2;3&#x003b3;2. ion currents were induced by gaba concentrations that evoked approximately 20% of the maximal response ( n &#x0003d; 4&#x02013;5/concentration). the following concentrations of gaba were used: 1&#x000a0;&#x000b5;m for &#x003b1;1&#x003b2;2&#x003b3;2, 10&#x000a0;&#x000b5;m &#x003b1;2&#x003b2;3&#x003b3;2, 10&#x000a0;&#x000b5;m for &#x003b1;3&#x003b2;3&#x003b3;2, and 3&#x000a0;&#x000b5;m for &#x003b1;5&#x003b2;3&#x003b3;2 receptor subtype. alogabat was also tested for functional activity on native gaba a -&#x003b1;5 receptors in rat hippocampal slices: modulation of isoguvacine-induced population spikes ( ballard et al., 2009 ) and paired-pulse inhibition (ppi) ( xie and tietz, 1991 ). population spikes (pss) were recorded every 30&#x000a0;s by the stimulation of the schaffer collaterals, and isoguvacine was applied consecutively and in increasing concentrations for at least 4&#x000a0;min to the slices (control). after the washout of isoguvacine, alogabat (300&#x000a0;nm) was added to the bath perfusion, and a new isoguvacine concentration-response curve was obtained (alogabat). the ps amplitudes were normalized to the control ps obtained before the first application of isoguvacine and were fitted individually for each slice ( n &#x0003d; 3 slices). the ppi of ps was measured in the absence (control) and presence of alogabat at 0.3&#x000a0;&#x000b5;m ( n &#x0003d; 3 slices from one animal) and 1&#x000a0;&#x000b5;m ( n &#x0003d; 6 slices from two animals). the paired-pulse protocol consisted of two stimuli timely spaced by 20&#x000a0;ms, which were applied at the schaffer collaterals in rat hippocampal slices. we used a low number of animals based on our experience with the assay, which is highly robust and reproducible, and in alignment with our commitment to reducing the number of animals used. 2.2.3 selectivity screening the selectivity of alogabat (10&#x000a0;&#x000b5;m) over more than 70 receptors was assessed by radioligand binding studies conducted using eurofins cerep sa (celle l&#x000e9;vescault, france), following the methods described on www.eurofinsdiscoveryservices.com . 2.3 in vivo experiments 2.3.1 ethics approval experiments performed at f.hoffmann-la roche ag (basel, switzerland) complied with the swiss federal and cantonal laws on animal research and aaalac regulations and received prior approval from the cantonal veterinary office. the eeg study was conducted at brains online (ca, united states) in accordance with the guide for the care and use of laboratory animals (national research council 2011) after gaining approval from the institutional animal care and use committee. the pentylenetetrazole (ptz) and maximal electroshock (mes) tests were conducted at vivocore inc., canada, which is a facility licensed by the ontario ministry of agriculture, food, and rural affairs and accredited by the canadian council on animal care. all in vivo studies are reported in compliance with the arrive guidelines ( percie du sert et al., 2020 ). 2.3.2 animals all animals were group-housed in holding rooms at controlled temperature and humidity under a 12&#x000a0;h light/dark cycle and were allowed to acclimate for at least 7&#x000a0;days. twenty-six male wistar rats (charles river, germany; &#x0223c;160&#x000a0;g) and sixteen male cntnap2 &#x02212;/&#x02212; mice (bred at roche basel; 18&#x02013;22&#x000a0;g) were used in receptor occupancy studies. thirty-two male fischer rats (charles river, germany) were assessed in mri experiments (&#x0223c;250&#x000a0;g). seventeen male wistar rats (envigo, united states) were assessed in eeg experiments. one hundred male btbr mice (bred in roche basel) were assessed in grooming and open-field tests (n &#x0003d; 60, &#x0223c;30&#x000a0;g) and for digging behavior (n &#x0003d; 40, &#x0223c;30&#x000a0;g). fifty-seven male cntnap2 &#x02212;/&#x02212; mice (bred in roche basel; 5&#x02013;6&#x000a0;weeks) and wildtype littermates (n &#x0003d; 15) were assessed in grooming and open-field tests. one hundred male sprague&#x02013;dawley rats (charles river, canada) were used to evaluate antiepileptic effects in the ptz (70&#x02013;100&#x000a0;g, n &#x0003d; 40) and mes (&#x0003c;50&#x000a0;g n &#x0003d; 60) tests. forty-eight male sprague&#x02013;dawley rats (charles river, france) were used in the rotarod test (&#x0223c;170&#x02013;200&#x000a0;g). one hundred and forty-one male lister hooded (lh) rats (charles river, germany) were used in the cognition tests: 5-choice serial reaction time (5-csrt) task (n &#x0003d; 11, &#x0223c;400&#x000a0;g); continuous performance test (cpt; n &#x0003d; 11, &#x0223c;400&#x000a0;g); paired associates learning (pal) task (n &#x0003d; 12, &#x0223c;400&#x000a0;g); context fear conditioning (n &#x0003d; 67, &#x0223c;250&#x000a0;g); and morris water maze (n &#x0003d; 40, 350&#x02013;400&#x000a0;g). 2.3.3 alogabat treatment alogabat was formulated in 2% hydroxypropyl cellulose in water (or 0.3% tween 80 in saline for in vivo occupancy and grooming/digging experiments). the administration volume was 10&#x000a0;ml/kg (mice) and 5&#x000a0;ml/kg (rats). each dose was expressed as the weight of the base. alogabat was administered with a pre-treatment time of 30&#x000a0;min in mice and 60&#x000a0;min in rats (except for the eeg study), based on pharmacokinetic data indicating the time of maximal drug plasma concentration. treatment groups were assigned randomly. dose groups were provided as coded vials to allow blinded assessment during the conduct of each experiment. to minimize potential confounders regarding the time of day for behavioral testing, animals were split into separate cohorts (balanced for treatment groups) and tested during the same period. 2.3.4 receptor occupancy studies 2.3.4.1 in vivo occupancy in rats male wistar rats (n &#x0003d; 26, &#x0223c;160&#x000a0;g) were administered vehicle or alogabat (0.3, 1, 3, 10, 30, and 100&#x000a0;mg/kg, intraperitoneally [i.p.], n &#x0003d; 3/group) or the gaba a -&#x003b1;5 blocker l-655,708 at 10&#x000a0;mg/kg i.p. (n &#x0003d; 2). fifteen minutes later, the gaba a -&#x003b1;5 radioligand [ 3 h]ro0154513 was administered intravenously (i.v.) to assess ro ( ballard et al., 2009 ; hipp et al., 2021 ). non-specific binding was determined by pre-treatment with the established gaba a -&#x003b1;5 receptor blocker l-655,708 (10&#x000a0;mg/kg i.p.; n &#x0003d; 2). 2.3.4.2 ex vivo occupancy in cntnap2 &#x02212;/&#x02212; mice cntnap2 &#x02212;/&#x02212; mice ( penagarikano et al., 2011 ) (n &#x0003d; 16, 18&#x02013;22&#x000a0;g) were administered the vehicle or alogabat (30, 60, and 100&#x000a0;mg/kg) i.p. (n &#x0003d; 4/group), and ro was assessed in brain sections with the highly selective gaba a -&#x003b1;5 radioligand, [ 3 h]l-655,708, 30&#x000a0;min post-administration. 2.3.5 pharmacological mri in rats male fischer rats (n &#x0003d; 32, &#x0223c;250&#x000a0;g) were administered vehicle or alogabat (3, 10, and 30&#x000a0;mg/kg) i.p. (n &#x0003d; 8/dose). phmri was performed under medetomidine sedation in a small-animal scanner (4.7t/40&#x000a0;cm; bruker biospin, germany), and blood perfusion was analyzed according to previously published procedures ( bruns et al., 2009 ). fifteen minutes after drug treatment, rats were initially anesthetized using isoflurane (4%) in the carrier gas composed of oxygen and air (1:5), supplied to the spontaneously breathing animals in an inhalation box. upon the induction of anesthesia, a subcutaneous (s.c.) bolus injection of 0.2&#x000a0;mg/kg (1&#x000a0;ml/kg) of medetomidine prepared from 1:5 diluted dormilan &#x000ae; was administered, and the animal was transferred onto a rat cradle for inserting an s.c. catheter and starting continuous infusion of 1:10 diluted dormilan &#x000ae; (medetomidine) at a dose of 0.1&#x000a0;mg/kg/h (1&#x000a0;ml/kg/h). the head was immobilized in a stereotaxic frame. respiratory rate, body temperature, and o 2 and co 2 levels in inhaled and exhaled air were continuously monitored using a powerlab data acquisition system (adinstruments, spechbach, germany). body temperature was maintained at 37&#x000b0;c with a feedback-regulated electric heating blanket. immediately after the last imaging assessment, rats were euthanized by decapitation under anesthesia, and plasma samples were collected at approximately 40&#x000a0;min post-administration of alogabat. images were processed and analyzed using in-house developed software written in idl (rsi, boulder, co, united states) and matlab (the mathworks inc., natick, ma, united states). 2.3.6 eeg in rats male wistar rats (n &#x0003d; 17) were surgically prepared with wireless implanted transmitters to enable simultaneous recording of eeg, hippocampal (ca3) local field potential (lfp), and emg. rats were anesthetized using isoflurane (2%, 800&#x000a0;ml/min o2). bupivacaine/epinephrine was used for local analgesia, while finadyne or carprofen was used for peri-/post-operative analgesia. amoxicillin was used as an antibiotic. the animals were placed in a stereotaxic frame (kopf instruments, united states). a subcutaneous pocket was created near the dorsal flank, into which a transmitter (f50-eee, data sciences international, physio tel f50-eee small animal cns telemetry; three bipolar channels, biopotential lead, outer diameter 0.3&#x000a0;mm) was inserted. the transmitter included three bipolar channels: channel 1 (eeg): two screws in the left hemisphere (frontal: 11&#x000a0;mm anterior and 2.5&#x000a0;mm lateral to bregma; central: 3&#x000a0;mm anterior and 3.5&#x000a0;mm lateral to lambda); channel 2 (lfp): a single wire electrode targeting the ca3 region of the right hippocampus; and channel 3 (emg): electrodes placed in the neck muscle for recording emg activity, aiding in sleep stage classification. after a 2-week recovery, rats were administered the vehicle or alogabat (10&#x000a0;mg/kg) using a cross-over design (1-week interval). if the setup allowed, the positive control diazepam (2&#x000a0;mg/kg) was assessed. all drugs were administered i.v. via an implanted cannula so that brain exposure was expected within a few minutes of administration. eeg spectral power was analyzed quantitatively up to 1&#x000a0;h post-administration. only animals with clean eeg recordings were included in the analysis. eeg data in the awake state were used for the analyses reported in this study. we first investigated the effects on power over predefined theta and beta power ranges, defined a priori as 6&#x02013;10&#x000a0;hz and 20&#x02013;30&#x000a0;hz, respectively, based on previous studies with gabaa drugs ( visser et al., 2003 ; van lier et al., 2004 ). then, we evaluated frequency-specific effects across the 2&#x02013;128&#x000a0;hz range. 2.3.7 grooming behavior and open-field test in btbr and cntnap2 &#x02212;/&#x02212; mice male btbr mice (n &#x0003d; 60, &#x0223c;30&#x000a0;g) were pre-treated with the vehicle or alogabat at 30, 60, 90, and 120&#x000a0;mg/kg i.p. (n &#x0003d; 12/dose). male cntnap2 &#x02212;/&#x02212; mice (n &#x0003d; 57, 5&#x02013;6&#x000a0;weeks) and wildtype littermates (n &#x0003d; 15) received sub-chronic treatment (8&#x02013;10&#x000a0;days) with the vehicle or alogabat at 30, 60, and 100&#x000a0;mg/kg i.p. (n &#x0003d; 14&#x02013;15/dose). spontaneous locomotor activity was assessed in both groups of mice for 1&#x000a0;h in an open field (42 &#x000d7; 42 &#x000d7; 30.5&#x000a0;cm; 20 lux at the center of the arena) with a small amount of sawdust bedding. movement of the animal was detected by interruptions in an array of photobeams from horizontally located infrared sources placed around the open field, measured using a versamax system (accuscan instruments inc., columbus, oh, united states). activity was measured as the distance traveled (cm). one week later, each mouse was placed into a type-ii cage (21.5 &#x000d7; 15.5 &#x000d7; 13.0&#x000a0;cm; 40 lux) for 5&#x000a0;min habituation, and then the cumulative time (s) spent grooming during 10&#x000a0;min was recorded manually by a blinded observer. distance traveled (cm) during the session was measured using a video tracking system (ethovision, noldus information technology, netherlands). plasma samples were collected from btbr mice 1&#x000a0;week after testing and 30&#x000a0;min after treatment ( n &#x0003d; 6/dose). plasma samples were collected from cntnap2 &#x02212;/&#x02212; mice 1&#x000a0;day later and 30&#x000a0;min after treatment ( n &#x0003d; 4/dose). 2.3.8 digging behavior in btbr mice a separate group of male btbr mice (n &#x0003d; 40, &#x0223c;30&#x000a0;g) were pre-treated with vehicle or alogabat at 30, 60, and 100&#x000a0;mg/kg i.p. (n &#x0003d; 10/dose) and were placed into a small circular dish (d &#x0003d; 10&#x000a0;cm) filled with fresh thick sawdust located in the middle of a clean type-ii cage (21.5 &#x000d7; 15.5 &#x000d7; 13.0&#x000a0;cm; 40 lux). the cumulative time (s) spent digging over 5&#x000a0;min was recorded manually by a blinded observer. the distance traveled (cm) and speed were also measured in the arena, outside the dish (ethovision, noldus information technology, netherlands). plasma samples were collected immediately after the digging test, i.e., 35&#x02013;40&#x000a0;min post-administration ( n &#x0003d; 3/dose). 2.3.9 evaluation of antiepileptic effects in rats vehicle or alogabat (5, 15, or 30&#x000a0;mg/kg) was administered p.o. (n &#x0003d; 8/dose) and assessed for seizures induced by (1) subcutaneous (s.c.) ptz and (2) the maximum electrical stimulus (mes) model in male sprague&#x02013;dawley rats (ptz: 70&#x02013;100&#x000a0;g, n &#x0003d; 40; mes: &#x0003c;50&#x000a0;g n &#x0003d; 60, charles river, canada). diazepam (synthesized at f.hoffmann-la roche ag) was included in each experiment as a positive control and administered at 3&#x000a0;mg/kg i.p., 30&#x000a0;min prior to testing. immediately following testing, a terminal blood sample was collected under anesthesia. 2.3.9.1 pentylenetetrazole test following the designated pre-treatment time, ptz was administered at 75&#x000a0;mg/kg s.c. animals were transferred to a single cage and monitored closely for the onset of clonic seizure, and the percentage of each group showing seizures was recorded. protection was defined as the complete absence of clonic seizure, including forelimb clonus, over the 30&#x000a0;min observation period. 2.3.9.2 maximal electroshock test following the designated pre-treatment time, rats received maximal electroshock (mes: 150&#x000a0;ma, 0.2&#x000a0;s duration, 60&#x000a0;hz) via corneal electrodes moistened with saline (shock simulator type 221; harvard apparatus). due to inconsistency in responses by rats to this type of stimuli, all test animals (n &#x0003d; 60) were subjected to two screening sessions on two separate days, and 40 rats were selected based on their reliability to have tonic seizures. drug testing was conducted on the third day, during which the rats received the standard maximal electroshock, and the presence or absence of a tonic seizure was recorded and expressed as the percentage of animals in each group that showed seizures. protection was defined as the absence of a full tonic seizure within 15&#x000a0;s of stimulus delivery. 2.3.10 combination with diazepam on rotarod performance in rats forty-eight male sprague&#x02013;dawley rats (&#x0223c;170&#x02013;200&#x000a0;g) were pre-trained to the rotarod (47750 rota-rod ng, ugo basile) at 8&#x000a0;rpm for 120&#x000a0;s. one day later, rats were administered alogabat (or vehicle) p.o., 30&#x000a0;min prior to diazepam or vehicle i.p., and they were assessed on the rotarod 30&#x000a0;min later. each rat was given three attempts to remain on the rotarod, with a maximum duration of 120&#x000a0;s per attempt. treatment groups (n &#x0003d; 8/group) consisted of alogabat alone (30&#x000a0;mg/kg), diazepam alone (5&#x000a0;mg/kg), or alogabat at 3, 10, and 30&#x000a0;mg/kg in combination with diazepam (5&#x000a0;mg/kg). the maximum time (s) spent on the rotarod was recorded. after the completion of rotarod testing, animals were euthanized under isoflurane anesthesia for plasma sample collection at approximately 70&#x000a0;min post-administration of alogabat. 2.3.11 cognition testing in rats 2.3.11.1 operant and touchscreen cognition tests separate groups of male lister hooded (lh) rats (&#x0223c;400&#x000a0;g) were pre-trained in the operant and touch screen tests, as described in supplementary material . the 5-csrt task (n &#x0003d; 11) is a test of attention. the primary parameter is the total percentage of correct responses. continuous performance test (cpt; n &#x0003d; 11) assesses sustained attention. the primary parameter is the discrimination sensitivity index (d prime), which is a ratio based on the rate at which rats make correct and incorrect responses. the paired associates learning (pal) task (n &#x0003d; 12) assesses visual&#x02013;spatial memory. the primary parameter is the total percentage of correct responses. a latin-squares design was used to assess the vehicle and doses of alogabat (3, 10, and 30&#x000a0;mg/kg p.o.). rats were tested twice weekly with at least a 2-day interval between test sessions. rats were trained between test days to maintain baseline performance. 2.3.11.2 context fear conditioning two cohorts of male lh rats (&#x0223c;250&#x000a0;g; n &#x0003d; 67) were assessed for context fear conditioning (cfc) in two experiments: (1) vehicle or alogabat at 10 and 30&#x000a0;mg/kg (n &#x0003d; 9/dose); (2) vehicle or alogabat at 1, 3, and 10&#x000a0;mg/kg (n &#x0003d; 10/dose) administered p.o., 60&#x000a0;min prior to the acquisition session. rats were placed into a novel test chamber (45&#x000a0;cm &#x000d7; 45&#x000a0;cm &#x000d7; 46.5&#x000a0;cm) with a grid floor and clear plastic walls (tse-systems gmbh, germany). during the acquisition session, a 2-min habituation phase was followed by the delivery of a mild foot shock (0.8&#x000a0;ma for 1&#x000a0;s) applied through the grid floor. following a 1&#x000a0;min interval, a second foot shock was delivered. the animals remained in the chambers for a further 30&#x000a0;s. one day later, the animals were returned to the same test chamber for a 5-min period without any foot shock. rodents respond to danger in a species-specific manner by freezing, i.e., the animals will withhold all movement, except for respiration, to avoid detection. the amount of freezing behavior was measured by the computer as the time spent immobile (minimum threshold of 1&#x000a0;s) and was expressed as the percentage of time spent freezing during the 5-min session. following cfc, plasma samples were collected 1&#x02013;2&#x000a0;days later from rats pre-treated with the same dose at 60&#x000a0;min post-administration ( n &#x0003d; 4/dose). 2.3.11.3 morris water maze male lh rats (350&#x02013;400&#x000a0;g) were pre-treated with vehicle or 10 or 30&#x000a0;mg/kg alogabat p.o. (n &#x0003d; 10/dose) once daily during cued acquisition (visible platform; three trials per day for 2&#x000a0;days), followed by a 2-day interval and then spatial acquisition (hidden platform; three trials per day for 4&#x000a0;days) in the morris water maze (mwm; computer tracking system hvs image ltd., united kingdom) ( ballard et al., 2005 ). twenty-four hours later, the platform was removed, and the rats were pre-treated with vehicle or alogabat and allowed to swim in the maze for 60&#x000a0;s (probe trial) to assess the retention/spatial memory of the platform position, expressed as the percentage of distance traveled in each quadrant. for the mwm, plasma samples were collected immediately after the last trial on the 12th day of treatment at approximately 70&#x000a0;min post-administration ( n &#x0003d; 4&#x02013;5/dose). 2.3.12 plasma sampling and analysis rodents were deeply anesthetized with 5% isoflurane, and blood was collected following decapitation with a guillotine or via cardiac puncture (ptz and mes). during eeg experiments, blood was collected from a cannula in the right femoral artery. blood samples were centrifuged in edta-coated eppendorf tubes (4,000&#x000a0;rpm, 4&#x000b0;c, 5&#x000a0;min), and plasma was collected, immediately frozen, and stored at &#x02212;80&#x000b0;c. samples were analyzed for the concentration of alogabat using qualified liquid chromatography coupled to tandem mass spectrometry (lc-ms/ms) assays. 2.3.13 statistical analysis sample sizes were determined based on historical data for each experiment within each laboratory. 2.3.13.1 eeg linear mixed-effects models (lmms) were used since these can account for incomplete datasets, which was the case in this study. specific contrasts were derived and tested using t-tests within the model using satterthwaite approximation for degrees of freedom. models were derived for each compound individually: y &#x0223c; compound &#x0002b; (1&#x0007c;animal). the significance of differences in the peak frequency was assessed using random permutation tests (10,000). 2.3.13.2 phmri analysis was performed with jmp (sas institute inc., cary, united states) and matlab (the mathworks inc., natick, ma, united states). global (whole-brain) absolute-perfusion values from the vehicle and the three dose groups were tested for a linear trend across the four doses using a one-way anova framework. the same analysis was applied roi-wise to the normalized-perfusion values. multiple testing across the single rois was accounted for by controlling the false discovery rate (fdr) at 10% using the benjamini&#x02013;hochberg approach. to also obtain an overall activation&#x02013;strength metric, normalized-perfusion values of each dose group were compared roi-wise to those of the vehicle group using welch&#x02019;s t-test without multiple-testing correction. the number of significantly modulated rois at each dose was then taken as a measure of &#x0201c;pattern strength.&#x0201d; the mean and the upper 95% confidence limit of the corresponding chance levels were estimated via random group-label permutations (100,000 runs per group). significance levels of the actual pattern strengths were determined based on the distributions obtained through the permutation procedure. 2.3.13.3 behavior all statistical analyses were performed using prism (graphpad software). one-factor anova was used for between-group comparison (i.e., dose), with repeated measures for within-subject comparison (i.e., time bins and platform quadrants). dunnett&#x02019;s test was used for post hoc comparisons. student&#x02019;s unpaired two-tailed t-test was used when two groups were compared. the chi-square test was used to compare the percentage of groups. rotarod data were analyzed using a non-parametric kruskal&#x02013;wallis test, followed by dunn&#x02019;s multiple comparison test. statistical significance was predetermined as p &#x0003c; 0.05. 3 results 3.1 binding affinity for gaba a receptors containing &#x003b1;5 and other &#x003b1; subunits the aim of these radioligand binding studies was to determine the binding selectivity of alogabat at the rat and human gaba a receptors containing &#x003b1;5 compared to &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits. alogabat had a high affinity for gaba a -&#x003b1;5&#x003b2;3&#x003b3;2 receptors in rats (ki 7.9&#x000a0;nm), with approximately 37-, 26-, and 18-fold selectivity compared to gaba a &#x003b1;1&#x003b2;3&#x003b3;2, &#x003b1;2&#x003b2;3&#x003b3;2, and &#x003b1;3&#x003b2;3&#x003b3;2, respectively ( figure 1b ; see supplementary table s1 ). alogabat had a similar pharmacological profile in human recombinant gaba a receptor subtypes (see supplementary table s1 ). 3.2 functional activity at recombinant and native gaba a receptors we undertook electrophysiological studies in hek293 cells and oocytes to assess the functional activity of alogabat on cloned rat and human gaba a receptor subtypes containing &#x003b1;5, &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits. alogabat enhanced gaba-evoked responses of rat and human &#x003b1;5-containing receptors by 167% ( figure 1c ) and 72% (see supplementary table s2 ), respectively. the maximum amount of potentiation was slightly lower at human receptors. this may be due to the different expression systems used, i.e., hek293 cells for rat receptors and xenopus oocytes for human receptors. at the highest concentrations tested, alogabat potentiated other receptor subtypes to a much lesser extent than &#x003b1;5-containing receptors. the potency of alogabat was comparable between gaba a -&#x003b1;5 receptors containing either &#x003b3;2 or &#x003b3;3 subunits, i.e., gaba a -&#x003b1;5&#x003b2;3&#x003b3;2 and gaba a -&#x003b1;5&#x003b2;3&#x003b3;3 receptors (see supplementary figure s1 ). at native gaba a receptors in rat hippocampal slices, alogabat positively modulated gabaergic inhibition of ca1 pyramidal cells, as shown by a leftward shift of the concentration-dependent inhibition of the population spike by isoguvacine ( figure 1d ) and enhanced paired-pulse inhibition of the population spike during field potential recordings ( figure 1e ). together, these results confirm the binding selectivity of alogabat and demonstrate that alogabat is a functionally selective pam of gaba-evoked responses. 3.3 selectivity data we assessed alogabat in radioligand binding studies with more than 70 receptors and showed that alogabat at 10&#x000a0;&#x000b5;m had over 917-fold binding selectivity for the gaba a -&#x003b1;5&#x003b2;3&#x003b3;2 receptor subtype against all other targets tested (see supplementary table s3 ). 3.4 receptor occupancy in wistar rats and cntnap2 &#x02212;/&#x02212; mice the main objective of these studies was to visualize and quantify gaba a -&#x003b1;5 ro by alogabat. alogabat decreased the specific binding of the gaba a -&#x003b1;5 receptor-specific radioligand [ 3 h]ro0154513 in the hippocampus of rats in a dose-dependent manner. the highest dose of alogabat (100&#x000a0;mg/kg i.p.) reduced specific binding by 100%, i.e., to the same binding level as that of 10&#x000a0;mg/kg l-655,708 ( figure 2a ). a total plasma concentration of 669&#x000a0;ng/ml and a total brain concentration of 208&#x000a0;ng/g were required to produce half-maximal gaba a -&#x003b1;5 ro (ec 50 ) in the hippocampus in rats. in cntnap2 &#x02212;/&#x02212; mice, estimated gaba a -&#x003b1;5 ro based on the ex vivo study with [ 3 h]l-655,708 was 43%, 46%, and 71% at doses of 30, 60, and 100&#x000a0;mg/kg i.p., respectively ( figure 2b ). in addition, the rat occupancy curve was used to calculate ro related to plasma exposure for all in vivo experiments described in this manuscript below (also refer to supplementary tables s4&#x02013;s5 ). figure 2 figure 2 . receptor occupancy and phmri signature of alogabat following acute administration. (a) concentration-dependent blockade of [ 3 h]ro0154513 binding by alogabat in wistar rats: with increasing concentrations from the different doses (0.3&#x02013;100&#x000a0;mg/kg i.p., n &#x0003d; 3/dose) of alogabat (vehicle &#x0003d; without pre-treatment, n &#x0003d; 3). (b) representative autoradiograms of alogabat ex vivo occupancy in cntnap2 &#x02212;/&#x02212; mice via in vitro incubation of the highly selective gaba a -&#x003b1;5 receptor radioligand [ 3 h]l-655,708 to sagittal brain sections. the cntnap2&#x02212;/&#x02212; mice were treated with vehicle and 30, 60, or 100&#x000a0;mg/kg i.p. alogabat (n &#x0003d; 4/dose). (c) trend of normalized-perfusion response pattern strength increasing with dose, given as numbers (&#x000b1; 95% confidence intervals) of significantly (de-)activated regions of interest (rois) following the administration of alogabat (n &#x0003d; 8/dose) to fischer (f344) rats under medetomidine sedation. &#x0201c;chance level&#x0201d; &#x0003d; mean (black dotted line) and 95th percentile (gray dotted line) derived from the permutation test. significant deviations in the number of modulated rois from the chance level are denoted by &#x0002a; p &#x0003c; 0.05, &#x0002a;&#x0002a; p &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a; p &#x0003c; 0.001 (uncorrected). ro is the calculated receptor occupancy for gaba a -&#x003b1;5 from measured plasma concentrations at each dose. (d) sagittal schematic of rat brain showing rois with a significant dose-dependent modulation (linear trend of normalized perfusion). rois passing false discovery rate control at 10% are shown, with roi outlines indicating uncorrected significance level (no outline, p &#x0003c; 0.05; dotted outline, p &#x0003c; 0.01; and solid outline, p &#x0003c; 0.001). roi abbreviations: acbsh, nucleus accumbens shell; amg, amygdala; drn, dorsal raphe nucleus; hpcfi, fimbria hippocampi; insc, insular cortex; lc, locus coeruleus; m1, primary motor cortex; mpfc/cg, medial prefrontal, cingulate cortex; pir, piriform (entorhinal) cortex; prh, perirhinal cortex; s1, primary somatosensory cortex; sn, substantia nigra; th, thalamus; vc, visual cortex. 3.5 pharmacological mri signature in rats the purpose of this study was to evaluate the effects of alogabat on regional neural activity. blood perfusion, measured quantitatively by phmri, was taken as a proxy for neural activity. the administration of a single dose of alogabat at 3&#x02013;30&#x000a0;mg/kg i.p. in rats resulted in moderate but consistent and dose-dependent changes in neural activity patterns compared to treatment with the vehicle ( figure 2c ). significant dose-dependent modulation of normalized perfusion by alogabat was observed in limbic brain regions, i.e., the nucleus accumbens (shell), amygdala, and hippocampus (fimbria); in several cortical brain regions, the thalamus and brainstem nuclei; and in the substantia nigra ( figure 2d ). a linear dose effect was also observed on whole-brain absolute perfusion. alogabat target engagement in brain tissue ranged from 54% to 84% ro. 3.6 eeg signature in rats the aim of this study was to determine whether alogabat induces a characteristic eeg signature that could be used as a translational pharmacodynamic marker. as a first step and based on previous findings on the eeg effects of gaba a drugs ( van lier et al., 2004 ; visser et al., 2003 ; friedman et al., 1992 ), we investigated eeg spectral power change in the theta (6&#x02013;10&#x000a0;hz) and beta (20&#x02013;30&#x000a0;hz) frequency bands. alogabat, administered as 10&#x000a0;mg/kg i.v. (5&#x000a0;min infusion), significantly increased eeg beta-band activity by 21% &#x000b1; 11% relative to the baseline (mean &#x000b1; sd) and decreased theta-band activity by 32% &#x000b1; 19% ( figures 3a,b ). frequency-resolved changes confirmed a decrease in theta power (approximately 6&#x02013;10&#x000a0;hz) and revealed broader beta and gamma modulation (approximately 20&#x02013;50&#x000a0;hz) ( figures 3c&#x02013;e ). the calculated ro after the application of alogabat was 77%&#x02013;85% for gaba a -&#x003b1;5 (see supplementary table s6 ). the overall spectral pattern was qualitatively similar to that of diazepam; however, the peak frequency in the beta frequency range was higher for alogabat (32&#x000a0;hz for alogabat vs. 22.6&#x000a0;hz for diazepam; p &#x0003d; 0.006, random permutation test), and its amplitude was greater for diazepam (142% &#x000b1; 44% increase for diazepam vs. 27% &#x000b1; 16% increase for alogabat; p &#x0003c; 0.001). this is likely related to the high binding and functional selectivity of alogabat for &#x003b1;5-containing gaba a receptors compared to the non-selective profile of diazepam. figure 3 figure 3 . pharmacodynamic effect of alogabat on eeg spectral power. (a,b) modulations of vehicle ( n &#x0003d; 12), alogabat 10&#x000a0;mg/kg ( n &#x0003d; 9), and diazepam 2&#x000a0;mg/kg ( n &#x0003d; 7, positive control) in the beta (20&#x02013;30&#x000a0;hz) and theta (6&#x02013;10&#x000a0;hz) power. (c&#x02013;e) effects of individual compounds and vehicle on the eeg power spectrum. each individual recording is displayed as a light gray line, and the group average and its 95% confidence intervals are shown as colored bands. for all panels, power averaged over 0.2&#x02013;1&#x000a0;h post dosing is shown relative to pre-dosing baseline average over &#x02212;1 to &#x02212;0.2&#x000a0;h before dosing. statistics: &#x0002a; p &#x0003c; 0.05 versus vehicle (linear mixed-effects models followed by t-tests). 3.7 repetitive behaviors in mouse models relevant to asd the inbred mouse strain btbr and the cntnap2 &#x02212;/&#x02212; mouse show abnormalities in core asd behavioral domains, such as repetitive behaviors. self-grooming and digging are more elevated in the btbr mouse than in other strains, i.e., c57bl/6j ( mcfarlane et al., 2008 ), and cntnap2 &#x02212;/&#x02212; mice show more elevated grooming than their wildtype littermates ( penagarikano et al., 2011 ). the aim of the following experiments was to determine whether alogabat has a specific effect on repetitive behaviors independent of potential effects on overall locomotor activity. we assessed the effects of subchronic treatment on cntnap2 &#x02212;/&#x02212; mice to exclude potential tolerance to the effects of alogabat. 3.7.1 open field in btbr and cntnap2 &#x02212;/&#x02212; mice in btbr mice, acute administration of alogabat (30&#x02013;120&#x000a0;mg/kg i.p.) had no effect on the total activity over 1&#x000a0;h measured in an open field [f(4,55) &#x0003d; 2.04], although during the first 10&#x000a0;min, alogabat at 90 and 120&#x000a0;mg/kg significantly reduced the distance traveled [f(4,55) &#x0003d; 9.623, p &#x0003c; 0.001, figure 4a ]. there was also no effect of sub-chronic alogabat (30&#x02013;100&#x000a0;mg/kg i.p.) on the total activity over 1&#x000a0;h in cntnap2 &#x02212;/&#x02212; mice [f(3,53) &#x0003d; 0.98]. during the first 5&#x000a0;min, 100&#x000a0;mg/kg reduced the distance traveled in cntnap2 &#x02212;/&#x02212; mice to the same level as vehicle-treated wildtype mice ( figure 4b ). alogabat did not induce a major impairment of locomotor activity in the open field. figure 4 figure 4 . effect of alogabat on repetitive behaviors in btbr and cntnap2 &#x02212;/&#x02212; mice. (a) alogabat was administered i.p. 30&#x000a0;min prior to the assessment of locomotor activity in an open-field test in btbr mice: distance traveled (cm) per 5&#x000a0;min time bin ( line graph ) and in 1&#x000a0;h total ( bar chart inset ). (b) alogabat was administered i.p. once daily for 2&#x02013;3&#x000a0;days, and on the test day, it was administered 30&#x000a0;min prior to testing cntnap2 &#x02212;/&#x02212; mice in an open field: distance traveled (cm) per 5&#x000a0;min time bin ( line graph ) and in 1&#x000a0;h total ( bar chart insert ). in btbr mice, on a separate test day, alogabat was administered i.p. 30&#x000a0;min prior to the grooming test: (c) duration (s) of grooming behavior and (e) distance (cm) traveled during the 10&#x000a0;min period in the test chamber. in cntnap2 &#x02212;/&#x02212; mice, alogabat was administered i.p. once daily for 8&#x02013;10&#x000a0;days, and on the test day, it was administered 30&#x000a0;min prior to the grooming test: (d) duration (s) of grooming behavior and (f) distance traveled during the 10&#x000a0;min period in the test chamber. data are presented as individual points (circles) and mean &#x000b1; sem (btbr: n &#x0003d; 12/group; cntnap2 &#x02212;/&#x02212; : n &#x0003d; 14&#x02013;15/group). statistics: &#x0002a; p &#x0003c; 0.05, &#x0002a;&#x0002a; p &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a; p &#x0003c; 0.001 vs. vehicle (veh)-treated btbr or cntnap2 &#x02212;/&#x02212; mice. &#x000a7;&#x000a7;&#x000a7; p &#x0003c; 0.001 vehicle-treated wildtype (wt-v) mice vs. vehicle (v)-treated cntnap2 &#x02212;/&#x02212; mice. alogabat was administered i.p. 30&#x000a0;min prior to the assessment of digging behavior in btbr mice: (g) duration (s) of digging behavior, (h) distance traveled (cm), and (i) speed (cm/s) during the 5&#x000a0;min period in the test chamber. data are presented as individual points (circles) and mean &#x000b1; sem ( n &#x0003d; 12/group). statistics: &#x0002a;&#x0002a; p &#x0003c; 0.01 and &#x0002a;&#x0002a;&#x0002a; p &#x0003c; 0.001 vs. vehicle-treated btbr mice. ro is the calculated receptor occupancy for gaba a -&#x003b1;5 from the measured plasma concentrations at each dose. 3.7.2 grooming behavior in btbr and cntnap2 &#x02212;/&#x02212; mice acute administration of alogabat in btbr mice dose-dependently attenuated grooming behavior at 60, 90, and 120&#x000a0;mg/kg i.p. [f(4,55) &#x0003d; 6.946, p &#x0003d; 0.0001, figure 4c ] without reducing locomotor activity in the same test arena ( figure 4e ). in contrast, doses of 60 and 90&#x000a0;mg/kg increased the distance traveled [f(4,55) &#x0003d; 3.454, p &#x0003c; 0.05]. alogabat had a specific effect on grooming behavior at plasma concentrations corresponding to calculated gaba a -&#x003b1;5 ro levels of 45%&#x02013;70% (see supplementary table s4 ). sub-chronic administration of alogabat in cntnap2 &#x02212;/&#x02212; mice attenuated grooming behavior at 60 and 100&#x000a0;mg/kg i.p. [f(3,53) &#x0003d; 10.57, p &#x0003c; 0.0001, figure 4d ], with no effect on locomotor activity measured in the same test arena [f(3,53) &#x0003d; 0.74, figure 4f ]. alogabat had a specific effect on repetitive grooming behavior at plasma concentrations that correspond with calculated gaba a -&#x003b1;5 ro of 52%&#x02013;79% (see supplementary table s4 ). 3.7.3 digging behavior in btbr mice there was no effect of acute alogabat administration on digging behavior at doses up to 100&#x000a0;mg/kg i.p. [f(3,36) &#x0003d; 0.8, figure 4g ], corresponding to a calculated gaba a -&#x003b1;5 ro level of 67% (see supplementary table s4 ). alogabat at 100&#x000a0;mg/kg reduced the distance traveled [f(3,36) &#x0003d; 12.1, p &#x0003c; 0.001, figure 4h ] and speed [f(3,36) &#x0003d; 11.5, p &#x0003c; 0.001, figure 4i ] in the same arena. 3.8 anticonvulsant activity in rats the purpose of these experiments was to evaluate the antiepileptic properties of alogabat against seizures induced by ptz and the mes model. alogabat administered in combination with a convulsant dose of ptz completely blocked seizures at 15 and 30&#x000a0;mg/kg ( figure 5a ), which corresponds to calculated gaba a -&#x003b1;5 ro levels of 71% and 77% (see supplementary table s5 ). meanwhile, in the mes test, alogabat at 5&#x000a0;mg/kg (57% ro, see supplementary table s5 ) showed a significant reduction in the percent of rats that had tonic seizures ( figure 5b ); there was only a tendency for reduction at 15&#x000a0;mg/kg ( p &#x0003d; 0.1) and 30&#x000a0;mg/kg ( p &#x0003d; 0.06). the positive control, diazepam, significantly reduced the percentage of rats that had seizures in both the ptz and mes tests. figure 5 figure 5 . evaluation of alogabat for effects on anticonvulsant, motor, and cognitive tests. alogabat was administered p.o. 60&#x000a0;min prior to the following behavior tests. assessment of potential anticonvulsant activity in (a) ptz and (b) mes tests in rats. diazepam (dzp) at 3&#x000a0;mg/kg i.p. was included as a positive control. data are presented as individual points (circles) and the percentage of rats per group showing seizures ( n &#x0003d; 8/group). (c) time (s) spent on the rotarod at 16&#x000a0;rpm in rats administered alogabat alone (30&#x000a0;mg/kg, gray bar with black outline) or alogabat at 3, 10, and 30&#x000a0;mg/kg co-administered with diazepam at 5&#x000a0;mg/kg i.p. (gray bars with red outline) compared with vehicle (open bar) or diazepam (open bar with red outline). data are presented as individual points (circles) and median &#x000b1; interquartile range (n &#x0003d; 8/group). assessment of cognition in rats: (d) attention in the 5-choice serial reaction time (5-csrt) task; (e) sustained attention in the touchscreen continuous performance test (cpt); (f) visual&#x02013;spatial memory in the touchscreen pal task. cfc at (g) 10 and 30&#x000a0;mg/kg; (h) 1, 3, and 10&#x000a0;mg/kg. spatial learning and memory in the mwm: alogabat was administered once daily for 11&#x000a0;days prior to the probe trial. (i) percentage of distance traveled in all four quadrants: vehicle; 10&#x000a0;mg/kg; 30&#x000a0;mg/kg. data are presented as individual points (circles) and mean &#x000b1; sem for pal ( n &#x0003d; 12/dose; within-subjects), 5-csrt and cpt ( n &#x0003d; 11/dose, within-subjects), cfc ( n &#x0003d; 9&#x02013;10/group), and mwm ( n &#x0003d; 10/group). statistics: &#x0002a; p &#x0003c; 0.05, &#x0002a;&#x0002a; p &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a; p &#x0003c; 0.001 vs. vehicle (veh or 0)-treated rats; mwm statistics: &#x0002a; p &#x0003c; 0.05, &#x0002a;&#x0002a; p &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a; p &#x0003c; 0.001 vs. percentage of distance in the platform quadrant. ro is the calculated receptor occupancy of alogabat for gaba a -&#x003b1;5 from measured plasma concentrations at each dose. 3.9 combination with diazepam on rotarod performance in rats classical benzodiazepines, such as diazepam, are known to induce sedation and ataxia, which can be measured by the rotarod task in rodents. the aim of this experiment was to determine whether alogabat affects rotarod performance when administered alone and, second, whether alogabat modulates the sedative/motor effect of diazepam on rotarod performance when given in combination. diazepam at 5&#x000a0;mg/kg i.p. significantly impaired rotarod performance. alogabat (3&#x02013;30&#x000a0;mg/kg p.o.) co-administered with diazepam did not worsen the effects of diazepam on rotarod performance ( figure 5c ). alogabat administered alone at 30&#x000a0;mg/kg p.o. did not differ from vehicle-treated rats, corresponding to a calculated gaba a -&#x003b1;5 ro level of 88% (see supplementary table s5 ). 3.10 evaluation of cognition in rats since non-selective gaba a pams, such as diazepam, have been shown to impair cognition ( ballard et al., 2005 ), the aim of the following experiments was to study the potential effects of acute administration of alogabat on cognition in rats. this included attention in the 5-csrt task and associative (fear) memory in cfc. we also assessed visual&#x02013;spatial memory (pal task) and attention (cpt) in a touchscreen system, which provides a translational approach for assessing cognition ( hvoslef-eide et al., 2016 ). chronic treatment with alogabat was also assessed on spatial learning and memory in the mwm. in the 5-csrt task, alogabat at 30&#x000a0;mg/kg induced a small but statistically significant reduction in percent correct (3%; within-subjects comparison; f(3,30) &#x0003d; 5.6, p &#x0003c; 0.01; figure 5d ). however, alogabat did not impair attention in cpt (f(2,20) &#x0003d; 0.3; figure 5e ) or visual&#x02013;spatial memory in the pal task (f(2,22) &#x0003d; 2.6; figure 5f ). in the cfc test, alogabat was administered before the acquisition session to determine whether there was an effect on learning the association between foot shock and the surrounding context. in the first experiment, alogabat impaired cfc at 10 and 30&#x000a0;mg/kg, corresponding to calculated gaba a -&#x003b1;5 ro levels of 75% and 81% (f(2,24) &#x0003d; 10.99, p &#x0003c; 0.001; figure 5g ). a second experiment was undertaken to explore lower doses, and it showed that alogabat did not significantly impair cfc at 1, 3, and 10&#x000a0;mg/kg (f(3,36) &#x0003d; 0.9; figure 5h ), corresponding to the calculated gaba a -&#x003b1;5 ro levels of 35%, 56%, and 72%. this suggests that the dose of 10&#x000a0;mg/kg is approximately the threshold level for the impairment of cfc and is likely dependent on the level of ro achieved per subject. in the mwm test, chronic administration of alogabat at 10 and 30&#x000a0;mg/kg did not significantly impair the acquisition of the hidden platform position (see supplementary figure s2 ). twenty-four hours later, the platform was removed, and the rats were allowed to swim in the maze for 60&#x000a0;s (probe trial) to assess memory-retention of the platform position. the groups receiving vehicle [f(3,27) &#x0003d; 8, p &#x0003c; 0.001] and 10&#x000a0;mg/kg [f(3,27) &#x0003d; 7, p &#x0003c; 0.01] had learned the spatial position of the platform, as shown by their preference for the platform quadrant ( figure 5i ). however, rats that received 30&#x000a0;mg/kg alogabat showed impaired spatial memory of the platform position during the probe trial [f(3,27) &#x0003d; 3, p &#x0003d; 0.08; figure 5i ], and gaba a -&#x003b1;5 ro was estimated to be 79%. in summary, alogabat impaired context and spatial memory at gaba a -&#x003b1;5 ro above 70%. 4 discussion 4.1 in vitro and in vivo characterization of alogabat alogabat was shown to be a potent and functionally selective gaba a -&#x003b1;5 receptor pam in vitro . the functional activity of alogabat was confirmed at native gaba a receptors in rat hippocampal slices. in vivo binding experiments demonstrated dose-dependent target engagement of alogabat in rats and cntnap2 &#x02212;/&#x02212; mice. the highest specific binding was observed in the hippocampus, which is consistent with the known distribution of the gaba a -&#x003b1;5 receptor subtype in rodents ( pirker et al., 2000 ). phmri studies in rats demonstrated dose-dependent perfusion changes, indicating circuit modulation by alogabat. there were consistent changes in the neural activity pattern across dose groups, with modulation of neural activity in, among others, the medial prefrontal cortex, cingulate cortex, motor cortex, perirhinal cortex, nucleus accumbens shell, amygdala, hippocampus fimbria, and substantia nigra. 4.2 eeg signature acute administration of alogabat in rats induced an eeg signature characterized by a power decrease in theta and an increase in the beta frequency range, which was qualitatively similar to the eeg signature of non-selective gaba a pams such as diazepam ( van lier et al., 2004 ; visser et al., 2003 ; friedman et al., 1992 ). the lower magnitude of induced eeg beta-band power by alogabat compared to diazepam is likely attributed to its &#x003b1;5-selectivity, resulting in an overall lower magnitude of gaba a receptor modulation. this eeg signature of alogabat is qualitatively a mirror image of the eeg signature of basmisanil, a highly selective gaba a -&#x003b1;5 negative allosteric modulator (nam), which we recently found to induce an increase in the theta power and a decrease in the beta-band eeg power in healthy volunteers ( hipp et al., 2021 ). furthermore, the eeg signature of alogabat is in agreement with the link between beta-band activity and single-nucleotide polymorphisms (snps) in gaba a receptor genes ( porjesz et al., 2002 ; smit et al., 2018 ) and ndds (dup15q syndrome, as) involving gene copy number variations of gabrb3, gabra5 , and gabrg3 ( frohlich et al., 2019a ; frohlich et al., 2019b ). gaba a receptor-related changes in beta-band activity are believed to reflect the modulation of recurrent excitatory&#x02013;inhibitory feedback loops in the cortical tissue ( whittington et al., 2000 ; traub and jefferys, 1999 ). for the administered doses, the calculated receptor occupancies were in the range of 77%&#x02013;84% for &#x003b1;5-containing receptors and 22%&#x02013;34% for &#x003b1;1-containing receptors (with different pam effects (e max ) at &#x003b1;5 vs. &#x003b1;1). thus, at the studied doses, alogabat has some effect on &#x003b1;1-containing receptors, and further work is needed to systematically study lower doses of alogabat, including those &#x0003c;70% ro without the impairment of cognition in wt rats, to confirm whether the modulation of &#x003b1;5-containing receptors alone is sufficient to induce the described eeg effect. nonetheless, eeg theta- and beta-band power are promising candidates for translational mechanistic biomarkers of gaba a -&#x003b1;5 receptor function and could be used in the further development of alogabat. 4.3 behavioral effects of alogabat in animal models relevant to asd we assessed the effects of alogabat in two different mouse models relevant to asd, one phenotypic and one genetic. acute administration of alogabat significantly and dose-dependently attenuated excessive grooming, but not digging, behavior in btbr mice. sub-chronic administration of alogabat significantly attenuated elevated grooming behavior in cntnap2 &#x02212;/&#x02212; mice. efficacy in these different models was linked to gaba a -&#x003b1;5 ro above 50%. despite initial findings of a transiently decreased activity in an open-field test, alogabat increased the activity of btbr mice and had no effect on the activity of cntnap2 &#x02212;/&#x02212; mice during the grooming test, supporting the specific effect of alogabat on repetitive grooming. we have tested additional compounds with similar properties, e.g., ro7015738, and have confirmed that gaba a -&#x003b1;5 pams reduce repetitive behaviors in these mouse models ( buettelmann et al., 2018 ). these results align well with recently published data showing that gaba a -&#x003b1;5 receptor deficiency causes autism-like behaviors in mice, including increased grooming and reduced social contacts ( zurek et al., 2016 ), and with sh-053-2&#x02032;f-r-ch3, a gaba a -&#x003b1;5 pam, which was recently shown to have positive effects on social and cognitive deficits in a rat model of autism ( souza et al., 2024 ). our data are valuable in providing information on the ro required for in vivo effects on repetitive behavior. however, it should be noted that this effect may not directly translate to all individuals with asd as it is a heterogeneous disorder, whereas these mouse models exhibit specific genetic or phenotypic deficits. 4.4 anticonvulsant effects of alogabat it has been proposed that the reduction of gabaergic inhibitory activity results in hyperexcitability of minicolumn circuits, explaining some of the symptomatology observed in some ndds, including the high incidence of seizures and auditory&#x02013;tactile hypersensitivity ( rubenstein and merzenich, 2003 ; frye et al., 2016 ). in the current study, we demonstrated that alogabat exhibits an anticonvulsant profile with activity comparable to the benzodiazepine drug class in acutely induced seizure models (electrical and chemical). alogabat had a small effect on seizures in the mes test, whereas in the ptz test, alogabat was shown to completely block seizures at calculated gaba a -&#x003b1;5 ro &#x0003e;70%. since ptz is a gaba a antagonist, this supports the assessment of alogabat for anticonvulsant activity in disorders where there is dysfunction of the gabaergic system. furthermore, in a separate eeg study, we observed that one out of eight rats had frequent spike-and-wave discharge (swd) activity, which was alleviated following treatment with alogabat (see supplementary figures s3a&#x02013;s3c ; methods in supplementary material ). to better understand the temporal dynamics of swd occurrence and the suppressing effect of alogabat, we performed a follow-up study on three additional rats that showed pronounced swd. both 3 and 10&#x000a0;mg/kg alogabat substantially reduced the number of swds within the first 3&#x000a0;h of recording, when the same rats showed increased swd numbers in the vehicle control condition (see supplementary figures s3d&#x02013;s3f ), which corresponds to the calculated gaba a -&#x003b1;5 ro level of 30%&#x02013;46% (see supplementary table s6 ). from a circuit perspective, the consensus is that such epileptic activity is generated by dysregulated thalamocortical circuitry, with abnormal interactions between reticular thalamic neurons and thalamic relay cells acting as the trigger and cortical circuits serving as the generator ( sitnikova et al., 2023 ). considering that in rats, &#x003b1;5-subunit-containing gaba a receptors are enriched in the cortex and hippocampus ( serwanski et al., 2006 ; hu et al., 2019 ), mediating dendritic inhibition on pyramidal neurons ( ali and thomson, 2008 ; schulz et al., 2018 ), we hypothesize that alogabat could suppress swd generation by enhancing the inhibition of cortical pyramidal neurons. however, more systematic work is required to confirm that alogabat can prevent swd activity. 4.5 assessment of non-specific behavioral effects non-selective gaba a pams, such as diazepam and chlordiazepoxide, are effective anxiolytics in clinical use but have also been shown to impair cognition in rodents and humans. gaba a -&#x003b1;5 receptors are believed to play a major role in cognition since they are predominantly expressed in the hippocampus in rats, where they regulate nmdar-dependent synaptic plasticity underlying learning and memory processes ( schulz et al., 2018 ; fritschy et al., 1997 ; schulz et al., 2019 ; davenport et al., 2021 ). moreover, it has been proposed that gaba a pams may induce memory impairment by modulating hippocampal function ( mcnaughton and morris, 1987 ). therefore, alogabat was evaluated in several rodent tests of cognition to determine whether a selective gaba a -&#x003b1;5 pam would induce cognitive impairment following acute administration in rats. there was no effect of alogabat up to 70% gaba a -&#x003b1;5 ro on cognition (visual&#x02013;spatial memory, attention, context fear conditioning, spatial learning, and memory). cognitive impairment was only observed at high doses (&#x0003e;70% ro) and supra-therapeutic levels of alogabat in associative (fear) learning (cfc) and spatial memory in the mwm in wildtype rats. the impairment at high doses is likely linked to the loss of selectivity toward gaba a &#x003b1;1, &#x003b1;2, and &#x003b1;3 receptor subtypes (&#x003b1;1 ro was calculated as 19%&#x02013;25% at these doses; see supplementary table s6 ). in addition to the loss of selectivity, we cannot exclude the possibility that these effects may be a consequence of gaba a -&#x003b1;5 receptor saturation, i.e., excessive &#x003b1;5 activity in wildtype subjects may be detrimental. the cognitive impairment observed in wildtype rats may translate to healthy human subjects; however, our focus is on the effect of &#x003b1;5 pams in disease conditions with impaired gaba a signaling and impaired cognition, where our hypothesis is that an &#x003b1;5 pam would have beneficial effects. alogabat had no effect on social approach/avoidance, the elevated plus maze, and the vogel conflict test in rats at ro levels up to 80% (see supplementary figure s4 and methods in supplementary material ), suggesting that alogabat does not exhibit an anxiolytic-like effect in rodents. this might be explained by the low expression of gaba a -&#x003b1;5 in the amygdala, a key node controlling anxiety-like behaviors. potential anxiolytic effects of alogabat in humans cannot be excluded as this receptor subtype is much more abundant in the human amygdala. since benzodiazepines, such as diazepam, are frequently used to treat anxiety and seizures in ndds, it was important to establish that alogabat at relevant therapeutic doses in mouse models did not worsen the sedative/motor-impairing effects of diazepam in the rotarod test. alogabat did not worsen diazepam-induced motor impairment; on the contrary, in combination, it reduced the motor impairments, which is more likely due to the more localized and precise inhibitory effect, counterbalancing the broader suppression of neuronal activity by diazepam, or due to lower intrinsic activity at &#x003b1;1 receptors compared to diazepam. we have previously shown that a gaba a -&#x003b1;5 nam, which binds at the benzodiazepine binding site of the receptor, does not decrease the anxiolytic activity of chlordiazepoxide (see supplementary figure s5 ); therefore, it is unlikely that alogabat will interfere with the anxiolytic effect of the classical benzodiazepines. 5 conclusion multiple lines of evidence point to deficits in gabaergic signaling in epilepsy and ndds, such as asd and deletion as, with a prominent role attributed to gaba a receptors, including the gaba a -&#x003b1;5 receptor subtype. the current data for alogabat showed robust dose-dependent efficacy on repetitive behaviors in two disease-relevant mouse models and anti-seizure activity in the ptz rat model at gaba a -&#x003b1;5 ro above 50%. our in vivo occupancy measurements using the selective &#x003b1;5 tracer l-655,708 were highly valuable for understanding plasma and csf exposures (as a surrogate of free brain concentration) and their relationship to in vivo effects. we observed that there was a 34-fold shift between the csf concentration of alogabat in the in vivo occupancy study and that of alogabat in vitro binding data (ki value). the receptor occupancy of alogabat correlates well with pd effects ( in vivo effects) and is consistent across the different studies/species (see supplementary table s6 ). this finding highlights the importance of using pet tracers in drug development. our data suggest that gaba a -&#x003b1;5 pams may have potential benefits in individuals with autistic features and in conditions with clinical and nonclinical manifestations of cortical hyperexcitability and epilepsy. however, alogabat is unlikely to work across all ndds and should be utilized as a precision medicine to target a specific subgroup of the ndd population with deficient gaba a pathway signaling, or specifically gaba a -&#x003b1;5. interestingly, recent data suggest that gaba a -&#x003b1;5 pams may also have therapeutic potential in schizophrenia, alzheimer&#x02019;s disease, and depression ( perez et al., 2023 ; luscher et al., 2023 ; koh et al., 2013 ). with regard to the current status of alogabat, good-laboratory practice (glp) toxicology and safety pharmacology studies in rats and minipigs showed an overall benign safety profile, which supported its clinical investigations in phase-1 studies in healthy volunteers and phase-2 trials in asd and deletion as patients (nct03507569, nct03774576, nct03847987, nct04299464, nct05630066, and eudract&#x00023;2019-003524-20). the outcome of these studies, including pet, eeg, and effects on cognition, will be reported in the future. data availability statement the original contributions presented in the study are included in the article/ supplementary material , further inquiries can be directed to the corresponding author. ethics statement experiments performed at f. hoffmann-la roche ag (basel, switzerland) complied with swiss federal and cantonal laws on animal research and aaalac regulations and received prior approval from the cantonal veterinary office. the eeg study was conducted at brains online (ca, united states) in accordance with the guide for the care and use of laboratory animals (national research council 2011) after receiving approval from the institutional animal care and use committee. the ptz and mes tests were conducted at vivocore inc., canada, which is a facility licensed by the ontario ministry of agriculture, food, and rural affairs and accredited by the canadian council on animal care. all in vivo studies are reported in compliance with the arrive guidelines ( percie du sert et al., 2020 ). the study was conducted in accordance with the local legislation and institutional requirements. author contributions gc: supervision, writing - original draft, investigation, formal analysis. tmb: formal analysis, investigation, writing - review and editing, methodology. fk: formal analysis, writing - original draft, investigation, methodology. mh: writing - original draft, investigation, methodology, formal analysis. jfh: data curation, visualization, methodology, writing - original draft, formal analysis. pg: methodology, data curation, formal analysis, writing - original draft. tm: investigation, writing - original draft, formal analysis, methodology. bk: investigation, writing - original draft, methodology, formal analysis. anb: formal analysis, writing - original draft, data curation. epp: writing - original draft, methodology, investigation. ps: methodology, investigation, writing - original draft, formal analysis. pj: writing - original draft, formal analysis. rr: methodology, writing - original draft, investigation, formal analysis. bb: methodology, investigation, writing - original draft. hk: methodology, writing - original draft, investigation. ao-m: writing - original draft, formal analysis, methodology. alb: methodology, writing - original draft, investigation. jms: investigation, formal analysis, writing - original draft. db: methodology, writing - original draft, investigation. ms: writing - original draft, methodology, investigation. eco&#x00027;c: investigation, writing - original draft, methodology. m-ch: investigation, conceptualization, writing - review and editing, supervision, writing - original draft, methodology. funding the author(s) declare that financial support was received for the research and/or publication of this article. the funding was provided by f. hoffmann-la roche ag switzerland. acknowledgments the authors thank gregoire friz, maria karg, and judith lengyel (molecular biology and binding assays); v&#x000e9;ronique graf, rachel haab, and marie-claire pflimlin ( in vitro electrophysiology); brigitte algeyer, severine bandinelli, sean durkin, audrey genet, marie haman, martine maco, and roger wyler (behavioral pharmacology); and stephanie sch&#x000f6;ppenthau, s&#x000e9;bastien debilly, and thomas bielser ( in vivo phmri). the rat ptz and mes studies were carried out under the scientific guidance of dr guy higgins, intervivo solutions, and coordinated by leo silenieks at vivocore inc., ontario, canada. the rat eeg data acquisition was undertaken by brains on-line llc, south san francisco, united states, and the data analysis was undertaken by pg, vanessa keeney, and andr&#x000e9;s olivares at roche. conflict of interest authors gc, tmb, fk, mh, jfh, pg, tm, bk, ab, epp, ps, pj, rr, bb, hk, ao-m, ab, jms, ms, eco&#x00027;c, and m-ch were employed by f. hoffmann-la roche ag switzerland. all employees (former and current) may be eligible for stock and stock options. author db was employed by hiqscreen s&#x000e0;rl. generative ai statement the author(s) declare that no generative ai was used in the creation of this manuscript. publisher&#x02019;s note all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. supplementary material the supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2025.1626078/full&#x00023;supplementary-material abbreviations as, angelman syndrome; asd, autism spectrum disorder; cfc, context fear conditioning; cntnap2, contactin-associated protein-like 2; cpt, continuous performance test; 5-csrt, 5-choice serial reaction time; eeg, electroencephalography; gaba, gamma-aminobutyric acid; gad, glutamic acid decarboxylase; i.p., intraperitoneally; i.v., intravenously; lfp, local field potential; mes, maximum electrical stimulus; mwm, morris water maze; ndds, neurodevelopmental disorders; pal, paired associates learning; pam, positive allosteric modulator; phmri, pharmacological magnetic resonance imaging; p.o, per os; ptz, pentylenetetrazole; ro, receptor occupancy; pet, positron emission tomography. references abrahams, b. s., and geschwind, d. h. (2008). advances in autism genetics: on the threshold of a new neurobiology. nat. rev. genet. 9, 341&#x02013;355. doi:10.1038/nrg2346 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar ali, a. b., and thomson, a. m. (2008). synaptic alpha 5 subunit-containing gabaa receptors mediate ipsps elicited by dendrite-preferring cells in rat neocortex. cereb. cortex 18, 1260&#x02013;1271. doi:10.1093/cercor/bhm160 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar american psychiatric association (2008). diagnostic and statistical manual of mental disorders . 5th ed. washington: american psychiatric association . google scholar ballard, t. m., knoflach, f., prinssen, e., borroni, e., vivian, j. a., basile, j., et al. (2009). ro4938581, a novel cognitive enhancer acting at gabaa alpha5 subunit-containing receptors. psychopharmacol. berl. 202, 207&#x02013;223. doi:10.1007/s00213-008-1357-7 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar ballard, t. m., woolley, m. l., prinssen, e., huwyler, j., porter, r., and spooren, w. (2005). the effect of the mglu5 receptor antagonist mpep in rodent tests of anxiety and cognition: a comparison. psychopharmacol. berl. 179, 218&#x02013;229. doi:10.1007/s00213-005-2211-9 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar banerjee, a., garcia-oscos, f., roychowdhury, s., galindo, l. c., hall, s., kilgard, m. p., et al. (2013). impairment of cortical gabaergic synaptic transmission in an environmental rat model of autism. int. j. neuropsychopharmacol. 16, 1309&#x02013;1318. doi:10.1017/s1461145712001216 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar bourgeron, t. (2015). from the genetic architecture to synaptic plasticity in autism spectrum disorder. nat. rev. neurosci. 16, 551&#x02013;563. doi:10.1038/nrn3992 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar braat, s., and kooy, r. f. (2015). the gabaa receptor as a therapeutic target for neurodevelopmental disorders. neuron 86, 1119&#x02013;1130. doi:10.1016/j.neuron.2015.03.042 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar bruns, a., kunnecke, b., risterucci, c., moreau, j. l., and von kienlin, m. (2009). validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological mri in rats. magn. reson med. 61, 1451&#x02013;1458. doi:10.1002/mrm.21779 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar buettelmann, b., cecere, g., fasching, b., groebke zbinden, k., hernandez, m.-c., knust, h., et al. (2018). preparation of new isoxazolyl ether derivatives as gabaa &#x003b1;5 receptor positive allosteric modulators (pams) . copyright &#x000a9; 2025 american chemical society acs . available online at: https://worldwide.espacent.com/patent/search/family/057530563/publication/wo2018104419a1?q&#x0003d;wo2018104419a1 google scholar buiting, k. (2010). prader-willi syndrome and angelman syndrome. am. j. med. genet. c semin. med. genet. 154c, 365&#x02013;376. doi:10.1002/ajmg.c.30273 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar chao, h. t., chen, h., samaco, r. c., xue, m., chahrour, m., yoo, j., et al. (2010). dysfunction in gaba signalling mediates autism-like stereotypies and rett syndrome phenotypes. nature 468, 263&#x02013;269. doi:10.1038/nature09582 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar davenport, c. m., rajappa, r., katchan, l., taylor, c. r., tsai, m. c., smith, c. m., et al. (2021). relocation of an extrasynaptic gaba(a) receptor to inhibitory synapses freezes excitatory synaptic strength and preserves memory. neuron 109, 123&#x02013;134 e4. doi:10.1016/j.neuron.2020.09.037 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar delong, r. (2007). gaba(a) receptor alpha5 subunit as a candidate gene for autism and bipolar disorder: a proposed endophenotype with parent-of-origin and gain-of-function features,with or without oculocutaneous albinism. autism 11, 135&#x02013;147. doi:10.1177/1362361307075705 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar delorey, t. m. (2005). gabrb3 gene deficient mice: a potential model of autism spectrum disorder. int. rev. neurobiol. 71, 359&#x02013;382. doi:10.1016/s0074-7742(05)71015-1 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar delorey, t. m., sahbaie, p., hashemi, e., homanics, g. e., and clark, j. d. (2008). gabrb3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: a potential model of autism spectrum disorder. behav. brain res. 187, 207&#x02013;220. doi:10.1016/j.bbr.2007.09.009 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar dhossche, d., applegate, h., abraham, a., maertens, p., bland, l., bencsath, a., et al. (2002). elevated plasma gamma-aminobutyric acid (gaba) levels in autistic youngsters: stimulus for a gaba hypothesis of autism. med. sci. monit. 8, pr1&#x02013;pr6. pubmed abstract &#x0007c; google scholar di nanni, n., bersanelli, m., cupaioli, f. a., milanesi, l., mezzelani, a., and mosca, e. (2019). network-based integrative analysis of genomics, epigenomics and transcriptomics in autism spectrum disorders. int. j. mol. sci. 20, 3363. doi:10.3390/ijms20133363 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar dufour, b. d., mcbride, e., bartley, t., juarez, p., and martinez-cerdeno, v. (2023). distinct patterns of gabaergic interneuron pathology in autism are associated with intellectual impairment and stereotypic behaviors. autism 27, 1730&#x02013;1745. doi:10.1177/13623613231154053 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar fatemi, s. h., halt, a. r., stary, j. m., kanodia, r., schulz, s. c., and realmuto, g. r. (2002). glutamic acid decarboxylase 65 and 67 kda proteins are reduced in autistic parietal and cerebellar cortices. biol. psychiatry 52, 805&#x02013;810. doi:10.1016/s0006-3223(02)01430-0 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar friedman, h., greenblatt, d. j., peters, g. r., metzler, c. m., charlton, m. d., harmatz, j. s., et al. (1992). pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. clin. pharmacol. ther. 52, 139&#x02013;150. doi:10.1038/clpt.1992.123 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar fritschy, j. m., benke, d., johnson, d. k., mohler, h., and rudolph, u. (1997). gabaa-receptor alpha-subunit is an essential prerequisite for receptor formation in vivo . neuroscience 81, 1043&#x02013;1053. doi:10.1016/s0306-4522(97)00244-3 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar frohlich, j., miller, m. t., bird, l. m., garces, p., purtell, h., hoener, m. c., et al. (2019a). electrophysiological phenotype in angelman syndrome differs between genotypes. biol. psychiatry 85, 752&#x02013;759. doi:10.1016/j.biopsych.2019.01.008 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar frohlich, j., reiter, l. t., saravanapandian, v., distefano, c., huberty, s., hyde, c., et al. (2019b). mechanisms underlying the eeg biomarker in dup15q syndrome. mol. autism 10, 29. doi:10.1186/s13229-019-0280-6 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar frye, r. e., casanova, m. f., fatemi, s. h., folsom, t. d., reutiman, t. j., brown, g. l., et al. (2016). neuropathological mechanisms of seizures in autism spectrum disorder. front. neurosci. 10, 192. doi:10.3389/fnins.2016.00192 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar fukuda, t., itoh, m., ichikawa, t., washiyama, k., and goto, y. (2005). delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of mecp2-deficient mice. j. neuropathol. exp. neurol. 64, 537&#x02013;544. doi:10.1093/jnen/64.6.537 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar gaetz, w., bloy, l., wang, d. j., port, r. g., blaskey, l., levy, s. e., et al. (2014). gaba estimation in the brains of children on the autism spectrum: measurement precision and regional cortical variation. neuroimage 86, 1&#x02013;9. doi:10.1016/j.neuroimage.2013.05.068 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar han, s., tai, c., jones, c. j., scheuer, t., and catterall, w. a. (2014). enhancement of inhibitory neurotransmission by gabaa receptors having &#x003b1;2,3-subunits ameliorates behavioral deficits in a mouse model of autism. neuron 81, 1282&#x02013;1289. doi:10.1016/j.neuron.2014.01.016 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar han, s., tai, c., westenbroek, r. e., yu, f. h., cheah, c. s., potter, g. b., et al. (2012). autistic-like behaviour in scn1a&#x0002b;/- mice and rescue by enhanced gaba-mediated neurotransmission. nature 489, 385&#x02013;390. doi:10.1038/nature11356 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar hipp, j. f., knoflach, f., comley, r., ballard, t. m., honer, m., trube, g., et al. (2021). basmisanil, a highly selective gaba a -&#x003b1;5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man. sci. rep. 11, 7700. doi:10.1038/s41598-021-87307-7 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar hogart, a., wu, d., lasalle, j. m., and schanen, n. c. (2010). the comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. neurobiol. dis. 38, 181&#x02013;191. doi:10.1016/j.nbd.2008.08.011 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar hu, x., rocco, b. r., fee, c., and sibille, e. (2019). cell type-specific gene expression of alpha 5 subunit-containing gamma-aminobutyric acid subtype a receptors in human and mouse frontal cortex. mol. neuropsychiatry 4, 204&#x02013;215. doi:10.1159/000495840 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar hvoslef-eide, m., nilsson, s. r., saksida, l. m., and bussey, t. j. (2016). cognitive translation using the rodent touchscreen testing approach. curr. top. behav. neurosci. 28, 423&#x02013;447. doi:10.1007/7854_2015_5007 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar kalsner, l., and chamberlain, s. j. (2015). prader-willi, angelman, and 15q11-q13 duplication syndromes. pediatr. clin. north am. 62, 587&#x02013;606. doi:10.1016/j.pcl.2015.03.004 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar koh, m. t., rosenzweig-lipson, s., and gallagher, m. (2013). selective gaba(a) &#x003b1;5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. neuropharmacology 64, 145&#x02013;152. doi:10.1016/j.neuropharm.2012.06.023 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar lim, c. s., kim, h., yu, n. k., kang, s. j., kim, t., ko, h. g., et al. (2017). enhancing inhibitory synaptic function reverses spatial memory deficits in shank2 mutant mice. neuropharmacology 112, 104&#x02013;112. doi:10.1016/j.neuropharm.2016.08.016 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar luk, h. m., and lo, i. f. (2016). angelman syndrome in hong kong chinese: a 20 years&#x00027; experience. eur. j. med. genet. 59, 315&#x02013;319. doi:10.1016/j.ejmg.2016.05.003 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar luscher, b., maguire, j. l., rudolph, u., and sibille, e. (2023). gaba(a) receptors as targets for treating affective and cognitive symptoms of depression. trends pharmacol. sci. 44, 586&#x02013;600. doi:10.1016/j.tips.2023.06.009 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mcfarlane, h. g., kusek, g. k., yang, m., phoenix, j. l., bolivar, v. j., and crawley, j. n. (2008). autism-like behavioral phenotypes in btbr t&#x0002b;tf/j mice. genes brain behav. 7, 152&#x02013;163. doi:10.1111/j.1601-183x.2007.00330.x pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mcnaughton, n., and morris, r. g. (1987). chlordiazepoxide, an anxiolytic benzodiazepine, impairs place navigation in rats. behav. brain res. 24, 39&#x02013;46. doi:10.1016/0166-4328(87)90034-9 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mendez, m. a., horder, j., myers, j., coghlan, s., stokes, p., erritzoe, d., et al. (2013). the brain gaba-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)c]ro15-4513 positron emission tomography study. neuropharmacology 68, 195&#x02013;201. doi:10.1016/j.neuropharm.2012.04.008 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mermer, f., poliquin, s., rigsby, k., rastogi, a., shen, w., romero-morales, a., et al. (2021). common molecular mechanisms of slc6a1 variant-mediated neurodevelopmental disorders in astrocytes and neurons. brain 144, 2499&#x02013;2512. doi:10.1093/brain/awab207 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mertz, l. g., christensen, r., vogel, i., hertz, j. m., nielsen, k. b., gronskov, k., et al. (2013). angelman syndrome in denmark. birth incidence, genetic findings, and age at diagnosis. am. j. med. genet. a 161a, 2197&#x02013;2203. doi:10.1002/ajmg.a.36058 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mesbah-oskui, l., penna, a., orser, b. a., and horner, r. l. (2017). reduced expression of &#x003b1;5gaba a receptors elicits autism-like alterations in eeg patterns and sleep-wake behavior. neurotoxicol teratol. 61, 115&#x02013;122. doi:10.1016/j.ntt.2016.10.009 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mohler, h. (2011). the rise of a new gaba pharmacology. neuropharmacology 60, 1042&#x02013;1049. doi:10.1016/j.neuropharm.2010.10.020 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mori, t., mori, k., fujii, e., toda, y., miyazaki, m., harada, m., et al. (2012). evaluation of the gabaergic nervous system in autistic brain: (123)i-iomazenil spect study. brain dev. 34, 648&#x02013;654. doi:10.1016/j.braindev.2011.10.007 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar myers, j. f., comley, r. a., and gunn, r. n. (2017). quantification of [ 11 c]ro15-4513 gaba a &#x003b1;5 specific binding and regional selectivity in humans. j. cereb. blood flow. metab. 37, 2137&#x02013;2148. doi:10.1177/0271678x16661339 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar nakamura, t., arima-yoshida, f., sakaue, f., nasu-nishimura, y., takeda, y., matsuura, k., et al. (2016). px-rics-deficient mice mimic autism spectrum disorder in jacobsen syndrome through impaired gabaa receptor trafficking. nat. commun. 7, 10861. doi:10.1038/ncomms10861 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar orefice, l. l., zimmerman, a. l., chirila, a. m., sleboda, s. j., head, j. p., and ginty, d. d. (2016). peripheral mechanosensory neuron dysfunction underlies tactile and behavioral deficits in mouse models of asds. cell 166, 299&#x02013;313. doi:10.1016/j.cell.2016.05.033 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar penagarikano, o., abrahams, b. s., herman, e. i., winden, k. d., gdalyahu, a., dong, h., et al. (2011). absence of cntnap2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. cell 147, 235&#x02013;246. doi:10.1016/j.cell.2011.08.040 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar percie du sert, n., hurst, v., ahluwalia, a., alam, s., avey, m. t., baker, m., et al. (2020). the arrive guidelines 2.0: updated guidelines for reporting animal research. plos biol. 18, e3000410. doi:10.1371/journal.pbio.3000410 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar perez, s. m., mccoy, a. m., prevot, t. d., mian, m. y., carreno, f. r., frazer, a., et al. (2023). hippocampal &#x003b1;5-gaba(a) receptors modulate dopamine neuron activity in the rat ventral tegmental area. biol. psychiatry glob. open sci. 3, 78&#x02013;86. doi:10.1016/j.bpsgos.2021.12.010 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar pirker, s., schwarzer, c., wieselthaler, a., sieghart, w., and sperk, g. (2000). gaba(a) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. neuroscience 101, 815&#x02013;850. doi:10.1016/s0306-4522(00)00442-5 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar pizzarelli, r., and cherubini, e. (2011). alterations of gabaergic signaling in autism spectrum disorders. neural plast. 2011, 297153. doi:10.1155/2011/297153 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar porjesz, b., almasy, l., edenberg, h. j., wang, k., chorlian, d. b., foroud, t., et al. (2002). linkage disequilibrium between the beta frequency of the human eeg and a gabaa receptor gene locus. proc. natl. acad. sci. u. s. a. 99, 3729&#x02013;3733. doi:10.1073/pnas.052716399 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar puts, n. a. j., wodka, e. l., harris, a. d., crocetti, d., tommerdahl, m., mostofsky, s. h., et al. (2017). reduced gaba and altered somatosensory function in children with autism spectrum disorder. autism res. 10, 608&#x02013;619. doi:10.1002/aur.1691 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar robertson, c. e., ratai, e. m., and kanwisher, n. (2016). reduced gabaergic action in the autistic brain. curr. biol. 26, 80&#x02013;85. doi:10.1016/j.cub.2015.11.019 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar rojas, d. c., singel, d., steinmetz, s., hepburn, s., and brown, m. s. (2014). decreased left perisylvian gaba concentration in children with autism and unaffected siblings. neuroimage 86, 28&#x02013;34. doi:10.1016/j.neuroimage.2013.01.045 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar rubenstein, j. l., and merzenich, m. m. (2003). model of autism: increased ratio of excitation/inhibition in key neural systems. genes brain behav. 2, 255&#x02013;267. doi:10.1034/j.1601-183x.2003.00037.x pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar sanders, s. j. (2015). first glimpses of the neurobiology of autism spectrum disorder. curr. opin. genet. dev. 33, 80&#x02013;92. doi:10.1016/j.gde.2015.10.002 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2018). dendrite-targeting interneurons control synaptic nmda-receptor activation via nonlinear &#x003b1;5-gaba a receptors. nat. commun. 9, 3576. doi:10.1038/s41467-018-06004-8 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2019). enhanced dendritic inhibition and impaired nmdar activation in a mouse model of down syndrome. j. neurosci. 39, 5210&#x02013;5221. doi:10.1523/jneurosci.2723-18.2019 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar serwanski, d. r., miralles, c. p., christie, s. b., mehta, a. k., li, x., and de blas, a. l. (2006). synaptic and nonsynaptic localization of gabaa receptors containing the alpha5 subunit in the rat brain. j. comp. neurol. 499, 458&#x02013;470. doi:10.1002/cne.21115 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar sieghart, w. (2006). structure, pharmacology, and function of gabaa receptor subtypes. adv. pharmacol. 54, 231&#x02013;263. doi:10.1016/s1054-3589(06)54010-4 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar sitnikova, e., rutskova, e., and smirnov, k. (2023). alpha2-adrenergic receptors as a pharmacological target for spike-wave epilepsy. int. j. mol. sci. 24, 1477. doi:10.3390/ijms24021477 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar smit, d. j. a., wright, m. j., meyers, j. l., martin, n. g., ho, y. y. w., malone, s. m., et al. (2018). genome-wide association analysis links multiple psychiatric liability genes to oscillatory brain activity. hum. brain mapp. 39, 4183&#x02013;4195. doi:10.1002/hbm.24238 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar souza, a. j., freitas, i. s., sharmin, d., cook, j. m., guimaraes, f. s., and gomes, f. v. (2024). an alpha 5-gaba(a) receptor positive allosteric modulator attenuates social and cognitive deficits without changing dopamine system hyperactivity in rats exposed to valproic acid in utero. autism res. 17, 1534&#x02013;1544. doi:10.1002/aur.3178 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar sur, c., fresu, l., howell, o., mckernan, r. m., and atack, j. r. (1999). autoradiographic localization of alpha5 subunit-containing gabaa receptors in rat brain. brain res. 822, 265&#x02013;270. doi:10.1016/s0006-8993(99)01152-x pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar traub, r. d. w. m., and jefferys, j. g. r. (1999). fast oscillations in cortical circuits . the mit press . google scholar van lier, h., drinkenburg, w. h., van eeten, y. j., and coenen, a. m. (2004). effects of diazepam and zolpidem on eeg beta frequencies are behavior-specific in rats. neuropharmacology 47, 163&#x02013;174. doi:10.1016/j.neuropharm.2004.03.017 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar visser, s. a., wolters, f. l., gubbens-stibbe, j. m., tukker, e., van der graaf, p. h., peletier, l. a., et al. (2003). mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of gabaa receptor modulators: in vitro-in vivo correlations. j. pharmacol. exp. ther. 304, 88&#x02013;101. doi:10.1124/jpet.102.042341 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar vithlani, m., terunuma, m., and moss, s. j. (2011). the dynamic modulation of gaba(a) receptor trafficking and its role in regulating the plasticity of inhibitory synapses. physiol. rev. 91, 1009&#x02013;1022. doi:10.1152/physrev.00015.2010 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar warrier, v., baron-cohen, s., and chakrabarti, b. (2013). genetic variation in gabrb3 is associated with asperger syndrome and multiple endophenotypes relevant to autism. mol. autism 4, 48. doi:10.1186/2040-2392-4-48 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar whittington, m. a., traub, r. d., kopell, n., ermentrout, b., and buhl, e. h. (2000). inhibition-based rhythms: experimental and mathematical observations on network dynamics. int. j. psychophysiol. 38, 315&#x02013;336. doi:10.1016/s0167-8760(00)00173-2 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar xie, x. h., and tietz, e. i. (1991). chronic benzodiazepine treatment of rats induces reduction of paired-pulse inhibition in ca1 region of in vitro hippocampus. brain res. 561, 69&#x02013;76. doi:10.1016/0006-8993(91)90750-p pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar zurek, a. a., kemp, s. w., aga, z., walker, s., milenkovic, m., ramsey, a. j., et al. (2016). &#x003b1;5gabaa receptor deficiency causes autism-like behaviors. ann. clin. transl. neurol. 3, 392&#x02013;398. doi:10.1002/acn3.303 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar keywords: autism spectrum disorder, angelman syndrome, gaba a , gaba a -&#x003b1;5, positron emission tomography (pet), electroencephalography, pharmacological mri, biomarker citation: cecere g, ballard tm, knoflach f, honer m, hipp jf, garces p, mueggler t, k&#x000fc;nnecke b, bruns a, prinssen ep, schoenenberger p, janz p, redondo r, biemans b, knust h, olivares-morales a, brigo a, schulz jm, bertrand d, saxe m, o&#x02019;connor ec and hernandez m-c (2025) preclinical pharmacology of alogabat: a novel gaba a -&#x003b1;5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gaba a signaling. front. pharmacol. 16:1626078. doi: 10.3389/fphar.2025.1626078 received: 09 may 2025; accepted: 18 june 2025; published: 21 july 2025. edited by: agenor limon , university of texas medical branch at galveston, united states reviewed by: hansen wang , university of toronto, canada junzhan jing , baylor college of medicine, united states azar omrani , boehringer ingelheim, germany copyright &#x000a9; 2025 cecere, ballard, knoflach, honer, hipp, garces, mueggler, k&#x000fc;nnecke, bruns, prinssen, schoenenberger, janz, redondo, biemans, knust, olivares-morales, brigo, schulz, bertrand, saxe, o&#x02019;connor and hernandez. this is an open-access article distributed under the terms of the creative commons attribution license (cc by). the use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. no use, distribution or reproduction is permitted which does not comply with these terms. &#x0002a;correspondence: maria-clemencia hernandez, bwfyawety2xlbwvuy2lhlmhlcm5hbmrlekbyb2nozs5jb20= &#x02020; these authors have contributed equally to this work &#x02021; present address: theresa m. ballard, galwyn (uk) ltd., dartmouth, united kingdom barbara biemans, b2discovery llc, riehen, switzerland michael saxe, translational in vivo sciences, biogen, cambridge, ma, united states disclaimer: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. download article download pdf readcube epub xml share on export citation endnote reference manager simple text file bibtex 2,218 total views 442 downloads citation numbers are available from dimensions view article impact view altmetric score share on edited by a l agenor limon reviewed by j j junzhan jing a o azar omrani h w hansen wang table of contents abstract 1 introduction 2 materials and methods 3 results 4 discussion 5 conclusion data availability statement ethics statement author contributions funding acknowledgments conflict of interest generative ai statement publisher&#x02019;s note supplementary material abbreviations references export citation endnote reference manager simple text file bibtex check for updates frontiers&#39; impact articles published with frontiers have received 12 million total citations your research is the real superpower - learn how we maximise its impact through our leading community journals explore our impact metrics supplementary material download article download download pdf readcube epub xml guidelines author guidelines services for authors policies and publication ethics editor guidelines fee policy explore articles research topics journals how we publish outreach frontiers forum frontiers policy labs frontiers for young minds frontiers planet prize connect help center emails and alerts contact us submit career opportunities follow us © 2025 frontiers media s.a. all rights reserved privacy policy | terms and conditions [["shallowreactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverrendered":13,"path":14,"pinia":15},["shallowreactive",3],{},["reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","frontiers articles","https://article-pages-2024.frontiersin.org/",["set"],["shallowreactive",12],{},true,"/journals/pharmacology/articles/10.3389/fphar.2025.1626078/full",["reactive",16],{"main":17,"user":511,"article":512,"articlehub":968,"mainheader":972},{"ibar":18,"footer":264,"newslettercomponent":-1,"snackbaritem":346,"toggleshowsnackbar":347,"contentfuljournal":348,"graphjournal":412,"settingsfeaturesswitchers":416,"templatetogglebanner":417,"tenantconfig":476},{"tenantlogo":19,"journallogo":19,"aboutus":20,"submiturl":113,"showsubmitbutton":13,"journal":114,"sectionterm":195,"aboutjournal":196,"mainlinks":245,"journallinks":252,"helpcenterlink":261},"",[21,38,47,71,87],{"title":22,"links":23},"who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"arialabel":28},"mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"arialabel":28},"history","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"arialabel":28},"leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"arialabel":28},"awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"impact and progress",[41,44],{"text":42,"url":43,"target":27,"arialabel":28},"frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"arialabel":28},"our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"arialabel":28},"how we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"arialabel":28},"open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"arialabel":28},"peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"arialabel":28},"research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"arialabel":28},"research topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"arialabel":28},"fair² data management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"arialabel":28},"fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"services",[74,78,81,84],{"text":75,"url":76,"target":77,"arialabel":28},"societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"arialabel":28},"national consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"arialabel":28},"institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"arialabel":28},"collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"more from frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"arialabel":93},"frontiers forum","https://forum.frontiersin.org/","this link will take you to the frontiers forum website",{"text":95,"url":96,"target":27,"arialabel":28},"frontiers planet prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"arialabel":100},"press office","https://pressoffice.frontiersin.org/","this link will take you to the frontiers press office website",{"text":102,"url":103,"target":27,"arialabel":104},"sustainability","https://www.frontiersin.org/about/sustainability","link to information about frontiers' sustainability",{"text":106,"url":107,"target":77,"arialabel":108},"career opportunities","https://careers.frontiersin.org/","this link will take you to the frontiers careers website",{"text":110,"url":111,"target":27,"arialabel":112},"contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=1&fieldid=62&specialtyid=0&entitytype=2&entityid=176",{"id":115,"name":116,"slug":117,"sections":118},176,"frontiers in pharmacology","pharmacology",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191],{"id":120,"name":121,"slug":122},182,"cardiovascular and smooth muscle pharmacology","cardiovascular-and-smooth-muscle-pharmacology",{"id":124,"name":125,"slug":126},199,"drug metabolism and transport","drug-metabolism-and-transport",{"id":128,"name":129,"slug":130},202,"drugs outcomes research and policies","drugs-outcomes-research-and-policies",{"id":132,"name":133,"slug":134},184,"ethnopharmacology","ethnopharmacology",{"id":136,"name":137,"slug":138},183,"experimental pharmacology and drug discovery","experimental-pharmacology-and-drug-discovery",{"id":140,"name":141,"slug":142},186,"gastrointestinal and hepatic pharmacology","gastrointestinal-and-hepatic-pharmacology",{"id":144,"name":145,"slug":146},188,"inflammation pharmacology","inflammation-pharmacology",{"id":148,"name":149,"slug":150},178,"integrative and regenerative pharmacology","integrative-and-regenerative-pharmacology",{"id":152,"name":153,"slug":154},26,"neuropharmacology","neuropharmacology",{"id":156,"name":157,"slug":158},196,"obstetric and pediatric pharmacology","obstetric-and-pediatric-pharmacology",{"id":160,"name":161,"slug":162},2186,"pharmacoepidemiology","pharmacoepidemiology",{"id":164,"name":165,"slug":166},198,"pharmacogenetics and pharmacogenomics","pharmacogenetics-and-pharmacogenomics",{"id":168,"name":169,"slug":170},192,"pharmacology of anti-cancer drugs","pharmacology-of-anti-cancer-drugs",{"id":172,"name":173,"slug":174},2216,"pharmacology of infectious diseases","pharmacology-of-infectious-diseases",{"id":176,"name":177,"slug":178},179,"pharmacology of ion channels and channelopathies","pharmacology-of-ion-channels-and-channelopathies",{"id":180,"name":181,"slug":182},195,"predictive toxicology","predictive-toxicology",{"id":184,"name":185,"slug":186},1357,"renal pharmacology","renal-pharmacology",{"id":188,"name":189,"slug":190},190,"respiratory pharmacology","respiratory-pharmacology",{"id":192,"name":193,"slug":194},1251,"translational pharmacology","translational-pharmacology","sections",[197,221],{"title":198,"links":199},"scope",[200,203,206,209,212,215,218],{"text":201,"url":202,"target":27,"arialabel":28},"field chief editors","https://www.frontiersin.org/journals/pharmacology/about#about-editors",{"text":204,"url":205,"target":27,"arialabel":28},"mission & scope","https://www.frontiersin.org/journals/pharmacology/about#about-scope",{"text":207,"url":208,"target":27,"arialabel":28},"facts","https://www.frontiersin.org/journals/pharmacology/about#about-facts",{"text":210,"url":211,"target":27,"arialabel":28},"journal sections","https://www.frontiersin.org/journals/pharmacology/about#about-submission",{"text":213,"url":214,"target":27,"arialabel":28},"open access statement","https://www.frontiersin.org/journals/pharmacology/about#about-open",{"text":216,"url":217,"target":27,"arialabel":28},"copyright statement","https://www.frontiersin.org/journals/pharmacology/about#copyright-statement",{"text":219,"url":220,"target":27,"arialabel":28},"quality","https://www.frontiersin.org/journals/pharmacology/about#about-quality",{"title":222,"links":223},"for authors",[224,227,230,233,236,239,242],{"text":225,"url":226,"target":27,"arialabel":28},"why submit?","https://www.frontiersin.org/journals/pharmacology/for-authors/why-submit",{"text":228,"url":229,"target":27,"arialabel":28},"article types","https://www.frontiersin.org/journals/pharmacology/for-authors/article-types",{"text":231,"url":232,"target":27,"arialabel":28},"author guidelines","https://www.frontiersin.org/journals/pharmacology/for-authors/author-guidelines",{"text":234,"url":235,"target":27,"arialabel":28},"editor guidelines","https://www.frontiersin.org/journals/pharmacology/for-authors/editor-guidelines",{"text":237,"url":238,"target":27,"arialabel":28},"publishing fees","https://www.frontiersin.org/journals/pharmacology/for-authors/publishing-fees",{"text":240,"url":241,"target":27,"arialabel":28},"submission checklist","https://www.frontiersin.org/journals/pharmacology/for-authors/submission-checklist",{"text":243,"url":244,"target":27,"arialabel":28},"contact editorial office","https://www.frontiersin.org/journals/pharmacology/for-authors/contact-editorial-office",[246,249],{"text":247,"url":248,"target":27,"arialabel":28},"all journals","https://www.frontiersin.org/journals",{"text":250,"url":251,"target":27,"arialabel":28},"all articles","https://www.frontiersin.org/articles",[253,256,258],{"text":254,"url":255,"target":27,"arialabel":28},"articles","articles",{"text":63,"url":257,"target":27,"arialabel":28},"research-topics",{"text":259,"url":260,"target":27,"arialabel":28},"editorial board","editors",{"text":262,"url":263,"target":77,"arialabel":262},"help center","https://helpcenter.frontiersin.org",{"blocks":265,"sociallinks":319,"copyright":343,"termsandconditionsurl":344,"privacypolicyurl":345},[266,280,290,304],{"title":267,"links":268},"guidelines",[269,271,274,277,279],{"text":231,"url":270,"target":27,"arialabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":272,"url":273,"target":27,"arialabel":28},"services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":275,"url":276,"target":27,"arialabel":28},"policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":234,"url":278,"target":27,"arialabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"arialabel":28},{"title":281,"links":282},"explore",[283,284,287,289],{"text":254,"url":251,"target":27,"arialabel":28},{"text":285,"url":286,"target":27,"arialabel":28},"research topics ","https://www.frontiersin.org/research-topics",{"text":288,"url":248,"target":27,"arialabel":28},"journals",{"text":51,"url":52,"target":27,"arialabel":28},{"title":291,"links":292},"outreach",[293,296,299,303],{"text":294,"url":92,"target":77,"arialabel":295},"frontiers forum ","frontiers forum website",{"text":297,"url":298,"target":77,"arialabel":28},"frontiers policy labs ","https://policylabs.frontiersin.org/",{"text":300,"url":301,"target":77,"arialabel":302},"frontiers for young minds","https://kids.frontiersin.org/","frontiers for young minds journal",{"text":95,"url":96,"target":27,"arialabel":28},{"title":305,"links":306},"connect",[307,308,312,315,318],{"text":262,"url":263,"target":77,"arialabel":262},{"text":309,"url":310,"target":77,"arialabel":311},"emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","subscribe to frontiers emails",{"text":313,"url":111,"target":27,"arialabel":314},"contact us ","subscribe to newsletter",{"text":316,"url":317,"target":27,"arialabel":28},"submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"arialabel":28},[320,328,333,338],{"link":321,"type":324,"color":325,"icon":326,"size":327,"hiddentext":13},{"text":322,"url":323,"target":77,"arialabel":322},"frontiers facebook","https://www.facebook.com/frontiersin","link","grey","facebook","medium",{"link":329,"type":324,"color":325,"icon":332,"size":327,"hiddentext":13},{"text":330,"url":331,"target":77,"arialabel":28},"frontiers twitter","https://twitter.com/frontiersin","twitter",{"link":334,"type":324,"color":325,"icon":337,"size":327,"hiddentext":13},{"text":335,"url":336,"target":77,"arialabel":28},"frontiers linkedin","https://www.linkedin.com/company/frontiers","linkedin",{"link":339,"type":324,"color":325,"icon":342,"size":327,"hiddentext":13},{"text":340,"url":341,"target":77,"arialabel":28},"frontiers instagram","https://www.instagram.com/frontiersin_","instagram","frontiers media s.a. all rights reserved","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":349,"identifier":115,"name":116,"slug":117,"banner":350,"description":405,"mission":406,"palette":407,"impactfactor":408,"citescore":409,"citations":410,"showtagline":28,"twitter":411},"journal",[351],{"id":352,"src":353,"name":354,"tags":355,"type":363,"width":364,"height":365,"idhash":366,"archive":367,"brandid":368,"limited":367,"filesize":369,"ispublic":370,"original":371,"copyright":372,"extension":373,"thumbnails":375,"datecreated":383,"description":384,"orientation":385,"usercreated":386,"watermarked":367,"datemodified":383,"datepublished":387,"ecsarchivefiles":388,"propertyoptions":389,"property_channel":394,"property_sub-type":396,"property_asset_type":398,"activeoriginalfocuspoint":400,"property_office_department":403},"754e12a9-443f-4ea8-ab01e0811e45131d","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/webimage-9d720582-24ad-4d2e-9205ab9d241919da.jpg","fphar_main visual_purple_website",[356,357,358,359,360,361,362],"pain","medical","pharmaceutical","antibiotic","concept","capsule","treatment","image",5844,3896,"79b643019a2651e0",0,"22c10171-81b3-4da6-99342f272a32e8bb",8675243,1,"https://brand.frontiersin.org/m/79b643019a2651e0/original/fphar_main-visual_purple_website.jpeg","copyright (c) 2017 marian weyo/shutterstock. no use without permission.",[374],"jpeg",{"mini":376,"thul":377,"webimage":353,"guidelines":378,"websitejpg_xl":379,"websitewebp_l":380,"websitewebp_m":381,"websitewebp_xl":382},"https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/mini-97eef455-249b-43bd-9d8f02fee86046d3.jpg","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/thul-b2dbd910-1ddf-4ed3-b1500df973953144.jpg","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/guidelines-fphar_main visual_purple_website.png","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitejpg_xl-fphar_main visual_purple_website.jpg","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitewebp_l-fphar_main visual_purple_website.webp","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitewebp_m-fphar_main visual_purple_website.webp","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitewebp_xl-fphar_main visual_purple_website.webp","2022-06-27t10:00:45z","pills tablets capsule or medicament freely laid on glass background.","landscape","caroline sutter","2022-06-27t09:27:09z",[],[390,391,392,393],"414fb2d4-2283-43fd-be14e534eca67928","6c18119b-14bd-4951-b437696f4357bd33","7c692885-db25-4858-b1fb4ff47b241e9b","d88c0047-ec30-4506-a7df28a4d765e1cf",[395],"frontiersin_org",[397],"main_visual",[399],"photography",{"x":401,"y":402},2922,1948,[404],"publishing","the world's most cited pharmacology and pharmacy journal, advancing global pharmacological discoveries to prevent and treat human disease.","\u003cp>frontiers in pharmacology is an interdisciplinary journal that publishes research on the interactions between drugs and living beings to prevent and cure human disease.\u003c/p>\n\n\u003cp>led by field chief editor heike wulff (university of california, davis, us), frontiers in pharmacology explores basic and clinical pharmacology, medicinal chemistry, pharmacy, and toxicology to clarify the fundamental processes of disease treatment and drug effects. indexed in pubmed central (pmc), scopus, web of science (scie), and the doaj, the journal welcomes academic, industrial, and clinical work focused on pharmacology.\u003c/p>\n\n\u003cp>topics include, but are not limited to:\u003c/p>\n\u003cul>\n \u003cli>cardiovascular and smooth muscle pharmacology\u003c/li>\n \u003cli>drug metabolism and transport\u003c/li>\n \u003cli>drugs outcomes research and policies\u003c/li>\n \u003cli>elsi in science and genetics\u003c/li>\n \u003cli>ethnopharmacology\u003c/li>\n \u003cli>experimental pharmacology and drug discovery\u003c/li>\n \u003cli>gastrointestinal and hepatic pharmacology\u003c/li>\n \u003cli>inflammation pharmacology\u003c/li>\n \u003cli>integrative and regenerative pharmacology\u003c/li>\n \u003cli>neuropharmacology\u003c/li>\n \u003cli>obstetric and pediatric pharmacology\u003c/li>\n \u003cli>pharmacoepidemiology\u003c/li>\n \u003cli>pharmacogenetics and pharmacogenomics\u003c/li>\n \u003cli>pharmacology of anti-cancer drugs\u003c/li>\n \u003cli>pharmacology of infectious diseases\u003c/li>\n \u003cli>pharmacology of ion channels and channelopathies\u003c/li>\n \u003cli>predictive toxicology\u003c/li>\n \u003cli>renal pharmacology\u003c/li>\n \u003cli>respiratory pharmacology\u003c/li>\n \u003cli>translational pharmacology.\u003c/li>\n\u003c/ul>\n\n\u003cp>all submissions to the journal involving natural products, including plant extracts or preparations, must adhere to \u003ci>'the four pillars of ethnopharmacology'\u003c/i> to be considered for peer review, regardless of the specialty section, as a baseline standard for sample characterization. these are a set of mandatory guidelines designed to maintain the scientific, cultural, and ethical integrity of the journal, and describe what the leading journals in the field consider as the basic aspects of good research (full conphymp statement available \u003ca href=\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.953205/full\" target=\"_blank\">here\u003c/a>, conphymp statement overview \u003ca href=\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1338710/full\" target=\"_blank\">here\u003c/a>, and ga-tool \u003ca href=\"https://ga-online.org/best-practice/\" target=\"_blank\">here\u003c/a>). please refer to the \u003ca href=\"https://assets.ctfassets.net/41vi7p4898pd/63dcrrxgncg4b1stfayeh8/1b87b9a742b0610ace5b19fd11f62359/four_pillars_ethnopharmacology_2025.pdf\" target=\"_blank\">full version\u003c/a> of these guidelines before submitting a manuscript to the journal.\u003c/p> \n\u003cp>to be considered for publication in frontiers in pharmacology, studies incorporating complementary or alternative medicine must be based on a set of data linked to local or traditional uses that can be evaluated pharmacologically. a clear and plausible set of pharmacological data must be generated in these studies. similarly, the journal endorses protocols including a minimum of 2 cell-lines in vitro as an evidential basis to demonstrate proposed anti-cancer effects in all relevant studies submitted to all specialty sections in the journal.\u003c/p>\n\u003cp>isolated data mining studies using disproportionality analyses of databases containing spontaneously reported adverse events, frequently lead to misinterpretation due to various reporting biases, lack of structured control, and insufficient demographic details. presenting such analyses in isolation typically does not yield clinically actionable safety findings without the broader context of a comprehensive signal evaluation. to ensure rigor and relevance, all submissions to the journal must be complemented by a proper systematic review and/or thorough analyses of reported cases, and adhere to the readus-pv guidelines (\u003ca href=\"https://www.equator-network.org/reporting-guidelines/the-reporting-of-a-disproportionality-analysis-for-drug-safety-signal-detection-using-individual-case-safety-reports-in-pharmacovigilance-readus-pv-development-and-statement/\" target=\"_blank\">the reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance\u003c/a>). authors are expected to ensure compliance with the corresponding \u003ca href=\"https://readus-statement.org/wp-content/uploads/2024/03/readus-checklist.pdf\" target=\"_blank\">checklist\u003c/a> before proceeding with submission to the journal. full publication of the readus-pv guidelines is available \u003ca href=\"https://pmc.ncbi.nlm.nih.gov/articles/pmc11116242/pdf/40264_2024_article_1421.pdf\" target=\"_blank\">here\u003c/a>.\u003c/p>\n\n\u003cp>frontiers’ journals require that manuscripts primarily comprising computational studies of public data, such as nhanes or mendelian randomization studies, must include appropriate validation. please refer to the \u003ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology:~:text=complaints%20and%20allegations.-,standards%20for%20research%20methodology,-experiments\">frontiers standards for research methodology policy\u003c/a>, for more information. manuscripts not adhering to these standards will not be considered.\u003cp>\n\n\u003cp>further unique criteria for the conception and review of submissions may apply, where appropriate, for individual specialty sections.\u003c/p>\n\n\u003cp>the journal welcomes submissions that support and advance the \u003ca href=\"https://www.globalgoals.org/goals/\" target=\"_blank\">un sustainable development goals\u003c/a> (sdgs), notably the \u003ca href=\"https://www.globalgoals.org/goals/3-good-health-and-well-being/\" target=\"_blank\">sdg 3: good health and well-being\u003c/a>.\u003c/p>\n\n\u003cp>manuscripts that focus solely on clinical trials, patient management, or conventional therapies without a focus on pharmacological research are not suitable for publication in this journal. additionally, studies that are purely statistical or predictive in nature, without providing novel insights into pharmacological mechanisms or drug development, are not within the scope of this journal.\u003c/p>\n\n\u003cp>frontiers in pharmacology is committed to advancing developments in the field of pharmacological discoveries by allowing unrestricted access to articles and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.\u003c/p>\n\n\u003cb>\u003cp>ethics information\u003c/p>\u003c/b>\n\u003cp>research involving human subjects should comply with the ethical guidelines outlined in the \u003ca href= https://www.wma.net/policies-post/wma-declaration-of-helsinki/” target=”_blank”>world medical association’s declaration of helsinki\u003c/a>.\u003c/p>\n\u003cp>similarly, authors are required to specify the institutional and national standards adhered to for the care and use of laboratory animals. transparent and accurate reporting of animal studies is required, with references to guidelines such as \u003ca href=\"https://arriveguidelines.org/arrive-guidelines\" target=\"_blank\">arrive\u003c/a> and \u003ca href=\"https://nc3rs.org.uk/sites/default/files/2022-01/the%20improve%20guidelines%20%28poster%29.pdf\" target=\"_blank\"> improve\u003c/a>.\u003c/p>\n\u003cp>extended information on research ethics can be found under the frontiers policies and publication ethics page.\u003c/p>","purple","5.6","6.3","531663","@frontpharmacol",{"id":115,"name":116,"slug":117,"abbreviation":413,"isonline":13,"isopenforsubmissions":13,"citescore":414,"impactfactor":415},"fphar",8.9,4.8,{"displaytitlepilllabels":13,"displayrelatedarticlesbox":13,"showeditors":13,"showreviewers":13,"showloopimpactlink":13,"enablefigshare":347,"usexmlimages":13},{"ispublic":13,"allowcompanyusers":347,"whitelistemails":418,"enablealljournals":13,"whitelistjournals":440},[419,420,421,422,423,424,425,426,427,424,428,429,430,431,432,433,434,435,436,437,438,439],"y2fybg9zlmxvcmnhqgzyb250awvyc2lulm9yzw==","zgfuawvslmx1ekbmcm9udgllcnnpbi5vcmc=","bgf1cmeudgvuyubmcm9udgllcnnpbi5vcmc=","cmfmywvslnjpyw5jag9aznjvbnrpzxjzaw4ub3jn","amftzxmuc21hbgxib25lqgzyb250awvyc2lulm9yzw==","znjhbi5tb3jlbm9aznjvbnrpzxjzaw4ub3jn","c2ftdwvslmzlcm5hbmrlekbmcm9udgllcnnpbi5vcmc=","ymfyymfyys5jyxjjyw5naxvaznjvbnrpzxjzaw4ub3jn","axzhbi5zyw50yw1hcmlhqgzyb250awvyc2lulm9yzw==","ahvllnryyw5aznjvbnrpzxjzaw4ub3jn","z29uy2fsby52yxjnyxnaznjvbnrpzxjzaw4ub3jn","bhvjawuuc2vubkbmcm9udgllcnnpbi5vcmc=","bg9ybi5mcmfzzxjaznjvbnrpzxjzaw4ub3jn","zwxzys5jyxjyb25aznjvbnrpzxjzaw4ub3jn","bwfhcnrlbi52yw5kawpja0bmcm9udgllcnnpbi5vcmc=","ymluzgh1lmtyaxnobmfuqgzyb250awvyc2lulm9yzw==","bwf0dghldy5hdhr3yxrlcnnaznjvbnrpzxjzaw4ub3jn","z2l1bglhlnzhbhnly2noaubmcm9udgllcnnpbi5vcmc=","zmfiawfulmrlbgxhbw9ydgvaznjvbnrpzxjzaw4ub3jn","dmlqyxlhbi5wcebwaxrzb2x1dglvbnmuy29t","z3vpbgxhdw1llnnldxjhdebmcm9udgllcnnpbi5vcmc=",[441,442,443,444,445,446,370,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,115,469,470,471,472,473,474,475],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,451,141,1335,2655,1238,604,698,1547,1440,403,1239,755,2136,609,1534,{"spaceid":370,"name":370,"availablejournalpages":477,"announcement":481},[255,260,257,478,479,480],"volumes","about","community-reviewers",{"__typename":482,"sys":483,"preheader":42,"title":485,"description":486,"image":487,"link":509},"announcement",{"id":484},"5ittnttqgazppgh6rx0alm","articles published with frontiers have received 12 million total citations","your research is the real superpower - learn how we maximise its impact through our leading community journals",[488],{"archive":367,"brandid":368,"copyright":28,"datecreated":489,"datemodified":490,"datepublished":491,"description":28,"extension":492,"filesize":494,"height":495,"id":496,"ispublic":367,"limited":367,"name":497,"orientation":385,"original":28,"thumbnails":498,"type":363,"watermarked":367,"width":505,"videopreviewurls":506,"tags":507,"textmetaproperties":508,"src":499},"2025-06-18t12:58:01z","2025-06-18t14:15:34z","2025-06-18t12:57:32z",[493],"png",1365026,920,"7c5269c4-3c83-4591-951a74d15b95daea","impact metrics banner for article pages",{"webimage":499,"thul":500,"mini":501,"websitewebp_l":502,"websitewebp_m":503,"guidelines":504},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/websitewebp_l/impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/websitewebp_m/impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/guidelines/impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":510,"url":43,"target":27,"arialabel":28},"explore our impact metrics",{"loggeduserinfo":-1},{"currentarticle":513,"ispreviewpage":347,"hassupplementaldata":347,"showcrossmarkwidget":13,"articletemplate":758,"currentarticlepagemetainfo":759,"xmlparsedarticlecontent":-1,"xmlparsingerror":-1},{"id":514,"doi":515,"title":516,"acceptancedate":517,"receptiondate":518,"publicationdate":519,"lastmodifieddate":520,"ispublished":13,"abstract":521,"researchtopic":28,"articletype":522,"stage":525,"keywords":527,"authors":536,"editors":682,"reviewers":690,"journal":712,"section":719,"impactmetrics":721,"volume":724,"articlevolume":725,"relatedarticles":726,"ispublishedv2":13,"contents":727,"files":731},1626078,"10.3389/fphar.2025.1626078","preclinical pharmacology of alogabat: a novel gabaa-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gabaa signaling","2025-06-18t08:27:15.000z","2025-05-09t23:15:40.000z","2025-07-21t00:00:00.000z","2025-10-21t02:34:53.269z","backgroundalterations in the gabaergic system contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder (asd) and angelman syndrome (as), particularly in cases involving large deletions in the 15q11–13 region. positive modulation of gabaa-α5 receptors may provide a novel therapeutic approach without the typical side effects associated with non-selective gabaa positive allosteric modulators such as diazepam.methodsalogabat was assessed for binding and functional activity at gabaa-α5β3γ2 receptors in vitro and in electrophysiological studies using hippocampal slices. in vivo studies in rodents included receptor occupancy (ro) using a selective gabaa-α5 tracer (autoradiography), pharmacological mri, and electroencephalography (eeg). alogabat was evaluated for its effects on the repetitive behavior phenotype in btbr and contactin-associated protein-like 2 (cntnap2−/−) knockout mice, seizure models, cognitive performance in rats, and rotarod performance following combination treatment with diazepam.resultsalogabat is a potent positive allosteric modulator of gabaa-α5 receptors, with binding and functional selectivity. receptor occupancy studies provided direct proof of dose-dependent target engagement. functional circuit modulation was demonstrated by dose-dependent regional perfusion changes in pharmacological mri and changes in eeg theta- and beta-band power in rats. at >50% gabaa-α5 receptor occupancy, alogabat normalized elevated self-grooming behavior in both cntnap2−/− and btbr mice and exhibited antiepileptic activity in rats. alogabat did not impair cognition in wildtype rats at gabaa-α5 receptor occupancy up to 75%, although impairment occurred at higher doses, probably due to increased activity at other receptor subtypes and/or saturation of α5 receptors. alogabat did not worsen diazepam-induced impairment on the rotarod test.conclusionalogabat showed beneficial effects in mouse models relevant to neurodevelopmental disorders and anti-seizure activity at doses that did not produce cognitive, sedative, or motoric side effects.",{"id":523,"name":524},24,"original research",{"id":526,"name":19},18,[528,529,530,531,532,533,534,535],"biomarker","autism spectrum disorder","electroencephalography","positron emission tomography (pet)","angelman syndrome","gabaa","gabaa-α5","pharmacological mri",[537,546,554,560,566,573,580,587,594,600,606,612,617,623,629,635,643,650,656,664,668,675],{"id":538,"firstname":539,"middlename":19,"lastname":540,"givennames":541,"iscorresponding":347,"isprofilepublic":13,"userid":538,"email":-1,"affiliations":542},3088634,"giuseppe","cecere","giuseppe ",[543],{"organizationname":544,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"medicinal chemistry","switzerland",{"id":547,"firstname":548,"middlename":19,"lastname":549,"givennames":550,"iscorresponding":347,"isprofilepublic":13,"userid":547,"email":-1,"affiliations":551},3064665,"theresa m.","ballard","theresa m. ",[552],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"neuroscience and rare diseases",{"id":367,"firstname":555,"middlename":19,"lastname":556,"givennames":557,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":558},"frederic","knoflach","frederic ",[559],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":561,"middlename":19,"lastname":562,"givennames":563,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":564},"michael","honer","michael ",[565],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":567,"firstname":568,"middlename":19,"lastname":569,"givennames":570,"iscorresponding":347,"isprofilepublic":13,"userid":567,"email":-1,"affiliations":571},81732,"joerg f.","hipp","joerg f. ",[572],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":574,"firstname":575,"middlename":19,"lastname":576,"givennames":577,"iscorresponding":347,"isprofilepublic":13,"userid":574,"email":-1,"affiliations":578},2412410,"pilar","garces","pilar ",[579],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":581,"firstname":582,"middlename":19,"lastname":583,"givennames":584,"iscorresponding":347,"isprofilepublic":13,"userid":581,"email":-1,"affiliations":585},13967,"thomas","mueggler","thomas ",[586],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":588,"firstname":589,"middlename":19,"lastname":590,"givennames":591,"iscorresponding":347,"isprofilepublic":13,"userid":588,"email":-1,"affiliations":592},577428,"basil","künnecke","basil ",[593],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":595,"middlename":19,"lastname":596,"givennames":597,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":598},"andreas","bruns","andreas ",[599],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":601,"middlename":19,"lastname":602,"givennames":603,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":604},"eric p.","prinssen","eric p. ",[605],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":607,"middlename":19,"lastname":608,"givennames":609,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":610},"philipp","schoenenberger","philipp ",[611],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":613,"firstname":607,"middlename":19,"lastname":614,"givennames":609,"iscorresponding":347,"isprofilepublic":13,"userid":613,"email":-1,"affiliations":615},2424959,"janz",[616],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":618,"middlename":19,"lastname":619,"givennames":620,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":621},"roger","redondo","roger ",[622],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":624,"middlename":19,"lastname":625,"givennames":626,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":627},"barbara","biemans","barbara ",[628],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":630,"middlename":19,"lastname":631,"givennames":632,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":633},"henner","knust","henner ",[634],{"organizationname":544,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":636,"firstname":637,"middlename":19,"lastname":638,"givennames":639,"iscorresponding":347,"isprofilepublic":13,"userid":636,"email":-1,"affiliations":640},2264913,"andrés","olivares-morales","andrés ",[641],{"organizationname":642,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"pharmaceutical sciences",{"id":644,"firstname":645,"middlename":19,"lastname":646,"givennames":647,"iscorresponding":347,"isprofilepublic":13,"userid":644,"email":-1,"affiliations":648},1172717,"alessandro","brigo","alessandro ",[649],{"organizationname":642,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":651,"middlename":19,"lastname":652,"givennames":653,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":654},"jan michael","schulz","jan michael ",[655],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":657,"firstname":658,"middlename":19,"lastname":659,"givennames":660,"iscorresponding":347,"isprofilepublic":13,"userid":657,"email":-1,"affiliations":661},157846,"daniel","bertrand","daniel ",[662],{"organizationname":663,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"hiqscreen sàrl",{"id":367,"firstname":561,"middlename":19,"lastname":665,"givennames":563,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":666},"saxe",[667],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":669,"firstname":670,"middlename":19,"lastname":671,"givennames":672,"iscorresponding":347,"isprofilepublic":13,"userid":669,"email":-1,"affiliations":673},2733790,"eoin c.","o’connor","eoin c. ",[674],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":676,"firstname":677,"middlename":19,"lastname":678,"givennames":679,"iscorresponding":347,"isprofilepublic":13,"userid":676,"email":-1,"affiliations":680},2269471,"maria-clemencia","hernandez","maria-clemencia ",[681],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},[683],{"id":684,"firstname":685,"middlename":19,"lastname":686,"givennames":687,"iscorresponding":347,"isprofilepublic":13,"userid":684,"email":-1,"affiliations":688},52072,"agenor","limon","agenor ",[689],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},[691,698,705],{"id":692,"firstname":693,"middlename":19,"lastname":694,"givennames":695,"iscorresponding":347,"isprofilepublic":13,"userid":692,"email":-1,"affiliations":696},1285968,"junzhan","jing","junzhan ",[697],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},{"id":699,"firstname":700,"middlename":19,"lastname":701,"givennames":702,"iscorresponding":347,"isprofilepublic":13,"userid":699,"email":-1,"affiliations":703},1380630,"azar","omrani","azar ",[704],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},{"id":706,"firstname":707,"middlename":19,"lastname":708,"givennames":709,"iscorresponding":347,"isprofilepublic":13,"userid":706,"email":-1,"affiliations":710},39673,"hansen","wang","hansen ",[711],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},{"id":115,"slug":117,"name":116,"shortname":713,"electronicissn":714,"field":715,"specialtyid":28,"journalsectionpaths":717},"front. pharmacol.","1663-9812",{"id":716,"domainid":370},62,[718],{"section":719},{"id":152,"name":153,"slug":154,"specialtyid":720},762,{"views":722,"downloads":723,"citations":367},2218,442,16,"volume 16 - 2025",[],{"titlehtml":728,"fulltexthtml":729,"menuhtml":730},"preclinical pharmacology of alogabat: a novel gaba\u003csub>a\u003c/sub>-&#x003b1;5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gaba\u003csub>a\u003c/sub> signaling","\u003cdiv class=\"journalabstract\">\u003ca id=\"h1\" name=\"h1\">\u003c/a>\u003cdiv class=\"authors\">\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/3088634\" class=\"user-id-3088634\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/3088634/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"giuseppe cecere&#x;\">giuseppe cecere\u003c/a>\u003csup>1\u003c/sup>\u003csup>&#x02020;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/3064665\" class=\"user-id-3064665\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/3064665/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"theresa m. ballard&#x;&#x;\">theresa m. ballard\u003c/a>\u003csup>2\u003c/sup>\u003csup>&#x02020;\u003c/sup>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"frederic knoflach&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">frederic knoflach\u003csup>2\u003c/sup>\u003csup>&#x02020;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"michael honer\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">michael honer\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/81732\" class=\"user-id-81732\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/81732/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"joerg f. hipp\">joerg f. hipp\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2412410\" class=\"user-id-2412410\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2412410/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"pilar garces\">pilar garces\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/13967\" class=\"user-id-13967\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/13967/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"thomas mueggler\">thomas mueggler\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/577428\" class=\"user-id-577428\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/577428/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"basil k&#xfc;nnecke\">basil k&#x000fc;nnecke\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"andreas bruns\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">andreas bruns\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"eric p. prinssen\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">eric p. prinssen\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"philipp schoenenberger\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">philipp schoenenberger\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2424959\" class=\"user-id-2424959\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2424959/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"philipp janz\">philipp janz\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"roger redondo\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">roger redondo\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"barbara biemans&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">barbara biemans\u003csup>2\u003c/sup>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"henner knust\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">henner knust\u003csup>1\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2264913\" class=\"user-id-2264913\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2264913/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"andr&#xe;s olivares-morales\">andr&#x000e9;s olivares-morales\u003c/a>\u003csup>3\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/1172717\" class=\"user-id-1172717\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1172717/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"alessandro brigo\">alessandro brigo\u003c/a>\u003csup>3\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"jan michael schulz\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">jan michael schulz\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/157846\" class=\"user-id-157846\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/157846/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"daniel bertrand\">daniel bertrand\u003c/a>\u003csup>4\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"michael saxe&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">michael saxe\u003csup>2\u003c/sup>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2733790\" class=\"user-id-2733790\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2733790/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"eoin c. o&#x;connor\">eoin c. o&#x02019;connor\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2269471\" class=\"user-id-2269471\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2269471/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"maria-clemencia hernandez&#xa;\">maria-clemencia hernandez\u003c/a>\u003csup>2\u003c/sup>&#x0002a;\u003c/span>\u003c/div>\u003cul class=\"notes\">\u003cli>\u003cspan>\u003csup>1\u003c/sup>\u003c/span>medicinal chemistry, roche pharmaceutical research and early development, roche innovation center basel, basel, switzerland\u003c/li>\u003cli>\u003cspan>\u003csup>2\u003c/sup>\u003c/span>neuroscience and rare diseases, roche pharmaceutical research and early development, roche innovation center basel, basel, switzerland\u003c/li>\u003cli>\u003cspan>\u003csup>3\u003c/sup>\u003c/span>pharmaceutical sciences, roche pharmaceutical research and early development, roche innovation center basel, basel, switzerland\u003c/li>\u003cli>\u003cspan>\u003csup>4\u003c/sup>\u003c/span>hiqscreen s&#x000e0;rl, v&#x000e9;senaz, switzerland\u003c/li>\u003c/ul>\u003cp class=\"mb0\">\u003cb>background:\u003c/b> alterations in the gabaergic system contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder (asd) and angelman syndrome (as), particularly in cases involving large deletions in the 15q11&#x02013;13 region. positive modulation of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors may provide a novel therapeutic approach without the typical side effects associated with non-selective gaba\u003csub>a\u003c/sub> positive allosteric modulators such as diazepam.\u003c/p>\u003cp class=\"mb0\">\u003cb>methods:\u003c/b> alogabat was assessed for binding and functional activity at gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 receptors \u003cem>in vitro\u003c/em> and in electrophysiological studies using hippocampal slices. \u003cem>in vivo\u003c/em> studies in rodents included receptor occupancy (ro) using a selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 tracer (autoradiography), pharmacological mri, and electroencephalography (eeg). alogabat was evaluated for its effects on the repetitive behavior phenotype in btbr and contactin-associated protein-like 2 (cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup>) knockout mice, seizure models, cognitive performance in rats, and rotarod performance following combination treatment with diazepam.\u003c/p>\u003cp class=\"mb0\">\u003cb>results:\u003c/b> alogabat is a potent positive allosteric modulator of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors, with binding and functional selectivity. receptor occupancy studies provided direct proof of dose-dependent target engagement. functional circuit modulation was demonstrated by dose-dependent regional perfusion changes in pharmacological mri and changes in eeg theta- and beta-band power in rats. at &#x0003e;50% gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor occupancy, alogabat normalized elevated self-grooming behavior in both cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> and btbr mice and exhibited antiepileptic activity in rats. alogabat did not impair cognition in wildtype rats at gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor occupancy up to 75%, although impairment occurred at higher doses, probably due to increased activity at other receptor subtypes and/or saturation of &#x003b1;5 receptors. alogabat did not worsen diazepam-induced impairment on the rotarod test.\u003c/p>\u003cp class=\"mb0\">\u003cb>conclusion:\u003c/b> alogabat showed beneficial effects in mouse models relevant to neurodevelopmental disorders and anti-seizure activity at doses that did not produce cognitive, sedative, or motoric side effects.\u003c/p>\u003cdiv class=\"clear\">\u003c/div>\u003c/div>\u003cdiv class=\"journalfulltext\">\u003ca id=\"h2\" name=\"h2\">\u003c/a>\u003ch2>1 introduction\u003c/h2>\u003cp class=\"mb15\">alterations in the gabaergic system, the main inhibitory neurotransmitter system in the brain, may contribute to the pathophysiology of neurodevelopmental disorders (ndds), such as autism spectrum disorder (asd) and angelman syndrome (as). asd is a complex, heterogeneous ndd with both genetic and environmental factors (\u003ca href=\"#b7\">bourgeron, 2015\u003c/a>) contributing to aberrant changes in brain growth, neuronal development, and functional connectivity (\u003ca href=\"#b18\">dhossche et al., 2002\u003c/a>; \u003ca href=\"#b55\">pizzarelli and cherubini, 2011\u003c/a>; \u003ca href=\"#b8\">braat and kooy, 2015\u003c/a>; \u003ca href=\"#b58\">robertson et al., 2016\u003c/a>). asd is characterized by two core domains: impairments in social interaction and communication and the presence of repetitive or restricted behaviors, interests, or activities (\u003ca href=\"#b3\">american psychiatric association, 2008\u003c/a>). there are a range of comorbid conditions, including irritability, depression, anxiety, attention deficits, obsessive-compulsive symptoms, seizures, and sleep disruption. as is a rare genetic ndd with a prevalence of 1 in 12,000 to 20,000 births (\u003ca href=\"#b38\">luk and lo, 2016\u003c/a>; \u003ca href=\"#b44\">mertz et al., 2013\u003c/a>). individuals with as often present with autistic features, severe intellectual disability, microcephaly, speech impairment, bursts of laughter, sleep problems, movement disorders, and epilepsy (\u003ca href=\"#b12\">buiting, 2010\u003c/a>; \u003ca href=\"#b35\">kalsner and chamberlain, 2015\u003c/a>).\u003c/p>\u003cp class=\"mb15\">gaba\u003csub>a\u003c/sub> receptors are ligand-gated chloride channels. there are 19 genes encoding gaba\u003csub>a\u003c/sub> receptor subunits that assemble as pentamers, with the most common stoichiometry being two &#x003b1;, two &#x003b2;, and one &#x003b3; subunit. gaba\u003csub>a\u003c/sub> subunit combinations give rise to functional, circuit, and behavioral specificity (\u003ca href=\"#b65\">sieghart, 2006\u003c/a>; \u003ca href=\"#b73\">vithlani et al., 2011\u003c/a>). gaba\u003csub>a\u003c/sub> receptors that contain the &#x003b1;5 subunit (gaba\u003csub>a\u003c/sub>-&#x003b1;5) are of particular interest due to their restricted pattern of expression and unique physiological and pharmacological properties (\u003ca href=\"#b69\">sur et al., 1999\u003c/a>; \u003ca href=\"#b46\">mohler, 2011\u003c/a>). in humans, gaba\u003csub>a\u003c/sub> receptors containing the &#x003b1;5 subunit are preferentially localized in the hippocampus, prefrontal cortex, nucleus accumbens, amygdala, insular cortex, anterior cingulate, and cingulate cortex&#x02014;key regions believed to be involved in the neuropathology and pathophysiology of asd (\u003ca href=\"#b42\">mendez et al., 2013\u003c/a>; \u003ca href=\"#b48\">myers et al., 2017\u003c/a>). the \u003cem>gabra5\u003c/em> gene has been proposed as a candidate gene for asd (\u003ca href=\"#b15\">delong, 2007\u003c/a>; \u003ca href=\"#b45\">mesbah-oskui et al., 2017\u003c/a>; \u003ca href=\"#b74\">warrier et al., 2013\u003c/a>; \u003ca href=\"#b19\">di nanni et al., 2019\u003c/a>), suggesting decreased gabaergic inhibition in a subpopulation of autistic individuals. mutations involving the gaba\u003csub>a\u003c/sub> receptor subunit genes \u003cem>gabra5\u003c/em>, \u003cem>gabrb3\u003c/em>, and \u003cem>gabrg3\u003c/em> (encoding the &#x003b1;5, &#x003b2;3, and &#x003b3;3 subunits) found on chromosomal region 15q11&#x02013;q13 have been associated with ndds including as, epilepsy, and prader&#x02013;willi syndrome in addition to asd (\u003ca href=\"#b32\">hogart et al., 2010\u003c/a>; \u003ca href=\"#b61\">sanders, 2015\u003c/a>). as is predominantly caused by the loss of function of the maternally inherited \u003cem>ube3a\u003c/em> gene; however, approximately 75% of individuals with as carry a large deletion of the maternal 15q11&#x02013;q13 chromosomal region. clinical studies have shown that individuals with as who have large deletions (deletion as) exhibit more severe symptoms than those in whom \u003cem>ube3a\u003c/em> is the only gene affected, suggesting that the \u003cem>gabra5\u003c/em>, \u003cem>gabrb3\u003c/em>, and \u003cem>gabrg3\u003c/em> genes are relevant to the etiology of the disease.\u003c/p>\u003cp class=\"mb15\">imaging studies using pet and magnetic resonance spectroscopy have shown reduced gaba\u003csub>a\u003c/sub> receptor binding in the superior and medial frontal cortex (\u003ca href=\"#b47\">mori et al., 2012\u003c/a>) and reduced gaba levels in individuals with asd (\u003ca href=\"#b58\">robertson et al., 2016\u003c/a>; \u003ca href=\"#b28\">gaetz et al., 2014\u003c/a>; \u003ca href=\"#b59\">rojas et al., 2014\u003c/a>; \u003ca href=\"#b57\">puts et al., 2017\u003c/a>). postmortem studies have shown reduced numbers of inhibitory interneurons (\u003ca href=\"#b20\">dufour et al., 2023\u003c/a>), reduced expression of gaba\u003csub>a\u003c/sub> receptor subunits (\u003ca href=\"#b16\">delorey, 2005\u003c/a>; \u003ca href=\"#b1\">abrahams and geschwind, 2008\u003c/a>), and reduced levels of the gaba-synthesizing enzymes such as glutamic acid decarboxylase (gad) 65 and 67 (\u003ca href=\"#b21\">fatemi et al., 2002\u003c/a>). there is increasing evidence from genetic, environmental, and phenotypic rodent models relevant to asd indicating that gabaergic circuit dysfunctions contribute to autism-like phenotypes (\u003ca href=\"#b27\">fukuda et al., 2005\u003c/a>; \u003ca href=\"#b13\">chao et al., 2010\u003c/a>; \u003ca href=\"#b6\">banerjee et al., 2013\u003c/a>). such deficits may result from multiple causes, including a reduced number of gabaergic interneurons, altered interneuron function, impaired gaba\u003csub>a\u003c/sub> receptor trafficking to the membrane, reduced expression of gaba\u003csub>a\u003c/sub> receptor subunits, and reduced gaba uptake function of gat-1 in neurons (\u003ca href=\"#b49\">nakamura et al., 2016\u003c/a>; \u003ca href=\"#b50\">orefice et al., 2016\u003c/a>; \u003ca href=\"#b43\">mermer et al., 2021\u003c/a>). supportive evidence is provided by the observation of autism-like behaviors in both gaba\u003csub>a\u003c/sub>-&#x003b1;5 and &#x003b2;3 subunit knockout mice (\u003ca href=\"#b77\">zurek et al., 2016\u003c/a>; \u003ca href=\"#b17\">delorey et al., 2008\u003c/a>). regarding possible therapeutic approaches, enhancement of the gaba\u003csub>a\u003c/sub> receptor activity by non-selective benzodiazepines has been shown to ameliorate autism-like behavioral deficits in mouse models; however, due to sedation that is likely mediated by the activation of the gaba\u003csub>a\u003c/sub>-&#x003b1;1 subtype, very narrow therapeutic margins were observed (\u003ca href=\"#b30\">han et al., 2012\u003c/a>; \u003ca href=\"#b29\">han et al., 2014\u003c/a>; \u003ca href=\"#b37\">lim et al., 2017\u003c/a>). interestingly, a recent study showed that a gaba\u003csub>a\u003c/sub>-&#x003b1;5 positive allosteric modulator (pam), sh-053-2&#x02032;f-r-ch3, attenuated social and cognitive deficits in male rats exposed to valproic acid \u003cem>in utero\u003c/em>, a rat model relevant to autism (\u003ca href=\"#b68\">souza et al., 2024\u003c/a>).\u003c/p>\u003cp class=\"mb15\">the aim of the current study was to determine whether a selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 pam, alogabat (also known as ro7017773 or rg7816), would produce beneficial effects in animal models relevant to autism-like repetitive behavior&#x02014;specifically btbr mice (\u003ca href=\"#b40\">mcfarlane et al., 2008\u003c/a>) and contactin-associated protein-like 2 [cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup>] homozygous knockout mice (\u003ca href=\"#b51\">penagarikano et al., 2011\u003c/a>)&#x02014;and anti-seizure activity, without the typical side effects of non-selective gaba\u003csub>a\u003c/sub> pams, such as sedation and cognitive impairment. furthermore, target engagement was assessed by \u003cem>in vivo\u003c/em> receptor occupancy (ro) and pharmacological mri (phmri) in rodents, and an electroencephalography (eeg) study in rats was undertaken to identify a putative pharmacodynamic readout for future clinical trials.\u003c/p>\u003ca id=\"h3\" name=\"h3\">\u003c/a>\u003ch2>2 materials and methods\u003c/h2>\u003cp class=\"mb15\">further information for each method listed below can be found in the \u003ca href=\"#sm1\">supplementary material\u003c/a>.\u003c/p>\u003ca id=\"h3-1\" name=\"h3-1\">\u003c/a>\u003ch3 class=\"pt0\">2.1 materials\u003c/h3>\u003cp class=\"mb0\">alogabat [ro7017773; c\u003csub>21\u003c/sub>h\u003csub>23\u003c/sub>n\u003csub>5\u003c/sub>o\u003csub>4\u003c/sub>; 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl) methoxy)-n-(tetrahydropyran-4-yl)pyridazine-3-carboxamide (iupac name); molecular weight: 409.44&#x000a0;gmol\u003csup>&#x02212;1\u003c/sup>] was synthesized at f.hoffmann-la roche ag, switzerland [\u003ca href=\"#f1\">figure 1a\u003c/a>; see example 8 in \u003ca href=\"#b10\">buettelmann et al., 2018\u003c/a>]. the discovery of alogabat and the related chemical series will be disclosed in future publications. diazepam, l-655,708, [\u003csup>3\u003c/sup>h]flumazenil, [\u003csup>3\u003c/sup>h]l-655,708, and [\u003csup>3\u003c/sup>h]ro0154513 were synthesized at f.hoffmann-la roche ag, switzerland.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 1\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" name=\"figure1\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" alt=\"www.frontiersin.org\" id=\"f1\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 1\u003c/b>. \u003cem>in vitro\u003c/em> pharmacology of alogabat. \u003cb>(a)\u003c/b> chemical structure of alogabat (ro7017773; c21h23n5o4); 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl) methoxy)-n-(tetrahydropyran-4-yl)pyridazine-3-carboxamide (iupac name); molecular weight, 409.44&#x000a0;gmol\u003csup>&#x02212;1\u003c/sup>. \u003cb>(b)\u003c/b> concentration-response curves of alogabat in [\u003csup>3\u003c/sup>h]flumazenil competition-binding assays with membranes expressing different rat recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (\u003cem>n\u003c/em> &#x0003d; 10&#x02013;20/concentration). \u003cb>(c)\u003c/b> concentration-response curves of the effects of alogabat in hek293 cells expressing different rat recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (\u003cem>n\u003c/em> &#x0003d; 4&#x02013;5/concentration). data in the graphs are shown as the mean (symbols) &#x000b1; sem (error bars). error bars smaller than the symbol size are not shown. \u003cb>(d)\u003c/b> isoguvacine concentration-response curves obtained in the presence and absence of alogabat in rat hippocampal slices. the points represent the mean values &#x000b1; sem of three slices. the sigmoidal curves were fit through these points. \u003cb>(e)\u003c/b> the ppi of ps was measured in the absence (control) and presence of alogabat at 0.3&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 3 slices) and 1&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 6 slices). ps1 and ps2 are the responses induced by the first and second stimulus, respectively. the data are normalized to the amplitude of ps1 and presented as the mean &#x000b1; sem.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h3-2\" name=\"h3-2\">\u003c/a>\u003ch3 class=\"pt0\">2.2 \u003cem>in vitro\u003c/em> experiments\u003c/h3>\u003ca id=\"h7-2-1\" name=\"h7-2-1\">\u003c/a>\u003ch4>2.2.1 gaba\u003csub>a\u003c/sub> receptor radioligand binding assays\u003c/h4>\u003cp class=\"mb0\">the affinity of alogabat for rat and human gaba\u003csub>a\u003c/sub> receptors containing &#x003b1;5, &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits was measured by [\u003csup>3\u003c/sup>h]flumazenil competition-binding assays with membranes expressing different rat recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (\u003cem>n\u003c/em> &#x0003d; 10&#x02013;20/concentration) and for human &#x003b1;4 and &#x003b1;6 by [\u003csup>3\u003c/sup>h]ro0154513, as previously described (\u003ca href=\"#b4\">ballard et al., 2009\u003c/a>; \u003ca href=\"#b31\">hipp et al., 2021\u003c/a>).\u003c/p>\u003ca id=\"h7-2-2\" name=\"h7-2-2\">\u003c/a>\u003ch4>2.2.2 gaba\u003csub>a\u003c/sub> receptor electrophysiological studies\u003c/h4>\u003cp class=\"mb0\">alogabat was tested for functional activity on four different cloned rat and human gaba\u003csub>a\u003c/sub> receptor subtypes (\u003ca href=\"#b10\">buettelmann et al., 2018\u003c/a>), namely, &#x003b1;1&#x003b2;2&#x003b3;2, &#x003b1;2&#x003b2;3&#x003b3;2, &#x003b1;3&#x003b2;3&#x003b3;2, and &#x003b1;5&#x003b2;3&#x003b3;2. ion currents were induced by gaba concentrations that evoked approximately 20% of the maximal response (\u003cem>n\u003c/em> &#x0003d; 4&#x02013;5/concentration). the following concentrations of gaba were used: 1&#x000a0;&#x000b5;m for &#x003b1;1&#x003b2;2&#x003b3;2, 10&#x000a0;&#x000b5;m &#x003b1;2&#x003b2;3&#x003b3;2, 10&#x000a0;&#x000b5;m for &#x003b1;3&#x003b2;3&#x003b3;2, and 3&#x000a0;&#x000b5;m for &#x003b1;5&#x003b2;3&#x003b3;2 receptor subtype.\u003c/p>\u003cp class=\"mb0\">alogabat was also tested for functional activity on native gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors in rat hippocampal slices: modulation of isoguvacine-induced population spikes (\u003ca href=\"#b4\">ballard et al., 2009\u003c/a>) and paired-pulse inhibition (ppi) (\u003ca href=\"#b76\">xie and tietz, 1991\u003c/a>). population spikes (pss) were recorded every 30&#x000a0;s by the stimulation of the schaffer collaterals, and isoguvacine was applied consecutively and in increasing concentrations for at least 4&#x000a0;min to the slices (control). after the washout of isoguvacine, alogabat (300&#x000a0;nm) was added to the bath perfusion, and a new isoguvacine concentration-response curve was obtained (alogabat). the ps amplitudes were normalized to the control ps obtained before the first application of isoguvacine and were fitted individually for each slice (\u003cem>n\u003c/em> &#x0003d; 3 slices).\u003c/p>\u003cp class=\"mb0\">the ppi of ps was measured in the absence (control) and presence of alogabat at 0.3&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 3 slices from one animal) and 1&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 6 slices from two animals). the paired-pulse protocol consisted of two stimuli timely spaced by 20&#x000a0;ms, which were applied at the schaffer collaterals in rat hippocampal slices. we used a low number of animals based on our experience with the assay, which is highly robust and reproducible, and in alignment with our commitment to reducing the number of animals used.\u003c/p>\u003ca id=\"h7-2-3\" name=\"h7-2-3\">\u003c/a>\u003ch4>2.2.3 selectivity screening\u003c/h4>\u003cp class=\"mb0\">the selectivity of alogabat (10&#x000a0;&#x000b5;m) over more than 70 receptors was assessed by radioligand binding studies conducted using eurofins cerep sa (celle l&#x000e9;vescault, france), following the methods described on \u003ca href=\"http://www.eurofinsdiscoveryservices.com/\">www.eurofinsdiscoveryservices.com\u003c/a>.\u003c/p>\u003ca id=\"h3-3\" name=\"h3-3\">\u003c/a>\u003ch3 class=\"pt0\">2.3 \u003cem>in vivo\u003c/em> experiments\u003c/h3>\u003ca id=\"h7-3-1\" name=\"h7-3-1\">\u003c/a>\u003ch4>2.3.1 ethics approval\u003c/h4>\u003cp class=\"mb0\">experiments performed at f.hoffmann-la roche ag (basel, switzerland) complied with the swiss federal and cantonal laws on animal research and aaalac regulations and received prior approval from the cantonal veterinary office. the eeg study was conducted at brains online (ca, united states) in accordance with the guide for the care and use of laboratory animals (national research council 2011) after gaining approval from the institutional animal care and use committee. the pentylenetetrazole (ptz) and maximal electroshock (mes) tests were conducted at vivocore inc., canada, which is a facility licensed by the ontario ministry of agriculture, food, and rural affairs and accredited by the canadian council on animal care. all \u003cem>in vivo\u003c/em> studies are reported in compliance with the arrive guidelines (\u003ca href=\"#b52\">percie du sert et al., 2020\u003c/a>).\u003c/p>\u003ca id=\"h7-3-2\" name=\"h7-3-2\">\u003c/a>\u003ch4>2.3.2 animals\u003c/h4>\u003cp class=\"mb0\">all animals were group-housed in holding rooms at controlled temperature and humidity under a 12&#x000a0;h light/dark cycle and were allowed to acclimate for at least 7&#x000a0;days. twenty-six male wistar rats (charles river, germany; &#x0223c;160&#x000a0;g) and sixteen male cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (bred at roche basel; 18&#x02013;22&#x000a0;g) were used in receptor occupancy studies. thirty-two male fischer rats (charles river, germany) were assessed in mri experiments (&#x0223c;250&#x000a0;g). seventeen male wistar rats (envigo, united states) were assessed in eeg experiments. one hundred male btbr mice (bred in roche basel) were assessed in grooming and open-field tests (n &#x0003d; 60, &#x0223c;30&#x000a0;g) and for digging behavior (n &#x0003d; 40, &#x0223c;30&#x000a0;g). fifty-seven male cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (bred in roche basel; 5&#x02013;6&#x000a0;weeks) and wildtype littermates (n &#x0003d; 15) were assessed in grooming and open-field tests. one hundred male sprague&#x02013;dawley rats (charles river, canada) were used to evaluate antiepileptic effects in the ptz (70&#x02013;100&#x000a0;g, n &#x0003d; 40) and mes (&#x0003c;50&#x000a0;g n &#x0003d; 60) tests. forty-eight male sprague&#x02013;dawley rats (charles river, france) were used in the rotarod test (&#x0223c;170&#x02013;200&#x000a0;g). one hundred and forty-one male lister hooded (lh) rats (charles river, germany) were used in the cognition tests: 5-choice serial reaction time (5-csrt) task (n &#x0003d; 11, &#x0223c;400&#x000a0;g); continuous performance test (cpt; n &#x0003d; 11, &#x0223c;400&#x000a0;g); paired associates learning (pal) task (n &#x0003d; 12, &#x0223c;400&#x000a0;g); context fear conditioning (n &#x0003d; 67, &#x0223c;250&#x000a0;g); and morris water maze (n &#x0003d; 40, 350&#x02013;400&#x000a0;g).\u003c/p>\u003ca id=\"h7-3-3\" name=\"h7-3-3\">\u003c/a>\u003ch4>2.3.3 alogabat treatment\u003c/h4>\u003cp class=\"mb0\">alogabat was formulated in 2% hydroxypropyl cellulose in water (or 0.3% tween 80 in saline for \u003cem>in vivo\u003c/em> occupancy and grooming/digging experiments). the administration volume was 10&#x000a0;ml/kg (mice) and 5&#x000a0;ml/kg (rats). each dose was expressed as the weight of the base. alogabat was administered with a pre-treatment time of 30&#x000a0;min in mice and 60&#x000a0;min in rats (except for the eeg study), based on pharmacokinetic data indicating the time of maximal drug plasma concentration. treatment groups were assigned randomly. dose groups were provided as coded vials to allow blinded assessment during the conduct of each experiment. to minimize potential confounders regarding the time of day for behavioral testing, animals were split into separate cohorts (balanced for treatment groups) and tested during the same period.\u003c/p>\u003ca id=\"h7-3-4\" name=\"h7-3-4\">\u003c/a>\u003ch4>2.3.4 receptor occupancy studies\u003c/h4>\u003ch5>2.3.4.1 \u003cem>in vivo\u003c/em> occupancy in rats\u003c/h5>\u003cp class=\"mb0\">male wistar rats (n &#x0003d; 26, &#x0223c;160&#x000a0;g) were administered vehicle or alogabat (0.3, 1, 3, 10, 30, and 100&#x000a0;mg/kg, intraperitoneally [i.p.], n &#x0003d; 3/group) or the gaba\u003csub>a\u003c/sub>-&#x003b1;5 blocker l-655,708 at 10&#x000a0;mg/kg i.p. (n &#x0003d; 2). fifteen minutes later, the gaba\u003csub>a\u003c/sub>-&#x003b1;5 radioligand [\u003csup>3\u003c/sup>h]ro0154513 was administered intravenously (i.v.) to assess ro (\u003ca href=\"#b4\">ballard et al., 2009\u003c/a>; \u003ca href=\"#b31\">hipp et al., 2021\u003c/a>). non-specific binding was determined by pre-treatment with the established gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor blocker l-655,708 (10&#x000a0;mg/kg i.p.; n &#x0003d; 2).\u003c/p>\u003ch5>2.3.4.2 \u003cem>ex vivo\u003c/em> occupancy in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h5>\u003cp class=\"mb0\">cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (\u003ca href=\"#b51\">penagarikano et al., 2011\u003c/a>) (n &#x0003d; 16, 18&#x02013;22&#x000a0;g) were administered the vehicle or alogabat (30, 60, and 100&#x000a0;mg/kg) i.p. (n &#x0003d; 4/group), and ro was assessed in brain sections with the highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 radioligand, [\u003csup>3\u003c/sup>h]l-655,708, 30&#x000a0;min post-administration.\u003c/p>\u003ca id=\"h7-3-5\" name=\"h7-3-5\">\u003c/a>\u003ch4>2.3.5 pharmacological mri in rats\u003c/h4>\u003cp class=\"mb0\">male fischer rats (n &#x0003d; 32, &#x0223c;250&#x000a0;g) were administered vehicle or alogabat (3, 10, and 30&#x000a0;mg/kg) i.p. (n &#x0003d; 8/dose). phmri was performed under medetomidine sedation in a small-animal scanner (4.7t/40&#x000a0;cm; bruker biospin, germany), and blood perfusion was analyzed according to previously published procedures (\u003ca href=\"#b9\">bruns et al., 2009\u003c/a>). fifteen minutes after drug treatment, rats were initially anesthetized using isoflurane (4%) in the carrier gas composed of oxygen and air (1:5), supplied to the spontaneously breathing animals in an inhalation box. upon the induction of anesthesia, a subcutaneous (s.c.) bolus injection of 0.2&#x000a0;mg/kg (1&#x000a0;ml/kg) of medetomidine prepared from 1:5 diluted dormilan\u003csup>&#x000ae;\u003c/sup> was administered, and the animal was transferred onto a rat cradle for inserting an s.c. catheter and starting continuous infusion of 1:10 diluted dormilan\u003csup>&#x000ae;\u003c/sup> (medetomidine) at a dose of 0.1&#x000a0;mg/kg/h (1&#x000a0;ml/kg/h). the head was immobilized in a stereotaxic frame. respiratory rate, body temperature, and o\u003csub>2\u003c/sub> and co\u003csub>2\u003c/sub> levels in inhaled and exhaled air were continuously monitored using a powerlab data acquisition system (adinstruments, spechbach, germany). body temperature was maintained at 37&#x000b0;c with a feedback-regulated electric heating blanket. immediately after the last imaging assessment, rats were euthanized by decapitation under anesthesia, and plasma samples were collected at approximately 40&#x000a0;min post-administration of alogabat. images were processed and analyzed using in-house developed software written in idl (rsi, boulder, co, united states) and matlab (the mathworks inc., natick, ma, united states).\u003c/p>\u003ca id=\"h7-3-6\" name=\"h7-3-6\">\u003c/a>\u003ch4>2.3.6 eeg in rats\u003c/h4>\u003cp class=\"mb0\">male wistar rats (n &#x0003d; 17) were surgically prepared with wireless implanted transmitters to enable simultaneous recording of eeg, hippocampal (ca3) local field potential (lfp), and emg. rats were anesthetized using isoflurane (2%, 800&#x000a0;ml/min o2). bupivacaine/epinephrine was used for local analgesia, while finadyne or carprofen was used for peri-/post-operative analgesia. amoxicillin was used as an antibiotic. the animals were placed in a stereotaxic frame (kopf instruments, united states). a subcutaneous pocket was created near the dorsal flank, into which a transmitter (f50-eee, data sciences international, physio tel f50-eee small animal cns telemetry; three bipolar channels, biopotential lead, outer diameter 0.3&#x000a0;mm) was inserted. the transmitter included three bipolar channels: channel 1 (eeg): two screws in the left hemisphere (frontal: 11&#x000a0;mm anterior and 2.5&#x000a0;mm lateral to bregma; central: 3&#x000a0;mm anterior and 3.5&#x000a0;mm lateral to lambda); channel 2 (lfp): a single wire electrode targeting the ca3 region of the right hippocampus; and channel 3 (emg): electrodes placed in the neck muscle for recording emg activity, aiding in sleep stage classification.\u003c/p>\u003cp class=\"mb0\">after a 2-week recovery, rats were administered the vehicle or alogabat (10&#x000a0;mg/kg) using a cross-over design (1-week interval). if the setup allowed, the positive control diazepam (2&#x000a0;mg/kg) was assessed. all drugs were administered i.v. via an implanted cannula so that brain exposure was expected within a few minutes of administration. eeg spectral power was analyzed quantitatively up to 1&#x000a0;h post-administration. only animals with clean eeg recordings were included in the analysis. eeg data in the awake state were used for the analyses reported in this study. we first investigated the effects on power over predefined theta and beta power ranges, defined \u003cem>a priori\u003c/em> as 6&#x02013;10&#x000a0;hz and 20&#x02013;30&#x000a0;hz, respectively, based on previous studies with gabaa drugs (\u003ca href=\"#b72\">visser et al., 2003\u003c/a>; \u003ca href=\"#b71\">van lier et al., 2004\u003c/a>). then, we evaluated frequency-specific effects across the 2&#x02013;128&#x000a0;hz range.\u003c/p>\u003ca id=\"h7-3-7\" name=\"h7-3-7\">\u003c/a>\u003ch4>2.3.7 grooming behavior and open-field test in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h4>\u003cp class=\"mb0\">male btbr mice (n &#x0003d; 60, &#x0223c;30&#x000a0;g) were pre-treated with the vehicle or alogabat at 30, 60, 90, and 120&#x000a0;mg/kg i.p. (n &#x0003d; 12/dose). male cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (n &#x0003d; 57, 5&#x02013;6&#x000a0;weeks) and wildtype littermates (n &#x0003d; 15) received sub-chronic treatment (8&#x02013;10&#x000a0;days) with the vehicle or alogabat at 30, 60, and 100&#x000a0;mg/kg i.p. (n &#x0003d; 14&#x02013;15/dose). spontaneous locomotor activity was assessed in both groups of mice for 1&#x000a0;h in an open field (42 &#x000d7; 42 &#x000d7; 30.5&#x000a0;cm; 20 lux at the center of the arena) with a small amount of sawdust bedding. movement of the animal was detected by interruptions in an array of photobeams from horizontally located infrared sources placed around the open field, measured using a versamax system (accuscan instruments inc., columbus, oh, united states). activity was measured as the distance traveled (cm).\u003c/p>\u003cp class=\"mb0\">one week later, each mouse was placed into a type-ii cage (21.5 &#x000d7; 15.5 &#x000d7; 13.0&#x000a0;cm; 40 lux) for 5&#x000a0;min habituation, and then the cumulative time (s) spent grooming during 10&#x000a0;min was recorded manually by a blinded observer. distance traveled (cm) during the session was measured using a video tracking system (ethovision, noldus information technology, netherlands). plasma samples were collected from btbr mice 1&#x000a0;week after testing and 30&#x000a0;min after treatment (\u003cem>n\u003c/em> &#x0003d; 6/dose). plasma samples were collected from cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice 1&#x000a0;day later and 30&#x000a0;min after treatment (\u003cem>n\u003c/em> &#x0003d; 4/dose).\u003c/p>\u003ca id=\"h7-3-8\" name=\"h7-3-8\">\u003c/a>\u003ch4>2.3.8 digging behavior in btbr mice\u003c/h4>\u003cp class=\"mb0\">a separate group of male btbr mice (n &#x0003d; 40, &#x0223c;30&#x000a0;g) were pre-treated with vehicle or alogabat at 30, 60, and 100&#x000a0;mg/kg i.p. (n &#x0003d; 10/dose) and were placed into a small circular dish (d &#x0003d; 10&#x000a0;cm) filled with fresh thick sawdust located in the middle of a clean type-ii cage (21.5 &#x000d7; 15.5 &#x000d7; 13.0&#x000a0;cm; 40 lux). the cumulative time (s) spent digging over 5&#x000a0;min was recorded manually by a blinded observer. the distance traveled (cm) and speed were also measured in the arena, outside the dish (ethovision, noldus information technology, netherlands). plasma samples were collected immediately after the digging test, i.e., 35&#x02013;40&#x000a0;min post-administration (\u003cem>n\u003c/em> &#x0003d; 3/dose).\u003c/p>\u003ca id=\"h7-3-9\" name=\"h7-3-9\">\u003c/a>\u003ch4>2.3.9 evaluation of antiepileptic effects in rats\u003c/h4>\u003cp class=\"mb0\">vehicle or alogabat (5, 15, or 30&#x000a0;mg/kg) was administered p.o. (n &#x0003d; 8/dose) and assessed for seizures induced by (1) subcutaneous (s.c.) ptz and (2) the maximum electrical stimulus (mes) model in male sprague&#x02013;dawley rats (ptz: 70&#x02013;100&#x000a0;g, n &#x0003d; 40; mes: &#x0003c;50&#x000a0;g n &#x0003d; 60, charles river, canada). diazepam (synthesized at f.hoffmann-la roche ag) was included in each experiment as a positive control and administered at 3&#x000a0;mg/kg i.p., 30&#x000a0;min prior to testing. immediately following testing, a terminal blood sample was collected under anesthesia.\u003c/p>\u003ch5>2.3.9.1 pentylenetetrazole test\u003c/h5>\u003cp class=\"mb0\">following the designated pre-treatment time, ptz was administered at 75&#x000a0;mg/kg s.c. animals were transferred to a single cage and monitored closely for the onset of clonic seizure, and the percentage of each group showing seizures was recorded. protection was defined as the complete absence of clonic seizure, including forelimb clonus, over the 30&#x000a0;min observation period.\u003c/p>\u003ch5>2.3.9.2 maximal electroshock test\u003c/h5>\u003cp class=\"mb0\">following the designated pre-treatment time, rats received maximal electroshock (mes: 150&#x000a0;ma, 0.2&#x000a0;s duration, 60&#x000a0;hz) via corneal electrodes moistened with saline (shock simulator type 221; harvard apparatus). due to inconsistency in responses by rats to this type of stimuli, all test animals (n &#x0003d; 60) were subjected to two screening sessions on two separate days, and 40 rats were selected based on their reliability to have tonic seizures. drug testing was conducted on the third day, during which the rats received the standard maximal electroshock, and the presence or absence of a tonic seizure was recorded and expressed as the percentage of animals in each group that showed seizures. protection was defined as the absence of a full tonic seizure within 15&#x000a0;s of stimulus delivery.\u003c/p>\u003ca id=\"h7-3-10\" name=\"h7-3-10\">\u003c/a>\u003ch4>2.3.10 combination with diazepam on rotarod performance in rats\u003c/h4>\u003cp class=\"mb0\">forty-eight male sprague&#x02013;dawley rats (&#x0223c;170&#x02013;200&#x000a0;g) were pre-trained to the rotarod (47750 rota-rod ng, ugo basile) at 8&#x000a0;rpm for 120&#x000a0;s. one day later, rats were administered alogabat (or vehicle) p.o., 30&#x000a0;min prior to diazepam or vehicle i.p., and they were assessed on the rotarod 30&#x000a0;min later. each rat was given three attempts to remain on the rotarod, with a maximum duration of 120&#x000a0;s per attempt. treatment groups (n &#x0003d; 8/group) consisted of alogabat alone (30&#x000a0;mg/kg), diazepam alone (5&#x000a0;mg/kg), or alogabat at 3, 10, and 30&#x000a0;mg/kg in combination with diazepam (5&#x000a0;mg/kg). the maximum time (s) spent on the rotarod was recorded. after the completion of rotarod testing, animals were euthanized under isoflurane anesthesia for plasma sample collection at approximately 70&#x000a0;min post-administration of alogabat.\u003c/p>\u003ca id=\"h7-3-11\" name=\"h7-3-11\">\u003c/a>\u003ch4>2.3.11 cognition testing in rats\u003c/h4>\u003ch5>2.3.11.1 operant and touchscreen cognition tests\u003c/h5>\u003cp class=\"mb0\">separate groups of male lister hooded (lh) rats (&#x0223c;400&#x000a0;g) were pre-trained in the operant and touch screen tests, as described in \u003ca href=\"#sm1\">supplementary material\u003c/a>. the 5-csrt task (n &#x0003d; 11) is a test of attention. the primary parameter is the total percentage of correct responses. continuous performance test (cpt; n &#x0003d; 11) assesses sustained attention. the primary parameter is the discrimination sensitivity index (d prime), which is a ratio based on the rate at which rats make correct and incorrect responses. the paired associates learning (pal) task (n &#x0003d; 12) assesses visual&#x02013;spatial memory. the primary parameter is the total percentage of correct responses. a latin-squares design was used to assess the vehicle and doses of alogabat (3, 10, and 30&#x000a0;mg/kg p.o.). rats were tested twice weekly with at least a 2-day interval between test sessions. rats were trained between test days to maintain baseline performance.\u003c/p>\u003ch5>2.3.11.2 context fear conditioning\u003c/h5>\u003cp class=\"mb0\">two cohorts of male lh rats (&#x0223c;250&#x000a0;g; n &#x0003d; 67) were assessed for context fear conditioning (cfc) in two experiments: (1) vehicle or alogabat at 10 and 30&#x000a0;mg/kg (n &#x0003d; 9/dose); (2) vehicle or alogabat at 1, 3, and 10&#x000a0;mg/kg (n &#x0003d; 10/dose) administered p.o., 60&#x000a0;min prior to the acquisition session. rats were placed into a novel test chamber (45&#x000a0;cm &#x000d7; 45&#x000a0;cm &#x000d7; 46.5&#x000a0;cm) with a grid floor and clear plastic walls (tse-systems gmbh, germany). during the acquisition session, a 2-min habituation phase was followed by the delivery of a mild foot shock (0.8&#x000a0;ma for 1&#x000a0;s) applied through the grid floor. following a 1&#x000a0;min interval, a second foot shock was delivered. the animals remained in the chambers for a further 30&#x000a0;s. one day later, the animals were returned to the same test chamber for a 5-min period without any foot shock. rodents respond to danger in a species-specific manner by freezing, i.e., the animals will withhold all movement, except for respiration, to avoid detection. the amount of freezing behavior was measured by the computer as the time spent immobile (minimum threshold of 1&#x000a0;s) and was expressed as the percentage of time spent freezing during the 5-min session. following cfc, plasma samples were collected 1&#x02013;2&#x000a0;days later from rats pre-treated with the same dose at 60&#x000a0;min post-administration (\u003cem>n\u003c/em> &#x0003d; 4/dose).\u003c/p>\u003ch5>2.3.11.3 morris water maze\u003c/h5>\u003cp class=\"mb0\">male lh rats (350&#x02013;400&#x000a0;g) were pre-treated with vehicle or 10 or 30&#x000a0;mg/kg alogabat p.o. (n &#x0003d; 10/dose) once daily during cued acquisition (visible platform; three trials per day for 2&#x000a0;days), followed by a 2-day interval and then spatial acquisition (hidden platform; three trials per day for 4&#x000a0;days) in the morris water maze (mwm; computer tracking system hvs image ltd., united kingdom) (\u003ca href=\"#b5\">ballard et al., 2005\u003c/a>). twenty-four hours later, the platform was removed, and the rats were pre-treated with vehicle or alogabat and allowed to swim in the maze for 60&#x000a0;s (probe trial) to assess the retention/spatial memory of the platform position, expressed as the percentage of distance traveled in each quadrant. for the mwm, plasma samples were collected immediately after the last trial on the 12th day of treatment at approximately 70&#x000a0;min post-administration (\u003cem>n\u003c/em> &#x0003d; 4&#x02013;5/dose).\u003c/p>\u003ca id=\"h7-3-12\" name=\"h7-3-12\">\u003c/a>\u003ch4>2.3.12 plasma sampling and analysis\u003c/h4>\u003cp class=\"mb0\">rodents were deeply anesthetized with 5% isoflurane, and blood was collected following decapitation with a guillotine or via cardiac puncture (ptz and mes). during eeg experiments, blood was collected from a cannula in the right femoral artery. blood samples were centrifuged in edta-coated eppendorf tubes (4,000&#x000a0;rpm, 4&#x000b0;c, 5&#x000a0;min), and plasma was collected, immediately frozen, and stored at &#x02212;80&#x000b0;c. samples were analyzed for the concentration of alogabat using qualified liquid chromatography coupled to tandem mass spectrometry (lc-ms/ms) assays.\u003c/p>\u003ca id=\"h7-3-13\" name=\"h7-3-13\">\u003c/a>\u003ch4>2.3.13 statistical analysis\u003c/h4>\u003cp class=\"mb0\">sample sizes were determined based on historical data for each experiment within each laboratory.\u003c/p>\u003ch5>2.3.13.1 eeg\u003c/h5>\u003cp class=\"mb0\">linear mixed-effects models (lmms) were used since these can account for incomplete datasets, which was the case in this study. specific contrasts were derived and tested using t-tests within the model using satterthwaite approximation for degrees of freedom. models were derived for each compound individually: y &#x0223c; compound &#x0002b; (1&#x0007c;animal). the significance of differences in the peak frequency was assessed using random permutation tests (10,000).\u003c/p>\u003ch5>2.3.13.2 phmri\u003c/h5>\u003cp class=\"mb0\">analysis was performed with jmp (sas institute inc., cary, united states) and matlab (the mathworks inc., natick, ma, united states). global (whole-brain) absolute-perfusion values from the vehicle and the three dose groups were tested for a linear trend across the four doses using a one-way anova framework. the same analysis was applied roi-wise to the normalized-perfusion values. multiple testing across the single rois was accounted for by controlling the false discovery rate (fdr) at 10% using the benjamini&#x02013;hochberg approach. to also obtain an overall activation&#x02013;strength metric, normalized-perfusion values of each dose group were compared roi-wise to those of the vehicle group using welch&#x02019;s t-test without multiple-testing correction. the number of significantly modulated rois at each dose was then taken as a measure of &#x0201c;pattern strength.&#x0201d; the mean and the upper 95% confidence limit of the corresponding chance levels were estimated via random group-label permutations (100,000 runs per group). significance levels of the actual pattern strengths were determined based on the distributions obtained through the permutation procedure.\u003c/p>\u003ch5>2.3.13.3 behavior\u003c/h5>\u003cp class=\"mb0\">all statistical analyses were performed using prism (graphpad software). one-factor anova was used for between-group comparison (i.e., dose), with repeated measures for within-subject comparison (i.e., time bins and platform quadrants). dunnett&#x02019;s test was used for \u003cem>post hoc\u003c/em> comparisons. student&#x02019;s unpaired two-tailed t-test was used when two groups were compared. the chi-square test was used to compare the percentage of groups. rotarod data were analyzed using a non-parametric kruskal&#x02013;wallis test, followed by dunn&#x02019;s multiple comparison test. statistical significance was predetermined as \u003cem>p\u003c/em> &#x0003c; 0.05.\u003c/p>\u003ca id=\"h4\" name=\"h4\">\u003c/a>\u003ch2>3 results\u003c/h2>\u003ca id=\"h4-1\" name=\"h4-1\">\u003c/a>\u003ch3 class=\"pt0\">3.1 binding affinity for gaba\u003csub>a\u003c/sub> receptors containing &#x003b1;5 and other &#x003b1; subunits\u003c/h3>\u003cp class=\"mb0\">the aim of these radioligand binding studies was to determine the binding selectivity of alogabat at the rat and human gaba\u003csub>a\u003c/sub> receptors containing &#x003b1;5 compared to &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits. alogabat had a high affinity for gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 receptors in rats (ki 7.9&#x000a0;nm), with approximately 37-, 26-, and 18-fold selectivity compared to gaba\u003csub>a\u003c/sub> &#x003b1;1&#x003b2;3&#x003b3;2, &#x003b1;2&#x003b2;3&#x003b3;2, and &#x003b1;3&#x003b2;3&#x003b3;2, respectively (\u003ca href=\"#f1\">figure 1b\u003c/a>; see \u003ca href=\"#sm1\">supplementary table s1\u003c/a>). alogabat had a similar pharmacological profile in human recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (see \u003ca href=\"#sm1\">supplementary table s1\u003c/a>).\u003c/p>\u003ca id=\"h4-2\" name=\"h4-2\">\u003c/a>\u003ch3 class=\"pt0\">3.2 functional activity at recombinant and native gaba\u003csub>a\u003c/sub> receptors\u003c/h3>\u003cp class=\"mb0\">we undertook electrophysiological studies in hek293 cells and oocytes to assess the functional activity of alogabat on cloned rat and human gaba\u003csub>a\u003c/sub> receptor subtypes containing &#x003b1;5, &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits. alogabat enhanced gaba-evoked responses of rat and human &#x003b1;5-containing receptors by 167% (\u003ca href=\"#f1\">figure 1c\u003c/a>) and 72% (see \u003ca href=\"#sm1\">supplementary table s2\u003c/a>), respectively. the maximum amount of potentiation was slightly lower at human receptors. this may be due to the different expression systems used, i.e., hek293 cells for rat receptors and \u003cem>xenopus\u003c/em> oocytes for human receptors. at the highest concentrations tested, alogabat potentiated other receptor subtypes to a much lesser extent than &#x003b1;5-containing receptors. the potency of alogabat was comparable between gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors containing either &#x003b3;2 or &#x003b3;3 subunits, i.e., gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 and gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;3 receptors (see \u003ca href=\"#sm1\">supplementary figure s1\u003c/a>).\u003c/p>\u003cp class=\"mb0\">at native gaba\u003csub>a\u003c/sub> receptors in rat hippocampal slices, alogabat positively modulated gabaergic inhibition of ca1 pyramidal cells, as shown by a leftward shift of the concentration-dependent inhibition of the population spike by isoguvacine (\u003ca href=\"#f1\">figure 1d\u003c/a>) and enhanced paired-pulse inhibition of the population spike during field potential recordings (\u003ca href=\"#f1\">figure 1e\u003c/a>). together, these results confirm the binding selectivity of alogabat and demonstrate that alogabat is a functionally selective pam of gaba-evoked responses.\u003c/p>\u003ca id=\"h4-3\" name=\"h4-3\">\u003c/a>\u003ch3 class=\"pt0\">3.3 selectivity data\u003c/h3>\u003cp class=\"mb0\">we assessed alogabat in radioligand binding studies with more than 70 receptors and showed that alogabat at 10&#x000a0;&#x000b5;m had over 917-fold binding selectivity for the gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 receptor subtype against all other targets tested (see \u003ca href=\"#sm1\">supplementary table s3\u003c/a>).\u003c/p>\u003ca id=\"h4-4\" name=\"h4-4\">\u003c/a>\u003ch3 class=\"pt0\">3.4 receptor occupancy in wistar rats and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h3>\u003cp class=\"mb0\">the main objective of these studies was to visualize and quantify gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro by alogabat. alogabat decreased the specific binding of the gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor-specific radioligand [\u003csup>3\u003c/sup>h]ro0154513 in the hippocampus of rats in a dose-dependent manner. the highest dose of alogabat (100&#x000a0;mg/kg i.p.) reduced specific binding by 100%, i.e., to the same binding level as that of 10&#x000a0;mg/kg l-655,708 (\u003ca href=\"#f2\">figure 2a\u003c/a>). a total plasma concentration of 669&#x000a0;ng/ml and a total brain concentration of 208&#x000a0;ng/g were required to produce half-maximal gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro (ec\u003csub>50\u003c/sub>) in the hippocampus in rats. in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice, estimated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro based on the \u003cem>ex vivo\u003c/em> study with [\u003csup>3\u003c/sup>h]l-655,708 was 43%, 46%, and 71% at doses of 30, 60, and 100&#x000a0;mg/kg i.p., respectively (\u003ca href=\"#f2\">figure 2b\u003c/a>). in addition, the rat occupancy curve was used to calculate ro related to plasma exposure for all \u003cem>in vivo\u003c/em> experiments described in this manuscript below (also refer to \u003ca href=\"#sm1\">supplementary tables s4&#x02013;s5\u003c/a>).\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 2\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" name=\"figure2\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" alt=\"www.frontiersin.org\" id=\"f2\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 2\u003c/b>. receptor occupancy and phmri signature of alogabat following acute administration. \u003cb>(a)\u003c/b> concentration-dependent blockade of [\u003csup>3\u003c/sup>h]ro0154513 binding by alogabat in wistar rats: with increasing concentrations from the different doses (0.3&#x02013;100&#x000a0;mg/kg i.p., n &#x0003d; 3/dose) of alogabat (vehicle &#x0003d; without pre-treatment, n &#x0003d; 3). \u003cb>(b)\u003c/b> representative autoradiograms of alogabat \u003cem>ex vivo\u003c/em> occupancy in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice via \u003cem>in vitro\u003c/em> incubation of the highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor radioligand [\u003csup>3\u003c/sup>h]l-655,708 to sagittal brain sections. the cntnap2&#x02212;/&#x02212; mice were treated with vehicle and 30, 60, or 100&#x000a0;mg/kg i.p. alogabat (n &#x0003d; 4/dose). \u003cb>(c)\u003c/b> trend of normalized-perfusion response pattern strength increasing with dose, given as numbers (&#x000b1; 95% confidence intervals) of significantly (de-)activated regions of interest (rois) following the administration of alogabat (n &#x0003d; 8/dose) to fischer (f344) rats under medetomidine sedation. &#x0201c;chance level&#x0201d; &#x0003d; mean (black dotted line) and 95th percentile (gray dotted line) derived from the permutation test. significant deviations in the number of modulated rois from the chance level are denoted by &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 (uncorrected). ro is the calculated receptor occupancy for gaba\u003csub>a\u003c/sub>-&#x003b1;5 from measured plasma concentrations at each dose. \u003cb>(d)\u003c/b> sagittal schematic of rat brain showing rois with a significant dose-dependent modulation (linear trend of normalized perfusion). rois passing false discovery rate control at 10% are shown, with roi outlines indicating uncorrected significance level (no outline, \u003cem>p\u003c/em> &#x0003c; 0.05; dotted outline, \u003cem>p\u003c/em> &#x0003c; 0.01; and solid outline, \u003cem>p\u003c/em> &#x0003c; 0.001). roi abbreviations: acbsh, nucleus accumbens shell; amg, amygdala; drn, dorsal raphe nucleus; hpcfi, fimbria hippocampi; insc, insular cortex; lc, locus coeruleus; m1, primary motor cortex; mpfc/cg, medial prefrontal, cingulate cortex; pir, piriform (entorhinal) cortex; prh, perirhinal cortex; s1, primary somatosensory cortex; sn, substantia nigra; th, thalamus; vc, visual cortex.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h4-5\" name=\"h4-5\">\u003c/a>\u003ch3 class=\"pt0\">3.5 pharmacological mri signature in rats\u003c/h3>\u003cp class=\"mb0\">the purpose of this study was to evaluate the effects of alogabat on regional neural activity. blood perfusion, measured quantitatively by phmri, was taken as a proxy for neural activity. the administration of a single dose of alogabat at 3&#x02013;30&#x000a0;mg/kg i.p. in rats resulted in moderate but consistent and dose-dependent changes in neural activity patterns compared to treatment with the vehicle (\u003ca href=\"#f2\">figure 2c\u003c/a>). significant dose-dependent modulation of normalized perfusion by alogabat was observed in limbic brain regions, i.e., the nucleus accumbens (shell), amygdala, and hippocampus (fimbria); in several cortical brain regions, the thalamus and brainstem nuclei; and in the substantia nigra (\u003ca href=\"#f2\">figure 2d\u003c/a>). a linear dose effect was also observed on whole-brain absolute perfusion. alogabat target engagement in brain tissue ranged from 54% to 84% ro.\u003c/p>\u003ca id=\"h4-6\" name=\"h4-6\">\u003c/a>\u003ch3 class=\"pt0\">3.6 eeg signature in rats\u003c/h3>\u003cp class=\"mb0\">the aim of this study was to determine whether alogabat induces a characteristic eeg signature that could be used as a translational pharmacodynamic marker. as a first step and based on previous findings on the eeg effects of gaba\u003csub>a\u003c/sub> drugs (\u003ca href=\"#b71\">van lier et al., 2004\u003c/a>; \u003ca href=\"#b72\">visser et al., 2003\u003c/a>; \u003ca href=\"#b22\">friedman et al., 1992\u003c/a>), we investigated eeg spectral power change in the theta (6&#x02013;10&#x000a0;hz) and beta (20&#x02013;30&#x000a0;hz) frequency bands. alogabat, administered as 10&#x000a0;mg/kg i.v. (5&#x000a0;min infusion), significantly increased eeg beta-band activity by 21% &#x000b1; 11% relative to the baseline (mean &#x000b1; sd) and decreased theta-band activity by 32% &#x000b1; 19% (\u003ca href=\"#f3\">figures 3a,b\u003c/a>). frequency-resolved changes confirmed a decrease in theta power (approximately 6&#x02013;10&#x000a0;hz) and revealed broader beta and gamma modulation (approximately 20&#x02013;50&#x000a0;hz) (\u003ca href=\"#f3\">figures 3c&#x02013;e\u003c/a>). the calculated ro after the application of alogabat was 77%&#x02013;85% for gaba\u003csub>a\u003c/sub>-&#x003b1;5 (see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). the overall spectral pattern was qualitatively similar to that of diazepam; however, the peak frequency in the beta frequency range was higher for alogabat (32&#x000a0;hz for alogabat vs. 22.6&#x000a0;hz for diazepam; \u003cem>p\u003c/em> &#x0003d; 0.006, random permutation test), and its amplitude was greater for diazepam (142% &#x000b1; 44% increase for diazepam vs. 27% &#x000b1; 16% increase for alogabat; \u003cem>p\u003c/em> &#x0003c; 0.001). this is likely related to the high binding and functional selectivity of alogabat for &#x003b1;5-containing gaba\u003csub>a\u003c/sub> receptors compared to the non-selective profile of diazepam.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 3\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" name=\"figure3\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" alt=\"www.frontiersin.org\" id=\"f3\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 3\u003c/b>. pharmacodynamic effect of alogabat on eeg spectral power. \u003cb>(a,b)\u003c/b> modulations of vehicle (\u003cem>n\u003c/em> &#x0003d; 12), alogabat 10&#x000a0;mg/kg (\u003cem>n\u003c/em> &#x0003d; 9), and diazepam 2&#x000a0;mg/kg (\u003cem>n\u003c/em> &#x0003d; 7, positive control) in the beta (20&#x02013;30&#x000a0;hz) and theta (6&#x02013;10&#x000a0;hz) power. \u003cb>(c&#x02013;e)\u003c/b> effects of individual compounds and vehicle on the eeg power spectrum. each individual recording is displayed as a light gray line, and the group average and its 95% confidence intervals are shown as colored bands. for all panels, power averaged over 0.2&#x02013;1&#x000a0;h post dosing is shown relative to pre-dosing baseline average over &#x02212;1 to &#x02212;0.2&#x000a0;h before dosing. statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05 versus vehicle (linear mixed-effects models followed by t-tests).\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h4-7\" name=\"h4-7\">\u003c/a>\u003ch3 class=\"pt0\">3.7 repetitive behaviors in mouse models relevant to asd\u003c/h3>\u003cp class=\"mb0\">the inbred mouse strain btbr and the cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mouse show abnormalities in core asd behavioral domains, such as repetitive behaviors. self-grooming and digging are more elevated in the btbr mouse than in other strains, i.e., c57bl/6j (\u003ca href=\"#b40\">mcfarlane et al., 2008\u003c/a>), and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice show more elevated grooming than their wildtype littermates (\u003ca href=\"#b51\">penagarikano et al., 2011\u003c/a>). the aim of the following experiments was to determine whether alogabat has a specific effect on repetitive behaviors independent of potential effects on overall locomotor activity. we assessed the effects of subchronic treatment on cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice to exclude potential tolerance to the effects of alogabat.\u003c/p>\u003ca id=\"h8-7-1\" name=\"h8-7-1\">\u003c/a>\u003ch4>3.7.1 open field in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h4>\u003cp class=\"mb0\">in btbr mice, acute administration of alogabat (30&#x02013;120&#x000a0;mg/kg i.p.) had no effect on the total activity over 1&#x000a0;h measured in an open field [f(4,55) &#x0003d; 2.04], although during the first 10&#x000a0;min, alogabat at 90 and 120&#x000a0;mg/kg significantly reduced the distance traveled [f(4,55) &#x0003d; 9.623, \u003cem>p\u003c/em> &#x0003c; 0.001, \u003ca href=\"#f4\">figure 4a\u003c/a>]. there was also no effect of sub-chronic alogabat (30&#x02013;100&#x000a0;mg/kg i.p.) on the total activity over 1&#x000a0;h in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice [f(3,53) &#x0003d; 0.98]. during the first 5&#x000a0;min, 100&#x000a0;mg/kg reduced the distance traveled in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice to the same level as vehicle-treated wildtype mice (\u003ca href=\"#f4\">figure 4b\u003c/a>). alogabat did not induce a major impairment of locomotor activity in the open field.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 4\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" name=\"figure4\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" alt=\"www.frontiersin.org\" id=\"f4\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 4\u003c/b>. effect of alogabat on repetitive behaviors in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. \u003cb>(a)\u003c/b> alogabat was administered i.p. 30&#x000a0;min prior to the assessment of locomotor activity in an open-field test in btbr mice: distance traveled (cm) per 5&#x000a0;min time bin (\u003cem>line graph\u003c/em>) and in 1&#x000a0;h total (\u003cem>bar chart inset\u003c/em>). \u003cb>(b)\u003c/b> alogabat was administered i.p. once daily for 2&#x02013;3&#x000a0;days, and on the test day, it was administered 30&#x000a0;min prior to testing cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice in an open field: distance traveled (cm) per 5&#x000a0;min time bin (\u003cem>line graph\u003c/em>) and in 1&#x000a0;h total (\u003cem>bar chart insert\u003c/em>). in btbr mice, on a separate test day, alogabat was administered i.p. 30&#x000a0;min prior to the grooming test: \u003cb>(c)\u003c/b> duration (s) of grooming behavior and \u003cb>(e)\u003c/b> distance (cm) traveled during the 10&#x000a0;min period in the test chamber. in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice, alogabat was administered i.p. once daily for 8&#x02013;10&#x000a0;days, and on the test day, it was administered 30&#x000a0;min prior to the grooming test: \u003cb>(d)\u003c/b> duration (s) of grooming behavior and \u003cb>(f)\u003c/b> distance traveled during the 10&#x000a0;min period in the test chamber. data are presented as individual points (circles) and mean &#x000b1; sem (btbr: \u003cem>n\u003c/em> &#x0003d; 12/group; cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup>: \u003cem>n\u003c/em> &#x0003d; 14&#x02013;15/group). statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. vehicle (veh)-treated btbr or cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. &#x000a7;&#x000a7;&#x000a7;\u003cem>p\u003c/em> &#x0003c; 0.001 vehicle-treated wildtype (wt-v) mice vs. vehicle (v)-treated cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. alogabat was administered i.p. 30&#x000a0;min prior to the assessment of digging behavior in btbr mice: \u003cb>(g)\u003c/b> duration (s) of digging behavior, \u003cb>(h)\u003c/b> distance traveled (cm), and \u003cb>(i)\u003c/b> speed (cm/s) during the 5&#x000a0;min period in the test chamber. data are presented as individual points (circles) and mean &#x000b1; sem (\u003cem>n\u003c/em> &#x0003d; 12/group). statistics: &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01 and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. vehicle-treated btbr mice. ro is the calculated receptor occupancy for gaba\u003csub>a\u003c/sub>-&#x003b1;5 from the measured plasma concentrations at each dose.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h8-7-2\" name=\"h8-7-2\">\u003c/a>\u003ch4>3.7.2 grooming behavior in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h4>\u003cp class=\"mb0\">acute administration of alogabat in btbr mice dose-dependently attenuated grooming behavior at 60, 90, and 120&#x000a0;mg/kg i.p. [f(4,55) &#x0003d; 6.946, \u003cem>p\u003c/em> &#x0003d; 0.0001, \u003ca href=\"#f4\">figure 4c\u003c/a>] without reducing locomotor activity in the same test arena (\u003ca href=\"#f4\">figure 4e\u003c/a>). in contrast, doses of 60 and 90&#x000a0;mg/kg increased the distance traveled [f(4,55) &#x0003d; 3.454, \u003cem>p\u003c/em> &#x0003c; 0.05]. alogabat had a specific effect on grooming behavior at plasma concentrations corresponding to calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 45%&#x02013;70% (see \u003ca href=\"#sm1\">supplementary table s4\u003c/a>).\u003c/p>\u003cp class=\"mb0\">sub-chronic administration of alogabat in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice attenuated grooming behavior at 60 and 100&#x000a0;mg/kg i.p. [f(3,53) &#x0003d; 10.57, \u003cem>p\u003c/em> &#x0003c; 0.0001, \u003ca href=\"#f4\">figure 4d\u003c/a>], with no effect on locomotor activity measured in the same test arena [f(3,53) &#x0003d; 0.74, \u003ca href=\"#f4\">figure 4f\u003c/a>]. alogabat had a specific effect on repetitive grooming behavior at plasma concentrations that correspond with calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro of 52%&#x02013;79% (see \u003ca href=\"#sm1\">supplementary table s4\u003c/a>).\u003c/p>\u003ca id=\"h8-7-3\" name=\"h8-7-3\">\u003c/a>\u003ch4>3.7.3 digging behavior in btbr mice\u003c/h4>\u003cp class=\"mb0\">there was no effect of acute alogabat administration on digging behavior at doses up to 100&#x000a0;mg/kg i.p. [f(3,36) &#x0003d; 0.8, \u003ca href=\"#f4\">figure 4g\u003c/a>], corresponding to a calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro level of 67% (see \u003ca href=\"#sm1\">supplementary table s4\u003c/a>). alogabat at 100&#x000a0;mg/kg reduced the distance traveled [f(3,36) &#x0003d; 12.1, \u003cem>p\u003c/em> &#x0003c; 0.001, \u003ca href=\"#f4\">figure 4h\u003c/a>] and speed [f(3,36) &#x0003d; 11.5, \u003cem>p\u003c/em> &#x0003c; 0.001, \u003ca href=\"#f4\">figure 4i\u003c/a>] in the same arena.\u003c/p>\u003ca id=\"h4-8\" name=\"h4-8\">\u003c/a>\u003ch3 class=\"pt0\">3.8 anticonvulsant activity in rats\u003c/h3>\u003cp class=\"mb0\">the purpose of these experiments was to evaluate the antiepileptic properties of alogabat against seizures induced by ptz and the mes model. alogabat administered in combination with a convulsant dose of ptz completely blocked seizures at 15 and 30&#x000a0;mg/kg (\u003ca href=\"#f5\">figure 5a\u003c/a>), which corresponds to calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 71% and 77% (see \u003ca href=\"#sm1\">supplementary table s5\u003c/a>). meanwhile, in the mes test, alogabat at 5&#x000a0;mg/kg (57% ro, see \u003ca href=\"#sm1\">supplementary table s5\u003c/a>) showed a significant reduction in the percent of rats that had tonic seizures (\u003ca href=\"#f5\">figure 5b\u003c/a>); there was only a tendency for reduction at 15&#x000a0;mg/kg (\u003cem>p\u003c/em> &#x0003d; 0.1) and 30&#x000a0;mg/kg (\u003cem>p\u003c/em> &#x0003d; 0.06). the positive control, diazepam, significantly reduced the percentage of rats that had seizures in both the ptz and mes tests.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 5\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" name=\"figure5\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" alt=\"www.frontiersin.org\" id=\"f5\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 5\u003c/b>. evaluation of alogabat for effects on anticonvulsant, motor, and cognitive tests. alogabat was administered p.o. 60&#x000a0;min prior to the following behavior tests. assessment of potential anticonvulsant activity in \u003cb>(a)\u003c/b> ptz and \u003cb>(b)\u003c/b> mes tests in rats. diazepam (dzp) at 3&#x000a0;mg/kg i.p. was included as a positive control. data are presented as individual points (circles) and the percentage of rats per group showing seizures (\u003cem>n\u003c/em> &#x0003d; 8/group). \u003cb>(c)\u003c/b> time (s) spent on the rotarod at 16&#x000a0;rpm in rats administered alogabat alone (30&#x000a0;mg/kg, gray bar with black outline) or alogabat at 3, 10, and 30&#x000a0;mg/kg co-administered with diazepam at 5&#x000a0;mg/kg i.p. (gray bars with red outline) compared with vehicle (open bar) or diazepam (open bar with red outline). data are presented as individual points (circles) and median &#x000b1; interquartile range (n &#x0003d; 8/group). assessment of cognition in rats: \u003cb>(d)\u003c/b> attention in the 5-choice serial reaction time (5-csrt) task; \u003cb>(e)\u003c/b> sustained attention in the touchscreen continuous performance test (cpt); \u003cb>(f)\u003c/b> visual&#x02013;spatial memory in the touchscreen pal task. cfc at \u003cb>(g)\u003c/b> 10 and 30&#x000a0;mg/kg; \u003cb>(h)\u003c/b> 1, 3, and 10&#x000a0;mg/kg. spatial learning and memory in the mwm: alogabat was administered once daily for 11&#x000a0;days prior to the probe trial. \u003cb>(i)\u003c/b> percentage of distance traveled in all four quadrants: vehicle; 10&#x000a0;mg/kg; 30&#x000a0;mg/kg. data are presented as individual points (circles) and mean &#x000b1; sem for pal (\u003cem>n\u003c/em> &#x0003d; 12/dose; within-subjects), 5-csrt and cpt (\u003cem>n\u003c/em> &#x0003d; 11/dose, within-subjects), cfc (\u003cem>n\u003c/em> &#x0003d; 9&#x02013;10/group), and mwm (\u003cem>n\u003c/em> &#x0003d; 10/group). statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. vehicle (veh or 0)-treated rats; mwm statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. percentage of distance in the platform quadrant. ro is the calculated receptor occupancy of alogabat for gaba\u003csub>a\u003c/sub>-&#x003b1;5 from measured plasma concentrations at each dose.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h4-9\" name=\"h4-9\">\u003c/a>\u003ch3 class=\"pt0\">3.9 combination with diazepam on rotarod performance in rats\u003c/h3>\u003cp class=\"mb0\">classical benzodiazepines, such as diazepam, are known to induce sedation and ataxia, which can be measured by the rotarod task in rodents. the aim of this experiment was to determine whether alogabat affects rotarod performance when administered alone and, second, whether alogabat modulates the sedative/motor effect of diazepam on rotarod performance when given in combination. diazepam at 5&#x000a0;mg/kg i.p. significantly impaired rotarod performance. alogabat (3&#x02013;30&#x000a0;mg/kg p.o.) co-administered with diazepam did not worsen the effects of diazepam on rotarod performance (\u003ca href=\"#f5\">figure 5c\u003c/a>). alogabat administered alone at 30&#x000a0;mg/kg p.o. did not differ from vehicle-treated rats, corresponding to a calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro level of 88% (see \u003ca href=\"#sm1\">supplementary table s5\u003c/a>).\u003c/p>\u003ca id=\"h4-10\" name=\"h4-10\">\u003c/a>\u003ch3 class=\"pt0\">3.10 evaluation of cognition in rats\u003c/h3>\u003cp class=\"mb0\">since non-selective gaba\u003csub>a\u003c/sub> pams, such as diazepam, have been shown to impair cognition (\u003ca href=\"#b5\">ballard et al., 2005\u003c/a>), the aim of the following experiments was to study the potential effects of acute administration of alogabat on cognition in rats. this included attention in the 5-csrt task and associative (fear) memory in cfc. we also assessed visual&#x02013;spatial memory (pal task) and attention (cpt) in a touchscreen system, which provides a translational approach for assessing cognition (\u003ca href=\"#b34\">hvoslef-eide et al., 2016\u003c/a>). chronic treatment with alogabat was also assessed on spatial learning and memory in the mwm.\u003c/p>\u003cp class=\"mb0\">in the 5-csrt task, alogabat at 30&#x000a0;mg/kg induced a small but statistically significant reduction in percent correct (3%; within-subjects comparison; f(3,30) &#x0003d; 5.6, \u003cem>p\u003c/em> &#x0003c; 0.01; \u003ca href=\"#f5\">figure 5d\u003c/a>). however, alogabat did not impair attention in cpt (f(2,20) &#x0003d; 0.3; \u003ca href=\"#f5\">figure 5e\u003c/a>) or visual&#x02013;spatial memory in the pal task (f(2,22) &#x0003d; 2.6; \u003ca href=\"#f5\">figure 5f\u003c/a>).\u003c/p>\u003cp class=\"mb0\">in the cfc test, alogabat was administered before the acquisition session to determine whether there was an effect on learning the association between foot shock and the surrounding context. in the first experiment, alogabat impaired cfc at 10 and 30&#x000a0;mg/kg, corresponding to calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 75% and 81% (f(2,24) &#x0003d; 10.99, \u003cem>p\u003c/em> &#x0003c; 0.001; \u003ca href=\"#f5\">figure 5g\u003c/a>). a second experiment was undertaken to explore lower doses, and it showed that alogabat did not significantly impair cfc at 1, 3, and 10&#x000a0;mg/kg (f(3,36) &#x0003d; 0.9; \u003ca href=\"#f5\">figure 5h\u003c/a>), corresponding to the calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 35%, 56%, and 72%. this suggests that the dose of 10&#x000a0;mg/kg is approximately the threshold level for the impairment of cfc and is likely dependent on the level of ro achieved per subject.\u003c/p>\u003cp class=\"mb0\">in the mwm test, chronic administration of alogabat at 10 and 30&#x000a0;mg/kg did not significantly impair the acquisition of the hidden platform position (see \u003ca href=\"#sm1\">supplementary figure s2\u003c/a>). twenty-four hours later, the platform was removed, and the rats were allowed to swim in the maze for 60&#x000a0;s (probe trial) to assess memory-retention of the platform position. the groups receiving vehicle [f(3,27) &#x0003d; 8, \u003cem>p\u003c/em> &#x0003c; 0.001] and 10&#x000a0;mg/kg [f(3,27) &#x0003d; 7, \u003cem>p\u003c/em> &#x0003c; 0.01] had learned the spatial position of the platform, as shown by their preference for the platform quadrant (\u003ca href=\"#f5\">figure 5i\u003c/a>). however, rats that received 30&#x000a0;mg/kg alogabat showed impaired spatial memory of the platform position during the probe trial [f(3,27) &#x0003d; 3, p &#x0003d; 0.08; \u003ca href=\"#f5\">figure 5i\u003c/a>], and gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro was estimated to be 79%. in summary, alogabat impaired context and spatial memory at gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro above 70%.\u003c/p>\u003ca id=\"h5\" name=\"h5\">\u003c/a>\u003ch2>4 discussion\u003c/h2>\u003ca id=\"h5-1\" name=\"h5-1\">\u003c/a>\u003ch3 class=\"pt0\">4.1 \u003cem>in vitro\u003c/em> and \u003cem>in vivo\u003c/em> characterization of alogabat\u003c/h3>\u003cp class=\"mb0\">alogabat was shown to be a potent and functionally selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor pam \u003cem>in vitro\u003c/em>. the functional activity of alogabat was confirmed at native gaba\u003csub>a\u003c/sub> receptors in rat hippocampal slices. \u003cem>in vivo\u003c/em> binding experiments demonstrated dose-dependent target engagement of alogabat in rats and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. the highest specific binding was observed in the hippocampus, which is consistent with the known distribution of the gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor subtype in rodents (\u003ca href=\"#b54\">pirker et al., 2000\u003c/a>). phmri studies in rats demonstrated dose-dependent perfusion changes, indicating circuit modulation by alogabat. there were consistent changes in the neural activity pattern across dose groups, with modulation of neural activity in, among others, the medial prefrontal cortex, cingulate cortex, motor cortex, perirhinal cortex, nucleus accumbens shell, amygdala, hippocampus fimbria, and substantia nigra.\u003c/p>\u003ca id=\"h5-2\" name=\"h5-2\">\u003c/a>\u003ch3 class=\"pt0\">4.2 eeg signature\u003c/h3>\u003cp class=\"mb0\">acute administration of alogabat in rats induced an eeg signature characterized by a power decrease in theta and an increase in the beta frequency range, which was qualitatively similar to the eeg signature of non-selective gaba\u003csub>a\u003c/sub> pams such as diazepam (\u003ca href=\"#b71\">van lier et al., 2004\u003c/a>; \u003ca href=\"#b72\">visser et al., 2003\u003c/a>; \u003ca href=\"#b22\">friedman et al., 1992\u003c/a>). the lower magnitude of induced eeg beta-band power by alogabat compared to diazepam is likely attributed to its &#x003b1;5-selectivity, resulting in an overall lower magnitude of gaba\u003csub>a\u003c/sub> receptor modulation. this eeg signature of alogabat is qualitatively a mirror image of the eeg signature of basmisanil, a highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 negative allosteric modulator (nam), which we recently found to induce an increase in the theta power and a decrease in the beta-band eeg power in healthy volunteers (\u003ca href=\"#b31\">hipp et al., 2021\u003c/a>). furthermore, the eeg signature of alogabat is in agreement with the link between beta-band activity and single-nucleotide polymorphisms (snps) in gaba\u003csub>a\u003c/sub> receptor genes (\u003ca href=\"#b56\">porjesz et al., 2002\u003c/a>; \u003ca href=\"#b67\">smit et al., 2018\u003c/a>) and ndds (dup15q syndrome, as) involving gene copy number variations of \u003cem>gabrb3, gabra5\u003c/em>, and \u003cem>gabrg3\u003c/em> (\u003ca href=\"#b24\">frohlich et al., 2019a\u003c/a>; \u003ca href=\"#b25\">frohlich et al., 2019b\u003c/a>). gaba\u003csub>a\u003c/sub> receptor-related changes in beta-band activity are believed to reflect the modulation of recurrent excitatory&#x02013;inhibitory feedback loops in the cortical tissue (\u003ca href=\"#b75\">whittington et al., 2000\u003c/a>; \u003ca href=\"#b70\">traub and jefferys, 1999\u003c/a>). for the administered doses, the calculated receptor occupancies were in the range of 77%&#x02013;84% for &#x003b1;5-containing receptors and 22%&#x02013;34% for &#x003b1;1-containing receptors (with different pam effects (e\u003csub>max\u003c/sub>) at &#x003b1;5 vs. &#x003b1;1). thus, at the studied doses, alogabat has some effect on &#x003b1;1-containing receptors, and further work is needed to systematically study lower doses of alogabat, including those &#x0003c;70% ro without the impairment of cognition in wt rats, to confirm whether the modulation of &#x003b1;5-containing receptors alone is sufficient to induce the described eeg effect. nonetheless, eeg theta- and beta-band power are promising candidates for translational mechanistic biomarkers of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor function and could be used in the further development of alogabat.\u003c/p>\u003ca id=\"h5-3\" name=\"h5-3\">\u003c/a>\u003ch3 class=\"pt0\">4.3 behavioral effects of alogabat in animal models relevant to asd\u003c/h3>\u003cp class=\"mb0\">we assessed the effects of alogabat in two different mouse models relevant to asd, one phenotypic and one genetic. acute administration of alogabat significantly and dose-dependently attenuated excessive grooming, but not digging, behavior in btbr mice. sub-chronic administration of alogabat significantly attenuated elevated grooming behavior in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. efficacy in these different models was linked to gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro above 50%. despite initial findings of a transiently decreased activity in an open-field test, alogabat increased the activity of btbr mice and had no effect on the activity of cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice during the grooming test, supporting the specific effect of alogabat on repetitive grooming. we have tested additional compounds with similar properties, e.g., ro7015738, and have confirmed that gaba\u003csub>a\u003c/sub>-&#x003b1;5 pams reduce repetitive behaviors in these mouse models (\u003ca href=\"#b10\">buettelmann et al., 2018\u003c/a>). these results align well with recently published data showing that gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor deficiency causes autism-like behaviors in mice, including increased grooming and reduced social contacts (\u003ca href=\"#b77\">zurek et al., 2016\u003c/a>), and with sh-053-2&#x02032;f-r-ch3, a gaba\u003csub>a\u003c/sub>-&#x003b1;5 pam, which was recently shown to have positive effects on social and cognitive deficits in a rat model of autism (\u003ca href=\"#b68\">souza et al., 2024\u003c/a>). our data are valuable in providing information on the ro required for \u003cem>in vivo\u003c/em> effects on repetitive behavior. however, it should be noted that this effect may not directly translate to all individuals with asd as it is a heterogeneous disorder, whereas these mouse models exhibit specific genetic or phenotypic deficits.\u003c/p>\u003ca id=\"h5-4\" name=\"h5-4\">\u003c/a>\u003ch3 class=\"pt0\">4.4 anticonvulsant effects of alogabat\u003c/h3>\u003cp class=\"mb0\">it has been proposed that the reduction of gabaergic inhibitory activity results in hyperexcitability of minicolumn circuits, explaining some of the symptomatology observed in some ndds, including the high incidence of seizures and auditory&#x02013;tactile hypersensitivity (\u003ca href=\"#b60\">rubenstein and merzenich, 2003\u003c/a>; \u003ca href=\"#b26\">frye et al., 2016\u003c/a>). in the current study, we demonstrated that alogabat exhibits an anticonvulsant profile with activity comparable to the benzodiazepine drug class in acutely induced seizure models (electrical and chemical). alogabat had a small effect on seizures in the mes test, whereas in the ptz test, alogabat was shown to completely block seizures at calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro &#x0003e;70%. since ptz is a gaba\u003csub>a\u003c/sub> antagonist, this supports the assessment of alogabat for anticonvulsant activity in disorders where there is dysfunction of the gabaergic system. furthermore, in a separate eeg study, we observed that one out of eight rats had frequent spike-and-wave discharge (swd) activity, which was alleviated following treatment with alogabat (see \u003ca href=\"#sm1\">supplementary figures s3a&#x02013;s3c\u003c/a>; methods in \u003ca href=\"#sm1\">supplementary material\u003c/a>). to better understand the temporal dynamics of swd occurrence and the suppressing effect of alogabat, we performed a follow-up study on three additional rats that showed pronounced swd. both 3 and 10&#x000a0;mg/kg alogabat substantially reduced the number of swds within the first 3&#x000a0;h of recording, when the same rats showed increased swd numbers in the vehicle control condition (see \u003ca href=\"#sm1\">supplementary figures s3d&#x02013;s3f\u003c/a>), which corresponds to the calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro level of 30%&#x02013;46% (see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). from a circuit perspective, the consensus is that such epileptic activity is generated by dysregulated thalamocortical circuitry, with abnormal interactions between reticular thalamic neurons and thalamic relay cells acting as the trigger and cortical circuits serving as the generator (\u003ca href=\"#b66\">sitnikova et al., 2023\u003c/a>). considering that in rats, &#x003b1;5-subunit-containing gaba\u003csub>a\u003c/sub> receptors are enriched in the cortex and hippocampus (\u003ca href=\"#b64\">serwanski et al., 2006\u003c/a>; \u003ca href=\"#b33\">hu et al., 2019\u003c/a>), mediating dendritic inhibition on pyramidal neurons (\u003ca href=\"#b2\">ali and thomson, 2008\u003c/a>; \u003ca href=\"#b62\">schulz et al., 2018\u003c/a>), we hypothesize that alogabat could suppress swd generation by enhancing the inhibition of cortical pyramidal neurons. however, more systematic work is required to confirm that alogabat can prevent swd activity.\u003c/p>\u003ca id=\"h5-5\" name=\"h5-5\">\u003c/a>\u003ch3 class=\"pt0\">4.5 assessment of non-specific behavioral effects\u003c/h3>\u003cp class=\"mb0\">non-selective gaba\u003csub>a\u003c/sub> pams, such as diazepam and chlordiazepoxide, are effective anxiolytics in clinical use but have also been shown to impair cognition in rodents and humans. gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors are believed to play a major role in cognition since they are predominantly expressed in the hippocampus in rats, where they regulate nmdar-dependent synaptic plasticity underlying learning and memory processes (\u003ca href=\"#b62\">schulz et al., 2018\u003c/a>; \u003ca href=\"#b23\">fritschy et al., 1997\u003c/a>; \u003ca href=\"#b63\">schulz et al., 2019\u003c/a>; \u003ca href=\"#b14\">davenport et al., 2021\u003c/a>). moreover, it has been proposed that gaba\u003csub>a\u003c/sub> pams may induce memory impairment by modulating hippocampal function (\u003ca href=\"#b41\">mcnaughton and morris, 1987\u003c/a>). therefore, alogabat was evaluated in several rodent tests of cognition to determine whether a selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 pam would induce cognitive impairment following acute administration in rats. there was no effect of alogabat up to 70% gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro on cognition (visual&#x02013;spatial memory, attention, context fear conditioning, spatial learning, and memory). cognitive impairment was only observed at high doses (&#x0003e;70% ro) and supra-therapeutic levels of alogabat in associative (fear) learning (cfc) and spatial memory in the mwm in wildtype rats. the impairment at high doses is likely linked to the loss of selectivity toward gaba\u003csub>a\u003c/sub> &#x003b1;1, &#x003b1;2, and &#x003b1;3 receptor subtypes (&#x003b1;1 ro was calculated as 19%&#x02013;25% at these doses; see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). in addition to the loss of selectivity, we cannot exclude the possibility that these effects may be a consequence of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor saturation, i.e., excessive &#x003b1;5 activity in wildtype subjects may be detrimental. the cognitive impairment observed in wildtype rats may translate to healthy human subjects; however, our focus is on the effect of &#x003b1;5 pams in disease conditions with impaired gaba\u003csub>a\u003c/sub> signaling and impaired cognition, where our hypothesis is that an &#x003b1;5 pam would have beneficial effects.\u003c/p>\u003cp class=\"mb0\">alogabat had no effect on social approach/avoidance, the elevated plus maze, and the vogel conflict test in rats at ro levels up to 80% (see \u003ca href=\"#sm1\">supplementary figure s4\u003c/a> and methods in \u003ca href=\"#sm1\">supplementary material\u003c/a>), suggesting that alogabat does not exhibit an anxiolytic-like effect in rodents. this might be explained by the low expression of gaba\u003csub>a\u003c/sub>-&#x003b1;5 in the amygdala, a key node controlling anxiety-like behaviors. potential anxiolytic effects of alogabat in humans cannot be excluded as this receptor subtype is much more abundant in the human amygdala. since benzodiazepines, such as diazepam, are frequently used to treat anxiety and seizures in ndds, it was important to establish that alogabat at relevant therapeutic doses in mouse models did not worsen the sedative/motor-impairing effects of diazepam in the rotarod test. alogabat did not worsen diazepam-induced motor impairment; on the contrary, in combination, it reduced the motor impairments, which is more likely due to the more localized and precise inhibitory effect, counterbalancing the broader suppression of neuronal activity by diazepam, or due to lower intrinsic activity at &#x003b1;1 receptors compared to diazepam. we have previously shown that a gaba\u003csub>a\u003c/sub>-&#x003b1;5 nam, which binds at the benzodiazepine binding site of the receptor, does not decrease the anxiolytic activity of chlordiazepoxide (see \u003ca href=\"#sm1\">supplementary figure s5\u003c/a>); therefore, it is unlikely that alogabat will interfere with the anxiolytic effect of the classical benzodiazepines.\u003c/p>\u003ca id=\"h6\" name=\"h6\">\u003c/a>\u003ch2>5 conclusion\u003c/h2>\u003cp class=\"mb15\">multiple lines of evidence point to deficits in gabaergic signaling in epilepsy and ndds, such as asd and deletion as, with a prominent role attributed to gaba\u003csub>a\u003c/sub> receptors, including the gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor subtype. the current data for alogabat showed robust dose-dependent efficacy on repetitive behaviors in two disease-relevant mouse models and anti-seizure activity in the ptz rat model at gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro above 50%. our \u003cem>in vivo\u003c/em> occupancy measurements using the selective &#x003b1;5 tracer l-655,708 were highly valuable for understanding plasma and csf exposures (as a surrogate of free brain concentration) and their relationship to \u003cem>in vivo\u003c/em> effects. we observed that there was a 34-fold shift between the csf concentration of alogabat in the \u003cem>in vivo\u003c/em> occupancy study and that of alogabat \u003cem>in vitro\u003c/em> binding data (ki value). the receptor occupancy of alogabat correlates well with pd effects (\u003cem>in vivo\u003c/em> effects) and is consistent across the different studies/species (see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). this finding highlights the importance of using pet tracers in drug development.\u003c/p>\u003cp class=\"mb15\">our data suggest that gaba\u003csub>a\u003c/sub>-&#x003b1;5 pams may have potential benefits in individuals with autistic features and in conditions with clinical and nonclinical manifestations of cortical hyperexcitability and epilepsy. however, alogabat is unlikely to work across all ndds and should be utilized as a precision medicine to target a specific subgroup of the ndd population with deficient gaba\u003csub>a\u003c/sub> pathway signaling, or specifically gaba\u003csub>a\u003c/sub>-&#x003b1;5. interestingly, recent data suggest that gaba\u003csub>a\u003c/sub>-&#x003b1;5 pams may also have therapeutic potential in schizophrenia, alzheimer&#x02019;s disease, and depression (\u003ca href=\"#b53\">perez et al., 2023\u003c/a>; \u003ca href=\"#b39\">luscher et al., 2023\u003c/a>; \u003ca href=\"#b36\">koh et al., 2013\u003c/a>). with regard to the current status of alogabat, good-laboratory practice (glp) toxicology and safety pharmacology studies in rats and minipigs showed an overall benign safety profile, which supported its clinical investigations in phase-1 studies in healthy volunteers and phase-2 trials in asd and deletion as patients (nct03507569, nct03774576, nct03847987, nct04299464, nct05630066, and eudract&#x00023;2019-003524-20). the outcome of these studies, including pet, eeg, and effects on cognition, will be reported in the future.\u003c/p>\u003ca id=\"h7\" name=\"h7\">\u003c/a>\u003ch2>data availability statement\u003c/h2>\u003cp class=\"mb15\">the original contributions presented in the study are included in the article/\u003ca href=\"#sm1\">supplementary material\u003c/a>, further inquiries can be directed to the corresponding author.\u003c/p>\u003ca id=\"h8\" name=\"h8\">\u003c/a>\u003ch2>ethics statement\u003c/h2>\u003cp class=\"mb0\">experiments performed at f. hoffmann-la roche ag (basel, switzerland) complied with swiss federal and cantonal laws on animal research and aaalac regulations and received prior approval from the cantonal veterinary office. the eeg study was conducted at brains online (ca, united states) in accordance with the guide for the care and use of laboratory animals (national research council 2011) after receiving approval from the institutional animal care and use committee. the ptz and mes tests were conducted at vivocore inc., canada, which is a facility licensed by the ontario ministry of agriculture, food, and rural affairs and accredited by the canadian council on animal care. all \u003cem>in vivo\u003c/em> studies are reported in compliance with the arrive guidelines (\u003ca href=\"#b52\">percie du sert et al., 2020\u003c/a>). the study was conducted in accordance with the local legislation and institutional requirements.\u003c/p>\u003ca id=\"h9\" name=\"h9\">\u003c/a>\u003ch2>author contributions\u003c/h2>\u003cp class=\"mb0\">gc: supervision, writing - original draft, investigation, formal analysis. tmb: formal analysis, investigation, writing - review and editing, methodology. fk: formal analysis, writing - original draft, investigation, methodology. mh: writing - original draft, investigation, methodology, formal analysis. jfh: data curation, visualization, methodology, writing - original draft, formal analysis. pg: methodology, data curation, formal analysis, writing - original draft. tm: investigation, writing - original draft, formal analysis, methodology. bk: investigation, writing - original draft, methodology, formal analysis. anb: formal analysis, writing - original draft, data curation. epp: writing - original draft, methodology, investigation. ps: methodology, investigation, writing - original draft, formal analysis. pj: writing - original draft, formal analysis. rr: methodology, writing - original draft, investigation, formal analysis. bb: methodology, investigation, writing - original draft. hk: methodology, writing - original draft, investigation. ao-m: writing - original draft, formal analysis, methodology. alb: methodology, writing - original draft, investigation. jms: investigation, formal analysis, writing - original draft. db: methodology, writing - original draft, investigation. ms: writing - original draft, methodology, investigation. eco&#x00027;c: investigation, writing - original draft, methodology. m-ch: investigation, conceptualization, writing - review and editing, supervision, writing - original draft, methodology.\u003c/p>\u003ca id=\"h10\" name=\"h10\">\u003c/a>\u003ch2>funding\u003c/h2>\u003cp class=\"mb0\">the author(s) declare that financial support was received for the research and/or publication of this article. the funding was provided by f. hoffmann-la roche ag switzerland.\u003c/p>\u003ca id=\"h11\" name=\"h11\">\u003c/a>\u003ch2>acknowledgments\u003c/h2>\u003cp class=\"mb03\">the authors thank gregoire friz, maria karg, and judith lengyel (molecular biology and binding assays); v&#x000e9;ronique graf, rachel haab, and marie-claire pflimlin (\u003cem>in vitro\u003c/em> electrophysiology); brigitte algeyer, severine bandinelli, sean durkin, audrey genet, marie haman, martine maco, and roger wyler (behavioral pharmacology); and stephanie sch&#x000f6;ppenthau, s&#x000e9;bastien debilly, and thomas bielser (\u003cem>in vivo\u003c/em> phmri). the rat ptz and mes studies were carried out under the scientific guidance of dr guy higgins, intervivo solutions, and coordinated by leo silenieks at vivocore inc., ontario, canada. the rat eeg data acquisition was undertaken by brains on-line llc, south san francisco, united states, and the data analysis was undertaken by pg, vanessa keeney, and andr&#x000e9;s olivares at roche.\u003c/p>\u003ca id=\"h12\" name=\"h12\">\u003c/a>\u003ch2>conflict of interest\u003c/h2>\u003cp class=\"mb0\">authors gc, tmb, fk, mh, jfh, pg, tm, bk, ab, epp, ps, pj, rr, bb, hk, ao-m, ab, jms, ms, eco&#x00027;c, and m-ch were employed by f. hoffmann-la roche ag switzerland. all employees (former and current) may be eligible for stock and stock options. author db was employed by hiqscreen s&#x000e0;rl.\u003c/p>\u003ca id=\"h13\" name=\"h13\">\u003c/a>\u003ch2>generative ai statement\u003c/h2>\u003cp class=\"mb15\">the author(s) declare that no generative ai was used in the creation of this manuscript.\u003c/p>\u003ca id=\"h14\" name=\"h14\">\u003c/a>\u003ch2>publisher&#x02019;s note\u003c/h2>\u003cp class=\"mb15\">all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.\u003c/p>\u003ca id=\"h15\" name=\"h15\">\u003c/a>\u003ch2>supplementary material\u003c/h2>\u003cp class=\"mb15\" id=\"sm1\">the supplementary material for this article can be found online at: \u003ca href=\"https://www.frontiersin.org/articles/10.3389/fphar.2025.1626078/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fphar.2025.1626078/full&#x00023;supplementary-material\u003c/a>\u003c/p>\u003ca id=\"h16\" name=\"h16\">\u003c/a>\u003ch2>abbreviations\u003c/h2>\u003cp class=\"mb15\">as, angelman syndrome; asd, autism spectrum disorder; cfc, context fear conditioning; cntnap2, contactin-associated protein-like 2; cpt, continuous performance test; 5-csrt, 5-choice serial reaction time; eeg, electroencephalography; gaba, gamma-aminobutyric acid; gad, glutamic acid decarboxylase; i.p., intraperitoneally; i.v., intravenously; lfp, local field potential; mes, maximum electrical stimulus; mwm, morris water maze; ndds, neurodevelopmental disorders; pal, paired associates learning; pam, positive allosteric modulator; phmri, pharmacological magnetic resonance imaging; p.o, per os; ptz, pentylenetetrazole; ro, receptor occupancy; pet, positron emission tomography.\u003c/p>\u003ca id=\"h17\" name=\"h17\">\u003c/a>\u003ch2>references\u003c/h2>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b1\" id=\"b1\">\u003c/a>abrahams, b. s., and geschwind, d. h. (2008). advances in autism genetics: on the threshold of a new neurobiology. \u003cem>nat. rev. genet.\u003c/em> 9, 341&#x02013;355. doi:10.1038/nrg2346\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/18414403/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nrg2346\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=advances+in+autism+genetics:+on+the+threshold+of+a+new+neurobiology&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b2\" id=\"b2\">\u003c/a>ali, a. b., and thomson, a. m. (2008). synaptic alpha 5 subunit-containing gabaa receptors mediate ipsps elicited by dendrite-preferring cells in rat neocortex. \u003cem>cereb. cortex\u003c/em> 18, 1260&#x02013;1271. doi:10.1093/cercor/bhm160\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17951598/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1093/cercor/bhm160\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=synaptic+alpha+5+subunit-containing+gabaa+receptors+mediate+ipsps+elicited+by+dendrite-preferring+cells+in+rat+neocortex&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\" style=\"margin-bottom:0.5em;\">\u003cp class=\"referencescopy1\">\u003ca name=\"b3\" id=\"b3\">\u003c/a>american psychiatric association (2008). \u003cem>diagnostic and statistical manual of mental disorders\u003c/em>. 5th ed. washington: \u003cspan class=\"publisher-name\">american psychiatric association\u003c/span>. \u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=american+psychiatric+association+%2c+diagnostic+and+statistical+manual+of+mental+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b4\" id=\"b4\">\u003c/a>ballard, t. m., knoflach, f., prinssen, e., borroni, e., vivian, j. a., basile, j., et al. (2009). ro4938581, a novel cognitive enhancer acting at gabaa alpha5 subunit-containing receptors. \u003cem>psychopharmacol. berl.\u003c/em> 202, 207&#x02013;223. doi:10.1007/s00213-008-1357-7\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/18936916/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1007/s00213-008-1357-7\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=ro4938581%2c+a+novel+cognitive+enhancer+acting+at+gabaa+alpha5+subunit-containing+receptors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b5\" id=\"b5\">\u003c/a>ballard, t. m., woolley, m. l., prinssen, e., huwyler, j., porter, r., and spooren, w. (2005). the effect of the mglu5 receptor antagonist mpep in rodent tests of anxiety and cognition: a comparison. \u003cem>psychopharmacol. berl.\u003c/em> 179, 218&#x02013;229. doi:10.1007/s00213-005-2211-9\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/15739074/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1007/s00213-005-2211-9\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+effect+of+the+mglu5+receptor+antagonist+mpep+in+rodent+tests+of+anxiety+and+cognition:+a+comparison&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b6\" id=\"b6\">\u003c/a>banerjee, a., garcia-oscos, f., roychowdhury, s., galindo, l. c., hall, s., kilgard, m. p., et al. (2013). impairment of cortical gabaergic synaptic transmission in an environmental rat model of autism. \u003cem>int. j. neuropsychopharmacol.\u003c/em> 16, 1309&#x02013;1318. doi:10.1017/s1461145712001216\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23228615/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1017/s1461145712001216\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=impairment+of+cortical+gabaergic+synaptic+transmission+in+an+environmental+rat+model+of+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b7\" id=\"b7\">\u003c/a>bourgeron, t. (2015). from the genetic architecture to synaptic plasticity in autism spectrum disorder. \u003cem>nat. rev. neurosci.\u003c/em> 16, 551&#x02013;563. doi:10.1038/nrn3992\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26289574/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nrn3992\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=from+the+genetic+architecture+to+synaptic+plasticity+in+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b8\" id=\"b8\">\u003c/a>braat, s., and kooy, r. f. (2015). the gabaa receptor as a therapeutic target for neurodevelopmental disorders. \u003cem>neuron\u003c/em> 86, 1119&#x02013;1130. doi:10.1016/j.neuron.2015.03.042\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26050032/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuron.2015.03.042\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+gabaa+receptor+as+a+therapeutic+target+for+neurodevelopmental+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b9\" id=\"b9\">\u003c/a>bruns, a., kunnecke, b., risterucci, c., moreau, j. l., and von kienlin, m. (2009). validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological mri in rats. \u003cem>magn. reson med.\u003c/em> 61, 1451&#x02013;1458. doi:10.1002/mrm.21779\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/19358231/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/mrm.21779\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=validation+of+cerebral+blood+perfusion+imaging+as+a+modality+for+quantitative+pharmacological+mri+in+rats&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\" style=\"margin-bottom:0.5em;\">\u003cp class=\"referencescopy1\">\u003ca name=\"b10\" id=\"b10\">\u003c/a>buettelmann, b., cecere, g., fasching, b., groebke zbinden, k., hernandez, m.-c., knust, h., et al. (2018). \u003cem>preparation of new isoxazolyl ether derivatives as gabaa &#x003b1;5 receptor positive allosteric modulators (pams)\u003c/em>. \u003cspan class=\"publisher-name\">copyright &#x000a9; 2025 american chemical society acs\u003c/span>. available online at: \u003ca href=\"https://worldwide.espacent.com/patent/search/family/057530563/publication/wo2018104419a1?q=wo2018104419a1\">https://worldwide.espacent.com/patent/search/family/057530563/publication/wo2018104419a1?q&#x0003d;wo2018104419a1\u003c/a>\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=â buettelmannâ bcecereâ gfaschingâ bgroebke+zbindenâ khernandezâ m-cknustâ het+al+2018+preparation+of+new+isoxazolyl+ether+derivatives+as+gabaa+î±5+receptor+positive+allosteric+modulators+pams+copyright+â©+2025+american+chemical+society+acs+available+online+at:+https://worldwideespacentcom/patent/search/family/057530563/publication/wo2018104419a1?q=wo2018104419a1&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b12\" id=\"b12\">\u003c/a>buiting, k. (2010). prader-willi syndrome and angelman syndrome. \u003cem>am. j. med. genet. c semin. med. genet.\u003c/em> 154c, 365&#x02013;376. doi:10.1002/ajmg.c.30273\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/20803659/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/ajmg.c.30273\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=prader-willi+syndrome+and+angelman+syndrome&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b13\" id=\"b13\">\u003c/a>chao, h. t., chen, h., samaco, r. c., xue, m., chahrour, m., yoo, j., et al. (2010). dysfunction in gaba signalling mediates autism-like stereotypies and rett syndrome phenotypes. \u003cem>nature\u003c/em> 468, 263&#x02013;269. doi:10.1038/nature09582\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21068835/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nature09582\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=dysfunction+in+gaba+signalling+mediates+autism-like+stereotypies+and+rett+syndrome+phenotypes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b14\" id=\"b14\">\u003c/a>davenport, c. m., rajappa, r., katchan, l., taylor, c. r., tsai, m. c., smith, c. m., et al. (2021). relocation of an extrasynaptic gaba(a) receptor to inhibitory synapses freezes excitatory synaptic strength and preserves memory. \u003cem>neuron\u003c/em> 109, 123&#x02013;134 e4. doi:10.1016/j.neuron.2020.09.037\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/33096025/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuron.2020.09.037\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=relocation+of+an+extrasynaptic+gabaa+receptor+to+inhibitory+synapses+freezes+excitatory+synaptic+strength+and+preserves+memory&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b15\" id=\"b15\">\u003c/a>delong, r. (2007). gaba(a) receptor alpha5 subunit as a candidate gene for autism and bipolar disorder: a proposed endophenotype with parent-of-origin and gain-of-function features,with or without oculocutaneous albinism. \u003cem>autism\u003c/em> 11, 135&#x02013;147. doi:10.1177/1362361307075705\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17353214/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1177/1362361307075705\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa+receptor+alpha5+subunit+as+a+candidate+gene+for+autism+and+bipolar+disorder:+a+proposed+endophenotype+with+parent-of-origin+and+gain-of-function+features%2cwith+or+without+oculocutaneous+albinism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b16\" id=\"b16\">\u003c/a>delorey, t. m. (2005). gabrb3 gene deficient mice: a potential model of autism spectrum disorder. \u003cem>int. rev. neurobiol.\u003c/em> 71, 359&#x02013;382. doi:10.1016/s0074-7742(05)71015-1\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/16512358/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0074-7742(05)71015-1\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabrb3+gene+deficient+mice:+a+potential+model+of+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b17\" id=\"b17\">\u003c/a>delorey, t. m., sahbaie, p., hashemi, e., homanics, g. e., and clark, j. d. (2008). gabrb3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: a potential model of autism spectrum disorder. \u003cem>behav. brain res.\u003c/em> 187, 207&#x02013;220. doi:10.1016/j.bbr.2007.09.009\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17983671/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.bbr.2007.09.009\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabrb3+gene+deficient+mice+exhibit+impaired+social+and+exploratory+behaviors%2c+deficits+in+non-selective+attention+and+hypoplasia+of+cerebellar+vermal+lobules:+a+potential+model+of+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b18\" id=\"b18\">\u003c/a>dhossche, d., applegate, h., abraham, a., maertens, p., bland, l., bencsath, a., et al. (2002). elevated plasma gamma-aminobutyric acid (gaba) levels in autistic youngsters: stimulus for a gaba hypothesis of autism. \u003cem>med. sci. monit.\u003c/em> 8, pr1&#x02013;pr6.\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/12165753/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=elevated+plasma+gamma-aminobutyric+acid+gaba+levels+in+autistic+youngsters:+stimulus+for+a+gaba+hypothesis+of+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b19\" id=\"b19\">\u003c/a>di nanni, n., bersanelli, m., cupaioli, f. a., milanesi, l., mezzelani, a., and mosca, e. (2019). network-based integrative analysis of genomics, epigenomics and transcriptomics in autism spectrum disorders. \u003cem>int. j. mol. sci.\u003c/em> 20, 3363. doi:10.3390/ijms20133363\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/31323926/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.3390/ijms20133363\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=network-based+integrative+analysis+of+genomics%2c+epigenomics+and+transcriptomics+in+autism+spectrum+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b20\" id=\"b20\">\u003c/a>dufour, b. d., mcbride, e., bartley, t., juarez, p., and martinez-cerdeno, v. (2023). distinct patterns of gabaergic interneuron pathology in autism are associated with intellectual impairment and stereotypic behaviors. \u003cem>autism\u003c/em> 27, 1730&#x02013;1745. doi:10.1177/13623613231154053\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/36935610/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1177/13623613231154053\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=distinct+patterns+of+gabaergic+interneuron+pathology+in+autism+are+associated+with+intellectual+impairment+and+stereotypic+behaviors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b21\" id=\"b21\">\u003c/a>fatemi, s. h., halt, a. r., stary, j. m., kanodia, r., schulz, s. c., and realmuto, g. r. (2002). glutamic acid decarboxylase 65 and 67 kda proteins are reduced in autistic parietal and cerebellar cortices. \u003cem>biol. psychiatry\u003c/em> 52, 805&#x02013;810. doi:10.1016/s0006-3223(02)01430-0\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/12372652/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0006-3223(02)01430-0\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=glutamic+acid+decarboxylase+65+and+67+kda+proteins+are+reduced+in+autistic+parietal+and+cerebellar+cortices&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b22\" id=\"b22\">\u003c/a>friedman, h., greenblatt, d. j., peters, g. r., metzler, c. m., charlton, m. d., harmatz, j. s., et al. (1992). pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. \u003cem>clin. pharmacol. ther.\u003c/em> 52, 139&#x02013;150. doi:10.1038/clpt.1992.123\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/1505149/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/clpt.1992.123\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=pharmacokinetics+and+pharmacodynamics+of+oral+diazepam:+effect+of+dose%2c+plasma+concentration%2c+and+time&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b23\" id=\"b23\">\u003c/a>fritschy, j. m., benke, d., johnson, d. k., mohler, h., and rudolph, u. (1997). gabaa-receptor alpha-subunit is an essential prerequisite for receptor formation \u003cem>in vivo\u003c/em>. \u003cem>neuroscience\u003c/em> 81, 1043&#x02013;1053. doi:10.1016/s0306-4522(97)00244-3\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/9330366/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0306-4522(97)00244-3\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa-receptor+alpha-subunit+is+an+essential+prerequisite+for+receptor+formation+in+vivo&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b24\" id=\"b24\">\u003c/a>frohlich, j., miller, m. t., bird, l. m., garces, p., purtell, h., hoener, m. c., et al. (2019a). electrophysiological phenotype in angelman syndrome differs between genotypes. \u003cem>biol. psychiatry\u003c/em> 85, 752&#x02013;759. doi:10.1016/j.biopsych.2019.01.008\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/30826071/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.biopsych.2019.01.008\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=electrophysiological+phenotype+in+angelman+syndrome+differs+between+genotypes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b25\" id=\"b25\">\u003c/a>frohlich, j., reiter, l. t., saravanapandian, v., distefano, c., huberty, s., hyde, c., et al. (2019b). mechanisms underlying the eeg biomarker in dup15q syndrome. \u003cem>mol. autism\u003c/em> 10, 29. doi:10.1186/s13229-019-0280-6\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/31312421/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1186/s13229-019-0280-6\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=mechanisms+underlying+the+eeg+biomarker+in+dup15q+syndrome&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b26\" id=\"b26\">\u003c/a>frye, r. e., casanova, m. f., fatemi, s. h., folsom, t. d., reutiman, t. j., brown, g. l., et al. (2016). neuropathological mechanisms of seizures in autism spectrum disorder. \u003cem>front. neurosci.\u003c/em> 10, 192. doi:10.3389/fnins.2016.00192\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27242398/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.3389/fnins.2016.00192\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=neuropathological+mechanisms+of+seizures+in+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b27\" id=\"b27\">\u003c/a>fukuda, t., itoh, m., ichikawa, t., washiyama, k., and goto, y. (2005). delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of mecp2-deficient mice. \u003cem>j. neuropathol. exp. neurol.\u003c/em> 64, 537&#x02013;544. doi:10.1093/jnen/64.6.537\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/15977646/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1093/jnen/64.6.537\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=delayed+maturation+of+neuronal+architecture+and+synaptogenesis+in+cerebral+cortex+of+mecp2-deficient+mice&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b28\" id=\"b28\">\u003c/a>gaetz, w., bloy, l., wang, d. j., port, r. g., blaskey, l., levy, s. e., et al. (2014). gaba estimation in the brains of children on the autism spectrum: measurement precision and regional cortical variation. \u003cem>neuroimage\u003c/em> 86, 1&#x02013;9. doi:10.1016/j.neuroimage.2013.05.068\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23707581/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuroimage.2013.05.068\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gaba+estimation+in+the+brains+of+children+on+the+autism+spectrum:+measurement+precision+and+regional+cortical+variation&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b29\" id=\"b29\">\u003c/a>han, s., tai, c., jones, c. j., scheuer, t., and catterall, w. a. (2014). enhancement of inhibitory neurotransmission by gabaa receptors having &#x003b1;2,3-subunits ameliorates behavioral deficits in a mouse model of autism. \u003cem>neuron\u003c/em> 81, 1282&#x02013;1289. doi:10.1016/j.neuron.2014.01.016\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/24656250/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuron.2014.01.016\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=enhancement+of+inhibitory+neurotransmission+by+gabaa+receptors+having+î±2%2c3-subunits+ameliorates+behavioral+deficits+in+a+mouse+model+of+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b30\" id=\"b30\">\u003c/a>han, s., tai, c., westenbroek, r. e., yu, f. h., cheah, c. s., potter, g. b., et al. (2012). autistic-like behaviour in scn1a&#x0002b;/- mice and rescue by enhanced gaba-mediated neurotransmission. \u003cem>nature\u003c/em> 489, 385&#x02013;390. doi:10.1038/nature11356\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22914087/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nature11356\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=autistic-like+behaviour+in+scn1a+/-+mice+and+rescue+by+enhanced+gaba-mediated+neurotransmission&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b31\" id=\"b31\">\u003c/a>hipp, j. f., knoflach, f., comley, r., ballard, t. m., honer, m., trube, g., et al. (2021). basmisanil, a highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man. \u003cem>sci. rep.\u003c/em> 11, 7700. doi:10.1038/s41598-021-87307-7\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/33833333/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/s41598-021-87307-7\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=basmisanil%2c+a+highly+selective+gabaa-î±5+negative+allosteric+modulator:+preclinical+pharmacology+and+demonstration+of+functional+target+engagement+in+man&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b32\" id=\"b32\">\u003c/a>hogart, a., wu, d., lasalle, j. m., and schanen, n. c. (2010). the comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. \u003cem>neurobiol. dis.\u003c/em> 38, 181&#x02013;191. doi:10.1016/j.nbd.2008.08.011\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/18840528/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.nbd.2008.08.011\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+comorbidity+of+autism+with+the+genomic+disorders+of+chromosome+15q112-q13&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b33\" id=\"b33\">\u003c/a>hu, x., rocco, b. r., fee, c., and sibille, e. (2019). cell type-specific gene expression of alpha 5 subunit-containing gamma-aminobutyric acid subtype a receptors in human and mouse frontal cortex. \u003cem>mol. neuropsychiatry\u003c/em> 4, 204&#x02013;215. doi:10.1159/000495840\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/30815456/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1159/000495840\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=cell+type-specific+gene+expression+of+alpha+5+subunit-containing+gamma-aminobutyric+acid+subtype+a+receptors+in+human+and+mouse+frontal+cortex&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b34\" id=\"b34\">\u003c/a>hvoslef-eide, m., nilsson, s. r., saksida, l. m., and bussey, t. j. (2016). cognitive translation using the rodent touchscreen testing approach. \u003cem>curr. top. behav. neurosci.\u003c/em> 28, 423&#x02013;447. doi:10.1007/7854_2015_5007\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27305921/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1007/7854_2015_5007\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=cognitive+translation+using+the+rodent+touchscreen+testing+approach&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b35\" id=\"b35\">\u003c/a>kalsner, l., and chamberlain, s. j. (2015). prader-willi, angelman, and 15q11-q13 duplication syndromes. \u003cem>pediatr. clin. north am.\u003c/em> 62, 587&#x02013;606. doi:10.1016/j.pcl.2015.03.004\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26022164/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.pcl.2015.03.004\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=prader-willi%2c+angelman%2c+and+15q11-q13+duplication+syndromes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b36\" id=\"b36\">\u003c/a>koh, m. t., rosenzweig-lipson, s., and gallagher, m. (2013). selective gaba(a) &#x003b1;5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. \u003cem>neuropharmacology\u003c/em> 64, 145&#x02013;152. doi:10.1016/j.neuropharm.2012.06.023\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22732440/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2012.06.023\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=selective+gabaa+î±5+positive+allosteric+modulators+improve+cognitive+function+in+aged+rats+with+memory+impairment&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b37\" id=\"b37\">\u003c/a>lim, c. s., kim, h., yu, n. k., kang, s. j., kim, t., ko, h. g., et al. (2017). enhancing inhibitory synaptic function reverses spatial memory deficits in shank2 mutant mice. \u003cem>neuropharmacology\u003c/em> 112, 104&#x02013;112. doi:10.1016/j.neuropharm.2016.08.016\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27544825/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2016.08.016\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=enhancing+inhibitory+synaptic+function+reverses+spatial+memory+deficits+in+shank2+mutant+mice&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b38\" id=\"b38\">\u003c/a>luk, h. m., and lo, i. f. (2016). angelman syndrome in hong kong chinese: a 20 years&#x00027; experience. \u003cem>eur. j. med. genet.\u003c/em> 59, 315&#x02013;319. doi:10.1016/j.ejmg.2016.05.003\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27174604/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.ejmg.2016.05.003\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=angelman+syndrome+in+hong+kong+chinese:+a+20+years'+experience&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b39\" id=\"b39\">\u003c/a>luscher, b., maguire, j. l., rudolph, u., and sibille, e. (2023). gaba(a) receptors as targets for treating affective and cognitive symptoms of depression. \u003cem>trends pharmacol. sci.\u003c/em> 44, 586&#x02013;600. doi:10.1016/j.tips.2023.06.009\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/37543478/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.tips.2023.06.009\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa+receptors+as+targets+for+treating+affective+and+cognitive+symptoms+of+depression&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b40\" id=\"b40\">\u003c/a>mcfarlane, h. g., kusek, g. k., yang, m., phoenix, j. l., bolivar, v. j., and crawley, j. n. (2008). autism-like behavioral phenotypes in btbr t&#x0002b;tf/j mice. \u003cem>genes brain behav.\u003c/em> 7, 152&#x02013;163. doi:10.1111/j.1601-183x.2007.00330.x\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17559418/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1111/j.1601-183x.2007.00330.x\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=autism-like+behavioral+phenotypes+in+btbr+t+tf/j+mice&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b41\" id=\"b41\">\u003c/a>mcnaughton, n., and morris, r. g. (1987). chlordiazepoxide, an anxiolytic benzodiazepine, impairs place navigation in rats. \u003cem>behav. brain res.\u003c/em> 24, 39&#x02013;46. doi:10.1016/0166-4328(87)90034-9\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/3580114/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/0166-4328(87)90034-9\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=chlordiazepoxide%2c+an+anxiolytic+benzodiazepine%2c+impairs+place+navigation+in+rats&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b42\" id=\"b42\">\u003c/a>mendez, m. a., horder, j., myers, j., coghlan, s., stokes, p., erritzoe, d., et al. (2013). the brain gaba-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)c]ro15-4513 positron emission tomography study. \u003cem>neuropharmacology\u003c/em> 68, 195&#x02013;201. doi:10.1016/j.neuropharm.2012.04.008\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22546616/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2012.04.008\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+brain+gaba-benzodiazepine+receptor+alpha-5+subtype+in+autism+spectrum+disorder:+a+pilot+%5b11c%5dro15-4513+positron+emission+tomography+study&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b43\" id=\"b43\">\u003c/a>mermer, f., poliquin, s., rigsby, k., rastogi, a., shen, w., romero-morales, a., et al. (2021). common molecular mechanisms of slc6a1 variant-mediated neurodevelopmental disorders in astrocytes and neurons. \u003cem>brain\u003c/em> 144, 2499&#x02013;2512. doi:10.1093/brain/awab207\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/34028503/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1093/brain/awab207\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=common+molecular+mechanisms+of+slc6a1+variant-mediated+neurodevelopmental+disorders+in+astrocytes+and+neurons&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b44\" id=\"b44\">\u003c/a>mertz, l. g., christensen, r., vogel, i., hertz, j. m., nielsen, k. b., gronskov, k., et al. (2013). angelman syndrome in denmark. birth incidence, genetic findings, and age at diagnosis. \u003cem>am. j. med. genet. a\u003c/em> 161a, 2197&#x02013;2203. doi:10.1002/ajmg.a.36058\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23913711/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/ajmg.a.36058\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=angelman+syndrome+in+denmark+birth+incidence%2c+genetic+findings%2c+and+age+at+diagnosis&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b45\" id=\"b45\">\u003c/a>mesbah-oskui, l., penna, a., orser, b. a., and horner, r. l. (2017). reduced expression of &#x003b1;5gaba\u003csub>a\u003c/sub> receptors elicits autism-like alterations in eeg patterns and sleep-wake behavior. \u003cem>neurotoxicol teratol.\u003c/em> 61, 115&#x02013;122. doi:10.1016/j.ntt.2016.10.009\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27793660/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.ntt.2016.10.009\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=reduced+expression+of+î±5gabaa+receptors+elicits+autism-like+alterations+in+eeg+patterns+and+sleep-wake+behavior&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b46\" id=\"b46\">\u003c/a>mohler, h. (2011). the rise of a new gaba pharmacology. \u003cem>neuropharmacology\u003c/em> 60, 1042&#x02013;1049. doi:10.1016/j.neuropharm.2010.10.020\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21035473/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2010.10.020\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+rise+of+a+new+gaba+pharmacology&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b47\" id=\"b47\">\u003c/a>mori, t., mori, k., fujii, e., toda, y., miyazaki, m., harada, m., et al. (2012). evaluation of the gabaergic nervous system in autistic brain: (123)i-iomazenil spect study. \u003cem>brain dev.\u003c/em> 34, 648&#x02013;654. doi:10.1016/j.braindev.2011.10.007\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22099869/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.braindev.2011.10.007\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=evaluation+of+the+gabaergic+nervous+system+in+autistic+brain:+123i-iomazenil+spect+study&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b48\" id=\"b48\">\u003c/a>myers, j. f., comley, r. a., and gunn, r. n. (2017). quantification of [\u003csup>11\u003c/sup>c]ro15-4513 gaba\u003csub>a\u003c/sub>&#x003b1;5 specific binding and regional selectivity in humans. \u003cem>j. cereb. blood flow. metab.\u003c/em> 37, 2137&#x02013;2148. doi:10.1177/0271678x16661339\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27466376/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1177/0271678x16661339\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=quantification+of+%5b11c%5dro15-4513+gabaaî±5+specific+binding+and+regional+selectivity+in+humans&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b49\" id=\"b49\">\u003c/a>nakamura, t., arima-yoshida, f., sakaue, f., nasu-nishimura, y., takeda, y., matsuura, k., et al. (2016). px-rics-deficient mice mimic autism spectrum disorder in jacobsen syndrome through impaired gabaa receptor trafficking. \u003cem>nat. commun.\u003c/em> 7, 10861. doi:10.1038/ncomms10861\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26979507/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/ncomms10861\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=px-rics-deficient+mice+mimic+autism+spectrum+disorder+in+jacobsen+syndrome+through+impaired+gabaa+receptor+trafficking&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b50\" id=\"b50\">\u003c/a>orefice, l. l., zimmerman, a. l., chirila, a. m., sleboda, s. j., head, j. p., and ginty, d. d. (2016). peripheral mechanosensory neuron dysfunction underlies tactile and behavioral deficits in mouse models of asds. \u003cem>cell\u003c/em> 166, 299&#x02013;313. doi:10.1016/j.cell.2016.05.033\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27293187/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.cell.2016.05.033\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=peripheral+mechanosensory+neuron+dysfunction+underlies+tactile+and+behavioral+deficits+in+mouse+models+of+asds&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b51\" id=\"b51\">\u003c/a>penagarikano, o., abrahams, b. s., herman, e. i., winden, k. d., gdalyahu, a., dong, h., et al. (2011). absence of cntnap2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. \u003cem>cell\u003c/em> 147, 235&#x02013;246. doi:10.1016/j.cell.2011.08.040\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21962519/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.cell.2011.08.040\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=absence+of+cntnap2+leads+to+epilepsy%2c+neuronal+migration+abnormalities%2c+and+core+autism-related+deficits&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b52\" id=\"b52\">\u003c/a>percie du sert, n., hurst, v., ahluwalia, a., alam, s., avey, m. t., baker, m., et al. (2020). the arrive guidelines 2.0: updated guidelines for reporting animal research. \u003cem>plos biol.\u003c/em> 18, e3000410. doi:10.1371/journal.pbio.3000410\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/32663219/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1371/journal.pbio.3000410\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+arrive+guidelines+20:+updated+guidelines+for+reporting+animal+research&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b53\" id=\"b53\">\u003c/a>perez, s. m., mccoy, a. m., prevot, t. d., mian, m. y., carreno, f. r., frazer, a., et al. (2023). hippocampal &#x003b1;5-gaba(a) receptors modulate dopamine neuron activity in the rat ventral tegmental area. \u003cem>biol. psychiatry glob. open sci.\u003c/em> 3, 78&#x02013;86. doi:10.1016/j.bpsgos.2021.12.010\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/36712569/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.bpsgos.2021.12.010\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=hippocampal+î±5-gabaa+receptors+modulate+dopamine+neuron+activity+in+the+rat+ventral+tegmental+area&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b54\" id=\"b54\">\u003c/a>pirker, s., schwarzer, c., wieselthaler, a., sieghart, w., and sperk, g. (2000). gaba(a) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. \u003cem>neuroscience\u003c/em> 101, 815&#x02013;850. doi:10.1016/s0306-4522(00)00442-5\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/11113332/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0306-4522(00)00442-5\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa+receptors:+immunocytochemical+distribution+of+13+subunits+in+the+adult+rat+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b55\" id=\"b55\">\u003c/a>pizzarelli, r., and cherubini, e. (2011). alterations of gabaergic signaling in autism spectrum disorders. \u003cem>neural plast.\u003c/em> 2011, 297153. doi:10.1155/2011/297153\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21766041/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1155/2011/297153\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=alterations+of+gabaergic+signaling+in+autism+spectrum+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b56\" id=\"b56\">\u003c/a>porjesz, b., almasy, l., edenberg, h. j., wang, k., chorlian, d. b., foroud, t., et al. (2002). linkage disequilibrium between the beta frequency of the human eeg and a gabaa receptor gene locus. \u003cem>proc. natl. acad. sci. u. s. a.\u003c/em> 99, 3729&#x02013;3733. doi:10.1073/pnas.052716399\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/11891318/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1073/pnas.052716399\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=linkage+disequilibrium+between+the+beta+frequency+of+the+human+eeg+and+a+gabaa+receptor+gene+locus&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b57\" id=\"b57\">\u003c/a>puts, n. a. j., wodka, e. l., harris, a. d., crocetti, d., tommerdahl, m., mostofsky, s. h., et al. (2017). reduced gaba and altered somatosensory function in children with autism spectrum disorder. \u003cem>autism res.\u003c/em> 10, 608&#x02013;619. doi:10.1002/aur.1691\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27611990/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/aur.1691\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=reduced+gaba+and+altered+somatosensory+function+in+children+with+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b58\" id=\"b58\">\u003c/a>robertson, c. e., ratai, e. m., and kanwisher, n. (2016). reduced gabaergic action in the autistic brain. \u003cem>curr. biol.\u003c/em> 26, 80&#x02013;85. doi:10.1016/j.cub.2015.11.019\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26711497/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.cub.2015.11.019\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=reduced+gabaergic+action+in+the+autistic+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b59\" id=\"b59\">\u003c/a>rojas, d. c., singel, d., steinmetz, s., hepburn, s., and brown, m. s. (2014). decreased left perisylvian gaba concentration in children with autism and unaffected siblings. \u003cem>neuroimage\u003c/em> 86, 28&#x02013;34. doi:10.1016/j.neuroimage.2013.01.045\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23370056/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuroimage.2013.01.045\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=decreased+left+perisylvian+gaba+concentration+in+children+with+autism+and+unaffected+siblings&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b60\" id=\"b60\">\u003c/a>rubenstein, j. l., and merzenich, m. m. (2003). model of autism: increased ratio of excitation/inhibition in key neural systems. \u003cem>genes brain behav.\u003c/em> 2, 255&#x02013;267. doi:10.1034/j.1601-183x.2003.00037.x\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/14606691/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1034/j.1601-183x.2003.00037.x\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=model+of+autism:+increased+ratio+of+excitation/inhibition+in+key+neural+systems&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b61\" id=\"b61\">\u003c/a>sanders, s. j. (2015). first glimpses of the neurobiology of autism spectrum disorder. \u003cem>curr. opin. genet. dev.\u003c/em> 33, 80&#x02013;92. doi:10.1016/j.gde.2015.10.002\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26547130/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.gde.2015.10.002\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=first+glimpses+of+the+neurobiology+of+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b62\" id=\"b62\">\u003c/a>schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2018). dendrite-targeting interneurons control synaptic nmda-receptor activation \u003cem>via\u003c/em> nonlinear &#x003b1;5-gaba\u003csub>a\u003c/sub> receptors. \u003cem>nat. commun.\u003c/em> 9, 3576. doi:10.1038/s41467-018-06004-8\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/30177704/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/s41467-018-06004-8\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=dendrite-targeting+interneurons+control+synaptic+nmda-receptor+activation+via+nonlinear+î±5-gabaa+receptors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b63\" id=\"b63\">\u003c/a>schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2019). enhanced dendritic inhibition and impaired nmdar activation in a mouse model of down syndrome. \u003cem>j. neurosci.\u003c/em> 39, 5210&#x02013;5221. doi:10.1523/jneurosci.2723-18.2019\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/31000585/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1523/jneurosci.2723-18.2019\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=enhanced+dendritic+inhibition+and+impaired+nmdar+activation+in+a+mouse+model+of+down+syndrome&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b64\" id=\"b64\">\u003c/a>serwanski, d. r., miralles, c. p., christie, s. b., mehta, a. k., li, x., and de blas, a. l. (2006). synaptic and nonsynaptic localization of gabaa receptors containing the alpha5 subunit in the rat brain. \u003cem>j. comp. neurol.\u003c/em> 499, 458&#x02013;470. doi:10.1002/cne.21115\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/16998906/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/cne.21115\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=synaptic+and+nonsynaptic+localization+of+gabaa+receptors+containing+the+alpha5+subunit+in+the+rat+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b65\" id=\"b65\">\u003c/a>sieghart, w. (2006). structure, pharmacology, and function of gabaa receptor subtypes. \u003cem>adv. pharmacol.\u003c/em> 54, 231&#x02013;263. doi:10.1016/s1054-3589(06)54010-4\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17175817/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s1054-3589(06)54010-4\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=structure%2c+pharmacology%2c+and+function+of+gabaa+receptor+subtypes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b66\" id=\"b66\">\u003c/a>sitnikova, e., rutskova, e., and smirnov, k. (2023). alpha2-adrenergic receptors as a pharmacological target for spike-wave epilepsy. \u003cem>int. j. mol. sci.\u003c/em> 24, 1477. doi:10.3390/ijms24021477\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/36674992/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.3390/ijms24021477\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=alpha2-adrenergic+receptors+as+a+pharmacological+target+for+spike-wave+epilepsy&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b67\" id=\"b67\">\u003c/a>smit, d. j. a., wright, m. j., meyers, j. l., martin, n. g., ho, y. y. w., malone, s. m., et al. (2018). genome-wide association analysis links multiple psychiatric liability genes to oscillatory brain activity. \u003cem>hum. brain mapp.\u003c/em> 39, 4183&#x02013;4195. doi:10.1002/hbm.24238\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/29947131/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/hbm.24238\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=genome-wide+association+analysis+links+multiple+psychiatric+liability+genes+to+oscillatory+brain+activity&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b68\" id=\"b68\">\u003c/a>souza, a. j., freitas, i. s., sharmin, d., cook, j. m., guimaraes, f. s., and gomes, f. v. (2024). an alpha 5-gaba(a) receptor positive allosteric modulator attenuates social and cognitive deficits without changing dopamine system hyperactivity in rats exposed to valproic acid in utero. \u003cem>autism res.\u003c/em> 17, 1534&#x02013;1544. doi:10.1002/aur.3178\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/39169698/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/aur.3178\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=an+alpha+5-gabaa+receptor+positive+allosteric+modulator+attenuates+social+and+cognitive+deficits+without+changing+dopamine+system+hyperactivity+in+rats+exposed+to+valproic+acid+in+utero&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b69\" id=\"b69\">\u003c/a>sur, c., fresu, l., howell, o., mckernan, r. m., and atack, j. r. (1999). autoradiographic localization of alpha5 subunit-containing gabaa receptors in rat brain. \u003cem>brain res.\u003c/em> 822, 265&#x02013;270. doi:10.1016/s0006-8993(99)01152-x\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/10082908/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0006-8993(99)01152-x\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=autoradiographic+localization+of+alpha5+subunit-containing+gabaa+receptors+in+rat+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\" style=\"margin-bottom:0.5em;\">\u003cp class=\"referencescopy1\">\u003ca name=\"b70\" id=\"b70\">\u003c/a>traub, r. d. w. m., and jefferys, j. g. r. (1999). \u003cem>fast oscillations in cortical circuits\u003c/em>. \u003cspan class=\"publisher-name\">the mit press\u003c/span>. \u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=â traubâ r+d+w+mjefferysâ j+g+r+1999+fast+oscillations+in+cortical+circuits+the+mit+press&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b71\" id=\"b71\">\u003c/a>van lier, h., drinkenburg, w. h., van eeten, y. j., and coenen, a. m. (2004). effects of diazepam and zolpidem on eeg beta frequencies are behavior-specific in rats. \u003cem>neuropharmacology\u003c/em> 47, 163&#x02013;174. doi:10.1016/j.neuropharm.2004.03.017\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/15223295/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2004.03.017\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=effects+of+diazepam+and+zolpidem+on+eeg+beta+frequencies+are+behavior-specific+in+rats&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b72\" id=\"b72\">\u003c/a>visser, s. a., wolters, f. l., gubbens-stibbe, j. m., tukker, e., van der graaf, p. h., peletier, l. a., et al. (2003). mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of gabaa receptor modulators: in vitro-in vivo correlations. \u003cem>j. pharmacol. exp. ther.\u003c/em> 304, 88&#x02013;101. doi:10.1124/jpet.102.042341\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/12490579/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1124/jpet.102.042341\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=mechanism-based+pharmacokinetic/pharmacodynamic+modeling+of+the+electroencephalogram+effects+of+gabaa+receptor+modulators:+in+vitro-in+vivo+correlations&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b73\" id=\"b73\">\u003c/a>vithlani, m., terunuma, m., and moss, s. j. (2011). the dynamic modulation of gaba(a) receptor trafficking and its role in regulating the plasticity of inhibitory synapses. \u003cem>physiol. rev.\u003c/em> 91, 1009&#x02013;1022. doi:10.1152/physrev.00015.2010\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21742794/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1152/physrev.00015.2010\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+dynamic+modulation+of+gabaa+receptor+trafficking+and+its+role+in+regulating+the+plasticity+of+inhibitory+synapses&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b74\" id=\"b74\">\u003c/a>warrier, v., baron-cohen, s., and chakrabarti, b. (2013). genetic variation in gabrb3 is associated with asperger syndrome and multiple endophenotypes relevant to autism. \u003cem>mol. autism\u003c/em> 4, 48. doi:10.1186/2040-2392-4-48\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/24321478/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1186/2040-2392-4-48\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=genetic+variation+in+gabrb3+is+associated+with+asperger+syndrome+and+multiple+endophenotypes+relevant+to+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b75\" id=\"b75\">\u003c/a>whittington, m. a., traub, r. d., kopell, n., ermentrout, b., and buhl, e. h. (2000). inhibition-based rhythms: experimental and mathematical observations on network dynamics. \u003cem>int. j. psychophysiol.\u003c/em> 38, 315&#x02013;336. doi:10.1016/s0167-8760(00)00173-2\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/11102670/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0167-8760(00)00173-2\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=inhibition-based+rhythms:+experimental+and+mathematical+observations+on+network+dynamics&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b76\" id=\"b76\">\u003c/a>xie, x. h., and tietz, e. i. (1991). chronic benzodiazepine treatment of rats induces reduction of paired-pulse inhibition in ca1 region of \u003cem>in vitro\u003c/em> hippocampus. \u003cem>brain res.\u003c/em> 561, 69&#x02013;76. doi:10.1016/0006-8993(91)90750-p\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/1797351/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/0006-8993(91)90750-p\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=chronic+benzodiazepine+treatment+of+rats+induces+reduction+of+paired-pulse+inhibition+in+ca1+region+of+in+vitro+hippocampus&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b77\" id=\"b77\">\u003c/a>zurek, a. a., kemp, s. w., aga, z., walker, s., milenkovic, m., ramsey, a. j., et al. (2016). &#x003b1;5gabaa receptor deficiency causes autism-like behaviors. \u003cem>ann. clin. transl. neurol.\u003c/em> 3, 392&#x02013;398. doi:10.1002/acn3.303\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27231709/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/acn3.303\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=î±5gabaa+receptor+deficiency+causes+autism-like+behaviors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003c/div>\u003cdiv class=\"thinlinem20\">\u003c/div>\u003cdiv class=\"abstractsummary\">\u003cp>\u003cspan>keywords:\u003c/span> autism spectrum disorder, angelman syndrome, gaba\u003csub>a\u003c/sub>, gaba\u003csub>a\u003c/sub>-&#x003b1;5, positron emission tomography (pet), electroencephalography, pharmacological mri, biomarker\u003c/p>\u003cp>\u003cspan>citation:\u003c/span> cecere g, ballard tm, knoflach f, honer m, hipp jf, garces p, mueggler t, k&#x000fc;nnecke b, bruns a, prinssen ep, schoenenberger p, janz p, redondo r, biemans b, knust h, olivares-morales a, brigo a, schulz jm, bertrand d, saxe m, o&#x02019;connor ec and hernandez m-c (2025) preclinical pharmacology of alogabat: a novel gaba\u003csub>a\u003c/sub>-&#x003b1;5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gaba\u003csub>a\u003c/sub> signaling. \u003cem>front. pharmacol.\u003c/em> 16:1626078. doi: 10.3389/fphar.2025.1626078\u003c/p>\u003cp id=\"timestamps\">\u003cspan>received:\u003c/span> 09 may 2025; \u003cspan>accepted:\u003c/span> 18 june 2025;\u003cbr>\u003cspan>published:\u003c/span> 21 july 2025.\u003c/p>\u003cdiv>\u003cp>edited by:\u003c/p> \u003ca href=\"https://loop.frontiersin.org/people/52072/overview\">agenor limon\u003c/a>, university of texas medical branch at galveston, united states\u003c/div>\u003cdiv>\u003cp>reviewed by:\u003c/p> \u003ca href=\"https://loop.frontiersin.org/people/39673/overview\">hansen wang\u003c/a>, university of toronto, canada\u003cbr>\u003ca href=\"https://loop.frontiersin.org/people/1285968/overview\">junzhan jing\u003c/a>, baylor college of medicine, united states\u003cbr>\u003ca href=\"https://loop.frontiersin.org/people/1380630/overview\">azar omrani\u003c/a>, boehringer ingelheim, germany\u003c/div>\u003cp>\u003cspan>copyright\u003c/span> &#x000a9; 2025 cecere, ballard, knoflach, honer, hipp, garces, mueggler, k&#x000fc;nnecke, bruns, prinssen, schoenenberger, janz, redondo, biemans, knust, olivares-morales, brigo, schulz, bertrand, saxe, o&#x02019;connor and hernandez. this is an open-access article distributed under the terms of the \u003ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">creative commons attribution license (cc by).\u003c/a> the use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. no use, distribution or reproduction is permitted which does not comply with these terms.\u003c/p>\u003cp>\u003cspan>&#x0002a;correspondence:\u003c/span> maria-clemencia hernandez, \u003ca id=\"encmail\">bwfyawety2xlbwvuy2lhlmhlcm5hbmrlekbyb2nozs5jb20=\u003c/a>\u003c/p>\u003cp>\u003cspan>\u003csup>&#x02020;\u003c/sup>\u003c/span>these authors have contributed equally to this work\u003c/p>\u003cp>\u003cspan>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cb>present address:\u003c/b> theresa m. ballard, galwyn (uk) ltd., dartmouth, united kingdom\u003cbr>barbara biemans, b2discovery llc, riehen, switzerland\u003cbr>michael saxe, translational in vivo sciences, biogen, cambridge, ma, united states\u003c/p>\u003cdiv class=\"clear\">\u003c/div>\u003c/div>","\u003cul class=\"flyoutjournal\">\u003cli>\u003ca href=\"#h1\">abstract\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h2\">1 introduction\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h3\">2 materials and methods\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h4\">3 results\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h5\">4 discussion\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h6\">5 conclusion\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h7\">data availability statement\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h8\">ethics statement\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h9\">author contributions\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h10\">funding\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h11\">acknowledgments\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h12\">conflict of interest\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h13\">generative ai statement\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h14\">publisher&#x02019;s note\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h15\">supplementary material\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h16\">abbreviations\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h17\">references\u003c/a>\u003c/li>\u003c/ul>",[732,740,746,752],{"name":733,"fileserverpackageentryid":734,"fileserverid":735,"fileserverversionnumber":736,"type":737},"fphar-16-1626078.xml","fphar-16-1626078-r1/fphar-16-1626078.xml","1626078/xml",2,{"code":738,"name":739},"nlm_xml","xml",{"name":741,"fileserverpackageentryid":19,"fileserverid":742,"fileserverversionnumber":736,"type":743},"epub.epub","1626078/epub",{"code":744,"name":745},"epub","epub",{"name":747,"fileserverpackageentryid":19,"fileserverid":748,"fileserverversionnumber":736,"type":749},"publishers-proof.pdf","1626078/publishers-proof",{"code":750,"name":751},"pdf","pdf",{"name":753,"fileserverpackageentryid":19,"fileserverid":754,"fileserverversionnumber":370,"type":755},"supplementary file 1.docx","1626078/supplementary-file/1",{"code":756,"name":757},"supplementary_material","docx","v3",{"title":760,"link":761,"meta":765,"script":956},"frontiers | preclinical pharmacology of alogabat: a novel gabaa-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gabaa signaling",[762],{"rel":763,"href":764},"canonical","https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1626078/full",[766,769,772,774,777,781,784,788,791,794,797,799,801,803,805,807,810,813,815,818,820,822,825,828,831,834,837,841,845,848,851,854,856,859,861,864,866,869,871,874,876,879,881,884,886,889,891,894,896,899,901,904,906,909,911,914,916,919,922,925,927,930,932,935,938,941,943,946,948,951,953],{"hid":767,"property":767,"name":767,"content":768},"description","backgroundalterations in the gabaergic system contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder (asd) and...",{"hid":770,"property":770,"name":771,"content":760},"og:title","title",{"hid":773,"property":773,"name":767,"content":768},"og:description",{"hid":775,"name":775,"content":776},"keywords","biomarker,autism spectrum disorder,electroencephalography,positron emission tomography (pet),angelman syndrome,gabaa,gabaa-α5,pharmacological mri",{"hid":778,"property":778,"name":779,"content":780},"og:site_name","site_name","frontiers",{"hid":782,"property":782,"name":363,"content":783},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg",{"hid":785,"property":785,"name":786,"content":787},"og:type","type","article",{"hid":789,"property":789,"name":790,"content":764},"og:url","url",{"hid":792,"name":792,"content":793},"twitter:card","summary_large_image",{"hid":795,"name":795,"content":796},"citation_volume","16",{"hid":798,"name":798,"content":116},"citation_journal_title",{"hid":800,"name":800,"content":780},"citation_publisher",{"hid":802,"name":802,"content":713},"citation_journal_abbrev",{"hid":804,"name":804,"content":714},"citation_issn",{"hid":806,"name":806,"content":515},"citation_doi",{"hid":808,"name":808,"content":809},"citation_firstpage","1626078",{"hid":811,"name":811,"content":812},"citation_language","english",{"hid":814,"name":814,"content":516},"citation_title",{"hid":816,"name":816,"content":817},"citation_keywords","biomarker; autism spectrum disorder; electroencephalography; positron emission tomography (pet); angelman syndrome; gabaa; gabaa-α5; pharmacological mri",{"hid":819,"name":819,"content":521},"citation_abstract",{"hid":821,"name":821,"content":524},"citation_article_type",{"hid":823,"name":823,"content":824},"citation_pdf_url","https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1626078/pdf",{"hid":826,"name":826,"content":827},"citation_xml_url","https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1626078/xml",{"hid":829,"name":829,"content":830},"citation_fulltext_world_readable","yes",{"hid":832,"name":832,"content":833},"citation_online_date","2025/06/18",{"hid":835,"name":835,"content":836},"citation_publication_date","2025/07/21",{"hid":838,"name":839,"content":840},"citation_author_0","citation_author","cecere, giuseppe ",{"hid":842,"name":843,"content":844},"citation_author_institution_0","citation_author_institution","medicinal chemistry, switzerland",{"hid":846,"name":839,"content":847},"citation_author_1","ballard, theresa m. ",{"hid":849,"name":843,"content":850},"citation_author_institution_1","neuroscience and rare diseases, switzerland",{"hid":852,"name":839,"content":853},"citation_author_2","knoflach, frederic ",{"hid":855,"name":843,"content":850},"citation_author_institution_2",{"hid":857,"name":839,"content":858},"citation_author_3","honer, michael ",{"hid":860,"name":843,"content":850},"citation_author_institution_3",{"hid":862,"name":839,"content":863},"citation_author_4","hipp, joerg f. ",{"hid":865,"name":843,"content":850},"citation_author_institution_4",{"hid":867,"name":839,"content":868},"citation_author_5","garces, pilar ",{"hid":870,"name":843,"content":850},"citation_author_institution_5",{"hid":872,"name":839,"content":873},"citation_author_6","mueggler, thomas ",{"hid":875,"name":843,"content":850},"citation_author_institution_6",{"hid":877,"name":839,"content":878},"citation_author_7","künnecke, basil ",{"hid":880,"name":843,"content":850},"citation_author_institution_7",{"hid":882,"name":839,"content":883},"citation_author_8","bruns, andreas ",{"hid":885,"name":843,"content":850},"citation_author_institution_8",{"hid":887,"name":839,"content":888},"citation_author_9","prinssen, eric p. ",{"hid":890,"name":843,"content":850},"citation_author_institution_9",{"hid":892,"name":839,"content":893},"citation_author_10","schoenenberger, philipp ",{"hid":895,"name":843,"content":850},"citation_author_institution_10",{"hid":897,"name":839,"content":898},"citation_author_11","janz, philipp ",{"hid":900,"name":843,"content":850},"citation_author_institution_11",{"hid":902,"name":839,"content":903},"citation_author_12","redondo, roger ",{"hid":905,"name":843,"content":850},"citation_author_institution_12",{"hid":907,"name":839,"content":908},"citation_author_13","biemans, barbara ",{"hid":910,"name":843,"content":850},"citation_author_institution_13",{"hid":912,"name":839,"content":913},"citation_author_14","knust, henner ",{"hid":915,"name":843,"content":844},"citation_author_institution_14",{"hid":917,"name":839,"content":918},"citation_author_15","olivares-morales, andrés ",{"hid":920,"name":843,"content":921},"citation_author_institution_15","pharmaceutical sciences, switzerland",{"hid":923,"name":839,"content":924},"citation_author_16","brigo, alessandro ",{"hid":926,"name":843,"content":921},"citation_author_institution_16",{"hid":928,"name":839,"content":929},"citation_author_17","schulz, jan michael ",{"hid":931,"name":843,"content":850},"citation_author_institution_17",{"hid":933,"name":839,"content":934},"citation_author_18","bertrand, daniel ",{"hid":936,"name":843,"content":937},"citation_author_institution_18","hiqscreen sàrl, switzerland",{"hid":939,"name":839,"content":940},"citation_author_19","saxe, michael ",{"hid":942,"name":843,"content":850},"citation_author_institution_19",{"hid":944,"name":839,"content":945},"citation_author_20","o’connor, eoin c. ",{"hid":947,"name":843,"content":850},"citation_author_institution_20",{"hid":949,"name":839,"content":950},"citation_author_21","hernandez, maria-clemencia ",{"hid":952,"name":843,"content":850},"citation_author_institution_21",{"hid":954,"name":954,"content":955},"dc.identifier","doi:10.3389/fphar.2025.1626078",[957,960,962,964,966],{"src":958,"body":13,"type":959,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":961,"body":13,"type":959,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/mathjax.js?config=tex-mml-am_chtml",{"src":963,"body":13,"type":959,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":965,"body":13,"type":959,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fphar.2025.1626078?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":967,"body":13,"type":959,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articlehubslug":19,"articlehubpage":969,"articlehubarticleslist":970,"canjournalhasarticlehub":347,"articledoilist":971},{},[],[],{"title":19,"image":-1,"breadcrumbs":973,"linkscollection":974,"metricscollection":976},[],{"total":367,"items":975},[],{"total":367,"items":977},[]] window.__nuxt__={};window.__nuxt__.config={public:{isdevmode:false,appname:"article-pages-2024",baseurl:"https://www.frontiersin.org",domain:"frontiersin.org",loopurl:"https://loop.frontiersin.org",ssmaindomain:"frontiersin.org",contentfulurl:"https://graphql.contentful.com/content/v1/spaces",spaceid:1,spacename:"frontiers",livespaceid:1,tenantlogourl:"",frontiersgraphurl:"https://apollo-federation-gateway.frontiersin.org",registrationapiurl:"https://onboarding-ui.frontiersin.org",emaildigestapiurl:"https://api-email-digest.frontiersin.org",journalfilesapiurl:"https://files-journal-api.frontiersin.org",searchapiurl:"https://search-api.frontiersin.org",productionforumapiurl:"https://production-forum-api-v2.frontiersin.org",gtmserverurl:"https://tag-manager.frontiersin.org",gtmid:"gtm-m322fv2",gtmauth:"owvbwxfajr21yqv1fe1caq",gtmpreview:"env-1",figsharepluginurl:"https://widgets.figshare.com/static/figshare.js",figshareapiurl:"https://api.figshare.com/v2/collections/search",figsharetimeout:3000,crossmarkpublisheddate:"2015/08/24",googlerecaptchasitekey:"6ldg3i0uaaaaaoc4quh35ubhgjotehp_stxhgr_v",googlerecaptchakeyname:"frontiersrecaptchav2",faviconsize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantfavicon-frontiers.png",faviconsize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantfavicon-frontiers.png",faviconsize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantfavicon-frontiers.png",faviconsize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantfavicon-frontiers.png",faviconsize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantfavicon-frontiers.png",socialmediaimg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/guidelines-frontiers_logo_1200x628_1-91to1.png",linkedarticlecopytext:"'{\"articletypecopytext\":[{\"articletypeid\":0,\"originalarticlecopytext\":\"part of this article's content has been mentioned in:\",\"linkedarticlecopytext\":\"this article mentions parts of:\"},{\"articletypeid\":122,\"originalarticlecopytext\":\"parts of this article's content have been modified or rectified in:\",\"linkedarticlecopytext\":\"this article is an erratum on:\"},{\"articletypeid\":129,\"originalarticlecopytext\":\"parts of this article's content have been modified or rectified in:\",\"linkedarticlecopytext\":\"this article is an addendum to:\"},{\"articletypeid\":128,\"originalarticlecopytext\":\"a correction has been applied to this article in:\",\"linkedarticlecopytext\":\"this article is a correction to:\"},{\"articletypeid\":134,\"originalarticlecopytext\":\"a retraction of this article was approved in:\",\"linkedarticlecopytext\":\"this article is a retraction of:\"},{\"articletypeid\":29,\"originalarticlecopytext\":\"a commentary has been posted on this article:\",\"linkedarticlecopytext\":\"this article is a commentary on:\"},{\"articletypeid\":30,\"originalarticlecopytext\":\"a commentary has been posted on this article:\",\"linkedarticlecopytext\":\"this article is a commentary on:\"}],\"articleidcopytext\":[]}'\n",acceptedarticleexcludedjournalids:"'[2766,979]'\n",articletypeconfigurablelabel:"\u003c\u003carticle-type:uppercase>> article",settingsfeaturesswitchers:"'{\"displaytitlepilllabels\":true,\"displayrelatedarticlesbox\":true,\"showeditors\":true,\"showreviewers\":true,\"showloopimpactlink\":true,\"enablefigshare\":false,\"usexmlimages\":true}'\n",journalswitharticlehub:"'{\"strings\":[\"science\"]}'\n",terminologysettings:"'{\"terms\":[{\"sequencenumber\":1,\"key\":\"frontiers\",\"tenantterm\":\"frontiers\",\"frontiersdefaultterm\":\"frontiers\",\"category\":\"customer\"},{\"sequencenumber\":2,\"key\":\"submission_system\",\"tenantterm\":\"submission system\",\"frontiersdefaultterm\":\"submission system\",\"category\":\"product\"},{\"sequencenumber\":3,\"key\":\"public_pages\",\"tenantterm\":\"public pages\",\"frontiersdefaultterm\":\"public pages\",\"category\":\"product\"},{\"sequencenumber\":4,\"key\":\"my_frontiers\",\"tenantterm\":\"my frontiers\",\"frontiersdefaultterm\":\"my frontiers\",\"category\":\"product\"},{\"sequencenumber\":5,\"key\":\"digital_editorial_office\",\"tenantterm\":\"digital editorial office\",\"frontiersdefaultterm\":\"digital editorial office\",\"category\":\"product\"},{\"sequencenumber\":6,\"key\":\"deo\",\"tenantterm\":\"deo\",\"frontiersdefaultterm\":\"deo\",\"category\":\"product\"},{\"sequencenumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantterm\":\"digital editorial office for chiefs\",\"frontiersdefaultterm\":\"digital editorial office for chiefs\",\"category\":\"product\"},{\"sequencenumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantterm\":\"digital editorial office for eof\",\"frontiersdefaultterm\":\"digital editorial office for eof\",\"category\":\"product\"},{\"sequencenumber\":9,\"key\":\"editorial_office\",\"tenantterm\":\"editorial office\",\"frontiersdefaultterm\":\"editorial office\",\"category\":\"product\"},{\"sequencenumber\":10,\"key\":\"eof\",\"tenantterm\":\"eof\",\"frontiersdefaultterm\":\"eof\",\"category\":\"product\"},{\"sequencenumber\":11,\"key\":\"research_topic_management\",\"tenantterm\":\"research topic management\",\"frontiersdefaultterm\":\"research topic management\",\"category\":\"product\"},{\"sequencenumber\":12,\"key\":\"review_forum\",\"tenantterm\":\"review forum\",\"frontiersdefaultterm\":\"review forum\",\"category\":\"product\"},{\"sequencenumber\":13,\"key\":\"accounting_office\",\"tenantterm\":\"accounting office\",\"frontiersdefaultterm\":\"accounting office\",\"category\":\"product\"},{\"sequencenumber\":14,\"key\":\"aof\",\"tenantterm\":\"aof\",\"frontiersdefaultterm\":\"aof\",\"category\":\"product\"},{\"sequencenumber\":15,\"key\":\"publishing_office\",\"tenantterm\":\"publishing office\",\"frontiersdefaultterm\":\"publishing office\",\"category\":\"product\"},{\"sequencenumber\":16,\"key\":\"production_office\",\"tenantterm\":\"production office forum\",\"frontiersdefaultterm\":\"production office forum\",\"category\":\"product\"},{\"sequencenumber\":17,\"key\":\"pof\",\"tenantterm\":\"pof\",\"frontiersdefaultterm\":\"pof\",\"category\":\"product\"},{\"sequencenumber\":18,\"key\":\"book_office_forum\",\"tenantterm\":\"book office forum\",\"frontiersdefaultterm\":\"book office forum\",\"category\":\"product\"},{\"sequencenumber\":19,\"key\":\"bof\",\"tenantterm\":\"bof\",\"frontiersdefaultterm\":\"bof\",\"category\":\"product\"},{\"sequencenumber\":20,\"key\":\"aira\",\"tenantterm\":\"aira\",\"frontiersdefaultterm\":\"aira\",\"category\":\"product\"},{\"sequencenumber\":21,\"key\":\"editorial_board_management\",\"tenantterm\":\"editorial board management\",\"frontiersdefaultterm\":\"editorial board management\",\"category\":\"product\"},{\"sequencenumber\":22,\"key\":\"ebm\",\"tenantterm\":\"ebm\",\"frontiersdefaultterm\":\"ebm\",\"category\":\"product\"},{\"sequencenumber\":23,\"key\":\"domain\",\"tenantterm\":\"domain\",\"frontiersdefaultterm\":\"domain\",\"category\":\"taxonomy\"},{\"sequencenumber\":24,\"key\":\"journal\",\"tenantterm\":\"journal\",\"frontiersdefaultterm\":\"journal\",\"category\":\"taxonomy\"},{\"sequencenumber\":25,\"key\":\"section\",\"tenantterm\":\"section\",\"frontiersdefaultterm\":\"section\",\"category\":\"taxonomy\"},{\"sequencenumber\":26,\"key\":\"domains\",\"tenantterm\":\"domains\",\"frontiersdefaultterm\":\"domains\",\"category\":\"taxonomy\"},{\"sequencenumber\":27,\"key\":\"specialty_section\",\"tenantterm\":\"specialty section\",\"frontiersdefaultterm\":\"specialty section\",\"category\":\"taxonomy\"},{\"sequencenumber\":28,\"key\":\"specialty_journal\",\"tenantterm\":\"specialty journal\",\"frontiersdefaultterm\":\"specialty journal\",\"category\":\"taxonomy\"},{\"sequencenumber\":29,\"key\":\"journals\",\"tenantterm\":\"journals\",\"frontiersdefaultterm\":\"journals\",\"category\":\"taxonomy\"},{\"sequencenumber\":30,\"key\":\"sections\",\"tenantterm\":\"sections\",\"frontiersdefaultterm\":\"sections\",\"category\":\"taxonomy\"},{\"sequencenumber\":31,\"key\":\"specialty_sections\",\"tenantterm\":\"specialty sections\",\"frontiersdefaultterm\":\"specialty sections\",\"category\":\"taxonomy\"},{\"sequencenumber\":32,\"key\":\"specialty_journals\",\"tenantterm\":\"specialty journals\",\"frontiersdefaultterm\":\"specialty journals\",\"category\":\"taxonomy\"},{\"sequencenumber\":33,\"key\":\"manuscript\",\"tenantterm\":\"manuscript\",\"frontiersdefaultterm\":\"manuscript\",\"category\":\"core\"},{\"sequencenumber\":34,\"key\":\"manuscripts\",\"tenantterm\":\"manuscripts\",\"frontiersdefaultterm\":\"manuscripts\",\"category\":\"core\"},{\"sequencenumber\":35,\"key\":\"article\",\"tenantterm\":\"article\",\"frontiersdefaultterm\":\"article\",\"category\":\"core\"},{\"sequencenumber\":36,\"key\":\"articles\",\"tenantterm\":\"articles\",\"frontiersdefaultterm\":\"articles\",\"category\":\"core\"},{\"sequencenumber\":37,\"key\":\"article_type\",\"tenantterm\":\"article type\",\"frontiersdefaultterm\":\"article type\",\"category\":\"core\"},{\"sequencenumber\":38,\"key\":\"article_types\",\"tenantterm\":\"article types\",\"frontiersdefaultterm\":\"article types\",\"category\":\"core\"},{\"sequencenumber\":39,\"key\":\"author\",\"tenantterm\":\"author\",\"frontiersdefaultterm\":\"author\",\"category\":\"label (role)\"},{\"sequencenumber\":40,\"key\":\"authors\",\"tenantterm\":\"authors\",\"frontiersdefaultterm\":\"authors\",\"category\":\"label (role)\"},{\"sequencenumber\":41,\"key\":\"authoring\",\"tenantterm\":\"authoring\",\"frontiersdefaultterm\":\"authoring\",\"category\":\"core\"},{\"sequencenumber\":42,\"key\":\"authored\",\"tenantterm\":\"authored\",\"frontiersdefaultterm\":\"authored\",\"category\":\"core\"},{\"sequencenumber\":43,\"key\":\"accept\",\"tenantterm\":\"accept\",\"frontiersdefaultterm\":\"accept\",\"category\":\"process\"},{\"sequencenumber\":44,\"key\":\"accepted\",\"tenantterm\":\"accepted\",\"frontiersdefaultterm\":\"accepted\",\"category\":\"process\"},{\"sequencenumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantterm\":\"assistant field chief editor\",\"frontiersdefaultterm\":\"assistant field chief editor\",\"description\":\"an editorial role on a field journal that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantterm\":\"assistant specialty chief editor\",\"frontiersdefaultterm\":\"assistant specialty chief editor\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantterm\":\"assistant specialty chief editors\",\"frontiersdefaultterm\":\"assistant specialty chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":48,\"key\":\"associate_editor\",\"tenantterm\":\"associate editor\",\"frontiersdefaultterm\":\"associate editor\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":49,\"key\":\"specialty_chief_editor\",\"tenantterm\":\"specialty chief editor\",\"frontiersdefaultterm\":\"specialty chief editor\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":50,\"key\":\"specialty_chief_editors\",\"tenantterm\":\"specialty chief editors\",\"frontiersdefaultterm\":\"specialty chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":51,\"key\":\"chief_editor\",\"tenantterm\":\"chief editor\",\"frontiersdefaultterm\":\"chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":52,\"key\":\"chief_editors\",\"tenantterm\":\"chief editors\",\"frontiersdefaultterm\":\"chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":53,\"key\":\"call_for_participation\",\"tenantterm\":\"call for participation\",\"frontiersdefaultterm\":\"call for participation\",\"category\":\"process\"},{\"sequencenumber\":54,\"key\":\"citation\",\"tenantterm\":\"citation\",\"frontiersdefaultterm\":\"citation\",\"category\":\"misc.\"},{\"sequencenumber\":55,\"key\":\"citations\",\"tenantterm\":\"citations\",\"frontiersdefaultterm\":\"citations\",\"category\":\"misc.\"},{\"sequencenumber\":56,\"key\":\"contributor\",\"tenantterm\":\"contributor\",\"frontiersdefaultterm\":\"contributor\",\"category\":\"label (role)\"},{\"sequencenumber\":57,\"key\":\"contributors\",\"tenantterm\":\"contributors\",\"frontiersdefaultterm\":\"contributors\",\"category\":\"label (role)\"},{\"sequencenumber\":58,\"key\":\"corresponding_author\",\"tenantterm\":\"corresponding author\",\"frontiersdefaultterm\":\"corresponding author\",\"category\":\"label (role)\"},{\"sequencenumber\":59,\"key\":\"corresponding_authors\",\"tenantterm\":\"corresponding authors\",\"frontiersdefaultterm\":\"corresponding authors\",\"category\":\"label (role)\"},{\"sequencenumber\":60,\"key\":\"decline\",\"tenantterm\":\"decline\",\"frontiersdefaultterm\":\"decline\",\"category\":\"process\"},{\"sequencenumber\":61,\"key\":\"declined\",\"tenantterm\":\"declined\",\"frontiersdefaultterm\":\"declined\",\"category\":\"process\"},{\"sequencenumber\":62,\"key\":\"reject\",\"tenantterm\":\"reject\",\"frontiersdefaultterm\":\"reject\",\"category\":\"process\"},{\"sequencenumber\":63,\"key\":\"rejected\",\"tenantterm\":\"rejected\",\"frontiersdefaultterm\":\"rejected\",\"category\":\"process\"},{\"sequencenumber\":64,\"key\":\"publish\",\"tenantterm\":\"publish\",\"frontiersdefaultterm\":\"publish\",\"category\":\"core\"},{\"sequencenumber\":65,\"key\":\"published\",\"tenantterm\":\"published\",\"frontiersdefaultterm\":\"published\",\"category\":\"core\"},{\"sequencenumber\":66,\"key\":\"publication\",\"tenantterm\":\"publication\",\"frontiersdefaultterm\":\"publication\",\"category\":\"core\"},{\"sequencenumber\":67,\"key\":\"peer_review\",\"tenantterm\":\"peer review\",\"frontiersdefaultterm\":\"peer review\",\"category\":\"peer review process\"},{\"sequencenumber\":68,\"key\":\"peer_reviewed\",\"tenantterm\":\"peer reviewed\",\"frontiersdefaultterm\":\"peer reviewed\",\"category\":\"peer review process\"},{\"sequencenumber\":69,\"key\":\"initial_validation\",\"tenantterm\":\"initial validation\",\"frontiersdefaultterm\":\"initial validation\",\"category\":\"peer review process\"},{\"sequencenumber\":70,\"key\":\"editorial_assignment\",\"tenantterm\":\"editorial assignment\",\"frontiersdefaultterm\":\"editorial assignment\",\"category\":\"peer review process\"},{\"sequencenumber\":71,\"key\":\"independent_review\",\"tenantterm\":\"independent review\",\"frontiersdefaultterm\":\"independent review\",\"category\":\"peer review process\"},{\"sequencenumber\":72,\"key\":\"interactive_review\",\"tenantterm\":\"interactive review\",\"frontiersdefaultterm\":\"interactive review\",\"category\":\"peer review process\"},{\"sequencenumber\":73,\"key\":\"review\",\"tenantterm\":\"review\",\"frontiersdefaultterm\":\"review\",\"category\":\"peer review process\"},{\"sequencenumber\":74,\"key\":\"reviewing\",\"tenantterm\":\"reviewing\",\"frontiersdefaultterm\":\"reviewing\",\"category\":\"peer review process\"},{\"sequencenumber\":75,\"key\":\"reviewer\",\"tenantterm\":\"reviewer\",\"frontiersdefaultterm\":\"reviewer\",\"category\":\"label (role)\"},{\"sequencenumber\":76,\"key\":\"reviewers\",\"tenantterm\":\"reviewers\",\"frontiersdefaultterm\":\"reviewers\",\"category\":\"label (role)\"},{\"sequencenumber\":77,\"key\":\"review_finalized\",\"tenantterm\":\"review finalized\",\"frontiersdefaultterm\":\"review finalized\",\"category\":\"peer review process\"},{\"sequencenumber\":78,\"key\":\"final_decision\",\"tenantterm\":\"final decision\",\"frontiersdefaultterm\":\"final decision\",\"category\":\"peer review process\"},{\"sequencenumber\":79,\"key\":\"final_validation\",\"tenantterm\":\"final validation\",\"frontiersdefaultterm\":\"final validation\",\"category\":\"peer review process\"},{\"sequencenumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantterm\":\"recommend to accept manuscript\",\"frontiersdefaultterm\":\"accept manuscript\",\"category\":\"process\"},{\"sequencenumber\":81,\"key\":\"fee\",\"tenantterm\":\"fee\",\"frontiersdefaultterm\":\"fee\",\"category\":\"accounting\"},{\"sequencenumber\":82,\"key\":\"fees\",\"tenantterm\":\"fees\",\"frontiersdefaultterm\":\"fees\",\"category\":\"accounting\"},{\"sequencenumber\":83,\"key\":\"guest_associate_editor\",\"tenantterm\":\"guest associate editor\",\"frontiersdefaultterm\":\"guest associate editor\",\"category\":\"label (role)\"},{\"sequencenumber\":84,\"key\":\"guest_associate_editors\",\"tenantterm\":\"guest associate editors\",\"frontiersdefaultterm\":\"guest associate editors\",\"category\":\"label (role)\"},{\"sequencenumber\":85,\"key\":\"in_review\",\"tenantterm\":\"in review\",\"frontiersdefaultterm\":\"in review\",\"category\":\"peer review process\"},{\"sequencenumber\":86,\"key\":\"institutional_member\",\"tenantterm\":\"institutional partner\",\"frontiersdefaultterm\":\"institutional partner\",\"category\":\"accounting\"},{\"sequencenumber\":87,\"key\":\"institutional_membership\",\"tenantterm\":\"institutional partnership\",\"frontiersdefaultterm\":\"institutional partnership\",\"category\":\"accounting\"},{\"sequencenumber\":88,\"key\":\"article_processing_charge\",\"tenantterm\":\"article processing charge\",\"frontiersdefaultterm\":\"article processing charge\",\"category\":\"accounting\"},{\"sequencenumber\":89,\"key\":\"article_processing_charges\",\"tenantterm\":\"article processing charges\",\"frontiersdefaultterm\":\"article processing charges\",\"category\":\"accounting\"},{\"sequencenumber\":90,\"key\":\"apcs\",\"tenantterm\":\"apcs\",\"frontiersdefaultterm\":\"apcs\",\"category\":\"accounting\"},{\"sequencenumber\":91,\"key\":\"apc\",\"tenantterm\":\"apc\",\"frontiersdefaultterm\":\"apc\",\"category\":\"accounting\"},{\"sequencenumber\":92,\"key\":\"received\",\"tenantterm\":\"received\",\"frontiersdefaultterm\":\"received\",\"description\":\"date manuscript was received on.\",\"category\":\"core\"},{\"sequencenumber\":93,\"key\":\"transferred\",\"tenantterm\":\"transferred\",\"frontiersdefaultterm\":\"transferred\",\"category\":\"core\"},{\"sequencenumber\":94,\"key\":\"transfer\",\"tenantterm\":\"transfer\",\"frontiersdefaultterm\":\"transfer\",\"category\":\"core\"},{\"sequencenumber\":95,\"key\":\"research_topic\",\"tenantterm\":\"research topic\",\"frontiersdefaultterm\":\"research topic\",\"category\":\"core\"},{\"sequencenumber\":96,\"key\":\"research_topics\",\"tenantterm\":\"research topics\",\"frontiersdefaultterm\":\"research topics\",\"category\":\"core\"},{\"sequencenumber\":97,\"key\":\"topic_editor\",\"tenantterm\":\"topic editor\",\"frontiersdefaultterm\":\"topic editor\",\"category\":\"label (role)\"},{\"sequencenumber\":98,\"key\":\"review_editor\",\"tenantterm\":\"community reviewer\",\"frontiersdefaultterm\":\"review editor\",\"category\":\"label (role)\"},{\"sequencenumber\":99,\"key\":\"title\",\"tenantterm\":\"title\",\"frontiersdefaultterm\":\"title\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":100,\"key\":\"running_title\",\"tenantterm\":\"running title\",\"frontiersdefaultterm\":\"running title\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":101,\"key\":\"submit\",\"tenantterm\":\"submit\",\"frontiersdefaultterm\":\"submit\",\"category\":\"process\"},{\"sequencenumber\":102,\"key\":\"submitted\",\"tenantterm\":\"submitted\",\"frontiersdefaultterm\":\"submitted\",\"category\":\"process\"},{\"sequencenumber\":103,\"key\":\"submitting\",\"tenantterm\":\"submitting\",\"frontiersdefaultterm\":\"submitting\",\"category\":\"process\"},{\"sequencenumber\":104,\"key\":\"t_e\",\"tenantterm\":\"te\",\"frontiersdefaultterm\":\"te\",\"category\":\"label (role)\"},{\"sequencenumber\":105,\"key\":\"topic\",\"tenantterm\":\"topic\",\"frontiersdefaultterm\":\"topic\",\"category\":\"process\"},{\"sequencenumber\":106,\"key\":\"topic_summary\",\"tenantterm\":\"topic summary\",\"frontiersdefaultterm\":\"topic summary\",\"category\":\"process\"},{\"sequencenumber\":107,\"key\":\"figure\",\"tenantterm\":\"figure\",\"frontiersdefaultterm\":\"figure\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":108,\"key\":\"figures\",\"tenantterm\":\"figures\",\"frontiersdefaultterm\":\"figures\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":109,\"key\":\"editorial_file\",\"tenantterm\":\"editorial file\",\"frontiersdefaultterm\":\"editorial file\",\"category\":\"core\"},{\"sequencenumber\":110,\"key\":\"editorial_files\",\"tenantterm\":\"editorial files\",\"frontiersdefaultterm\":\"editorial files\",\"category\":\"core\"},{\"sequencenumber\":111,\"key\":\"e_book\",\"tenantterm\":\"e-book\",\"frontiersdefaultterm\":\"e-book\",\"category\":\"core\"},{\"sequencenumber\":112,\"key\":\"organization\",\"tenantterm\":\"organization\",\"frontiersdefaultterm\":\"organization\",\"category\":\"core\"},{\"sequencenumber\":113,\"key\":\"institution\",\"tenantterm\":\"institution\",\"frontiersdefaultterm\":\"institution\",\"category\":\"core\"},{\"sequencenumber\":114,\"key\":\"reference\",\"tenantterm\":\"reference\",\"frontiersdefaultterm\":\"reference\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":115,\"key\":\"references\",\"tenantterm\":\"references\",\"frontiersdefaultterm\":\"references\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":116,\"key\":\"sce\",\"tenantterm\":\"sce\",\"frontiersdefaultterm\":\"sce\",\"description\":\"abbreviation for specialty chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":117,\"key\":\"submission\",\"tenantterm\":\"submission\",\"frontiersdefaultterm\":\"submission\",\"category\":\"process\"},{\"sequencenumber\":118,\"key\":\"submissions\",\"tenantterm\":\"submissions\",\"frontiersdefaultterm\":\"submissions\",\"category\":\"process\"},{\"sequencenumber\":119,\"key\":\"editing\",\"tenantterm\":\"editing\",\"frontiersdefaultterm\":\"editing\",\"category\":\"process\"},{\"sequencenumber\":120,\"key\":\"in_preparation\",\"tenantterm\":\"in preparation\",\"frontiersdefaultterm\":\"in preparation\",\"category\":\"process\"},{\"sequencenumber\":121,\"key\":\"country_region\",\"tenantterm\":\"country/region\",\"frontiersdefaultterm\":\"country/region\",\"description\":\"because of political issues, some of the country listings are actually classified as `regions` and we need to include this. however other clients may not want to do this.\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":122,\"key\":\"countries_regions\",\"tenantterm\":\"countries/regions\",\"frontiersdefaultterm\":\"countries/regions\",\"description\":\"because of political issues, some of the country listings are actually classified as `regions` and we need to include this. however other clients may not want to do this.\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":123,\"key\":\"specialty\",\"tenantterm\":\"specialty\",\"frontiersdefaultterm\":\"specialty\",\"category\":\"core\"},{\"sequencenumber\":124,\"key\":\"specialties\",\"tenantterm\":\"specialties\",\"frontiersdefaultterm\":\"specialties\",\"category\":\"core\"},{\"sequencenumber\":125,\"key\":\"associate_editors\",\"tenantterm\":\"associate editors\",\"frontiersdefaultterm\":\"associate editors\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":126,\"key\":\"reviewed\",\"tenantterm\":\"reviewed\",\"frontiersdefaultterm\":\"reviewed\",\"category\":\"peer review process\"},{\"sequencenumber\":127,\"key\":\"institutional_members\",\"tenantterm\":\"institutional partners\",\"frontiersdefaultterm\":\"institutional partners\",\"category\":\"accounting\"},{\"sequencenumber\":128,\"key\":\"institutional_memberships\",\"tenantterm\":\"institutional partnerships\",\"frontiersdefaultterm\":\"institutional partnerships\",\"category\":\"accounting\"},{\"sequencenumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantterm\":\"assistant field chief editors\",\"frontiersdefaultterm\":\"assistant field chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":130,\"key\":\"publications\",\"tenantterm\":\"publications\",\"frontiersdefaultterm\":\"publications\",\"category\":\"process\"},{\"sequencenumber\":131,\"key\":\"ae_accepted\",\"tenantterm\":\"recommended acceptance\",\"frontiersdefaultterm\":\"accepted\",\"category\":\"process\"},{\"sequencenumber\":132,\"key\":\"field_journal\",\"tenantterm\":\"field journal\",\"frontiersdefaultterm\":\"field journal\",\"category\":\"taxonomy\"},{\"sequencenumber\":133,\"key\":\"field_journals\",\"tenantterm\":\"field journals\",\"frontiersdefaultterm\":\"field journals\",\"category\":\"taxonomy\"},{\"sequencenumber\":134,\"key\":\"program_manager\",\"tenantterm\":\"program manager\",\"frontiersdefaultterm\":\"program manager\",\"category\":\"label (role)\"},{\"sequencenumber\":135,\"key\":\"journal_manager\",\"tenantterm\":\"journal manager\",\"frontiersdefaultterm\":\"journal manager\",\"category\":\"label (role)\"},{\"sequencenumber\":136,\"key\":\"journal_specialist\",\"tenantterm\":\"journal specialist\",\"frontiersdefaultterm\":\"journal specialist\",\"category\":\"label (role)\"},{\"sequencenumber\":137,\"key\":\"program_managers\",\"tenantterm\":\"program managers\",\"frontiersdefaultterm\":\"program managers\",\"category\":\"label (role)\"},{\"sequencenumber\":138,\"key\":\"journal_managers\",\"tenantterm\":\"journal managers\",\"frontiersdefaultterm\":\"journal managers\",\"category\":\"label (role)\"},{\"sequencenumber\":139,\"key\":\"journal_specialists\",\"tenantterm\":\"journal specialists\",\"frontiersdefaultterm\":\"journal specialists\",\"category\":\"label (role)\"},{\"sequencenumber\":140,\"key\":\"cover_letter\",\"tenantterm\":\"manuscript contribution to the field\",\"frontiersdefaultterm\":\"manuscript contribution to the field\",\"category\":\"process\"},{\"sequencenumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantterm\":\"recommended to accept manuscript\",\"frontiersdefaultterm\":\"accepted manuscript\",\"category\":\"process\"},{\"sequencenumber\":142,\"key\":\"recommend_for_rejection\",\"tenantterm\":\"recommend for rejection\",\"frontiersdefaultterm\":\"recommend for rejection\",\"category\":\"process\"},{\"sequencenumber\":143,\"key\":\"recommended_for_rejection\",\"tenantterm\":\"recommended for rejection\",\"frontiersdefaultterm\":\"recommended for rejection\",\"category\":\"process\"},{\"sequencenumber\":144,\"key\":\"ae\",\"tenantterm\":\"ae\",\"frontiersdefaultterm\":\"ae\",\"description\":\"associate editor - board member\",\"category\":\"label (role)\"},{\"sequencenumber\":145,\"key\":\"re\",\"tenantterm\":\"re\",\"frontiersdefaultterm\":\"re\",\"description\":\"review editor\",\"category\":\"label (role)\"},{\"sequencenumber\":146,\"key\":\"rev\",\"tenantterm\":\"rev\",\"frontiersdefaultterm\":\"rev\",\"description\":\"reviewer\",\"category\":\"label (role)\"},{\"sequencenumber\":147,\"key\":\"aut\",\"tenantterm\":\"aut\",\"frontiersdefaultterm\":\"aut\",\"description\":\"author\",\"category\":\"label (role)\"},{\"sequencenumber\":148,\"key\":\"coraut\",\"tenantterm\":\"coraut\",\"frontiersdefaultterm\":\"coraut\",\"description\":\"corresponding author\",\"category\":\"label (role)\"},{\"sequencenumber\":149,\"key\":\"saut\",\"tenantterm\":\"saut\",\"frontiersdefaultterm\":\"saut\",\"description\":\"submitting author\",\"category\":\"label (role)\"},{\"sequencenumber\":150,\"key\":\"coaut\",\"tenantterm\":\"coaut\",\"frontiersdefaultterm\":\"coaut\",\"description\":\"co-author\",\"category\":\"label (role)\"},{\"sequencenumber\":151,\"key\":\"tsof\",\"tenantterm\":\"tsof\",\"frontiersdefaultterm\":\"tsof\",\"description\":\"typesetter\",\"category\":\"label (role)\"},{\"sequencenumber\":152,\"key\":\"typesetting_office\",\"tenantterm\":\"typesetting office\",\"frontiersdefaultterm\":\"typesetting office\",\"category\":\"product\"},{\"sequencenumber\":153,\"key\":\"config\",\"tenantterm\":\"config\",\"frontiersdefaultterm\":\"config\",\"description\":\"configuration office role\",\"category\":\"label (role)\"},{\"sequencenumber\":154,\"key\":\"jm\",\"tenantterm\":\"jm\",\"frontiersdefaultterm\":\"jm\",\"description\":\"journal manager\",\"category\":\"label (role)\"},{\"sequencenumber\":155,\"key\":\"rte\",\"tenantterm\":\"rte\",\"frontiersdefaultterm\":\"rte\",\"description\":\"research topic editor\",\"category\":\"label (role)\"},{\"sequencenumber\":156,\"key\":\"organizations\",\"tenantterm\":\"organizations\",\"frontiersdefaultterm\":\"organizations\",\"category\":\"core\"},{\"sequencenumber\":157,\"key\":\"publishing\",\"tenantterm\":\"publishing\",\"frontiersdefaultterm\":\"publishing\",\"category\":\"core\"},{\"sequencenumber\":158,\"key\":\"acceptance\",\"tenantterm\":\"acceptance\",\"frontiersdefaultterm\":\"acceptance\",\"category\":\"process\"},{\"sequencenumber\":159,\"key\":\"preferred_associate_editor\",\"tenantterm\":\"preferred associate editor\",\"frontiersdefaultterm\":\"preferred associate editor\",\"category\":\"label (role)\"},{\"sequencenumber\":160,\"key\":\"topic_editors\",\"tenantterm\":\"topic editors\",\"frontiersdefaultterm\":\"topic editors\",\"category\":\"label (role)\"},{\"sequencenumber\":161,\"key\":\"institutions\",\"tenantterm\":\"institutions\",\"frontiersdefaultterm\":\"institutions\",\"category\":\"core\"},{\"sequencenumber\":162,\"key\":\"author(s)\",\"tenantterm\":\"author(s)\",\"frontiersdefaultterm\":\"author(s)\",\"category\":\"label (role)\"},{\"sequencenumber\":163,\"key\":\"figure(s)\",\"tenantterm\":\"figure(s)\",\"frontiersdefaultterm\":\"figure(s)\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":164,\"key\":\"co-authors\",\"tenantterm\":\"co-authors\",\"frontiersdefaultterm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"label (role)\"},{\"sequencenumber\":165,\"key\":\"editorial_board_members\",\"tenantterm\":\"editorial board members\",\"frontiersdefaultterm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"label (role)\"},{\"sequencenumber\":166,\"key\":\"editorial_board\",\"tenantterm\":\"editorial board\",\"frontiersdefaultterm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"product\"},{\"sequencenumber\":167,\"key\":\"co-authorship\",\"tenantterm\":\"co-authorship\",\"frontiersdefaultterm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"misc.\"},{\"sequencenumber\":168,\"key\":\"role_id_1\",\"tenantterm\":\"registration office\",\"frontiersdefaultterm\":\"registration office\",\"category\":\"user role\"},{\"sequencenumber\":169,\"key\":\"role_id_2\",\"tenantterm\":\"editorial office\",\"frontiersdefaultterm\":\"editorial office\",\"category\":\"user role\"},{\"sequencenumber\":170,\"key\":\"role_id_7\",\"tenantterm\":\"field chief editor\",\"frontiersdefaultterm\":\"field chief editor\",\"category\":\"user role\"},{\"sequencenumber\":171,\"key\":\"role_id_8\",\"tenantterm\":\"assistant field chief editor\",\"frontiersdefaultterm\":\"assistant field chief editor\",\"category\":\"user role\"},{\"sequencenumber\":172,\"key\":\"role_id_9\",\"tenantterm\":\"specialty chief editor\",\"frontiersdefaultterm\":\"specialty chief editor\",\"category\":\"user role\"},{\"sequencenumber\":173,\"key\":\"role_id_10\",\"tenantterm\":\"assistant specialty chief editor\",\"frontiersdefaultterm\":\"assistant specialty chief editor\",\"category\":\"user role\"},{\"sequencenumber\":174,\"key\":\"role_id_11\",\"tenantterm\":\"associate editor\",\"frontiersdefaultterm\":\"associate editor\",\"category\":\"user role\"},{\"sequencenumber\":175,\"key\":\"role_id_12\",\"tenantterm\":\"guest associate editor\",\"frontiersdefaultterm\":\"guest associate editor\",\"category\":\"user role\"},{\"sequencenumber\":176,\"key\":\"role_id_13\",\"tenantterm\":\"review editor\",\"frontiersdefaultterm\":\"review editor\",\"category\":\"user role\"},{\"sequencenumber\":177,\"key\":\"role_id_14\",\"tenantterm\":\"reviewer\",\"frontiersdefaultterm\":\"reviewer\",\"category\":\"user role\"},{\"sequencenumber\":178,\"key\":\"role_id_15\",\"tenantterm\":\"author\",\"frontiersdefaultterm\":\"author\",\"category\":\"user role\"},{\"sequencenumber\":179,\"key\":\"role_id_16\",\"tenantterm\":\"corresponding author\",\"frontiersdefaultterm\":\"corresponding author\",\"category\":\"user role\"},{\"sequencenumber\":180,\"key\":\"role_id_17\",\"tenantterm\":\"submitting author\",\"frontiersdefaultterm\":\"submitting author\",\"category\":\"user role\"},{\"sequencenumber\":181,\"key\":\"role_id_18\",\"tenantterm\":\"co-author\",\"frontiersdefaultterm\":\"co-author\",\"category\":\"user role\"},{\"sequencenumber\":182,\"key\":\"role_id_20\",\"tenantterm\":\"production office\",\"frontiersdefaultterm\":\"production office\",\"category\":\"user role\"},{\"sequencenumber\":183,\"key\":\"role_id_22\",\"tenantterm\":\"typesetting office (typesetter)\",\"frontiersdefaultterm\":\"typesetting office (typesetter)\",\"category\":\"user role\"},{\"sequencenumber\":184,\"key\":\"role_id_24\",\"tenantterm\":\"registered user\",\"frontiersdefaultterm\":\"registered user\",\"category\":\"user role\"},{\"sequencenumber\":185,\"key\":\"role_id_35\",\"tenantterm\":\"job office\",\"frontiersdefaultterm\":\"job office\",\"category\":\"user role\"},{\"sequencenumber\":186,\"key\":\"role_id_41\",\"tenantterm\":\"special event administrator\",\"frontiersdefaultterm\":\"special event administrator\",\"category\":\"user role\"},{\"sequencenumber\":187,\"key\":\"role_id_42\",\"tenantterm\":\"special event reviewer\",\"frontiersdefaultterm\":\"special event reviewer\",\"category\":\"user role\"},{\"sequencenumber\":188,\"key\":\"role_id_43\",\"tenantterm\":\"submit abstract\",\"frontiersdefaultterm\":\"submit abstract\",\"category\":\"user role\"},{\"sequencenumber\":189,\"key\":\"role_id_52\",\"tenantterm\":\"events office\",\"frontiersdefaultterm\":\"events office\",\"category\":\"user role\"},{\"sequencenumber\":190,\"key\":\"role_id_53\",\"tenantterm\":\"event administrator\",\"frontiersdefaultterm\":\"event administrator\",\"category\":\"user role\"},{\"sequencenumber\":191,\"key\":\"role_id_89\",\"tenantterm\":\"content management office\",\"frontiersdefaultterm\":\"content management office\",\"category\":\"user role\"},{\"sequencenumber\":192,\"key\":\"role_id_98\",\"tenantterm\":\"accounting office\",\"frontiersdefaultterm\":\"accounting office\",\"category\":\"user role\"},{\"sequencenumber\":193,\"key\":\"role_id_99\",\"tenantterm\":\"projects\",\"frontiersdefaultterm\":\"projects\",\"category\":\"user role\"},{\"sequencenumber\":194,\"key\":\"role_id_103\",\"tenantterm\":\"configuration office\",\"frontiersdefaultterm\":\"configuration office\",\"category\":\"user role\"},{\"sequencenumber\":195,\"key\":\"role_id_104\",\"tenantterm\":\"beta user\",\"frontiersdefaultterm\":\"beta user\",\"category\":\"user role\"},{\"sequencenumber\":196,\"key\":\"role_id_106\",\"tenantterm\":\"wfconf\",\"frontiersdefaultterm\":\"wfconf\",\"category\":\"user role\"},{\"sequencenumber\":197,\"key\":\"role_id_107\",\"tenantterm\":\"rt management beta user\",\"frontiersdefaultterm\":\"rt management beta user\",\"category\":\"user role\"},{\"sequencenumber\":198,\"key\":\"role_id_108\",\"tenantterm\":\"deo beta user\",\"frontiersdefaultterm\":\"deo beta user\",\"category\":\"user role\"},{\"sequencenumber\":199,\"key\":\"role_id_109\",\"tenantterm\":\"search beta user\",\"frontiersdefaultterm\":\"search beta user\",\"category\":\"user role\"},{\"sequencenumber\":200,\"key\":\"role_id_110\",\"tenantterm\":\"journal manager\",\"frontiersdefaultterm\":\"journal manager\",\"category\":\"user role\"},{\"sequencenumber\":201,\"key\":\"role_id_111\",\"tenantterm\":\"myfrontiers beta user\",\"frontiersdefaultterm\":\"myfrontiers beta user\",\"category\":\"user role\"},{\"sequencenumber\":202,\"key\":\"role_id_21\",\"tenantterm\":\"copy editor\",\"frontiersdefaultterm\":\"copy editor\",\"category\":\"user role\"},{\"sequencenumber\":203,\"key\":\"role_id_1_abr\",\"tenantterm\":\"rof\",\"frontiersdefaultterm\":\"rof\",\"category\":\"user role\"},{\"sequencenumber\":204,\"key\":\"role_id_2_abr\",\"tenantterm\":\"eof\",\"frontiersdefaultterm\":\"eof\",\"category\":\"user role\"},{\"sequencenumber\":205,\"key\":\"role_id_7_abr\",\"tenantterm\":\"fce\",\"frontiersdefaultterm\":\"fce\",\"category\":\"user role\"},{\"sequencenumber\":206,\"key\":\"role_id_8_abr\",\"tenantterm\":\"afce\",\"frontiersdefaultterm\":\"afce\",\"category\":\"user role\"},{\"sequencenumber\":207,\"key\":\"role_id_9_abr\",\"tenantterm\":\"sce\",\"frontiersdefaultterm\":\"sce\",\"category\":\"user role\"},{\"sequencenumber\":208,\"key\":\"role_id_10_abr\",\"tenantterm\":\"asce\",\"frontiersdefaultterm\":\"asce\",\"category\":\"user role\"},{\"sequencenumber\":209,\"key\":\"role_id_11_abr\",\"tenantterm\":\"ae\",\"frontiersdefaultterm\":\"ae\",\"category\":\"user role\"},{\"sequencenumber\":210,\"key\":\"role_id_12_abr\",\"tenantterm\":\"gae\",\"frontiersdefaultterm\":\"gae\",\"category\":\"user role\"},{\"sequencenumber\":211,\"key\":\"role_id_13_abr\",\"tenantterm\":\"re\",\"frontiersdefaultterm\":\"re\",\"category\":\"user role\"},{\"sequencenumber\":212,\"key\":\"role_id_14_abr\",\"tenantterm\":\"rev\",\"frontiersdefaultterm\":\"rev\",\"category\":\"user role\"},{\"sequencenumber\":213,\"key\":\"role_id_15_abr\",\"tenantterm\":\"aut\",\"frontiersdefaultterm\":\"aut\",\"category\":\"user role\"},{\"sequencenumber\":214,\"key\":\"role_id_16_abr\",\"tenantterm\":\"coraut\",\"frontiersdefaultterm\":\"coraut\",\"category\":\"user role\"},{\"sequencenumber\":215,\"key\":\"role_id_17_abr\",\"tenantterm\":\"saut\",\"frontiersdefaultterm\":\"saut\",\"category\":\"user role\"},{\"sequencenumber\":216,\"key\":\"role_id_18_abr\",\"tenantterm\":\"coaut\",\"frontiersdefaultterm\":\"coaut\",\"category\":\"user role\"},{\"sequencenumber\":217,\"key\":\"role_id_20_abr\",\"tenantterm\":\"pof\",\"frontiersdefaultterm\":\"pof\",\"category\":\"user role\"},{\"sequencenumber\":218,\"key\":\"role_id_22_abr\",\"tenantterm\":\"tsof\",\"frontiersdefaultterm\":\"tsof\",\"category\":\"user role\"},{\"sequencenumber\":219,\"key\":\"role_id_24_abr\",\"tenantterm\":\"ru\",\"frontiersdefaultterm\":\"ru\",\"category\":\"user role\"},{\"sequencenumber\":220,\"key\":\"role_id_35_abr\",\"tenantterm\":\"jof\",\"frontiersdefaultterm\":\"jof\",\"category\":\"user role\"},{\"sequencenumber\":221,\"key\":\"role_id_41_abr\",\"tenantterm\":\"se-adm\",\"frontiersdefaultterm\":\"se-adm\",\"category\":\"user role\"},{\"sequencenumber\":222,\"key\":\"role_id_42_abr\",\"tenantterm\":\"se-rev\",\"frontiersdefaultterm\":\"se-rev\",\"category\":\"user role\"},{\"sequencenumber\":223,\"key\":\"role_id_43_abr\",\"tenantterm\":\"se-aut\",\"frontiersdefaultterm\":\"se-aut\",\"category\":\"user role\"},{\"sequencenumber\":224,\"key\":\"role_id_52_abr\",\"tenantterm\":\"evof\",\"frontiersdefaultterm\":\"evof\",\"category\":\"user role\"},{\"sequencenumber\":225,\"key\":\"role_id_53_abr\",\"tenantterm\":\"ev-adm\",\"frontiersdefaultterm\":\"ev-adm\",\"category\":\"user role\"},{\"sequencenumber\":226,\"key\":\"role_id_89_abr\",\"tenantterm\":\"comof\",\"frontiersdefaultterm\":\"comof\",\"category\":\"user role\"},{\"sequencenumber\":227,\"key\":\"role_id_98_abr\",\"tenantterm\":\"aof\",\"frontiersdefaultterm\":\"aof\",\"category\":\"user role\"},{\"sequencenumber\":228,\"key\":\"role_id_99_abr\",\"tenantterm\":\"projects\",\"frontiersdefaultterm\":\"projects\",\"category\":\"user role\"},{\"sequencenumber\":229,\"key\":\"role_id_103_abr\",\"tenantterm\":\"config\",\"frontiersdefaultterm\":\"config\",\"category\":\"user role\"},{\"sequencenumber\":230,\"key\":\"role_id_104_abr\",\"tenantterm\":\"beta\",\"frontiersdefaultterm\":\"beta\",\"category\":\"user role\"},{\"sequencenumber\":231,\"key\":\"role_id_106_abr\",\"tenantterm\":\"wfconf\",\"frontiersdefaultterm\":\"wfconf\",\"category\":\"user role\"},{\"sequencenumber\":232,\"key\":\"role_id_107_abr\",\"tenantterm\":\"rtbeta\",\"frontiersdefaultterm\":\"rtbeta\",\"category\":\"user role\"},{\"sequencenumber\":233,\"key\":\"role_id_108_abr\",\"tenantterm\":\"deobeta\",\"frontiersdefaultterm\":\"deobeta\",\"category\":\"user role\"},{\"sequencenumber\":234,\"key\":\"role_id_109_abr\",\"tenantterm\":\"searchbeta\",\"frontiersdefaultterm\":\"searchbeta\",\"category\":\"user role\"},{\"sequencenumber\":235,\"key\":\"role_id_110_abr\",\"tenantterm\":\"jm\",\"frontiersdefaultterm\":\"jm\",\"category\":\"user role\"},{\"sequencenumber\":236,\"key\":\"role_id_111_abr\",\"tenantterm\":\"mfbeta\",\"frontiersdefaultterm\":\"mfbeta\",\"category\":\"user role\"},{\"sequencenumber\":237,\"key\":\"role_id_21_abr\",\"tenantterm\":\"coped\",\"frontiersdefaultterm\":\"coped\",\"category\":\"user role\"},{\"sequencenumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantterm\":\"editorial board\",\"frontiersdefaultterm\":\"editorial board\",\"description\":\"this is the label for the review editorial board\",\"category\":\"label\"},{\"sequencenumber\":239,\"key\":\"field_chief_editor\",\"tenantterm\":\"field chief editor\",\"frontiersdefaultterm\":\"field chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":240,\"key\":\"field_chief_editors\",\"tenantterm\":\"field chief editors\",\"frontiersdefaultterm\":\"field chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":241,\"key\":\"editor\",\"tenantterm\":\"editor\",\"frontiersdefaultterm\":\"editor\",\"category\":\"label (role)\"},{\"sequencenumber\":242,\"key\":\"editors\",\"tenantterm\":\"editors\",\"frontiersdefaultterm\":\"editors\",\"category\":\"label (role)\"},{\"sequencenumber\":243,\"key\":\"board\",\"tenantterm\":\"board\",\"frontiersdefaultterm\":\"board\",\"category\":\"label\"},{\"sequencenumber\":244,\"key\":\"boards\",\"tenantterm\":\"boards\",\"frontiersdefaultterm\":\"boards\",\"category\":\"label\"},{\"sequencenumber\":245,\"key\":\"article_collection\",\"tenantterm\":\"article collection\",\"frontiersdefaultterm\":\"article collection\",\"category\":\"label\"},{\"sequencenumber\":246,\"key\":\"article_collections\",\"tenantterm\":\"article collections\",\"frontiersdefaultterm\":\"article collections\",\"category\":\"label\"},{\"sequencenumber\":247,\"key\":\"handling_editor\",\"tenantterm\":\"handling editor\",\"frontiersdefaultterm\":\"associate editor\",\"description\":\"this terminology key is for the person assigned to edit a manuscript. it is a label for the temporary handling editor assignment.\",\"category\":\"label (role)\"},{\"sequencenumber\":248,\"key\":\"handling_editors\",\"tenantterm\":\"handling editors\",\"frontiersdefaultterm\":\"associate editors\",\"description\":\"this terminology key is for the person assigned to edit a manuscript. it is a label for the temporary handling editor assignment.\",\"category\":\"label (role)\"},{\"sequencenumber\":249,\"key\":\"ae_accept\",\"tenantterm\":\"recommend acceptance\",\"frontiersdefaultterm\":\"accept\",\"category\":\"process\"},{\"sequencenumber\":250,\"key\":\"rtm\",\"tenantterm\":\"rtm\",\"frontiersdefaultterm\":\"rtm\",\"category\":\"product\"},{\"sequencenumber\":251,\"key\":\"frontiers_media_sa\",\"tenantterm\":\"frontiers media s.a\",\"frontiersdefaultterm\":\"frontiers media s.a\",\"category\":\"customer\"},{\"sequencenumber\":252,\"key\":\"review_editors\",\"tenantterm\":\"community reviewers\",\"frontiersdefaultterm\":\"review editors\",\"category\":\"label (role)\"},{\"sequencenumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantterm\":\"chief editor\",\"frontiersdefaultterm\":\"chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantterm\":\"chief editors\",\"frontiersdefaultterm\":\"chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":255,\"key\":\"call_for_papers\",\"tenantterm\":\"call for papers\",\"frontiersdefaultterm\":\"call for papers\",\"category\":\"label\"},{\"sequencenumber\":256,\"key\":\"calls_for_papers\",\"tenantterm\":\"calls for papers\",\"frontiersdefaultterm\":\"calls for papers\",\"category\":\"label\"},{\"sequencenumber\":257,\"key\":\"supervising_editor\",\"tenantterm\":\"supervising editor\",\"frontiersdefaultterm\":\"supervising editor\",\"description\":\"a chief or assistant chief editor who is assigned to a manuscript to supervise.\",\"category\":\"role\",\"externalkey\":\"supervising_editor\"},{\"sequencenumber\":258,\"key\":\"supervising_editors\",\"tenantterm\":\"supervising editors\",\"frontiersdefaultterm\":\"supervising editors\",\"description\":\"a chief or assistant chief editor who is assigned to a manuscript to supervise.\",\"category\":\"role\",\"externalkey\":\"supervising_editors\"},{\"sequencenumber\":259,\"key\":\"reviewer_endorse\",\"tenantterm\":\"endorse\",\"frontiersdefaultterm\":\"endorse\",\"category\":\"label\"},{\"sequencenumber\":260,\"key\":\"reviewer_endorsed\",\"tenantterm\":\"endorsed\",\"frontiersdefaultterm\":\"endorsed\",\"category\":\"label\"},{\"sequencenumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantterm\":\"endorse publication\",\"frontiersdefaultterm\":\"endorse publication\",\"category\":\"label\"},{\"sequencenumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantterm\":\"endorsed publication\",\"frontiersdefaultterm\":\"endorsed publication\",\"category\":\"label\"},{\"sequencenumber\":263,\"key\":\"editor_role\",\"tenantterm\":\"editor role\",\"frontiersdefaultterm\":\"editor role\",\"category\":\"label\"},{\"sequencenumber\":264,\"key\":\"editor_roles\",\"tenantterm\":\"editor roles\",\"frontiersdefaultterm\":\"editor roles\",\"category\":\"label\"},{\"sequencenumber\":265,\"key\":\"editorial_role\",\"tenantterm\":\"editorial role\",\"frontiersdefaultterm\":\"editorial role\",\"category\":\"label\"},{\"sequencenumber\":266,\"key\":\"editorial_roles\",\"tenantterm\":\"editorial roles\",\"frontiersdefaultterm\":\"editorial roles\",\"category\":\"label\"},{\"sequencenumber\":267,\"key\":\"call_for_paper\",\"tenantterm\":\"call for paper\",\"frontiersdefaultterm\":\"call for paper\",\"category\":\"label\"},{\"sequencenumber\":268,\"key\":\"research_topic_abstract\",\"tenantterm\":\"manuscript summary\",\"frontiersdefaultterm\":\"manuscript summary\",\"category\":\"process\"},{\"sequencenumber\":269,\"key\":\"research_topic_abstracts\",\"tenantterm\":\"manuscript summaries\",\"frontiersdefaultterm\":\"manuscript summaries\",\"category\":\"process\"},{\"sequencenumber\":270,\"key\":\"submissions_team_manager\",\"tenantterm\":\"journal manager\",\"frontiersdefaultterm\":\"content manager\",\"category\":\"process\"},{\"sequencenumber\":271,\"key\":\"submissions_team\",\"tenantterm\":\"journal team\",\"frontiersdefaultterm\":\"content team\",\"category\":\"process\"},{\"sequencenumber\":272,\"key\":\"topic_coordinator\",\"tenantterm\":\"topic coordinator\",\"frontiersdefaultterm\":\"topic coordinator\",\"category\":\"process\"},{\"sequencenumber\":273,\"key\":\"topic_coordinators\",\"tenantterm\":\"topic coordinators\",\"frontiersdefaultterm\":\"topic coordinators\",\"category\":\"process\"},{\"sequencenumber\":274,\"key\":\"frontiers_journal_team\",\"tenantterm\":\"frontiers journal team\",\"frontiersdefaultterm\":\"frontiers journal team\",\"category\":\"label (role)\"},{\"sequencenumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantterm\":\"rt:ic submission\",\"frontiersdefaultterm\":\"rt:ic submission\",\"category\":\"label (role)\"},{\"sequencenumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantterm\":\"rt:ic submission participant\",\"frontiersdefaultterm\":\"rt:ic submission participant\",\"category\":\"label (role)\"}]}'\n",impactgtmid:"gtm-njf2ml9b",impactgtmauth:"fyo-7nodm9w37qgfms03sa",impactgtmpreview:"env-1",impactgooglemapsapikey:"aizasyctehx2eu8pwfi86gw9fi00ftcykk6ifr8",qualtricsv4tov3:"'{\"enabled\":true,\"interceptid\":\"si_er0e2ze69oz8yn4\",\"projectid\":\"zn_cloy77jhkpc8gai\",\"brandid\":\"frontiersin\"}'\n",qualtricsumux:"'{\"enabled\":false,\"interceptid\":\"si_89fphy3etxqbwtu\",\"projectid\":\"zn_cloy77jhkpc8gai\",\"brandid\":\"frontiersin\"}'\n",qualtricscontinuousbrand:"'{\"enabled\":true,\"interceptid\":\"si_9zut94ut81fcrh4\",\"projectid\":\"zn_cloy77jhkpc8gai\",\"brandid\":\"frontiersin\"}'\n",defaultarticletemplate:"v3"},app:{baseurl:"/",buildid:"f2d5b6d8-d01c-4534-90b9-d659f10f17ca",buildassetsdir:"ap-2024/_nuxt",cdnurl:""}}## Methods
alogabat was assessed for binding and functional activity at gaba a -&#x003b1;5&#x003b2;3&#x003b3;2 receptors in vitro and in electrophysiological studies using hippocampal slices. in vivo studies in rodents included receptor occupancy (ro) using a selective gaba a -&#x003b1;5 tracer (autoradiography), pharmacological mri, and electroencephalography (eeg). alogabat was evaluated for its effects on the repetitive behavior phenotype in btbr and contactin-associated protein-like 2 (cntnap2 &#x02212;/&#x02212; ) knockout mice, seizure models, cognitive performance in rats, and rotarod performance following combination treatment with diazepam. results: alogabat is a potent positive allosteric modulator of gaba a -&#x003b1;5 receptors, with binding and functional selectivity. receptor occupancy studies provided direct proof of dose-dependent target engagement. functional circuit modulation was demonstrated by dose-dependent regional perfusion changes in pharmacological mri and changes in eeg theta- and beta-band power in rats. at &#x0003e;50% gaba a -&#x003b1;5 receptor occupancy, alogabat normalized elevated self-grooming behavior in both cntnap2 &#x02212;/&#x02212; and btbr mice and exhibited antiepileptic activity in rats. alogabat did not impair cognition in wildtype rats at gaba a -&#x003b1;5 receptor occupancy up to 75%, although impairment occurred at higher doses, probably due to increased activity at other receptor subtypes and/or saturation of &#x003b1;5 receptors. alogabat did not worsen diazepam-induced impairment on the rotarod test. conclusion: alogabat showed beneficial effects in mouse models relevant to neurodevelopmental disorders and anti-seizure activity at doses that did not produce cognitive, sedative, or motoric side effects. 1 introduction alterations in the gabaergic system, the main inhibitory neurotransmitter system in the brain, may contribute to the pathophysiology of neurodevelopmental disorders (ndds), such as autism spectrum disorder (asd) and angelman syndrome (as). asd is a complex, heterogeneous ndd with both genetic and environmental factors ( bourgeron, 2015 ) contributing to aberrant changes in brain growth, neuronal development, and functional connectivity ( dhossche et al., 2002 ; pizzarelli and cherubini, 2011 ; braat and kooy, 2015 ; robertson et al., 2016 ). asd is characterized by two core domains: impairments in social interaction and communication and the presence of repetitive or restricted behaviors, interests, or activities ( american psychiatric association, 2008 ). there are a range of comorbid conditions, including irritability, depression, anxiety, attention deficits, obsessive-compulsive symptoms, seizures, and sleep disruption. as is a rare genetic ndd with a prevalence of 1 in 12,000 to 20,000 births ( luk and lo, 2016 ; mertz et al., 2013 ). individuals with as often present with autistic features, severe intellectual disability, microcephaly, speech impairment, bursts of laughter, sleep problems, movement disorders, and epilepsy ( buiting, 2010 ; kalsner and chamberlain, 2015 ). gaba a receptors are ligand-gated chloride channels. there are 19 genes encoding gaba a receptor subunits that assemble as pentamers, with the most common stoichiometry being two &#x003b1;, two &#x003b2;, and one &#x003b3; subunit. gaba a subunit combinations give rise to functional, circuit, and behavioral specificity ( sieghart, 2006 ; vithlani et al., 2011 ). gaba a receptors that contain the &#x003b1;5 subunit (gaba a -&#x003b1;5) are of particular interest due to their restricted pattern of expression and unique physiological and pharmacological properties ( sur et al., 1999 ; mohler, 2011 ). in humans, gaba a receptors containing the &#x003b1;5 subunit are preferentially localized in the hippocampus, prefrontal cortex, nucleus accumbens, amygdala, insular cortex, anterior cingulate, and cingulate cortex&#x02014;key regions believed to be involved in the neuropathology and pathophysiology of asd ( mendez et al., 2013 ; myers et al., 2017 ). the gabra5 gene has been proposed as a candidate gene for asd ( delong, 2007 ; mesbah-oskui et al., 2017 ; warrier et al., 2013 ; di nanni et al., 2019 ), suggesting decreased gabaergic inhibition in a subpopulation of autistic individuals. mutations involving the gaba a receptor subunit genes gabra5 , gabrb3 , and gabrg3 (encoding the &#x003b1;5, &#x003b2;3, and &#x003b3;3 subunits) found on chromosomal region 15q11&#x02013;q13 have been associated with ndds including as, epilepsy, and prader&#x02013;willi syndrome in addition to asd ( hogart et al., 2010 ; sanders, 2015 ). as is predominantly caused by the loss of function of the maternally inherited ube3a gene; however, approximately 75% of individuals with as carry a large deletion of the maternal 15q11&#x02013;q13 chromosomal region. clinical studies have shown that individuals with as who have large deletions (deletion as) exhibit more severe symptoms than those in whom ube3a is the only gene affected, suggesting that the gabra5 , gabrb3 , and gabrg3 genes are relevant to the etiology of the disease. imaging studies using pet and magnetic resonance spectroscopy have shown reduced gaba a receptor binding in the superior and medial frontal cortex ( mori et al., 2012 ) and reduced gaba levels in individuals with asd ( robertson et al., 2016 ; gaetz et al., 2014 ; rojas et al., 2014 ; puts et al., 2017 ). postmortem studies have shown reduced numbers of inhibitory interneurons ( dufour et al., 2023 ), reduced expression of gaba a receptor subunits ( delorey, 2005 ; abrahams and geschwind, 2008 ), and reduced levels of the gaba-synthesizing enzymes such as glutamic acid decarboxylase (gad) 65 and 67 ( fatemi et al., 2002 ). there is increasing evidence from genetic, environmental, and phenotypic rodent models relevant to asd indicating that gabaergic circuit dysfunctions contribute to autism-like phenotypes ( fukuda et al., 2005 ; chao et al., 2010 ; banerjee et al., 2013 ). such deficits may result from multiple causes, including a reduced number of gabaergic interneurons, altered interneuron function, impaired gaba a receptor trafficking to the membrane, reduced expression of gaba a receptor subunits, and reduced gaba uptake function of gat-1 in neurons ( nakamura et al., 2016 ; orefice et al., 2016 ; mermer et al., 2021 ). supportive evidence is provided by the observation of autism-like behaviors in both gaba a -&#x003b1;5 and &#x003b2;3 subunit knockout mice ( zurek et al., 2016 ; delorey et al., 2008 ). regarding possible therapeutic approaches, enhancement of the gaba a receptor activity by non-selective benzodiazepines has been shown to ameliorate autism-like behavioral deficits in mouse models; however, due to sedation that is likely mediated by the activation of the gaba a -&#x003b1;1 subtype, very narrow therapeutic margins were observed ( han et al., 2012 ; han et al., 2014 ; lim et al., 2017 ). interestingly, a recent study showed that a gaba a -&#x003b1;5 positive allosteric modulator (pam), sh-053-2&#x02032;f-r-ch3, attenuated social and cognitive deficits in male rats exposed to valproic acid in utero , a rat model relevant to autism ( souza et al., 2024 ). the aim of the current study was to determine whether a selective gaba a -&#x003b1;5 pam, alogabat (also known as ro7017773 or rg7816), would produce beneficial effects in animal models relevant to autism-like repetitive behavior&#x02014;specifically btbr mice ( mcfarlane et al., 2008 ) and contactin-associated protein-like 2 [cntnap2 &#x02212;/&#x02212; ] homozygous knockout mice ( penagarikano et al., 2011 )&#x02014;and anti-seizure activity, without the typical side effects of non-selective gaba a pams, such as sedation and cognitive impairment. furthermore, target engagement was assessed by in vivo receptor occupancy (ro) and pharmacological mri (phmri) in rodents, and an electroencephalography (eeg) study in rats was undertaken to identify a putative pharmacodynamic readout for future clinical trials. 2 materials and methods further information for each method listed below can be found in the supplementary material . 2.1 materials alogabat [ro7017773; c 21 h 23 n 5 o 4 ; 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl) methoxy)-n-(tetrahydropyran-4-yl)pyridazine-3-carboxamide (iupac name); molecular weight: 409.44&#x000a0;gmol &#x02212;1 ] was synthesized at f.hoffmann-la roche ag, switzerland [ figure 1a ; see example 8 in buettelmann et al., 2018 ]. the discovery of alogabat and the related chemical series will be disclosed in future publications. diazepam, l-655,708, [ 3 h]flumazenil, [ 3 h]l-655,708, and [ 3 h]ro0154513 were synthesized at f.hoffmann-la roche ag, switzerland. figure 1 figure 1 . in vitro pharmacology of alogabat. (a) chemical structure of alogabat (ro7017773; c21h23n5o4); 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl) methoxy)-n-(tetrahydropyran-4-yl)pyridazine-3-carboxamide (iupac name); molecular weight, 409.44&#x000a0;gmol &#x02212;1 . (b) concentration-response curves of alogabat in [ 3 h]flumazenil competition-binding assays with membranes expressing different rat recombinant gaba a receptor subtypes ( n &#x0003d; 10&#x02013;20/concentration). (c) concentration-response curves of the effects of alogabat in hek293 cells expressing different rat recombinant gaba a receptor subtypes ( n &#x0003d; 4&#x02013;5/concentration). data in the graphs are shown as the mean (symbols) &#x000b1; sem (error bars). error bars smaller than the symbol size are not shown. (d) isoguvacine concentration-response curves obtained in the presence and absence of alogabat in rat hippocampal slices. the points represent the mean values &#x000b1; sem of three slices. the sigmoidal curves were fit through these points. (e) the ppi of ps was measured in the absence (control) and presence of alogabat at 0.3&#x000a0;&#x000b5;m ( n &#x0003d; 3 slices) and 1&#x000a0;&#x000b5;m ( n &#x0003d; 6 slices). ps1 and ps2 are the responses induced by the first and second stimulus, respectively. the data are normalized to the amplitude of ps1 and presented as the mean &#x000b1; sem. 2.2 in vitro experiments 2.2.1 gaba a receptor radioligand binding assays the affinity of alogabat for rat and human gaba a receptors containing &#x003b1;5, &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits was measured by [ 3 h]flumazenil competition-binding assays with membranes expressing different rat recombinant gaba a receptor subtypes ( n &#x0003d; 10&#x02013;20/concentration) and for human &#x003b1;4 and &#x003b1;6 by [ 3 h]ro0154513, as previously described ( ballard et al., 2009 ; hipp et al., 2021 ). 2.2.2 gaba a receptor electrophysiological studies alogabat was tested for functional activity on four different cloned rat and human gaba a receptor subtypes ( buettelmann et al., 2018 ), namely, &#x003b1;1&#x003b2;2&#x003b3;2, &#x003b1;2&#x003b2;3&#x003b3;2, &#x003b1;3&#x003b2;3&#x003b3;2, and &#x003b1;5&#x003b2;3&#x003b3;2. ion currents were induced by gaba concentrations that evoked approximately 20% of the maximal response ( n &#x0003d; 4&#x02013;5/concentration). the following concentrations of gaba were used: 1&#x000a0;&#x000b5;m for &#x003b1;1&#x003b2;2&#x003b3;2, 10&#x000a0;&#x000b5;m &#x003b1;2&#x003b2;3&#x003b3;2, 10&#x000a0;&#x000b5;m for &#x003b1;3&#x003b2;3&#x003b3;2, and 3&#x000a0;&#x000b5;m for &#x003b1;5&#x003b2;3&#x003b3;2 receptor subtype. alogabat was also tested for functional activity on native gaba a -&#x003b1;5 receptors in rat hippocampal slices: modulation of isoguvacine-induced population spikes ( ballard et al., 2009 ) and paired-pulse inhibition (ppi) ( xie and tietz, 1991 ). population spikes (pss) were recorded every 30&#x000a0;s by the stimulation of the schaffer collaterals, and isoguvacine was applied consecutively and in increasing concentrations for at least 4&#x000a0;min to the slices (control). after the washout of isoguvacine, alogabat (300&#x000a0;nm) was added to the bath perfusion, and a new isoguvacine concentration-response curve was obtained (alogabat). the ps amplitudes were normalized to the control ps obtained before the first application of isoguvacine and were fitted individually for each slice ( n &#x0003d; 3 slices). the ppi of ps was measured in the absence (control) and presence of alogabat at 0.3&#x000a0;&#x000b5;m ( n &#x0003d; 3 slices from one animal) and 1&#x000a0;&#x000b5;m ( n &#x0003d; 6 slices from two animals). the paired-pulse protocol consisted of two stimuli timely spaced by 20&#x000a0;ms, which were applied at the schaffer collaterals in rat hippocampal slices. we used a low number of animals based on our experience with the assay, which is highly robust and reproducible, and in alignment with our commitment to reducing the number of animals used. 2.2.3 selectivity screening the selectivity of alogabat (10&#x000a0;&#x000b5;m) over more than 70 receptors was assessed by radioligand binding studies conducted using eurofins cerep sa (celle l&#x000e9;vescault, france), following the methods described on www.eurofinsdiscoveryservices.com . 2.3 in vivo experiments 2.3.1 ethics approval experiments performed at f.hoffmann-la roche ag (basel, switzerland) complied with the swiss federal and cantonal laws on animal research and aaalac regulations and received prior approval from the cantonal veterinary office. the eeg study was conducted at brains online (ca, united states) in accordance with the guide for the care and use of laboratory animals (national research council 2011) after gaining approval from the institutional animal care and use committee. the pentylenetetrazole (ptz) and maximal electroshock (mes) tests were conducted at vivocore inc., canada, which is a facility licensed by the ontario ministry of agriculture, food, and rural affairs and accredited by the canadian council on animal care. all in vivo studies are reported in compliance with the arrive guidelines ( percie du sert et al., 2020 ). 2.3.2 animals all animals were group-housed in holding rooms at controlled temperature and humidity under a 12&#x000a0;h light/dark cycle and were allowed to acclimate for at least 7&#x000a0;days. twenty-six male wistar rats (charles river, germany; &#x0223c;160&#x000a0;g) and sixteen male cntnap2 &#x02212;/&#x02212; mice (bred at roche basel; 18&#x02013;22&#x000a0;g) were used in receptor occupancy studies. thirty-two male fischer rats (charles river, germany) were assessed in mri experiments (&#x0223c;250&#x000a0;g). seventeen male wistar rats (envigo, united states) were assessed in eeg experiments. one hundred male btbr mice (bred in roche basel) were assessed in grooming and open-field tests (n &#x0003d; 60, &#x0223c;30&#x000a0;g) and for digging behavior (n &#x0003d; 40, &#x0223c;30&#x000a0;g). fifty-seven male cntnap2 &#x02212;/&#x02212; mice (bred in roche basel; 5&#x02013;6&#x000a0;weeks) and wildtype littermates (n &#x0003d; 15) were assessed in grooming and open-field tests. one hundred male sprague&#x02013;dawley rats (charles river, canada) were used to evaluate antiepileptic effects in the ptz (70&#x02013;100&#x000a0;g, n &#x0003d; 40) and mes (&#x0003c;50&#x000a0;g n &#x0003d; 60) tests. forty-eight male sprague&#x02013;dawley rats (charles river, france) were used in the rotarod test (&#x0223c;170&#x02013;200&#x000a0;g). one hundred and forty-one male lister hooded (lh) rats (charles river, germany) were used in the cognition tests: 5-choice serial reaction time (5-csrt) task (n &#x0003d; 11, &#x0223c;400&#x000a0;g); continuous performance test (cpt; n &#x0003d; 11, &#x0223c;400&#x000a0;g); paired associates learning (pal) task (n &#x0003d; 12, &#x0223c;400&#x000a0;g); context fear conditioning (n &#x0003d; 67, &#x0223c;250&#x000a0;g); and morris water maze (n &#x0003d; 40, 350&#x02013;400&#x000a0;g). 2.3.3 alogabat treatment alogabat was formulated in 2% hydroxypropyl cellulose in water (or 0.3% tween 80 in saline for in vivo occupancy and grooming/digging experiments). the administration volume was 10&#x000a0;ml/kg (mice) and 5&#x000a0;ml/kg (rats). each dose was expressed as the weight of the base. alogabat was administered with a pre-treatment time of 30&#x000a0;min in mice and 60&#x000a0;min in rats (except for the eeg study), based on pharmacokinetic data indicating the time of maximal drug plasma concentration. treatment groups were assigned randomly. dose groups were provided as coded vials to allow blinded assessment during the conduct of each experiment. to minimize potential confounders regarding the time of day for behavioral testing, animals were split into separate cohorts (balanced for treatment groups) and tested during the same period. 2.3.4 receptor occupancy studies 2.3.4.1 in vivo occupancy in rats male wistar rats (n &#x0003d; 26, &#x0223c;160&#x000a0;g) were administered vehicle or alogabat (0.3, 1, 3, 10, 30, and 100&#x000a0;mg/kg, intraperitoneally [i.p.], n &#x0003d; 3/group) or the gaba a -&#x003b1;5 blocker l-655,708 at 10&#x000a0;mg/kg i.p. (n &#x0003d; 2). fifteen minutes later, the gaba a -&#x003b1;5 radioligand [ 3 h]ro0154513 was administered intravenously (i.v.) to assess ro ( ballard et al., 2009 ; hipp et al., 2021 ). non-specific binding was determined by pre-treatment with the established gaba a -&#x003b1;5 receptor blocker l-655,708 (10&#x000a0;mg/kg i.p.; n &#x0003d; 2). 2.3.4.2 ex vivo occupancy in cntnap2 &#x02212;/&#x02212; mice cntnap2 &#x02212;/&#x02212; mice ( penagarikano et al., 2011 ) (n &#x0003d; 16, 18&#x02013;22&#x000a0;g) were administered the vehicle or alogabat (30, 60, and 100&#x000a0;mg/kg) i.p. (n &#x0003d; 4/group), and ro was assessed in brain sections with the highly selective gaba a -&#x003b1;5 radioligand, [ 3 h]l-655,708, 30&#x000a0;min post-administration. 2.3.5 pharmacological mri in rats male fischer rats (n &#x0003d; 32, &#x0223c;250&#x000a0;g) were administered vehicle or alogabat (3, 10, and 30&#x000a0;mg/kg) i.p. (n &#x0003d; 8/dose). phmri was performed under medetomidine sedation in a small-animal scanner (4.7t/40&#x000a0;cm; bruker biospin, germany), and blood perfusion was analyzed according to previously published procedures ( bruns et al., 2009 ). fifteen minutes after drug treatment, rats were initially anesthetized using isoflurane (4%) in the carrier gas composed of oxygen and air (1:5), supplied to the spontaneously breathing animals in an inhalation box. upon the induction of anesthesia, a subcutaneous (s.c.) bolus injection of 0.2&#x000a0;mg/kg (1&#x000a0;ml/kg) of medetomidine prepared from 1:5 diluted dormilan &#x000ae; was administered, and the animal was transferred onto a rat cradle for inserting an s.c. catheter and starting continuous infusion of 1:10 diluted dormilan &#x000ae; (medetomidine) at a dose of 0.1&#x000a0;mg/kg/h (1&#x000a0;ml/kg/h). the head was immobilized in a stereotaxic frame. respiratory rate, body temperature, and o 2 and co 2 levels in inhaled and exhaled air were continuously monitored using a powerlab data acquisition system (adinstruments, spechbach, germany). body temperature was maintained at 37&#x000b0;c with a feedback-regulated electric heating blanket. immediately after the last imaging assessment, rats were euthanized by decapitation under anesthesia, and plasma samples were collected at approximately 40&#x000a0;min post-administration of alogabat. images were processed and analyzed using in-house developed software written in idl (rsi, boulder, co, united states) and matlab (the mathworks inc., natick, ma, united states). 2.3.6 eeg in rats male wistar rats (n &#x0003d; 17) were surgically prepared with wireless implanted transmitters to enable simultaneous recording of eeg, hippocampal (ca3) local field potential (lfp), and emg. rats were anesthetized using isoflurane (2%, 800&#x000a0;ml/min o2). bupivacaine/epinephrine was used for local analgesia, while finadyne or carprofen was used for peri-/post-operative analgesia. amoxicillin was used as an antibiotic. the animals were placed in a stereotaxic frame (kopf instruments, united states). a subcutaneous pocket was created near the dorsal flank, into which a transmitter (f50-eee, data sciences international, physio tel f50-eee small animal cns telemetry; three bipolar channels, biopotential lead, outer diameter 0.3&#x000a0;mm) was inserted. the transmitter included three bipolar channels: channel 1 (eeg): two screws in the left hemisphere (frontal: 11&#x000a0;mm anterior and 2.5&#x000a0;mm lateral to bregma; central: 3&#x000a0;mm anterior and 3.5&#x000a0;mm lateral to lambda); channel 2 (lfp): a single wire electrode targeting the ca3 region of the right hippocampus; and channel 3 (emg): electrodes placed in the neck muscle for recording emg activity, aiding in sleep stage classification. after a 2-week recovery, rats were administered the vehicle or alogabat (10&#x000a0;mg/kg) using a cross-over design (1-week interval). if the setup allowed, the positive control diazepam (2&#x000a0;mg/kg) was assessed. all drugs were administered i.v. via an implanted cannula so that brain exposure was expected within a few minutes of administration. eeg spectral power was analyzed quantitatively up to 1&#x000a0;h post-administration. only animals with clean eeg recordings were included in the analysis. eeg data in the awake state were used for the analyses reported in this study. we first investigated the effects on power over predefined theta and beta power ranges, defined a priori as 6&#x02013;10&#x000a0;hz and 20&#x02013;30&#x000a0;hz, respectively, based on previous studies with gabaa drugs ( visser et al., 2003 ; van lier et al., 2004 ). then, we evaluated frequency-specific effects across the 2&#x02013;128&#x000a0;hz range. 2.3.7 grooming behavior and open-field test in btbr and cntnap2 &#x02212;/&#x02212; mice male btbr mice (n &#x0003d; 60, &#x0223c;30&#x000a0;g) were pre-treated with the vehicle or alogabat at 30, 60, 90, and 120&#x000a0;mg/kg i.p. (n &#x0003d; 12/dose). male cntnap2 &#x02212;/&#x02212; mice (n &#x0003d; 57, 5&#x02013;6&#x000a0;weeks) and wildtype littermates (n &#x0003d; 15) received sub-chronic treatment (8&#x02013;10&#x000a0;days) with the vehicle or alogabat at 30, 60, and 100&#x000a0;mg/kg i.p. (n &#x0003d; 14&#x02013;15/dose). spontaneous locomotor activity was assessed in both groups of mice for 1&#x000a0;h in an open field (42 &#x000d7; 42 &#x000d7; 30.5&#x000a0;cm; 20 lux at the center of the arena) with a small amount of sawdust bedding. movement of the animal was detected by interruptions in an array of photobeams from horizontally located infrared sources placed around the open field, measured using a versamax system (accuscan instruments inc., columbus, oh, united states). activity was measured as the distance traveled (cm). one week later, each mouse was placed into a type-ii cage (21.5 &#x000d7; 15.5 &#x000d7; 13.0&#x000a0;cm; 40 lux) for 5&#x000a0;min habituation, and then the cumulative time (s) spent grooming during 10&#x000a0;min was recorded manually by a blinded observer. distance traveled (cm) during the session was measured using a video tracking system (ethovision, noldus information technology, netherlands). plasma samples were collected from btbr mice 1&#x000a0;week after testing and 30&#x000a0;min after treatment ( n &#x0003d; 6/dose). plasma samples were collected from cntnap2 &#x02212;/&#x02212; mice 1&#x000a0;day later and 30&#x000a0;min after treatment ( n &#x0003d; 4/dose). 2.3.8 digging behavior in btbr mice a separate group of male btbr mice (n &#x0003d; 40, &#x0223c;30&#x000a0;g) were pre-treated with vehicle or alogabat at 30, 60, and 100&#x000a0;mg/kg i.p. (n &#x0003d; 10/dose) and were placed into a small circular dish (d &#x0003d; 10&#x000a0;cm) filled with fresh thick sawdust located in the middle of a clean type-ii cage (21.5 &#x000d7; 15.5 &#x000d7; 13.0&#x000a0;cm; 40 lux). the cumulative time (s) spent digging over 5&#x000a0;min was recorded manually by a blinded observer. the distance traveled (cm) and speed were also measured in the arena, outside the dish (ethovision, noldus information technology, netherlands). plasma samples were collected immediately after the digging test, i.e., 35&#x02013;40&#x000a0;min post-administration ( n &#x0003d; 3/dose). 2.3.9 evaluation of antiepileptic effects in rats vehicle or alogabat (5, 15, or 30&#x000a0;mg/kg) was administered p.o. (n &#x0003d; 8/dose) and assessed for seizures induced by (1) subcutaneous (s.c.) ptz and (2) the maximum electrical stimulus (mes) model in male sprague&#x02013;dawley rats (ptz: 70&#x02013;100&#x000a0;g, n &#x0003d; 40; mes: &#x0003c;50&#x000a0;g n &#x0003d; 60, charles river, canada). diazepam (synthesized at f.hoffmann-la roche ag) was included in each experiment as a positive control and administered at 3&#x000a0;mg/kg i.p., 30&#x000a0;min prior to testing. immediately following testing, a terminal blood sample was collected under anesthesia. 2.3.9.1 pentylenetetrazole test following the designated pre-treatment time, ptz was administered at 75&#x000a0;mg/kg s.c. animals were transferred to a single cage and monitored closely for the onset of clonic seizure, and the percentage of each group showing seizures was recorded. protection was defined as the complete absence of clonic seizure, including forelimb clonus, over the 30&#x000a0;min observation period. 2.3.9.2 maximal electroshock test following the designated pre-treatment time, rats received maximal electroshock (mes: 150&#x000a0;ma, 0.2&#x000a0;s duration, 60&#x000a0;hz) via corneal electrodes moistened with saline (shock simulator type 221; harvard apparatus). due to inconsistency in responses by rats to this type of stimuli, all test animals (n &#x0003d; 60) were subjected to two screening sessions on two separate days, and 40 rats were selected based on their reliability to have tonic seizures. drug testing was conducted on the third day, during which the rats received the standard maximal electroshock, and the presence or absence of a tonic seizure was recorded and expressed as the percentage of animals in each group that showed seizures. protection was defined as the absence of a full tonic seizure within 15&#x000a0;s of stimulus delivery. 2.3.10 combination with diazepam on rotarod performance in rats forty-eight male sprague&#x02013;dawley rats (&#x0223c;170&#x02013;200&#x000a0;g) were pre-trained to the rotarod (47750 rota-rod ng, ugo basile) at 8&#x000a0;rpm for 120&#x000a0;s. one day later, rats were administered alogabat (or vehicle) p.o., 30&#x000a0;min prior to diazepam or vehicle i.p., and they were assessed on the rotarod 30&#x000a0;min later. each rat was given three attempts to remain on the rotarod, with a maximum duration of 120&#x000a0;s per attempt. treatment groups (n &#x0003d; 8/group) consisted of alogabat alone (30&#x000a0;mg/kg), diazepam alone (5&#x000a0;mg/kg), or alogabat at 3, 10, and 30&#x000a0;mg/kg in combination with diazepam (5&#x000a0;mg/kg). the maximum time (s) spent on the rotarod was recorded. after the completion of rotarod testing, animals were euthanized under isoflurane anesthesia for plasma sample collection at approximately 70&#x000a0;min post-administration of alogabat. 2.3.11 cognition testing in rats 2.3.11.1 operant and touchscreen cognition tests separate groups of male lister hooded (lh) rats (&#x0223c;400&#x000a0;g) were pre-trained in the operant and touch screen tests, as described in supplementary material . the 5-csrt task (n &#x0003d; 11) is a test of attention. the primary parameter is the total percentage of correct responses. continuous performance test (cpt; n &#x0003d; 11) assesses sustained attention. the primary parameter is the discrimination sensitivity index (d prime), which is a ratio based on the rate at which rats make correct and incorrect responses. the paired associates learning (pal) task (n &#x0003d; 12) assesses visual&#x02013;spatial memory. the primary parameter is the total percentage of correct responses. a latin-squares design was used to assess the vehicle and doses of alogabat (3, 10, and 30&#x000a0;mg/kg p.o.). rats were tested twice weekly with at least a 2-day interval between test sessions. rats were trained between test days to maintain baseline performance. 2.3.11.2 context fear conditioning two cohorts of male lh rats (&#x0223c;250&#x000a0;g; n &#x0003d; 67) were assessed for context fear conditioning (cfc) in two experiments: (1) vehicle or alogabat at 10 and 30&#x000a0;mg/kg (n &#x0003d; 9/dose); (2) vehicle or alogabat at 1, 3, and 10&#x000a0;mg/kg (n &#x0003d; 10/dose) administered p.o., 60&#x000a0;min prior to the acquisition session. rats were placed into a novel test chamber (45&#x000a0;cm &#x000d7; 45&#x000a0;cm &#x000d7; 46.5&#x000a0;cm) with a grid floor and clear plastic walls (tse-systems gmbh, germany). during the acquisition session, a 2-min habituation phase was followed by the delivery of a mild foot shock (0.8&#x000a0;ma for 1&#x000a0;s) applied through the grid floor. following a 1&#x000a0;min interval, a second foot shock was delivered. the animals remained in the chambers for a further 30&#x000a0;s. one day later, the animals were returned to the same test chamber for a 5-min period without any foot shock. rodents respond to danger in a species-specific manner by freezing, i.e., the animals will withhold all movement, except for respiration, to avoid detection. the amount of freezing behavior was measured by the computer as the time spent immobile (minimum threshold of 1&#x000a0;s) and was expressed as the percentage of time spent freezing during the 5-min session. following cfc, plasma samples were collected 1&#x02013;2&#x000a0;days later from rats pre-treated with the same dose at 60&#x000a0;min post-administration ( n &#x0003d; 4/dose). 2.3.11.3 morris water maze male lh rats (350&#x02013;400&#x000a0;g) were pre-treated with vehicle or 10 or 30&#x000a0;mg/kg alogabat p.o. (n &#x0003d; 10/dose) once daily during cued acquisition (visible platform; three trials per day for 2&#x000a0;days), followed by a 2-day interval and then spatial acquisition (hidden platform; three trials per day for 4&#x000a0;days) in the morris water maze (mwm; computer tracking system hvs image ltd., united kingdom) ( ballard et al., 2005 ). twenty-four hours later, the platform was removed, and the rats were pre-treated with vehicle or alogabat and allowed to swim in the maze for 60&#x000a0;s (probe trial) to assess the retention/spatial memory of the platform position, expressed as the percentage of distance traveled in each quadrant. for the mwm, plasma samples were collected immediately after the last trial on the 12th day of treatment at approximately 70&#x000a0;min post-administration ( n &#x0003d; 4&#x02013;5/dose). 2.3.12 plasma sampling and analysis rodents were deeply anesthetized with 5% isoflurane, and blood was collected following decapitation with a guillotine or via cardiac puncture (ptz and mes). during eeg experiments, blood was collected from a cannula in the right femoral artery. blood samples were centrifuged in edta-coated eppendorf tubes (4,000&#x000a0;rpm, 4&#x000b0;c, 5&#x000a0;min), and plasma was collected, immediately frozen, and stored at &#x02212;80&#x000b0;c. samples were analyzed for the concentration of alogabat using qualified liquid chromatography coupled to tandem mass spectrometry (lc-ms/ms) assays. 2.3.13 statistical analysis sample sizes were determined based on historical data for each experiment within each laboratory. 2.3.13.1 eeg linear mixed-effects models (lmms) were used since these can account for incomplete datasets, which was the case in this study. specific contrasts were derived and tested using t-tests within the model using satterthwaite approximation for degrees of freedom. models were derived for each compound individually: y &#x0223c; compound &#x0002b; (1&#x0007c;animal). the significance of differences in the peak frequency was assessed using random permutation tests (10,000). 2.3.13.2 phmri analysis was performed with jmp (sas institute inc., cary, united states) and matlab (the mathworks inc., natick, ma, united states). global (whole-brain) absolute-perfusion values from the vehicle and the three dose groups were tested for a linear trend across the four doses using a one-way anova framework. the same analysis was applied roi-wise to the normalized-perfusion values. multiple testing across the single rois was accounted for by controlling the false discovery rate (fdr) at 10% using the benjamini&#x02013;hochberg approach. to also obtain an overall activation&#x02013;strength metric, normalized-perfusion values of each dose group were compared roi-wise to those of the vehicle group using welch&#x02019;s t-test without multiple-testing correction. the number of significantly modulated rois at each dose was then taken as a measure of &#x0201c;pattern strength.&#x0201d; the mean and the upper 95% confidence limit of the corresponding chance levels were estimated via random group-label permutations (100,000 runs per group). significance levels of the actual pattern strengths were determined based on the distributions obtained through the permutation procedure. 2.3.13.3 behavior all statistical analyses were performed using prism (graphpad software). one-factor anova was used for between-group comparison (i.e., dose), with repeated measures for within-subject comparison (i.e., time bins and platform quadrants). dunnett&#x02019;s test was used for post hoc comparisons. student&#x02019;s unpaired two-tailed t-test was used when two groups were compared. the chi-square test was used to compare the percentage of groups. rotarod data were analyzed using a non-parametric kruskal&#x02013;wallis test, followed by dunn&#x02019;s multiple comparison test. statistical significance was predetermined as p &#x0003c; 0.05. 3 results 3.1 binding affinity for gaba a receptors containing &#x003b1;5 and other &#x003b1; subunits the aim of these radioligand binding studies was to determine the binding selectivity of alogabat at the rat and human gaba a receptors containing &#x003b1;5 compared to &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits. alogabat had a high affinity for gaba a -&#x003b1;5&#x003b2;3&#x003b3;2 receptors in rats (ki 7.9&#x000a0;nm), with approximately 37-, 26-, and 18-fold selectivity compared to gaba a &#x003b1;1&#x003b2;3&#x003b3;2, &#x003b1;2&#x003b2;3&#x003b3;2, and &#x003b1;3&#x003b2;3&#x003b3;2, respectively ( figure 1b ; see supplementary table s1 ). alogabat had a similar pharmacological profile in human recombinant gaba a receptor subtypes (see supplementary table s1 ). 3.2 functional activity at recombinant and native gaba a receptors we undertook electrophysiological studies in hek293 cells and oocytes to assess the functional activity of alogabat on cloned rat and human gaba a receptor subtypes containing &#x003b1;5, &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits. alogabat enhanced gaba-evoked responses of rat and human &#x003b1;5-containing receptors by 167% ( figure 1c ) and 72% (see supplementary table s2 ), respectively. the maximum amount of potentiation was slightly lower at human receptors. this may be due to the different expression systems used, i.e., hek293 cells for rat receptors and xenopus oocytes for human receptors. at the highest concentrations tested, alogabat potentiated other receptor subtypes to a much lesser extent than &#x003b1;5-containing receptors. the potency of alogabat was comparable between gaba a -&#x003b1;5 receptors containing either &#x003b3;2 or &#x003b3;3 subunits, i.e., gaba a -&#x003b1;5&#x003b2;3&#x003b3;2 and gaba a -&#x003b1;5&#x003b2;3&#x003b3;3 receptors (see supplementary figure s1 ). at native gaba a receptors in rat hippocampal slices, alogabat positively modulated gabaergic inhibition of ca1 pyramidal cells, as shown by a leftward shift of the concentration-dependent inhibition of the population spike by isoguvacine ( figure 1d ) and enhanced paired-pulse inhibition of the population spike during field potential recordings ( figure 1e ). together, these results confirm the binding selectivity of alogabat and demonstrate that alogabat is a functionally selective pam of gaba-evoked responses. 3.3 selectivity data we assessed alogabat in radioligand binding studies with more than 70 receptors and showed that alogabat at 10&#x000a0;&#x000b5;m had over 917-fold binding selectivity for the gaba a -&#x003b1;5&#x003b2;3&#x003b3;2 receptor subtype against all other targets tested (see supplementary table s3 ). 3.4 receptor occupancy in wistar rats and cntnap2 &#x02212;/&#x02212; mice the main objective of these studies was to visualize and quantify gaba a -&#x003b1;5 ro by alogabat. alogabat decreased the specific binding of the gaba a -&#x003b1;5 receptor-specific radioligand [ 3 h]ro0154513 in the hippocampus of rats in a dose-dependent manner. the highest dose of alogabat (100&#x000a0;mg/kg i.p.) reduced specific binding by 100%, i.e., to the same binding level as that of 10&#x000a0;mg/kg l-655,708 ( figure 2a ). a total plasma concentration of 669&#x000a0;ng/ml and a total brain concentration of 208&#x000a0;ng/g were required to produce half-maximal gaba a -&#x003b1;5 ro (ec 50 ) in the hippocampus in rats. in cntnap2 &#x02212;/&#x02212; mice, estimated gaba a -&#x003b1;5 ro based on the ex vivo study with [ 3 h]l-655,708 was 43%, 46%, and 71% at doses of 30, 60, and 100&#x000a0;mg/kg i.p., respectively ( figure 2b ). in addition, the rat occupancy curve was used to calculate ro related to plasma exposure for all in vivo experiments described in this manuscript below (also refer to supplementary tables s4&#x02013;s5 ). figure 2 figure 2 . receptor occupancy and phmri signature of alogabat following acute administration. (a) concentration-dependent blockade of [ 3 h]ro0154513 binding by alogabat in wistar rats: with increasing concentrations from the different doses (0.3&#x02013;100&#x000a0;mg/kg i.p., n &#x0003d; 3/dose) of alogabat (vehicle &#x0003d; without pre-treatment, n &#x0003d; 3). (b) representative autoradiograms of alogabat ex vivo occupancy in cntnap2 &#x02212;/&#x02212; mice via in vitro incubation of the highly selective gaba a -&#x003b1;5 receptor radioligand [ 3 h]l-655,708 to sagittal brain sections. the cntnap2&#x02212;/&#x02212; mice were treated with vehicle and 30, 60, or 100&#x000a0;mg/kg i.p. alogabat (n &#x0003d; 4/dose). (c) trend of normalized-perfusion response pattern strength increasing with dose, given as numbers (&#x000b1; 95% confidence intervals) of significantly (de-)activated regions of interest (rois) following the administration of alogabat (n &#x0003d; 8/dose) to fischer (f344) rats under medetomidine sedation. &#x0201c;chance level&#x0201d; &#x0003d; mean (black dotted line) and 95th percentile (gray dotted line) derived from the permutation test. significant deviations in the number of modulated rois from the chance level are denoted by &#x0002a; p &#x0003c; 0.05, &#x0002a;&#x0002a; p &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a; p &#x0003c; 0.001 (uncorrected). ro is the calculated receptor occupancy for gaba a -&#x003b1;5 from measured plasma concentrations at each dose. (d) sagittal schematic of rat brain showing rois with a significant dose-dependent modulation (linear trend of normalized perfusion). rois passing false discovery rate control at 10% are shown, with roi outlines indicating uncorrected significance level (no outline, p &#x0003c; 0.05; dotted outline, p &#x0003c; 0.01; and solid outline, p &#x0003c; 0.001). roi abbreviations: acbsh, nucleus accumbens shell; amg, amygdala; drn, dorsal raphe nucleus; hpcfi, fimbria hippocampi; insc, insular cortex; lc, locus coeruleus; m1, primary motor cortex; mpfc/cg, medial prefrontal, cingulate cortex; pir, piriform (entorhinal) cortex; prh, perirhinal cortex; s1, primary somatosensory cortex; sn, substantia nigra; th, thalamus; vc, visual cortex. 3.5 pharmacological mri signature in rats the purpose of this study was to evaluate the effects of alogabat on regional neural activity. blood perfusion, measured quantitatively by phmri, was taken as a proxy for neural activity. the administration of a single dose of alogabat at 3&#x02013;30&#x000a0;mg/kg i.p. in rats resulted in moderate but consistent and dose-dependent changes in neural activity patterns compared to treatment with the vehicle ( figure 2c ). significant dose-dependent modulation of normalized perfusion by alogabat was observed in limbic brain regions, i.e., the nucleus accumbens (shell), amygdala, and hippocampus (fimbria); in several cortical brain regions, the thalamus and brainstem nuclei; and in the substantia nigra ( figure 2d ). a linear dose effect was also observed on whole-brain absolute perfusion. alogabat target engagement in brain tissue ranged from 54% to 84% ro. 3.6 eeg signature in rats the aim of this study was to determine whether alogabat induces a characteristic eeg signature that could be used as a translational pharmacodynamic marker. as a first step and based on previous findings on the eeg effects of gaba a drugs ( van lier et al., 2004 ; visser et al., 2003 ; friedman et al., 1992 ), we investigated eeg spectral power change in the theta (6&#x02013;10&#x000a0;hz) and beta (20&#x02013;30&#x000a0;hz) frequency bands. alogabat, administered as 10&#x000a0;mg/kg i.v. (5&#x000a0;min infusion), significantly increased eeg beta-band activity by 21% &#x000b1; 11% relative to the baseline (mean &#x000b1; sd) and decreased theta-band activity by 32% &#x000b1; 19% ( figures 3a,b ). frequency-resolved changes confirmed a decrease in theta power (approximately 6&#x02013;10&#x000a0;hz) and revealed broader beta and gamma modulation (approximately 20&#x02013;50&#x000a0;hz) ( figures 3c&#x02013;e ). the calculated ro after the application of alogabat was 77%&#x02013;85% for gaba a -&#x003b1;5 (see supplementary table s6 ). the overall spectral pattern was qualitatively similar to that of diazepam; however, the peak frequency in the beta frequency range was higher for alogabat (32&#x000a0;hz for alogabat vs. 22.6&#x000a0;hz for diazepam; p &#x0003d; 0.006, random permutation test), and its amplitude was greater for diazepam (142% &#x000b1; 44% increase for diazepam vs. 27% &#x000b1; 16% increase for alogabat; p &#x0003c; 0.001). this is likely related to the high binding and functional selectivity of alogabat for &#x003b1;5-containing gaba a receptors compared to the non-selective profile of diazepam. figure 3 figure 3 . pharmacodynamic effect of alogabat on eeg spectral power. (a,b) modulations of vehicle ( n &#x0003d; 12), alogabat 10&#x000a0;mg/kg ( n &#x0003d; 9), and diazepam 2&#x000a0;mg/kg ( n &#x0003d; 7, positive control) in the beta (20&#x02013;30&#x000a0;hz) and theta (6&#x02013;10&#x000a0;hz) power. (c&#x02013;e) effects of individual compounds and vehicle on the eeg power spectrum. each individual recording is displayed as a light gray line, and the group average and its 95% confidence intervals are shown as colored bands. for all panels, power averaged over 0.2&#x02013;1&#x000a0;h post dosing is shown relative to pre-dosing baseline average over &#x02212;1 to &#x02212;0.2&#x000a0;h before dosing. statistics: &#x0002a; p &#x0003c; 0.05 versus vehicle (linear mixed-effects models followed by t-tests). 3.7 repetitive behaviors in mouse models relevant to asd the inbred mouse strain btbr and the cntnap2 &#x02212;/&#x02212; mouse show abnormalities in core asd behavioral domains, such as repetitive behaviors. self-grooming and digging are more elevated in the btbr mouse than in other strains, i.e., c57bl/6j ( mcfarlane et al., 2008 ), and cntnap2 &#x02212;/&#x02212; mice show more elevated grooming than their wildtype littermates ( penagarikano et al., 2011 ). the aim of the following experiments was to determine whether alogabat has a specific effect on repetitive behaviors independent of potential effects on overall locomotor activity. we assessed the effects of subchronic treatment on cntnap2 &#x02212;/&#x02212; mice to exclude potential tolerance to the effects of alogabat. 3.7.1 open field in btbr and cntnap2 &#x02212;/&#x02212; mice in btbr mice, acute administration of alogabat (30&#x02013;120&#x000a0;mg/kg i.p.) had no effect on the total activity over 1&#x000a0;h measured in an open field [f(4,55) &#x0003d; 2.04], although during the first 10&#x000a0;min, alogabat at 90 and 120&#x000a0;mg/kg significantly reduced the distance traveled [f(4,55) &#x0003d; 9.623, p &#x0003c; 0.001, figure 4a ]. there was also no effect of sub-chronic alogabat (30&#x02013;100&#x000a0;mg/kg i.p.) on the total activity over 1&#x000a0;h in cntnap2 &#x02212;/&#x02212; mice [f(3,53) &#x0003d; 0.98]. during the first 5&#x000a0;min, 100&#x000a0;mg/kg reduced the distance traveled in cntnap2 &#x02212;/&#x02212; mice to the same level as vehicle-treated wildtype mice ( figure 4b ). alogabat did not induce a major impairment of locomotor activity in the open field. figure 4 figure 4 . effect of alogabat on repetitive behaviors in btbr and cntnap2 &#x02212;/&#x02212; mice. (a) alogabat was administered i.p. 30&#x000a0;min prior to the assessment of locomotor activity in an open-field test in btbr mice: distance traveled (cm) per 5&#x000a0;min time bin ( line graph ) and in 1&#x000a0;h total ( bar chart inset ). (b) alogabat was administered i.p. once daily for 2&#x02013;3&#x000a0;days, and on the test day, it was administered 30&#x000a0;min prior to testing cntnap2 &#x02212;/&#x02212; mice in an open field: distance traveled (cm) per 5&#x000a0;min time bin ( line graph ) and in 1&#x000a0;h total ( bar chart insert ). in btbr mice, on a separate test day, alogabat was administered i.p. 30&#x000a0;min prior to the grooming test: (c) duration (s) of grooming behavior and (e) distance (cm) traveled during the 10&#x000a0;min period in the test chamber. in cntnap2 &#x02212;/&#x02212; mice, alogabat was administered i.p. once daily for 8&#x02013;10&#x000a0;days, and on the test day, it was administered 30&#x000a0;min prior to the grooming test: (d) duration (s) of grooming behavior and (f) distance traveled during the 10&#x000a0;min period in the test chamber. data are presented as individual points (circles) and mean &#x000b1; sem (btbr: n &#x0003d; 12/group; cntnap2 &#x02212;/&#x02212; : n &#x0003d; 14&#x02013;15/group). statistics: &#x0002a; p &#x0003c; 0.05, &#x0002a;&#x0002a; p &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a; p &#x0003c; 0.001 vs. vehicle (veh)-treated btbr or cntnap2 &#x02212;/&#x02212; mice. &#x000a7;&#x000a7;&#x000a7; p &#x0003c; 0.001 vehicle-treated wildtype (wt-v) mice vs. vehicle (v)-treated cntnap2 &#x02212;/&#x02212; mice. alogabat was administered i.p. 30&#x000a0;min prior to the assessment of digging behavior in btbr mice: (g) duration (s) of digging behavior, (h) distance traveled (cm), and (i) speed (cm/s) during the 5&#x000a0;min period in the test chamber. data are presented as individual points (circles) and mean &#x000b1; sem ( n &#x0003d; 12/group). statistics: &#x0002a;&#x0002a; p &#x0003c; 0.01 and &#x0002a;&#x0002a;&#x0002a; p &#x0003c; 0.001 vs. vehicle-treated btbr mice. ro is the calculated receptor occupancy for gaba a -&#x003b1;5 from the measured plasma concentrations at each dose. 3.7.2 grooming behavior in btbr and cntnap2 &#x02212;/&#x02212; mice acute administration of alogabat in btbr mice dose-dependently attenuated grooming behavior at 60, 90, and 120&#x000a0;mg/kg i.p. [f(4,55) &#x0003d; 6.946, p &#x0003d; 0.0001, figure 4c ] without reducing locomotor activity in the same test arena ( figure 4e ). in contrast, doses of 60 and 90&#x000a0;mg/kg increased the distance traveled [f(4,55) &#x0003d; 3.454, p &#x0003c; 0.05]. alogabat had a specific effect on grooming behavior at plasma concentrations corresponding to calculated gaba a -&#x003b1;5 ro levels of 45%&#x02013;70% (see supplementary table s4 ). sub-chronic administration of alogabat in cntnap2 &#x02212;/&#x02212; mice attenuated grooming behavior at 60 and 100&#x000a0;mg/kg i.p. [f(3,53) &#x0003d; 10.57, p &#x0003c; 0.0001, figure 4d ], with no effect on locomotor activity measured in the same test arena [f(3,53) &#x0003d; 0.74, figure 4f ]. alogabat had a specific effect on repetitive grooming behavior at plasma concentrations that correspond with calculated gaba a -&#x003b1;5 ro of 52%&#x02013;79% (see supplementary table s4 ). 3.7.3 digging behavior in btbr mice there was no effect of acute alogabat administration on digging behavior at doses up to 100&#x000a0;mg/kg i.p. [f(3,36) &#x0003d; 0.8, figure 4g ], corresponding to a calculated gaba a -&#x003b1;5 ro level of 67% (see supplementary table s4 ). alogabat at 100&#x000a0;mg/kg reduced the distance traveled [f(3,36) &#x0003d; 12.1, p &#x0003c; 0.001, figure 4h ] and speed [f(3,36) &#x0003d; 11.5, p &#x0003c; 0.001, figure 4i ] in the same arena. 3.8 anticonvulsant activity in rats the purpose of these experiments was to evaluate the antiepileptic properties of alogabat against seizures induced by ptz and the mes model. alogabat administered in combination with a convulsant dose of ptz completely blocked seizures at 15 and 30&#x000a0;mg/kg ( figure 5a ), which corresponds to calculated gaba a -&#x003b1;5 ro levels of 71% and 77% (see supplementary table s5 ). meanwhile, in the mes test, alogabat at 5&#x000a0;mg/kg (57% ro, see supplementary table s5 ) showed a significant reduction in the percent of rats that had tonic seizures ( figure 5b ); there was only a tendency for reduction at 15&#x000a0;mg/kg ( p &#x0003d; 0.1) and 30&#x000a0;mg/kg ( p &#x0003d; 0.06). the positive control, diazepam, significantly reduced the percentage of rats that had seizures in both the ptz and mes tests. figure 5 figure 5 . evaluation of alogabat for effects on anticonvulsant, motor, and cognitive tests. alogabat was administered p.o. 60&#x000a0;min prior to the following behavior tests. assessment of potential anticonvulsant activity in (a) ptz and (b) mes tests in rats. diazepam (dzp) at 3&#x000a0;mg/kg i.p. was included as a positive control. data are presented as individual points (circles) and the percentage of rats per group showing seizures ( n &#x0003d; 8/group). (c) time (s) spent on the rotarod at 16&#x000a0;rpm in rats administered alogabat alone (30&#x000a0;mg/kg, gray bar with black outline) or alogabat at 3, 10, and 30&#x000a0;mg/kg co-administered with diazepam at 5&#x000a0;mg/kg i.p. (gray bars with red outline) compared with vehicle (open bar) or diazepam (open bar with red outline). data are presented as individual points (circles) and median &#x000b1; interquartile range (n &#x0003d; 8/group). assessment of cognition in rats: (d) attention in the 5-choice serial reaction time (5-csrt) task; (e) sustained attention in the touchscreen continuous performance test (cpt); (f) visual&#x02013;spatial memory in the touchscreen pal task. cfc at (g) 10 and 30&#x000a0;mg/kg; (h) 1, 3, and 10&#x000a0;mg/kg. spatial learning and memory in the mwm: alogabat was administered once daily for 11&#x000a0;days prior to the probe trial. (i) percentage of distance traveled in all four quadrants: vehicle; 10&#x000a0;mg/kg; 30&#x000a0;mg/kg. data are presented as individual points (circles) and mean &#x000b1; sem for pal ( n &#x0003d; 12/dose; within-subjects), 5-csrt and cpt ( n &#x0003d; 11/dose, within-subjects), cfc ( n &#x0003d; 9&#x02013;10/group), and mwm ( n &#x0003d; 10/group). statistics: &#x0002a; p &#x0003c; 0.05, &#x0002a;&#x0002a; p &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a; p &#x0003c; 0.001 vs. vehicle (veh or 0)-treated rats; mwm statistics: &#x0002a; p &#x0003c; 0.05, &#x0002a;&#x0002a; p &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a; p &#x0003c; 0.001 vs. percentage of distance in the platform quadrant. ro is the calculated receptor occupancy of alogabat for gaba a -&#x003b1;5 from measured plasma concentrations at each dose. 3.9 combination with diazepam on rotarod performance in rats classical benzodiazepines, such as diazepam, are known to induce sedation and ataxia, which can be measured by the rotarod task in rodents. the aim of this experiment was to determine whether alogabat affects rotarod performance when administered alone and, second, whether alogabat modulates the sedative/motor effect of diazepam on rotarod performance when given in combination. diazepam at 5&#x000a0;mg/kg i.p. significantly impaired rotarod performance. alogabat (3&#x02013;30&#x000a0;mg/kg p.o.) co-administered with diazepam did not worsen the effects of diazepam on rotarod performance ( figure 5c ). alogabat administered alone at 30&#x000a0;mg/kg p.o. did not differ from vehicle-treated rats, corresponding to a calculated gaba a -&#x003b1;5 ro level of 88% (see supplementary table s5 ). 3.10 evaluation of cognition in rats since non-selective gaba a pams, such as diazepam, have been shown to impair cognition ( ballard et al., 2005 ), the aim of the following experiments was to study the potential effects of acute administration of alogabat on cognition in rats. this included attention in the 5-csrt task and associative (fear) memory in cfc. we also assessed visual&#x02013;spatial memory (pal task) and attention (cpt) in a touchscreen system, which provides a translational approach for assessing cognition ( hvoslef-eide et al., 2016 ). chronic treatment with alogabat was also assessed on spatial learning and memory in the mwm. in the 5-csrt task, alogabat at 30&#x000a0;mg/kg induced a small but statistically significant reduction in percent correct (3%; within-subjects comparison; f(3,30) &#x0003d; 5.6, p &#x0003c; 0.01; figure 5d ). however, alogabat did not impair attention in cpt (f(2,20) &#x0003d; 0.3; figure 5e ) or visual&#x02013;spatial memory in the pal task (f(2,22) &#x0003d; 2.6; figure 5f ). in the cfc test, alogabat was administered before the acquisition session to determine whether there was an effect on learning the association between foot shock and the surrounding context. in the first experiment, alogabat impaired cfc at 10 and 30&#x000a0;mg/kg, corresponding to calculated gaba a -&#x003b1;5 ro levels of 75% and 81% (f(2,24) &#x0003d; 10.99, p &#x0003c; 0.001; figure 5g ). a second experiment was undertaken to explore lower doses, and it showed that alogabat did not significantly impair cfc at 1, 3, and 10&#x000a0;mg/kg (f(3,36) &#x0003d; 0.9; figure 5h ), corresponding to the calculated gaba a -&#x003b1;5 ro levels of 35%, 56%, and 72%. this suggests that the dose of 10&#x000a0;mg/kg is approximately the threshold level for the impairment of cfc and is likely dependent on the level of ro achieved per subject. in the mwm test, chronic administration of alogabat at 10 and 30&#x000a0;mg/kg did not significantly impair the acquisition of the hidden platform position (see supplementary figure s2 ). twenty-four hours later, the platform was removed, and the rats were allowed to swim in the maze for 60&#x000a0;s (probe trial) to assess memory-retention of the platform position. the groups receiving vehicle [f(3,27) &#x0003d; 8, p &#x0003c; 0.001] and 10&#x000a0;mg/kg [f(3,27) &#x0003d; 7, p &#x0003c; 0.01] had learned the spatial position of the platform, as shown by their preference for the platform quadrant ( figure 5i ). however, rats that received 30&#x000a0;mg/kg alogabat showed impaired spatial memory of the platform position during the probe trial [f(3,27) &#x0003d; 3, p &#x0003d; 0.08; figure 5i ], and gaba a -&#x003b1;5 ro was estimated to be 79%. in summary, alogabat impaired context and spatial memory at gaba a -&#x003b1;5 ro above 70%. 4 discussion 4.1 in vitro and in vivo characterization of alogabat alogabat was shown to be a potent and functionally selective gaba a -&#x003b1;5 receptor pam in vitro . the functional activity of alogabat was confirmed at native gaba a receptors in rat hippocampal slices. in vivo binding experiments demonstrated dose-dependent target engagement of alogabat in rats and cntnap2 &#x02212;/&#x02212; mice. the highest specific binding was observed in the hippocampus, which is consistent with the known distribution of the gaba a -&#x003b1;5 receptor subtype in rodents ( pirker et al., 2000 ). phmri studies in rats demonstrated dose-dependent perfusion changes, indicating circuit modulation by alogabat. there were consistent changes in the neural activity pattern across dose groups, with modulation of neural activity in, among others, the medial prefrontal cortex, cingulate cortex, motor cortex, perirhinal cortex, nucleus accumbens shell, amygdala, hippocampus fimbria, and substantia nigra. 4.2 eeg signature acute administration of alogabat in rats induced an eeg signature characterized by a power decrease in theta and an increase in the beta frequency range, which was qualitatively similar to the eeg signature of non-selective gaba a pams such as diazepam ( van lier et al., 2004 ; visser et al., 2003 ; friedman et al., 1992 ). the lower magnitude of induced eeg beta-band power by alogabat compared to diazepam is likely attributed to its &#x003b1;5-selectivity, resulting in an overall lower magnitude of gaba a receptor modulation. this eeg signature of alogabat is qualitatively a mirror image of the eeg signature of basmisanil, a highly selective gaba a -&#x003b1;5 negative allosteric modulator (nam), which we recently found to induce an increase in the theta power and a decrease in the beta-band eeg power in healthy volunteers ( hipp et al., 2021 ). furthermore, the eeg signature of alogabat is in agreement with the link between beta-band activity and single-nucleotide polymorphisms (snps) in gaba a receptor genes ( porjesz et al., 2002 ; smit et al., 2018 ) and ndds (dup15q syndrome, as) involving gene copy number variations of gabrb3, gabra5 , and gabrg3 ( frohlich et al., 2019a ; frohlich et al., 2019b ). gaba a receptor-related changes in beta-band activity are believed to reflect the modulation of recurrent excitatory&#x02013;inhibitory feedback loops in the cortical tissue ( whittington et al., 2000 ; traub and jefferys, 1999 ). for the administered doses, the calculated receptor occupancies were in the range of 77%&#x02013;84% for &#x003b1;5-containing receptors and 22%&#x02013;34% for &#x003b1;1-containing receptors (with different pam effects (e max ) at &#x003b1;5 vs. &#x003b1;1). thus, at the studied doses, alogabat has some effect on &#x003b1;1-containing receptors, and further work is needed to systematically study lower doses of alogabat, including those &#x0003c;70% ro without the impairment of cognition in wt rats, to confirm whether the modulation of &#x003b1;5-containing receptors alone is sufficient to induce the described eeg effect. nonetheless, eeg theta- and beta-band power are promising candidates for translational mechanistic biomarkers of gaba a -&#x003b1;5 receptor function and could be used in the further development of alogabat. 4.3 behavioral effects of alogabat in animal models relevant to asd we assessed the effects of alogabat in two different mouse models relevant to asd, one phenotypic and one genetic. acute administration of alogabat significantly and dose-dependently attenuated excessive grooming, but not digging, behavior in btbr mice. sub-chronic administration of alogabat significantly attenuated elevated grooming behavior in cntnap2 &#x02212;/&#x02212; mice. efficacy in these different models was linked to gaba a -&#x003b1;5 ro above 50%. despite initial findings of a transiently decreased activity in an open-field test, alogabat increased the activity of btbr mice and had no effect on the activity of cntnap2 &#x02212;/&#x02212; mice during the grooming test, supporting the specific effect of alogabat on repetitive grooming. we have tested additional compounds with similar properties, e.g., ro7015738, and have confirmed that gaba a -&#x003b1;5 pams reduce repetitive behaviors in these mouse models ( buettelmann et al., 2018 ). these results align well with recently published data showing that gaba a -&#x003b1;5 receptor deficiency causes autism-like behaviors in mice, including increased grooming and reduced social contacts ( zurek et al., 2016 ), and with sh-053-2&#x02032;f-r-ch3, a gaba a -&#x003b1;5 pam, which was recently shown to have positive effects on social and cognitive deficits in a rat model of autism ( souza et al., 2024 ). our data are valuable in providing information on the ro required for in vivo effects on repetitive behavior. however, it should be noted that this effect may not directly translate to all individuals with asd as it is a heterogeneous disorder, whereas these mouse models exhibit specific genetic or phenotypic deficits. 4.4 anticonvulsant effects of alogabat it has been proposed that the reduction of gabaergic inhibitory activity results in hyperexcitability of minicolumn circuits, explaining some of the symptomatology observed in some ndds, including the high incidence of seizures and auditory&#x02013;tactile hypersensitivity ( rubenstein and merzenich, 2003 ; frye et al., 2016 ). in the current study, we demonstrated that alogabat exhibits an anticonvulsant profile with activity comparable to the benzodiazepine drug class in acutely induced seizure models (electrical and chemical). alogabat had a small effect on seizures in the mes test, whereas in the ptz test, alogabat was shown to completely block seizures at calculated gaba a -&#x003b1;5 ro &#x0003e;70%. since ptz is a gaba a antagonist, this supports the assessment of alogabat for anticonvulsant activity in disorders where there is dysfunction of the gabaergic system. furthermore, in a separate eeg study, we observed that one out of eight rats had frequent spike-and-wave discharge (swd) activity, which was alleviated following treatment with alogabat (see supplementary figures s3a&#x02013;s3c ; methods in supplementary material ). to better understand the temporal dynamics of swd occurrence and the suppressing effect of alogabat, we performed a follow-up study on three additional rats that showed pronounced swd. both 3 and 10&#x000a0;mg/kg alogabat substantially reduced the number of swds within the first 3&#x000a0;h of recording, when the same rats showed increased swd numbers in the vehicle control condition (see supplementary figures s3d&#x02013;s3f ), which corresponds to the calculated gaba a -&#x003b1;5 ro level of 30%&#x02013;46% (see supplementary table s6 ). from a circuit perspective, the consensus is that such epileptic activity is generated by dysregulated thalamocortical circuitry, with abnormal interactions between reticular thalamic neurons and thalamic relay cells acting as the trigger and cortical circuits serving as the generator ( sitnikova et al., 2023 ). considering that in rats, &#x003b1;5-subunit-containing gaba a receptors are enriched in the cortex and hippocampus ( serwanski et al., 2006 ; hu et al., 2019 ), mediating dendritic inhibition on pyramidal neurons ( ali and thomson, 2008 ; schulz et al., 2018 ), we hypothesize that alogabat could suppress swd generation by enhancing the inhibition of cortical pyramidal neurons. however, more systematic work is required to confirm that alogabat can prevent swd activity. 4.5 assessment of non-specific behavioral effects non-selective gaba a pams, such as diazepam and chlordiazepoxide, are effective anxiolytics in clinical use but have also been shown to impair cognition in rodents and humans. gaba a -&#x003b1;5 receptors are believed to play a major role in cognition since they are predominantly expressed in the hippocampus in rats, where they regulate nmdar-dependent synaptic plasticity underlying learning and memory processes ( schulz et al., 2018 ; fritschy et al., 1997 ; schulz et al., 2019 ; davenport et al., 2021 ). moreover, it has been proposed that gaba a pams may induce memory impairment by modulating hippocampal function ( mcnaughton and morris, 1987 ). therefore, alogabat was evaluated in several rodent tests of cognition to determine whether a selective gaba a -&#x003b1;5 pam would induce cognitive impairment following acute administration in rats. there was no effect of alogabat up to 70% gaba a -&#x003b1;5 ro on cognition (visual&#x02013;spatial memory, attention, context fear conditioning, spatial learning, and memory). cognitive impairment was only observed at high doses (&#x0003e;70% ro) and supra-therapeutic levels of alogabat in associative (fear) learning (cfc) and spatial memory in the mwm in wildtype rats. the impairment at high doses is likely linked to the loss of selectivity toward gaba a &#x003b1;1, &#x003b1;2, and &#x003b1;3 receptor subtypes (&#x003b1;1 ro was calculated as 19%&#x02013;25% at these doses; see supplementary table s6 ). in addition to the loss of selectivity, we cannot exclude the possibility that these effects may be a consequence of gaba a -&#x003b1;5 receptor saturation, i.e., excessive &#x003b1;5 activity in wildtype subjects may be detrimental. the cognitive impairment observed in wildtype rats may translate to healthy human subjects; however, our focus is on the effect of &#x003b1;5 pams in disease conditions with impaired gaba a signaling and impaired cognition, where our hypothesis is that an &#x003b1;5 pam would have beneficial effects. alogabat had no effect on social approach/avoidance, the elevated plus maze, and the vogel conflict test in rats at ro levels up to 80% (see supplementary figure s4 and methods in supplementary material ), suggesting that alogabat does not exhibit an anxiolytic-like effect in rodents. this might be explained by the low expression of gaba a -&#x003b1;5 in the amygdala, a key node controlling anxiety-like behaviors. potential anxiolytic effects of alogabat in humans cannot be excluded as this receptor subtype is much more abundant in the human amygdala. since benzodiazepines, such as diazepam, are frequently used to treat anxiety and seizures in ndds, it was important to establish that alogabat at relevant therapeutic doses in mouse models did not worsen the sedative/motor-impairing effects of diazepam in the rotarod test. alogabat did not worsen diazepam-induced motor impairment; on the contrary, in combination, it reduced the motor impairments, which is more likely due to the more localized and precise inhibitory effect, counterbalancing the broader suppression of neuronal activity by diazepam, or due to lower intrinsic activity at &#x003b1;1 receptors compared to diazepam. we have previously shown that a gaba a -&#x003b1;5 nam, which binds at the benzodiazepine binding site of the receptor, does not decrease the anxiolytic activity of chlordiazepoxide (see supplementary figure s5 ); therefore, it is unlikely that alogabat will interfere with the anxiolytic effect of the classical benzodiazepines. 5 conclusion multiple lines of evidence point to deficits in gabaergic signaling in epilepsy and ndds, such as asd and deletion as, with a prominent role attributed to gaba a receptors, including the gaba a -&#x003b1;5 receptor subtype. the current data for alogabat showed robust dose-dependent efficacy on repetitive behaviors in two disease-relevant mouse models and anti-seizure activity in the ptz rat model at gaba a -&#x003b1;5 ro above 50%. our in vivo occupancy measurements using the selective &#x003b1;5 tracer l-655,708 were highly valuable for understanding plasma and csf exposures (as a surrogate of free brain concentration) and their relationship to in vivo effects. we observed that there was a 34-fold shift between the csf concentration of alogabat in the in vivo occupancy study and that of alogabat in vitro binding data (ki value). the receptor occupancy of alogabat correlates well with pd effects ( in vivo effects) and is consistent across the different studies/species (see supplementary table s6 ). this finding highlights the importance of using pet tracers in drug development. our data suggest that gaba a -&#x003b1;5 pams may have potential benefits in individuals with autistic features and in conditions with clinical and nonclinical manifestations of cortical hyperexcitability and epilepsy. however, alogabat is unlikely to work across all ndds and should be utilized as a precision medicine to target a specific subgroup of the ndd population with deficient gaba a pathway signaling, or specifically gaba a -&#x003b1;5. interestingly, recent data suggest that gaba a -&#x003b1;5 pams may also have therapeutic potential in schizophrenia, alzheimer&#x02019;s disease, and depression ( perez et al., 2023 ; luscher et al., 2023 ; koh et al., 2013 ). with regard to the current status of alogabat, good-laboratory practice (glp) toxicology and safety pharmacology studies in rats and minipigs showed an overall benign safety profile, which supported its clinical investigations in phase-1 studies in healthy volunteers and phase-2 trials in asd and deletion as patients (nct03507569, nct03774576, nct03847987, nct04299464, nct05630066, and eudract&#x00023;2019-003524-20). the outcome of these studies, including pet, eeg, and effects on cognition, will be reported in the future. data availability statement the original contributions presented in the study are included in the article/ supplementary material , further inquiries can be directed to the corresponding author. ethics statement experiments performed at f. hoffmann-la roche ag (basel, switzerland) complied with swiss federal and cantonal laws on animal research and aaalac regulations and received prior approval from the cantonal veterinary office. the eeg study was conducted at brains online (ca, united states) in accordance with the guide for the care and use of laboratory animals (national research council 2011) after receiving approval from the institutional animal care and use committee. the ptz and mes tests were conducted at vivocore inc., canada, which is a facility licensed by the ontario ministry of agriculture, food, and rural affairs and accredited by the canadian council on animal care. all in vivo studies are reported in compliance with the arrive guidelines ( percie du sert et al., 2020 ). the study was conducted in accordance with the local legislation and institutional requirements. author contributions gc: supervision, writing - original draft, investigation, formal analysis. tmb: formal analysis, investigation, writing - review and editing, methodology. fk: formal analysis, writing - original draft, investigation, methodology. mh: writing - original draft, investigation, methodology, formal analysis. jfh: data curation, visualization, methodology, writing - original draft, formal analysis. pg: methodology, data curation, formal analysis, writing - original draft. tm: investigation, writing - original draft, formal analysis, methodology. bk: investigation, writing - original draft, methodology, formal analysis. anb: formal analysis, writing - original draft, data curation. epp: writing - original draft, methodology, investigation. ps: methodology, investigation, writing - original draft, formal analysis. pj: writing - original draft, formal analysis. rr: methodology, writing - original draft, investigation, formal analysis. bb: methodology, investigation, writing - original draft. hk: methodology, writing - original draft, investigation. ao-m: writing - original draft, formal analysis, methodology. alb: methodology, writing - original draft, investigation. jms: investigation, formal analysis, writing - original draft. db: methodology, writing - original draft, investigation. ms: writing - original draft, methodology, investigation. eco&#x00027;c: investigation, writing - original draft, methodology. m-ch: investigation, conceptualization, writing - review and editing, supervision, writing - original draft, methodology. funding the author(s) declare that financial support was received for the research and/or publication of this article. the funding was provided by f. hoffmann-la roche ag switzerland. acknowledgments the authors thank gregoire friz, maria karg, and judith lengyel (molecular biology and binding assays); v&#x000e9;ronique graf, rachel haab, and marie-claire pflimlin ( in vitro electrophysiology); brigitte algeyer, severine bandinelli, sean durkin, audrey genet, marie haman, martine maco, and roger wyler (behavioral pharmacology); and stephanie sch&#x000f6;ppenthau, s&#x000e9;bastien debilly, and thomas bielser ( in vivo phmri). the rat ptz and mes studies were carried out under the scientific guidance of dr guy higgins, intervivo solutions, and coordinated by leo silenieks at vivocore inc., ontario, canada. the rat eeg data acquisition was undertaken by brains on-line llc, south san francisco, united states, and the data analysis was undertaken by pg, vanessa keeney, and andr&#x000e9;s olivares at roche. conflict of interest authors gc, tmb, fk, mh, jfh, pg, tm, bk, ab, epp, ps, pj, rr, bb, hk, ao-m, ab, jms, ms, eco&#x00027;c, and m-ch were employed by f. hoffmann-la roche ag switzerland. all employees (former and current) may be eligible for stock and stock options. author db was employed by hiqscreen s&#x000e0;rl. generative ai statement the author(s) declare that no generative ai was used in the creation of this manuscript. publisher&#x02019;s note all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. supplementary material the supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2025.1626078/full&#x00023;supplementary-material abbreviations as, angelman syndrome; asd, autism spectrum disorder; cfc, context fear conditioning; cntnap2, contactin-associated protein-like 2; cpt, continuous performance test; 5-csrt, 5-choice serial reaction time; eeg, electroencephalography; gaba, gamma-aminobutyric acid; gad, glutamic acid decarboxylase; i.p., intraperitoneally; i.v., intravenously; lfp, local field potential; mes, maximum electrical stimulus; mwm, morris water maze; ndds, neurodevelopmental disorders; pal, paired associates learning; pam, positive allosteric modulator; phmri, pharmacological magnetic resonance imaging; p.o, per os; ptz, pentylenetetrazole; ro, receptor occupancy; pet, positron emission tomography. references abrahams, b. s., and geschwind, d. h. (2008). advances in autism genetics: on the threshold of a new neurobiology. nat. rev. genet. 9, 341&#x02013;355. doi:10.1038/nrg2346 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar ali, a. b., and thomson, a. m. (2008). synaptic alpha 5 subunit-containing gabaa receptors mediate ipsps elicited by dendrite-preferring cells in rat neocortex. cereb. cortex 18, 1260&#x02013;1271. doi:10.1093/cercor/bhm160 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar american psychiatric association (2008). diagnostic and statistical manual of mental disorders . 5th ed. washington: american psychiatric association . google scholar ballard, t. m., knoflach, f., prinssen, e., borroni, e., vivian, j. a., basile, j., et al. (2009). ro4938581, a novel cognitive enhancer acting at gabaa alpha5 subunit-containing receptors. psychopharmacol. berl. 202, 207&#x02013;223. doi:10.1007/s00213-008-1357-7 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar ballard, t. m., woolley, m. l., prinssen, e., huwyler, j., porter, r., and spooren, w. (2005). the effect of the mglu5 receptor antagonist mpep in rodent tests of anxiety and cognition: a comparison. psychopharmacol. berl. 179, 218&#x02013;229. doi:10.1007/s00213-005-2211-9 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar banerjee, a., garcia-oscos, f., roychowdhury, s., galindo, l. c., hall, s., kilgard, m. p., et al. (2013). impairment of cortical gabaergic synaptic transmission in an environmental rat model of autism. int. j. neuropsychopharmacol. 16, 1309&#x02013;1318. doi:10.1017/s1461145712001216 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar bourgeron, t. (2015). from the genetic architecture to synaptic plasticity in autism spectrum disorder. nat. rev. neurosci. 16, 551&#x02013;563. doi:10.1038/nrn3992 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar braat, s., and kooy, r. f. (2015). the gabaa receptor as a therapeutic target for neurodevelopmental disorders. neuron 86, 1119&#x02013;1130. doi:10.1016/j.neuron.2015.03.042 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar bruns, a., kunnecke, b., risterucci, c., moreau, j. l., and von kienlin, m. (2009). validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological mri in rats. magn. reson med. 61, 1451&#x02013;1458. doi:10.1002/mrm.21779 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar buettelmann, b., cecere, g., fasching, b., groebke zbinden, k., hernandez, m.-c., knust, h., et al. (2018). preparation of new isoxazolyl ether derivatives as gabaa &#x003b1;5 receptor positive allosteric modulators (pams) . copyright &#x000a9; 2025 american chemical society acs . available online at: https://worldwide.espacent.com/patent/search/family/057530563/publication/wo2018104419a1?q&#x0003d;wo2018104419a1 google scholar buiting, k. (2010). prader-willi syndrome and angelman syndrome. am. j. med. genet. c semin. med. genet. 154c, 365&#x02013;376. doi:10.1002/ajmg.c.30273 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar chao, h. t., chen, h., samaco, r. c., xue, m., chahrour, m., yoo, j., et al. (2010). dysfunction in gaba signalling mediates autism-like stereotypies and rett syndrome phenotypes. nature 468, 263&#x02013;269. doi:10.1038/nature09582 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar davenport, c. m., rajappa, r., katchan, l., taylor, c. r., tsai, m. c., smith, c. m., et al. (2021). relocation of an extrasynaptic gaba(a) receptor to inhibitory synapses freezes excitatory synaptic strength and preserves memory. neuron 109, 123&#x02013;134 e4. doi:10.1016/j.neuron.2020.09.037 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar delong, r. (2007). gaba(a) receptor alpha5 subunit as a candidate gene for autism and bipolar disorder: a proposed endophenotype with parent-of-origin and gain-of-function features,with or without oculocutaneous albinism. autism 11, 135&#x02013;147. doi:10.1177/1362361307075705 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar delorey, t. m. (2005). gabrb3 gene deficient mice: a potential model of autism spectrum disorder. int. rev. neurobiol. 71, 359&#x02013;382. doi:10.1016/s0074-7742(05)71015-1 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar delorey, t. m., sahbaie, p., hashemi, e., homanics, g. e., and clark, j. d. (2008). gabrb3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: a potential model of autism spectrum disorder. behav. brain res. 187, 207&#x02013;220. doi:10.1016/j.bbr.2007.09.009 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar dhossche, d., applegate, h., abraham, a., maertens, p., bland, l., bencsath, a., et al. (2002). elevated plasma gamma-aminobutyric acid (gaba) levels in autistic youngsters: stimulus for a gaba hypothesis of autism. med. sci. monit. 8, pr1&#x02013;pr6. pubmed abstract &#x0007c; google scholar di nanni, n., bersanelli, m., cupaioli, f. a., milanesi, l., mezzelani, a., and mosca, e. (2019). network-based integrative analysis of genomics, epigenomics and transcriptomics in autism spectrum disorders. int. j. mol. sci. 20, 3363. doi:10.3390/ijms20133363 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar dufour, b. d., mcbride, e., bartley, t., juarez, p., and martinez-cerdeno, v. (2023). distinct patterns of gabaergic interneuron pathology in autism are associated with intellectual impairment and stereotypic behaviors. autism 27, 1730&#x02013;1745. doi:10.1177/13623613231154053 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar fatemi, s. h., halt, a. r., stary, j. m., kanodia, r., schulz, s. c., and realmuto, g. r. (2002). glutamic acid decarboxylase 65 and 67 kda proteins are reduced in autistic parietal and cerebellar cortices. biol. psychiatry 52, 805&#x02013;810. doi:10.1016/s0006-3223(02)01430-0 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar friedman, h., greenblatt, d. j., peters, g. r., metzler, c. m., charlton, m. d., harmatz, j. s., et al. (1992). pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. clin. pharmacol. ther. 52, 139&#x02013;150. doi:10.1038/clpt.1992.123 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar fritschy, j. m., benke, d., johnson, d. k., mohler, h., and rudolph, u. (1997). gabaa-receptor alpha-subunit is an essential prerequisite for receptor formation in vivo . neuroscience 81, 1043&#x02013;1053. doi:10.1016/s0306-4522(97)00244-3 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar frohlich, j., miller, m. t., bird, l. m., garces, p., purtell, h., hoener, m. c., et al. (2019a). electrophysiological phenotype in angelman syndrome differs between genotypes. biol. psychiatry 85, 752&#x02013;759. doi:10.1016/j.biopsych.2019.01.008 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar frohlich, j., reiter, l. t., saravanapandian, v., distefano, c., huberty, s., hyde, c., et al. (2019b). mechanisms underlying the eeg biomarker in dup15q syndrome. mol. autism 10, 29. doi:10.1186/s13229-019-0280-6 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar frye, r. e., casanova, m. f., fatemi, s. h., folsom, t. d., reutiman, t. j., brown, g. l., et al. (2016). neuropathological mechanisms of seizures in autism spectrum disorder. front. neurosci. 10, 192. doi:10.3389/fnins.2016.00192 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar fukuda, t., itoh, m., ichikawa, t., washiyama, k., and goto, y. (2005). delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of mecp2-deficient mice. j. neuropathol. exp. neurol. 64, 537&#x02013;544. doi:10.1093/jnen/64.6.537 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar gaetz, w., bloy, l., wang, d. j., port, r. g., blaskey, l., levy, s. e., et al. (2014). gaba estimation in the brains of children on the autism spectrum: measurement precision and regional cortical variation. neuroimage 86, 1&#x02013;9. doi:10.1016/j.neuroimage.2013.05.068 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar han, s., tai, c., jones, c. j., scheuer, t., and catterall, w. a. (2014). enhancement of inhibitory neurotransmission by gabaa receptors having &#x003b1;2,3-subunits ameliorates behavioral deficits in a mouse model of autism. neuron 81, 1282&#x02013;1289. doi:10.1016/j.neuron.2014.01.016 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar han, s., tai, c., westenbroek, r. e., yu, f. h., cheah, c. s., potter, g. b., et al. (2012). autistic-like behaviour in scn1a&#x0002b;/- mice and rescue by enhanced gaba-mediated neurotransmission. nature 489, 385&#x02013;390. doi:10.1038/nature11356 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar hipp, j. f., knoflach, f., comley, r., ballard, t. m., honer, m., trube, g., et al. (2021). basmisanil, a highly selective gaba a -&#x003b1;5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man. sci. rep. 11, 7700. doi:10.1038/s41598-021-87307-7 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar hogart, a., wu, d., lasalle, j. m., and schanen, n. c. (2010). the comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. neurobiol. dis. 38, 181&#x02013;191. doi:10.1016/j.nbd.2008.08.011 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar hu, x., rocco, b. r., fee, c., and sibille, e. (2019). cell type-specific gene expression of alpha 5 subunit-containing gamma-aminobutyric acid subtype a receptors in human and mouse frontal cortex. mol. neuropsychiatry 4, 204&#x02013;215. doi:10.1159/000495840 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar hvoslef-eide, m., nilsson, s. r., saksida, l. m., and bussey, t. j. (2016). cognitive translation using the rodent touchscreen testing approach. curr. top. behav. neurosci. 28, 423&#x02013;447. doi:10.1007/7854_2015_5007 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar kalsner, l., and chamberlain, s. j. (2015). prader-willi, angelman, and 15q11-q13 duplication syndromes. pediatr. clin. north am. 62, 587&#x02013;606. doi:10.1016/j.pcl.2015.03.004 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar koh, m. t., rosenzweig-lipson, s., and gallagher, m. (2013). selective gaba(a) &#x003b1;5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. neuropharmacology 64, 145&#x02013;152. doi:10.1016/j.neuropharm.2012.06.023 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar lim, c. s., kim, h., yu, n. k., kang, s. j., kim, t., ko, h. g., et al. (2017). enhancing inhibitory synaptic function reverses spatial memory deficits in shank2 mutant mice. neuropharmacology 112, 104&#x02013;112. doi:10.1016/j.neuropharm.2016.08.016 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar luk, h. m., and lo, i. f. (2016). angelman syndrome in hong kong chinese: a 20 years&#x00027; experience. eur. j. med. genet. 59, 315&#x02013;319. doi:10.1016/j.ejmg.2016.05.003 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar luscher, b., maguire, j. l., rudolph, u., and sibille, e. (2023). gaba(a) receptors as targets for treating affective and cognitive symptoms of depression. trends pharmacol. sci. 44, 586&#x02013;600. doi:10.1016/j.tips.2023.06.009 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mcfarlane, h. g., kusek, g. k., yang, m., phoenix, j. l., bolivar, v. j., and crawley, j. n. (2008). autism-like behavioral phenotypes in btbr t&#x0002b;tf/j mice. genes brain behav. 7, 152&#x02013;163. doi:10.1111/j.1601-183x.2007.00330.x pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mcnaughton, n., and morris, r. g. (1987). chlordiazepoxide, an anxiolytic benzodiazepine, impairs place navigation in rats. behav. brain res. 24, 39&#x02013;46. doi:10.1016/0166-4328(87)90034-9 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mendez, m. a., horder, j., myers, j., coghlan, s., stokes, p., erritzoe, d., et al. (2013). the brain gaba-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)c]ro15-4513 positron emission tomography study. neuropharmacology 68, 195&#x02013;201. doi:10.1016/j.neuropharm.2012.04.008 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mermer, f., poliquin, s., rigsby, k., rastogi, a., shen, w., romero-morales, a., et al. (2021). common molecular mechanisms of slc6a1 variant-mediated neurodevelopmental disorders in astrocytes and neurons. brain 144, 2499&#x02013;2512. doi:10.1093/brain/awab207 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mertz, l. g., christensen, r., vogel, i., hertz, j. m., nielsen, k. b., gronskov, k., et al. (2013). angelman syndrome in denmark. birth incidence, genetic findings, and age at diagnosis. am. j. med. genet. a 161a, 2197&#x02013;2203. doi:10.1002/ajmg.a.36058 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mesbah-oskui, l., penna, a., orser, b. a., and horner, r. l. (2017). reduced expression of &#x003b1;5gaba a receptors elicits autism-like alterations in eeg patterns and sleep-wake behavior. neurotoxicol teratol. 61, 115&#x02013;122. doi:10.1016/j.ntt.2016.10.009 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mohler, h. (2011). the rise of a new gaba pharmacology. neuropharmacology 60, 1042&#x02013;1049. doi:10.1016/j.neuropharm.2010.10.020 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mori, t., mori, k., fujii, e., toda, y., miyazaki, m., harada, m., et al. (2012). evaluation of the gabaergic nervous system in autistic brain: (123)i-iomazenil spect study. brain dev. 34, 648&#x02013;654. doi:10.1016/j.braindev.2011.10.007 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar myers, j. f., comley, r. a., and gunn, r. n. (2017). quantification of [ 11 c]ro15-4513 gaba a &#x003b1;5 specific binding and regional selectivity in humans. j. cereb. blood flow. metab. 37, 2137&#x02013;2148. doi:10.1177/0271678x16661339 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar nakamura, t., arima-yoshida, f., sakaue, f., nasu-nishimura, y., takeda, y., matsuura, k., et al. (2016). px-rics-deficient mice mimic autism spectrum disorder in jacobsen syndrome through impaired gabaa receptor trafficking. nat. commun. 7, 10861. doi:10.1038/ncomms10861 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar orefice, l. l., zimmerman, a. l., chirila, a. m., sleboda, s. j., head, j. p., and ginty, d. d. (2016). peripheral mechanosensory neuron dysfunction underlies tactile and behavioral deficits in mouse models of asds. cell 166, 299&#x02013;313. doi:10.1016/j.cell.2016.05.033 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar penagarikano, o., abrahams, b. s., herman, e. i., winden, k. d., gdalyahu, a., dong, h., et al. (2011). absence of cntnap2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. cell 147, 235&#x02013;246. doi:10.1016/j.cell.2011.08.040 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar percie du sert, n., hurst, v., ahluwalia, a., alam, s., avey, m. t., baker, m., et al. (2020). the arrive guidelines 2.0: updated guidelines for reporting animal research. plos biol. 18, e3000410. doi:10.1371/journal.pbio.3000410 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar perez, s. m., mccoy, a. m., prevot, t. d., mian, m. y., carreno, f. r., frazer, a., et al. (2023). hippocampal &#x003b1;5-gaba(a) receptors modulate dopamine neuron activity in the rat ventral tegmental area. biol. psychiatry glob. open sci. 3, 78&#x02013;86. doi:10.1016/j.bpsgos.2021.12.010 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar pirker, s., schwarzer, c., wieselthaler, a., sieghart, w., and sperk, g. (2000). gaba(a) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. neuroscience 101, 815&#x02013;850. doi:10.1016/s0306-4522(00)00442-5 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar pizzarelli, r., and cherubini, e. (2011). alterations of gabaergic signaling in autism spectrum disorders. neural plast. 2011, 297153. doi:10.1155/2011/297153 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar porjesz, b., almasy, l., edenberg, h. j., wang, k., chorlian, d. b., foroud, t., et al. (2002). linkage disequilibrium between the beta frequency of the human eeg and a gabaa receptor gene locus. proc. natl. acad. sci. u. s. a. 99, 3729&#x02013;3733. doi:10.1073/pnas.052716399 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar puts, n. a. j., wodka, e. l., harris, a. d., crocetti, d., tommerdahl, m., mostofsky, s. h., et al. (2017). reduced gaba and altered somatosensory function in children with autism spectrum disorder. autism res. 10, 608&#x02013;619. doi:10.1002/aur.1691 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar robertson, c. e., ratai, e. m., and kanwisher, n. (2016). reduced gabaergic action in the autistic brain. curr. biol. 26, 80&#x02013;85. doi:10.1016/j.cub.2015.11.019 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar rojas, d. c., singel, d., steinmetz, s., hepburn, s., and brown, m. s. (2014). decreased left perisylvian gaba concentration in children with autism and unaffected siblings. neuroimage 86, 28&#x02013;34. doi:10.1016/j.neuroimage.2013.01.045 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar rubenstein, j. l., and merzenich, m. m. (2003). model of autism: increased ratio of excitation/inhibition in key neural systems. genes brain behav. 2, 255&#x02013;267. doi:10.1034/j.1601-183x.2003.00037.x pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar sanders, s. j. (2015). first glimpses of the neurobiology of autism spectrum disorder. curr. opin. genet. dev. 33, 80&#x02013;92. doi:10.1016/j.gde.2015.10.002 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2018). dendrite-targeting interneurons control synaptic nmda-receptor activation via nonlinear &#x003b1;5-gaba a receptors. nat. commun. 9, 3576. doi:10.1038/s41467-018-06004-8 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2019). enhanced dendritic inhibition and impaired nmdar activation in a mouse model of down syndrome. j. neurosci. 39, 5210&#x02013;5221. doi:10.1523/jneurosci.2723-18.2019 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar serwanski, d. r., miralles, c. p., christie, s. b., mehta, a. k., li, x., and de blas, a. l. (2006). synaptic and nonsynaptic localization of gabaa receptors containing the alpha5 subunit in the rat brain. j. comp. neurol. 499, 458&#x02013;470. doi:10.1002/cne.21115 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar sieghart, w. (2006). structure, pharmacology, and function of gabaa receptor subtypes. adv. pharmacol. 54, 231&#x02013;263. doi:10.1016/s1054-3589(06)54010-4 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar sitnikova, e., rutskova, e., and smirnov, k. (2023). alpha2-adrenergic receptors as a pharmacological target for spike-wave epilepsy. int. j. mol. sci. 24, 1477. doi:10.3390/ijms24021477 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar smit, d. j. a., wright, m. j., meyers, j. l., martin, n. g., ho, y. y. w., malone, s. m., et al. (2018). genome-wide association analysis links multiple psychiatric liability genes to oscillatory brain activity. hum. brain mapp. 39, 4183&#x02013;4195. doi:10.1002/hbm.24238 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar souza, a. j., freitas, i. s., sharmin, d., cook, j. m., guimaraes, f. s., and gomes, f. v. (2024). an alpha 5-gaba(a) receptor positive allosteric modulator attenuates social and cognitive deficits without changing dopamine system hyperactivity in rats exposed to valproic acid in utero. autism res. 17, 1534&#x02013;1544. doi:10.1002/aur.3178 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar sur, c., fresu, l., howell, o., mckernan, r. m., and atack, j. r. (1999). autoradiographic localization of alpha5 subunit-containing gabaa receptors in rat brain. brain res. 822, 265&#x02013;270. doi:10.1016/s0006-8993(99)01152-x pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar traub, r. d. w. m., and jefferys, j. g. r. (1999). fast oscillations in cortical circuits . the mit press . google scholar van lier, h., drinkenburg, w. h., van eeten, y. j., and coenen, a. m. (2004). effects of diazepam and zolpidem on eeg beta frequencies are behavior-specific in rats. neuropharmacology 47, 163&#x02013;174. doi:10.1016/j.neuropharm.2004.03.017 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar visser, s. a., wolters, f. l., gubbens-stibbe, j. m., tukker, e., van der graaf, p. h., peletier, l. a., et al. (2003). mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of gabaa receptor modulators: in vitro-in vivo correlations. j. pharmacol. exp. ther. 304, 88&#x02013;101. doi:10.1124/jpet.102.042341 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar vithlani, m., terunuma, m., and moss, s. j. (2011). the dynamic modulation of gaba(a) receptor trafficking and its role in regulating the plasticity of inhibitory synapses. physiol. rev. 91, 1009&#x02013;1022. doi:10.1152/physrev.00015.2010 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar warrier, v., baron-cohen, s., and chakrabarti, b. (2013). genetic variation in gabrb3 is associated with asperger syndrome and multiple endophenotypes relevant to autism. mol. autism 4, 48. doi:10.1186/2040-2392-4-48 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar whittington, m. a., traub, r. d., kopell, n., ermentrout, b., and buhl, e. h. (2000). inhibition-based rhythms: experimental and mathematical observations on network dynamics. int. j. psychophysiol. 38, 315&#x02013;336. doi:10.1016/s0167-8760(00)00173-2 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar xie, x. h., and tietz, e. i. (1991). chronic benzodiazepine treatment of rats induces reduction of paired-pulse inhibition in ca1 region of in vitro hippocampus. brain res. 561, 69&#x02013;76. doi:10.1016/0006-8993(91)90750-p pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar zurek, a. a., kemp, s. w., aga, z., walker, s., milenkovic, m., ramsey, a. j., et al. (2016). &#x003b1;5gabaa receptor deficiency causes autism-like behaviors. ann. clin. transl. neurol. 3, 392&#x02013;398. doi:10.1002/acn3.303 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar keywords: autism spectrum disorder, angelman syndrome, gaba a , gaba a -&#x003b1;5, positron emission tomography (pet), electroencephalography, pharmacological mri, biomarker citation: cecere g, ballard tm, knoflach f, honer m, hipp jf, garces p, mueggler t, k&#x000fc;nnecke b, bruns a, prinssen ep, schoenenberger p, janz p, redondo r, biemans b, knust h, olivares-morales a, brigo a, schulz jm, bertrand d, saxe m, o&#x02019;connor ec and hernandez m-c (2025) preclinical pharmacology of alogabat: a novel gaba a -&#x003b1;5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gaba a signaling. front. pharmacol. 16:1626078. doi: 10.3389/fphar.2025.1626078 received: 09 may 2025; accepted: 18 june 2025; published: 21 july 2025. edited by: agenor limon , university of texas medical branch at galveston, united states reviewed by: hansen wang , university of toronto, canada junzhan jing , baylor college of medicine, united states azar omrani , boehringer ingelheim, germany copyright &#x000a9; 2025 cecere, ballard, knoflach, honer, hipp, garces, mueggler, k&#x000fc;nnecke, bruns, prinssen, schoenenberger, janz, redondo, biemans, knust, olivares-morales, brigo, schulz, bertrand, saxe, o&#x02019;connor and hernandez. this is an open-access article distributed under the terms of the creative commons attribution license (cc by). the use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. no use, distribution or reproduction is permitted which does not comply with these terms. &#x0002a;correspondence: maria-clemencia hernandez, bwfyawety2xlbwvuy2lhlmhlcm5hbmrlekbyb2nozs5jb20= &#x02020; these authors have contributed equally to this work &#x02021; present address: theresa m. ballard, galwyn (uk) ltd., dartmouth, united kingdom barbara biemans, b2discovery llc, riehen, switzerland michael saxe, translational in vivo sciences, biogen, cambridge, ma, united states disclaimer: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. download article download pdf readcube epub xml share on export citation endnote reference manager simple text file bibtex 2,218 total views 442 downloads citation numbers are available from dimensions view article impact view altmetric score share on edited by a l agenor limon reviewed by j j junzhan jing a o azar omrani h w hansen wang table of contents abstract 1 introduction 2 materials and methods 3 results 4 discussion 5 conclusion data availability statement ethics statement author contributions funding acknowledgments conflict of interest generative ai statement publisher&#x02019;s note supplementary material abbreviations references export citation endnote reference manager simple text file bibtex check for updates frontiers&#39; impact articles published with frontiers have received 12 million total citations your research is the real superpower - learn how we maximise its impact through our leading community journals explore our impact metrics supplementary material download article download download pdf readcube epub xml guidelines author guidelines services for authors policies and publication ethics editor guidelines fee policy explore articles research topics journals how we publish outreach frontiers forum frontiers policy labs frontiers for young minds frontiers planet prize connect help center emails and alerts contact us submit career opportunities follow us © 2025 frontiers media s.a. all rights reserved privacy policy | terms and conditions [["shallowreactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverrendered":13,"path":14,"pinia":15},["shallowreactive",3],{},["reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","frontiers articles","https://article-pages-2024.frontiersin.org/",["set"],["shallowreactive",12],{},true,"/journals/pharmacology/articles/10.3389/fphar.2025.1626078/full",["reactive",16],{"main":17,"user":511,"article":512,"articlehub":968,"mainheader":972},{"ibar":18,"footer":264,"newslettercomponent":-1,"snackbaritem":346,"toggleshowsnackbar":347,"contentfuljournal":348,"graphjournal":412,"settingsfeaturesswitchers":416,"templatetogglebanner":417,"tenantconfig":476},{"tenantlogo":19,"journallogo":19,"aboutus":20,"submiturl":113,"showsubmitbutton":13,"journal":114,"sectionterm":195,"aboutjournal":196,"mainlinks":245,"journallinks":252,"helpcenterlink":261},"",[21,38,47,71,87],{"title":22,"links":23},"who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"arialabel":28},"mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"arialabel":28},"history","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"arialabel":28},"leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"arialabel":28},"awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"impact and progress",[41,44],{"text":42,"url":43,"target":27,"arialabel":28},"frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"arialabel":28},"our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"arialabel":28},"how we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"arialabel":28},"open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"arialabel":28},"peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"arialabel":28},"research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"arialabel":28},"research topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"arialabel":28},"fair² data management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"arialabel":28},"fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"services",[74,78,81,84],{"text":75,"url":76,"target":77,"arialabel":28},"societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"arialabel":28},"national consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"arialabel":28},"institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"arialabel":28},"collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"more from frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"arialabel":93},"frontiers forum","https://forum.frontiersin.org/","this link will take you to the frontiers forum website",{"text":95,"url":96,"target":27,"arialabel":28},"frontiers planet prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"arialabel":100},"press office","https://pressoffice.frontiersin.org/","this link will take you to the frontiers press office website",{"text":102,"url":103,"target":27,"arialabel":104},"sustainability","https://www.frontiersin.org/about/sustainability","link to information about frontiers' sustainability",{"text":106,"url":107,"target":77,"arialabel":108},"career opportunities","https://careers.frontiersin.org/","this link will take you to the frontiers careers website",{"text":110,"url":111,"target":27,"arialabel":112},"contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=1&fieldid=62&specialtyid=0&entitytype=2&entityid=176",{"id":115,"name":116,"slug":117,"sections":118},176,"frontiers in pharmacology","pharmacology",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191],{"id":120,"name":121,"slug":122},182,"cardiovascular and smooth muscle pharmacology","cardiovascular-and-smooth-muscle-pharmacology",{"id":124,"name":125,"slug":126},199,"drug metabolism and transport","drug-metabolism-and-transport",{"id":128,"name":129,"slug":130},202,"drugs outcomes research and policies","drugs-outcomes-research-and-policies",{"id":132,"name":133,"slug":134},184,"ethnopharmacology","ethnopharmacology",{"id":136,"name":137,"slug":138},183,"experimental pharmacology and drug discovery","experimental-pharmacology-and-drug-discovery",{"id":140,"name":141,"slug":142},186,"gastrointestinal and hepatic pharmacology","gastrointestinal-and-hepatic-pharmacology",{"id":144,"name":145,"slug":146},188,"inflammation pharmacology","inflammation-pharmacology",{"id":148,"name":149,"slug":150},178,"integrative and regenerative pharmacology","integrative-and-regenerative-pharmacology",{"id":152,"name":153,"slug":154},26,"neuropharmacology","neuropharmacology",{"id":156,"name":157,"slug":158},196,"obstetric and pediatric pharmacology","obstetric-and-pediatric-pharmacology",{"id":160,"name":161,"slug":162},2186,"pharmacoepidemiology","pharmacoepidemiology",{"id":164,"name":165,"slug":166},198,"pharmacogenetics and pharmacogenomics","pharmacogenetics-and-pharmacogenomics",{"id":168,"name":169,"slug":170},192,"pharmacology of anti-cancer drugs","pharmacology-of-anti-cancer-drugs",{"id":172,"name":173,"slug":174},2216,"pharmacology of infectious diseases","pharmacology-of-infectious-diseases",{"id":176,"name":177,"slug":178},179,"pharmacology of ion channels and channelopathies","pharmacology-of-ion-channels-and-channelopathies",{"id":180,"name":181,"slug":182},195,"predictive toxicology","predictive-toxicology",{"id":184,"name":185,"slug":186},1357,"renal pharmacology","renal-pharmacology",{"id":188,"name":189,"slug":190},190,"respiratory pharmacology","respiratory-pharmacology",{"id":192,"name":193,"slug":194},1251,"translational pharmacology","translational-pharmacology","sections",[197,221],{"title":198,"links":199},"scope",[200,203,206,209,212,215,218],{"text":201,"url":202,"target":27,"arialabel":28},"field chief editors","https://www.frontiersin.org/journals/pharmacology/about#about-editors",{"text":204,"url":205,"target":27,"arialabel":28},"mission & scope","https://www.frontiersin.org/journals/pharmacology/about#about-scope",{"text":207,"url":208,"target":27,"arialabel":28},"facts","https://www.frontiersin.org/journals/pharmacology/about#about-facts",{"text":210,"url":211,"target":27,"arialabel":28},"journal sections","https://www.frontiersin.org/journals/pharmacology/about#about-submission",{"text":213,"url":214,"target":27,"arialabel":28},"open access statement","https://www.frontiersin.org/journals/pharmacology/about#about-open",{"text":216,"url":217,"target":27,"arialabel":28},"copyright statement","https://www.frontiersin.org/journals/pharmacology/about#copyright-statement",{"text":219,"url":220,"target":27,"arialabel":28},"quality","https://www.frontiersin.org/journals/pharmacology/about#about-quality",{"title":222,"links":223},"for authors",[224,227,230,233,236,239,242],{"text":225,"url":226,"target":27,"arialabel":28},"why submit?","https://www.frontiersin.org/journals/pharmacology/for-authors/why-submit",{"text":228,"url":229,"target":27,"arialabel":28},"article types","https://www.frontiersin.org/journals/pharmacology/for-authors/article-types",{"text":231,"url":232,"target":27,"arialabel":28},"author guidelines","https://www.frontiersin.org/journals/pharmacology/for-authors/author-guidelines",{"text":234,"url":235,"target":27,"arialabel":28},"editor guidelines","https://www.frontiersin.org/journals/pharmacology/for-authors/editor-guidelines",{"text":237,"url":238,"target":27,"arialabel":28},"publishing fees","https://www.frontiersin.org/journals/pharmacology/for-authors/publishing-fees",{"text":240,"url":241,"target":27,"arialabel":28},"submission checklist","https://www.frontiersin.org/journals/pharmacology/for-authors/submission-checklist",{"text":243,"url":244,"target":27,"arialabel":28},"contact editorial office","https://www.frontiersin.org/journals/pharmacology/for-authors/contact-editorial-office",[246,249],{"text":247,"url":248,"target":27,"arialabel":28},"all journals","https://www.frontiersin.org/journals",{"text":250,"url":251,"target":27,"arialabel":28},"all articles","https://www.frontiersin.org/articles",[253,256,258],{"text":254,"url":255,"target":27,"arialabel":28},"articles","articles",{"text":63,"url":257,"target":27,"arialabel":28},"research-topics",{"text":259,"url":260,"target":27,"arialabel":28},"editorial board","editors",{"text":262,"url":263,"target":77,"arialabel":262},"help center","https://helpcenter.frontiersin.org",{"blocks":265,"sociallinks":319,"copyright":343,"termsandconditionsurl":344,"privacypolicyurl":345},[266,280,290,304],{"title":267,"links":268},"guidelines",[269,271,274,277,279],{"text":231,"url":270,"target":27,"arialabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":272,"url":273,"target":27,"arialabel":28},"services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":275,"url":276,"target":27,"arialabel":28},"policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":234,"url":278,"target":27,"arialabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"arialabel":28},{"title":281,"links":282},"explore",[283,284,287,289],{"text":254,"url":251,"target":27,"arialabel":28},{"text":285,"url":286,"target":27,"arialabel":28},"research topics ","https://www.frontiersin.org/research-topics",{"text":288,"url":248,"target":27,"arialabel":28},"journals",{"text":51,"url":52,"target":27,"arialabel":28},{"title":291,"links":292},"outreach",[293,296,299,303],{"text":294,"url":92,"target":77,"arialabel":295},"frontiers forum ","frontiers forum website",{"text":297,"url":298,"target":77,"arialabel":28},"frontiers policy labs ","https://policylabs.frontiersin.org/",{"text":300,"url":301,"target":77,"arialabel":302},"frontiers for young minds","https://kids.frontiersin.org/","frontiers for young minds journal",{"text":95,"url":96,"target":27,"arialabel":28},{"title":305,"links":306},"connect",[307,308,312,315,318],{"text":262,"url":263,"target":77,"arialabel":262},{"text":309,"url":310,"target":77,"arialabel":311},"emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","subscribe to frontiers emails",{"text":313,"url":111,"target":27,"arialabel":314},"contact us ","subscribe to newsletter",{"text":316,"url":317,"target":27,"arialabel":28},"submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"arialabel":28},[320,328,333,338],{"link":321,"type":324,"color":325,"icon":326,"size":327,"hiddentext":13},{"text":322,"url":323,"target":77,"arialabel":322},"frontiers facebook","https://www.facebook.com/frontiersin","link","grey","facebook","medium",{"link":329,"type":324,"color":325,"icon":332,"size":327,"hiddentext":13},{"text":330,"url":331,"target":77,"arialabel":28},"frontiers twitter","https://twitter.com/frontiersin","twitter",{"link":334,"type":324,"color":325,"icon":337,"size":327,"hiddentext":13},{"text":335,"url":336,"target":77,"arialabel":28},"frontiers linkedin","https://www.linkedin.com/company/frontiers","linkedin",{"link":339,"type":324,"color":325,"icon":342,"size":327,"hiddentext":13},{"text":340,"url":341,"target":77,"arialabel":28},"frontiers instagram","https://www.instagram.com/frontiersin_","instagram","frontiers media s.a. all rights reserved","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":349,"identifier":115,"name":116,"slug":117,"banner":350,"description":405,"mission":406,"palette":407,"impactfactor":408,"citescore":409,"citations":410,"showtagline":28,"twitter":411},"journal",[351],{"id":352,"src":353,"name":354,"tags":355,"type":363,"width":364,"height":365,"idhash":366,"archive":367,"brandid":368,"limited":367,"filesize":369,"ispublic":370,"original":371,"copyright":372,"extension":373,"thumbnails":375,"datecreated":383,"description":384,"orientation":385,"usercreated":386,"watermarked":367,"datemodified":383,"datepublished":387,"ecsarchivefiles":388,"propertyoptions":389,"property_channel":394,"property_sub-type":396,"property_asset_type":398,"activeoriginalfocuspoint":400,"property_office_department":403},"754e12a9-443f-4ea8-ab01e0811e45131d","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/webimage-9d720582-24ad-4d2e-9205ab9d241919da.jpg","fphar_main visual_purple_website",[356,357,358,359,360,361,362],"pain","medical","pharmaceutical","antibiotic","concept","capsule","treatment","image",5844,3896,"79b643019a2651e0",0,"22c10171-81b3-4da6-99342f272a32e8bb",8675243,1,"https://brand.frontiersin.org/m/79b643019a2651e0/original/fphar_main-visual_purple_website.jpeg","copyright (c) 2017 marian weyo/shutterstock. no use without permission.",[374],"jpeg",{"mini":376,"thul":377,"webimage":353,"guidelines":378,"websitejpg_xl":379,"websitewebp_l":380,"websitewebp_m":381,"websitewebp_xl":382},"https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/mini-97eef455-249b-43bd-9d8f02fee86046d3.jpg","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/thul-b2dbd910-1ddf-4ed3-b1500df973953144.jpg","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/guidelines-fphar_main visual_purple_website.png","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitejpg_xl-fphar_main visual_purple_website.jpg","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitewebp_l-fphar_main visual_purple_website.webp","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitewebp_m-fphar_main visual_purple_website.webp","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitewebp_xl-fphar_main visual_purple_website.webp","2022-06-27t10:00:45z","pills tablets capsule or medicament freely laid on glass background.","landscape","caroline sutter","2022-06-27t09:27:09z",[],[390,391,392,393],"414fb2d4-2283-43fd-be14e534eca67928","6c18119b-14bd-4951-b437696f4357bd33","7c692885-db25-4858-b1fb4ff47b241e9b","d88c0047-ec30-4506-a7df28a4d765e1cf",[395],"frontiersin_org",[397],"main_visual",[399],"photography",{"x":401,"y":402},2922,1948,[404],"publishing","the world's most cited pharmacology and pharmacy journal, advancing global pharmacological discoveries to prevent and treat human disease.","\u003cp>frontiers in pharmacology is an interdisciplinary journal that publishes research on the interactions between drugs and living beings to prevent and cure human disease.\u003c/p>\n\n\u003cp>led by field chief editor heike wulff (university of california, davis, us), frontiers in pharmacology explores basic and clinical pharmacology, medicinal chemistry, pharmacy, and toxicology to clarify the fundamental processes of disease treatment and drug effects. indexed in pubmed central (pmc), scopus, web of science (scie), and the doaj, the journal welcomes academic, industrial, and clinical work focused on pharmacology.\u003c/p>\n\n\u003cp>topics include, but are not limited to:\u003c/p>\n\u003cul>\n \u003cli>cardiovascular and smooth muscle pharmacology\u003c/li>\n \u003cli>drug metabolism and transport\u003c/li>\n \u003cli>drugs outcomes research and policies\u003c/li>\n \u003cli>elsi in science and genetics\u003c/li>\n \u003cli>ethnopharmacology\u003c/li>\n \u003cli>experimental pharmacology and drug discovery\u003c/li>\n \u003cli>gastrointestinal and hepatic pharmacology\u003c/li>\n \u003cli>inflammation pharmacology\u003c/li>\n \u003cli>integrative and regenerative pharmacology\u003c/li>\n \u003cli>neuropharmacology\u003c/li>\n \u003cli>obstetric and pediatric pharmacology\u003c/li>\n \u003cli>pharmacoepidemiology\u003c/li>\n \u003cli>pharmacogenetics and pharmacogenomics\u003c/li>\n \u003cli>pharmacology of anti-cancer drugs\u003c/li>\n \u003cli>pharmacology of infectious diseases\u003c/li>\n \u003cli>pharmacology of ion channels and channelopathies\u003c/li>\n \u003cli>predictive toxicology\u003c/li>\n \u003cli>renal pharmacology\u003c/li>\n \u003cli>respiratory pharmacology\u003c/li>\n \u003cli>translational pharmacology.\u003c/li>\n\u003c/ul>\n\n\u003cp>all submissions to the journal involving natural products, including plant extracts or preparations, must adhere to \u003ci>'the four pillars of ethnopharmacology'\u003c/i> to be considered for peer review, regardless of the specialty section, as a baseline standard for sample characterization. these are a set of mandatory guidelines designed to maintain the scientific, cultural, and ethical integrity of the journal, and describe what the leading journals in the field consider as the basic aspects of good research (full conphymp statement available \u003ca href=\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.953205/full\" target=\"_blank\">here\u003c/a>, conphymp statement overview \u003ca href=\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1338710/full\" target=\"_blank\">here\u003c/a>, and ga-tool \u003ca href=\"https://ga-online.org/best-practice/\" target=\"_blank\">here\u003c/a>). please refer to the \u003ca href=\"https://assets.ctfassets.net/41vi7p4898pd/63dcrrxgncg4b1stfayeh8/1b87b9a742b0610ace5b19fd11f62359/four_pillars_ethnopharmacology_2025.pdf\" target=\"_blank\">full version\u003c/a> of these guidelines before submitting a manuscript to the journal.\u003c/p> \n\u003cp>to be considered for publication in frontiers in pharmacology, studies incorporating complementary or alternative medicine must be based on a set of data linked to local or traditional uses that can be evaluated pharmacologically. a clear and plausible set of pharmacological data must be generated in these studies. similarly, the journal endorses protocols including a minimum of 2 cell-lines in vitro as an evidential basis to demonstrate proposed anti-cancer effects in all relevant studies submitted to all specialty sections in the journal.\u003c/p>\n\u003cp>isolated data mining studies using disproportionality analyses of databases containing spontaneously reported adverse events, frequently lead to misinterpretation due to various reporting biases, lack of structured control, and insufficient demographic details. presenting such analyses in isolation typically does not yield clinically actionable safety findings without the broader context of a comprehensive signal evaluation. to ensure rigor and relevance, all submissions to the journal must be complemented by a proper systematic review and/or thorough analyses of reported cases, and adhere to the readus-pv guidelines (\u003ca href=\"https://www.equator-network.org/reporting-guidelines/the-reporting-of-a-disproportionality-analysis-for-drug-safety-signal-detection-using-individual-case-safety-reports-in-pharmacovigilance-readus-pv-development-and-statement/\" target=\"_blank\">the reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance\u003c/a>). authors are expected to ensure compliance with the corresponding \u003ca href=\"https://readus-statement.org/wp-content/uploads/2024/03/readus-checklist.pdf\" target=\"_blank\">checklist\u003c/a> before proceeding with submission to the journal. full publication of the readus-pv guidelines is available \u003ca href=\"https://pmc.ncbi.nlm.nih.gov/articles/pmc11116242/pdf/40264_2024_article_1421.pdf\" target=\"_blank\">here\u003c/a>.\u003c/p>\n\n\u003cp>frontiers’ journals require that manuscripts primarily comprising computational studies of public data, such as nhanes or mendelian randomization studies, must include appropriate validation. please refer to the \u003ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology:~:text=complaints%20and%20allegations.-,standards%20for%20research%20methodology,-experiments\">frontiers standards for research methodology policy\u003c/a>, for more information. manuscripts not adhering to these standards will not be considered.\u003cp>\n\n\u003cp>further unique criteria for the conception and review of submissions may apply, where appropriate, for individual specialty sections.\u003c/p>\n\n\u003cp>the journal welcomes submissions that support and advance the \u003ca href=\"https://www.globalgoals.org/goals/\" target=\"_blank\">un sustainable development goals\u003c/a> (sdgs), notably the \u003ca href=\"https://www.globalgoals.org/goals/3-good-health-and-well-being/\" target=\"_blank\">sdg 3: good health and well-being\u003c/a>.\u003c/p>\n\n\u003cp>manuscripts that focus solely on clinical trials, patient management, or conventional therapies without a focus on pharmacological research are not suitable for publication in this journal. additionally, studies that are purely statistical or predictive in nature, without providing novel insights into pharmacological mechanisms or drug development, are not within the scope of this journal.\u003c/p>\n\n\u003cp>frontiers in pharmacology is committed to advancing developments in the field of pharmacological discoveries by allowing unrestricted access to articles and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.\u003c/p>\n\n\u003cb>\u003cp>ethics information\u003c/p>\u003c/b>\n\u003cp>research involving human subjects should comply with the ethical guidelines outlined in the \u003ca href= https://www.wma.net/policies-post/wma-declaration-of-helsinki/” target=”_blank”>world medical association’s declaration of helsinki\u003c/a>.\u003c/p>\n\u003cp>similarly, authors are required to specify the institutional and national standards adhered to for the care and use of laboratory animals. transparent and accurate reporting of animal studies is required, with references to guidelines such as \u003ca href=\"https://arriveguidelines.org/arrive-guidelines\" target=\"_blank\">arrive\u003c/a> and \u003ca href=\"https://nc3rs.org.uk/sites/default/files/2022-01/the%20improve%20guidelines%20%28poster%29.pdf\" target=\"_blank\"> improve\u003c/a>.\u003c/p>\n\u003cp>extended information on research ethics can be found under the frontiers policies and publication ethics page.\u003c/p>","purple","5.6","6.3","531663","@frontpharmacol",{"id":115,"name":116,"slug":117,"abbreviation":413,"isonline":13,"isopenforsubmissions":13,"citescore":414,"impactfactor":415},"fphar",8.9,4.8,{"displaytitlepilllabels":13,"displayrelatedarticlesbox":13,"showeditors":13,"showreviewers":13,"showloopimpactlink":13,"enablefigshare":347,"usexmlimages":13},{"ispublic":13,"allowcompanyusers":347,"whitelistemails":418,"enablealljournals":13,"whitelistjournals":440},[419,420,421,422,423,424,425,426,427,424,428,429,430,431,432,433,434,435,436,437,438,439],"y2fybg9zlmxvcmnhqgzyb250awvyc2lulm9yzw==","zgfuawvslmx1ekbmcm9udgllcnnpbi5vcmc=","bgf1cmeudgvuyubmcm9udgllcnnpbi5vcmc=","cmfmywvslnjpyw5jag9aznjvbnrpzxjzaw4ub3jn","amftzxmuc21hbgxib25lqgzyb250awvyc2lulm9yzw==","znjhbi5tb3jlbm9aznjvbnrpzxjzaw4ub3jn","c2ftdwvslmzlcm5hbmrlekbmcm9udgllcnnpbi5vcmc=","ymfyymfyys5jyxjjyw5naxvaznjvbnrpzxjzaw4ub3jn","axzhbi5zyw50yw1hcmlhqgzyb250awvyc2lulm9yzw==","ahvllnryyw5aznjvbnrpzxjzaw4ub3jn","z29uy2fsby52yxjnyxnaznjvbnrpzxjzaw4ub3jn","bhvjawuuc2vubkbmcm9udgllcnnpbi5vcmc=","bg9ybi5mcmfzzxjaznjvbnrpzxjzaw4ub3jn","zwxzys5jyxjyb25aznjvbnrpzxjzaw4ub3jn","bwfhcnrlbi52yw5kawpja0bmcm9udgllcnnpbi5vcmc=","ymluzgh1lmtyaxnobmfuqgzyb250awvyc2lulm9yzw==","bwf0dghldy5hdhr3yxrlcnnaznjvbnrpzxjzaw4ub3jn","z2l1bglhlnzhbhnly2noaubmcm9udgllcnnpbi5vcmc=","zmfiawfulmrlbgxhbw9ydgvaznjvbnrpzxjzaw4ub3jn","dmlqyxlhbi5wcebwaxrzb2x1dglvbnmuy29t","z3vpbgxhdw1llnnldxjhdebmcm9udgllcnnpbi5vcmc=",[441,442,443,444,445,446,370,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,115,469,470,471,472,473,474,475],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,451,141,1335,2655,1238,604,698,1547,1440,403,1239,755,2136,609,1534,{"spaceid":370,"name":370,"availablejournalpages":477,"announcement":481},[255,260,257,478,479,480],"volumes","about","community-reviewers",{"__typename":482,"sys":483,"preheader":42,"title":485,"description":486,"image":487,"link":509},"announcement",{"id":484},"5ittnttqgazppgh6rx0alm","articles published with frontiers have received 12 million total citations","your research is the real superpower - learn how we maximise its impact through our leading community journals",[488],{"archive":367,"brandid":368,"copyright":28,"datecreated":489,"datemodified":490,"datepublished":491,"description":28,"extension":492,"filesize":494,"height":495,"id":496,"ispublic":367,"limited":367,"name":497,"orientation":385,"original":28,"thumbnails":498,"type":363,"watermarked":367,"width":505,"videopreviewurls":506,"tags":507,"textmetaproperties":508,"src":499},"2025-06-18t12:58:01z","2025-06-18t14:15:34z","2025-06-18t12:57:32z",[493],"png",1365026,920,"7c5269c4-3c83-4591-951a74d15b95daea","impact metrics banner for article pages",{"webimage":499,"thul":500,"mini":501,"websitewebp_l":502,"websitewebp_m":503,"guidelines":504},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/websitewebp_l/impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/websitewebp_m/impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/guidelines/impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":510,"url":43,"target":27,"arialabel":28},"explore our impact metrics",{"loggeduserinfo":-1},{"currentarticle":513,"ispreviewpage":347,"hassupplementaldata":347,"showcrossmarkwidget":13,"articletemplate":758,"currentarticlepagemetainfo":759,"xmlparsedarticlecontent":-1,"xmlparsingerror":-1},{"id":514,"doi":515,"title":516,"acceptancedate":517,"receptiondate":518,"publicationdate":519,"lastmodifieddate":520,"ispublished":13,"abstract":521,"researchtopic":28,"articletype":522,"stage":525,"keywords":527,"authors":536,"editors":682,"reviewers":690,"journal":712,"section":719,"impactmetrics":721,"volume":724,"articlevolume":725,"relatedarticles":726,"ispublishedv2":13,"contents":727,"files":731},1626078,"10.3389/fphar.2025.1626078","preclinical pharmacology of alogabat: a novel gabaa-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gabaa signaling","2025-06-18t08:27:15.000z","2025-05-09t23:15:40.000z","2025-07-21t00:00:00.000z","2025-10-21t02:34:53.269z","backgroundalterations in the gabaergic system contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder (asd) and angelman syndrome (as), particularly in cases involving large deletions in the 15q11–13 region. positive modulation of gabaa-α5 receptors may provide a novel therapeutic approach without the typical side effects associated with non-selective gabaa positive allosteric modulators such as diazepam.methodsalogabat was assessed for binding and functional activity at gabaa-α5β3γ2 receptors in vitro and in electrophysiological studies using hippocampal slices. in vivo studies in rodents included receptor occupancy (ro) using a selective gabaa-α5 tracer (autoradiography), pharmacological mri, and electroencephalography (eeg). alogabat was evaluated for its effects on the repetitive behavior phenotype in btbr and contactin-associated protein-like 2 (cntnap2−/−) knockout mice, seizure models, cognitive performance in rats, and rotarod performance following combination treatment with diazepam.resultsalogabat is a potent positive allosteric modulator of gabaa-α5 receptors, with binding and functional selectivity. receptor occupancy studies provided direct proof of dose-dependent target engagement. functional circuit modulation was demonstrated by dose-dependent regional perfusion changes in pharmacological mri and changes in eeg theta- and beta-band power in rats. at >50% gabaa-α5 receptor occupancy, alogabat normalized elevated self-grooming behavior in both cntnap2−/− and btbr mice and exhibited antiepileptic activity in rats. alogabat did not impair cognition in wildtype rats at gabaa-α5 receptor occupancy up to 75%, although impairment occurred at higher doses, probably due to increased activity at other receptor subtypes and/or saturation of α5 receptors. alogabat did not worsen diazepam-induced impairment on the rotarod test.conclusionalogabat showed beneficial effects in mouse models relevant to neurodevelopmental disorders and anti-seizure activity at doses that did not produce cognitive, sedative, or motoric side effects.",{"id":523,"name":524},24,"original research",{"id":526,"name":19},18,[528,529,530,531,532,533,534,535],"biomarker","autism spectrum disorder","electroencephalography","positron emission tomography (pet)","angelman syndrome","gabaa","gabaa-α5","pharmacological mri",[537,546,554,560,566,573,580,587,594,600,606,612,617,623,629,635,643,650,656,664,668,675],{"id":538,"firstname":539,"middlename":19,"lastname":540,"givennames":541,"iscorresponding":347,"isprofilepublic":13,"userid":538,"email":-1,"affiliations":542},3088634,"giuseppe","cecere","giuseppe ",[543],{"organizationname":544,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"medicinal chemistry","switzerland",{"id":547,"firstname":548,"middlename":19,"lastname":549,"givennames":550,"iscorresponding":347,"isprofilepublic":13,"userid":547,"email":-1,"affiliations":551},3064665,"theresa m.","ballard","theresa m. ",[552],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"neuroscience and rare diseases",{"id":367,"firstname":555,"middlename":19,"lastname":556,"givennames":557,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":558},"frederic","knoflach","frederic ",[559],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":561,"middlename":19,"lastname":562,"givennames":563,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":564},"michael","honer","michael ",[565],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":567,"firstname":568,"middlename":19,"lastname":569,"givennames":570,"iscorresponding":347,"isprofilepublic":13,"userid":567,"email":-1,"affiliations":571},81732,"joerg f.","hipp","joerg f. ",[572],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":574,"firstname":575,"middlename":19,"lastname":576,"givennames":577,"iscorresponding":347,"isprofilepublic":13,"userid":574,"email":-1,"affiliations":578},2412410,"pilar","garces","pilar ",[579],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":581,"firstname":582,"middlename":19,"lastname":583,"givennames":584,"iscorresponding":347,"isprofilepublic":13,"userid":581,"email":-1,"affiliations":585},13967,"thomas","mueggler","thomas ",[586],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":588,"firstname":589,"middlename":19,"lastname":590,"givennames":591,"iscorresponding":347,"isprofilepublic":13,"userid":588,"email":-1,"affiliations":592},577428,"basil","künnecke","basil ",[593],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":595,"middlename":19,"lastname":596,"givennames":597,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":598},"andreas","bruns","andreas ",[599],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":601,"middlename":19,"lastname":602,"givennames":603,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":604},"eric p.","prinssen","eric p. ",[605],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":607,"middlename":19,"lastname":608,"givennames":609,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":610},"philipp","schoenenberger","philipp ",[611],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":613,"firstname":607,"middlename":19,"lastname":614,"givennames":609,"iscorresponding":347,"isprofilepublic":13,"userid":613,"email":-1,"affiliations":615},2424959,"janz",[616],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":618,"middlename":19,"lastname":619,"givennames":620,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":621},"roger","redondo","roger ",[622],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":624,"middlename":19,"lastname":625,"givennames":626,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":627},"barbara","biemans","barbara ",[628],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":630,"middlename":19,"lastname":631,"givennames":632,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":633},"henner","knust","henner ",[634],{"organizationname":544,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":636,"firstname":637,"middlename":19,"lastname":638,"givennames":639,"iscorresponding":347,"isprofilepublic":13,"userid":636,"email":-1,"affiliations":640},2264913,"andrés","olivares-morales","andrés ",[641],{"organizationname":642,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"pharmaceutical sciences",{"id":644,"firstname":645,"middlename":19,"lastname":646,"givennames":647,"iscorresponding":347,"isprofilepublic":13,"userid":644,"email":-1,"affiliations":648},1172717,"alessandro","brigo","alessandro ",[649],{"organizationname":642,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":651,"middlename":19,"lastname":652,"givennames":653,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":654},"jan michael","schulz","jan michael ",[655],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":657,"firstname":658,"middlename":19,"lastname":659,"givennames":660,"iscorresponding":347,"isprofilepublic":13,"userid":657,"email":-1,"affiliations":661},157846,"daniel","bertrand","daniel ",[662],{"organizationname":663,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"hiqscreen sàrl",{"id":367,"firstname":561,"middlename":19,"lastname":665,"givennames":563,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":666},"saxe",[667],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":669,"firstname":670,"middlename":19,"lastname":671,"givennames":672,"iscorresponding":347,"isprofilepublic":13,"userid":669,"email":-1,"affiliations":673},2733790,"eoin c.","o’connor","eoin c. ",[674],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":676,"firstname":677,"middlename":19,"lastname":678,"givennames":679,"iscorresponding":347,"isprofilepublic":13,"userid":676,"email":-1,"affiliations":680},2269471,"maria-clemencia","hernandez","maria-clemencia ",[681],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},[683],{"id":684,"firstname":685,"middlename":19,"lastname":686,"givennames":687,"iscorresponding":347,"isprofilepublic":13,"userid":684,"email":-1,"affiliations":688},52072,"agenor","limon","agenor ",[689],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},[691,698,705],{"id":692,"firstname":693,"middlename":19,"lastname":694,"givennames":695,"iscorresponding":347,"isprofilepublic":13,"userid":692,"email":-1,"affiliations":696},1285968,"junzhan","jing","junzhan ",[697],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},{"id":699,"firstname":700,"middlename":19,"lastname":701,"givennames":702,"iscorresponding":347,"isprofilepublic":13,"userid":699,"email":-1,"affiliations":703},1380630,"azar","omrani","azar ",[704],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},{"id":706,"firstname":707,"middlename":19,"lastname":708,"givennames":709,"iscorresponding":347,"isprofilepublic":13,"userid":706,"email":-1,"affiliations":710},39673,"hansen","wang","hansen ",[711],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},{"id":115,"slug":117,"name":116,"shortname":713,"electronicissn":714,"field":715,"specialtyid":28,"journalsectionpaths":717},"front. pharmacol.","1663-9812",{"id":716,"domainid":370},62,[718],{"section":719},{"id":152,"name":153,"slug":154,"specialtyid":720},762,{"views":722,"downloads":723,"citations":367},2218,442,16,"volume 16 - 2025",[],{"titlehtml":728,"fulltexthtml":729,"menuhtml":730},"preclinical pharmacology of alogabat: a novel gaba\u003csub>a\u003c/sub>-&#x003b1;5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gaba\u003csub>a\u003c/sub> signaling","\u003cdiv class=\"journalabstract\">\u003ca id=\"h1\" name=\"h1\">\u003c/a>\u003cdiv class=\"authors\">\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/3088634\" class=\"user-id-3088634\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/3088634/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"giuseppe cecere&#x;\">giuseppe cecere\u003c/a>\u003csup>1\u003c/sup>\u003csup>&#x02020;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/3064665\" class=\"user-id-3064665\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/3064665/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"theresa m. ballard&#x;&#x;\">theresa m. ballard\u003c/a>\u003csup>2\u003c/sup>\u003csup>&#x02020;\u003c/sup>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"frederic knoflach&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">frederic knoflach\u003csup>2\u003c/sup>\u003csup>&#x02020;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"michael honer\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">michael honer\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/81732\" class=\"user-id-81732\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/81732/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"joerg f. hipp\">joerg f. hipp\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2412410\" class=\"user-id-2412410\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2412410/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"pilar garces\">pilar garces\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/13967\" class=\"user-id-13967\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/13967/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"thomas mueggler\">thomas mueggler\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/577428\" class=\"user-id-577428\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/577428/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"basil k&#xfc;nnecke\">basil k&#x000fc;nnecke\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"andreas bruns\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">andreas bruns\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"eric p. prinssen\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">eric p. prinssen\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"philipp schoenenberger\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">philipp schoenenberger\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2424959\" class=\"user-id-2424959\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2424959/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"philipp janz\">philipp janz\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"roger redondo\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">roger redondo\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"barbara biemans&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">barbara biemans\u003csup>2\u003c/sup>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"henner knust\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">henner knust\u003csup>1\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2264913\" class=\"user-id-2264913\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2264913/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"andr&#xe;s olivares-morales\">andr&#x000e9;s olivares-morales\u003c/a>\u003csup>3\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/1172717\" class=\"user-id-1172717\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1172717/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"alessandro brigo\">alessandro brigo\u003c/a>\u003csup>3\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"jan michael schulz\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">jan michael schulz\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/157846\" class=\"user-id-157846\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/157846/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"daniel bertrand\">daniel bertrand\u003c/a>\u003csup>4\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"michael saxe&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">michael saxe\u003csup>2\u003c/sup>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2733790\" class=\"user-id-2733790\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2733790/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"eoin c. o&#x;connor\">eoin c. o&#x02019;connor\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2269471\" class=\"user-id-2269471\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2269471/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"maria-clemencia hernandez&#xa;\">maria-clemencia hernandez\u003c/a>\u003csup>2\u003c/sup>&#x0002a;\u003c/span>\u003c/div>\u003cul class=\"notes\">\u003cli>\u003cspan>\u003csup>1\u003c/sup>\u003c/span>medicinal chemistry, roche pharmaceutical research and early development, roche innovation center basel, basel, switzerland\u003c/li>\u003cli>\u003cspan>\u003csup>2\u003c/sup>\u003c/span>neuroscience and rare diseases, roche pharmaceutical research and early development, roche innovation center basel, basel, switzerland\u003c/li>\u003cli>\u003cspan>\u003csup>3\u003c/sup>\u003c/span>pharmaceutical sciences, roche pharmaceutical research and early development, roche innovation center basel, basel, switzerland\u003c/li>\u003cli>\u003cspan>\u003csup>4\u003c/sup>\u003c/span>hiqscreen s&#x000e0;rl, v&#x000e9;senaz, switzerland\u003c/li>\u003c/ul>\u003cp class=\"mb0\">\u003cb>background:\u003c/b> alterations in the gabaergic system contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder (asd) and angelman syndrome (as), particularly in cases involving large deletions in the 15q11&#x02013;13 region. positive modulation of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors may provide a novel therapeutic approach without the typical side effects associated with non-selective gaba\u003csub>a\u003c/sub> positive allosteric modulators such as diazepam.\u003c/p>\u003cp class=\"mb0\">\u003cb>methods:\u003c/b> alogabat was assessed for binding and functional activity at gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 receptors \u003cem>in vitro\u003c/em> and in electrophysiological studies using hippocampal slices. \u003cem>in vivo\u003c/em> studies in rodents included receptor occupancy (ro) using a selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 tracer (autoradiography), pharmacological mri, and electroencephalography (eeg). alogabat was evaluated for its effects on the repetitive behavior phenotype in btbr and contactin-associated protein-like 2 (cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup>) knockout mice, seizure models, cognitive performance in rats, and rotarod performance following combination treatment with diazepam.\u003c/p>\u003cp class=\"mb0\">\u003cb>results:\u003c/b> alogabat is a potent positive allosteric modulator of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors, with binding and functional selectivity. receptor occupancy studies provided direct proof of dose-dependent target engagement. functional circuit modulation was demonstrated by dose-dependent regional perfusion changes in pharmacological mri and changes in eeg theta- and beta-band power in rats. at &#x0003e;50% gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor occupancy, alogabat normalized elevated self-grooming behavior in both cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> and btbr mice and exhibited antiepileptic activity in rats. alogabat did not impair cognition in wildtype rats at gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor occupancy up to 75%, although impairment occurred at higher doses, probably due to increased activity at other receptor subtypes and/or saturation of &#x003b1;5 receptors. alogabat did not worsen diazepam-induced impairment on the rotarod test.\u003c/p>\u003cp class=\"mb0\">\u003cb>conclusion:\u003c/b> alogabat showed beneficial effects in mouse models relevant to neurodevelopmental disorders and anti-seizure activity at doses that did not produce cognitive, sedative, or motoric side effects.\u003c/p>\u003cdiv class=\"clear\">\u003c/div>\u003c/div>\u003cdiv class=\"journalfulltext\">\u003ca id=\"h2\" name=\"h2\">\u003c/a>\u003ch2>1 introduction\u003c/h2>\u003cp class=\"mb15\">alterations in the gabaergic system, the main inhibitory neurotransmitter system in the brain, may contribute to the pathophysiology of neurodevelopmental disorders (ndds), such as autism spectrum disorder (asd) and angelman syndrome (as). asd is a complex, heterogeneous ndd with both genetic and environmental factors (\u003ca href=\"#b7\">bourgeron, 2015\u003c/a>) contributing to aberrant changes in brain growth, neuronal development, and functional connectivity (\u003ca href=\"#b18\">dhossche et al., 2002\u003c/a>; \u003ca href=\"#b55\">pizzarelli and cherubini, 2011\u003c/a>; \u003ca href=\"#b8\">braat and kooy, 2015\u003c/a>; \u003ca href=\"#b58\">robertson et al., 2016\u003c/a>). asd is characterized by two core domains: impairments in social interaction and communication and the presence of repetitive or restricted behaviors, interests, or activities (\u003ca href=\"#b3\">american psychiatric association, 2008\u003c/a>). there are a range of comorbid conditions, including irritability, depression, anxiety, attention deficits, obsessive-compulsive symptoms, seizures, and sleep disruption. as is a rare genetic ndd with a prevalence of 1 in 12,000 to 20,000 births (\u003ca href=\"#b38\">luk and lo, 2016\u003c/a>; \u003ca href=\"#b44\">mertz et al., 2013\u003c/a>). individuals with as often present with autistic features, severe intellectual disability, microcephaly, speech impairment, bursts of laughter, sleep problems, movement disorders, and epilepsy (\u003ca href=\"#b12\">buiting, 2010\u003c/a>; \u003ca href=\"#b35\">kalsner and chamberlain, 2015\u003c/a>).\u003c/p>\u003cp class=\"mb15\">gaba\u003csub>a\u003c/sub> receptors are ligand-gated chloride channels. there are 19 genes encoding gaba\u003csub>a\u003c/sub> receptor subunits that assemble as pentamers, with the most common stoichiometry being two &#x003b1;, two &#x003b2;, and one &#x003b3; subunit. gaba\u003csub>a\u003c/sub> subunit combinations give rise to functional, circuit, and behavioral specificity (\u003ca href=\"#b65\">sieghart, 2006\u003c/a>; \u003ca href=\"#b73\">vithlani et al., 2011\u003c/a>). gaba\u003csub>a\u003c/sub> receptors that contain the &#x003b1;5 subunit (gaba\u003csub>a\u003c/sub>-&#x003b1;5) are of particular interest due to their restricted pattern of expression and unique physiological and pharmacological properties (\u003ca href=\"#b69\">sur et al., 1999\u003c/a>; \u003ca href=\"#b46\">mohler, 2011\u003c/a>). in humans, gaba\u003csub>a\u003c/sub> receptors containing the &#x003b1;5 subunit are preferentially localized in the hippocampus, prefrontal cortex, nucleus accumbens, amygdala, insular cortex, anterior cingulate, and cingulate cortex&#x02014;key regions believed to be involved in the neuropathology and pathophysiology of asd (\u003ca href=\"#b42\">mendez et al., 2013\u003c/a>; \u003ca href=\"#b48\">myers et al., 2017\u003c/a>). the \u003cem>gabra5\u003c/em> gene has been proposed as a candidate gene for asd (\u003ca href=\"#b15\">delong, 2007\u003c/a>; \u003ca href=\"#b45\">mesbah-oskui et al., 2017\u003c/a>; \u003ca href=\"#b74\">warrier et al., 2013\u003c/a>; \u003ca href=\"#b19\">di nanni et al., 2019\u003c/a>), suggesting decreased gabaergic inhibition in a subpopulation of autistic individuals. mutations involving the gaba\u003csub>a\u003c/sub> receptor subunit genes \u003cem>gabra5\u003c/em>, \u003cem>gabrb3\u003c/em>, and \u003cem>gabrg3\u003c/em> (encoding the &#x003b1;5, &#x003b2;3, and &#x003b3;3 subunits) found on chromosomal region 15q11&#x02013;q13 have been associated with ndds including as, epilepsy, and prader&#x02013;willi syndrome in addition to asd (\u003ca href=\"#b32\">hogart et al., 2010\u003c/a>; \u003ca href=\"#b61\">sanders, 2015\u003c/a>). as is predominantly caused by the loss of function of the maternally inherited \u003cem>ube3a\u003c/em> gene; however, approximately 75% of individuals with as carry a large deletion of the maternal 15q11&#x02013;q13 chromosomal region. clinical studies have shown that individuals with as who have large deletions (deletion as) exhibit more severe symptoms than those in whom \u003cem>ube3a\u003c/em> is the only gene affected, suggesting that the \u003cem>gabra5\u003c/em>, \u003cem>gabrb3\u003c/em>, and \u003cem>gabrg3\u003c/em> genes are relevant to the etiology of the disease.\u003c/p>\u003cp class=\"mb15\">imaging studies using pet and magnetic resonance spectroscopy have shown reduced gaba\u003csub>a\u003c/sub> receptor binding in the superior and medial frontal cortex (\u003ca href=\"#b47\">mori et al., 2012\u003c/a>) and reduced gaba levels in individuals with asd (\u003ca href=\"#b58\">robertson et al., 2016\u003c/a>; \u003ca href=\"#b28\">gaetz et al., 2014\u003c/a>; \u003ca href=\"#b59\">rojas et al., 2014\u003c/a>; \u003ca href=\"#b57\">puts et al., 2017\u003c/a>). postmortem studies have shown reduced numbers of inhibitory interneurons (\u003ca href=\"#b20\">dufour et al., 2023\u003c/a>), reduced expression of gaba\u003csub>a\u003c/sub> receptor subunits (\u003ca href=\"#b16\">delorey, 2005\u003c/a>; \u003ca href=\"#b1\">abrahams and geschwind, 2008\u003c/a>), and reduced levels of the gaba-synthesizing enzymes such as glutamic acid decarboxylase (gad) 65 and 67 (\u003ca href=\"#b21\">fatemi et al., 2002\u003c/a>). there is increasing evidence from genetic, environmental, and phenotypic rodent models relevant to asd indicating that gabaergic circuit dysfunctions contribute to autism-like phenotypes (\u003ca href=\"#b27\">fukuda et al., 2005\u003c/a>; \u003ca href=\"#b13\">chao et al., 2010\u003c/a>; \u003ca href=\"#b6\">banerjee et al., 2013\u003c/a>). such deficits may result from multiple causes, including a reduced number of gabaergic interneurons, altered interneuron function, impaired gaba\u003csub>a\u003c/sub> receptor trafficking to the membrane, reduced expression of gaba\u003csub>a\u003c/sub> receptor subunits, and reduced gaba uptake function of gat-1 in neurons (\u003ca href=\"#b49\">nakamura et al., 2016\u003c/a>; \u003ca href=\"#b50\">orefice et al., 2016\u003c/a>; \u003ca href=\"#b43\">mermer et al., 2021\u003c/a>). supportive evidence is provided by the observation of autism-like behaviors in both gaba\u003csub>a\u003c/sub>-&#x003b1;5 and &#x003b2;3 subunit knockout mice (\u003ca href=\"#b77\">zurek et al., 2016\u003c/a>; \u003ca href=\"#b17\">delorey et al., 2008\u003c/a>). regarding possible therapeutic approaches, enhancement of the gaba\u003csub>a\u003c/sub> receptor activity by non-selective benzodiazepines has been shown to ameliorate autism-like behavioral deficits in mouse models; however, due to sedation that is likely mediated by the activation of the gaba\u003csub>a\u003c/sub>-&#x003b1;1 subtype, very narrow therapeutic margins were observed (\u003ca href=\"#b30\">han et al., 2012\u003c/a>; \u003ca href=\"#b29\">han et al., 2014\u003c/a>; \u003ca href=\"#b37\">lim et al., 2017\u003c/a>). interestingly, a recent study showed that a gaba\u003csub>a\u003c/sub>-&#x003b1;5 positive allosteric modulator (pam), sh-053-2&#x02032;f-r-ch3, attenuated social and cognitive deficits in male rats exposed to valproic acid \u003cem>in utero\u003c/em>, a rat model relevant to autism (\u003ca href=\"#b68\">souza et al., 2024\u003c/a>).\u003c/p>\u003cp class=\"mb15\">the aim of the current study was to determine whether a selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 pam, alogabat (also known as ro7017773 or rg7816), would produce beneficial effects in animal models relevant to autism-like repetitive behavior&#x02014;specifically btbr mice (\u003ca href=\"#b40\">mcfarlane et al., 2008\u003c/a>) and contactin-associated protein-like 2 [cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup>] homozygous knockout mice (\u003ca href=\"#b51\">penagarikano et al., 2011\u003c/a>)&#x02014;and anti-seizure activity, without the typical side effects of non-selective gaba\u003csub>a\u003c/sub> pams, such as sedation and cognitive impairment. furthermore, target engagement was assessed by \u003cem>in vivo\u003c/em> receptor occupancy (ro) and pharmacological mri (phmri) in rodents, and an electroencephalography (eeg) study in rats was undertaken to identify a putative pharmacodynamic readout for future clinical trials.\u003c/p>\u003ca id=\"h3\" name=\"h3\">\u003c/a>\u003ch2>2 materials and methods\u003c/h2>\u003cp class=\"mb15\">further information for each method listed below can be found in the \u003ca href=\"#sm1\">supplementary material\u003c/a>.\u003c/p>\u003ca id=\"h3-1\" name=\"h3-1\">\u003c/a>\u003ch3 class=\"pt0\">2.1 materials\u003c/h3>\u003cp class=\"mb0\">alogabat [ro7017773; c\u003csub>21\u003c/sub>h\u003csub>23\u003c/sub>n\u003csub>5\u003c/sub>o\u003csub>4\u003c/sub>; 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl) methoxy)-n-(tetrahydropyran-4-yl)pyridazine-3-carboxamide (iupac name); molecular weight: 409.44&#x000a0;gmol\u003csup>&#x02212;1\u003c/sup>] was synthesized at f.hoffmann-la roche ag, switzerland [\u003ca href=\"#f1\">figure 1a\u003c/a>; see example 8 in \u003ca href=\"#b10\">buettelmann et al., 2018\u003c/a>]. the discovery of alogabat and the related chemical series will be disclosed in future publications. diazepam, l-655,708, [\u003csup>3\u003c/sup>h]flumazenil, [\u003csup>3\u003c/sup>h]l-655,708, and [\u003csup>3\u003c/sup>h]ro0154513 were synthesized at f.hoffmann-la roche ag, switzerland.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 1\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" name=\"figure1\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" alt=\"www.frontiersin.org\" id=\"f1\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 1\u003c/b>. \u003cem>in vitro\u003c/em> pharmacology of alogabat. \u003cb>(a)\u003c/b> chemical structure of alogabat (ro7017773; c21h23n5o4); 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl) methoxy)-n-(tetrahydropyran-4-yl)pyridazine-3-carboxamide (iupac name); molecular weight, 409.44&#x000a0;gmol\u003csup>&#x02212;1\u003c/sup>. \u003cb>(b)\u003c/b> concentration-response curves of alogabat in [\u003csup>3\u003c/sup>h]flumazenil competition-binding assays with membranes expressing different rat recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (\u003cem>n\u003c/em> &#x0003d; 10&#x02013;20/concentration). \u003cb>(c)\u003c/b> concentration-response curves of the effects of alogabat in hek293 cells expressing different rat recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (\u003cem>n\u003c/em> &#x0003d; 4&#x02013;5/concentration). data in the graphs are shown as the mean (symbols) &#x000b1; sem (error bars). error bars smaller than the symbol size are not shown. \u003cb>(d)\u003c/b> isoguvacine concentration-response curves obtained in the presence and absence of alogabat in rat hippocampal slices. the points represent the mean values &#x000b1; sem of three slices. the sigmoidal curves were fit through these points. \u003cb>(e)\u003c/b> the ppi of ps was measured in the absence (control) and presence of alogabat at 0.3&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 3 slices) and 1&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 6 slices). ps1 and ps2 are the responses induced by the first and second stimulus, respectively. the data are normalized to the amplitude of ps1 and presented as the mean &#x000b1; sem.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h3-2\" name=\"h3-2\">\u003c/a>\u003ch3 class=\"pt0\">2.2 \u003cem>in vitro\u003c/em> experiments\u003c/h3>\u003ca id=\"h7-2-1\" name=\"h7-2-1\">\u003c/a>\u003ch4>2.2.1 gaba\u003csub>a\u003c/sub> receptor radioligand binding assays\u003c/h4>\u003cp class=\"mb0\">the affinity of alogabat for rat and human gaba\u003csub>a\u003c/sub> receptors containing &#x003b1;5, &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits was measured by [\u003csup>3\u003c/sup>h]flumazenil competition-binding assays with membranes expressing different rat recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (\u003cem>n\u003c/em> &#x0003d; 10&#x02013;20/concentration) and for human &#x003b1;4 and &#x003b1;6 by [\u003csup>3\u003c/sup>h]ro0154513, as previously described (\u003ca href=\"#b4\">ballard et al., 2009\u003c/a>; \u003ca href=\"#b31\">hipp et al., 2021\u003c/a>).\u003c/p>\u003ca id=\"h7-2-2\" name=\"h7-2-2\">\u003c/a>\u003ch4>2.2.2 gaba\u003csub>a\u003c/sub> receptor electrophysiological studies\u003c/h4>\u003cp class=\"mb0\">alogabat was tested for functional activity on four different cloned rat and human gaba\u003csub>a\u003c/sub> receptor subtypes (\u003ca href=\"#b10\">buettelmann et al., 2018\u003c/a>), namely, &#x003b1;1&#x003b2;2&#x003b3;2, &#x003b1;2&#x003b2;3&#x003b3;2, &#x003b1;3&#x003b2;3&#x003b3;2, and &#x003b1;5&#x003b2;3&#x003b3;2. ion currents were induced by gaba concentrations that evoked approximately 20% of the maximal response (\u003cem>n\u003c/em> &#x0003d; 4&#x02013;5/concentration). the following concentrations of gaba were used: 1&#x000a0;&#x000b5;m for &#x003b1;1&#x003b2;2&#x003b3;2, 10&#x000a0;&#x000b5;m &#x003b1;2&#x003b2;3&#x003b3;2, 10&#x000a0;&#x000b5;m for &#x003b1;3&#x003b2;3&#x003b3;2, and 3&#x000a0;&#x000b5;m for &#x003b1;5&#x003b2;3&#x003b3;2 receptor subtype.\u003c/p>\u003cp class=\"mb0\">alogabat was also tested for functional activity on native gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors in rat hippocampal slices: modulation of isoguvacine-induced population spikes (\u003ca href=\"#b4\">ballard et al., 2009\u003c/a>) and paired-pulse inhibition (ppi) (\u003ca href=\"#b76\">xie and tietz, 1991\u003c/a>). population spikes (pss) were recorded every 30&#x000a0;s by the stimulation of the schaffer collaterals, and isoguvacine was applied consecutively and in increasing concentrations for at least 4&#x000a0;min to the slices (control). after the washout of isoguvacine, alogabat (300&#x000a0;nm) was added to the bath perfusion, and a new isoguvacine concentration-response curve was obtained (alogabat). the ps amplitudes were normalized to the control ps obtained before the first application of isoguvacine and were fitted individually for each slice (\u003cem>n\u003c/em> &#x0003d; 3 slices).\u003c/p>\u003cp class=\"mb0\">the ppi of ps was measured in the absence (control) and presence of alogabat at 0.3&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 3 slices from one animal) and 1&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 6 slices from two animals). the paired-pulse protocol consisted of two stimuli timely spaced by 20&#x000a0;ms, which were applied at the schaffer collaterals in rat hippocampal slices. we used a low number of animals based on our experience with the assay, which is highly robust and reproducible, and in alignment with our commitment to reducing the number of animals used.\u003c/p>\u003ca id=\"h7-2-3\" name=\"h7-2-3\">\u003c/a>\u003ch4>2.2.3 selectivity screening\u003c/h4>\u003cp class=\"mb0\">the selectivity of alogabat (10&#x000a0;&#x000b5;m) over more than 70 receptors was assessed by radioligand binding studies conducted using eurofins cerep sa (celle l&#x000e9;vescault, france), following the methods described on \u003ca href=\"http://www.eurofinsdiscoveryservices.com/\">www.eurofinsdiscoveryservices.com\u003c/a>.\u003c/p>\u003ca id=\"h3-3\" name=\"h3-3\">\u003c/a>\u003ch3 class=\"pt0\">2.3 \u003cem>in vivo\u003c/em> experiments\u003c/h3>\u003ca id=\"h7-3-1\" name=\"h7-3-1\">\u003c/a>\u003ch4>2.3.1 ethics approval\u003c/h4>\u003cp class=\"mb0\">experiments performed at f.hoffmann-la roche ag (basel, switzerland) complied with the swiss federal and cantonal laws on animal research and aaalac regulations and received prior approval from the cantonal veterinary office. the eeg study was conducted at brains online (ca, united states) in accordance with the guide for the care and use of laboratory animals (national research council 2011) after gaining approval from the institutional animal care and use committee. the pentylenetetrazole (ptz) and maximal electroshock (mes) tests were conducted at vivocore inc., canada, which is a facility licensed by the ontario ministry of agriculture, food, and rural affairs and accredited by the canadian council on animal care. all \u003cem>in vivo\u003c/em> studies are reported in compliance with the arrive guidelines (\u003ca href=\"#b52\">percie du sert et al., 2020\u003c/a>).\u003c/p>\u003ca id=\"h7-3-2\" name=\"h7-3-2\">\u003c/a>\u003ch4>2.3.2 animals\u003c/h4>\u003cp class=\"mb0\">all animals were group-housed in holding rooms at controlled temperature and humidity under a 12&#x000a0;h light/dark cycle and were allowed to acclimate for at least 7&#x000a0;days. twenty-six male wistar rats (charles river, germany; &#x0223c;160&#x000a0;g) and sixteen male cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (bred at roche basel; 18&#x02013;22&#x000a0;g) were used in receptor occupancy studies. thirty-two male fischer rats (charles river, germany) were assessed in mri experiments (&#x0223c;250&#x000a0;g). seventeen male wistar rats (envigo, united states) were assessed in eeg experiments. one hundred male btbr mice (bred in roche basel) were assessed in grooming and open-field tests (n &#x0003d; 60, &#x0223c;30&#x000a0;g) and for digging behavior (n &#x0003d; 40, &#x0223c;30&#x000a0;g). fifty-seven male cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (bred in roche basel; 5&#x02013;6&#x000a0;weeks) and wildtype littermates (n &#x0003d; 15) were assessed in grooming and open-field tests. one hundred male sprague&#x02013;dawley rats (charles river, canada) were used to evaluate antiepileptic effects in the ptz (70&#x02013;100&#x000a0;g, n &#x0003d; 40) and mes (&#x0003c;50&#x000a0;g n &#x0003d; 60) tests. forty-eight male sprague&#x02013;dawley rats (charles river, france) were used in the rotarod test (&#x0223c;170&#x02013;200&#x000a0;g). one hundred and forty-one male lister hooded (lh) rats (charles river, germany) were used in the cognition tests: 5-choice serial reaction time (5-csrt) task (n &#x0003d; 11, &#x0223c;400&#x000a0;g); continuous performance test (cpt; n &#x0003d; 11, &#x0223c;400&#x000a0;g); paired associates learning (pal) task (n &#x0003d; 12, &#x0223c;400&#x000a0;g); context fear conditioning (n &#x0003d; 67, &#x0223c;250&#x000a0;g); and morris water maze (n &#x0003d; 40, 350&#x02013;400&#x000a0;g).\u003c/p>\u003ca id=\"h7-3-3\" name=\"h7-3-3\">\u003c/a>\u003ch4>2.3.3 alogabat treatment\u003c/h4>\u003cp class=\"mb0\">alogabat was formulated in 2% hydroxypropyl cellulose in water (or 0.3% tween 80 in saline for \u003cem>in vivo\u003c/em> occupancy and grooming/digging experiments). the administration volume was 10&#x000a0;ml/kg (mice) and 5&#x000a0;ml/kg (rats). each dose was expressed as the weight of the base. alogabat was administered with a pre-treatment time of 30&#x000a0;min in mice and 60&#x000a0;min in rats (except for the eeg study), based on pharmacokinetic data indicating the time of maximal drug plasma concentration. treatment groups were assigned randomly. dose groups were provided as coded vials to allow blinded assessment during the conduct of each experiment. to minimize potential confounders regarding the time of day for behavioral testing, animals were split into separate cohorts (balanced for treatment groups) and tested during the same period.\u003c/p>\u003ca id=\"h7-3-4\" name=\"h7-3-4\">\u003c/a>\u003ch4>2.3.4 receptor occupancy studies\u003c/h4>\u003ch5>2.3.4.1 \u003cem>in vivo\u003c/em> occupancy in rats\u003c/h5>\u003cp class=\"mb0\">male wistar rats (n &#x0003d; 26, &#x0223c;160&#x000a0;g) were administered vehicle or alogabat (0.3, 1, 3, 10, 30, and 100&#x000a0;mg/kg, intraperitoneally [i.p.], n &#x0003d; 3/group) or the gaba\u003csub>a\u003c/sub>-&#x003b1;5 blocker l-655,708 at 10&#x000a0;mg/kg i.p. (n &#x0003d; 2). fifteen minutes later, the gaba\u003csub>a\u003c/sub>-&#x003b1;5 radioligand [\u003csup>3\u003c/sup>h]ro0154513 was administered intravenously (i.v.) to assess ro (\u003ca href=\"#b4\">ballard et al., 2009\u003c/a>; \u003ca href=\"#b31\">hipp et al., 2021\u003c/a>). non-specific binding was determined by pre-treatment with the established gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor blocker l-655,708 (10&#x000a0;mg/kg i.p.; n &#x0003d; 2).\u003c/p>\u003ch5>2.3.4.2 \u003cem>ex vivo\u003c/em> occupancy in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h5>\u003cp class=\"mb0\">cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (\u003ca href=\"#b51\">penagarikano et al., 2011\u003c/a>) (n &#x0003d; 16, 18&#x02013;22&#x000a0;g) were administered the vehicle or alogabat (30, 60, and 100&#x000a0;mg/kg) i.p. (n &#x0003d; 4/group), and ro was assessed in brain sections with the highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 radioligand, [\u003csup>3\u003c/sup>h]l-655,708, 30&#x000a0;min post-administration.\u003c/p>\u003ca id=\"h7-3-5\" name=\"h7-3-5\">\u003c/a>\u003ch4>2.3.5 pharmacological mri in rats\u003c/h4>\u003cp class=\"mb0\">male fischer rats (n &#x0003d; 32, &#x0223c;250&#x000a0;g) were administered vehicle or alogabat (3, 10, and 30&#x000a0;mg/kg) i.p. (n &#x0003d; 8/dose). phmri was performed under medetomidine sedation in a small-animal scanner (4.7t/40&#x000a0;cm; bruker biospin, germany), and blood perfusion was analyzed according to previously published procedures (\u003ca href=\"#b9\">bruns et al., 2009\u003c/a>). fifteen minutes after drug treatment, rats were initially anesthetized using isoflurane (4%) in the carrier gas composed of oxygen and air (1:5), supplied to the spontaneously breathing animals in an inhalation box. upon the induction of anesthesia, a subcutaneous (s.c.) bolus injection of 0.2&#x000a0;mg/kg (1&#x000a0;ml/kg) of medetomidine prepared from 1:5 diluted dormilan\u003csup>&#x000ae;\u003c/sup> was administered, and the animal was transferred onto a rat cradle for inserting an s.c. catheter and starting continuous infusion of 1:10 diluted dormilan\u003csup>&#x000ae;\u003c/sup> (medetomidine) at a dose of 0.1&#x000a0;mg/kg/h (1&#x000a0;ml/kg/h). the head was immobilized in a stereotaxic frame. respiratory rate, body temperature, and o\u003csub>2\u003c/sub> and co\u003csub>2\u003c/sub> levels in inhaled and exhaled air were continuously monitored using a powerlab data acquisition system (adinstruments, spechbach, germany). body temperature was maintained at 37&#x000b0;c with a feedback-regulated electric heating blanket. immediately after the last imaging assessment, rats were euthanized by decapitation under anesthesia, and plasma samples were collected at approximately 40&#x000a0;min post-administration of alogabat. images were processed and analyzed using in-house developed software written in idl (rsi, boulder, co, united states) and matlab (the mathworks inc., natick, ma, united states).\u003c/p>\u003ca id=\"h7-3-6\" name=\"h7-3-6\">\u003c/a>\u003ch4>2.3.6 eeg in rats\u003c/h4>\u003cp class=\"mb0\">male wistar rats (n &#x0003d; 17) were surgically prepared with wireless implanted transmitters to enable simultaneous recording of eeg, hippocampal (ca3) local field potential (lfp), and emg. rats were anesthetized using isoflurane (2%, 800&#x000a0;ml/min o2). bupivacaine/epinephrine was used for local analgesia, while finadyne or carprofen was used for peri-/post-operative analgesia. amoxicillin was used as an antibiotic. the animals were placed in a stereotaxic frame (kopf instruments, united states). a subcutaneous pocket was created near the dorsal flank, into which a transmitter (f50-eee, data sciences international, physio tel f50-eee small animal cns telemetry; three bipolar channels, biopotential lead, outer diameter 0.3&#x000a0;mm) was inserted. the transmitter included three bipolar channels: channel 1 (eeg): two screws in the left hemisphere (frontal: 11&#x000a0;mm anterior and 2.5&#x000a0;mm lateral to bregma; central: 3&#x000a0;mm anterior and 3.5&#x000a0;mm lateral to lambda); channel 2 (lfp): a single wire electrode targeting the ca3 region of the right hippocampus; and channel 3 (emg): electrodes placed in the neck muscle for recording emg activity, aiding in sleep stage classification.\u003c/p>\u003cp class=\"mb0\">after a 2-week recovery, rats were administered the vehicle or alogabat (10&#x000a0;mg/kg) using a cross-over design (1-week interval). if the setup allowed, the positive control diazepam (2&#x000a0;mg/kg) was assessed. all drugs were administered i.v. via an implanted cannula so that brain exposure was expected within a few minutes of administration. eeg spectral power was analyzed quantitatively up to 1&#x000a0;h post-administration. only animals with clean eeg recordings were included in the analysis. eeg data in the awake state were used for the analyses reported in this study. we first investigated the effects on power over predefined theta and beta power ranges, defined \u003cem>a priori\u003c/em> as 6&#x02013;10&#x000a0;hz and 20&#x02013;30&#x000a0;hz, respectively, based on previous studies with gabaa drugs (\u003ca href=\"#b72\">visser et al., 2003\u003c/a>; \u003ca href=\"#b71\">van lier et al., 2004\u003c/a>). then, we evaluated frequency-specific effects across the 2&#x02013;128&#x000a0;hz range.\u003c/p>\u003ca id=\"h7-3-7\" name=\"h7-3-7\">\u003c/a>\u003ch4>2.3.7 grooming behavior and open-field test in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h4>\u003cp class=\"mb0\">male btbr mice (n &#x0003d; 60, &#x0223c;30&#x000a0;g) were pre-treated with the vehicle or alogabat at 30, 60, 90, and 120&#x000a0;mg/kg i.p. (n &#x0003d; 12/dose). male cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (n &#x0003d; 57, 5&#x02013;6&#x000a0;weeks) and wildtype littermates (n &#x0003d; 15) received sub-chronic treatment (8&#x02013;10&#x000a0;days) with the vehicle or alogabat at 30, 60, and 100&#x000a0;mg/kg i.p. (n &#x0003d; 14&#x02013;15/dose). spontaneous locomotor activity was assessed in both groups of mice for 1&#x000a0;h in an open field (42 &#x000d7; 42 &#x000d7; 30.5&#x000a0;cm; 20 lux at the center of the arena) with a small amount of sawdust bedding. movement of the animal was detected by interruptions in an array of photobeams from horizontally located infrared sources placed around the open field, measured using a versamax system (accuscan instruments inc., columbus, oh, united states). activity was measured as the distance traveled (cm).\u003c/p>\u003cp class=\"mb0\">one week later, each mouse was placed into a type-ii cage (21.5 &#x000d7; 15.5 &#x000d7; 13.0&#x000a0;cm; 40 lux) for 5&#x000a0;min habituation, and then the cumulative time (s) spent grooming during 10&#x000a0;min was recorded manually by a blinded observer. distance traveled (cm) during the session was measured using a video tracking system (ethovision, noldus information technology, netherlands). plasma samples were collected from btbr mice 1&#x000a0;week after testing and 30&#x000a0;min after treatment (\u003cem>n\u003c/em> &#x0003d; 6/dose). plasma samples were collected from cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice 1&#x000a0;day later and 30&#x000a0;min after treatment (\u003cem>n\u003c/em> &#x0003d; 4/dose).\u003c/p>\u003ca id=\"h7-3-8\" name=\"h7-3-8\">\u003c/a>\u003ch4>2.3.8 digging behavior in btbr mice\u003c/h4>\u003cp class=\"mb0\">a separate group of male btbr mice (n &#x0003d; 40, &#x0223c;30&#x000a0;g) were pre-treated with vehicle or alogabat at 30, 60, and 100&#x000a0;mg/kg i.p. (n &#x0003d; 10/dose) and were placed into a small circular dish (d &#x0003d; 10&#x000a0;cm) filled with fresh thick sawdust located in the middle of a clean type-ii cage (21.5 &#x000d7; 15.5 &#x000d7; 13.0&#x000a0;cm; 40 lux). the cumulative time (s) spent digging over 5&#x000a0;min was recorded manually by a blinded observer. the distance traveled (cm) and speed were also measured in the arena, outside the dish (ethovision, noldus information technology, netherlands). plasma samples were collected immediately after the digging test, i.e., 35&#x02013;40&#x000a0;min post-administration (\u003cem>n\u003c/em> &#x0003d; 3/dose).\u003c/p>\u003ca id=\"h7-3-9\" name=\"h7-3-9\">\u003c/a>\u003ch4>2.3.9 evaluation of antiepileptic effects in rats\u003c/h4>\u003cp class=\"mb0\">vehicle or alogabat (5, 15, or 30&#x000a0;mg/kg) was administered p.o. (n &#x0003d; 8/dose) and assessed for seizures induced by (1) subcutaneous (s.c.) ptz and (2) the maximum electrical stimulus (mes) model in male sprague&#x02013;dawley rats (ptz: 70&#x02013;100&#x000a0;g, n &#x0003d; 40; mes: &#x0003c;50&#x000a0;g n &#x0003d; 60, charles river, canada). diazepam (synthesized at f.hoffmann-la roche ag) was included in each experiment as a positive control and administered at 3&#x000a0;mg/kg i.p., 30&#x000a0;min prior to testing. immediately following testing, a terminal blood sample was collected under anesthesia.\u003c/p>\u003ch5>2.3.9.1 pentylenetetrazole test\u003c/h5>\u003cp class=\"mb0\">following the designated pre-treatment time, ptz was administered at 75&#x000a0;mg/kg s.c. animals were transferred to a single cage and monitored closely for the onset of clonic seizure, and the percentage of each group showing seizures was recorded. protection was defined as the complete absence of clonic seizure, including forelimb clonus, over the 30&#x000a0;min observation period.\u003c/p>\u003ch5>2.3.9.2 maximal electroshock test\u003c/h5>\u003cp class=\"mb0\">following the designated pre-treatment time, rats received maximal electroshock (mes: 150&#x000a0;ma, 0.2&#x000a0;s duration, 60&#x000a0;hz) via corneal electrodes moistened with saline (shock simulator type 221; harvard apparatus). due to inconsistency in responses by rats to this type of stimuli, all test animals (n &#x0003d; 60) were subjected to two screening sessions on two separate days, and 40 rats were selected based on their reliability to have tonic seizures. drug testing was conducted on the third day, during which the rats received the standard maximal electroshock, and the presence or absence of a tonic seizure was recorded and expressed as the percentage of animals in each group that showed seizures. protection was defined as the absence of a full tonic seizure within 15&#x000a0;s of stimulus delivery.\u003c/p>\u003ca id=\"h7-3-10\" name=\"h7-3-10\">\u003c/a>\u003ch4>2.3.10 combination with diazepam on rotarod performance in rats\u003c/h4>\u003cp class=\"mb0\">forty-eight male sprague&#x02013;dawley rats (&#x0223c;170&#x02013;200&#x000a0;g) were pre-trained to the rotarod (47750 rota-rod ng, ugo basile) at 8&#x000a0;rpm for 120&#x000a0;s. one day later, rats were administered alogabat (or vehicle) p.o., 30&#x000a0;min prior to diazepam or vehicle i.p., and they were assessed on the rotarod 30&#x000a0;min later. each rat was given three attempts to remain on the rotarod, with a maximum duration of 120&#x000a0;s per attempt. treatment groups (n &#x0003d; 8/group) consisted of alogabat alone (30&#x000a0;mg/kg), diazepam alone (5&#x000a0;mg/kg), or alogabat at 3, 10, and 30&#x000a0;mg/kg in combination with diazepam (5&#x000a0;mg/kg). the maximum time (s) spent on the rotarod was recorded. after the completion of rotarod testing, animals were euthanized under isoflurane anesthesia for plasma sample collection at approximately 70&#x000a0;min post-administration of alogabat.\u003c/p>\u003ca id=\"h7-3-11\" name=\"h7-3-11\">\u003c/a>\u003ch4>2.3.11 cognition testing in rats\u003c/h4>\u003ch5>2.3.11.1 operant and touchscreen cognition tests\u003c/h5>\u003cp class=\"mb0\">separate groups of male lister hooded (lh) rats (&#x0223c;400&#x000a0;g) were pre-trained in the operant and touch screen tests, as described in \u003ca href=\"#sm1\">supplementary material\u003c/a>. the 5-csrt task (n &#x0003d; 11) is a test of attention. the primary parameter is the total percentage of correct responses. continuous performance test (cpt; n &#x0003d; 11) assesses sustained attention. the primary parameter is the discrimination sensitivity index (d prime), which is a ratio based on the rate at which rats make correct and incorrect responses. the paired associates learning (pal) task (n &#x0003d; 12) assesses visual&#x02013;spatial memory. the primary parameter is the total percentage of correct responses. a latin-squares design was used to assess the vehicle and doses of alogabat (3, 10, and 30&#x000a0;mg/kg p.o.). rats were tested twice weekly with at least a 2-day interval between test sessions. rats were trained between test days to maintain baseline performance.\u003c/p>\u003ch5>2.3.11.2 context fear conditioning\u003c/h5>\u003cp class=\"mb0\">two cohorts of male lh rats (&#x0223c;250&#x000a0;g; n &#x0003d; 67) were assessed for context fear conditioning (cfc) in two experiments: (1) vehicle or alogabat at 10 and 30&#x000a0;mg/kg (n &#x0003d; 9/dose); (2) vehicle or alogabat at 1, 3, and 10&#x000a0;mg/kg (n &#x0003d; 10/dose) administered p.o., 60&#x000a0;min prior to the acquisition session. rats were placed into a novel test chamber (45&#x000a0;cm &#x000d7; 45&#x000a0;cm &#x000d7; 46.5&#x000a0;cm) with a grid floor and clear plastic walls (tse-systems gmbh, germany). during the acquisition session, a 2-min habituation phase was followed by the delivery of a mild foot shock (0.8&#x000a0;ma for 1&#x000a0;s) applied through the grid floor. following a 1&#x000a0;min interval, a second foot shock was delivered. the animals remained in the chambers for a further 30&#x000a0;s. one day later, the animals were returned to the same test chamber for a 5-min period without any foot shock. rodents respond to danger in a species-specific manner by freezing, i.e., the animals will withhold all movement, except for respiration, to avoid detection. the amount of freezing behavior was measured by the computer as the time spent immobile (minimum threshold of 1&#x000a0;s) and was expressed as the percentage of time spent freezing during the 5-min session. following cfc, plasma samples were collected 1&#x02013;2&#x000a0;days later from rats pre-treated with the same dose at 60&#x000a0;min post-administration (\u003cem>n\u003c/em> &#x0003d; 4/dose).\u003c/p>\u003ch5>2.3.11.3 morris water maze\u003c/h5>\u003cp class=\"mb0\">male lh rats (350&#x02013;400&#x000a0;g) were pre-treated with vehicle or 10 or 30&#x000a0;mg/kg alogabat p.o. (n &#x0003d; 10/dose) once daily during cued acquisition (visible platform; three trials per day for 2&#x000a0;days), followed by a 2-day interval and then spatial acquisition (hidden platform; three trials per day for 4&#x000a0;days) in the morris water maze (mwm; computer tracking system hvs image ltd., united kingdom) (\u003ca href=\"#b5\">ballard et al., 2005\u003c/a>). twenty-four hours later, the platform was removed, and the rats were pre-treated with vehicle or alogabat and allowed to swim in the maze for 60&#x000a0;s (probe trial) to assess the retention/spatial memory of the platform position, expressed as the percentage of distance traveled in each quadrant. for the mwm, plasma samples were collected immediately after the last trial on the 12th day of treatment at approximately 70&#x000a0;min post-administration (\u003cem>n\u003c/em> &#x0003d; 4&#x02013;5/dose).\u003c/p>\u003ca id=\"h7-3-12\" name=\"h7-3-12\">\u003c/a>\u003ch4>2.3.12 plasma sampling and analysis\u003c/h4>\u003cp class=\"mb0\">rodents were deeply anesthetized with 5% isoflurane, and blood was collected following decapitation with a guillotine or via cardiac puncture (ptz and mes). during eeg experiments, blood was collected from a cannula in the right femoral artery. blood samples were centrifuged in edta-coated eppendorf tubes (4,000&#x000a0;rpm, 4&#x000b0;c, 5&#x000a0;min), and plasma was collected, immediately frozen, and stored at &#x02212;80&#x000b0;c. samples were analyzed for the concentration of alogabat using qualified liquid chromatography coupled to tandem mass spectrometry (lc-ms/ms) assays.\u003c/p>\u003ca id=\"h7-3-13\" name=\"h7-3-13\">\u003c/a>\u003ch4>2.3.13 statistical analysis\u003c/h4>\u003cp class=\"mb0\">sample sizes were determined based on historical data for each experiment within each laboratory.\u003c/p>\u003ch5>2.3.13.1 eeg\u003c/h5>\u003cp class=\"mb0\">linear mixed-effects models (lmms) were used since these can account for incomplete datasets, which was the case in this study. specific contrasts were derived and tested using t-tests within the model using satterthwaite approximation for degrees of freedom. models were derived for each compound individually: y &#x0223c; compound &#x0002b; (1&#x0007c;animal). the significance of differences in the peak frequency was assessed using random permutation tests (10,000).\u003c/p>\u003ch5>2.3.13.2 phmri\u003c/h5>\u003cp class=\"mb0\">analysis was performed with jmp (sas institute inc., cary, united states) and matlab (the mathworks inc., natick, ma, united states). global (whole-brain) absolute-perfusion values from the vehicle and the three dose groups were tested for a linear trend across the four doses using a one-way anova framework. the same analysis was applied roi-wise to the normalized-perfusion values. multiple testing across the single rois was accounted for by controlling the false discovery rate (fdr) at 10% using the benjamini&#x02013;hochberg approach. to also obtain an overall activation&#x02013;strength metric, normalized-perfusion values of each dose group were compared roi-wise to those of the vehicle group using welch&#x02019;s t-test without multiple-testing correction. the number of significantly modulated rois at each dose was then taken as a measure of &#x0201c;pattern strength.&#x0201d; the mean and the upper 95% confidence limit of the corresponding chance levels were estimated via random group-label permutations (100,000 runs per group). significance levels of the actual pattern strengths were determined based on the distributions obtained through the permutation procedure.\u003c/p>\u003ch5>2.3.13.3 behavior\u003c/h5>\u003cp class=\"mb0\">all statistical analyses were performed using prism (graphpad software). one-factor anova was used for between-group comparison (i.e., dose), with repeated measures for within-subject comparison (i.e., time bins and platform quadrants). dunnett&#x02019;s test was used for \u003cem>post hoc\u003c/em> comparisons. student&#x02019;s unpaired two-tailed t-test was used when two groups were compared. the chi-square test was used to compare the percentage of groups. rotarod data were analyzed using a non-parametric kruskal&#x02013;wallis test, followed by dunn&#x02019;s multiple comparison test. statistical significance was predetermined as \u003cem>p\u003c/em> &#x0003c; 0.05.\u003c/p>\u003ca id=\"h4\" name=\"h4\">\u003c/a>\u003ch2>3 results\u003c/h2>\u003ca id=\"h4-1\" name=\"h4-1\">\u003c/a>\u003ch3 class=\"pt0\">3.1 binding affinity for gaba\u003csub>a\u003c/sub> receptors containing &#x003b1;5 and other &#x003b1; subunits\u003c/h3>\u003cp class=\"mb0\">the aim of these radioligand binding studies was to determine the binding selectivity of alogabat at the rat and human gaba\u003csub>a\u003c/sub> receptors containing &#x003b1;5 compared to &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits. alogabat had a high affinity for gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 receptors in rats (ki 7.9&#x000a0;nm), with approximately 37-, 26-, and 18-fold selectivity compared to gaba\u003csub>a\u003c/sub> &#x003b1;1&#x003b2;3&#x003b3;2, &#x003b1;2&#x003b2;3&#x003b3;2, and &#x003b1;3&#x003b2;3&#x003b3;2, respectively (\u003ca href=\"#f1\">figure 1b\u003c/a>; see \u003ca href=\"#sm1\">supplementary table s1\u003c/a>). alogabat had a similar pharmacological profile in human recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (see \u003ca href=\"#sm1\">supplementary table s1\u003c/a>).\u003c/p>\u003ca id=\"h4-2\" name=\"h4-2\">\u003c/a>\u003ch3 class=\"pt0\">3.2 functional activity at recombinant and native gaba\u003csub>a\u003c/sub> receptors\u003c/h3>\u003cp class=\"mb0\">we undertook electrophysiological studies in hek293 cells and oocytes to assess the functional activity of alogabat on cloned rat and human gaba\u003csub>a\u003c/sub> receptor subtypes containing &#x003b1;5, &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits. alogabat enhanced gaba-evoked responses of rat and human &#x003b1;5-containing receptors by 167% (\u003ca href=\"#f1\">figure 1c\u003c/a>) and 72% (see \u003ca href=\"#sm1\">supplementary table s2\u003c/a>), respectively. the maximum amount of potentiation was slightly lower at human receptors. this may be due to the different expression systems used, i.e., hek293 cells for rat receptors and \u003cem>xenopus\u003c/em> oocytes for human receptors. at the highest concentrations tested, alogabat potentiated other receptor subtypes to a much lesser extent than &#x003b1;5-containing receptors. the potency of alogabat was comparable between gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors containing either &#x003b3;2 or &#x003b3;3 subunits, i.e., gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 and gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;3 receptors (see \u003ca href=\"#sm1\">supplementary figure s1\u003c/a>).\u003c/p>\u003cp class=\"mb0\">at native gaba\u003csub>a\u003c/sub> receptors in rat hippocampal slices, alogabat positively modulated gabaergic inhibition of ca1 pyramidal cells, as shown by a leftward shift of the concentration-dependent inhibition of the population spike by isoguvacine (\u003ca href=\"#f1\">figure 1d\u003c/a>) and enhanced paired-pulse inhibition of the population spike during field potential recordings (\u003ca href=\"#f1\">figure 1e\u003c/a>). together, these results confirm the binding selectivity of alogabat and demonstrate that alogabat is a functionally selective pam of gaba-evoked responses.\u003c/p>\u003ca id=\"h4-3\" name=\"h4-3\">\u003c/a>\u003ch3 class=\"pt0\">3.3 selectivity data\u003c/h3>\u003cp class=\"mb0\">we assessed alogabat in radioligand binding studies with more than 70 receptors and showed that alogabat at 10&#x000a0;&#x000b5;m had over 917-fold binding selectivity for the gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 receptor subtype against all other targets tested (see \u003ca href=\"#sm1\">supplementary table s3\u003c/a>).\u003c/p>\u003ca id=\"h4-4\" name=\"h4-4\">\u003c/a>\u003ch3 class=\"pt0\">3.4 receptor occupancy in wistar rats and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h3>\u003cp class=\"mb0\">the main objective of these studies was to visualize and quantify gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro by alogabat. alogabat decreased the specific binding of the gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor-specific radioligand [\u003csup>3\u003c/sup>h]ro0154513 in the hippocampus of rats in a dose-dependent manner. the highest dose of alogabat (100&#x000a0;mg/kg i.p.) reduced specific binding by 100%, i.e., to the same binding level as that of 10&#x000a0;mg/kg l-655,708 (\u003ca href=\"#f2\">figure 2a\u003c/a>). a total plasma concentration of 669&#x000a0;ng/ml and a total brain concentration of 208&#x000a0;ng/g were required to produce half-maximal gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro (ec\u003csub>50\u003c/sub>) in the hippocampus in rats. in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice, estimated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro based on the \u003cem>ex vivo\u003c/em> study with [\u003csup>3\u003c/sup>h]l-655,708 was 43%, 46%, and 71% at doses of 30, 60, and 100&#x000a0;mg/kg i.p., respectively (\u003ca href=\"#f2\">figure 2b\u003c/a>). in addition, the rat occupancy curve was used to calculate ro related to plasma exposure for all \u003cem>in vivo\u003c/em> experiments described in this manuscript below (also refer to \u003ca href=\"#sm1\">supplementary tables s4&#x02013;s5\u003c/a>).\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 2\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" name=\"figure2\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" alt=\"www.frontiersin.org\" id=\"f2\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 2\u003c/b>. receptor occupancy and phmri signature of alogabat following acute administration. \u003cb>(a)\u003c/b> concentration-dependent blockade of [\u003csup>3\u003c/sup>h]ro0154513 binding by alogabat in wistar rats: with increasing concentrations from the different doses (0.3&#x02013;100&#x000a0;mg/kg i.p., n &#x0003d; 3/dose) of alogabat (vehicle &#x0003d; without pre-treatment, n &#x0003d; 3). \u003cb>(b)\u003c/b> representative autoradiograms of alogabat \u003cem>ex vivo\u003c/em> occupancy in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice via \u003cem>in vitro\u003c/em> incubation of the highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor radioligand [\u003csup>3\u003c/sup>h]l-655,708 to sagittal brain sections. the cntnap2&#x02212;/&#x02212; mice were treated with vehicle and 30, 60, or 100&#x000a0;mg/kg i.p. alogabat (n &#x0003d; 4/dose). \u003cb>(c)\u003c/b> trend of normalized-perfusion response pattern strength increasing with dose, given as numbers (&#x000b1; 95% confidence intervals) of significantly (de-)activated regions of interest (rois) following the administration of alogabat (n &#x0003d; 8/dose) to fischer (f344) rats under medetomidine sedation. &#x0201c;chance level&#x0201d; &#x0003d; mean (black dotted line) and 95th percentile (gray dotted line) derived from the permutation test. significant deviations in the number of modulated rois from the chance level are denoted by &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 (uncorrected). ro is the calculated receptor occupancy for gaba\u003csub>a\u003c/sub>-&#x003b1;5 from measured plasma concentrations at each dose. \u003cb>(d)\u003c/b> sagittal schematic of rat brain showing rois with a significant dose-dependent modulation (linear trend of normalized perfusion). rois passing false discovery rate control at 10% are shown, with roi outlines indicating uncorrected significance level (no outline, \u003cem>p\u003c/em> &#x0003c; 0.05; dotted outline, \u003cem>p\u003c/em> &#x0003c; 0.01; and solid outline, \u003cem>p\u003c/em> &#x0003c; 0.001). roi abbreviations: acbsh, nucleus accumbens shell; amg, amygdala; drn, dorsal raphe nucleus; hpcfi, fimbria hippocampi; insc, insular cortex; lc, locus coeruleus; m1, primary motor cortex; mpfc/cg, medial prefrontal, cingulate cortex; pir, piriform (entorhinal) cortex; prh, perirhinal cortex; s1, primary somatosensory cortex; sn, substantia nigra; th, thalamus; vc, visual cortex.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h4-5\" name=\"h4-5\">\u003c/a>\u003ch3 class=\"pt0\">3.5 pharmacological mri signature in rats\u003c/h3>\u003cp class=\"mb0\">the purpose of this study was to evaluate the effects of alogabat on regional neural activity. blood perfusion, measured quantitatively by phmri, was taken as a proxy for neural activity. the administration of a single dose of alogabat at 3&#x02013;30&#x000a0;mg/kg i.p. in rats resulted in moderate but consistent and dose-dependent changes in neural activity patterns compared to treatment with the vehicle (\u003ca href=\"#f2\">figure 2c\u003c/a>). significant dose-dependent modulation of normalized perfusion by alogabat was observed in limbic brain regions, i.e., the nucleus accumbens (shell), amygdala, and hippocampus (fimbria); in several cortical brain regions, the thalamus and brainstem nuclei; and in the substantia nigra (\u003ca href=\"#f2\">figure 2d\u003c/a>). a linear dose effect was also observed on whole-brain absolute perfusion. alogabat target engagement in brain tissue ranged from 54% to 84% ro.\u003c/p>\u003ca id=\"h4-6\" name=\"h4-6\">\u003c/a>\u003ch3 class=\"pt0\">3.6 eeg signature in rats\u003c/h3>\u003cp class=\"mb0\">the aim of this study was to determine whether alogabat induces a characteristic eeg signature that could be used as a translational pharmacodynamic marker. as a first step and based on previous findings on the eeg effects of gaba\u003csub>a\u003c/sub> drugs (\u003ca href=\"#b71\">van lier et al., 2004\u003c/a>; \u003ca href=\"#b72\">visser et al., 2003\u003c/a>; \u003ca href=\"#b22\">friedman et al., 1992\u003c/a>), we investigated eeg spectral power change in the theta (6&#x02013;10&#x000a0;hz) and beta (20&#x02013;30&#x000a0;hz) frequency bands. alogabat, administered as 10&#x000a0;mg/kg i.v. (5&#x000a0;min infusion), significantly increased eeg beta-band activity by 21% &#x000b1; 11% relative to the baseline (mean &#x000b1; sd) and decreased theta-band activity by 32% &#x000b1; 19% (\u003ca href=\"#f3\">figures 3a,b\u003c/a>). frequency-resolved changes confirmed a decrease in theta power (approximately 6&#x02013;10&#x000a0;hz) and revealed broader beta and gamma modulation (approximately 20&#x02013;50&#x000a0;hz) (\u003ca href=\"#f3\">figures 3c&#x02013;e\u003c/a>). the calculated ro after the application of alogabat was 77%&#x02013;85% for gaba\u003csub>a\u003c/sub>-&#x003b1;5 (see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). the overall spectral pattern was qualitatively similar to that of diazepam; however, the peak frequency in the beta frequency range was higher for alogabat (32&#x000a0;hz for alogabat vs. 22.6&#x000a0;hz for diazepam; \u003cem>p\u003c/em> &#x0003d; 0.006, random permutation test), and its amplitude was greater for diazepam (142% &#x000b1; 44% increase for diazepam vs. 27% &#x000b1; 16% increase for alogabat; \u003cem>p\u003c/em> &#x0003c; 0.001). this is likely related to the high binding and functional selectivity of alogabat for &#x003b1;5-containing gaba\u003csub>a\u003c/sub> receptors compared to the non-selective profile of diazepam.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 3\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" name=\"figure3\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" alt=\"www.frontiersin.org\" id=\"f3\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 3\u003c/b>. pharmacodynamic effect of alogabat on eeg spectral power. \u003cb>(a,b)\u003c/b> modulations of vehicle (\u003cem>n\u003c/em> &#x0003d; 12), alogabat 10&#x000a0;mg/kg (\u003cem>n\u003c/em> &#x0003d; 9), and diazepam 2&#x000a0;mg/kg (\u003cem>n\u003c/em> &#x0003d; 7, positive control) in the beta (20&#x02013;30&#x000a0;hz) and theta (6&#x02013;10&#x000a0;hz) power. \u003cb>(c&#x02013;e)\u003c/b> effects of individual compounds and vehicle on the eeg power spectrum. each individual recording is displayed as a light gray line, and the group average and its 95% confidence intervals are shown as colored bands. for all panels, power averaged over 0.2&#x02013;1&#x000a0;h post dosing is shown relative to pre-dosing baseline average over &#x02212;1 to &#x02212;0.2&#x000a0;h before dosing. statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05 versus vehicle (linear mixed-effects models followed by t-tests).\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h4-7\" name=\"h4-7\">\u003c/a>\u003ch3 class=\"pt0\">3.7 repetitive behaviors in mouse models relevant to asd\u003c/h3>\u003cp class=\"mb0\">the inbred mouse strain btbr and the cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mouse show abnormalities in core asd behavioral domains, such as repetitive behaviors. self-grooming and digging are more elevated in the btbr mouse than in other strains, i.e., c57bl/6j (\u003ca href=\"#b40\">mcfarlane et al., 2008\u003c/a>), and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice show more elevated grooming than their wildtype littermates (\u003ca href=\"#b51\">penagarikano et al., 2011\u003c/a>). the aim of the following experiments was to determine whether alogabat has a specific effect on repetitive behaviors independent of potential effects on overall locomotor activity. we assessed the effects of subchronic treatment on cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice to exclude potential tolerance to the effects of alogabat.\u003c/p>\u003ca id=\"h8-7-1\" name=\"h8-7-1\">\u003c/a>\u003ch4>3.7.1 open field in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h4>\u003cp class=\"mb0\">in btbr mice, acute administration of alogabat (30&#x02013;120&#x000a0;mg/kg i.p.) had no effect on the total activity over 1&#x000a0;h measured in an open field [f(4,55) &#x0003d; 2.04], although during the first 10&#x000a0;min, alogabat at 90 and 120&#x000a0;mg/kg significantly reduced the distance traveled [f(4,55) &#x0003d; 9.623, \u003cem>p\u003c/em> &#x0003c; 0.001, \u003ca href=\"#f4\">figure 4a\u003c/a>]. there was also no effect of sub-chronic alogabat (30&#x02013;100&#x000a0;mg/kg i.p.) on the total activity over 1&#x000a0;h in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice [f(3,53) &#x0003d; 0.98]. during the first 5&#x000a0;min, 100&#x000a0;mg/kg reduced the distance traveled in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice to the same level as vehicle-treated wildtype mice (\u003ca href=\"#f4\">figure 4b\u003c/a>). alogabat did not induce a major impairment of locomotor activity in the open field.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 4\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" name=\"figure4\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" alt=\"www.frontiersin.org\" id=\"f4\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 4\u003c/b>. effect of alogabat on repetitive behaviors in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. \u003cb>(a)\u003c/b> alogabat was administered i.p. 30&#x000a0;min prior to the assessment of locomotor activity in an open-field test in btbr mice: distance traveled (cm) per 5&#x000a0;min time bin (\u003cem>line graph\u003c/em>) and in 1&#x000a0;h total (\u003cem>bar chart inset\u003c/em>). \u003cb>(b)\u003c/b> alogabat was administered i.p. once daily for 2&#x02013;3&#x000a0;days, and on the test day, it was administered 30&#x000a0;min prior to testing cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice in an open field: distance traveled (cm) per 5&#x000a0;min time bin (\u003cem>line graph\u003c/em>) and in 1&#x000a0;h total (\u003cem>bar chart insert\u003c/em>). in btbr mice, on a separate test day, alogabat was administered i.p. 30&#x000a0;min prior to the grooming test: \u003cb>(c)\u003c/b> duration (s) of grooming behavior and \u003cb>(e)\u003c/b> distance (cm) traveled during the 10&#x000a0;min period in the test chamber. in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice, alogabat was administered i.p. once daily for 8&#x02013;10&#x000a0;days, and on the test day, it was administered 30&#x000a0;min prior to the grooming test: \u003cb>(d)\u003c/b> duration (s) of grooming behavior and \u003cb>(f)\u003c/b> distance traveled during the 10&#x000a0;min period in the test chamber. data are presented as individual points (circles) and mean &#x000b1; sem (btbr: \u003cem>n\u003c/em> &#x0003d; 12/group; cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup>: \u003cem>n\u003c/em> &#x0003d; 14&#x02013;15/group). statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. vehicle (veh)-treated btbr or cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. &#x000a7;&#x000a7;&#x000a7;\u003cem>p\u003c/em> &#x0003c; 0.001 vehicle-treated wildtype (wt-v) mice vs. vehicle (v)-treated cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. alogabat was administered i.p. 30&#x000a0;min prior to the assessment of digging behavior in btbr mice: \u003cb>(g)\u003c/b> duration (s) of digging behavior, \u003cb>(h)\u003c/b> distance traveled (cm), and \u003cb>(i)\u003c/b> speed (cm/s) during the 5&#x000a0;min period in the test chamber. data are presented as individual points (circles) and mean &#x000b1; sem (\u003cem>n\u003c/em> &#x0003d; 12/group). statistics: &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01 and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. vehicle-treated btbr mice. ro is the calculated receptor occupancy for gaba\u003csub>a\u003c/sub>-&#x003b1;5 from the measured plasma concentrations at each dose.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h8-7-2\" name=\"h8-7-2\">\u003c/a>\u003ch4>3.7.2 grooming behavior in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h4>\u003cp class=\"mb0\">acute administration of alogabat in btbr mice dose-dependently attenuated grooming behavior at 60, 90, and 120&#x000a0;mg/kg i.p. [f(4,55) &#x0003d; 6.946, \u003cem>p\u003c/em> &#x0003d; 0.0001, \u003ca href=\"#f4\">figure 4c\u003c/a>] without reducing locomotor activity in the same test arena (\u003ca href=\"#f4\">figure 4e\u003c/a>). in contrast, doses of 60 and 90&#x000a0;mg/kg increased the distance traveled [f(4,55) &#x0003d; 3.454, \u003cem>p\u003c/em> &#x0003c; 0.05]. alogabat had a specific effect on grooming behavior at plasma concentrations corresponding to calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 45%&#x02013;70% (see \u003ca href=\"#sm1\">supplementary table s4\u003c/a>).\u003c/p>\u003cp class=\"mb0\">sub-chronic administration of alogabat in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice attenuated grooming behavior at 60 and 100&#x000a0;mg/kg i.p. [f(3,53) &#x0003d; 10.57, \u003cem>p\u003c/em> &#x0003c; 0.0001, \u003ca href=\"#f4\">figure 4d\u003c/a>], with no effect on locomotor activity measured in the same test arena [f(3,53) &#x0003d; 0.74, \u003ca href=\"#f4\">figure 4f\u003c/a>]. alogabat had a specific effect on repetitive grooming behavior at plasma concentrations that correspond with calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro of 52%&#x02013;79% (see \u003ca href=\"#sm1\">supplementary table s4\u003c/a>).\u003c/p>\u003ca id=\"h8-7-3\" name=\"h8-7-3\">\u003c/a>\u003ch4>3.7.3 digging behavior in btbr mice\u003c/h4>\u003cp class=\"mb0\">there was no effect of acute alogabat administration on digging behavior at doses up to 100&#x000a0;mg/kg i.p. [f(3,36) &#x0003d; 0.8, \u003ca href=\"#f4\">figure 4g\u003c/a>], corresponding to a calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro level of 67% (see \u003ca href=\"#sm1\">supplementary table s4\u003c/a>). alogabat at 100&#x000a0;mg/kg reduced the distance traveled [f(3,36) &#x0003d; 12.1, \u003cem>p\u003c/em> &#x0003c; 0.001, \u003ca href=\"#f4\">figure 4h\u003c/a>] and speed [f(3,36) &#x0003d; 11.5, \u003cem>p\u003c/em> &#x0003c; 0.001, \u003ca href=\"#f4\">figure 4i\u003c/a>] in the same arena.\u003c/p>\u003ca id=\"h4-8\" name=\"h4-8\">\u003c/a>\u003ch3 class=\"pt0\">3.8 anticonvulsant activity in rats\u003c/h3>\u003cp class=\"mb0\">the purpose of these experiments was to evaluate the antiepileptic properties of alogabat against seizures induced by ptz and the mes model. alogabat administered in combination with a convulsant dose of ptz completely blocked seizures at 15 and 30&#x000a0;mg/kg (\u003ca href=\"#f5\">figure 5a\u003c/a>), which corresponds to calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 71% and 77% (see \u003ca href=\"#sm1\">supplementary table s5\u003c/a>). meanwhile, in the mes test, alogabat at 5&#x000a0;mg/kg (57% ro, see \u003ca href=\"#sm1\">supplementary table s5\u003c/a>) showed a significant reduction in the percent of rats that had tonic seizures (\u003ca href=\"#f5\">figure 5b\u003c/a>); there was only a tendency for reduction at 15&#x000a0;mg/kg (\u003cem>p\u003c/em> &#x0003d; 0.1) and 30&#x000a0;mg/kg (\u003cem>p\u003c/em> &#x0003d; 0.06). the positive control, diazepam, significantly reduced the percentage of rats that had seizures in both the ptz and mes tests.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 5\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" name=\"figure5\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" alt=\"www.frontiersin.org\" id=\"f5\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 5\u003c/b>. evaluation of alogabat for effects on anticonvulsant, motor, and cognitive tests. alogabat was administered p.o. 60&#x000a0;min prior to the following behavior tests. assessment of potential anticonvulsant activity in \u003cb>(a)\u003c/b> ptz and \u003cb>(b)\u003c/b> mes tests in rats. diazepam (dzp) at 3&#x000a0;mg/kg i.p. was included as a positive control. data are presented as individual points (circles) and the percentage of rats per group showing seizures (\u003cem>n\u003c/em> &#x0003d; 8/group). \u003cb>(c)\u003c/b> time (s) spent on the rotarod at 16&#x000a0;rpm in rats administered alogabat alone (30&#x000a0;mg/kg, gray bar with black outline) or alogabat at 3, 10, and 30&#x000a0;mg/kg co-administered with diazepam at 5&#x000a0;mg/kg i.p. (gray bars with red outline) compared with vehicle (open bar) or diazepam (open bar with red outline). data are presented as individual points (circles) and median &#x000b1; interquartile range (n &#x0003d; 8/group). assessment of cognition in rats: \u003cb>(d)\u003c/b> attention in the 5-choice serial reaction time (5-csrt) task; \u003cb>(e)\u003c/b> sustained attention in the touchscreen continuous performance test (cpt); \u003cb>(f)\u003c/b> visual&#x02013;spatial memory in the touchscreen pal task. cfc at \u003cb>(g)\u003c/b> 10 and 30&#x000a0;mg/kg; \u003cb>(h)\u003c/b> 1, 3, and 10&#x000a0;mg/kg. spatial learning and memory in the mwm: alogabat was administered once daily for 11&#x000a0;days prior to the probe trial. \u003cb>(i)\u003c/b> percentage of distance traveled in all four quadrants: vehicle; 10&#x000a0;mg/kg; 30&#x000a0;mg/kg. data are presented as individual points (circles) and mean &#x000b1; sem for pal (\u003cem>n\u003c/em> &#x0003d; 12/dose; within-subjects), 5-csrt and cpt (\u003cem>n\u003c/em> &#x0003d; 11/dose, within-subjects), cfc (\u003cem>n\u003c/em> &#x0003d; 9&#x02013;10/group), and mwm (\u003cem>n\u003c/em> &#x0003d; 10/group). statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. vehicle (veh or 0)-treated rats; mwm statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. percentage of distance in the platform quadrant. ro is the calculated receptor occupancy of alogabat for gaba\u003csub>a\u003c/sub>-&#x003b1;5 from measured plasma concentrations at each dose.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h4-9\" name=\"h4-9\">\u003c/a>\u003ch3 class=\"pt0\">3.9 combination with diazepam on rotarod performance in rats\u003c/h3>\u003cp class=\"mb0\">classical benzodiazepines, such as diazepam, are known to induce sedation and ataxia, which can be measured by the rotarod task in rodents. the aim of this experiment was to determine whether alogabat affects rotarod performance when administered alone and, second, whether alogabat modulates the sedative/motor effect of diazepam on rotarod performance when given in combination. diazepam at 5&#x000a0;mg/kg i.p. significantly impaired rotarod performance. alogabat (3&#x02013;30&#x000a0;mg/kg p.o.) co-administered with diazepam did not worsen the effects of diazepam on rotarod performance (\u003ca href=\"#f5\">figure 5c\u003c/a>). alogabat administered alone at 30&#x000a0;mg/kg p.o. did not differ from vehicle-treated rats, corresponding to a calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro level of 88% (see \u003ca href=\"#sm1\">supplementary table s5\u003c/a>).\u003c/p>\u003ca id=\"h4-10\" name=\"h4-10\">\u003c/a>\u003ch3 class=\"pt0\">3.10 evaluation of cognition in rats\u003c/h3>\u003cp class=\"mb0\">since non-selective gaba\u003csub>a\u003c/sub> pams, such as diazepam, have been shown to impair cognition (\u003ca href=\"#b5\">ballard et al., 2005\u003c/a>), the aim of the following experiments was to study the potential effects of acute administration of alogabat on cognition in rats. this included attention in the 5-csrt task and associative (fear) memory in cfc. we also assessed visual&#x02013;spatial memory (pal task) and attention (cpt) in a touchscreen system, which provides a translational approach for assessing cognition (\u003ca href=\"#b34\">hvoslef-eide et al., 2016\u003c/a>). chronic treatment with alogabat was also assessed on spatial learning and memory in the mwm.\u003c/p>\u003cp class=\"mb0\">in the 5-csrt task, alogabat at 30&#x000a0;mg/kg induced a small but statistically significant reduction in percent correct (3%; within-subjects comparison; f(3,30) &#x0003d; 5.6, \u003cem>p\u003c/em> &#x0003c; 0.01; \u003ca href=\"#f5\">figure 5d\u003c/a>). however, alogabat did not impair attention in cpt (f(2,20) &#x0003d; 0.3; \u003ca href=\"#f5\">figure 5e\u003c/a>) or visual&#x02013;spatial memory in the pal task (f(2,22) &#x0003d; 2.6; \u003ca href=\"#f5\">figure 5f\u003c/a>).\u003c/p>\u003cp class=\"mb0\">in the cfc test, alogabat was administered before the acquisition session to determine whether there was an effect on learning the association between foot shock and the surrounding context. in the first experiment, alogabat impaired cfc at 10 and 30&#x000a0;mg/kg, corresponding to calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 75% and 81% (f(2,24) &#x0003d; 10.99, \u003cem>p\u003c/em> &#x0003c; 0.001; \u003ca href=\"#f5\">figure 5g\u003c/a>). a second experiment was undertaken to explore lower doses, and it showed that alogabat did not significantly impair cfc at 1, 3, and 10&#x000a0;mg/kg (f(3,36) &#x0003d; 0.9; \u003ca href=\"#f5\">figure 5h\u003c/a>), corresponding to the calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 35%, 56%, and 72%. this suggests that the dose of 10&#x000a0;mg/kg is approximately the threshold level for the impairment of cfc and is likely dependent on the level of ro achieved per subject.\u003c/p>\u003cp class=\"mb0\">in the mwm test, chronic administration of alogabat at 10 and 30&#x000a0;mg/kg did not significantly impair the acquisition of the hidden platform position (see \u003ca href=\"#sm1\">supplementary figure s2\u003c/a>). twenty-four hours later, the platform was removed, and the rats were allowed to swim in the maze for 60&#x000a0;s (probe trial) to assess memory-retention of the platform position. the groups receiving vehicle [f(3,27) &#x0003d; 8, \u003cem>p\u003c/em> &#x0003c; 0.001] and 10&#x000a0;mg/kg [f(3,27) &#x0003d; 7, \u003cem>p\u003c/em> &#x0003c; 0.01] had learned the spatial position of the platform, as shown by their preference for the platform quadrant (\u003ca href=\"#f5\">figure 5i\u003c/a>). however, rats that received 30&#x000a0;mg/kg alogabat showed impaired spatial memory of the platform position during the probe trial [f(3,27) &#x0003d; 3, p &#x0003d; 0.08; \u003ca href=\"#f5\">figure 5i\u003c/a>], and gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro was estimated to be 79%. in summary, alogabat impaired context and spatial memory at gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro above 70%.\u003c/p>\u003ca id=\"h5\" name=\"h5\">\u003c/a>\u003ch2>4 discussion\u003c/h2>\u003ca id=\"h5-1\" name=\"h5-1\">\u003c/a>\u003ch3 class=\"pt0\">4.1 \u003cem>in vitro\u003c/em> and \u003cem>in vivo\u003c/em> characterization of alogabat\u003c/h3>\u003cp class=\"mb0\">alogabat was shown to be a potent and functionally selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor pam \u003cem>in vitro\u003c/em>. the functional activity of alogabat was confirmed at native gaba\u003csub>a\u003c/sub> receptors in rat hippocampal slices. \u003cem>in vivo\u003c/em> binding experiments demonstrated dose-dependent target engagement of alogabat in rats and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. the highest specific binding was observed in the hippocampus, which is consistent with the known distribution of the gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor subtype in rodents (\u003ca href=\"#b54\">pirker et al., 2000\u003c/a>). phmri studies in rats demonstrated dose-dependent perfusion changes, indicating circuit modulation by alogabat. there were consistent changes in the neural activity pattern across dose groups, with modulation of neural activity in, among others, the medial prefrontal cortex, cingulate cortex, motor cortex, perirhinal cortex, nucleus accumbens shell, amygdala, hippocampus fimbria, and substantia nigra.\u003c/p>\u003ca id=\"h5-2\" name=\"h5-2\">\u003c/a>\u003ch3 class=\"pt0\">4.2 eeg signature\u003c/h3>\u003cp class=\"mb0\">acute administration of alogabat in rats induced an eeg signature characterized by a power decrease in theta and an increase in the beta frequency range, which was qualitatively similar to the eeg signature of non-selective gaba\u003csub>a\u003c/sub> pams such as diazepam (\u003ca href=\"#b71\">van lier et al., 2004\u003c/a>; \u003ca href=\"#b72\">visser et al., 2003\u003c/a>; \u003ca href=\"#b22\">friedman et al., 1992\u003c/a>). the lower magnitude of induced eeg beta-band power by alogabat compared to diazepam is likely attributed to its &#x003b1;5-selectivity, resulting in an overall lower magnitude of gaba\u003csub>a\u003c/sub> receptor modulation. this eeg signature of alogabat is qualitatively a mirror image of the eeg signature of basmisanil, a highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 negative allosteric modulator (nam), which we recently found to induce an increase in the theta power and a decrease in the beta-band eeg power in healthy volunteers (\u003ca href=\"#b31\">hipp et al., 2021\u003c/a>). furthermore, the eeg signature of alogabat is in agreement with the link between beta-band activity and single-nucleotide polymorphisms (snps) in gaba\u003csub>a\u003c/sub> receptor genes (\u003ca href=\"#b56\">porjesz et al., 2002\u003c/a>; \u003ca href=\"#b67\">smit et al., 2018\u003c/a>) and ndds (dup15q syndrome, as) involving gene copy number variations of \u003cem>gabrb3, gabra5\u003c/em>, and \u003cem>gabrg3\u003c/em> (\u003ca href=\"#b24\">frohlich et al., 2019a\u003c/a>; \u003ca href=\"#b25\">frohlich et al., 2019b\u003c/a>). gaba\u003csub>a\u003c/sub> receptor-related changes in beta-band activity are believed to reflect the modulation of recurrent excitatory&#x02013;inhibitory feedback loops in the cortical tissue (\u003ca href=\"#b75\">whittington et al., 2000\u003c/a>; \u003ca href=\"#b70\">traub and jefferys, 1999\u003c/a>). for the administered doses, the calculated receptor occupancies were in the range of 77%&#x02013;84% for &#x003b1;5-containing receptors and 22%&#x02013;34% for &#x003b1;1-containing receptors (with different pam effects (e\u003csub>max\u003c/sub>) at &#x003b1;5 vs. &#x003b1;1). thus, at the studied doses, alogabat has some effect on &#x003b1;1-containing receptors, and further work is needed to systematically study lower doses of alogabat, including those &#x0003c;70% ro without the impairment of cognition in wt rats, to confirm whether the modulation of &#x003b1;5-containing receptors alone is sufficient to induce the described eeg effect. nonetheless, eeg theta- and beta-band power are promising candidates for translational mechanistic biomarkers of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor function and could be used in the further development of alogabat.\u003c/p>\u003ca id=\"h5-3\" name=\"h5-3\">\u003c/a>\u003ch3 class=\"pt0\">4.3 behavioral effects of alogabat in animal models relevant to asd\u003c/h3>\u003cp class=\"mb0\">we assessed the effects of alogabat in two different mouse models relevant to asd, one phenotypic and one genetic. acute administration of alogabat significantly and dose-dependently attenuated excessive grooming, but not digging, behavior in btbr mice. sub-chronic administration of alogabat significantly attenuated elevated grooming behavior in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. efficacy in these different models was linked to gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro above 50%. despite initial findings of a transiently decreased activity in an open-field test, alogabat increased the activity of btbr mice and had no effect on the activity of cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice during the grooming test, supporting the specific effect of alogabat on repetitive grooming. we have tested additional compounds with similar properties, e.g., ro7015738, and have confirmed that gaba\u003csub>a\u003c/sub>-&#x003b1;5 pams reduce repetitive behaviors in these mouse models (\u003ca href=\"#b10\">buettelmann et al., 2018\u003c/a>). these results align well with recently published data showing that gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor deficiency causes autism-like behaviors in mice, including increased grooming and reduced social contacts (\u003ca href=\"#b77\">zurek et al., 2016\u003c/a>), and with sh-053-2&#x02032;f-r-ch3, a gaba\u003csub>a\u003c/sub>-&#x003b1;5 pam, which was recently shown to have positive effects on social and cognitive deficits in a rat model of autism (\u003ca href=\"#b68\">souza et al., 2024\u003c/a>). our data are valuable in providing information on the ro required for \u003cem>in vivo\u003c/em> effects on repetitive behavior. however, it should be noted that this effect may not directly translate to all individuals with asd as it is a heterogeneous disorder, whereas these mouse models exhibit specific genetic or phenotypic deficits.\u003c/p>\u003ca id=\"h5-4\" name=\"h5-4\">\u003c/a>\u003ch3 class=\"pt0\">4.4 anticonvulsant effects of alogabat\u003c/h3>\u003cp class=\"mb0\">it has been proposed that the reduction of gabaergic inhibitory activity results in hyperexcitability of minicolumn circuits, explaining some of the symptomatology observed in some ndds, including the high incidence of seizures and auditory&#x02013;tactile hypersensitivity (\u003ca href=\"#b60\">rubenstein and merzenich, 2003\u003c/a>; \u003ca href=\"#b26\">frye et al., 2016\u003c/a>). in the current study, we demonstrated that alogabat exhibits an anticonvulsant profile with activity comparable to the benzodiazepine drug class in acutely induced seizure models (electrical and chemical). alogabat had a small effect on seizures in the mes test, whereas in the ptz test, alogabat was shown to completely block seizures at calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro &#x0003e;70%. since ptz is a gaba\u003csub>a\u003c/sub> antagonist, this supports the assessment of alogabat for anticonvulsant activity in disorders where there is dysfunction of the gabaergic system. furthermore, in a separate eeg study, we observed that one out of eight rats had frequent spike-and-wave discharge (swd) activity, which was alleviated following treatment with alogabat (see \u003ca href=\"#sm1\">supplementary figures s3a&#x02013;s3c\u003c/a>; methods in \u003ca href=\"#sm1\">supplementary material\u003c/a>). to better understand the temporal dynamics of swd occurrence and the suppressing effect of alogabat, we performed a follow-up study on three additional rats that showed pronounced swd. both 3 and 10&#x000a0;mg/kg alogabat substantially reduced the number of swds within the first 3&#x000a0;h of recording, when the same rats showed increased swd numbers in the vehicle control condition (see \u003ca href=\"#sm1\">supplementary figures s3d&#x02013;s3f\u003c/a>), which corresponds to the calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro level of 30%&#x02013;46% (see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). from a circuit perspective, the consensus is that such epileptic activity is generated by dysregulated thalamocortical circuitry, with abnormal interactions between reticular thalamic neurons and thalamic relay cells acting as the trigger and cortical circuits serving as the generator (\u003ca href=\"#b66\">sitnikova et al., 2023\u003c/a>). considering that in rats, &#x003b1;5-subunit-containing gaba\u003csub>a\u003c/sub> receptors are enriched in the cortex and hippocampus (\u003ca href=\"#b64\">serwanski et al., 2006\u003c/a>; \u003ca href=\"#b33\">hu et al., 2019\u003c/a>), mediating dendritic inhibition on pyramidal neurons (\u003ca href=\"#b2\">ali and thomson, 2008\u003c/a>; \u003ca href=\"#b62\">schulz et al., 2018\u003c/a>), we hypothesize that alogabat could suppress swd generation by enhancing the inhibition of cortical pyramidal neurons. however, more systematic work is required to confirm that alogabat can prevent swd activity.\u003c/p>\u003ca id=\"h5-5\" name=\"h5-5\">\u003c/a>\u003ch3 class=\"pt0\">4.5 assessment of non-specific behavioral effects\u003c/h3>\u003cp class=\"mb0\">non-selective gaba\u003csub>a\u003c/sub> pams, such as diazepam and chlordiazepoxide, are effective anxiolytics in clinical use but have also been shown to impair cognition in rodents and humans. gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors are believed to play a major role in cognition since they are predominantly expressed in the hippocampus in rats, where they regulate nmdar-dependent synaptic plasticity underlying learning and memory processes (\u003ca href=\"#b62\">schulz et al., 2018\u003c/a>; \u003ca href=\"#b23\">fritschy et al., 1997\u003c/a>; \u003ca href=\"#b63\">schulz et al., 2019\u003c/a>; \u003ca href=\"#b14\">davenport et al., 2021\u003c/a>). moreover, it has been proposed that gaba\u003csub>a\u003c/sub> pams may induce memory impairment by modulating hippocampal function (\u003ca href=\"#b41\">mcnaughton and morris, 1987\u003c/a>). therefore, alogabat was evaluated in several rodent tests of cognition to determine whether a selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 pam would induce cognitive impairment following acute administration in rats. there was no effect of alogabat up to 70% gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro on cognition (visual&#x02013;spatial memory, attention, context fear conditioning, spatial learning, and memory). cognitive impairment was only observed at high doses (&#x0003e;70% ro) and supra-therapeutic levels of alogabat in associative (fear) learning (cfc) and spatial memory in the mwm in wildtype rats. the impairment at high doses is likely linked to the loss of selectivity toward gaba\u003csub>a\u003c/sub> &#x003b1;1, &#x003b1;2, and &#x003b1;3 receptor subtypes (&#x003b1;1 ro was calculated as 19%&#x02013;25% at these doses; see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). in addition to the loss of selectivity, we cannot exclude the possibility that these effects may be a consequence of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor saturation, i.e., excessive &#x003b1;5 activity in wildtype subjects may be detrimental. the cognitive impairment observed in wildtype rats may translate to healthy human subjects; however, our focus is on the effect of &#x003b1;5 pams in disease conditions with impaired gaba\u003csub>a\u003c/sub> signaling and impaired cognition, where our hypothesis is that an &#x003b1;5 pam would have beneficial effects.\u003c/p>\u003cp class=\"mb0\">alogabat had no effect on social approach/avoidance, the elevated plus maze, and the vogel conflict test in rats at ro levels up to 80% (see \u003ca href=\"#sm1\">supplementary figure s4\u003c/a> and methods in \u003ca href=\"#sm1\">supplementary material\u003c/a>), suggesting that alogabat does not exhibit an anxiolytic-like effect in rodents. this might be explained by the low expression of gaba\u003csub>a\u003c/sub>-&#x003b1;5 in the amygdala, a key node controlling anxiety-like behaviors. potential anxiolytic effects of alogabat in humans cannot be excluded as this receptor subtype is much more abundant in the human amygdala. since benzodiazepines, such as diazepam, are frequently used to treat anxiety and seizures in ndds, it was important to establish that alogabat at relevant therapeutic doses in mouse models did not worsen the sedative/motor-impairing effects of diazepam in the rotarod test. alogabat did not worsen diazepam-induced motor impairment; on the contrary, in combination, it reduced the motor impairments, which is more likely due to the more localized and precise inhibitory effect, counterbalancing the broader suppression of neuronal activity by diazepam, or due to lower intrinsic activity at &#x003b1;1 receptors compared to diazepam. we have previously shown that a gaba\u003csub>a\u003c/sub>-&#x003b1;5 nam, which binds at the benzodiazepine binding site of the receptor, does not decrease the anxiolytic activity of chlordiazepoxide (see \u003ca href=\"#sm1\">supplementary figure s5\u003c/a>); therefore, it is unlikely that alogabat will interfere with the anxiolytic effect of the classical benzodiazepines.\u003c/p>\u003ca id=\"h6\" name=\"h6\">\u003c/a>\u003ch2>5 conclusion\u003c/h2>\u003cp class=\"mb15\">multiple lines of evidence point to deficits in gabaergic signaling in epilepsy and ndds, such as asd and deletion as, with a prominent role attributed to gaba\u003csub>a\u003c/sub> receptors, including the gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor subtype. the current data for alogabat showed robust dose-dependent efficacy on repetitive behaviors in two disease-relevant mouse models and anti-seizure activity in the ptz rat model at gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro above 50%. our \u003cem>in vivo\u003c/em> occupancy measurements using the selective &#x003b1;5 tracer l-655,708 were highly valuable for understanding plasma and csf exposures (as a surrogate of free brain concentration) and their relationship to \u003cem>in vivo\u003c/em> effects. we observed that there was a 34-fold shift between the csf concentration of alogabat in the \u003cem>in vivo\u003c/em> occupancy study and that of alogabat \u003cem>in vitro\u003c/em> binding data (ki value). the receptor occupancy of alogabat correlates well with pd effects (\u003cem>in vivo\u003c/em> effects) and is consistent across the different studies/species (see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). this finding highlights the importance of using pet tracers in drug development.\u003c/p>\u003cp class=\"mb15\">our data suggest that gaba\u003csub>a\u003c/sub>-&#x003b1;5 pams may have potential benefits in individuals with autistic features and in conditions with clinical and nonclinical manifestations of cortical hyperexcitability and epilepsy. however, alogabat is unlikely to work across all ndds and should be utilized as a precision medicine to target a specific subgroup of the ndd population with deficient gaba\u003csub>a\u003c/sub> pathway signaling, or specifically gaba\u003csub>a\u003c/sub>-&#x003b1;5. interestingly, recent data suggest that gaba\u003csub>a\u003c/sub>-&#x003b1;5 pams may also have therapeutic potential in schizophrenia, alzheimer&#x02019;s disease, and depression (\u003ca href=\"#b53\">perez et al., 2023\u003c/a>; \u003ca href=\"#b39\">luscher et al., 2023\u003c/a>; \u003ca href=\"#b36\">koh et al., 2013\u003c/a>). with regard to the current status of alogabat, good-laboratory practice (glp) toxicology and safety pharmacology studies in rats and minipigs showed an overall benign safety profile, which supported its clinical investigations in phase-1 studies in healthy volunteers and phase-2 trials in asd and deletion as patients (nct03507569, nct03774576, nct03847987, nct04299464, nct05630066, and eudract&#x00023;2019-003524-20). the outcome of these studies, including pet, eeg, and effects on cognition, will be reported in the future.\u003c/p>\u003ca id=\"h7\" name=\"h7\">\u003c/a>\u003ch2>data availability statement\u003c/h2>\u003cp class=\"mb15\">the original contributions presented in the study are included in the article/\u003ca href=\"#sm1\">supplementary material\u003c/a>, further inquiries can be directed to the corresponding author.\u003c/p>\u003ca id=\"h8\" name=\"h8\">\u003c/a>\u003ch2>ethics statement\u003c/h2>\u003cp class=\"mb0\">experiments performed at f. hoffmann-la roche ag (basel, switzerland) complied with swiss federal and cantonal laws on animal research and aaalac regulations and received prior approval from the cantonal veterinary office. the eeg study was conducted at brains online (ca, united states) in accordance with the guide for the care and use of laboratory animals (national research council 2011) after receiving approval from the institutional animal care and use committee. the ptz and mes tests were conducted at vivocore inc., canada, which is a facility licensed by the ontario ministry of agriculture, food, and rural affairs and accredited by the canadian council on animal care. all \u003cem>in vivo\u003c/em> studies are reported in compliance with the arrive guidelines (\u003ca href=\"#b52\">percie du sert et al., 2020\u003c/a>). the study was conducted in accordance with the local legislation and institutional requirements.\u003c/p>\u003ca id=\"h9\" name=\"h9\">\u003c/a>\u003ch2>author contributions\u003c/h2>\u003cp class=\"mb0\">gc: supervision, writing - original draft, investigation, formal analysis. tmb: formal analysis, investigation, writing - review and editing, methodology. fk: formal analysis, writing - original draft, investigation, methodology. mh: writing - original draft, investigation, methodology, formal analysis. jfh: data curation, visualization, methodology, writing - original draft, formal analysis. pg: methodology, data curation, formal analysis, writing - original draft. tm: investigation, writing - original draft, formal analysis, methodology. bk: investigation, writing - original draft, methodology, formal analysis. anb: formal analysis, writing - original draft, data curation. epp: writing - original draft, methodology, investigation. ps: methodology, investigation, writing - original draft, formal analysis. pj: writing - original draft, formal analysis. rr: methodology, writing - original draft, investigation, formal analysis. bb: methodology, investigation, writing - original draft. hk: methodology, writing - original draft, investigation. ao-m: writing - original draft, formal analysis, methodology. alb: methodology, writing - original draft, investigation. jms: investigation, formal analysis, writing - original draft. db: methodology, writing - original draft, investigation. ms: writing - original draft, methodology, investigation. eco&#x00027;c: investigation, writing - original draft, methodology. m-ch: investigation, conceptualization, writing - review and editing, supervision, writing - original draft, methodology.\u003c/p>\u003ca id=\"h10\" name=\"h10\">\u003c/a>\u003ch2>funding\u003c/h2>\u003cp class=\"mb0\">the author(s) declare that financial support was received for the research and/or publication of this article. the funding was provided by f. hoffmann-la roche ag switzerland.\u003c/p>\u003ca id=\"h11\" name=\"h11\">\u003c/a>\u003ch2>acknowledgments\u003c/h2>\u003cp class=\"mb03\">the authors thank gregoire friz, maria karg, and judith lengyel (molecular biology and binding assays); v&#x000e9;ronique graf, rachel haab, and marie-claire pflimlin (\u003cem>in vitro\u003c/em> electrophysiology); brigitte algeyer, severine bandinelli, sean durkin, audrey genet, marie haman, martine maco, and roger wyler (behavioral pharmacology); and stephanie sch&#x000f6;ppenthau, s&#x000e9;bastien debilly, and thomas bielser (\u003cem>in vivo\u003c/em> phmri). the rat ptz and mes studies were carried out under the scientific guidance of dr guy higgins, intervivo solutions, and coordinated by leo silenieks at vivocore inc., ontario, canada. the rat eeg data acquisition was undertaken by brains on-line llc, south san francisco, united states, and the data analysis was undertaken by pg, vanessa keeney, and andr&#x000e9;s olivares at roche.\u003c/p>\u003ca id=\"h12\" name=\"h12\">\u003c/a>\u003ch2>conflict of interest\u003c/h2>\u003cp class=\"mb0\">authors gc, tmb, fk, mh, jfh, pg, tm, bk, ab, epp, ps, pj, rr, bb, hk, ao-m, ab, jms, ms, eco&#x00027;c, and m-ch were employed by f. hoffmann-la roche ag switzerland. all employees (former and current) may be eligible for stock and stock options. author db was employed by hiqscreen s&#x000e0;rl.\u003c/p>\u003ca id=\"h13\" name=\"h13\">\u003c/a>\u003ch2>generative ai statement\u003c/h2>\u003cp class=\"mb15\">the author(s) declare that no generative ai was used in the creation of this manuscript.\u003c/p>\u003ca id=\"h14\" name=\"h14\">\u003c/a>\u003ch2>publisher&#x02019;s note\u003c/h2>\u003cp class=\"mb15\">all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.\u003c/p>\u003ca id=\"h15\" name=\"h15\">\u003c/a>\u003ch2>supplementary material\u003c/h2>\u003cp class=\"mb15\" id=\"sm1\">the supplementary material for this article can be found online at: \u003ca href=\"https://www.frontiersin.org/articles/10.3389/fphar.2025.1626078/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fphar.2025.1626078/full&#x00023;supplementary-material\u003c/a>\u003c/p>\u003ca id=\"h16\" name=\"h16\">\u003c/a>\u003ch2>abbreviations\u003c/h2>\u003cp class=\"mb15\">as, angelman syndrome; asd, autism spectrum disorder; cfc, context fear conditioning; cntnap2, contactin-associated protein-like 2; cpt, continuous performance test; 5-csrt, 5-choice serial reaction time; eeg, electroencephalography; gaba, gamma-aminobutyric acid; gad, glutamic acid decarboxylase; i.p., intraperitoneally; i.v., intravenously; lfp, local field potential; mes, maximum electrical stimulus; mwm, morris water maze; ndds, neurodevelopmental disorders; pal, paired associates learning; pam, positive allosteric modulator; phmri, pharmacological magnetic resonance imaging; p.o, per os; ptz, pentylenetetrazole; ro, receptor occupancy; pet, positron emission tomography.\u003c/p>\u003ca id=\"h17\" name=\"h17\">\u003c/a>\u003ch2>references\u003c/h2>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b1\" id=\"b1\">\u003c/a>abrahams, b. s., and geschwind, d. h. (2008). advances in autism genetics: on the threshold of a new neurobiology. \u003cem>nat. rev. genet.\u003c/em> 9, 341&#x02013;355. doi:10.1038/nrg2346\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/18414403/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nrg2346\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=advances+in+autism+genetics:+on+the+threshold+of+a+new+neurobiology&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b2\" id=\"b2\">\u003c/a>ali, a. b., and thomson, a. m. (2008). synaptic alpha 5 subunit-containing gabaa receptors mediate ipsps elicited by dendrite-preferring cells in rat neocortex. \u003cem>cereb. cortex\u003c/em> 18, 1260&#x02013;1271. doi:10.1093/cercor/bhm160\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17951598/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1093/cercor/bhm160\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=synaptic+alpha+5+subunit-containing+gabaa+receptors+mediate+ipsps+elicited+by+dendrite-preferring+cells+in+rat+neocortex&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\" style=\"margin-bottom:0.5em;\">\u003cp class=\"referencescopy1\">\u003ca name=\"b3\" id=\"b3\">\u003c/a>american psychiatric association (2008). \u003cem>diagnostic and statistical manual of mental disorders\u003c/em>. 5th ed. washington: \u003cspan class=\"publisher-name\">american psychiatric association\u003c/span>. \u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=american+psychiatric+association+%2c+diagnostic+and+statistical+manual+of+mental+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b4\" id=\"b4\">\u003c/a>ballard, t. m., knoflach, f., prinssen, e., borroni, e., vivian, j. a., basile, j., et al. (2009). ro4938581, a novel cognitive enhancer acting at gabaa alpha5 subunit-containing receptors. \u003cem>psychopharmacol. berl.\u003c/em> 202, 207&#x02013;223. doi:10.1007/s00213-008-1357-7\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/18936916/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1007/s00213-008-1357-7\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=ro4938581%2c+a+novel+cognitive+enhancer+acting+at+gabaa+alpha5+subunit-containing+receptors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b5\" id=\"b5\">\u003c/a>ballard, t. m., woolley, m. l., prinssen, e., huwyler, j., porter, r., and spooren, w. (2005). the effect of the mglu5 receptor antagonist mpep in rodent tests of anxiety and cognition: a comparison. \u003cem>psychopharmacol. berl.\u003c/em> 179, 218&#x02013;229. doi:10.1007/s00213-005-2211-9\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/15739074/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1007/s00213-005-2211-9\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+effect+of+the+mglu5+receptor+antagonist+mpep+in+rodent+tests+of+anxiety+and+cognition:+a+comparison&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b6\" id=\"b6\">\u003c/a>banerjee, a., garcia-oscos, f., roychowdhury, s., galindo, l. c., hall, s., kilgard, m. p., et al. (2013). impairment of cortical gabaergic synaptic transmission in an environmental rat model of autism. \u003cem>int. j. neuropsychopharmacol.\u003c/em> 16, 1309&#x02013;1318. doi:10.1017/s1461145712001216\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23228615/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1017/s1461145712001216\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=impairment+of+cortical+gabaergic+synaptic+transmission+in+an+environmental+rat+model+of+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b7\" id=\"b7\">\u003c/a>bourgeron, t. (2015). from the genetic architecture to synaptic plasticity in autism spectrum disorder. \u003cem>nat. rev. neurosci.\u003c/em> 16, 551&#x02013;563. doi:10.1038/nrn3992\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26289574/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nrn3992\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=from+the+genetic+architecture+to+synaptic+plasticity+in+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b8\" id=\"b8\">\u003c/a>braat, s., and kooy, r. f. (2015). the gabaa receptor as a therapeutic target for neurodevelopmental disorders. \u003cem>neuron\u003c/em> 86, 1119&#x02013;1130. doi:10.1016/j.neuron.2015.03.042\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26050032/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuron.2015.03.042\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+gabaa+receptor+as+a+therapeutic+target+for+neurodevelopmental+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b9\" id=\"b9\">\u003c/a>bruns, a., kunnecke, b., risterucci, c., moreau, j. l., and von kienlin, m. (2009). validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological mri in rats. \u003cem>magn. reson med.\u003c/em> 61, 1451&#x02013;1458. doi:10.1002/mrm.21779\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/19358231/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/mrm.21779\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=validation+of+cerebral+blood+perfusion+imaging+as+a+modality+for+quantitative+pharmacological+mri+in+rats&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\" style=\"margin-bottom:0.5em;\">\u003cp class=\"referencescopy1\">\u003ca name=\"b10\" id=\"b10\">\u003c/a>buettelmann, b., cecere, g., fasching, b., groebke zbinden, k., hernandez, m.-c., knust, h., et al. (2018). \u003cem>preparation of new isoxazolyl ether derivatives as gabaa &#x003b1;5 receptor positive allosteric modulators (pams)\u003c/em>. \u003cspan class=\"publisher-name\">copyright &#x000a9; 2025 american chemical society acs\u003c/span>. available online at: \u003ca href=\"https://worldwide.espacent.com/patent/search/family/057530563/publication/wo2018104419a1?q=wo2018104419a1\">https://worldwide.espacent.com/patent/search/family/057530563/publication/wo2018104419a1?q&#x0003d;wo2018104419a1\u003c/a>\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=â buettelmannâ bcecereâ gfaschingâ bgroebke+zbindenâ khernandezâ m-cknustâ het+al+2018+preparation+of+new+isoxazolyl+ether+derivatives+as+gabaa+î±5+receptor+positive+allosteric+modulators+pams+copyright+â©+2025+american+chemical+society+acs+available+online+at:+https://worldwideespacentcom/patent/search/family/057530563/publication/wo2018104419a1?q=wo2018104419a1&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b12\" id=\"b12\">\u003c/a>buiting, k. (2010). prader-willi syndrome and angelman syndrome. \u003cem>am. j. med. genet. c semin. med. genet.\u003c/em> 154c, 365&#x02013;376. doi:10.1002/ajmg.c.30273\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/20803659/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/ajmg.c.30273\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=prader-willi+syndrome+and+angelman+syndrome&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b13\" id=\"b13\">\u003c/a>chao, h. t., chen, h., samaco, r. c., xue, m., chahrour, m., yoo, j., et al. (2010). dysfunction in gaba signalling mediates autism-like stereotypies and rett syndrome phenotypes. \u003cem>nature\u003c/em> 468, 263&#x02013;269. doi:10.1038/nature09582\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21068835/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nature09582\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=dysfunction+in+gaba+signalling+mediates+autism-like+stereotypies+and+rett+syndrome+phenotypes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b14\" id=\"b14\">\u003c/a>davenport, c. m., rajappa, r., katchan, l., taylor, c. r., tsai, m. c., smith, c. m., et al. (2021). relocation of an extrasynaptic gaba(a) receptor to inhibitory synapses freezes excitatory synaptic strength and preserves memory. \u003cem>neuron\u003c/em> 109, 123&#x02013;134 e4. doi:10.1016/j.neuron.2020.09.037\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/33096025/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuron.2020.09.037\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=relocation+of+an+extrasynaptic+gabaa+receptor+to+inhibitory+synapses+freezes+excitatory+synaptic+strength+and+preserves+memory&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b15\" id=\"b15\">\u003c/a>delong, r. (2007). gaba(a) receptor alpha5 subunit as a candidate gene for autism and bipolar disorder: a proposed endophenotype with parent-of-origin and gain-of-function features,with or without oculocutaneous albinism. \u003cem>autism\u003c/em> 11, 135&#x02013;147. doi:10.1177/1362361307075705\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17353214/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1177/1362361307075705\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa+receptor+alpha5+subunit+as+a+candidate+gene+for+autism+and+bipolar+disorder:+a+proposed+endophenotype+with+parent-of-origin+and+gain-of-function+features%2cwith+or+without+oculocutaneous+albinism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b16\" id=\"b16\">\u003c/a>delorey, t. m. (2005). gabrb3 gene deficient mice: a potential model of autism spectrum disorder. \u003cem>int. rev. neurobiol.\u003c/em> 71, 359&#x02013;382. doi:10.1016/s0074-7742(05)71015-1\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/16512358/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0074-7742(05)71015-1\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabrb3+gene+deficient+mice:+a+potential+model+of+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b17\" id=\"b17\">\u003c/a>delorey, t. m., sahbaie, p., hashemi, e., homanics, g. e., and clark, j. d. (2008). gabrb3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: a potential model of autism spectrum disorder. \u003cem>behav. brain res.\u003c/em> 187, 207&#x02013;220. doi:10.1016/j.bbr.2007.09.009\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17983671/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.bbr.2007.09.009\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabrb3+gene+deficient+mice+exhibit+impaired+social+and+exploratory+behaviors%2c+deficits+in+non-selective+attention+and+hypoplasia+of+cerebellar+vermal+lobules:+a+potential+model+of+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b18\" id=\"b18\">\u003c/a>dhossche, d., applegate, h., abraham, a., maertens, p., bland, l., bencsath, a., et al. (2002). elevated plasma gamma-aminobutyric acid (gaba) levels in autistic youngsters: stimulus for a gaba hypothesis of autism. \u003cem>med. sci. monit.\u003c/em> 8, pr1&#x02013;pr6.\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/12165753/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=elevated+plasma+gamma-aminobutyric+acid+gaba+levels+in+autistic+youngsters:+stimulus+for+a+gaba+hypothesis+of+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b19\" id=\"b19\">\u003c/a>di nanni, n., bersanelli, m., cupaioli, f. a., milanesi, l., mezzelani, a., and mosca, e. (2019). network-based integrative analysis of genomics, epigenomics and transcriptomics in autism spectrum disorders. \u003cem>int. j. mol. sci.\u003c/em> 20, 3363. doi:10.3390/ijms20133363\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/31323926/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.3390/ijms20133363\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=network-based+integrative+analysis+of+genomics%2c+epigenomics+and+transcriptomics+in+autism+spectrum+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b20\" id=\"b20\">\u003c/a>dufour, b. d., mcbride, e., bartley, t., juarez, p., and martinez-cerdeno, v. (2023). distinct patterns of gabaergic interneuron pathology in autism are associated with intellectual impairment and stereotypic behaviors. \u003cem>autism\u003c/em> 27, 1730&#x02013;1745. doi:10.1177/13623613231154053\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/36935610/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1177/13623613231154053\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=distinct+patterns+of+gabaergic+interneuron+pathology+in+autism+are+associated+with+intellectual+impairment+and+stereotypic+behaviors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b21\" id=\"b21\">\u003c/a>fatemi, s. h., halt, a. r., stary, j. m., kanodia, r., schulz, s. c., and realmuto, g. r. (2002). glutamic acid decarboxylase 65 and 67 kda proteins are reduced in autistic parietal and cerebellar cortices. \u003cem>biol. psychiatry\u003c/em> 52, 805&#x02013;810. doi:10.1016/s0006-3223(02)01430-0\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/12372652/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0006-3223(02)01430-0\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=glutamic+acid+decarboxylase+65+and+67+kda+proteins+are+reduced+in+autistic+parietal+and+cerebellar+cortices&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b22\" id=\"b22\">\u003c/a>friedman, h., greenblatt, d. j., peters, g. r., metzler, c. m., charlton, m. d., harmatz, j. s., et al. (1992). pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. \u003cem>clin. pharmacol. ther.\u003c/em> 52, 139&#x02013;150. doi:10.1038/clpt.1992.123\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/1505149/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/clpt.1992.123\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=pharmacokinetics+and+pharmacodynamics+of+oral+diazepam:+effect+of+dose%2c+plasma+concentration%2c+and+time&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b23\" id=\"b23\">\u003c/a>fritschy, j. m., benke, d., johnson, d. k., mohler, h., and rudolph, u. (1997). gabaa-receptor alpha-subunit is an essential prerequisite for receptor formation \u003cem>in vivo\u003c/em>. \u003cem>neuroscience\u003c/em> 81, 1043&#x02013;1053. doi:10.1016/s0306-4522(97)00244-3\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/9330366/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0306-4522(97)00244-3\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa-receptor+alpha-subunit+is+an+essential+prerequisite+for+receptor+formation+in+vivo&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b24\" id=\"b24\">\u003c/a>frohlich, j., miller, m. t., bird, l. m., garces, p., purtell, h., hoener, m. c., et al. (2019a). electrophysiological phenotype in angelman syndrome differs between genotypes. \u003cem>biol. psychiatry\u003c/em> 85, 752&#x02013;759. doi:10.1016/j.biopsych.2019.01.008\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/30826071/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.biopsych.2019.01.008\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=electrophysiological+phenotype+in+angelman+syndrome+differs+between+genotypes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b25\" id=\"b25\">\u003c/a>frohlich, j., reiter, l. t., saravanapandian, v., distefano, c., huberty, s., hyde, c., et al. (2019b). mechanisms underlying the eeg biomarker in dup15q syndrome. \u003cem>mol. autism\u003c/em> 10, 29. doi:10.1186/s13229-019-0280-6\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/31312421/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1186/s13229-019-0280-6\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=mechanisms+underlying+the+eeg+biomarker+in+dup15q+syndrome&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b26\" id=\"b26\">\u003c/a>frye, r. e., casanova, m. f., fatemi, s. h., folsom, t. d., reutiman, t. j., brown, g. l., et al. (2016). neuropathological mechanisms of seizures in autism spectrum disorder. \u003cem>front. neurosci.\u003c/em> 10, 192. doi:10.3389/fnins.2016.00192\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27242398/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.3389/fnins.2016.00192\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=neuropathological+mechanisms+of+seizures+in+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b27\" id=\"b27\">\u003c/a>fukuda, t., itoh, m., ichikawa, t., washiyama, k., and goto, y. (2005). delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of mecp2-deficient mice. \u003cem>j. neuropathol. exp. neurol.\u003c/em> 64, 537&#x02013;544. doi:10.1093/jnen/64.6.537\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/15977646/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1093/jnen/64.6.537\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=delayed+maturation+of+neuronal+architecture+and+synaptogenesis+in+cerebral+cortex+of+mecp2-deficient+mice&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b28\" id=\"b28\">\u003c/a>gaetz, w., bloy, l., wang, d. j., port, r. g., blaskey, l., levy, s. e., et al. (2014). gaba estimation in the brains of children on the autism spectrum: measurement precision and regional cortical variation. \u003cem>neuroimage\u003c/em> 86, 1&#x02013;9. doi:10.1016/j.neuroimage.2013.05.068\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23707581/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuroimage.2013.05.068\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gaba+estimation+in+the+brains+of+children+on+the+autism+spectrum:+measurement+precision+and+regional+cortical+variation&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b29\" id=\"b29\">\u003c/a>han, s., tai, c., jones, c. j., scheuer, t., and catterall, w. a. (2014). enhancement of inhibitory neurotransmission by gabaa receptors having &#x003b1;2,3-subunits ameliorates behavioral deficits in a mouse model of autism. \u003cem>neuron\u003c/em> 81, 1282&#x02013;1289. doi:10.1016/j.neuron.2014.01.016\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/24656250/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuron.2014.01.016\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=enhancement+of+inhibitory+neurotransmission+by+gabaa+receptors+having+î±2%2c3-subunits+ameliorates+behavioral+deficits+in+a+mouse+model+of+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b30\" id=\"b30\">\u003c/a>han, s., tai, c., westenbroek, r. e., yu, f. h., cheah, c. s., potter, g. b., et al. (2012). autistic-like behaviour in scn1a&#x0002b;/- mice and rescue by enhanced gaba-mediated neurotransmission. \u003cem>nature\u003c/em> 489, 385&#x02013;390. doi:10.1038/nature11356\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22914087/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nature11356\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=autistic-like+behaviour+in+scn1a+/-+mice+and+rescue+by+enhanced+gaba-mediated+neurotransmission&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b31\" id=\"b31\">\u003c/a>hipp, j. f., knoflach, f., comley, r., ballard, t. m., honer, m., trube, g., et al. (2021). basmisanil, a highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man. \u003cem>sci. rep.\u003c/em> 11, 7700. doi:10.1038/s41598-021-87307-7\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/33833333/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/s41598-021-87307-7\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=basmisanil%2c+a+highly+selective+gabaa-î±5+negative+allosteric+modulator:+preclinical+pharmacology+and+demonstration+of+functional+target+engagement+in+man&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b32\" id=\"b32\">\u003c/a>hogart, a., wu, d., lasalle, j. m., and schanen, n. c. (2010). the comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. \u003cem>neurobiol. dis.\u003c/em> 38, 181&#x02013;191. doi:10.1016/j.nbd.2008.08.011\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/18840528/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.nbd.2008.08.011\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+comorbidity+of+autism+with+the+genomic+disorders+of+chromosome+15q112-q13&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b33\" id=\"b33\">\u003c/a>hu, x., rocco, b. r., fee, c., and sibille, e. (2019). cell type-specific gene expression of alpha 5 subunit-containing gamma-aminobutyric acid subtype a receptors in human and mouse frontal cortex. \u003cem>mol. neuropsychiatry\u003c/em> 4, 204&#x02013;215. doi:10.1159/000495840\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/30815456/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1159/000495840\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=cell+type-specific+gene+expression+of+alpha+5+subunit-containing+gamma-aminobutyric+acid+subtype+a+receptors+in+human+and+mouse+frontal+cortex&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b34\" id=\"b34\">\u003c/a>hvoslef-eide, m., nilsson, s. r., saksida, l. m., and bussey, t. j. (2016). cognitive translation using the rodent touchscreen testing approach. \u003cem>curr. top. behav. neurosci.\u003c/em> 28, 423&#x02013;447. doi:10.1007/7854_2015_5007\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27305921/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1007/7854_2015_5007\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=cognitive+translation+using+the+rodent+touchscreen+testing+approach&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b35\" id=\"b35\">\u003c/a>kalsner, l., and chamberlain, s. j. (2015). prader-willi, angelman, and 15q11-q13 duplication syndromes. \u003cem>pediatr. clin. north am.\u003c/em> 62, 587&#x02013;606. doi:10.1016/j.pcl.2015.03.004\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26022164/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.pcl.2015.03.004\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=prader-willi%2c+angelman%2c+and+15q11-q13+duplication+syndromes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b36\" id=\"b36\">\u003c/a>koh, m. t., rosenzweig-lipson, s., and gallagher, m. (2013). selective gaba(a) &#x003b1;5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. \u003cem>neuropharmacology\u003c/em> 64, 145&#x02013;152. doi:10.1016/j.neuropharm.2012.06.023\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22732440/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2012.06.023\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=selective+gabaa+î±5+positive+allosteric+modulators+improve+cognitive+function+in+aged+rats+with+memory+impairment&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b37\" id=\"b37\">\u003c/a>lim, c. s., kim, h., yu, n. k., kang, s. j., kim, t., ko, h. g., et al. (2017). enhancing inhibitory synaptic function reverses spatial memory deficits in shank2 mutant mice. \u003cem>neuropharmacology\u003c/em> 112, 104&#x02013;112. doi:10.1016/j.neuropharm.2016.08.016\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27544825/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2016.08.016\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=enhancing+inhibitory+synaptic+function+reverses+spatial+memory+deficits+in+shank2+mutant+mice&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b38\" id=\"b38\">\u003c/a>luk, h. m., and lo, i. f. (2016). angelman syndrome in hong kong chinese: a 20 years&#x00027; experience. \u003cem>eur. j. med. genet.\u003c/em> 59, 315&#x02013;319. doi:10.1016/j.ejmg.2016.05.003\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27174604/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.ejmg.2016.05.003\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=angelman+syndrome+in+hong+kong+chinese:+a+20+years'+experience&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b39\" id=\"b39\">\u003c/a>luscher, b., maguire, j. l., rudolph, u., and sibille, e. (2023). gaba(a) receptors as targets for treating affective and cognitive symptoms of depression. \u003cem>trends pharmacol. sci.\u003c/em> 44, 586&#x02013;600. doi:10.1016/j.tips.2023.06.009\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/37543478/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.tips.2023.06.009\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa+receptors+as+targets+for+treating+affective+and+cognitive+symptoms+of+depression&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b40\" id=\"b40\">\u003c/a>mcfarlane, h. g., kusek, g. k., yang, m., phoenix, j. l., bolivar, v. j., and crawley, j. n. (2008). autism-like behavioral phenotypes in btbr t&#x0002b;tf/j mice. \u003cem>genes brain behav.\u003c/em> 7, 152&#x02013;163. doi:10.1111/j.1601-183x.2007.00330.x\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17559418/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1111/j.1601-183x.2007.00330.x\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=autism-like+behavioral+phenotypes+in+btbr+t+tf/j+mice&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b41\" id=\"b41\">\u003c/a>mcnaughton, n., and morris, r. g. (1987). chlordiazepoxide, an anxiolytic benzodiazepine, impairs place navigation in rats. \u003cem>behav. brain res.\u003c/em> 24, 39&#x02013;46. doi:10.1016/0166-4328(87)90034-9\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/3580114/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/0166-4328(87)90034-9\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=chlordiazepoxide%2c+an+anxiolytic+benzodiazepine%2c+impairs+place+navigation+in+rats&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b42\" id=\"b42\">\u003c/a>mendez, m. a., horder, j., myers, j., coghlan, s., stokes, p., erritzoe, d., et al. (2013). the brain gaba-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)c]ro15-4513 positron emission tomography study. \u003cem>neuropharmacology\u003c/em> 68, 195&#x02013;201. doi:10.1016/j.neuropharm.2012.04.008\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22546616/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2012.04.008\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+brain+gaba-benzodiazepine+receptor+alpha-5+subtype+in+autism+spectrum+disorder:+a+pilot+%5b11c%5dro15-4513+positron+emission+tomography+study&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b43\" id=\"b43\">\u003c/a>mermer, f., poliquin, s., rigsby, k., rastogi, a., shen, w., romero-morales, a., et al. (2021). common molecular mechanisms of slc6a1 variant-mediated neurodevelopmental disorders in astrocytes and neurons. \u003cem>brain\u003c/em> 144, 2499&#x02013;2512. doi:10.1093/brain/awab207\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/34028503/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1093/brain/awab207\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=common+molecular+mechanisms+of+slc6a1+variant-mediated+neurodevelopmental+disorders+in+astrocytes+and+neurons&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b44\" id=\"b44\">\u003c/a>mertz, l. g., christensen, r., vogel, i., hertz, j. m., nielsen, k. b., gronskov, k., et al. (2013). angelman syndrome in denmark. birth incidence, genetic findings, and age at diagnosis. \u003cem>am. j. med. genet. a\u003c/em> 161a, 2197&#x02013;2203. doi:10.1002/ajmg.a.36058\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23913711/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/ajmg.a.36058\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=angelman+syndrome+in+denmark+birth+incidence%2c+genetic+findings%2c+and+age+at+diagnosis&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b45\" id=\"b45\">\u003c/a>mesbah-oskui, l., penna, a., orser, b. a., and horner, r. l. (2017). reduced expression of &#x003b1;5gaba\u003csub>a\u003c/sub> receptors elicits autism-like alterations in eeg patterns and sleep-wake behavior. \u003cem>neurotoxicol teratol.\u003c/em> 61, 115&#x02013;122. doi:10.1016/j.ntt.2016.10.009\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27793660/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.ntt.2016.10.009\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=reduced+expression+of+î±5gabaa+receptors+elicits+autism-like+alterations+in+eeg+patterns+and+sleep-wake+behavior&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b46\" id=\"b46\">\u003c/a>mohler, h. (2011). the rise of a new gaba pharmacology. \u003cem>neuropharmacology\u003c/em> 60, 1042&#x02013;1049. doi:10.1016/j.neuropharm.2010.10.020\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21035473/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2010.10.020\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+rise+of+a+new+gaba+pharmacology&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b47\" id=\"b47\">\u003c/a>mori, t., mori, k., fujii, e., toda, y., miyazaki, m., harada, m., et al. (2012). evaluation of the gabaergic nervous system in autistic brain: (123)i-iomazenil spect study. \u003cem>brain dev.\u003c/em> 34, 648&#x02013;654. doi:10.1016/j.braindev.2011.10.007\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22099869/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.braindev.2011.10.007\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=evaluation+of+the+gabaergic+nervous+system+in+autistic+brain:+123i-iomazenil+spect+study&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b48\" id=\"b48\">\u003c/a>myers, j. f., comley, r. a., and gunn, r. n. (2017). quantification of [\u003csup>11\u003c/sup>c]ro15-4513 gaba\u003csub>a\u003c/sub>&#x003b1;5 specific binding and regional selectivity in humans. \u003cem>j. cereb. blood flow. metab.\u003c/em> 37, 2137&#x02013;2148. doi:10.1177/0271678x16661339\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27466376/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1177/0271678x16661339\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=quantification+of+%5b11c%5dro15-4513+gabaaî±5+specific+binding+and+regional+selectivity+in+humans&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b49\" id=\"b49\">\u003c/a>nakamura, t., arima-yoshida, f., sakaue, f., nasu-nishimura, y., takeda, y., matsuura, k., et al. (2016). px-rics-deficient mice mimic autism spectrum disorder in jacobsen syndrome through impaired gabaa receptor trafficking. \u003cem>nat. commun.\u003c/em> 7, 10861. doi:10.1038/ncomms10861\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26979507/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/ncomms10861\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=px-rics-deficient+mice+mimic+autism+spectrum+disorder+in+jacobsen+syndrome+through+impaired+gabaa+receptor+trafficking&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b50\" id=\"b50\">\u003c/a>orefice, l. l., zimmerman, a. l., chirila, a. m., sleboda, s. j., head, j. p., and ginty, d. d. (2016). peripheral mechanosensory neuron dysfunction underlies tactile and behavioral deficits in mouse models of asds. \u003cem>cell\u003c/em> 166, 299&#x02013;313. doi:10.1016/j.cell.2016.05.033\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27293187/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.cell.2016.05.033\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=peripheral+mechanosensory+neuron+dysfunction+underlies+tactile+and+behavioral+deficits+in+mouse+models+of+asds&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b51\" id=\"b51\">\u003c/a>penagarikano, o., abrahams, b. s., herman, e. i., winden, k. d., gdalyahu, a., dong, h., et al. (2011). absence of cntnap2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. \u003cem>cell\u003c/em> 147, 235&#x02013;246. doi:10.1016/j.cell.2011.08.040\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21962519/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.cell.2011.08.040\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=absence+of+cntnap2+leads+to+epilepsy%2c+neuronal+migration+abnormalities%2c+and+core+autism-related+deficits&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b52\" id=\"b52\">\u003c/a>percie du sert, n., hurst, v., ahluwalia, a., alam, s., avey, m. t., baker, m., et al. (2020). the arrive guidelines 2.0: updated guidelines for reporting animal research. \u003cem>plos biol.\u003c/em> 18, e3000410. doi:10.1371/journal.pbio.3000410\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/32663219/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1371/journal.pbio.3000410\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+arrive+guidelines+20:+updated+guidelines+for+reporting+animal+research&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b53\" id=\"b53\">\u003c/a>perez, s. m., mccoy, a. m., prevot, t. d., mian, m. y., carreno, f. r., frazer, a., et al. (2023). hippocampal &#x003b1;5-gaba(a) receptors modulate dopamine neuron activity in the rat ventral tegmental area. \u003cem>biol. psychiatry glob. open sci.\u003c/em> 3, 78&#x02013;86. doi:10.1016/j.bpsgos.2021.12.010\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/36712569/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.bpsgos.2021.12.010\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=hippocampal+î±5-gabaa+receptors+modulate+dopamine+neuron+activity+in+the+rat+ventral+tegmental+area&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b54\" id=\"b54\">\u003c/a>pirker, s., schwarzer, c., wieselthaler, a., sieghart, w., and sperk, g. (2000). gaba(a) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. \u003cem>neuroscience\u003c/em> 101, 815&#x02013;850. doi:10.1016/s0306-4522(00)00442-5\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/11113332/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0306-4522(00)00442-5\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa+receptors:+immunocytochemical+distribution+of+13+subunits+in+the+adult+rat+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b55\" id=\"b55\">\u003c/a>pizzarelli, r., and cherubini, e. (2011). alterations of gabaergic signaling in autism spectrum disorders. \u003cem>neural plast.\u003c/em> 2011, 297153. doi:10.1155/2011/297153\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21766041/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1155/2011/297153\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=alterations+of+gabaergic+signaling+in+autism+spectrum+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b56\" id=\"b56\">\u003c/a>porjesz, b., almasy, l., edenberg, h. j., wang, k., chorlian, d. b., foroud, t., et al. (2002). linkage disequilibrium between the beta frequency of the human eeg and a gabaa receptor gene locus. \u003cem>proc. natl. acad. sci. u. s. a.\u003c/em> 99, 3729&#x02013;3733. doi:10.1073/pnas.052716399\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/11891318/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1073/pnas.052716399\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=linkage+disequilibrium+between+the+beta+frequency+of+the+human+eeg+and+a+gabaa+receptor+gene+locus&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b57\" id=\"b57\">\u003c/a>puts, n. a. j., wodka, e. l., harris, a. d., crocetti, d., tommerdahl, m., mostofsky, s. h., et al. (2017). reduced gaba and altered somatosensory function in children with autism spectrum disorder. \u003cem>autism res.\u003c/em> 10, 608&#x02013;619. doi:10.1002/aur.1691\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27611990/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/aur.1691\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=reduced+gaba+and+altered+somatosensory+function+in+children+with+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b58\" id=\"b58\">\u003c/a>robertson, c. e., ratai, e. m., and kanwisher, n. (2016). reduced gabaergic action in the autistic brain. \u003cem>curr. biol.\u003c/em> 26, 80&#x02013;85. doi:10.1016/j.cub.2015.11.019\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26711497/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.cub.2015.11.019\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=reduced+gabaergic+action+in+the+autistic+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b59\" id=\"b59\">\u003c/a>rojas, d. c., singel, d., steinmetz, s., hepburn, s., and brown, m. s. (2014). decreased left perisylvian gaba concentration in children with autism and unaffected siblings. \u003cem>neuroimage\u003c/em> 86, 28&#x02013;34. doi:10.1016/j.neuroimage.2013.01.045\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23370056/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuroimage.2013.01.045\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=decreased+left+perisylvian+gaba+concentration+in+children+with+autism+and+unaffected+siblings&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b60\" id=\"b60\">\u003c/a>rubenstein, j. l., and merzenich, m. m. (2003). model of autism: increased ratio of excitation/inhibition in key neural systems. \u003cem>genes brain behav.\u003c/em> 2, 255&#x02013;267. doi:10.1034/j.1601-183x.2003.00037.x\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/14606691/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1034/j.1601-183x.2003.00037.x\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=model+of+autism:+increased+ratio+of+excitation/inhibition+in+key+neural+systems&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b61\" id=\"b61\">\u003c/a>sanders, s. j. (2015). first glimpses of the neurobiology of autism spectrum disorder. \u003cem>curr. opin. genet. dev.\u003c/em> 33, 80&#x02013;92. doi:10.1016/j.gde.2015.10.002\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26547130/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.gde.2015.10.002\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=first+glimpses+of+the+neurobiology+of+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b62\" id=\"b62\">\u003c/a>schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2018). dendrite-targeting interneurons control synaptic nmda-receptor activation \u003cem>via\u003c/em> nonlinear &#x003b1;5-gaba\u003csub>a\u003c/sub> receptors. \u003cem>nat. commun.\u003c/em> 9, 3576. doi:10.1038/s41467-018-06004-8\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/30177704/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/s41467-018-06004-8\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=dendrite-targeting+interneurons+control+synaptic+nmda-receptor+activation+via+nonlinear+î±5-gabaa+receptors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b63\" id=\"b63\">\u003c/a>schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2019). enhanced dendritic inhibition and impaired nmdar activation in a mouse model of down syndrome. \u003cem>j. neurosci.\u003c/em> 39, 5210&#x02013;5221. doi:10.1523/jneurosci.2723-18.2019\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/31000585/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1523/jneurosci.2723-18.2019\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=enhanced+dendritic+inhibition+and+impaired+nmdar+activation+in+a+mouse+model+of+down+syndrome&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b64\" id=\"b64\">\u003c/a>serwanski, d. r., miralles, c. p., christie, s. b., mehta, a. k., li, x., and de blas, a. l. (2006). synaptic and nonsynaptic localization of gabaa receptors containing the alpha5 subunit in the rat brain. \u003cem>j. comp. neurol.\u003c/em> 499, 458&#x02013;470. doi:10.1002/cne.21115\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/16998906/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/cne.21115\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=synaptic+and+nonsynaptic+localization+of+gabaa+receptors+containing+the+alpha5+subunit+in+the+rat+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b65\" id=\"b65\">\u003c/a>sieghart, w. (2006). structure, pharmacology, and function of gabaa receptor subtypes. \u003cem>adv. pharmacol.\u003c/em> 54, 231&#x02013;263. doi:10.1016/s1054-3589(06)54010-4\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17175817/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s1054-3589(06)54010-4\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=structure%2c+pharmacology%2c+and+function+of+gabaa+receptor+subtypes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b66\" id=\"b66\">\u003c/a>sitnikova, e., rutskova, e., and smirnov, k. (2023). alpha2-adrenergic receptors as a pharmacological target for spike-wave epilepsy. \u003cem>int. j. mol. sci.\u003c/em> 24, 1477. doi:10.3390/ijms24021477\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/36674992/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.3390/ijms24021477\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=alpha2-adrenergic+receptors+as+a+pharmacological+target+for+spike-wave+epilepsy&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b67\" id=\"b67\">\u003c/a>smit, d. j. a., wright, m. j., meyers, j. l., martin, n. g., ho, y. y. w., malone, s. m., et al. (2018). genome-wide association analysis links multiple psychiatric liability genes to oscillatory brain activity. \u003cem>hum. brain mapp.\u003c/em> 39, 4183&#x02013;4195. doi:10.1002/hbm.24238\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/29947131/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/hbm.24238\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=genome-wide+association+analysis+links+multiple+psychiatric+liability+genes+to+oscillatory+brain+activity&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b68\" id=\"b68\">\u003c/a>souza, a. j., freitas, i. s., sharmin, d., cook, j. m., guimaraes, f. s., and gomes, f. v. (2024). an alpha 5-gaba(a) receptor positive allosteric modulator attenuates social and cognitive deficits without changing dopamine system hyperactivity in rats exposed to valproic acid in utero. \u003cem>autism res.\u003c/em> 17, 1534&#x02013;1544. doi:10.1002/aur.3178\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/39169698/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/aur.3178\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=an+alpha+5-gabaa+receptor+positive+allosteric+modulator+attenuates+social+and+cognitive+deficits+without+changing+dopamine+system+hyperactivity+in+rats+exposed+to+valproic+acid+in+utero&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b69\" id=\"b69\">\u003c/a>sur, c., fresu, l., howell, o., mckernan, r. m., and atack, j. r. (1999). autoradiographic localization of alpha5 subunit-containing gabaa receptors in rat brain. \u003cem>brain res.\u003c/em> 822, 265&#x02013;270. doi:10.1016/s0006-8993(99)01152-x\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/10082908/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0006-8993(99)01152-x\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=autoradiographic+localization+of+alpha5+subunit-containing+gabaa+receptors+in+rat+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\" style=\"margin-bottom:0.5em;\">\u003cp class=\"referencescopy1\">\u003ca name=\"b70\" id=\"b70\">\u003c/a>traub, r. d. w. m., and jefferys, j. g. r. (1999). \u003cem>fast oscillations in cortical circuits\u003c/em>. \u003cspan class=\"publisher-name\">the mit press\u003c/span>. \u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=â traubâ r+d+w+mjefferysâ j+g+r+1999+fast+oscillations+in+cortical+circuits+the+mit+press&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b71\" id=\"b71\">\u003c/a>van lier, h., drinkenburg, w. h., van eeten, y. j., and coenen, a. m. (2004). effects of diazepam and zolpidem on eeg beta frequencies are behavior-specific in rats. \u003cem>neuropharmacology\u003c/em> 47, 163&#x02013;174. doi:10.1016/j.neuropharm.2004.03.017\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/15223295/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2004.03.017\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=effects+of+diazepam+and+zolpidem+on+eeg+beta+frequencies+are+behavior-specific+in+rats&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b72\" id=\"b72\">\u003c/a>visser, s. a., wolters, f. l., gubbens-stibbe, j. m., tukker, e., van der graaf, p. h., peletier, l. a., et al. (2003). mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of gabaa receptor modulators: in vitro-in vivo correlations. \u003cem>j. pharmacol. exp. ther.\u003c/em> 304, 88&#x02013;101. doi:10.1124/jpet.102.042341\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/12490579/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1124/jpet.102.042341\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=mechanism-based+pharmacokinetic/pharmacodynamic+modeling+of+the+electroencephalogram+effects+of+gabaa+receptor+modulators:+in+vitro-in+vivo+correlations&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b73\" id=\"b73\">\u003c/a>vithlani, m., terunuma, m., and moss, s. j. (2011). the dynamic modulation of gaba(a) receptor trafficking and its role in regulating the plasticity of inhibitory synapses. \u003cem>physiol. rev.\u003c/em> 91, 1009&#x02013;1022. doi:10.1152/physrev.00015.2010\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21742794/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1152/physrev.00015.2010\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+dynamic+modulation+of+gabaa+receptor+trafficking+and+its+role+in+regulating+the+plasticity+of+inhibitory+synapses&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b74\" id=\"b74\">\u003c/a>warrier, v., baron-cohen, s., and chakrabarti, b. (2013). genetic variation in gabrb3 is associated with asperger syndrome and multiple endophenotypes relevant to autism. \u003cem>mol. autism\u003c/em> 4, 48. doi:10.1186/2040-2392-4-48\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/24321478/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1186/2040-2392-4-48\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=genetic+variation+in+gabrb3+is+associated+with+asperger+syndrome+and+multiple+endophenotypes+relevant+to+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b75\" id=\"b75\">\u003c/a>whittington, m. a., traub, r. d., kopell, n., ermentrout, b., and buhl, e. h. (2000). inhibition-based rhythms: experimental and mathematical observations on network dynamics. \u003cem>int. j. psychophysiol.\u003c/em> 38, 315&#x02013;336. doi:10.1016/s0167-8760(00)00173-2\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/11102670/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0167-8760(00)00173-2\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=inhibition-based+rhythms:+experimental+and+mathematical+observations+on+network+dynamics&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b76\" id=\"b76\">\u003c/a>xie, x. h., and tietz, e. i. (1991). chronic benzodiazepine treatment of rats induces reduction of paired-pulse inhibition in ca1 region of \u003cem>in vitro\u003c/em> hippocampus. \u003cem>brain res.\u003c/em> 561, 69&#x02013;76. doi:10.1016/0006-8993(91)90750-p\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/1797351/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/0006-8993(91)90750-p\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=chronic+benzodiazepine+treatment+of+rats+induces+reduction+of+paired-pulse+inhibition+in+ca1+region+of+in+vitro+hippocampus&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b77\" id=\"b77\">\u003c/a>zurek, a. a., kemp, s. w., aga, z., walker, s., milenkovic, m., ramsey, a. j., et al. (2016). &#x003b1;5gabaa receptor deficiency causes autism-like behaviors. \u003cem>ann. clin. transl. neurol.\u003c/em> 3, 392&#x02013;398. doi:10.1002/acn3.303\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27231709/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/acn3.303\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=î±5gabaa+receptor+deficiency+causes+autism-like+behaviors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003c/div>\u003cdiv class=\"thinlinem20\">\u003c/div>\u003cdiv class=\"abstractsummary\">\u003cp>\u003cspan>keywords:\u003c/span> autism spectrum disorder, angelman syndrome, gaba\u003csub>a\u003c/sub>, gaba\u003csub>a\u003c/sub>-&#x003b1;5, positron emission tomography (pet), electroencephalography, pharmacological mri, biomarker\u003c/p>\u003cp>\u003cspan>citation:\u003c/span> cecere g, ballard tm, knoflach f, honer m, hipp jf, garces p, mueggler t, k&#x000fc;nnecke b, bruns a, prinssen ep, schoenenberger p, janz p, redondo r, biemans b, knust h, olivares-morales a, brigo a, schulz jm, bertrand d, saxe m, o&#x02019;connor ec and hernandez m-c (2025) preclinical pharmacology of alogabat: a novel gaba\u003csub>a\u003c/sub>-&#x003b1;5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gaba\u003csub>a\u003c/sub> signaling. \u003cem>front. pharmacol.\u003c/em> 16:1626078. doi: 10.3389/fphar.2025.1626078\u003c/p>\u003cp id=\"timestamps\">\u003cspan>received:\u003c/span> 09 may 2025; \u003cspan>accepted:\u003c/span> 18 june 2025;\u003cbr>\u003cspan>published:\u003c/span> 21 july 2025.\u003c/p>\u003cdiv>\u003cp>edited by:\u003c/p> \u003ca href=\"https://loop.frontiersin.org/people/52072/overview\">agenor limon\u003c/a>, university of texas medical branch at galveston, united states\u003c/div>\u003cdiv>\u003cp>reviewed by:\u003c/p> \u003ca href=\"https://loop.frontiersin.org/people/39673/overview\">hansen wang\u003c/a>, university of toronto, canada\u003cbr>\u003ca href=\"https://loop.frontiersin.org/people/1285968/overview\">junzhan jing\u003c/a>, baylor college of medicine, united states\u003cbr>\u003ca href=\"https://loop.frontiersin.org/people/1380630/overview\">azar omrani\u003c/a>, boehringer ingelheim, germany\u003c/div>\u003cp>\u003cspan>copyright\u003c/span> &#x000a9; 2025 cecere, ballard, knoflach, honer, hipp, garces, mueggler, k&#x000fc;nnecke, bruns, prinssen, schoenenberger, janz, redondo, biemans, knust, olivares-morales, brigo, schulz, bertrand, saxe, o&#x02019;connor and hernandez. this is an open-access article distributed under the terms of the \u003ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">creative commons attribution license (cc by).\u003c/a> the use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. no use, distribution or reproduction is permitted which does not comply with these terms.\u003c/p>\u003cp>\u003cspan>&#x0002a;correspondence:\u003c/span> maria-clemencia hernandez, \u003ca id=\"encmail\">bwfyawety2xlbwvuy2lhlmhlcm5hbmrlekbyb2nozs5jb20=\u003c/a>\u003c/p>\u003cp>\u003cspan>\u003csup>&#x02020;\u003c/sup>\u003c/span>these authors have contributed equally to this work\u003c/p>\u003cp>\u003cspan>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cb>present address:\u003c/b> theresa m. ballard, galwyn (uk) ltd., dartmouth, united kingdom\u003cbr>barbara biemans, b2discovery llc, riehen, switzerland\u003cbr>michael saxe, translational in vivo sciences, biogen, cambridge, ma, united states\u003c/p>\u003cdiv class=\"clear\">\u003c/div>\u003c/div>","\u003cul class=\"flyoutjournal\">\u003cli>\u003ca href=\"#h1\">abstract\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h2\">1 introduction\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h3\">2 materials and methods\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h4\">3 results\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h5\">4 discussion\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h6\">5 conclusion\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h7\">data availability statement\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h8\">ethics statement\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h9\">author contributions\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h10\">funding\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h11\">acknowledgments\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h12\">conflict of interest\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h13\">generative ai statement\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h14\">publisher&#x02019;s note\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h15\">supplementary material\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h16\">abbreviations\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h17\">references\u003c/a>\u003c/li>\u003c/ul>",[732,740,746,752],{"name":733,"fileserverpackageentryid":734,"fileserverid":735,"fileserverversionnumber":736,"type":737},"fphar-16-1626078.xml","fphar-16-1626078-r1/fphar-16-1626078.xml","1626078/xml",2,{"code":738,"name":739},"nlm_xml","xml",{"name":741,"fileserverpackageentryid":19,"fileserverid":742,"fileserverversionnumber":736,"type":743},"epub.epub","1626078/epub",{"code":744,"name":745},"epub","epub",{"name":747,"fileserverpackageentryid":19,"fileserverid":748,"fileserverversionnumber":736,"type":749},"publishers-proof.pdf","1626078/publishers-proof",{"code":750,"name":751},"pdf","pdf",{"name":753,"fileserverpackageentryid":19,"fileserverid":754,"fileserverversionnumber":370,"type":755},"supplementary file 1.docx","1626078/supplementary-file/1",{"code":756,"name":757},"supplementary_material","docx","v3",{"title":760,"link":761,"meta":765,"script":956},"frontiers | preclinical pharmacology of alogabat: a novel gabaa-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gabaa signaling",[762],{"rel":763,"href":764},"canonical","https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1626078/full",[766,769,772,774,777,781,784,788,791,794,797,799,801,803,805,807,810,813,815,818,820,822,825,828,831,834,837,841,845,848,851,854,856,859,861,864,866,869,871,874,876,879,881,884,886,889,891,894,896,899,901,904,906,909,911,914,916,919,922,925,927,930,932,935,938,941,943,946,948,951,953],{"hid":767,"property":767,"name":767,"content":768},"description","backgroundalterations in the gabaergic system contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder (asd) and...",{"hid":770,"property":770,"name":771,"content":760},"og:title","title",{"hid":773,"property":773,"name":767,"content":768},"og:description",{"hid":775,"name":775,"content":776},"keywords","biomarker,autism spectrum disorder,electroencephalography,positron emission tomography (pet),angelman syndrome,gabaa,gabaa-α5,pharmacological mri",{"hid":778,"property":778,"name":779,"content":780},"og:site_name","site_name","frontiers",{"hid":782,"property":782,"name":363,"content":783},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg",{"hid":785,"property":785,"name":786,"content":787},"og:type","type","article",{"hid":789,"property":789,"name":790,"content":764},"og:url","url",{"hid":792,"name":792,"content":793},"twitter:card","summary_large_image",{"hid":795,"name":795,"content":796},"citation_volume","16",{"hid":798,"name":798,"content":116},"citation_journal_title",{"hid":800,"name":800,"content":780},"citation_publisher",{"hid":802,"name":802,"content":713},"citation_journal_abbrev",{"hid":804,"name":804,"content":714},"citation_issn",{"hid":806,"name":806,"content":515},"citation_doi",{"hid":808,"name":808,"content":809},"citation_firstpage","1626078",{"hid":811,"name":811,"content":812},"citation_language","english",{"hid":814,"name":814,"content":516},"citation_title",{"hid":816,"name":816,"content":817},"citation_keywords","biomarker; autism spectrum disorder; electroencephalography; positron emission tomography (pet); angelman syndrome; gabaa; gabaa-α5; pharmacological mri",{"hid":819,"name":819,"content":521},"citation_abstract",{"hid":821,"name":821,"content":524},"citation_article_type",{"hid":823,"name":823,"content":824},"citation_pdf_url","https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1626078/pdf",{"hid":826,"name":826,"content":827},"citation_xml_url","https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1626078/xml",{"hid":829,"name":829,"content":830},"citation_fulltext_world_readable","yes",{"hid":832,"name":832,"content":833},"citation_online_date","2025/06/18",{"hid":835,"name":835,"content":836},"citation_publication_date","2025/07/21",{"hid":838,"name":839,"content":840},"citation_author_0","citation_author","cecere, giuseppe ",{"hid":842,"name":843,"content":844},"citation_author_institution_0","citation_author_institution","medicinal chemistry, switzerland",{"hid":846,"name":839,"content":847},"citation_author_1","ballard, theresa m. ",{"hid":849,"name":843,"content":850},"citation_author_institution_1","neuroscience and rare diseases, switzerland",{"hid":852,"name":839,"content":853},"citation_author_2","knoflach, frederic ",{"hid":855,"name":843,"content":850},"citation_author_institution_2",{"hid":857,"name":839,"content":858},"citation_author_3","honer, michael ",{"hid":860,"name":843,"content":850},"citation_author_institution_3",{"hid":862,"name":839,"content":863},"citation_author_4","hipp, joerg f. ",{"hid":865,"name":843,"content":850},"citation_author_institution_4",{"hid":867,"name":839,"content":868},"citation_author_5","garces, pilar ",{"hid":870,"name":843,"content":850},"citation_author_institution_5",{"hid":872,"name":839,"content":873},"citation_author_6","mueggler, thomas ",{"hid":875,"name":843,"content":850},"citation_author_institution_6",{"hid":877,"name":839,"content":878},"citation_author_7","künnecke, basil ",{"hid":880,"name":843,"content":850},"citation_author_institution_7",{"hid":882,"name":839,"content":883},"citation_author_8","bruns, andreas ",{"hid":885,"name":843,"content":850},"citation_author_institution_8",{"hid":887,"name":839,"content":888},"citation_author_9","prinssen, eric p. ",{"hid":890,"name":843,"content":850},"citation_author_institution_9",{"hid":892,"name":839,"content":893},"citation_author_10","schoenenberger, philipp ",{"hid":895,"name":843,"content":850},"citation_author_institution_10",{"hid":897,"name":839,"content":898},"citation_author_11","janz, philipp ",{"hid":900,"name":843,"content":850},"citation_author_institution_11",{"hid":902,"name":839,"content":903},"citation_author_12","redondo, roger ",{"hid":905,"name":843,"content":850},"citation_author_institution_12",{"hid":907,"name":839,"content":908},"citation_author_13","biemans, barbara ",{"hid":910,"name":843,"content":850},"citation_author_institution_13",{"hid":912,"name":839,"content":913},"citation_author_14","knust, henner ",{"hid":915,"name":843,"content":844},"citation_author_institution_14",{"hid":917,"name":839,"content":918},"citation_author_15","olivares-morales, andrés ",{"hid":920,"name":843,"content":921},"citation_author_institution_15","pharmaceutical sciences, switzerland",{"hid":923,"name":839,"content":924},"citation_author_16","brigo, alessandro ",{"hid":926,"name":843,"content":921},"citation_author_institution_16",{"hid":928,"name":839,"content":929},"citation_author_17","schulz, jan michael ",{"hid":931,"name":843,"content":850},"citation_author_institution_17",{"hid":933,"name":839,"content":934},"citation_author_18","bertrand, daniel ",{"hid":936,"name":843,"content":937},"citation_author_institution_18","hiqscreen sàrl, switzerland",{"hid":939,"name":839,"content":940},"citation_author_19","saxe, michael ",{"hid":942,"name":843,"content":850},"citation_author_institution_19",{"hid":944,"name":839,"content":945},"citation_author_20","o’connor, eoin c. ",{"hid":947,"name":843,"content":850},"citation_author_institution_20",{"hid":949,"name":839,"content":950},"citation_author_21","hernandez, maria-clemencia ",{"hid":952,"name":843,"content":850},"citation_author_institution_21",{"hid":954,"name":954,"content":955},"dc.identifier","doi:10.3389/fphar.2025.1626078",[957,960,962,964,966],{"src":958,"body":13,"type":959,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":961,"body":13,"type":959,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/mathjax.js?config=tex-mml-am_chtml",{"src":963,"body":13,"type":959,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":965,"body":13,"type":959,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fphar.2025.1626078?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":967,"body":13,"type":959,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articlehubslug":19,"articlehubpage":969,"articlehubarticleslist":970,"canjournalhasarticlehub":347,"articledoilist":971},{},[],[],{"title":19,"image":-1,"breadcrumbs":973,"linkscollection":974,"metricscollection":976},[],{"total":367,"items":975},[],{"total":367,"items":977},[]] window.__nuxt__={};window.__nuxt__.config={public:{isdevmode:false,appname:"article-pages-2024",baseurl:"https://www.frontiersin.org",domain:"frontiersin.org",loopurl:"https://loop.frontiersin.org",ssmaindomain:"frontiersin.org",contentfulurl:"https://graphql.contentful.com/content/v1/spaces",spaceid:1,spacename:"frontiers",livespaceid:1,tenantlogourl:"",frontiersgraphurl:"https://apollo-federation-gateway.frontiersin.org",registrationapiurl:"https://onboarding-ui.frontiersin.org",emaildigestapiurl:"https://api-email-digest.frontiersin.org",journalfilesapiurl:"https://files-journal-api.frontiersin.org",searchapiurl:"https://search-api.frontiersin.org",productionforumapiurl:"https://production-forum-api-v2.frontiersin.org",gtmserverurl:"https://tag-manager.frontiersin.org",gtmid:"gtm-m322fv2",gtmauth:"owvbwxfajr21yqv1fe1caq",gtmpreview:"env-1",figsharepluginurl:"https://widgets.figshare.com/static/figshare.js",figshareapiurl:"https://api.figshare.com/v2/collections/search",figsharetimeout:3000,crossmarkpublisheddate:"2015/08/24",googlerecaptchasitekey:"6ldg3i0uaaaaaoc4quh35ubhgjotehp_stxhgr_v",googlerecaptchakeyname:"frontiersrecaptchav2",faviconsize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantfavicon-frontiers.png",faviconsize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantfavicon-frontiers.png",faviconsize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantfavicon-frontiers.png",faviconsize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantfavicon-frontiers.png",faviconsize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantfavicon-frontiers.png",socialmediaimg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/guidelines-frontiers_logo_1200x628_1-91to1.png",linkedarticlecopytext:"'{\"articletypecopytext\":[{\"articletypeid\":0,\"originalarticlecopytext\":\"part of this article's content has been mentioned in:\",\"linkedarticlecopytext\":\"this article mentions parts of:\"},{\"articletypeid\":122,\"originalarticlecopytext\":\"parts of this article's content have been modified or rectified in:\",\"linkedarticlecopytext\":\"this article is an erratum on:\"},{\"articletypeid\":129,\"originalarticlecopytext\":\"parts of this article's content have been modified or rectified in:\",\"linkedarticlecopytext\":\"this article is an addendum to:\"},{\"articletypeid\":128,\"originalarticlecopytext\":\"a correction has been applied to this article in:\",\"linkedarticlecopytext\":\"this article is a correction to:\"},{\"articletypeid\":134,\"originalarticlecopytext\":\"a retraction of this article was approved in:\",\"linkedarticlecopytext\":\"this article is a retraction of:\"},{\"articletypeid\":29,\"originalarticlecopytext\":\"a commentary has been posted on this article:\",\"linkedarticlecopytext\":\"this article is a commentary on:\"},{\"articletypeid\":30,\"originalarticlecopytext\":\"a commentary has been posted on this article:\",\"linkedarticlecopytext\":\"this article is a commentary on:\"}],\"articleidcopytext\":[]}'\n",acceptedarticleexcludedjournalids:"'[2766,979]'\n",articletypeconfigurablelabel:"\u003c\u003carticle-type:uppercase>> article",settingsfeaturesswitchers:"'{\"displaytitlepilllabels\":true,\"displayrelatedarticlesbox\":true,\"showeditors\":true,\"showreviewers\":true,\"showloopimpactlink\":true,\"enablefigshare\":false,\"usexmlimages\":true}'\n",journalswitharticlehub:"'{\"strings\":[\"science\"]}'\n",terminologysettings:"'{\"terms\":[{\"sequencenumber\":1,\"key\":\"frontiers\",\"tenantterm\":\"frontiers\",\"frontiersdefaultterm\":\"frontiers\",\"category\":\"customer\"},{\"sequencenumber\":2,\"key\":\"submission_system\",\"tenantterm\":\"submission system\",\"frontiersdefaultterm\":\"submission system\",\"category\":\"product\"},{\"sequencenumber\":3,\"key\":\"public_pages\",\"tenantterm\":\"public pages\",\"frontiersdefaultterm\":\"public pages\",\"category\":\"product\"},{\"sequencenumber\":4,\"key\":\"my_frontiers\",\"tenantterm\":\"my frontiers\",\"frontiersdefaultterm\":\"my frontiers\",\"category\":\"product\"},{\"sequencenumber\":5,\"key\":\"digital_editorial_office\",\"tenantterm\":\"digital editorial office\",\"frontiersdefaultterm\":\"digital editorial office\",\"category\":\"product\"},{\"sequencenumber\":6,\"key\":\"deo\",\"tenantterm\":\"deo\",\"frontiersdefaultterm\":\"deo\",\"category\":\"product\"},{\"sequencenumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantterm\":\"digital editorial office for chiefs\",\"frontiersdefaultterm\":\"digital editorial office for chiefs\",\"category\":\"product\"},{\"sequencenumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantterm\":\"digital editorial office for eof\",\"frontiersdefaultterm\":\"digital editorial office for eof\",\"category\":\"product\"},{\"sequencenumber\":9,\"key\":\"editorial_office\",\"tenantterm\":\"editorial office\",\"frontiersdefaultterm\":\"editorial office\",\"category\":\"product\"},{\"sequencenumber\":10,\"key\":\"eof\",\"tenantterm\":\"eof\",\"frontiersdefaultterm\":\"eof\",\"category\":\"product\"},{\"sequencenumber\":11,\"key\":\"research_topic_management\",\"tenantterm\":\"research topic management\",\"frontiersdefaultterm\":\"research topic management\",\"category\":\"product\"},{\"sequencenumber\":12,\"key\":\"review_forum\",\"tenantterm\":\"review forum\",\"frontiersdefaultterm\":\"review forum\",\"category\":\"product\"},{\"sequencenumber\":13,\"key\":\"accounting_office\",\"tenantterm\":\"accounting office\",\"frontiersdefaultterm\":\"accounting office\",\"category\":\"product\"},{\"sequencenumber\":14,\"key\":\"aof\",\"tenantterm\":\"aof\",\"frontiersdefaultterm\":\"aof\",\"category\":\"product\"},{\"sequencenumber\":15,\"key\":\"publishing_office\",\"tenantterm\":\"publishing office\",\"frontiersdefaultterm\":\"publishing office\",\"category\":\"product\"},{\"sequencenumber\":16,\"key\":\"production_office\",\"tenantterm\":\"production office forum\",\"frontiersdefaultterm\":\"production office forum\",\"category\":\"product\"},{\"sequencenumber\":17,\"key\":\"pof\",\"tenantterm\":\"pof\",\"frontiersdefaultterm\":\"pof\",\"category\":\"product\"},{\"sequencenumber\":18,\"key\":\"book_office_forum\",\"tenantterm\":\"book office forum\",\"frontiersdefaultterm\":\"book office forum\",\"category\":\"product\"},{\"sequencenumber\":19,\"key\":\"bof\",\"tenantterm\":\"bof\",\"frontiersdefaultterm\":\"bof\",\"category\":\"product\"},{\"sequencenumber\":20,\"key\":\"aira\",\"tenantterm\":\"aira\",\"frontiersdefaultterm\":\"aira\",\"category\":\"product\"},{\"sequencenumber\":21,\"key\":\"editorial_board_management\",\"tenantterm\":\"editorial board management\",\"frontiersdefaultterm\":\"editorial board management\",\"category\":\"product\"},{\"sequencenumber\":22,\"key\":\"ebm\",\"tenantterm\":\"ebm\",\"frontiersdefaultterm\":\"ebm\",\"category\":\"product\"},{\"sequencenumber\":23,\"key\":\"domain\",\"tenantterm\":\"domain\",\"frontiersdefaultterm\":\"domain\",\"category\":\"taxonomy\"},{\"sequencenumber\":24,\"key\":\"journal\",\"tenantterm\":\"journal\",\"frontiersdefaultterm\":\"journal\",\"category\":\"taxonomy\"},{\"sequencenumber\":25,\"key\":\"section\",\"tenantterm\":\"section\",\"frontiersdefaultterm\":\"section\",\"category\":\"taxonomy\"},{\"sequencenumber\":26,\"key\":\"domains\",\"tenantterm\":\"domains\",\"frontiersdefaultterm\":\"domains\",\"category\":\"taxonomy\"},{\"sequencenumber\":27,\"key\":\"specialty_section\",\"tenantterm\":\"specialty section\",\"frontiersdefaultterm\":\"specialty section\",\"category\":\"taxonomy\"},{\"sequencenumber\":28,\"key\":\"specialty_journal\",\"tenantterm\":\"specialty journal\",\"frontiersdefaultterm\":\"specialty journal\",\"category\":\"taxonomy\"},{\"sequencenumber\":29,\"key\":\"journals\",\"tenantterm\":\"journals\",\"frontiersdefaultterm\":\"journals\",\"category\":\"taxonomy\"},{\"sequencenumber\":30,\"key\":\"sections\",\"tenantterm\":\"sections\",\"frontiersdefaultterm\":\"sections\",\"category\":\"taxonomy\"},{\"sequencenumber\":31,\"key\":\"specialty_sections\",\"tenantterm\":\"specialty sections\",\"frontiersdefaultterm\":\"specialty sections\",\"category\":\"taxonomy\"},{\"sequencenumber\":32,\"key\":\"specialty_journals\",\"tenantterm\":\"specialty journals\",\"frontiersdefaultterm\":\"specialty journals\",\"category\":\"taxonomy\"},{\"sequencenumber\":33,\"key\":\"manuscript\",\"tenantterm\":\"manuscript\",\"frontiersdefaultterm\":\"manuscript\",\"category\":\"core\"},{\"sequencenumber\":34,\"key\":\"manuscripts\",\"tenantterm\":\"manuscripts\",\"frontiersdefaultterm\":\"manuscripts\",\"category\":\"core\"},{\"sequencenumber\":35,\"key\":\"article\",\"tenantterm\":\"article\",\"frontiersdefaultterm\":\"article\",\"category\":\"core\"},{\"sequencenumber\":36,\"key\":\"articles\",\"tenantterm\":\"articles\",\"frontiersdefaultterm\":\"articles\",\"category\":\"core\"},{\"sequencenumber\":37,\"key\":\"article_type\",\"tenantterm\":\"article type\",\"frontiersdefaultterm\":\"article type\",\"category\":\"core\"},{\"sequencenumber\":38,\"key\":\"article_types\",\"tenantterm\":\"article types\",\"frontiersdefaultterm\":\"article types\",\"category\":\"core\"},{\"sequencenumber\":39,\"key\":\"author\",\"tenantterm\":\"author\",\"frontiersdefaultterm\":\"author\",\"category\":\"label (role)\"},{\"sequencenumber\":40,\"key\":\"authors\",\"tenantterm\":\"authors\",\"frontiersdefaultterm\":\"authors\",\"category\":\"label (role)\"},{\"sequencenumber\":41,\"key\":\"authoring\",\"tenantterm\":\"authoring\",\"frontiersdefaultterm\":\"authoring\",\"category\":\"core\"},{\"sequencenumber\":42,\"key\":\"authored\",\"tenantterm\":\"authored\",\"frontiersdefaultterm\":\"authored\",\"category\":\"core\"},{\"sequencenumber\":43,\"key\":\"accept\",\"tenantterm\":\"accept\",\"frontiersdefaultterm\":\"accept\",\"category\":\"process\"},{\"sequencenumber\":44,\"key\":\"accepted\",\"tenantterm\":\"accepted\",\"frontiersdefaultterm\":\"accepted\",\"category\":\"process\"},{\"sequencenumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantterm\":\"assistant field chief editor\",\"frontiersdefaultterm\":\"assistant field chief editor\",\"description\":\"an editorial role on a field journal that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantterm\":\"assistant specialty chief editor\",\"frontiersdefaultterm\":\"assistant specialty chief editor\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantterm\":\"assistant specialty chief editors\",\"frontiersdefaultterm\":\"assistant specialty chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":48,\"key\":\"associate_editor\",\"tenantterm\":\"associate editor\",\"frontiersdefaultterm\":\"associate editor\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":49,\"key\":\"specialty_chief_editor\",\"tenantterm\":\"specialty chief editor\",\"frontiersdefaultterm\":\"specialty chief editor\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":50,\"key\":\"specialty_chief_editors\",\"tenantterm\":\"specialty chief editors\",\"frontiersdefaultterm\":\"specialty chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":51,\"key\":\"chief_editor\",\"tenantterm\":\"chief editor\",\"frontiersdefaultterm\":\"chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":52,\"key\":\"chief_editors\",\"tenantterm\":\"chief editors\",\"frontiersdefaultterm\":\"chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":53,\"key\":\"call_for_participation\",\"tenantterm\":\"call for participation\",\"frontiersdefaultterm\":\"call for participation\",\"category\":\"process\"},{\"sequencenumber\":54,\"key\":\"citation\",\"tenantterm\":\"citation\",\"frontiersdefaultterm\":\"citation\",\"category\":\"misc.\"},{\"sequencenumber\":55,\"key\":\"citations\",\"tenantterm\":\"citations\",\"frontiersdefaultterm\":\"citations\",\"category\":\"misc.\"},{\"sequencenumber\":56,\"key\":\"contributor\",\"tenantterm\":\"contributor\",\"frontiersdefaultterm\":\"contributor\",\"category\":\"label (role)\"},{\"sequencenumber\":57,\"key\":\"contributors\",\"tenantterm\":\"contributors\",\"frontiersdefaultterm\":\"contributors\",\"category\":\"label (role)\"},{\"sequencenumber\":58,\"key\":\"corresponding_author\",\"tenantterm\":\"corresponding author\",\"frontiersdefaultterm\":\"corresponding author\",\"category\":\"label (role)\"},{\"sequencenumber\":59,\"key\":\"corresponding_authors\",\"tenantterm\":\"corresponding authors\",\"frontiersdefaultterm\":\"corresponding authors\",\"category\":\"label (role)\"},{\"sequencenumber\":60,\"key\":\"decline\",\"tenantterm\":\"decline\",\"frontiersdefaultterm\":\"decline\",\"category\":\"process\"},{\"sequencenumber\":61,\"key\":\"declined\",\"tenantterm\":\"declined\",\"frontiersdefaultterm\":\"declined\",\"category\":\"process\"},{\"sequencenumber\":62,\"key\":\"reject\",\"tenantterm\":\"reject\",\"frontiersdefaultterm\":\"reject\",\"category\":\"process\"},{\"sequencenumber\":63,\"key\":\"rejected\",\"tenantterm\":\"rejected\",\"frontiersdefaultterm\":\"rejected\",\"category\":\"process\"},{\"sequencenumber\":64,\"key\":\"publish\",\"tenantterm\":\"publish\",\"frontiersdefaultterm\":\"publish\",\"category\":\"core\"},{\"sequencenumber\":65,\"key\":\"published\",\"tenantterm\":\"published\",\"frontiersdefaultterm\":\"published\",\"category\":\"core\"},{\"sequencenumber\":66,\"key\":\"publication\",\"tenantterm\":\"publication\",\"frontiersdefaultterm\":\"publication\",\"category\":\"core\"},{\"sequencenumber\":67,\"key\":\"peer_review\",\"tenantterm\":\"peer review\",\"frontiersdefaultterm\":\"peer review\",\"category\":\"peer review process\"},{\"sequencenumber\":68,\"key\":\"peer_reviewed\",\"tenantterm\":\"peer reviewed\",\"frontiersdefaultterm\":\"peer reviewed\",\"category\":\"peer review process\"},{\"sequencenumber\":69,\"key\":\"initial_validation\",\"tenantterm\":\"initial validation\",\"frontiersdefaultterm\":\"initial validation\",\"category\":\"peer review process\"},{\"sequencenumber\":70,\"key\":\"editorial_assignment\",\"tenantterm\":\"editorial assignment\",\"frontiersdefaultterm\":\"editorial assignment\",\"category\":\"peer review process\"},{\"sequencenumber\":71,\"key\":\"independent_review\",\"tenantterm\":\"independent review\",\"frontiersdefaultterm\":\"independent review\",\"category\":\"peer review process\"},{\"sequencenumber\":72,\"key\":\"interactive_review\",\"tenantterm\":\"interactive review\",\"frontiersdefaultterm\":\"interactive review\",\"category\":\"peer review process\"},{\"sequencenumber\":73,\"key\":\"review\",\"tenantterm\":\"review\",\"frontiersdefaultterm\":\"review\",\"category\":\"peer review process\"},{\"sequencenumber\":74,\"key\":\"reviewing\",\"tenantterm\":\"reviewing\",\"frontiersdefaultterm\":\"reviewing\",\"category\":\"peer review process\"},{\"sequencenumber\":75,\"key\":\"reviewer\",\"tenantterm\":\"reviewer\",\"frontiersdefaultterm\":\"reviewer\",\"category\":\"label (role)\"},{\"sequencenumber\":76,\"key\":\"reviewers\",\"tenantterm\":\"reviewers\",\"frontiersdefaultterm\":\"reviewers\",\"category\":\"label (role)\"},{\"sequencenumber\":77,\"key\":\"review_finalized\",\"tenantterm\":\"review finalized\",\"frontiersdefaultterm\":\"review finalized\",\"category\":\"peer review process\"},{\"sequencenumber\":78,\"key\":\"final_decision\",\"tenantterm\":\"final decision\",\"frontiersdefaultterm\":\"final decision\",\"category\":\"peer review process\"},{\"sequencenumber\":79,\"key\":\"final_validation\",\"tenantterm\":\"final validation\",\"frontiersdefaultterm\":\"final validation\",\"category\":\"peer review process\"},{\"sequencenumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantterm\":\"recommend to accept manuscript\",\"frontiersdefaultterm\":\"accept manuscript\",\"category\":\"process\"},{\"sequencenumber\":81,\"key\":\"fee\",\"tenantterm\":\"fee\",\"frontiersdefaultterm\":\"fee\",\"category\":\"accounting\"},{\"sequencenumber\":82,\"key\":\"fees\",\"tenantterm\":\"fees\",\"frontiersdefaultterm\":\"fees\",\"category\":\"accounting\"},{\"sequencenumber\":83,\"key\":\"guest_associate_editor\",\"tenantterm\":\"guest associate editor\",\"frontiersdefaultterm\":\"guest associate editor\",\"category\":\"label (role)\"},{\"sequencenumber\":84,\"key\":\"guest_associate_editors\",\"tenantterm\":\"guest associate editors\",\"frontiersdefaultterm\":\"guest associate editors\",\"category\":\"label (role)\"},{\"sequencenumber\":85,\"key\":\"in_review\",\"tenantterm\":\"in review\",\"frontiersdefaultterm\":\"in review\",\"category\":\"peer review process\"},{\"sequencenumber\":86,\"key\":\"institutional_member\",\"tenantterm\":\"institutional partner\",\"frontiersdefaultterm\":\"institutional partner\",\"category\":\"accounting\"},{\"sequencenumber\":87,\"key\":\"institutional_membership\",\"tenantterm\":\"institutional partnership\",\"frontiersdefaultterm\":\"institutional partnership\",\"category\":\"accounting\"},{\"sequencenumber\":88,\"key\":\"article_processing_charge\",\"tenantterm\":\"article processing charge\",\"frontiersdefaultterm\":\"article processing charge\",\"category\":\"accounting\"},{\"sequencenumber\":89,\"key\":\"article_processing_charges\",\"tenantterm\":\"article processing charges\",\"frontiersdefaultterm\":\"article processing charges\",\"category\":\"accounting\"},{\"sequencenumber\":90,\"key\":\"apcs\",\"tenantterm\":\"apcs\",\"frontiersdefaultterm\":\"apcs\",\"category\":\"accounting\"},{\"sequencenumber\":91,\"key\":\"apc\",\"tenantterm\":\"apc\",\"frontiersdefaultterm\":\"apc\",\"category\":\"accounting\"},{\"sequencenumber\":92,\"key\":\"received\",\"tenantterm\":\"received\",\"frontiersdefaultterm\":\"received\",\"description\":\"date manuscript was received on.\",\"category\":\"core\"},{\"sequencenumber\":93,\"key\":\"transferred\",\"tenantterm\":\"transferred\",\"frontiersdefaultterm\":\"transferred\",\"category\":\"core\"},{\"sequencenumber\":94,\"key\":\"transfer\",\"tenantterm\":\"transfer\",\"frontiersdefaultterm\":\"transfer\",\"category\":\"core\"},{\"sequencenumber\":95,\"key\":\"research_topic\",\"tenantterm\":\"research topic\",\"frontiersdefaultterm\":\"research topic\",\"category\":\"core\"},{\"sequencenumber\":96,\"key\":\"research_topics\",\"tenantterm\":\"research topics\",\"frontiersdefaultterm\":\"research topics\",\"category\":\"core\"},{\"sequencenumber\":97,\"key\":\"topic_editor\",\"tenantterm\":\"topic editor\",\"frontiersdefaultterm\":\"topic editor\",\"category\":\"label (role)\"},{\"sequencenumber\":98,\"key\":\"review_editor\",\"tenantterm\":\"community reviewer\",\"frontiersdefaultterm\":\"review editor\",\"category\":\"label (role)\"},{\"sequencenumber\":99,\"key\":\"title\",\"tenantterm\":\"title\",\"frontiersdefaultterm\":\"title\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":100,\"key\":\"running_title\",\"tenantterm\":\"running title\",\"frontiersdefaultterm\":\"running title\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":101,\"key\":\"submit\",\"tenantterm\":\"submit\",\"frontiersdefaultterm\":\"submit\",\"category\":\"process\"},{\"sequencenumber\":102,\"key\":\"submitted\",\"tenantterm\":\"submitted\",\"frontiersdefaultterm\":\"submitted\",\"category\":\"process\"},{\"sequencenumber\":103,\"key\":\"submitting\",\"tenantterm\":\"submitting\",\"frontiersdefaultterm\":\"submitting\",\"category\":\"process\"},{\"sequencenumber\":104,\"key\":\"t_e\",\"tenantterm\":\"te\",\"frontiersdefaultterm\":\"te\",\"category\":\"label (role)\"},{\"sequencenumber\":105,\"key\":\"topic\",\"tenantterm\":\"topic\",\"frontiersdefaultterm\":\"topic\",\"category\":\"process\"},{\"sequencenumber\":106,\"key\":\"topic_summary\",\"tenantterm\":\"topic summary\",\"frontiersdefaultterm\":\"topic summary\",\"category\":\"process\"},{\"sequencenumber\":107,\"key\":\"figure\",\"tenantterm\":\"figure\",\"frontiersdefaultterm\":\"figure\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":108,\"key\":\"figures\",\"tenantterm\":\"figures\",\"frontiersdefaultterm\":\"figures\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":109,\"key\":\"editorial_file\",\"tenantterm\":\"editorial file\",\"frontiersdefaultterm\":\"editorial file\",\"category\":\"core\"},{\"sequencenumber\":110,\"key\":\"editorial_files\",\"tenantterm\":\"editorial files\",\"frontiersdefaultterm\":\"editorial files\",\"category\":\"core\"},{\"sequencenumber\":111,\"key\":\"e_book\",\"tenantterm\":\"e-book\",\"frontiersdefaultterm\":\"e-book\",\"category\":\"core\"},{\"sequencenumber\":112,\"key\":\"organization\",\"tenantterm\":\"organization\",\"frontiersdefaultterm\":\"organization\",\"category\":\"core\"},{\"sequencenumber\":113,\"key\":\"institution\",\"tenantterm\":\"institution\",\"frontiersdefaultterm\":\"institution\",\"category\":\"core\"},{\"sequencenumber\":114,\"key\":\"reference\",\"tenantterm\":\"reference\",\"frontiersdefaultterm\":\"reference\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":115,\"key\":\"references\",\"tenantterm\":\"references\",\"frontiersdefaultterm\":\"references\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":116,\"key\":\"sce\",\"tenantterm\":\"sce\",\"frontiersdefaultterm\":\"sce\",\"description\":\"abbreviation for specialty chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":117,\"key\":\"submission\",\"tenantterm\":\"submission\",\"frontiersdefaultterm\":\"submission\",\"category\":\"process\"},{\"sequencenumber\":118,\"key\":\"submissions\",\"tenantterm\":\"submissions\",\"frontiersdefaultterm\":\"submissions\",\"category\":\"process\"},{\"sequencenumber\":119,\"key\":\"editing\",\"tenantterm\":\"editing\",\"frontiersdefaultterm\":\"editing\",\"category\":\"process\"},{\"sequencenumber\":120,\"key\":\"in_preparation\",\"tenantterm\":\"in preparation\",\"frontiersdefaultterm\":\"in preparation\",\"category\":\"process\"},{\"sequencenumber\":121,\"key\":\"country_region\",\"tenantterm\":\"country/region\",\"frontiersdefaultterm\":\"country/region\",\"description\":\"because of political issues, some of the country listings are actually classified as `regions` and we need to include this. however other clients may not want to do this.\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":122,\"key\":\"countries_regions\",\"tenantterm\":\"countries/regions\",\"frontiersdefaultterm\":\"countries/regions\",\"description\":\"because of political issues, some of the country listings are actually classified as `regions` and we need to include this. however other clients may not want to do this.\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":123,\"key\":\"specialty\",\"tenantterm\":\"specialty\",\"frontiersdefaultterm\":\"specialty\",\"category\":\"core\"},{\"sequencenumber\":124,\"key\":\"specialties\",\"tenantterm\":\"specialties\",\"frontiersdefaultterm\":\"specialties\",\"category\":\"core\"},{\"sequencenumber\":125,\"key\":\"associate_editors\",\"tenantterm\":\"associate editors\",\"frontiersdefaultterm\":\"associate editors\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":126,\"key\":\"reviewed\",\"tenantterm\":\"reviewed\",\"frontiersdefaultterm\":\"reviewed\",\"category\":\"peer review process\"},{\"sequencenumber\":127,\"key\":\"institutional_members\",\"tenantterm\":\"institutional partners\",\"frontiersdefaultterm\":\"institutional partners\",\"category\":\"accounting\"},{\"sequencenumber\":128,\"key\":\"institutional_memberships\",\"tenantterm\":\"institutional partnerships\",\"frontiersdefaultterm\":\"institutional partnerships\",\"category\":\"accounting\"},{\"sequencenumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantterm\":\"assistant field chief editors\",\"frontiersdefaultterm\":\"assistant field chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":130,\"key\":\"publications\",\"tenantterm\":\"publications\",\"frontiersdefaultterm\":\"publications\",\"category\":\"process\"},{\"sequencenumber\":131,\"key\":\"ae_accepted\",\"tenantterm\":\"recommended acceptance\",\"frontiersdefaultterm\":\"accepted\",\"category\":\"process\"},{\"sequencenumber\":132,\"key\":\"field_journal\",\"tenantterm\":\"field journal\",\"frontiersdefaultterm\":\"field journal\",\"category\":\"taxonomy\"},{\"sequencenumber\":133,\"key\":\"field_journals\",\"tenantterm\":\"field journals\",\"frontiersdefaultterm\":\"field journals\",\"category\":\"taxonomy\"},{\"sequencenumber\":134,\"key\":\"program_manager\",\"tenantterm\":\"program manager\",\"frontiersdefaultterm\":\"program manager\",\"category\":\"label (role)\"},{\"sequencenumber\":135,\"key\":\"journal_manager\",\"tenantterm\":\"journal manager\",\"frontiersdefaultterm\":\"journal manager\",\"category\":\"label (role)\"},{\"sequencenumber\":136,\"key\":\"journal_specialist\",\"tenantterm\":\"journal specialist\",\"frontiersdefaultterm\":\"journal specialist\",\"category\":\"label (role)\"},{\"sequencenumber\":137,\"key\":\"program_managers\",\"tenantterm\":\"program managers\",\"frontiersdefaultterm\":\"program managers\",\"category\":\"label (role)\"},{\"sequencenumber\":138,\"key\":\"journal_managers\",\"tenantterm\":\"journal managers\",\"frontiersdefaultterm\":\"journal managers\",\"category\":\"label (role)\"},{\"sequencenumber\":139,\"key\":\"journal_specialists\",\"tenantterm\":\"journal specialists\",\"frontiersdefaultterm\":\"journal specialists\",\"category\":\"label (role)\"},{\"sequencenumber\":140,\"key\":\"cover_letter\",\"tenantterm\":\"manuscript contribution to the field\",\"frontiersdefaultterm\":\"manuscript contribution to the field\",\"category\":\"process\"},{\"sequencenumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantterm\":\"recommended to accept manuscript\",\"frontiersdefaultterm\":\"accepted manuscript\",\"category\":\"process\"},{\"sequencenumber\":142,\"key\":\"recommend_for_rejection\",\"tenantterm\":\"recommend for rejection\",\"frontiersdefaultterm\":\"recommend for rejection\",\"category\":\"process\"},{\"sequencenumber\":143,\"key\":\"recommended_for_rejection\",\"tenantterm\":\"recommended for rejection\",\"frontiersdefaultterm\":\"recommended for rejection\",\"category\":\"process\"},{\"sequencenumber\":144,\"key\":\"ae\",\"tenantterm\":\"ae\",\"frontiersdefaultterm\":\"ae\",\"description\":\"associate editor - board member\",\"category\":\"label (role)\"},{\"sequencenumber\":145,\"key\":\"re\",\"tenantterm\":\"re\",\"frontiersdefaultterm\":\"re\",\"description\":\"review editor\",\"category\":\"label (role)\"},{\"sequencenumber\":146,\"key\":\"rev\",\"tenantterm\":\"rev\",\"frontiersdefaultterm\":\"rev\",\"description\":\"reviewer\",\"category\":\"label (role)\"},{\"sequencenumber\":147,\"key\":\"aut\",\"tenantterm\":\"aut\",\"frontiersdefaultterm\":\"aut\",\"description\":\"author\",\"category\":\"label (role)\"},{\"sequencenumber\":148,\"key\":\"coraut\",\"tenantterm\":\"coraut\",\"frontiersdefaultterm\":\"coraut\",\"description\":\"corresponding author\",\"category\":\"label (role)\"},{\"sequencenumber\":149,\"key\":\"saut\",\"tenantterm\":\"saut\",\"frontiersdefaultterm\":\"saut\",\"description\":\"submitting author\",\"category\":\"label (role)\"},{\"sequencenumber\":150,\"key\":\"coaut\",\"tenantterm\":\"coaut\",\"frontiersdefaultterm\":\"coaut\",\"description\":\"co-author\",\"category\":\"label (role)\"},{\"sequencenumber\":151,\"key\":\"tsof\",\"tenantterm\":\"tsof\",\"frontiersdefaultterm\":\"tsof\",\"description\":\"typesetter\",\"category\":\"label (role)\"},{\"sequencenumber\":152,\"key\":\"typesetting_office\",\"tenantterm\":\"typesetting office\",\"frontiersdefaultterm\":\"typesetting office\",\"category\":\"product\"},{\"sequencenumber\":153,\"key\":\"config\",\"tenantterm\":\"config\",\"frontiersdefaultterm\":\"config\",\"description\":\"configuration office role\",\"category\":\"label (role)\"},{\"sequencenumber\":154,\"key\":\"jm\",\"tenantterm\":\"jm\",\"frontiersdefaultterm\":\"jm\",\"description\":\"journal manager\",\"category\":\"label (role)\"},{\"sequencenumber\":155,\"key\":\"rte\",\"tenantterm\":\"rte\",\"frontiersdefaultterm\":\"rte\",\"description\":\"research topic editor\",\"category\":\"label (role)\"},{\"sequencenumber\":156,\"key\":\"organizations\",\"tenantterm\":\"organizations\",\"frontiersdefaultterm\":\"organizations\",\"category\":\"core\"},{\"sequencenumber\":157,\"key\":\"publishing\",\"tenantterm\":\"publishing\",\"frontiersdefaultterm\":\"publishing\",\"category\":\"core\"},{\"sequencenumber\":158,\"key\":\"acceptance\",\"tenantterm\":\"acceptance\",\"frontiersdefaultterm\":\"acceptance\",\"category\":\"process\"},{\"sequencenumber\":159,\"key\":\"preferred_associate_editor\",\"tenantterm\":\"preferred associate editor\",\"frontiersdefaultterm\":\"preferred associate editor\",\"category\":\"label (role)\"},{\"sequencenumber\":160,\"key\":\"topic_editors\",\"tenantterm\":\"topic editors\",\"frontiersdefaultterm\":\"topic editors\",\"category\":\"label (role)\"},{\"sequencenumber\":161,\"key\":\"institutions\",\"tenantterm\":\"institutions\",\"frontiersdefaultterm\":\"institutions\",\"category\":\"core\"},{\"sequencenumber\":162,\"key\":\"author(s)\",\"tenantterm\":\"author(s)\",\"frontiersdefaultterm\":\"author(s)\",\"category\":\"label (role)\"},{\"sequencenumber\":163,\"key\":\"figure(s)\",\"tenantterm\":\"figure(s)\",\"frontiersdefaultterm\":\"figure(s)\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":164,\"key\":\"co-authors\",\"tenantterm\":\"co-authors\",\"frontiersdefaultterm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"label (role)\"},{\"sequencenumber\":165,\"key\":\"editorial_board_members\",\"tenantterm\":\"editorial board members\",\"frontiersdefaultterm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"label (role)\"},{\"sequencenumber\":166,\"key\":\"editorial_board\",\"tenantterm\":\"editorial board\",\"frontiersdefaultterm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"product\"},{\"sequencenumber\":167,\"key\":\"co-authorship\",\"tenantterm\":\"co-authorship\",\"frontiersdefaultterm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"misc.\"},{\"sequencenumber\":168,\"key\":\"role_id_1\",\"tenantterm\":\"registration office\",\"frontiersdefaultterm\":\"registration office\",\"category\":\"user role\"},{\"sequencenumber\":169,\"key\":\"role_id_2\",\"tenantterm\":\"editorial office\",\"frontiersdefaultterm\":\"editorial office\",\"category\":\"user role\"},{\"sequencenumber\":170,\"key\":\"role_id_7\",\"tenantterm\":\"field chief editor\",\"frontiersdefaultterm\":\"field chief editor\",\"category\":\"user role\"},{\"sequencenumber\":171,\"key\":\"role_id_8\",\"tenantterm\":\"assistant field chief editor\",\"frontiersdefaultterm\":\"assistant field chief editor\",\"category\":\"user role\"},{\"sequencenumber\":172,\"key\":\"role_id_9\",\"tenantterm\":\"specialty chief editor\",\"frontiersdefaultterm\":\"specialty chief editor\",\"category\":\"user role\"},{\"sequencenumber\":173,\"key\":\"role_id_10\",\"tenantterm\":\"assistant specialty chief editor\",\"frontiersdefaultterm\":\"assistant specialty chief editor\",\"category\":\"user role\"},{\"sequencenumber\":174,\"key\":\"role_id_11\",\"tenantterm\":\"associate editor\",\"frontiersdefaultterm\":\"associate editor\",\"category\":\"user role\"},{\"sequencenumber\":175,\"key\":\"role_id_12\",\"tenantterm\":\"guest associate editor\",\"frontiersdefaultterm\":\"guest associate editor\",\"category\":\"user role\"},{\"sequencenumber\":176,\"key\":\"role_id_13\",\"tenantterm\":\"review editor\",\"frontiersdefaultterm\":\"review editor\",\"category\":\"user role\"},{\"sequencenumber\":177,\"key\":\"role_id_14\",\"tenantterm\":\"reviewer\",\"frontiersdefaultterm\":\"reviewer\",\"category\":\"user role\"},{\"sequencenumber\":178,\"key\":\"role_id_15\",\"tenantterm\":\"author\",\"frontiersdefaultterm\":\"author\",\"category\":\"user role\"},{\"sequencenumber\":179,\"key\":\"role_id_16\",\"tenantterm\":\"corresponding author\",\"frontiersdefaultterm\":\"corresponding author\",\"category\":\"user role\"},{\"sequencenumber\":180,\"key\":\"role_id_17\",\"tenantterm\":\"submitting author\",\"frontiersdefaultterm\":\"submitting author\",\"category\":\"user role\"},{\"sequencenumber\":181,\"key\":\"role_id_18\",\"tenantterm\":\"co-author\",\"frontiersdefaultterm\":\"co-author\",\"category\":\"user role\"},{\"sequencenumber\":182,\"key\":\"role_id_20\",\"tenantterm\":\"production office\",\"frontiersdefaultterm\":\"production office\",\"category\":\"user role\"},{\"sequencenumber\":183,\"key\":\"role_id_22\",\"tenantterm\":\"typesetting office (typesetter)\",\"frontiersdefaultterm\":\"typesetting office (typesetter)\",\"category\":\"user role\"},{\"sequencenumber\":184,\"key\":\"role_id_24\",\"tenantterm\":\"registered user\",\"frontiersdefaultterm\":\"registered user\",\"category\":\"user role\"},{\"sequencenumber\":185,\"key\":\"role_id_35\",\"tenantterm\":\"job office\",\"frontiersdefaultterm\":\"job office\",\"category\":\"user role\"},{\"sequencenumber\":186,\"key\":\"role_id_41\",\"tenantterm\":\"special event administrator\",\"frontiersdefaultterm\":\"special event administrator\",\"category\":\"user role\"},{\"sequencenumber\":187,\"key\":\"role_id_42\",\"tenantterm\":\"special event reviewer\",\"frontiersdefaultterm\":\"special event reviewer\",\"category\":\"user role\"},{\"sequencenumber\":188,\"key\":\"role_id_43\",\"tenantterm\":\"submit abstract\",\"frontiersdefaultterm\":\"submit abstract\",\"category\":\"user role\"},{\"sequencenumber\":189,\"key\":\"role_id_52\",\"tenantterm\":\"events office\",\"frontiersdefaultterm\":\"events office\",\"category\":\"user role\"},{\"sequencenumber\":190,\"key\":\"role_id_53\",\"tenantterm\":\"event administrator\",\"frontiersdefaultterm\":\"event administrator\",\"category\":\"user role\"},{\"sequencenumber\":191,\"key\":\"role_id_89\",\"tenantterm\":\"content management office\",\"frontiersdefaultterm\":\"content management office\",\"category\":\"user role\"},{\"sequencenumber\":192,\"key\":\"role_id_98\",\"tenantterm\":\"accounting office\",\"frontiersdefaultterm\":\"accounting office\",\"category\":\"user role\"},{\"sequencenumber\":193,\"key\":\"role_id_99\",\"tenantterm\":\"projects\",\"frontiersdefaultterm\":\"projects\",\"category\":\"user role\"},{\"sequencenumber\":194,\"key\":\"role_id_103\",\"tenantterm\":\"configuration office\",\"frontiersdefaultterm\":\"configuration office\",\"category\":\"user role\"},{\"sequencenumber\":195,\"key\":\"role_id_104\",\"tenantterm\":\"beta user\",\"frontiersdefaultterm\":\"beta user\",\"category\":\"user role\"},{\"sequencenumber\":196,\"key\":\"role_id_106\",\"tenantterm\":\"wfconf\",\"frontiersdefaultterm\":\"wfconf\",\"category\":\"user role\"},{\"sequencenumber\":197,\"key\":\"role_id_107\",\"tenantterm\":\"rt management beta user\",\"frontiersdefaultterm\":\"rt management beta user\",\"category\":\"user role\"},{\"sequencenumber\":198,\"key\":\"role_id_108\",\"tenantterm\":\"deo beta user\",\"frontiersdefaultterm\":\"deo beta user\",\"category\":\"user role\"},{\"sequencenumber\":199,\"key\":\"role_id_109\",\"tenantterm\":\"search beta user\",\"frontiersdefaultterm\":\"search beta user\",\"category\":\"user role\"},{\"sequencenumber\":200,\"key\":\"role_id_110\",\"tenantterm\":\"journal manager\",\"frontiersdefaultterm\":\"journal manager\",\"category\":\"user role\"},{\"sequencenumber\":201,\"key\":\"role_id_111\",\"tenantterm\":\"myfrontiers beta user\",\"frontiersdefaultterm\":\"myfrontiers beta user\",\"category\":\"user role\"},{\"sequencenumber\":202,\"key\":\"role_id_21\",\"tenantterm\":\"copy editor\",\"frontiersdefaultterm\":\"copy editor\",\"category\":\"user role\"},{\"sequencenumber\":203,\"key\":\"role_id_1_abr\",\"tenantterm\":\"rof\",\"frontiersdefaultterm\":\"rof\",\"category\":\"user role\"},{\"sequencenumber\":204,\"key\":\"role_id_2_abr\",\"tenantterm\":\"eof\",\"frontiersdefaultterm\":\"eof\",\"category\":\"user role\"},{\"sequencenumber\":205,\"key\":\"role_id_7_abr\",\"tenantterm\":\"fce\",\"frontiersdefaultterm\":\"fce\",\"category\":\"user role\"},{\"sequencenumber\":206,\"key\":\"role_id_8_abr\",\"tenantterm\":\"afce\",\"frontiersdefaultterm\":\"afce\",\"category\":\"user role\"},{\"sequencenumber\":207,\"key\":\"role_id_9_abr\",\"tenantterm\":\"sce\",\"frontiersdefaultterm\":\"sce\",\"category\":\"user role\"},{\"sequencenumber\":208,\"key\":\"role_id_10_abr\",\"tenantterm\":\"asce\",\"frontiersdefaultterm\":\"asce\",\"category\":\"user role\"},{\"sequencenumber\":209,\"key\":\"role_id_11_abr\",\"tenantterm\":\"ae\",\"frontiersdefaultterm\":\"ae\",\"category\":\"user role\"},{\"sequencenumber\":210,\"key\":\"role_id_12_abr\",\"tenantterm\":\"gae\",\"frontiersdefaultterm\":\"gae\",\"category\":\"user role\"},{\"sequencenumber\":211,\"key\":\"role_id_13_abr\",\"tenantterm\":\"re\",\"frontiersdefaultterm\":\"re\",\"category\":\"user role\"},{\"sequencenumber\":212,\"key\":\"role_id_14_abr\",\"tenantterm\":\"rev\",\"frontiersdefaultterm\":\"rev\",\"category\":\"user role\"},{\"sequencenumber\":213,\"key\":\"role_id_15_abr\",\"tenantterm\":\"aut\",\"frontiersdefaultterm\":\"aut\",\"category\":\"user role\"},{\"sequencenumber\":214,\"key\":\"role_id_16_abr\",\"tenantterm\":\"coraut\",\"frontiersdefaultterm\":\"coraut\",\"category\":\"user role\"},{\"sequencenumber\":215,\"key\":\"role_id_17_abr\",\"tenantterm\":\"saut\",\"frontiersdefaultterm\":\"saut\",\"category\":\"user role\"},{\"sequencenumber\":216,\"key\":\"role_id_18_abr\",\"tenantterm\":\"coaut\",\"frontiersdefaultterm\":\"coaut\",\"category\":\"user role\"},{\"sequencenumber\":217,\"key\":\"role_id_20_abr\",\"tenantterm\":\"pof\",\"frontiersdefaultterm\":\"pof\",\"category\":\"user role\"},{\"sequencenumber\":218,\"key\":\"role_id_22_abr\",\"tenantterm\":\"tsof\",\"frontiersdefaultterm\":\"tsof\",\"category\":\"user role\"},{\"sequencenumber\":219,\"key\":\"role_id_24_abr\",\"tenantterm\":\"ru\",\"frontiersdefaultterm\":\"ru\",\"category\":\"user role\"},{\"sequencenumber\":220,\"key\":\"role_id_35_abr\",\"tenantterm\":\"jof\",\"frontiersdefaultterm\":\"jof\",\"category\":\"user role\"},{\"sequencenumber\":221,\"key\":\"role_id_41_abr\",\"tenantterm\":\"se-adm\",\"frontiersdefaultterm\":\"se-adm\",\"category\":\"user role\"},{\"sequencenumber\":222,\"key\":\"role_id_42_abr\",\"tenantterm\":\"se-rev\",\"frontiersdefaultterm\":\"se-rev\",\"category\":\"user role\"},{\"sequencenumber\":223,\"key\":\"role_id_43_abr\",\"tenantterm\":\"se-aut\",\"frontiersdefaultterm\":\"se-aut\",\"category\":\"user role\"},{\"sequencenumber\":224,\"key\":\"role_id_52_abr\",\"tenantterm\":\"evof\",\"frontiersdefaultterm\":\"evof\",\"category\":\"user role\"},{\"sequencenumber\":225,\"key\":\"role_id_53_abr\",\"tenantterm\":\"ev-adm\",\"frontiersdefaultterm\":\"ev-adm\",\"category\":\"user role\"},{\"sequencenumber\":226,\"key\":\"role_id_89_abr\",\"tenantterm\":\"comof\",\"frontiersdefaultterm\":\"comof\",\"category\":\"user role\"},{\"sequencenumber\":227,\"key\":\"role_id_98_abr\",\"tenantterm\":\"aof\",\"frontiersdefaultterm\":\"aof\",\"category\":\"user role\"},{\"sequencenumber\":228,\"key\":\"role_id_99_abr\",\"tenantterm\":\"projects\",\"frontiersdefaultterm\":\"projects\",\"category\":\"user role\"},{\"sequencenumber\":229,\"key\":\"role_id_103_abr\",\"tenantterm\":\"config\",\"frontiersdefaultterm\":\"config\",\"category\":\"user role\"},{\"sequencenumber\":230,\"key\":\"role_id_104_abr\",\"tenantterm\":\"beta\",\"frontiersdefaultterm\":\"beta\",\"category\":\"user role\"},{\"sequencenumber\":231,\"key\":\"role_id_106_abr\",\"tenantterm\":\"wfconf\",\"frontiersdefaultterm\":\"wfconf\",\"category\":\"user role\"},{\"sequencenumber\":232,\"key\":\"role_id_107_abr\",\"tenantterm\":\"rtbeta\",\"frontiersdefaultterm\":\"rtbeta\",\"category\":\"user role\"},{\"sequencenumber\":233,\"key\":\"role_id_108_abr\",\"tenantterm\":\"deobeta\",\"frontiersdefaultterm\":\"deobeta\",\"category\":\"user role\"},{\"sequencenumber\":234,\"key\":\"role_id_109_abr\",\"tenantterm\":\"searchbeta\",\"frontiersdefaultterm\":\"searchbeta\",\"category\":\"user role\"},{\"sequencenumber\":235,\"key\":\"role_id_110_abr\",\"tenantterm\":\"jm\",\"frontiersdefaultterm\":\"jm\",\"category\":\"user role\"},{\"sequencenumber\":236,\"key\":\"role_id_111_abr\",\"tenantterm\":\"mfbeta\",\"frontiersdefaultterm\":\"mfbeta\",\"category\":\"user role\"},{\"sequencenumber\":237,\"key\":\"role_id_21_abr\",\"tenantterm\":\"coped\",\"frontiersdefaultterm\":\"coped\",\"category\":\"user role\"},{\"sequencenumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantterm\":\"editorial board\",\"frontiersdefaultterm\":\"editorial board\",\"description\":\"this is the label for the review editorial board\",\"category\":\"label\"},{\"sequencenumber\":239,\"key\":\"field_chief_editor\",\"tenantterm\":\"field chief editor\",\"frontiersdefaultterm\":\"field chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":240,\"key\":\"field_chief_editors\",\"tenantterm\":\"field chief editors\",\"frontiersdefaultterm\":\"field chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":241,\"key\":\"editor\",\"tenantterm\":\"editor\",\"frontiersdefaultterm\":\"editor\",\"category\":\"label (role)\"},{\"sequencenumber\":242,\"key\":\"editors\",\"tenantterm\":\"editors\",\"frontiersdefaultterm\":\"editors\",\"category\":\"label (role)\"},{\"sequencenumber\":243,\"key\":\"board\",\"tenantterm\":\"board\",\"frontiersdefaultterm\":\"board\",\"category\":\"label\"},{\"sequencenumber\":244,\"key\":\"boards\",\"tenantterm\":\"boards\",\"frontiersdefaultterm\":\"boards\",\"category\":\"label\"},{\"sequencenumber\":245,\"key\":\"article_collection\",\"tenantterm\":\"article collection\",\"frontiersdefaultterm\":\"article collection\",\"category\":\"label\"},{\"sequencenumber\":246,\"key\":\"article_collections\",\"tenantterm\":\"article collections\",\"frontiersdefaultterm\":\"article collections\",\"category\":\"label\"},{\"sequencenumber\":247,\"key\":\"handling_editor\",\"tenantterm\":\"handling editor\",\"frontiersdefaultterm\":\"associate editor\",\"description\":\"this terminology key is for the person assigned to edit a manuscript. it is a label for the temporary handling editor assignment.\",\"category\":\"label (role)\"},{\"sequencenumber\":248,\"key\":\"handling_editors\",\"tenantterm\":\"handling editors\",\"frontiersdefaultterm\":\"associate editors\",\"description\":\"this terminology key is for the person assigned to edit a manuscript. it is a label for the temporary handling editor assignment.\",\"category\":\"label (role)\"},{\"sequencenumber\":249,\"key\":\"ae_accept\",\"tenantterm\":\"recommend acceptance\",\"frontiersdefaultterm\":\"accept\",\"category\":\"process\"},{\"sequencenumber\":250,\"key\":\"rtm\",\"tenantterm\":\"rtm\",\"frontiersdefaultterm\":\"rtm\",\"category\":\"product\"},{\"sequencenumber\":251,\"key\":\"frontiers_media_sa\",\"tenantterm\":\"frontiers media s.a\",\"frontiersdefaultterm\":\"frontiers media s.a\",\"category\":\"customer\"},{\"sequencenumber\":252,\"key\":\"review_editors\",\"tenantterm\":\"community reviewers\",\"frontiersdefaultterm\":\"review editors\",\"category\":\"label (role)\"},{\"sequencenumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantterm\":\"chief editor\",\"frontiersdefaultterm\":\"chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantterm\":\"chief editors\",\"frontiersdefaultterm\":\"chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":255,\"key\":\"call_for_papers\",\"tenantterm\":\"call for papers\",\"frontiersdefaultterm\":\"call for papers\",\"category\":\"label\"},{\"sequencenumber\":256,\"key\":\"calls_for_papers\",\"tenantterm\":\"calls for papers\",\"frontiersdefaultterm\":\"calls for papers\",\"category\":\"label\"},{\"sequencenumber\":257,\"key\":\"supervising_editor\",\"tenantterm\":\"supervising editor\",\"frontiersdefaultterm\":\"supervising editor\",\"description\":\"a chief or assistant chief editor who is assigned to a manuscript to supervise.\",\"category\":\"role\",\"externalkey\":\"supervising_editor\"},{\"sequencenumber\":258,\"key\":\"supervising_editors\",\"tenantterm\":\"supervising editors\",\"frontiersdefaultterm\":\"supervising editors\",\"description\":\"a chief or assistant chief editor who is assigned to a manuscript to supervise.\",\"category\":\"role\",\"externalkey\":\"supervising_editors\"},{\"sequencenumber\":259,\"key\":\"reviewer_endorse\",\"tenantterm\":\"endorse\",\"frontiersdefaultterm\":\"endorse\",\"category\":\"label\"},{\"sequencenumber\":260,\"key\":\"reviewer_endorsed\",\"tenantterm\":\"endorsed\",\"frontiersdefaultterm\":\"endorsed\",\"category\":\"label\"},{\"sequencenumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantterm\":\"endorse publication\",\"frontiersdefaultterm\":\"endorse publication\",\"category\":\"label\"},{\"sequencenumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantterm\":\"endorsed publication\",\"frontiersdefaultterm\":\"endorsed publication\",\"category\":\"label\"},{\"sequencenumber\":263,\"key\":\"editor_role\",\"tenantterm\":\"editor role\",\"frontiersdefaultterm\":\"editor role\",\"category\":\"label\"},{\"sequencenumber\":264,\"key\":\"editor_roles\",\"tenantterm\":\"editor roles\",\"frontiersdefaultterm\":\"editor roles\",\"category\":\"label\"},{\"sequencenumber\":265,\"key\":\"editorial_role\",\"tenantterm\":\"editorial role\",\"frontiersdefaultterm\":\"editorial role\",\"category\":\"label\"},{\"sequencenumber\":266,\"key\":\"editorial_roles\",\"tenantterm\":\"editorial roles\",\"frontiersdefaultterm\":\"editorial roles\",\"category\":\"label\"},{\"sequencenumber\":267,\"key\":\"call_for_paper\",\"tenantterm\":\"call for paper\",\"frontiersdefaultterm\":\"call for paper\",\"category\":\"label\"},{\"sequencenumber\":268,\"key\":\"research_topic_abstract\",\"tenantterm\":\"manuscript summary\",\"frontiersdefaultterm\":\"manuscript summary\",\"category\":\"process\"},{\"sequencenumber\":269,\"key\":\"research_topic_abstracts\",\"tenantterm\":\"manuscript summaries\",\"frontiersdefaultterm\":\"manuscript summaries\",\"category\":\"process\"},{\"sequencenumber\":270,\"key\":\"submissions_team_manager\",\"tenantterm\":\"journal manager\",\"frontiersdefaultterm\":\"content manager\",\"category\":\"process\"},{\"sequencenumber\":271,\"key\":\"submissions_team\",\"tenantterm\":\"journal team\",\"frontiersdefaultterm\":\"content team\",\"category\":\"process\"},{\"sequencenumber\":272,\"key\":\"topic_coordinator\",\"tenantterm\":\"topic coordinator\",\"frontiersdefaultterm\":\"topic coordinator\",\"category\":\"process\"},{\"sequencenumber\":273,\"key\":\"topic_coordinators\",\"tenantterm\":\"topic coordinators\",\"frontiersdefaultterm\":\"topic coordinators\",\"category\":\"process\"},{\"sequencenumber\":274,\"key\":\"frontiers_journal_team\",\"tenantterm\":\"frontiers journal team\",\"frontiersdefaultterm\":\"frontiers journal team\",\"category\":\"label (role)\"},{\"sequencenumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantterm\":\"rt:ic submission\",\"frontiersdefaultterm\":\"rt:ic submission\",\"category\":\"label (role)\"},{\"sequencenumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantterm\":\"rt:ic submission participant\",\"frontiersdefaultterm\":\"rt:ic submission participant\",\"category\":\"label (role)\"}]}'\n",impactgtmid:"gtm-njf2ml9b",impactgtmauth:"fyo-7nodm9w37qgfms03sa",impactgtmpreview:"env-1",impactgooglemapsapikey:"aizasyctehx2eu8pwfi86gw9fi00ftcykk6ifr8",qualtricsv4tov3:"'{\"enabled\":true,\"interceptid\":\"si_er0e2ze69oz8yn4\",\"projectid\":\"zn_cloy77jhkpc8gai\",\"brandid\":\"frontiersin\"}'\n",qualtricsumux:"'{\"enabled\":false,\"interceptid\":\"si_89fphy3etxqbwtu\",\"projectid\":\"zn_cloy77jhkpc8gai\",\"brandid\":\"frontiersin\"}'\n",qualtricscontinuousbrand:"'{\"enabled\":true,\"interceptid\":\"si_9zut94ut81fcrh4\",\"projectid\":\"zn_cloy77jhkpc8gai\",\"brandid\":\"frontiersin\"}'\n",defaultarticletemplate:"v3"},app:{baseurl:"/",buildid:"f2d5b6d8-d01c-4534-90b9-d659f10f17ca",buildassetsdir:"ap-2024/_nuxt",cdnurl:""}}## Results
alogabat is a potent positive allosteric modulator of gaba a -&#x003b1;5 receptors, with binding and functional selectivity. receptor occupancy studies provided direct proof of dose-dependent target engagement. functional circuit modulation was demonstrated by dose-dependent regional perfusion changes in pharmacological mri and changes in eeg theta- and beta-band power in rats. at &#x0003e;50% gaba a -&#x003b1;5 receptor occupancy, alogabat normalized elevated self-grooming behavior in both cntnap2 &#x02212;/&#x02212; and btbr mice and exhibited antiepileptic activity in rats. alogabat did not impair cognition in wildtype rats at gaba a -&#x003b1;5 receptor occupancy up to 75%, although impairment occurred at higher doses, probably due to increased activity at other receptor subtypes and/or saturation of &#x003b1;5 receptors. alogabat did not worsen diazepam-induced impairment on the rotarod test. conclusion: alogabat showed beneficial effects in mouse models relevant to neurodevelopmental disorders and anti-seizure activity at doses that did not produce cognitive, sedative, or motoric side effects. 1 introduction alterations in the gabaergic system, the main inhibitory neurotransmitter system in the brain, may contribute to the pathophysiology of neurodevelopmental disorders (ndds), such as autism spectrum disorder (asd) and angelman syndrome (as). asd is a complex, heterogeneous ndd with both genetic and environmental factors ( bourgeron, 2015 ) contributing to aberrant changes in brain growth, neuronal development, and functional connectivity ( dhossche et al., 2002 ; pizzarelli and cherubini, 2011 ; braat and kooy, 2015 ; robertson et al., 2016 ). asd is characterized by two core domains: impairments in social interaction and communication and the presence of repetitive or restricted behaviors, interests, or activities ( american psychiatric association, 2008 ). there are a range of comorbid conditions, including irritability, depression, anxiety, attention deficits, obsessive-compulsive symptoms, seizures, and sleep disruption. as is a rare genetic ndd with a prevalence of 1 in 12,000 to 20,000 births ( luk and lo, 2016 ; mertz et al., 2013 ). individuals with as often present with autistic features, severe intellectual disability, microcephaly, speech impairment, bursts of laughter, sleep problems, movement disorders, and epilepsy ( buiting, 2010 ; kalsner and chamberlain, 2015 ). gaba a receptors are ligand-gated chloride channels. there are 19 genes encoding gaba a receptor subunits that assemble as pentamers, with the most common stoichiometry being two &#x003b1;, two &#x003b2;, and one &#x003b3; subunit. gaba a subunit combinations give rise to functional, circuit, and behavioral specificity ( sieghart, 2006 ; vithlani et al., 2011 ). gaba a receptors that contain the &#x003b1;5 subunit (gaba a -&#x003b1;5) are of particular interest due to their restricted pattern of expression and unique physiological and pharmacological properties ( sur et al., 1999 ; mohler, 2011 ). in humans, gaba a receptors containing the &#x003b1;5 subunit are preferentially localized in the hippocampus, prefrontal cortex, nucleus accumbens, amygdala, insular cortex, anterior cingulate, and cingulate cortex&#x02014;key regions believed to be involved in the neuropathology and pathophysiology of asd ( mendez et al., 2013 ; myers et al., 2017 ). the gabra5 gene has been proposed as a candidate gene for asd ( delong, 2007 ; mesbah-oskui et al., 2017 ; warrier et al., 2013 ; di nanni et al., 2019 ), suggesting decreased gabaergic inhibition in a subpopulation of autistic individuals. mutations involving the gaba a receptor subunit genes gabra5 , gabrb3 , and gabrg3 (encoding the &#x003b1;5, &#x003b2;3, and &#x003b3;3 subunits) found on chromosomal region 15q11&#x02013;q13 have been associated with ndds including as, epilepsy, and prader&#x02013;willi syndrome in addition to asd ( hogart et al., 2010 ; sanders, 2015 ). as is predominantly caused by the loss of function of the maternally inherited ube3a gene; however, approximately 75% of individuals with as carry a large deletion of the maternal 15q11&#x02013;q13 chromosomal region. clinical studies have shown that individuals with as who have large deletions (deletion as) exhibit more severe symptoms than those in whom ube3a is the only gene affected, suggesting that the gabra5 , gabrb3 , and gabrg3 genes are relevant to the etiology of the disease. imaging studies using pet and magnetic resonance spectroscopy have shown reduced gaba a receptor binding in the superior and medial frontal cortex ( mori et al., 2012 ) and reduced gaba levels in individuals with asd ( robertson et al., 2016 ; gaetz et al., 2014 ; rojas et al., 2014 ; puts et al., 2017 ). postmortem studies have shown reduced numbers of inhibitory interneurons ( dufour et al., 2023 ), reduced expression of gaba a receptor subunits ( delorey, 2005 ; abrahams and geschwind, 2008 ), and reduced levels of the gaba-synthesizing enzymes such as glutamic acid decarboxylase (gad) 65 and 67 ( fatemi et al., 2002 ). there is increasing evidence from genetic, environmental, and phenotypic rodent models relevant to asd indicating that gabaergic circuit dysfunctions contribute to autism-like phenotypes ( fukuda et al., 2005 ; chao et al., 2010 ; banerjee et al., 2013 ). such deficits may result from multiple causes, including a reduced number of gabaergic interneurons, altered interneuron function, impaired gaba a receptor trafficking to the membrane, reduced expression of gaba a receptor subunits, and reduced gaba uptake function of gat-1 in neurons ( nakamura et al., 2016 ; orefice et al., 2016 ; mermer et al., 2021 ). supportive evidence is provided by the observation of autism-like behaviors in both gaba a -&#x003b1;5 and &#x003b2;3 subunit knockout mice ( zurek et al., 2016 ; delorey et al., 2008 ). regarding possible therapeutic approaches, enhancement of the gaba a receptor activity by non-selective benzodiazepines has been shown to ameliorate autism-like behavioral deficits in mouse models; however, due to sedation that is likely mediated by the activation of the gaba a -&#x003b1;1 subtype, very narrow therapeutic margins were observed ( han et al., 2012 ; han et al., 2014 ; lim et al., 2017 ). interestingly, a recent study showed that a gaba a -&#x003b1;5 positive allosteric modulator (pam), sh-053-2&#x02032;f-r-ch3, attenuated social and cognitive deficits in male rats exposed to valproic acid in utero , a rat model relevant to autism ( souza et al., 2024 ). the aim of the current study was to determine whether a selective gaba a -&#x003b1;5 pam, alogabat (also known as ro7017773 or rg7816), would produce beneficial effects in animal models relevant to autism-like repetitive behavior&#x02014;specifically btbr mice ( mcfarlane et al., 2008 ) and contactin-associated protein-like 2 [cntnap2 &#x02212;/&#x02212; ] homozygous knockout mice ( penagarikano et al., 2011 )&#x02014;and anti-seizure activity, without the typical side effects of non-selective gaba a pams, such as sedation and cognitive impairment. furthermore, target engagement was assessed by in vivo receptor occupancy (ro) and pharmacological mri (phmri) in rodents, and an electroencephalography (eeg) study in rats was undertaken to identify a putative pharmacodynamic readout for future clinical trials. 2 materials and methods further information for each method listed below can be found in the supplementary material . 2.1 materials alogabat [ro7017773; c 21 h 23 n 5 o 4 ; 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl) methoxy)-n-(tetrahydropyran-4-yl)pyridazine-3-carboxamide (iupac name); molecular weight: 409.44&#x000a0;gmol &#x02212;1 ] was synthesized at f.hoffmann-la roche ag, switzerland [ figure 1a ; see example 8 in buettelmann et al., 2018 ]. the discovery of alogabat and the related chemical series will be disclosed in future publications. diazepam, l-655,708, [ 3 h]flumazenil, [ 3 h]l-655,708, and [ 3 h]ro0154513 were synthesized at f.hoffmann-la roche ag, switzerland. figure 1 figure 1 . in vitro pharmacology of alogabat. (a) chemical structure of alogabat (ro7017773; c21h23n5o4); 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl) methoxy)-n-(tetrahydropyran-4-yl)pyridazine-3-carboxamide (iupac name); molecular weight, 409.44&#x000a0;gmol &#x02212;1 . (b) concentration-response curves of alogabat in [ 3 h]flumazenil competition-binding assays with membranes expressing different rat recombinant gaba a receptor subtypes ( n &#x0003d; 10&#x02013;20/concentration). (c) concentration-response curves of the effects of alogabat in hek293 cells expressing different rat recombinant gaba a receptor subtypes ( n &#x0003d; 4&#x02013;5/concentration). data in the graphs are shown as the mean (symbols) &#x000b1; sem (error bars). error bars smaller than the symbol size are not shown. (d) isoguvacine concentration-response curves obtained in the presence and absence of alogabat in rat hippocampal slices. the points represent the mean values &#x000b1; sem of three slices. the sigmoidal curves were fit through these points. (e) the ppi of ps was measured in the absence (control) and presence of alogabat at 0.3&#x000a0;&#x000b5;m ( n &#x0003d; 3 slices) and 1&#x000a0;&#x000b5;m ( n &#x0003d; 6 slices). ps1 and ps2 are the responses induced by the first and second stimulus, respectively. the data are normalized to the amplitude of ps1 and presented as the mean &#x000b1; sem. 2.2 in vitro experiments 2.2.1 gaba a receptor radioligand binding assays the affinity of alogabat for rat and human gaba a receptors containing &#x003b1;5, &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits was measured by [ 3 h]flumazenil competition-binding assays with membranes expressing different rat recombinant gaba a receptor subtypes ( n &#x0003d; 10&#x02013;20/concentration) and for human &#x003b1;4 and &#x003b1;6 by [ 3 h]ro0154513, as previously described ( ballard et al., 2009 ; hipp et al., 2021 ). 2.2.2 gaba a receptor electrophysiological studies alogabat was tested for functional activity on four different cloned rat and human gaba a receptor subtypes ( buettelmann et al., 2018 ), namely, &#x003b1;1&#x003b2;2&#x003b3;2, &#x003b1;2&#x003b2;3&#x003b3;2, &#x003b1;3&#x003b2;3&#x003b3;2, and &#x003b1;5&#x003b2;3&#x003b3;2. ion currents were induced by gaba concentrations that evoked approximately 20% of the maximal response ( n &#x0003d; 4&#x02013;5/concentration). the following concentrations of gaba were used: 1&#x000a0;&#x000b5;m for &#x003b1;1&#x003b2;2&#x003b3;2, 10&#x000a0;&#x000b5;m &#x003b1;2&#x003b2;3&#x003b3;2, 10&#x000a0;&#x000b5;m for &#x003b1;3&#x003b2;3&#x003b3;2, and 3&#x000a0;&#x000b5;m for &#x003b1;5&#x003b2;3&#x003b3;2 receptor subtype. alogabat was also tested for functional activity on native gaba a -&#x003b1;5 receptors in rat hippocampal slices: modulation of isoguvacine-induced population spikes ( ballard et al., 2009 ) and paired-pulse inhibition (ppi) ( xie and tietz, 1991 ). population spikes (pss) were recorded every 30&#x000a0;s by the stimulation of the schaffer collaterals, and isoguvacine was applied consecutively and in increasing concentrations for at least 4&#x000a0;min to the slices (control). after the washout of isoguvacine, alogabat (300&#x000a0;nm) was added to the bath perfusion, and a new isoguvacine concentration-response curve was obtained (alogabat). the ps amplitudes were normalized to the control ps obtained before the first application of isoguvacine and were fitted individually for each slice ( n &#x0003d; 3 slices). the ppi of ps was measured in the absence (control) and presence of alogabat at 0.3&#x000a0;&#x000b5;m ( n &#x0003d; 3 slices from one animal) and 1&#x000a0;&#x000b5;m ( n &#x0003d; 6 slices from two animals). the paired-pulse protocol consisted of two stimuli timely spaced by 20&#x000a0;ms, which were applied at the schaffer collaterals in rat hippocampal slices. we used a low number of animals based on our experience with the assay, which is highly robust and reproducible, and in alignment with our commitment to reducing the number of animals used. 2.2.3 selectivity screening the selectivity of alogabat (10&#x000a0;&#x000b5;m) over more than 70 receptors was assessed by radioligand binding studies conducted using eurofins cerep sa (celle l&#x000e9;vescault, france), following the methods described on www.eurofinsdiscoveryservices.com . 2.3 in vivo experiments 2.3.1 ethics approval experiments performed at f.hoffmann-la roche ag (basel, switzerland) complied with the swiss federal and cantonal laws on animal research and aaalac regulations and received prior approval from the cantonal veterinary office. the eeg study was conducted at brains online (ca, united states) in accordance with the guide for the care and use of laboratory animals (national research council 2011) after gaining approval from the institutional animal care and use committee. the pentylenetetrazole (ptz) and maximal electroshock (mes) tests were conducted at vivocore inc., canada, which is a facility licensed by the ontario ministry of agriculture, food, and rural affairs and accredited by the canadian council on animal care. all in vivo studies are reported in compliance with the arrive guidelines ( percie du sert et al., 2020 ). 2.3.2 animals all animals were group-housed in holding rooms at controlled temperature and humidity under a 12&#x000a0;h light/dark cycle and were allowed to acclimate for at least 7&#x000a0;days. twenty-six male wistar rats (charles river, germany; &#x0223c;160&#x000a0;g) and sixteen male cntnap2 &#x02212;/&#x02212; mice (bred at roche basel; 18&#x02013;22&#x000a0;g) were used in receptor occupancy studies. thirty-two male fischer rats (charles river, germany) were assessed in mri experiments (&#x0223c;250&#x000a0;g). seventeen male wistar rats (envigo, united states) were assessed in eeg experiments. one hundred male btbr mice (bred in roche basel) were assessed in grooming and open-field tests (n &#x0003d; 60, &#x0223c;30&#x000a0;g) and for digging behavior (n &#x0003d; 40, &#x0223c;30&#x000a0;g). fifty-seven male cntnap2 &#x02212;/&#x02212; mice (bred in roche basel; 5&#x02013;6&#x000a0;weeks) and wildtype littermates (n &#x0003d; 15) were assessed in grooming and open-field tests. one hundred male sprague&#x02013;dawley rats (charles river, canada) were used to evaluate antiepileptic effects in the ptz (70&#x02013;100&#x000a0;g, n &#x0003d; 40) and mes (&#x0003c;50&#x000a0;g n &#x0003d; 60) tests. forty-eight male sprague&#x02013;dawley rats (charles river, france) were used in the rotarod test (&#x0223c;170&#x02013;200&#x000a0;g). one hundred and forty-one male lister hooded (lh) rats (charles river, germany) were used in the cognition tests: 5-choice serial reaction time (5-csrt) task (n &#x0003d; 11, &#x0223c;400&#x000a0;g); continuous performance test (cpt; n &#x0003d; 11, &#x0223c;400&#x000a0;g); paired associates learning (pal) task (n &#x0003d; 12, &#x0223c;400&#x000a0;g); context fear conditioning (n &#x0003d; 67, &#x0223c;250&#x000a0;g); and morris water maze (n &#x0003d; 40, 350&#x02013;400&#x000a0;g). 2.3.3 alogabat treatment alogabat was formulated in 2% hydroxypropyl cellulose in water (or 0.3% tween 80 in saline for in vivo occupancy and grooming/digging experiments). the administration volume was 10&#x000a0;ml/kg (mice) and 5&#x000a0;ml/kg (rats). each dose was expressed as the weight of the base. alogabat was administered with a pre-treatment time of 30&#x000a0;min in mice and 60&#x000a0;min in rats (except for the eeg study), based on pharmacokinetic data indicating the time of maximal drug plasma concentration. treatment groups were assigned randomly. dose groups were provided as coded vials to allow blinded assessment during the conduct of each experiment. to minimize potential confounders regarding the time of day for behavioral testing, animals were split into separate cohorts (balanced for treatment groups) and tested during the same period. 2.3.4 receptor occupancy studies 2.3.4.1 in vivo occupancy in rats male wistar rats (n &#x0003d; 26, &#x0223c;160&#x000a0;g) were administered vehicle or alogabat (0.3, 1, 3, 10, 30, and 100&#x000a0;mg/kg, intraperitoneally [i.p.], n &#x0003d; 3/group) or the gaba a -&#x003b1;5 blocker l-655,708 at 10&#x000a0;mg/kg i.p. (n &#x0003d; 2). fifteen minutes later, the gaba a -&#x003b1;5 radioligand [ 3 h]ro0154513 was administered intravenously (i.v.) to assess ro ( ballard et al., 2009 ; hipp et al., 2021 ). non-specific binding was determined by pre-treatment with the established gaba a -&#x003b1;5 receptor blocker l-655,708 (10&#x000a0;mg/kg i.p.; n &#x0003d; 2). 2.3.4.2 ex vivo occupancy in cntnap2 &#x02212;/&#x02212; mice cntnap2 &#x02212;/&#x02212; mice ( penagarikano et al., 2011 ) (n &#x0003d; 16, 18&#x02013;22&#x000a0;g) were administered the vehicle or alogabat (30, 60, and 100&#x000a0;mg/kg) i.p. (n &#x0003d; 4/group), and ro was assessed in brain sections with the highly selective gaba a -&#x003b1;5 radioligand, [ 3 h]l-655,708, 30&#x000a0;min post-administration. 2.3.5 pharmacological mri in rats male fischer rats (n &#x0003d; 32, &#x0223c;250&#x000a0;g) were administered vehicle or alogabat (3, 10, and 30&#x000a0;mg/kg) i.p. (n &#x0003d; 8/dose). phmri was performed under medetomidine sedation in a small-animal scanner (4.7t/40&#x000a0;cm; bruker biospin, germany), and blood perfusion was analyzed according to previously published procedures ( bruns et al., 2009 ). fifteen minutes after drug treatment, rats were initially anesthetized using isoflurane (4%) in the carrier gas composed of oxygen and air (1:5), supplied to the spontaneously breathing animals in an inhalation box. upon the induction of anesthesia, a subcutaneous (s.c.) bolus injection of 0.2&#x000a0;mg/kg (1&#x000a0;ml/kg) of medetomidine prepared from 1:5 diluted dormilan &#x000ae; was administered, and the animal was transferred onto a rat cradle for inserting an s.c. catheter and starting continuous infusion of 1:10 diluted dormilan &#x000ae; (medetomidine) at a dose of 0.1&#x000a0;mg/kg/h (1&#x000a0;ml/kg/h). the head was immobilized in a stereotaxic frame. respiratory rate, body temperature, and o 2 and co 2 levels in inhaled and exhaled air were continuously monitored using a powerlab data acquisition system (adinstruments, spechbach, germany). body temperature was maintained at 37&#x000b0;c with a feedback-regulated electric heating blanket. immediately after the last imaging assessment, rats were euthanized by decapitation under anesthesia, and plasma samples were collected at approximately 40&#x000a0;min post-administration of alogabat. images were processed and analyzed using in-house developed software written in idl (rsi, boulder, co, united states) and matlab (the mathworks inc., natick, ma, united states). 2.3.6 eeg in rats male wistar rats (n &#x0003d; 17) were surgically prepared with wireless implanted transmitters to enable simultaneous recording of eeg, hippocampal (ca3) local field potential (lfp), and emg. rats were anesthetized using isoflurane (2%, 800&#x000a0;ml/min o2). bupivacaine/epinephrine was used for local analgesia, while finadyne or carprofen was used for peri-/post-operative analgesia. amoxicillin was used as an antibiotic. the animals were placed in a stereotaxic frame (kopf instruments, united states). a subcutaneous pocket was created near the dorsal flank, into which a transmitter (f50-eee, data sciences international, physio tel f50-eee small animal cns telemetry; three bipolar channels, biopotential lead, outer diameter 0.3&#x000a0;mm) was inserted. the transmitter included three bipolar channels: channel 1 (eeg): two screws in the left hemisphere (frontal: 11&#x000a0;mm anterior and 2.5&#x000a0;mm lateral to bregma; central: 3&#x000a0;mm anterior and 3.5&#x000a0;mm lateral to lambda); channel 2 (lfp): a single wire electrode targeting the ca3 region of the right hippocampus; and channel 3 (emg): electrodes placed in the neck muscle for recording emg activity, aiding in sleep stage classification. after a 2-week recovery, rats were administered the vehicle or alogabat (10&#x000a0;mg/kg) using a cross-over design (1-week interval). if the setup allowed, the positive control diazepam (2&#x000a0;mg/kg) was assessed. all drugs were administered i.v. via an implanted cannula so that brain exposure was expected within a few minutes of administration. eeg spectral power was analyzed quantitatively up to 1&#x000a0;h post-administration. only animals with clean eeg recordings were included in the analysis. eeg data in the awake state were used for the analyses reported in this study. we first investigated the effects on power over predefined theta and beta power ranges, defined a priori as 6&#x02013;10&#x000a0;hz and 20&#x02013;30&#x000a0;hz, respectively, based on previous studies with gabaa drugs ( visser et al., 2003 ; van lier et al., 2004 ). then, we evaluated frequency-specific effects across the 2&#x02013;128&#x000a0;hz range. 2.3.7 grooming behavior and open-field test in btbr and cntnap2 &#x02212;/&#x02212; mice male btbr mice (n &#x0003d; 60, &#x0223c;30&#x000a0;g) were pre-treated with the vehicle or alogabat at 30, 60, 90, and 120&#x000a0;mg/kg i.p. (n &#x0003d; 12/dose). male cntnap2 &#x02212;/&#x02212; mice (n &#x0003d; 57, 5&#x02013;6&#x000a0;weeks) and wildtype littermates (n &#x0003d; 15) received sub-chronic treatment (8&#x02013;10&#x000a0;days) with the vehicle or alogabat at 30, 60, and 100&#x000a0;mg/kg i.p. (n &#x0003d; 14&#x02013;15/dose). spontaneous locomotor activity was assessed in both groups of mice for 1&#x000a0;h in an open field (42 &#x000d7; 42 &#x000d7; 30.5&#x000a0;cm; 20 lux at the center of the arena) with a small amount of sawdust bedding. movement of the animal was detected by interruptions in an array of photobeams from horizontally located infrared sources placed around the open field, measured using a versamax system (accuscan instruments inc., columbus, oh, united states). activity was measured as the distance traveled (cm). one week later, each mouse was placed into a type-ii cage (21.5 &#x000d7; 15.5 &#x000d7; 13.0&#x000a0;cm; 40 lux) for 5&#x000a0;min habituation, and then the cumulative time (s) spent grooming during 10&#x000a0;min was recorded manually by a blinded observer. distance traveled (cm) during the session was measured using a video tracking system (ethovision, noldus information technology, netherlands). plasma samples were collected from btbr mice 1&#x000a0;week after testing and 30&#x000a0;min after treatment ( n &#x0003d; 6/dose). plasma samples were collected from cntnap2 &#x02212;/&#x02212; mice 1&#x000a0;day later and 30&#x000a0;min after treatment ( n &#x0003d; 4/dose). 2.3.8 digging behavior in btbr mice a separate group of male btbr mice (n &#x0003d; 40, &#x0223c;30&#x000a0;g) were pre-treated with vehicle or alogabat at 30, 60, and 100&#x000a0;mg/kg i.p. (n &#x0003d; 10/dose) and were placed into a small circular dish (d &#x0003d; 10&#x000a0;cm) filled with fresh thick sawdust located in the middle of a clean type-ii cage (21.5 &#x000d7; 15.5 &#x000d7; 13.0&#x000a0;cm; 40 lux). the cumulative time (s) spent digging over 5&#x000a0;min was recorded manually by a blinded observer. the distance traveled (cm) and speed were also measured in the arena, outside the dish (ethovision, noldus information technology, netherlands). plasma samples were collected immediately after the digging test, i.e., 35&#x02013;40&#x000a0;min post-administration ( n &#x0003d; 3/dose). 2.3.9 evaluation of antiepileptic effects in rats vehicle or alogabat (5, 15, or 30&#x000a0;mg/kg) was administered p.o. (n &#x0003d; 8/dose) and assessed for seizures induced by (1) subcutaneous (s.c.) ptz and (2) the maximum electrical stimulus (mes) model in male sprague&#x02013;dawley rats (ptz: 70&#x02013;100&#x000a0;g, n &#x0003d; 40; mes: &#x0003c;50&#x000a0;g n &#x0003d; 60, charles river, canada). diazepam (synthesized at f.hoffmann-la roche ag) was included in each experiment as a positive control and administered at 3&#x000a0;mg/kg i.p., 30&#x000a0;min prior to testing. immediately following testing, a terminal blood sample was collected under anesthesia. 2.3.9.1 pentylenetetrazole test following the designated pre-treatment time, ptz was administered at 75&#x000a0;mg/kg s.c. animals were transferred to a single cage and monitored closely for the onset of clonic seizure, and the percentage of each group showing seizures was recorded. protection was defined as the complete absence of clonic seizure, including forelimb clonus, over the 30&#x000a0;min observation period. 2.3.9.2 maximal electroshock test following the designated pre-treatment time, rats received maximal electroshock (mes: 150&#x000a0;ma, 0.2&#x000a0;s duration, 60&#x000a0;hz) via corneal electrodes moistened with saline (shock simulator type 221; harvard apparatus). due to inconsistency in responses by rats to this type of stimuli, all test animals (n &#x0003d; 60) were subjected to two screening sessions on two separate days, and 40 rats were selected based on their reliability to have tonic seizures. drug testing was conducted on the third day, during which the rats received the standard maximal electroshock, and the presence or absence of a tonic seizure was recorded and expressed as the percentage of animals in each group that showed seizures. protection was defined as the absence of a full tonic seizure within 15&#x000a0;s of stimulus delivery. 2.3.10 combination with diazepam on rotarod performance in rats forty-eight male sprague&#x02013;dawley rats (&#x0223c;170&#x02013;200&#x000a0;g) were pre-trained to the rotarod (47750 rota-rod ng, ugo basile) at 8&#x000a0;rpm for 120&#x000a0;s. one day later, rats were administered alogabat (or vehicle) p.o., 30&#x000a0;min prior to diazepam or vehicle i.p., and they were assessed on the rotarod 30&#x000a0;min later. each rat was given three attempts to remain on the rotarod, with a maximum duration of 120&#x000a0;s per attempt. treatment groups (n &#x0003d; 8/group) consisted of alogabat alone (30&#x000a0;mg/kg), diazepam alone (5&#x000a0;mg/kg), or alogabat at 3, 10, and 30&#x000a0;mg/kg in combination with diazepam (5&#x000a0;mg/kg). the maximum time (s) spent on the rotarod was recorded. after the completion of rotarod testing, animals were euthanized under isoflurane anesthesia for plasma sample collection at approximately 70&#x000a0;min post-administration of alogabat. 2.3.11 cognition testing in rats 2.3.11.1 operant and touchscreen cognition tests separate groups of male lister hooded (lh) rats (&#x0223c;400&#x000a0;g) were pre-trained in the operant and touch screen tests, as described in supplementary material . the 5-csrt task (n &#x0003d; 11) is a test of attention. the primary parameter is the total percentage of correct responses. continuous performance test (cpt; n &#x0003d; 11) assesses sustained attention. the primary parameter is the discrimination sensitivity index (d prime), which is a ratio based on the rate at which rats make correct and incorrect responses. the paired associates learning (pal) task (n &#x0003d; 12) assesses visual&#x02013;spatial memory. the primary parameter is the total percentage of correct responses. a latin-squares design was used to assess the vehicle and doses of alogabat (3, 10, and 30&#x000a0;mg/kg p.o.). rats were tested twice weekly with at least a 2-day interval between test sessions. rats were trained between test days to maintain baseline performance. 2.3.11.2 context fear conditioning two cohorts of male lh rats (&#x0223c;250&#x000a0;g; n &#x0003d; 67) were assessed for context fear conditioning (cfc) in two experiments: (1) vehicle or alogabat at 10 and 30&#x000a0;mg/kg (n &#x0003d; 9/dose); (2) vehicle or alogabat at 1, 3, and 10&#x000a0;mg/kg (n &#x0003d; 10/dose) administered p.o., 60&#x000a0;min prior to the acquisition session. rats were placed into a novel test chamber (45&#x000a0;cm &#x000d7; 45&#x000a0;cm &#x000d7; 46.5&#x000a0;cm) with a grid floor and clear plastic walls (tse-systems gmbh, germany). during the acquisition session, a 2-min habituation phase was followed by the delivery of a mild foot shock (0.8&#x000a0;ma for 1&#x000a0;s) applied through the grid floor. following a 1&#x000a0;min interval, a second foot shock was delivered. the animals remained in the chambers for a further 30&#x000a0;s. one day later, the animals were returned to the same test chamber for a 5-min period without any foot shock. rodents respond to danger in a species-specific manner by freezing, i.e., the animals will withhold all movement, except for respiration, to avoid detection. the amount of freezing behavior was measured by the computer as the time spent immobile (minimum threshold of 1&#x000a0;s) and was expressed as the percentage of time spent freezing during the 5-min session. following cfc, plasma samples were collected 1&#x02013;2&#x000a0;days later from rats pre-treated with the same dose at 60&#x000a0;min post-administration ( n &#x0003d; 4/dose). 2.3.11.3 morris water maze male lh rats (350&#x02013;400&#x000a0;g) were pre-treated with vehicle or 10 or 30&#x000a0;mg/kg alogabat p.o. (n &#x0003d; 10/dose) once daily during cued acquisition (visible platform; three trials per day for 2&#x000a0;days), followed by a 2-day interval and then spatial acquisition (hidden platform; three trials per day for 4&#x000a0;days) in the morris water maze (mwm; computer tracking system hvs image ltd., united kingdom) ( ballard et al., 2005 ). twenty-four hours later, the platform was removed, and the rats were pre-treated with vehicle or alogabat and allowed to swim in the maze for 60&#x000a0;s (probe trial) to assess the retention/spatial memory of the platform position, expressed as the percentage of distance traveled in each quadrant. for the mwm, plasma samples were collected immediately after the last trial on the 12th day of treatment at approximately 70&#x000a0;min post-administration ( n &#x0003d; 4&#x02013;5/dose). 2.3.12 plasma sampling and analysis rodents were deeply anesthetized with 5% isoflurane, and blood was collected following decapitation with a guillotine or via cardiac puncture (ptz and mes). during eeg experiments, blood was collected from a cannula in the right femoral artery. blood samples were centrifuged in edta-coated eppendorf tubes (4,000&#x000a0;rpm, 4&#x000b0;c, 5&#x000a0;min), and plasma was collected, immediately frozen, and stored at &#x02212;80&#x000b0;c. samples were analyzed for the concentration of alogabat using qualified liquid chromatography coupled to tandem mass spectrometry (lc-ms/ms) assays. 2.3.13 statistical analysis sample sizes were determined based on historical data for each experiment within each laboratory. 2.3.13.1 eeg linear mixed-effects models (lmms) were used since these can account for incomplete datasets, which was the case in this study. specific contrasts were derived and tested using t-tests within the model using satterthwaite approximation for degrees of freedom. models were derived for each compound individually: y &#x0223c; compound &#x0002b; (1&#x0007c;animal). the significance of differences in the peak frequency was assessed using random permutation tests (10,000). 2.3.13.2 phmri analysis was performed with jmp (sas institute inc., cary, united states) and matlab (the mathworks inc., natick, ma, united states). global (whole-brain) absolute-perfusion values from the vehicle and the three dose groups were tested for a linear trend across the four doses using a one-way anova framework. the same analysis was applied roi-wise to the normalized-perfusion values. multiple testing across the single rois was accounted for by controlling the false discovery rate (fdr) at 10% using the benjamini&#x02013;hochberg approach. to also obtain an overall activation&#x02013;strength metric, normalized-perfusion values of each dose group were compared roi-wise to those of the vehicle group using welch&#x02019;s t-test without multiple-testing correction. the number of significantly modulated rois at each dose was then taken as a measure of &#x0201c;pattern strength.&#x0201d; the mean and the upper 95% confidence limit of the corresponding chance levels were estimated via random group-label permutations (100,000 runs per group). significance levels of the actual pattern strengths were determined based on the distributions obtained through the permutation procedure. 2.3.13.3 behavior all statistical analyses were performed using prism (graphpad software). one-factor anova was used for between-group comparison (i.e., dose), with repeated measures for within-subject comparison (i.e., time bins and platform quadrants). dunnett&#x02019;s test was used for post hoc comparisons. student&#x02019;s unpaired two-tailed t-test was used when two groups were compared. the chi-square test was used to compare the percentage of groups. rotarod data were analyzed using a non-parametric kruskal&#x02013;wallis test, followed by dunn&#x02019;s multiple comparison test. statistical significance was predetermined as p &#x0003c; 0.05. 3 results 3.1 binding affinity for gaba a receptors containing &#x003b1;5 and other &#x003b1; subunits the aim of these radioligand binding studies was to determine the binding selectivity of alogabat at the rat and human gaba a receptors containing &#x003b1;5 compared to &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits. alogabat had a high affinity for gaba a -&#x003b1;5&#x003b2;3&#x003b3;2 receptors in rats (ki 7.9&#x000a0;nm), with approximately 37-, 26-, and 18-fold selectivity compared to gaba a &#x003b1;1&#x003b2;3&#x003b3;2, &#x003b1;2&#x003b2;3&#x003b3;2, and &#x003b1;3&#x003b2;3&#x003b3;2, respectively ( figure 1b ; see supplementary table s1 ). alogabat had a similar pharmacological profile in human recombinant gaba a receptor subtypes (see supplementary table s1 ). 3.2 functional activity at recombinant and native gaba a receptors we undertook electrophysiological studies in hek293 cells and oocytes to assess the functional activity of alogabat on cloned rat and human gaba a receptor subtypes containing &#x003b1;5, &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits. alogabat enhanced gaba-evoked responses of rat and human &#x003b1;5-containing receptors by 167% ( figure 1c ) and 72% (see supplementary table s2 ), respectively. the maximum amount of potentiation was slightly lower at human receptors. this may be due to the different expression systems used, i.e., hek293 cells for rat receptors and xenopus oocytes for human receptors. at the highest concentrations tested, alogabat potentiated other receptor subtypes to a much lesser extent than &#x003b1;5-containing receptors. the potency of alogabat was comparable between gaba a -&#x003b1;5 receptors containing either &#x003b3;2 or &#x003b3;3 subunits, i.e., gaba a -&#x003b1;5&#x003b2;3&#x003b3;2 and gaba a -&#x003b1;5&#x003b2;3&#x003b3;3 receptors (see supplementary figure s1 ). at native gaba a receptors in rat hippocampal slices, alogabat positively modulated gabaergic inhibition of ca1 pyramidal cells, as shown by a leftward shift of the concentration-dependent inhibition of the population spike by isoguvacine ( figure 1d ) and enhanced paired-pulse inhibition of the population spike during field potential recordings ( figure 1e ). together, these results confirm the binding selectivity of alogabat and demonstrate that alogabat is a functionally selective pam of gaba-evoked responses. 3.3 selectivity data we assessed alogabat in radioligand binding studies with more than 70 receptors and showed that alogabat at 10&#x000a0;&#x000b5;m had over 917-fold binding selectivity for the gaba a -&#x003b1;5&#x003b2;3&#x003b3;2 receptor subtype against all other targets tested (see supplementary table s3 ). 3.4 receptor occupancy in wistar rats and cntnap2 &#x02212;/&#x02212; mice the main objective of these studies was to visualize and quantify gaba a -&#x003b1;5 ro by alogabat. alogabat decreased the specific binding of the gaba a -&#x003b1;5 receptor-specific radioligand [ 3 h]ro0154513 in the hippocampus of rats in a dose-dependent manner. the highest dose of alogabat (100&#x000a0;mg/kg i.p.) reduced specific binding by 100%, i.e., to the same binding level as that of 10&#x000a0;mg/kg l-655,708 ( figure 2a ). a total plasma concentration of 669&#x000a0;ng/ml and a total brain concentration of 208&#x000a0;ng/g were required to produce half-maximal gaba a -&#x003b1;5 ro (ec 50 ) in the hippocampus in rats. in cntnap2 &#x02212;/&#x02212; mice, estimated gaba a -&#x003b1;5 ro based on the ex vivo study with [ 3 h]l-655,708 was 43%, 46%, and 71% at doses of 30, 60, and 100&#x000a0;mg/kg i.p., respectively ( figure 2b ). in addition, the rat occupancy curve was used to calculate ro related to plasma exposure for all in vivo experiments described in this manuscript below (also refer to supplementary tables s4&#x02013;s5 ). figure 2 figure 2 . receptor occupancy and phmri signature of alogabat following acute administration. (a) concentration-dependent blockade of [ 3 h]ro0154513 binding by alogabat in wistar rats: with increasing concentrations from the different doses (0.3&#x02013;100&#x000a0;mg/kg i.p., n &#x0003d; 3/dose) of alogabat (vehicle &#x0003d; without pre-treatment, n &#x0003d; 3). (b) representative autoradiograms of alogabat ex vivo occupancy in cntnap2 &#x02212;/&#x02212; mice via in vitro incubation of the highly selective gaba a -&#x003b1;5 receptor radioligand [ 3 h]l-655,708 to sagittal brain sections. the cntnap2&#x02212;/&#x02212; mice were treated with vehicle and 30, 60, or 100&#x000a0;mg/kg i.p. alogabat (n &#x0003d; 4/dose). (c) trend of normalized-perfusion response pattern strength increasing with dose, given as numbers (&#x000b1; 95% confidence intervals) of significantly (de-)activated regions of interest (rois) following the administration of alogabat (n &#x0003d; 8/dose) to fischer (f344) rats under medetomidine sedation. &#x0201c;chance level&#x0201d; &#x0003d; mean (black dotted line) and 95th percentile (gray dotted line) derived from the permutation test. significant deviations in the number of modulated rois from the chance level are denoted by &#x0002a; p &#x0003c; 0.05, &#x0002a;&#x0002a; p &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a; p &#x0003c; 0.001 (uncorrected). ro is the calculated receptor occupancy for gaba a -&#x003b1;5 from measured plasma concentrations at each dose. (d) sagittal schematic of rat brain showing rois with a significant dose-dependent modulation (linear trend of normalized perfusion). rois passing false discovery rate control at 10% are shown, with roi outlines indicating uncorrected significance level (no outline, p &#x0003c; 0.05; dotted outline, p &#x0003c; 0.01; and solid outline, p &#x0003c; 0.001). roi abbreviations: acbsh, nucleus accumbens shell; amg, amygdala; drn, dorsal raphe nucleus; hpcfi, fimbria hippocampi; insc, insular cortex; lc, locus coeruleus; m1, primary motor cortex; mpfc/cg, medial prefrontal, cingulate cortex; pir, piriform (entorhinal) cortex; prh, perirhinal cortex; s1, primary somatosensory cortex; sn, substantia nigra; th, thalamus; vc, visual cortex. 3.5 pharmacological mri signature in rats the purpose of this study was to evaluate the effects of alogabat on regional neural activity. blood perfusion, measured quantitatively by phmri, was taken as a proxy for neural activity. the administration of a single dose of alogabat at 3&#x02013;30&#x000a0;mg/kg i.p. in rats resulted in moderate but consistent and dose-dependent changes in neural activity patterns compared to treatment with the vehicle ( figure 2c ). significant dose-dependent modulation of normalized perfusion by alogabat was observed in limbic brain regions, i.e., the nucleus accumbens (shell), amygdala, and hippocampus (fimbria); in several cortical brain regions, the thalamus and brainstem nuclei; and in the substantia nigra ( figure 2d ). a linear dose effect was also observed on whole-brain absolute perfusion. alogabat target engagement in brain tissue ranged from 54% to 84% ro. 3.6 eeg signature in rats the aim of this study was to determine whether alogabat induces a characteristic eeg signature that could be used as a translational pharmacodynamic marker. as a first step and based on previous findings on the eeg effects of gaba a drugs ( van lier et al., 2004 ; visser et al., 2003 ; friedman et al., 1992 ), we investigated eeg spectral power change in the theta (6&#x02013;10&#x000a0;hz) and beta (20&#x02013;30&#x000a0;hz) frequency bands. alogabat, administered as 10&#x000a0;mg/kg i.v. (5&#x000a0;min infusion), significantly increased eeg beta-band activity by 21% &#x000b1; 11% relative to the baseline (mean &#x000b1; sd) and decreased theta-band activity by 32% &#x000b1; 19% ( figures 3a,b ). frequency-resolved changes confirmed a decrease in theta power (approximately 6&#x02013;10&#x000a0;hz) and revealed broader beta and gamma modulation (approximately 20&#x02013;50&#x000a0;hz) ( figures 3c&#x02013;e ). the calculated ro after the application of alogabat was 77%&#x02013;85% for gaba a -&#x003b1;5 (see supplementary table s6 ). the overall spectral pattern was qualitatively similar to that of diazepam; however, the peak frequency in the beta frequency range was higher for alogabat (32&#x000a0;hz for alogabat vs. 22.6&#x000a0;hz for diazepam; p &#x0003d; 0.006, random permutation test), and its amplitude was greater for diazepam (142% &#x000b1; 44% increase for diazepam vs. 27% &#x000b1; 16% increase for alogabat; p &#x0003c; 0.001). this is likely related to the high binding and functional selectivity of alogabat for &#x003b1;5-containing gaba a receptors compared to the non-selective profile of diazepam. figure 3 figure 3 . pharmacodynamic effect of alogabat on eeg spectral power. (a,b) modulations of vehicle ( n &#x0003d; 12), alogabat 10&#x000a0;mg/kg ( n &#x0003d; 9), and diazepam 2&#x000a0;mg/kg ( n &#x0003d; 7, positive control) in the beta (20&#x02013;30&#x000a0;hz) and theta (6&#x02013;10&#x000a0;hz) power. (c&#x02013;e) effects of individual compounds and vehicle on the eeg power spectrum. each individual recording is displayed as a light gray line, and the group average and its 95% confidence intervals are shown as colored bands. for all panels, power averaged over 0.2&#x02013;1&#x000a0;h post dosing is shown relative to pre-dosing baseline average over &#x02212;1 to &#x02212;0.2&#x000a0;h before dosing. statistics: &#x0002a; p &#x0003c; 0.05 versus vehicle (linear mixed-effects models followed by t-tests). 3.7 repetitive behaviors in mouse models relevant to asd the inbred mouse strain btbr and the cntnap2 &#x02212;/&#x02212; mouse show abnormalities in core asd behavioral domains, such as repetitive behaviors. self-grooming and digging are more elevated in the btbr mouse than in other strains, i.e., c57bl/6j ( mcfarlane et al., 2008 ), and cntnap2 &#x02212;/&#x02212; mice show more elevated grooming than their wildtype littermates ( penagarikano et al., 2011 ). the aim of the following experiments was to determine whether alogabat has a specific effect on repetitive behaviors independent of potential effects on overall locomotor activity. we assessed the effects of subchronic treatment on cntnap2 &#x02212;/&#x02212; mice to exclude potential tolerance to the effects of alogabat. 3.7.1 open field in btbr and cntnap2 &#x02212;/&#x02212; mice in btbr mice, acute administration of alogabat (30&#x02013;120&#x000a0;mg/kg i.p.) had no effect on the total activity over 1&#x000a0;h measured in an open field [f(4,55) &#x0003d; 2.04], although during the first 10&#x000a0;min, alogabat at 90 and 120&#x000a0;mg/kg significantly reduced the distance traveled [f(4,55) &#x0003d; 9.623, p &#x0003c; 0.001, figure 4a ]. there was also no effect of sub-chronic alogabat (30&#x02013;100&#x000a0;mg/kg i.p.) on the total activity over 1&#x000a0;h in cntnap2 &#x02212;/&#x02212; mice [f(3,53) &#x0003d; 0.98]. during the first 5&#x000a0;min, 100&#x000a0;mg/kg reduced the distance traveled in cntnap2 &#x02212;/&#x02212; mice to the same level as vehicle-treated wildtype mice ( figure 4b ). alogabat did not induce a major impairment of locomotor activity in the open field. figure 4 figure 4 . effect of alogabat on repetitive behaviors in btbr and cntnap2 &#x02212;/&#x02212; mice. (a) alogabat was administered i.p. 30&#x000a0;min prior to the assessment of locomotor activity in an open-field test in btbr mice: distance traveled (cm) per 5&#x000a0;min time bin ( line graph ) and in 1&#x000a0;h total ( bar chart inset ). (b) alogabat was administered i.p. once daily for 2&#x02013;3&#x000a0;days, and on the test day, it was administered 30&#x000a0;min prior to testing cntnap2 &#x02212;/&#x02212; mice in an open field: distance traveled (cm) per 5&#x000a0;min time bin ( line graph ) and in 1&#x000a0;h total ( bar chart insert ). in btbr mice, on a separate test day, alogabat was administered i.p. 30&#x000a0;min prior to the grooming test: (c) duration (s) of grooming behavior and (e) distance (cm) traveled during the 10&#x000a0;min period in the test chamber. in cntnap2 &#x02212;/&#x02212; mice, alogabat was administered i.p. once daily for 8&#x02013;10&#x000a0;days, and on the test day, it was administered 30&#x000a0;min prior to the grooming test: (d) duration (s) of grooming behavior and (f) distance traveled during the 10&#x000a0;min period in the test chamber. data are presented as individual points (circles) and mean &#x000b1; sem (btbr: n &#x0003d; 12/group; cntnap2 &#x02212;/&#x02212; : n &#x0003d; 14&#x02013;15/group). statistics: &#x0002a; p &#x0003c; 0.05, &#x0002a;&#x0002a; p &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a; p &#x0003c; 0.001 vs. vehicle (veh)-treated btbr or cntnap2 &#x02212;/&#x02212; mice. &#x000a7;&#x000a7;&#x000a7; p &#x0003c; 0.001 vehicle-treated wildtype (wt-v) mice vs. vehicle (v)-treated cntnap2 &#x02212;/&#x02212; mice. alogabat was administered i.p. 30&#x000a0;min prior to the assessment of digging behavior in btbr mice: (g) duration (s) of digging behavior, (h) distance traveled (cm), and (i) speed (cm/s) during the 5&#x000a0;min period in the test chamber. data are presented as individual points (circles) and mean &#x000b1; sem ( n &#x0003d; 12/group). statistics: &#x0002a;&#x0002a; p &#x0003c; 0.01 and &#x0002a;&#x0002a;&#x0002a; p &#x0003c; 0.001 vs. vehicle-treated btbr mice. ro is the calculated receptor occupancy for gaba a -&#x003b1;5 from the measured plasma concentrations at each dose. 3.7.2 grooming behavior in btbr and cntnap2 &#x02212;/&#x02212; mice acute administration of alogabat in btbr mice dose-dependently attenuated grooming behavior at 60, 90, and 120&#x000a0;mg/kg i.p. [f(4,55) &#x0003d; 6.946, p &#x0003d; 0.0001, figure 4c ] without reducing locomotor activity in the same test arena ( figure 4e ). in contrast, doses of 60 and 90&#x000a0;mg/kg increased the distance traveled [f(4,55) &#x0003d; 3.454, p &#x0003c; 0.05]. alogabat had a specific effect on grooming behavior at plasma concentrations corresponding to calculated gaba a -&#x003b1;5 ro levels of 45%&#x02013;70% (see supplementary table s4 ). sub-chronic administration of alogabat in cntnap2 &#x02212;/&#x02212; mice attenuated grooming behavior at 60 and 100&#x000a0;mg/kg i.p. [f(3,53) &#x0003d; 10.57, p &#x0003c; 0.0001, figure 4d ], with no effect on locomotor activity measured in the same test arena [f(3,53) &#x0003d; 0.74, figure 4f ]. alogabat had a specific effect on repetitive grooming behavior at plasma concentrations that correspond with calculated gaba a -&#x003b1;5 ro of 52%&#x02013;79% (see supplementary table s4 ). 3.7.3 digging behavior in btbr mice there was no effect of acute alogabat administration on digging behavior at doses up to 100&#x000a0;mg/kg i.p. [f(3,36) &#x0003d; 0.8, figure 4g ], corresponding to a calculated gaba a -&#x003b1;5 ro level of 67% (see supplementary table s4 ). alogabat at 100&#x000a0;mg/kg reduced the distance traveled [f(3,36) &#x0003d; 12.1, p &#x0003c; 0.001, figure 4h ] and speed [f(3,36) &#x0003d; 11.5, p &#x0003c; 0.001, figure 4i ] in the same arena. 3.8 anticonvulsant activity in rats the purpose of these experiments was to evaluate the antiepileptic properties of alogabat against seizures induced by ptz and the mes model. alogabat administered in combination with a convulsant dose of ptz completely blocked seizures at 15 and 30&#x000a0;mg/kg ( figure 5a ), which corresponds to calculated gaba a -&#x003b1;5 ro levels of 71% and 77% (see supplementary table s5 ). meanwhile, in the mes test, alogabat at 5&#x000a0;mg/kg (57% ro, see supplementary table s5 ) showed a significant reduction in the percent of rats that had tonic seizures ( figure 5b ); there was only a tendency for reduction at 15&#x000a0;mg/kg ( p &#x0003d; 0.1) and 30&#x000a0;mg/kg ( p &#x0003d; 0.06). the positive control, diazepam, significantly reduced the percentage of rats that had seizures in both the ptz and mes tests. figure 5 figure 5 . evaluation of alogabat for effects on anticonvulsant, motor, and cognitive tests. alogabat was administered p.o. 60&#x000a0;min prior to the following behavior tests. assessment of potential anticonvulsant activity in (a) ptz and (b) mes tests in rats. diazepam (dzp) at 3&#x000a0;mg/kg i.p. was included as a positive control. data are presented as individual points (circles) and the percentage of rats per group showing seizures ( n &#x0003d; 8/group). (c) time (s) spent on the rotarod at 16&#x000a0;rpm in rats administered alogabat alone (30&#x000a0;mg/kg, gray bar with black outline) or alogabat at 3, 10, and 30&#x000a0;mg/kg co-administered with diazepam at 5&#x000a0;mg/kg i.p. (gray bars with red outline) compared with vehicle (open bar) or diazepam (open bar with red outline). data are presented as individual points (circles) and median &#x000b1; interquartile range (n &#x0003d; 8/group). assessment of cognition in rats: (d) attention in the 5-choice serial reaction time (5-csrt) task; (e) sustained attention in the touchscreen continuous performance test (cpt); (f) visual&#x02013;spatial memory in the touchscreen pal task. cfc at (g) 10 and 30&#x000a0;mg/kg; (h) 1, 3, and 10&#x000a0;mg/kg. spatial learning and memory in the mwm: alogabat was administered once daily for 11&#x000a0;days prior to the probe trial. (i) percentage of distance traveled in all four quadrants: vehicle; 10&#x000a0;mg/kg; 30&#x000a0;mg/kg. data are presented as individual points (circles) and mean &#x000b1; sem for pal ( n &#x0003d; 12/dose; within-subjects), 5-csrt and cpt ( n &#x0003d; 11/dose, within-subjects), cfc ( n &#x0003d; 9&#x02013;10/group), and mwm ( n &#x0003d; 10/group). statistics: &#x0002a; p &#x0003c; 0.05, &#x0002a;&#x0002a; p &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a; p &#x0003c; 0.001 vs. vehicle (veh or 0)-treated rats; mwm statistics: &#x0002a; p &#x0003c; 0.05, &#x0002a;&#x0002a; p &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a; p &#x0003c; 0.001 vs. percentage of distance in the platform quadrant. ro is the calculated receptor occupancy of alogabat for gaba a -&#x003b1;5 from measured plasma concentrations at each dose. 3.9 combination with diazepam on rotarod performance in rats classical benzodiazepines, such as diazepam, are known to induce sedation and ataxia, which can be measured by the rotarod task in rodents. the aim of this experiment was to determine whether alogabat affects rotarod performance when administered alone and, second, whether alogabat modulates the sedative/motor effect of diazepam on rotarod performance when given in combination. diazepam at 5&#x000a0;mg/kg i.p. significantly impaired rotarod performance. alogabat (3&#x02013;30&#x000a0;mg/kg p.o.) co-administered with diazepam did not worsen the effects of diazepam on rotarod performance ( figure 5c ). alogabat administered alone at 30&#x000a0;mg/kg p.o. did not differ from vehicle-treated rats, corresponding to a calculated gaba a -&#x003b1;5 ro level of 88% (see supplementary table s5 ). 3.10 evaluation of cognition in rats since non-selective gaba a pams, such as diazepam, have been shown to impair cognition ( ballard et al., 2005 ), the aim of the following experiments was to study the potential effects of acute administration of alogabat on cognition in rats. this included attention in the 5-csrt task and associative (fear) memory in cfc. we also assessed visual&#x02013;spatial memory (pal task) and attention (cpt) in a touchscreen system, which provides a translational approach for assessing cognition ( hvoslef-eide et al., 2016 ). chronic treatment with alogabat was also assessed on spatial learning and memory in the mwm. in the 5-csrt task, alogabat at 30&#x000a0;mg/kg induced a small but statistically significant reduction in percent correct (3%; within-subjects comparison; f(3,30) &#x0003d; 5.6, p &#x0003c; 0.01; figure 5d ). however, alogabat did not impair attention in cpt (f(2,20) &#x0003d; 0.3; figure 5e ) or visual&#x02013;spatial memory in the pal task (f(2,22) &#x0003d; 2.6; figure 5f ). in the cfc test, alogabat was administered before the acquisition session to determine whether there was an effect on learning the association between foot shock and the surrounding context. in the first experiment, alogabat impaired cfc at 10 and 30&#x000a0;mg/kg, corresponding to calculated gaba a -&#x003b1;5 ro levels of 75% and 81% (f(2,24) &#x0003d; 10.99, p &#x0003c; 0.001; figure 5g ). a second experiment was undertaken to explore lower doses, and it showed that alogabat did not significantly impair cfc at 1, 3, and 10&#x000a0;mg/kg (f(3,36) &#x0003d; 0.9; figure 5h ), corresponding to the calculated gaba a -&#x003b1;5 ro levels of 35%, 56%, and 72%. this suggests that the dose of 10&#x000a0;mg/kg is approximately the threshold level for the impairment of cfc and is likely dependent on the level of ro achieved per subject. in the mwm test, chronic administration of alogabat at 10 and 30&#x000a0;mg/kg did not significantly impair the acquisition of the hidden platform position (see supplementary figure s2 ). twenty-four hours later, the platform was removed, and the rats were allowed to swim in the maze for 60&#x000a0;s (probe trial) to assess memory-retention of the platform position. the groups receiving vehicle [f(3,27) &#x0003d; 8, p &#x0003c; 0.001] and 10&#x000a0;mg/kg [f(3,27) &#x0003d; 7, p &#x0003c; 0.01] had learned the spatial position of the platform, as shown by their preference for the platform quadrant ( figure 5i ). however, rats that received 30&#x000a0;mg/kg alogabat showed impaired spatial memory of the platform position during the probe trial [f(3,27) &#x0003d; 3, p &#x0003d; 0.08; figure 5i ], and gaba a -&#x003b1;5 ro was estimated to be 79%. in summary, alogabat impaired context and spatial memory at gaba a -&#x003b1;5 ro above 70%. 4 discussion 4.1 in vitro and in vivo characterization of alogabat alogabat was shown to be a potent and functionally selective gaba a -&#x003b1;5 receptor pam in vitro . the functional activity of alogabat was confirmed at native gaba a receptors in rat hippocampal slices. in vivo binding experiments demonstrated dose-dependent target engagement of alogabat in rats and cntnap2 &#x02212;/&#x02212; mice. the highest specific binding was observed in the hippocampus, which is consistent with the known distribution of the gaba a -&#x003b1;5 receptor subtype in rodents ( pirker et al., 2000 ). phmri studies in rats demonstrated dose-dependent perfusion changes, indicating circuit modulation by alogabat. there were consistent changes in the neural activity pattern across dose groups, with modulation of neural activity in, among others, the medial prefrontal cortex, cingulate cortex, motor cortex, perirhinal cortex, nucleus accumbens shell, amygdala, hippocampus fimbria, and substantia nigra. 4.2 eeg signature acute administration of alogabat in rats induced an eeg signature characterized by a power decrease in theta and an increase in the beta frequency range, which was qualitatively similar to the eeg signature of non-selective gaba a pams such as diazepam ( van lier et al., 2004 ; visser et al., 2003 ; friedman et al., 1992 ). the lower magnitude of induced eeg beta-band power by alogabat compared to diazepam is likely attributed to its &#x003b1;5-selectivity, resulting in an overall lower magnitude of gaba a receptor modulation. this eeg signature of alogabat is qualitatively a mirror image of the eeg signature of basmisanil, a highly selective gaba a -&#x003b1;5 negative allosteric modulator (nam), which we recently found to induce an increase in the theta power and a decrease in the beta-band eeg power in healthy volunteers ( hipp et al., 2021 ). furthermore, the eeg signature of alogabat is in agreement with the link between beta-band activity and single-nucleotide polymorphisms (snps) in gaba a receptor genes ( porjesz et al., 2002 ; smit et al., 2018 ) and ndds (dup15q syndrome, as) involving gene copy number variations of gabrb3, gabra5 , and gabrg3 ( frohlich et al., 2019a ; frohlich et al., 2019b ). gaba a receptor-related changes in beta-band activity are believed to reflect the modulation of recurrent excitatory&#x02013;inhibitory feedback loops in the cortical tissue ( whittington et al., 2000 ; traub and jefferys, 1999 ). for the administered doses, the calculated receptor occupancies were in the range of 77%&#x02013;84% for &#x003b1;5-containing receptors and 22%&#x02013;34% for &#x003b1;1-containing receptors (with different pam effects (e max ) at &#x003b1;5 vs. &#x003b1;1). thus, at the studied doses, alogabat has some effect on &#x003b1;1-containing receptors, and further work is needed to systematically study lower doses of alogabat, including those &#x0003c;70% ro without the impairment of cognition in wt rats, to confirm whether the modulation of &#x003b1;5-containing receptors alone is sufficient to induce the described eeg effect. nonetheless, eeg theta- and beta-band power are promising candidates for translational mechanistic biomarkers of gaba a -&#x003b1;5 receptor function and could be used in the further development of alogabat. 4.3 behavioral effects of alogabat in animal models relevant to asd we assessed the effects of alogabat in two different mouse models relevant to asd, one phenotypic and one genetic. acute administration of alogabat significantly and dose-dependently attenuated excessive grooming, but not digging, behavior in btbr mice. sub-chronic administration of alogabat significantly attenuated elevated grooming behavior in cntnap2 &#x02212;/&#x02212; mice. efficacy in these different models was linked to gaba a -&#x003b1;5 ro above 50%. despite initial findings of a transiently decreased activity in an open-field test, alogabat increased the activity of btbr mice and had no effect on the activity of cntnap2 &#x02212;/&#x02212; mice during the grooming test, supporting the specific effect of alogabat on repetitive grooming. we have tested additional compounds with similar properties, e.g., ro7015738, and have confirmed that gaba a -&#x003b1;5 pams reduce repetitive behaviors in these mouse models ( buettelmann et al., 2018 ). these results align well with recently published data showing that gaba a -&#x003b1;5 receptor deficiency causes autism-like behaviors in mice, including increased grooming and reduced social contacts ( zurek et al., 2016 ), and with sh-053-2&#x02032;f-r-ch3, a gaba a -&#x003b1;5 pam, which was recently shown to have positive effects on social and cognitive deficits in a rat model of autism ( souza et al., 2024 ). our data are valuable in providing information on the ro required for in vivo effects on repetitive behavior. however, it should be noted that this effect may not directly translate to all individuals with asd as it is a heterogeneous disorder, whereas these mouse models exhibit specific genetic or phenotypic deficits. 4.4 anticonvulsant effects of alogabat it has been proposed that the reduction of gabaergic inhibitory activity results in hyperexcitability of minicolumn circuits, explaining some of the symptomatology observed in some ndds, including the high incidence of seizures and auditory&#x02013;tactile hypersensitivity ( rubenstein and merzenich, 2003 ; frye et al., 2016 ). in the current study, we demonstrated that alogabat exhibits an anticonvulsant profile with activity comparable to the benzodiazepine drug class in acutely induced seizure models (electrical and chemical). alogabat had a small effect on seizures in the mes test, whereas in the ptz test, alogabat was shown to completely block seizures at calculated gaba a -&#x003b1;5 ro &#x0003e;70%. since ptz is a gaba a antagonist, this supports the assessment of alogabat for anticonvulsant activity in disorders where there is dysfunction of the gabaergic system. furthermore, in a separate eeg study, we observed that one out of eight rats had frequent spike-and-wave discharge (swd) activity, which was alleviated following treatment with alogabat (see supplementary figures s3a&#x02013;s3c ; methods in supplementary material ). to better understand the temporal dynamics of swd occurrence and the suppressing effect of alogabat, we performed a follow-up study on three additional rats that showed pronounced swd. both 3 and 10&#x000a0;mg/kg alogabat substantially reduced the number of swds within the first 3&#x000a0;h of recording, when the same rats showed increased swd numbers in the vehicle control condition (see supplementary figures s3d&#x02013;s3f ), which corresponds to the calculated gaba a -&#x003b1;5 ro level of 30%&#x02013;46% (see supplementary table s6 ). from a circuit perspective, the consensus is that such epileptic activity is generated by dysregulated thalamocortical circuitry, with abnormal interactions between reticular thalamic neurons and thalamic relay cells acting as the trigger and cortical circuits serving as the generator ( sitnikova et al., 2023 ). considering that in rats, &#x003b1;5-subunit-containing gaba a receptors are enriched in the cortex and hippocampus ( serwanski et al., 2006 ; hu et al., 2019 ), mediating dendritic inhibition on pyramidal neurons ( ali and thomson, 2008 ; schulz et al., 2018 ), we hypothesize that alogabat could suppress swd generation by enhancing the inhibition of cortical pyramidal neurons. however, more systematic work is required to confirm that alogabat can prevent swd activity. 4.5 assessment of non-specific behavioral effects non-selective gaba a pams, such as diazepam and chlordiazepoxide, are effective anxiolytics in clinical use but have also been shown to impair cognition in rodents and humans. gaba a -&#x003b1;5 receptors are believed to play a major role in cognition since they are predominantly expressed in the hippocampus in rats, where they regulate nmdar-dependent synaptic plasticity underlying learning and memory processes ( schulz et al., 2018 ; fritschy et al., 1997 ; schulz et al., 2019 ; davenport et al., 2021 ). moreover, it has been proposed that gaba a pams may induce memory impairment by modulating hippocampal function ( mcnaughton and morris, 1987 ). therefore, alogabat was evaluated in several rodent tests of cognition to determine whether a selective gaba a -&#x003b1;5 pam would induce cognitive impairment following acute administration in rats. there was no effect of alogabat up to 70% gaba a -&#x003b1;5 ro on cognition (visual&#x02013;spatial memory, attention, context fear conditioning, spatial learning, and memory). cognitive impairment was only observed at high doses (&#x0003e;70% ro) and supra-therapeutic levels of alogabat in associative (fear) learning (cfc) and spatial memory in the mwm in wildtype rats. the impairment at high doses is likely linked to the loss of selectivity toward gaba a &#x003b1;1, &#x003b1;2, and &#x003b1;3 receptor subtypes (&#x003b1;1 ro was calculated as 19%&#x02013;25% at these doses; see supplementary table s6 ). in addition to the loss of selectivity, we cannot exclude the possibility that these effects may be a consequence of gaba a -&#x003b1;5 receptor saturation, i.e., excessive &#x003b1;5 activity in wildtype subjects may be detrimental. the cognitive impairment observed in wildtype rats may translate to healthy human subjects; however, our focus is on the effect of &#x003b1;5 pams in disease conditions with impaired gaba a signaling and impaired cognition, where our hypothesis is that an &#x003b1;5 pam would have beneficial effects. alogabat had no effect on social approach/avoidance, the elevated plus maze, and the vogel conflict test in rats at ro levels up to 80% (see supplementary figure s4 and methods in supplementary material ), suggesting that alogabat does not exhibit an anxiolytic-like effect in rodents. this might be explained by the low expression of gaba a -&#x003b1;5 in the amygdala, a key node controlling anxiety-like behaviors. potential anxiolytic effects of alogabat in humans cannot be excluded as this receptor subtype is much more abundant in the human amygdala. since benzodiazepines, such as diazepam, are frequently used to treat anxiety and seizures in ndds, it was important to establish that alogabat at relevant therapeutic doses in mouse models did not worsen the sedative/motor-impairing effects of diazepam in the rotarod test. alogabat did not worsen diazepam-induced motor impairment; on the contrary, in combination, it reduced the motor impairments, which is more likely due to the more localized and precise inhibitory effect, counterbalancing the broader suppression of neuronal activity by diazepam, or due to lower intrinsic activity at &#x003b1;1 receptors compared to diazepam. we have previously shown that a gaba a -&#x003b1;5 nam, which binds at the benzodiazepine binding site of the receptor, does not decrease the anxiolytic activity of chlordiazepoxide (see supplementary figure s5 ); therefore, it is unlikely that alogabat will interfere with the anxiolytic effect of the classical benzodiazepines. 5 conclusion multiple lines of evidence point to deficits in gabaergic signaling in epilepsy and ndds, such as asd and deletion as, with a prominent role attributed to gaba a receptors, including the gaba a -&#x003b1;5 receptor subtype. the current data for alogabat showed robust dose-dependent efficacy on repetitive behaviors in two disease-relevant mouse models and anti-seizure activity in the ptz rat model at gaba a -&#x003b1;5 ro above 50%. our in vivo occupancy measurements using the selective &#x003b1;5 tracer l-655,708 were highly valuable for understanding plasma and csf exposures (as a surrogate of free brain concentration) and their relationship to in vivo effects. we observed that there was a 34-fold shift between the csf concentration of alogabat in the in vivo occupancy study and that of alogabat in vitro binding data (ki value). the receptor occupancy of alogabat correlates well with pd effects ( in vivo effects) and is consistent across the different studies/species (see supplementary table s6 ). this finding highlights the importance of using pet tracers in drug development. our data suggest that gaba a -&#x003b1;5 pams may have potential benefits in individuals with autistic features and in conditions with clinical and nonclinical manifestations of cortical hyperexcitability and epilepsy. however, alogabat is unlikely to work across all ndds and should be utilized as a precision medicine to target a specific subgroup of the ndd population with deficient gaba a pathway signaling, or specifically gaba a -&#x003b1;5. interestingly, recent data suggest that gaba a -&#x003b1;5 pams may also have therapeutic potential in schizophrenia, alzheimer&#x02019;s disease, and depression ( perez et al., 2023 ; luscher et al., 2023 ; koh et al., 2013 ). with regard to the current status of alogabat, good-laboratory practice (glp) toxicology and safety pharmacology studies in rats and minipigs showed an overall benign safety profile, which supported its clinical investigations in phase-1 studies in healthy volunteers and phase-2 trials in asd and deletion as patients (nct03507569, nct03774576, nct03847987, nct04299464, nct05630066, and eudract&#x00023;2019-003524-20). the outcome of these studies, including pet, eeg, and effects on cognition, will be reported in the future. data availability statement the original contributions presented in the study are included in the article/ supplementary material , further inquiries can be directed to the corresponding author. ethics statement experiments performed at f. hoffmann-la roche ag (basel, switzerland) complied with swiss federal and cantonal laws on animal research and aaalac regulations and received prior approval from the cantonal veterinary office. the eeg study was conducted at brains online (ca, united states) in accordance with the guide for the care and use of laboratory animals (national research council 2011) after receiving approval from the institutional animal care and use committee. the ptz and mes tests were conducted at vivocore inc., canada, which is a facility licensed by the ontario ministry of agriculture, food, and rural affairs and accredited by the canadian council on animal care. all in vivo studies are reported in compliance with the arrive guidelines ( percie du sert et al., 2020 ). the study was conducted in accordance with the local legislation and institutional requirements. author contributions gc: supervision, writing - original draft, investigation, formal analysis. tmb: formal analysis, investigation, writing - review and editing, methodology. fk: formal analysis, writing - original draft, investigation, methodology. mh: writing - original draft, investigation, methodology, formal analysis. jfh: data curation, visualization, methodology, writing - original draft, formal analysis. pg: methodology, data curation, formal analysis, writing - original draft. tm: investigation, writing - original draft, formal analysis, methodology. bk: investigation, writing - original draft, methodology, formal analysis. anb: formal analysis, writing - original draft, data curation. epp: writing - original draft, methodology, investigation. ps: methodology, investigation, writing - original draft, formal analysis. pj: writing - original draft, formal analysis. rr: methodology, writing - original draft, investigation, formal analysis. bb: methodology, investigation, writing - original draft. hk: methodology, writing - original draft, investigation. ao-m: writing - original draft, formal analysis, methodology. alb: methodology, writing - original draft, investigation. jms: investigation, formal analysis, writing - original draft. db: methodology, writing - original draft, investigation. ms: writing - original draft, methodology, investigation. eco&#x00027;c: investigation, writing - original draft, methodology. m-ch: investigation, conceptualization, writing - review and editing, supervision, writing - original draft, methodology. funding the author(s) declare that financial support was received for the research and/or publication of this article. the funding was provided by f. hoffmann-la roche ag switzerland. acknowledgments the authors thank gregoire friz, maria karg, and judith lengyel (molecular biology and binding assays); v&#x000e9;ronique graf, rachel haab, and marie-claire pflimlin ( in vitro electrophysiology); brigitte algeyer, severine bandinelli, sean durkin, audrey genet, marie haman, martine maco, and roger wyler (behavioral pharmacology); and stephanie sch&#x000f6;ppenthau, s&#x000e9;bastien debilly, and thomas bielser ( in vivo phmri). the rat ptz and mes studies were carried out under the scientific guidance of dr guy higgins, intervivo solutions, and coordinated by leo silenieks at vivocore inc., ontario, canada. the rat eeg data acquisition was undertaken by brains on-line llc, south san francisco, united states, and the data analysis was undertaken by pg, vanessa keeney, and andr&#x000e9;s olivares at roche. conflict of interest authors gc, tmb, fk, mh, jfh, pg, tm, bk, ab, epp, ps, pj, rr, bb, hk, ao-m, ab, jms, ms, eco&#x00027;c, and m-ch were employed by f. hoffmann-la roche ag switzerland. all employees (former and current) may be eligible for stock and stock options. author db was employed by hiqscreen s&#x000e0;rl. generative ai statement the author(s) declare that no generative ai was used in the creation of this manuscript. publisher&#x02019;s note all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. supplementary material the supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2025.1626078/full&#x00023;supplementary-material abbreviations as, angelman syndrome; asd, autism spectrum disorder; cfc, context fear conditioning; cntnap2, contactin-associated protein-like 2; cpt, continuous performance test; 5-csrt, 5-choice serial reaction time; eeg, electroencephalography; gaba, gamma-aminobutyric acid; gad, glutamic acid decarboxylase; i.p., intraperitoneally; i.v., intravenously; lfp, local field potential; mes, maximum electrical stimulus; mwm, morris water maze; ndds, neurodevelopmental disorders; pal, paired associates learning; pam, positive allosteric modulator; phmri, pharmacological magnetic resonance imaging; p.o, per os; ptz, pentylenetetrazole; ro, receptor occupancy; pet, positron emission tomography. references abrahams, b. s., and geschwind, d. h. (2008). advances in autism genetics: on the threshold of a new neurobiology. nat. rev. genet. 9, 341&#x02013;355. doi:10.1038/nrg2346 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar ali, a. b., and thomson, a. m. (2008). synaptic alpha 5 subunit-containing gabaa receptors mediate ipsps elicited by dendrite-preferring cells in rat neocortex. cereb. cortex 18, 1260&#x02013;1271. doi:10.1093/cercor/bhm160 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar american psychiatric association (2008). diagnostic and statistical manual of mental disorders . 5th ed. washington: american psychiatric association . google scholar ballard, t. m., knoflach, f., prinssen, e., borroni, e., vivian, j. a., basile, j., et al. (2009). ro4938581, a novel cognitive enhancer acting at gabaa alpha5 subunit-containing receptors. psychopharmacol. berl. 202, 207&#x02013;223. doi:10.1007/s00213-008-1357-7 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar ballard, t. m., woolley, m. l., prinssen, e., huwyler, j., porter, r., and spooren, w. (2005). the effect of the mglu5 receptor antagonist mpep in rodent tests of anxiety and cognition: a comparison. psychopharmacol. berl. 179, 218&#x02013;229. doi:10.1007/s00213-005-2211-9 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar banerjee, a., garcia-oscos, f., roychowdhury, s., galindo, l. c., hall, s., kilgard, m. p., et al. (2013). impairment of cortical gabaergic synaptic transmission in an environmental rat model of autism. int. j. neuropsychopharmacol. 16, 1309&#x02013;1318. doi:10.1017/s1461145712001216 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar bourgeron, t. (2015). from the genetic architecture to synaptic plasticity in autism spectrum disorder. nat. rev. neurosci. 16, 551&#x02013;563. doi:10.1038/nrn3992 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar braat, s., and kooy, r. f. (2015). the gabaa receptor as a therapeutic target for neurodevelopmental disorders. neuron 86, 1119&#x02013;1130. doi:10.1016/j.neuron.2015.03.042 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar bruns, a., kunnecke, b., risterucci, c., moreau, j. l., and von kienlin, m. (2009). validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological mri in rats. magn. reson med. 61, 1451&#x02013;1458. doi:10.1002/mrm.21779 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar buettelmann, b., cecere, g., fasching, b., groebke zbinden, k., hernandez, m.-c., knust, h., et al. (2018). preparation of new isoxazolyl ether derivatives as gabaa &#x003b1;5 receptor positive allosteric modulators (pams) . copyright &#x000a9; 2025 american chemical society acs . available online at: https://worldwide.espacent.com/patent/search/family/057530563/publication/wo2018104419a1?q&#x0003d;wo2018104419a1 google scholar buiting, k. (2010). prader-willi syndrome and angelman syndrome. am. j. med. genet. c semin. med. genet. 154c, 365&#x02013;376. doi:10.1002/ajmg.c.30273 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar chao, h. t., chen, h., samaco, r. c., xue, m., chahrour, m., yoo, j., et al. (2010). dysfunction in gaba signalling mediates autism-like stereotypies and rett syndrome phenotypes. nature 468, 263&#x02013;269. doi:10.1038/nature09582 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar davenport, c. m., rajappa, r., katchan, l., taylor, c. r., tsai, m. c., smith, c. m., et al. (2021). relocation of an extrasynaptic gaba(a) receptor to inhibitory synapses freezes excitatory synaptic strength and preserves memory. neuron 109, 123&#x02013;134 e4. doi:10.1016/j.neuron.2020.09.037 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar delong, r. (2007). gaba(a) receptor alpha5 subunit as a candidate gene for autism and bipolar disorder: a proposed endophenotype with parent-of-origin and gain-of-function features,with or without oculocutaneous albinism. autism 11, 135&#x02013;147. doi:10.1177/1362361307075705 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar delorey, t. m. (2005). gabrb3 gene deficient mice: a potential model of autism spectrum disorder. int. rev. neurobiol. 71, 359&#x02013;382. doi:10.1016/s0074-7742(05)71015-1 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar delorey, t. m., sahbaie, p., hashemi, e., homanics, g. e., and clark, j. d. (2008). gabrb3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: a potential model of autism spectrum disorder. behav. brain res. 187, 207&#x02013;220. doi:10.1016/j.bbr.2007.09.009 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar dhossche, d., applegate, h., abraham, a., maertens, p., bland, l., bencsath, a., et al. (2002). elevated plasma gamma-aminobutyric acid (gaba) levels in autistic youngsters: stimulus for a gaba hypothesis of autism. med. sci. monit. 8, pr1&#x02013;pr6. pubmed abstract &#x0007c; google scholar di nanni, n., bersanelli, m., cupaioli, f. a., milanesi, l., mezzelani, a., and mosca, e. (2019). network-based integrative analysis of genomics, epigenomics and transcriptomics in autism spectrum disorders. int. j. mol. sci. 20, 3363. doi:10.3390/ijms20133363 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar dufour, b. d., mcbride, e., bartley, t., juarez, p., and martinez-cerdeno, v. (2023). distinct patterns of gabaergic interneuron pathology in autism are associated with intellectual impairment and stereotypic behaviors. autism 27, 1730&#x02013;1745. doi:10.1177/13623613231154053 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar fatemi, s. h., halt, a. r., stary, j. m., kanodia, r., schulz, s. c., and realmuto, g. r. (2002). glutamic acid decarboxylase 65 and 67 kda proteins are reduced in autistic parietal and cerebellar cortices. biol. psychiatry 52, 805&#x02013;810. doi:10.1016/s0006-3223(02)01430-0 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar friedman, h., greenblatt, d. j., peters, g. r., metzler, c. m., charlton, m. d., harmatz, j. s., et al. (1992). pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. clin. pharmacol. ther. 52, 139&#x02013;150. doi:10.1038/clpt.1992.123 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar fritschy, j. m., benke, d., johnson, d. k., mohler, h., and rudolph, u. (1997). gabaa-receptor alpha-subunit is an essential prerequisite for receptor formation in vivo . neuroscience 81, 1043&#x02013;1053. doi:10.1016/s0306-4522(97)00244-3 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar frohlich, j., miller, m. t., bird, l. m., garces, p., purtell, h., hoener, m. c., et al. (2019a). electrophysiological phenotype in angelman syndrome differs between genotypes. biol. psychiatry 85, 752&#x02013;759. doi:10.1016/j.biopsych.2019.01.008 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar frohlich, j., reiter, l. t., saravanapandian, v., distefano, c., huberty, s., hyde, c., et al. (2019b). mechanisms underlying the eeg biomarker in dup15q syndrome. mol. autism 10, 29. doi:10.1186/s13229-019-0280-6 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar frye, r. e., casanova, m. f., fatemi, s. h., folsom, t. d., reutiman, t. j., brown, g. l., et al. (2016). neuropathological mechanisms of seizures in autism spectrum disorder. front. neurosci. 10, 192. doi:10.3389/fnins.2016.00192 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar fukuda, t., itoh, m., ichikawa, t., washiyama, k., and goto, y. (2005). delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of mecp2-deficient mice. j. neuropathol. exp. neurol. 64, 537&#x02013;544. doi:10.1093/jnen/64.6.537 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar gaetz, w., bloy, l., wang, d. j., port, r. g., blaskey, l., levy, s. e., et al. (2014). gaba estimation in the brains of children on the autism spectrum: measurement precision and regional cortical variation. neuroimage 86, 1&#x02013;9. doi:10.1016/j.neuroimage.2013.05.068 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar han, s., tai, c., jones, c. j., scheuer, t., and catterall, w. a. (2014). enhancement of inhibitory neurotransmission by gabaa receptors having &#x003b1;2,3-subunits ameliorates behavioral deficits in a mouse model of autism. neuron 81, 1282&#x02013;1289. doi:10.1016/j.neuron.2014.01.016 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar han, s., tai, c., westenbroek, r. e., yu, f. h., cheah, c. s., potter, g. b., et al. (2012). autistic-like behaviour in scn1a&#x0002b;/- mice and rescue by enhanced gaba-mediated neurotransmission. nature 489, 385&#x02013;390. doi:10.1038/nature11356 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar hipp, j. f., knoflach, f., comley, r., ballard, t. m., honer, m., trube, g., et al. (2021). basmisanil, a highly selective gaba a -&#x003b1;5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man. sci. rep. 11, 7700. doi:10.1038/s41598-021-87307-7 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar hogart, a., wu, d., lasalle, j. m., and schanen, n. c. (2010). the comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. neurobiol. dis. 38, 181&#x02013;191. doi:10.1016/j.nbd.2008.08.011 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar hu, x., rocco, b. r., fee, c., and sibille, e. (2019). cell type-specific gene expression of alpha 5 subunit-containing gamma-aminobutyric acid subtype a receptors in human and mouse frontal cortex. mol. neuropsychiatry 4, 204&#x02013;215. doi:10.1159/000495840 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar hvoslef-eide, m., nilsson, s. r., saksida, l. m., and bussey, t. j. (2016). cognitive translation using the rodent touchscreen testing approach. curr. top. behav. neurosci. 28, 423&#x02013;447. doi:10.1007/7854_2015_5007 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar kalsner, l., and chamberlain, s. j. (2015). prader-willi, angelman, and 15q11-q13 duplication syndromes. pediatr. clin. north am. 62, 587&#x02013;606. doi:10.1016/j.pcl.2015.03.004 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar koh, m. t., rosenzweig-lipson, s., and gallagher, m. (2013). selective gaba(a) &#x003b1;5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. neuropharmacology 64, 145&#x02013;152. doi:10.1016/j.neuropharm.2012.06.023 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar lim, c. s., kim, h., yu, n. k., kang, s. j., kim, t., ko, h. g., et al. (2017). enhancing inhibitory synaptic function reverses spatial memory deficits in shank2 mutant mice. neuropharmacology 112, 104&#x02013;112. doi:10.1016/j.neuropharm.2016.08.016 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar luk, h. m., and lo, i. f. (2016). angelman syndrome in hong kong chinese: a 20 years&#x00027; experience. eur. j. med. genet. 59, 315&#x02013;319. doi:10.1016/j.ejmg.2016.05.003 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar luscher, b., maguire, j. l., rudolph, u., and sibille, e. (2023). gaba(a) receptors as targets for treating affective and cognitive symptoms of depression. trends pharmacol. sci. 44, 586&#x02013;600. doi:10.1016/j.tips.2023.06.009 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mcfarlane, h. g., kusek, g. k., yang, m., phoenix, j. l., bolivar, v. j., and crawley, j. n. (2008). autism-like behavioral phenotypes in btbr t&#x0002b;tf/j mice. genes brain behav. 7, 152&#x02013;163. doi:10.1111/j.1601-183x.2007.00330.x pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mcnaughton, n., and morris, r. g. (1987). chlordiazepoxide, an anxiolytic benzodiazepine, impairs place navigation in rats. behav. brain res. 24, 39&#x02013;46. doi:10.1016/0166-4328(87)90034-9 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mendez, m. a., horder, j., myers, j., coghlan, s., stokes, p., erritzoe, d., et al. (2013). the brain gaba-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)c]ro15-4513 positron emission tomography study. neuropharmacology 68, 195&#x02013;201. doi:10.1016/j.neuropharm.2012.04.008 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mermer, f., poliquin, s., rigsby, k., rastogi, a., shen, w., romero-morales, a., et al. (2021). common molecular mechanisms of slc6a1 variant-mediated neurodevelopmental disorders in astrocytes and neurons. brain 144, 2499&#x02013;2512. doi:10.1093/brain/awab207 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mertz, l. g., christensen, r., vogel, i., hertz, j. m., nielsen, k. b., gronskov, k., et al. (2013). angelman syndrome in denmark. birth incidence, genetic findings, and age at diagnosis. am. j. med. genet. a 161a, 2197&#x02013;2203. doi:10.1002/ajmg.a.36058 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mesbah-oskui, l., penna, a., orser, b. a., and horner, r. l. (2017). reduced expression of &#x003b1;5gaba a receptors elicits autism-like alterations in eeg patterns and sleep-wake behavior. neurotoxicol teratol. 61, 115&#x02013;122. doi:10.1016/j.ntt.2016.10.009 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mohler, h. (2011). the rise of a new gaba pharmacology. neuropharmacology 60, 1042&#x02013;1049. doi:10.1016/j.neuropharm.2010.10.020 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mori, t., mori, k., fujii, e., toda, y., miyazaki, m., harada, m., et al. (2012). evaluation of the gabaergic nervous system in autistic brain: (123)i-iomazenil spect study. brain dev. 34, 648&#x02013;654. doi:10.1016/j.braindev.2011.10.007 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar myers, j. f., comley, r. a., and gunn, r. n. (2017). quantification of [ 11 c]ro15-4513 gaba a &#x003b1;5 specific binding and regional selectivity in humans. j. cereb. blood flow. metab. 37, 2137&#x02013;2148. doi:10.1177/0271678x16661339 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar nakamura, t., arima-yoshida, f., sakaue, f., nasu-nishimura, y., takeda, y., matsuura, k., et al. (2016). px-rics-deficient mice mimic autism spectrum disorder in jacobsen syndrome through impaired gabaa receptor trafficking. nat. commun. 7, 10861. doi:10.1038/ncomms10861 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar orefice, l. l., zimmerman, a. l., chirila, a. m., sleboda, s. j., head, j. p., and ginty, d. d. (2016). peripheral mechanosensory neuron dysfunction underlies tactile and behavioral deficits in mouse models of asds. cell 166, 299&#x02013;313. doi:10.1016/j.cell.2016.05.033 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar penagarikano, o., abrahams, b. s., herman, e. i., winden, k. d., gdalyahu, a., dong, h., et al. (2011). absence of cntnap2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. cell 147, 235&#x02013;246. doi:10.1016/j.cell.2011.08.040 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar percie du sert, n., hurst, v., ahluwalia, a., alam, s., avey, m. t., baker, m., et al. (2020). the arrive guidelines 2.0: updated guidelines for reporting animal research. plos biol. 18, e3000410. doi:10.1371/journal.pbio.3000410 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar perez, s. m., mccoy, a. m., prevot, t. d., mian, m. y., carreno, f. r., frazer, a., et al. (2023). hippocampal &#x003b1;5-gaba(a) receptors modulate dopamine neuron activity in the rat ventral tegmental area. biol. psychiatry glob. open sci. 3, 78&#x02013;86. doi:10.1016/j.bpsgos.2021.12.010 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar pirker, s., schwarzer, c., wieselthaler, a., sieghart, w., and sperk, g. (2000). gaba(a) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. neuroscience 101, 815&#x02013;850. doi:10.1016/s0306-4522(00)00442-5 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar pizzarelli, r., and cherubini, e. (2011). alterations of gabaergic signaling in autism spectrum disorders. neural plast. 2011, 297153. doi:10.1155/2011/297153 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar porjesz, b., almasy, l., edenberg, h. j., wang, k., chorlian, d. b., foroud, t., et al. (2002). linkage disequilibrium between the beta frequency of the human eeg and a gabaa receptor gene locus. proc. natl. acad. sci. u. s. a. 99, 3729&#x02013;3733. doi:10.1073/pnas.052716399 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar puts, n. a. j., wodka, e. l., harris, a. d., crocetti, d., tommerdahl, m., mostofsky, s. h., et al. (2017). reduced gaba and altered somatosensory function in children with autism spectrum disorder. autism res. 10, 608&#x02013;619. doi:10.1002/aur.1691 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar robertson, c. e., ratai, e. m., and kanwisher, n. (2016). reduced gabaergic action in the autistic brain. curr. biol. 26, 80&#x02013;85. doi:10.1016/j.cub.2015.11.019 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar rojas, d. c., singel, d., steinmetz, s., hepburn, s., and brown, m. s. (2014). decreased left perisylvian gaba concentration in children with autism and unaffected siblings. neuroimage 86, 28&#x02013;34. doi:10.1016/j.neuroimage.2013.01.045 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar rubenstein, j. l., and merzenich, m. m. (2003). model of autism: increased ratio of excitation/inhibition in key neural systems. genes brain behav. 2, 255&#x02013;267. doi:10.1034/j.1601-183x.2003.00037.x pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar sanders, s. j. (2015). first glimpses of the neurobiology of autism spectrum disorder. curr. opin. genet. dev. 33, 80&#x02013;92. doi:10.1016/j.gde.2015.10.002 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2018). dendrite-targeting interneurons control synaptic nmda-receptor activation via nonlinear &#x003b1;5-gaba a receptors. nat. commun. 9, 3576. doi:10.1038/s41467-018-06004-8 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2019). enhanced dendritic inhibition and impaired nmdar activation in a mouse model of down syndrome. j. neurosci. 39, 5210&#x02013;5221. doi:10.1523/jneurosci.2723-18.2019 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar serwanski, d. r., miralles, c. p., christie, s. b., mehta, a. k., li, x., and de blas, a. l. (2006). synaptic and nonsynaptic localization of gabaa receptors containing the alpha5 subunit in the rat brain. j. comp. neurol. 499, 458&#x02013;470. doi:10.1002/cne.21115 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar sieghart, w. (2006). structure, pharmacology, and function of gabaa receptor subtypes. adv. pharmacol. 54, 231&#x02013;263. doi:10.1016/s1054-3589(06)54010-4 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar sitnikova, e., rutskova, e., and smirnov, k. (2023). alpha2-adrenergic receptors as a pharmacological target for spike-wave epilepsy. int. j. mol. sci. 24, 1477. doi:10.3390/ijms24021477 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar smit, d. j. a., wright, m. j., meyers, j. l., martin, n. g., ho, y. y. w., malone, s. m., et al. (2018). genome-wide association analysis links multiple psychiatric liability genes to oscillatory brain activity. hum. brain mapp. 39, 4183&#x02013;4195. doi:10.1002/hbm.24238 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar souza, a. j., freitas, i. s., sharmin, d., cook, j. m., guimaraes, f. s., and gomes, f. v. (2024). an alpha 5-gaba(a) receptor positive allosteric modulator attenuates social and cognitive deficits without changing dopamine system hyperactivity in rats exposed to valproic acid in utero. autism res. 17, 1534&#x02013;1544. doi:10.1002/aur.3178 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar sur, c., fresu, l., howell, o., mckernan, r. m., and atack, j. r. (1999). autoradiographic localization of alpha5 subunit-containing gabaa receptors in rat brain. brain res. 822, 265&#x02013;270. doi:10.1016/s0006-8993(99)01152-x pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar traub, r. d. w. m., and jefferys, j. g. r. (1999). fast oscillations in cortical circuits . the mit press . google scholar van lier, h., drinkenburg, w. h., van eeten, y. j., and coenen, a. m. (2004). effects of diazepam and zolpidem on eeg beta frequencies are behavior-specific in rats. neuropharmacology 47, 163&#x02013;174. doi:10.1016/j.neuropharm.2004.03.017 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar visser, s. a., wolters, f. l., gubbens-stibbe, j. m., tukker, e., van der graaf, p. h., peletier, l. a., et al. (2003). mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of gabaa receptor modulators: in vitro-in vivo correlations. j. pharmacol. exp. ther. 304, 88&#x02013;101. doi:10.1124/jpet.102.042341 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar vithlani, m., terunuma, m., and moss, s. j. (2011). the dynamic modulation of gaba(a) receptor trafficking and its role in regulating the plasticity of inhibitory synapses. physiol. rev. 91, 1009&#x02013;1022. doi:10.1152/physrev.00015.2010 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar warrier, v., baron-cohen, s., and chakrabarti, b. (2013). genetic variation in gabrb3 is associated with asperger syndrome and multiple endophenotypes relevant to autism. mol. autism 4, 48. doi:10.1186/2040-2392-4-48 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar whittington, m. a., traub, r. d., kopell, n., ermentrout, b., and buhl, e. h. (2000). inhibition-based rhythms: experimental and mathematical observations on network dynamics. int. j. psychophysiol. 38, 315&#x02013;336. doi:10.1016/s0167-8760(00)00173-2 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar xie, x. h., and tietz, e. i. (1991). chronic benzodiazepine treatment of rats induces reduction of paired-pulse inhibition in ca1 region of in vitro hippocampus. brain res. 561, 69&#x02013;76. doi:10.1016/0006-8993(91)90750-p pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar zurek, a. a., kemp, s. w., aga, z., walker, s., milenkovic, m., ramsey, a. j., et al. (2016). &#x003b1;5gabaa receptor deficiency causes autism-like behaviors. ann. clin. transl. neurol. 3, 392&#x02013;398. doi:10.1002/acn3.303 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar keywords: autism spectrum disorder, angelman syndrome, gaba a , gaba a -&#x003b1;5, positron emission tomography (pet), electroencephalography, pharmacological mri, biomarker citation: cecere g, ballard tm, knoflach f, honer m, hipp jf, garces p, mueggler t, k&#x000fc;nnecke b, bruns a, prinssen ep, schoenenberger p, janz p, redondo r, biemans b, knust h, olivares-morales a, brigo a, schulz jm, bertrand d, saxe m, o&#x02019;connor ec and hernandez m-c (2025) preclinical pharmacology of alogabat: a novel gaba a -&#x003b1;5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gaba a signaling. front. pharmacol. 16:1626078. doi: 10.3389/fphar.2025.1626078 received: 09 may 2025; accepted: 18 june 2025; published: 21 july 2025. edited by: agenor limon , university of texas medical branch at galveston, united states reviewed by: hansen wang , university of toronto, canada junzhan jing , baylor college of medicine, united states azar omrani , boehringer ingelheim, germany copyright &#x000a9; 2025 cecere, ballard, knoflach, honer, hipp, garces, mueggler, k&#x000fc;nnecke, bruns, prinssen, schoenenberger, janz, redondo, biemans, knust, olivares-morales, brigo, schulz, bertrand, saxe, o&#x02019;connor and hernandez. this is an open-access article distributed under the terms of the creative commons attribution license (cc by). the use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. no use, distribution or reproduction is permitted which does not comply with these terms. &#x0002a;correspondence: maria-clemencia hernandez, bwfyawety2xlbwvuy2lhlmhlcm5hbmrlekbyb2nozs5jb20= &#x02020; these authors have contributed equally to this work &#x02021; present address: theresa m. ballard, galwyn (uk) ltd., dartmouth, united kingdom barbara biemans, b2discovery llc, riehen, switzerland michael saxe, translational in vivo sciences, biogen, cambridge, ma, united states disclaimer: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. download article download pdf readcube epub xml share on export citation endnote reference manager simple text file bibtex 2,218 total views 442 downloads citation numbers are available from dimensions view article impact view altmetric score share on edited by a l agenor limon reviewed by j j junzhan jing a o azar omrani h w hansen wang table of contents abstract 1 introduction 2 materials and methods 3 results 4 discussion 5 conclusion data availability statement ethics statement author contributions funding acknowledgments conflict of interest generative ai statement publisher&#x02019;s note supplementary material abbreviations references export citation endnote reference manager simple text file bibtex check for updates frontiers&#39; impact articles published with frontiers have received 12 million total citations your research is the real superpower - learn how we maximise its impact through our leading community journals explore our impact metrics supplementary material download article download download pdf readcube epub xml guidelines author guidelines services for authors policies and publication ethics editor guidelines fee policy explore articles research topics journals how we publish outreach frontiers forum frontiers policy labs frontiers for young minds frontiers planet prize connect help center emails and alerts contact us submit career opportunities follow us © 2025 frontiers media s.a. all rights reserved privacy policy | terms and conditions [["shallowreactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverrendered":13,"path":14,"pinia":15},["shallowreactive",3],{},["reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","frontiers articles","https://article-pages-2024.frontiersin.org/",["set"],["shallowreactive",12],{},true,"/journals/pharmacology/articles/10.3389/fphar.2025.1626078/full",["reactive",16],{"main":17,"user":511,"article":512,"articlehub":968,"mainheader":972},{"ibar":18,"footer":264,"newslettercomponent":-1,"snackbaritem":346,"toggleshowsnackbar":347,"contentfuljournal":348,"graphjournal":412,"settingsfeaturesswitchers":416,"templatetogglebanner":417,"tenantconfig":476},{"tenantlogo":19,"journallogo":19,"aboutus":20,"submiturl":113,"showsubmitbutton":13,"journal":114,"sectionterm":195,"aboutjournal":196,"mainlinks":245,"journallinks":252,"helpcenterlink":261},"",[21,38,47,71,87],{"title":22,"links":23},"who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"arialabel":28},"mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"arialabel":28},"history","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"arialabel":28},"leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"arialabel":28},"awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"impact and progress",[41,44],{"text":42,"url":43,"target":27,"arialabel":28},"frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"arialabel":28},"our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"arialabel":28},"how we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"arialabel":28},"open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"arialabel":28},"peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"arialabel":28},"research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"arialabel":28},"research topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"arialabel":28},"fair² data management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"arialabel":28},"fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"services",[74,78,81,84],{"text":75,"url":76,"target":77,"arialabel":28},"societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"arialabel":28},"national consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"arialabel":28},"institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"arialabel":28},"collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"more from frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"arialabel":93},"frontiers forum","https://forum.frontiersin.org/","this link will take you to the frontiers forum website",{"text":95,"url":96,"target":27,"arialabel":28},"frontiers planet prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"arialabel":100},"press office","https://pressoffice.frontiersin.org/","this link will take you to the frontiers press office website",{"text":102,"url":103,"target":27,"arialabel":104},"sustainability","https://www.frontiersin.org/about/sustainability","link to information about frontiers' sustainability",{"text":106,"url":107,"target":77,"arialabel":108},"career opportunities","https://careers.frontiersin.org/","this link will take you to the frontiers careers website",{"text":110,"url":111,"target":27,"arialabel":112},"contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=1&fieldid=62&specialtyid=0&entitytype=2&entityid=176",{"id":115,"name":116,"slug":117,"sections":118},176,"frontiers in pharmacology","pharmacology",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191],{"id":120,"name":121,"slug":122},182,"cardiovascular and smooth muscle pharmacology","cardiovascular-and-smooth-muscle-pharmacology",{"id":124,"name":125,"slug":126},199,"drug metabolism and transport","drug-metabolism-and-transport",{"id":128,"name":129,"slug":130},202,"drugs outcomes research and policies","drugs-outcomes-research-and-policies",{"id":132,"name":133,"slug":134},184,"ethnopharmacology","ethnopharmacology",{"id":136,"name":137,"slug":138},183,"experimental pharmacology and drug discovery","experimental-pharmacology-and-drug-discovery",{"id":140,"name":141,"slug":142},186,"gastrointestinal and hepatic pharmacology","gastrointestinal-and-hepatic-pharmacology",{"id":144,"name":145,"slug":146},188,"inflammation pharmacology","inflammation-pharmacology",{"id":148,"name":149,"slug":150},178,"integrative and regenerative pharmacology","integrative-and-regenerative-pharmacology",{"id":152,"name":153,"slug":154},26,"neuropharmacology","neuropharmacology",{"id":156,"name":157,"slug":158},196,"obstetric and pediatric pharmacology","obstetric-and-pediatric-pharmacology",{"id":160,"name":161,"slug":162},2186,"pharmacoepidemiology","pharmacoepidemiology",{"id":164,"name":165,"slug":166},198,"pharmacogenetics and pharmacogenomics","pharmacogenetics-and-pharmacogenomics",{"id":168,"name":169,"slug":170},192,"pharmacology of anti-cancer drugs","pharmacology-of-anti-cancer-drugs",{"id":172,"name":173,"slug":174},2216,"pharmacology of infectious diseases","pharmacology-of-infectious-diseases",{"id":176,"name":177,"slug":178},179,"pharmacology of ion channels and channelopathies","pharmacology-of-ion-channels-and-channelopathies",{"id":180,"name":181,"slug":182},195,"predictive toxicology","predictive-toxicology",{"id":184,"name":185,"slug":186},1357,"renal pharmacology","renal-pharmacology",{"id":188,"name":189,"slug":190},190,"respiratory pharmacology","respiratory-pharmacology",{"id":192,"name":193,"slug":194},1251,"translational pharmacology","translational-pharmacology","sections",[197,221],{"title":198,"links":199},"scope",[200,203,206,209,212,215,218],{"text":201,"url":202,"target":27,"arialabel":28},"field chief editors","https://www.frontiersin.org/journals/pharmacology/about#about-editors",{"text":204,"url":205,"target":27,"arialabel":28},"mission & scope","https://www.frontiersin.org/journals/pharmacology/about#about-scope",{"text":207,"url":208,"target":27,"arialabel":28},"facts","https://www.frontiersin.org/journals/pharmacology/about#about-facts",{"text":210,"url":211,"target":27,"arialabel":28},"journal sections","https://www.frontiersin.org/journals/pharmacology/about#about-submission",{"text":213,"url":214,"target":27,"arialabel":28},"open access statement","https://www.frontiersin.org/journals/pharmacology/about#about-open",{"text":216,"url":217,"target":27,"arialabel":28},"copyright statement","https://www.frontiersin.org/journals/pharmacology/about#copyright-statement",{"text":219,"url":220,"target":27,"arialabel":28},"quality","https://www.frontiersin.org/journals/pharmacology/about#about-quality",{"title":222,"links":223},"for authors",[224,227,230,233,236,239,242],{"text":225,"url":226,"target":27,"arialabel":28},"why submit?","https://www.frontiersin.org/journals/pharmacology/for-authors/why-submit",{"text":228,"url":229,"target":27,"arialabel":28},"article types","https://www.frontiersin.org/journals/pharmacology/for-authors/article-types",{"text":231,"url":232,"target":27,"arialabel":28},"author guidelines","https://www.frontiersin.org/journals/pharmacology/for-authors/author-guidelines",{"text":234,"url":235,"target":27,"arialabel":28},"editor guidelines","https://www.frontiersin.org/journals/pharmacology/for-authors/editor-guidelines",{"text":237,"url":238,"target":27,"arialabel":28},"publishing fees","https://www.frontiersin.org/journals/pharmacology/for-authors/publishing-fees",{"text":240,"url":241,"target":27,"arialabel":28},"submission checklist","https://www.frontiersin.org/journals/pharmacology/for-authors/submission-checklist",{"text":243,"url":244,"target":27,"arialabel":28},"contact editorial office","https://www.frontiersin.org/journals/pharmacology/for-authors/contact-editorial-office",[246,249],{"text":247,"url":248,"target":27,"arialabel":28},"all journals","https://www.frontiersin.org/journals",{"text":250,"url":251,"target":27,"arialabel":28},"all articles","https://www.frontiersin.org/articles",[253,256,258],{"text":254,"url":255,"target":27,"arialabel":28},"articles","articles",{"text":63,"url":257,"target":27,"arialabel":28},"research-topics",{"text":259,"url":260,"target":27,"arialabel":28},"editorial board","editors",{"text":262,"url":263,"target":77,"arialabel":262},"help center","https://helpcenter.frontiersin.org",{"blocks":265,"sociallinks":319,"copyright":343,"termsandconditionsurl":344,"privacypolicyurl":345},[266,280,290,304],{"title":267,"links":268},"guidelines",[269,271,274,277,279],{"text":231,"url":270,"target":27,"arialabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":272,"url":273,"target":27,"arialabel":28},"services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":275,"url":276,"target":27,"arialabel":28},"policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":234,"url":278,"target":27,"arialabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"arialabel":28},{"title":281,"links":282},"explore",[283,284,287,289],{"text":254,"url":251,"target":27,"arialabel":28},{"text":285,"url":286,"target":27,"arialabel":28},"research topics ","https://www.frontiersin.org/research-topics",{"text":288,"url":248,"target":27,"arialabel":28},"journals",{"text":51,"url":52,"target":27,"arialabel":28},{"title":291,"links":292},"outreach",[293,296,299,303],{"text":294,"url":92,"target":77,"arialabel":295},"frontiers forum ","frontiers forum website",{"text":297,"url":298,"target":77,"arialabel":28},"frontiers policy labs ","https://policylabs.frontiersin.org/",{"text":300,"url":301,"target":77,"arialabel":302},"frontiers for young minds","https://kids.frontiersin.org/","frontiers for young minds journal",{"text":95,"url":96,"target":27,"arialabel":28},{"title":305,"links":306},"connect",[307,308,312,315,318],{"text":262,"url":263,"target":77,"arialabel":262},{"text":309,"url":310,"target":77,"arialabel":311},"emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","subscribe to frontiers emails",{"text":313,"url":111,"target":27,"arialabel":314},"contact us ","subscribe to newsletter",{"text":316,"url":317,"target":27,"arialabel":28},"submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"arialabel":28},[320,328,333,338],{"link":321,"type":324,"color":325,"icon":326,"size":327,"hiddentext":13},{"text":322,"url":323,"target":77,"arialabel":322},"frontiers facebook","https://www.facebook.com/frontiersin","link","grey","facebook","medium",{"link":329,"type":324,"color":325,"icon":332,"size":327,"hiddentext":13},{"text":330,"url":331,"target":77,"arialabel":28},"frontiers twitter","https://twitter.com/frontiersin","twitter",{"link":334,"type":324,"color":325,"icon":337,"size":327,"hiddentext":13},{"text":335,"url":336,"target":77,"arialabel":28},"frontiers linkedin","https://www.linkedin.com/company/frontiers","linkedin",{"link":339,"type":324,"color":325,"icon":342,"size":327,"hiddentext":13},{"text":340,"url":341,"target":77,"arialabel":28},"frontiers instagram","https://www.instagram.com/frontiersin_","instagram","frontiers media s.a. all rights reserved","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":349,"identifier":115,"name":116,"slug":117,"banner":350,"description":405,"mission":406,"palette":407,"impactfactor":408,"citescore":409,"citations":410,"showtagline":28,"twitter":411},"journal",[351],{"id":352,"src":353,"name":354,"tags":355,"type":363,"width":364,"height":365,"idhash":366,"archive":367,"brandid":368,"limited":367,"filesize":369,"ispublic":370,"original":371,"copyright":372,"extension":373,"thumbnails":375,"datecreated":383,"description":384,"orientation":385,"usercreated":386,"watermarked":367,"datemodified":383,"datepublished":387,"ecsarchivefiles":388,"propertyoptions":389,"property_channel":394,"property_sub-type":396,"property_asset_type":398,"activeoriginalfocuspoint":400,"property_office_department":403},"754e12a9-443f-4ea8-ab01e0811e45131d","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/webimage-9d720582-24ad-4d2e-9205ab9d241919da.jpg","fphar_main visual_purple_website",[356,357,358,359,360,361,362],"pain","medical","pharmaceutical","antibiotic","concept","capsule","treatment","image",5844,3896,"79b643019a2651e0",0,"22c10171-81b3-4da6-99342f272a32e8bb",8675243,1,"https://brand.frontiersin.org/m/79b643019a2651e0/original/fphar_main-visual_purple_website.jpeg","copyright (c) 2017 marian weyo/shutterstock. no use without permission.",[374],"jpeg",{"mini":376,"thul":377,"webimage":353,"guidelines":378,"websitejpg_xl":379,"websitewebp_l":380,"websitewebp_m":381,"websitewebp_xl":382},"https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/mini-97eef455-249b-43bd-9d8f02fee86046d3.jpg","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/thul-b2dbd910-1ddf-4ed3-b1500df973953144.jpg","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/guidelines-fphar_main visual_purple_website.png","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitejpg_xl-fphar_main visual_purple_website.jpg","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitewebp_l-fphar_main visual_purple_website.webp","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitewebp_m-fphar_main visual_purple_website.webp","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitewebp_xl-fphar_main visual_purple_website.webp","2022-06-27t10:00:45z","pills tablets capsule or medicament freely laid on glass background.","landscape","caroline sutter","2022-06-27t09:27:09z",[],[390,391,392,393],"414fb2d4-2283-43fd-be14e534eca67928","6c18119b-14bd-4951-b437696f4357bd33","7c692885-db25-4858-b1fb4ff47b241e9b","d88c0047-ec30-4506-a7df28a4d765e1cf",[395],"frontiersin_org",[397],"main_visual",[399],"photography",{"x":401,"y":402},2922,1948,[404],"publishing","the world's most cited pharmacology and pharmacy journal, advancing global pharmacological discoveries to prevent and treat human disease.","\u003cp>frontiers in pharmacology is an interdisciplinary journal that publishes research on the interactions between drugs and living beings to prevent and cure human disease.\u003c/p>\n\n\u003cp>led by field chief editor heike wulff (university of california, davis, us), frontiers in pharmacology explores basic and clinical pharmacology, medicinal chemistry, pharmacy, and toxicology to clarify the fundamental processes of disease treatment and drug effects. indexed in pubmed central (pmc), scopus, web of science (scie), and the doaj, the journal welcomes academic, industrial, and clinical work focused on pharmacology.\u003c/p>\n\n\u003cp>topics include, but are not limited to:\u003c/p>\n\u003cul>\n \u003cli>cardiovascular and smooth muscle pharmacology\u003c/li>\n \u003cli>drug metabolism and transport\u003c/li>\n \u003cli>drugs outcomes research and policies\u003c/li>\n \u003cli>elsi in science and genetics\u003c/li>\n \u003cli>ethnopharmacology\u003c/li>\n \u003cli>experimental pharmacology and drug discovery\u003c/li>\n \u003cli>gastrointestinal and hepatic pharmacology\u003c/li>\n \u003cli>inflammation pharmacology\u003c/li>\n \u003cli>integrative and regenerative pharmacology\u003c/li>\n \u003cli>neuropharmacology\u003c/li>\n \u003cli>obstetric and pediatric pharmacology\u003c/li>\n \u003cli>pharmacoepidemiology\u003c/li>\n \u003cli>pharmacogenetics and pharmacogenomics\u003c/li>\n \u003cli>pharmacology of anti-cancer drugs\u003c/li>\n \u003cli>pharmacology of infectious diseases\u003c/li>\n \u003cli>pharmacology of ion channels and channelopathies\u003c/li>\n \u003cli>predictive toxicology\u003c/li>\n \u003cli>renal pharmacology\u003c/li>\n \u003cli>respiratory pharmacology\u003c/li>\n \u003cli>translational pharmacology.\u003c/li>\n\u003c/ul>\n\n\u003cp>all submissions to the journal involving natural products, including plant extracts or preparations, must adhere to \u003ci>'the four pillars of ethnopharmacology'\u003c/i> to be considered for peer review, regardless of the specialty section, as a baseline standard for sample characterization. these are a set of mandatory guidelines designed to maintain the scientific, cultural, and ethical integrity of the journal, and describe what the leading journals in the field consider as the basic aspects of good research (full conphymp statement available \u003ca href=\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.953205/full\" target=\"_blank\">here\u003c/a>, conphymp statement overview \u003ca href=\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1338710/full\" target=\"_blank\">here\u003c/a>, and ga-tool \u003ca href=\"https://ga-online.org/best-practice/\" target=\"_blank\">here\u003c/a>). please refer to the \u003ca href=\"https://assets.ctfassets.net/41vi7p4898pd/63dcrrxgncg4b1stfayeh8/1b87b9a742b0610ace5b19fd11f62359/four_pillars_ethnopharmacology_2025.pdf\" target=\"_blank\">full version\u003c/a> of these guidelines before submitting a manuscript to the journal.\u003c/p> \n\u003cp>to be considered for publication in frontiers in pharmacology, studies incorporating complementary or alternative medicine must be based on a set of data linked to local or traditional uses that can be evaluated pharmacologically. a clear and plausible set of pharmacological data must be generated in these studies. similarly, the journal endorses protocols including a minimum of 2 cell-lines in vitro as an evidential basis to demonstrate proposed anti-cancer effects in all relevant studies submitted to all specialty sections in the journal.\u003c/p>\n\u003cp>isolated data mining studies using disproportionality analyses of databases containing spontaneously reported adverse events, frequently lead to misinterpretation due to various reporting biases, lack of structured control, and insufficient demographic details. presenting such analyses in isolation typically does not yield clinically actionable safety findings without the broader context of a comprehensive signal evaluation. to ensure rigor and relevance, all submissions to the journal must be complemented by a proper systematic review and/or thorough analyses of reported cases, and adhere to the readus-pv guidelines (\u003ca href=\"https://www.equator-network.org/reporting-guidelines/the-reporting-of-a-disproportionality-analysis-for-drug-safety-signal-detection-using-individual-case-safety-reports-in-pharmacovigilance-readus-pv-development-and-statement/\" target=\"_blank\">the reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance\u003c/a>). authors are expected to ensure compliance with the corresponding \u003ca href=\"https://readus-statement.org/wp-content/uploads/2024/03/readus-checklist.pdf\" target=\"_blank\">checklist\u003c/a> before proceeding with submission to the journal. full publication of the readus-pv guidelines is available \u003ca href=\"https://pmc.ncbi.nlm.nih.gov/articles/pmc11116242/pdf/40264_2024_article_1421.pdf\" target=\"_blank\">here\u003c/a>.\u003c/p>\n\n\u003cp>frontiers’ journals require that manuscripts primarily comprising computational studies of public data, such as nhanes or mendelian randomization studies, must include appropriate validation. please refer to the \u003ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology:~:text=complaints%20and%20allegations.-,standards%20for%20research%20methodology,-experiments\">frontiers standards for research methodology policy\u003c/a>, for more information. manuscripts not adhering to these standards will not be considered.\u003cp>\n\n\u003cp>further unique criteria for the conception and review of submissions may apply, where appropriate, for individual specialty sections.\u003c/p>\n\n\u003cp>the journal welcomes submissions that support and advance the \u003ca href=\"https://www.globalgoals.org/goals/\" target=\"_blank\">un sustainable development goals\u003c/a> (sdgs), notably the \u003ca href=\"https://www.globalgoals.org/goals/3-good-health-and-well-being/\" target=\"_blank\">sdg 3: good health and well-being\u003c/a>.\u003c/p>\n\n\u003cp>manuscripts that focus solely on clinical trials, patient management, or conventional therapies without a focus on pharmacological research are not suitable for publication in this journal. additionally, studies that are purely statistical or predictive in nature, without providing novel insights into pharmacological mechanisms or drug development, are not within the scope of this journal.\u003c/p>\n\n\u003cp>frontiers in pharmacology is committed to advancing developments in the field of pharmacological discoveries by allowing unrestricted access to articles and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.\u003c/p>\n\n\u003cb>\u003cp>ethics information\u003c/p>\u003c/b>\n\u003cp>research involving human subjects should comply with the ethical guidelines outlined in the \u003ca href= https://www.wma.net/policies-post/wma-declaration-of-helsinki/” target=”_blank”>world medical association’s declaration of helsinki\u003c/a>.\u003c/p>\n\u003cp>similarly, authors are required to specify the institutional and national standards adhered to for the care and use of laboratory animals. transparent and accurate reporting of animal studies is required, with references to guidelines such as \u003ca href=\"https://arriveguidelines.org/arrive-guidelines\" target=\"_blank\">arrive\u003c/a> and \u003ca href=\"https://nc3rs.org.uk/sites/default/files/2022-01/the%20improve%20guidelines%20%28poster%29.pdf\" target=\"_blank\"> improve\u003c/a>.\u003c/p>\n\u003cp>extended information on research ethics can be found under the frontiers policies and publication ethics page.\u003c/p>","purple","5.6","6.3","531663","@frontpharmacol",{"id":115,"name":116,"slug":117,"abbreviation":413,"isonline":13,"isopenforsubmissions":13,"citescore":414,"impactfactor":415},"fphar",8.9,4.8,{"displaytitlepilllabels":13,"displayrelatedarticlesbox":13,"showeditors":13,"showreviewers":13,"showloopimpactlink":13,"enablefigshare":347,"usexmlimages":13},{"ispublic":13,"allowcompanyusers":347,"whitelistemails":418,"enablealljournals":13,"whitelistjournals":440},[419,420,421,422,423,424,425,426,427,424,428,429,430,431,432,433,434,435,436,437,438,439],"y2fybg9zlmxvcmnhqgzyb250awvyc2lulm9yzw==","zgfuawvslmx1ekbmcm9udgllcnnpbi5vcmc=","bgf1cmeudgvuyubmcm9udgllcnnpbi5vcmc=","cmfmywvslnjpyw5jag9aznjvbnrpzxjzaw4ub3jn","amftzxmuc21hbgxib25lqgzyb250awvyc2lulm9yzw==","znjhbi5tb3jlbm9aznjvbnrpzxjzaw4ub3jn","c2ftdwvslmzlcm5hbmrlekbmcm9udgllcnnpbi5vcmc=","ymfyymfyys5jyxjjyw5naxvaznjvbnrpzxjzaw4ub3jn","axzhbi5zyw50yw1hcmlhqgzyb250awvyc2lulm9yzw==","ahvllnryyw5aznjvbnrpzxjzaw4ub3jn","z29uy2fsby52yxjnyxnaznjvbnrpzxjzaw4ub3jn","bhvjawuuc2vubkbmcm9udgllcnnpbi5vcmc=","bg9ybi5mcmfzzxjaznjvbnrpzxjzaw4ub3jn","zwxzys5jyxjyb25aznjvbnrpzxjzaw4ub3jn","bwfhcnrlbi52yw5kawpja0bmcm9udgllcnnpbi5vcmc=","ymluzgh1lmtyaxnobmfuqgzyb250awvyc2lulm9yzw==","bwf0dghldy5hdhr3yxrlcnnaznjvbnrpzxjzaw4ub3jn","z2l1bglhlnzhbhnly2noaubmcm9udgllcnnpbi5vcmc=","zmfiawfulmrlbgxhbw9ydgvaznjvbnrpzxjzaw4ub3jn","dmlqyxlhbi5wcebwaxrzb2x1dglvbnmuy29t","z3vpbgxhdw1llnnldxjhdebmcm9udgllcnnpbi5vcmc=",[441,442,443,444,445,446,370,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,115,469,470,471,472,473,474,475],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,451,141,1335,2655,1238,604,698,1547,1440,403,1239,755,2136,609,1534,{"spaceid":370,"name":370,"availablejournalpages":477,"announcement":481},[255,260,257,478,479,480],"volumes","about","community-reviewers",{"__typename":482,"sys":483,"preheader":42,"title":485,"description":486,"image":487,"link":509},"announcement",{"id":484},"5ittnttqgazppgh6rx0alm","articles published with frontiers have received 12 million total citations","your research is the real superpower - learn how we maximise its impact through our leading community journals",[488],{"archive":367,"brandid":368,"copyright":28,"datecreated":489,"datemodified":490,"datepublished":491,"description":28,"extension":492,"filesize":494,"height":495,"id":496,"ispublic":367,"limited":367,"name":497,"orientation":385,"original":28,"thumbnails":498,"type":363,"watermarked":367,"width":505,"videopreviewurls":506,"tags":507,"textmetaproperties":508,"src":499},"2025-06-18t12:58:01z","2025-06-18t14:15:34z","2025-06-18t12:57:32z",[493],"png",1365026,920,"7c5269c4-3c83-4591-951a74d15b95daea","impact metrics banner for article pages",{"webimage":499,"thul":500,"mini":501,"websitewebp_l":502,"websitewebp_m":503,"guidelines":504},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/websitewebp_l/impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/websitewebp_m/impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/guidelines/impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":510,"url":43,"target":27,"arialabel":28},"explore our impact metrics",{"loggeduserinfo":-1},{"currentarticle":513,"ispreviewpage":347,"hassupplementaldata":347,"showcrossmarkwidget":13,"articletemplate":758,"currentarticlepagemetainfo":759,"xmlparsedarticlecontent":-1,"xmlparsingerror":-1},{"id":514,"doi":515,"title":516,"acceptancedate":517,"receptiondate":518,"publicationdate":519,"lastmodifieddate":520,"ispublished":13,"abstract":521,"researchtopic":28,"articletype":522,"stage":525,"keywords":527,"authors":536,"editors":682,"reviewers":690,"journal":712,"section":719,"impactmetrics":721,"volume":724,"articlevolume":725,"relatedarticles":726,"ispublishedv2":13,"contents":727,"files":731},1626078,"10.3389/fphar.2025.1626078","preclinical pharmacology of alogabat: a novel gabaa-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gabaa signaling","2025-06-18t08:27:15.000z","2025-05-09t23:15:40.000z","2025-07-21t00:00:00.000z","2025-10-21t02:34:53.269z","backgroundalterations in the gabaergic system contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder (asd) and angelman syndrome (as), particularly in cases involving large deletions in the 15q11–13 region. positive modulation of gabaa-α5 receptors may provide a novel therapeutic approach without the typical side effects associated with non-selective gabaa positive allosteric modulators such as diazepam.methodsalogabat was assessed for binding and functional activity at gabaa-α5β3γ2 receptors in vitro and in electrophysiological studies using hippocampal slices. in vivo studies in rodents included receptor occupancy (ro) using a selective gabaa-α5 tracer (autoradiography), pharmacological mri, and electroencephalography (eeg). alogabat was evaluated for its effects on the repetitive behavior phenotype in btbr and contactin-associated protein-like 2 (cntnap2−/−) knockout mice, seizure models, cognitive performance in rats, and rotarod performance following combination treatment with diazepam.resultsalogabat is a potent positive allosteric modulator of gabaa-α5 receptors, with binding and functional selectivity. receptor occupancy studies provided direct proof of dose-dependent target engagement. functional circuit modulation was demonstrated by dose-dependent regional perfusion changes in pharmacological mri and changes in eeg theta- and beta-band power in rats. at >50% gabaa-α5 receptor occupancy, alogabat normalized elevated self-grooming behavior in both cntnap2−/− and btbr mice and exhibited antiepileptic activity in rats. alogabat did not impair cognition in wildtype rats at gabaa-α5 receptor occupancy up to 75%, although impairment occurred at higher doses, probably due to increased activity at other receptor subtypes and/or saturation of α5 receptors. alogabat did not worsen diazepam-induced impairment on the rotarod test.conclusionalogabat showed beneficial effects in mouse models relevant to neurodevelopmental disorders and anti-seizure activity at doses that did not produce cognitive, sedative, or motoric side effects.",{"id":523,"name":524},24,"original research",{"id":526,"name":19},18,[528,529,530,531,532,533,534,535],"biomarker","autism spectrum disorder","electroencephalography","positron emission tomography (pet)","angelman syndrome","gabaa","gabaa-α5","pharmacological mri",[537,546,554,560,566,573,580,587,594,600,606,612,617,623,629,635,643,650,656,664,668,675],{"id":538,"firstname":539,"middlename":19,"lastname":540,"givennames":541,"iscorresponding":347,"isprofilepublic":13,"userid":538,"email":-1,"affiliations":542},3088634,"giuseppe","cecere","giuseppe ",[543],{"organizationname":544,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"medicinal chemistry","switzerland",{"id":547,"firstname":548,"middlename":19,"lastname":549,"givennames":550,"iscorresponding":347,"isprofilepublic":13,"userid":547,"email":-1,"affiliations":551},3064665,"theresa m.","ballard","theresa m. ",[552],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"neuroscience and rare diseases",{"id":367,"firstname":555,"middlename":19,"lastname":556,"givennames":557,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":558},"frederic","knoflach","frederic ",[559],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":561,"middlename":19,"lastname":562,"givennames":563,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":564},"michael","honer","michael ",[565],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":567,"firstname":568,"middlename":19,"lastname":569,"givennames":570,"iscorresponding":347,"isprofilepublic":13,"userid":567,"email":-1,"affiliations":571},81732,"joerg f.","hipp","joerg f. ",[572],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":574,"firstname":575,"middlename":19,"lastname":576,"givennames":577,"iscorresponding":347,"isprofilepublic":13,"userid":574,"email":-1,"affiliations":578},2412410,"pilar","garces","pilar ",[579],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":581,"firstname":582,"middlename":19,"lastname":583,"givennames":584,"iscorresponding":347,"isprofilepublic":13,"userid":581,"email":-1,"affiliations":585},13967,"thomas","mueggler","thomas ",[586],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":588,"firstname":589,"middlename":19,"lastname":590,"givennames":591,"iscorresponding":347,"isprofilepublic":13,"userid":588,"email":-1,"affiliations":592},577428,"basil","künnecke","basil ",[593],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":595,"middlename":19,"lastname":596,"givennames":597,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":598},"andreas","bruns","andreas ",[599],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":601,"middlename":19,"lastname":602,"givennames":603,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":604},"eric p.","prinssen","eric p. ",[605],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":607,"middlename":19,"lastname":608,"givennames":609,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":610},"philipp","schoenenberger","philipp ",[611],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":613,"firstname":607,"middlename":19,"lastname":614,"givennames":609,"iscorresponding":347,"isprofilepublic":13,"userid":613,"email":-1,"affiliations":615},2424959,"janz",[616],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":618,"middlename":19,"lastname":619,"givennames":620,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":621},"roger","redondo","roger ",[622],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":624,"middlename":19,"lastname":625,"givennames":626,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":627},"barbara","biemans","barbara ",[628],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":630,"middlename":19,"lastname":631,"givennames":632,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":633},"henner","knust","henner ",[634],{"organizationname":544,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":636,"firstname":637,"middlename":19,"lastname":638,"givennames":639,"iscorresponding":347,"isprofilepublic":13,"userid":636,"email":-1,"affiliations":640},2264913,"andrés","olivares-morales","andrés ",[641],{"organizationname":642,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"pharmaceutical sciences",{"id":644,"firstname":645,"middlename":19,"lastname":646,"givennames":647,"iscorresponding":347,"isprofilepublic":13,"userid":644,"email":-1,"affiliations":648},1172717,"alessandro","brigo","alessandro ",[649],{"organizationname":642,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":651,"middlename":19,"lastname":652,"givennames":653,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":654},"jan michael","schulz","jan michael ",[655],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":657,"firstname":658,"middlename":19,"lastname":659,"givennames":660,"iscorresponding":347,"isprofilepublic":13,"userid":657,"email":-1,"affiliations":661},157846,"daniel","bertrand","daniel ",[662],{"organizationname":663,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"hiqscreen sàrl",{"id":367,"firstname":561,"middlename":19,"lastname":665,"givennames":563,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":666},"saxe",[667],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":669,"firstname":670,"middlename":19,"lastname":671,"givennames":672,"iscorresponding":347,"isprofilepublic":13,"userid":669,"email":-1,"affiliations":673},2733790,"eoin c.","o’connor","eoin c. ",[674],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":676,"firstname":677,"middlename":19,"lastname":678,"givennames":679,"iscorresponding":347,"isprofilepublic":13,"userid":676,"email":-1,"affiliations":680},2269471,"maria-clemencia","hernandez","maria-clemencia ",[681],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},[683],{"id":684,"firstname":685,"middlename":19,"lastname":686,"givennames":687,"iscorresponding":347,"isprofilepublic":13,"userid":684,"email":-1,"affiliations":688},52072,"agenor","limon","agenor ",[689],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},[691,698,705],{"id":692,"firstname":693,"middlename":19,"lastname":694,"givennames":695,"iscorresponding":347,"isprofilepublic":13,"userid":692,"email":-1,"affiliations":696},1285968,"junzhan","jing","junzhan ",[697],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},{"id":699,"firstname":700,"middlename":19,"lastname":701,"givennames":702,"iscorresponding":347,"isprofilepublic":13,"userid":699,"email":-1,"affiliations":703},1380630,"azar","omrani","azar ",[704],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},{"id":706,"firstname":707,"middlename":19,"lastname":708,"givennames":709,"iscorresponding":347,"isprofilepublic":13,"userid":706,"email":-1,"affiliations":710},39673,"hansen","wang","hansen ",[711],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},{"id":115,"slug":117,"name":116,"shortname":713,"electronicissn":714,"field":715,"specialtyid":28,"journalsectionpaths":717},"front. pharmacol.","1663-9812",{"id":716,"domainid":370},62,[718],{"section":719},{"id":152,"name":153,"slug":154,"specialtyid":720},762,{"views":722,"downloads":723,"citations":367},2218,442,16,"volume 16 - 2025",[],{"titlehtml":728,"fulltexthtml":729,"menuhtml":730},"preclinical pharmacology of alogabat: a novel gaba\u003csub>a\u003c/sub>-&#x003b1;5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gaba\u003csub>a\u003c/sub> signaling","\u003cdiv class=\"journalabstract\">\u003ca id=\"h1\" name=\"h1\">\u003c/a>\u003cdiv class=\"authors\">\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/3088634\" class=\"user-id-3088634\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/3088634/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"giuseppe cecere&#x;\">giuseppe cecere\u003c/a>\u003csup>1\u003c/sup>\u003csup>&#x02020;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/3064665\" class=\"user-id-3064665\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/3064665/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"theresa m. ballard&#x;&#x;\">theresa m. ballard\u003c/a>\u003csup>2\u003c/sup>\u003csup>&#x02020;\u003c/sup>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"frederic knoflach&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">frederic knoflach\u003csup>2\u003c/sup>\u003csup>&#x02020;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"michael honer\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">michael honer\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/81732\" class=\"user-id-81732\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/81732/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"joerg f. hipp\">joerg f. hipp\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2412410\" class=\"user-id-2412410\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2412410/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"pilar garces\">pilar garces\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/13967\" class=\"user-id-13967\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/13967/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"thomas mueggler\">thomas mueggler\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/577428\" class=\"user-id-577428\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/577428/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"basil k&#xfc;nnecke\">basil k&#x000fc;nnecke\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"andreas bruns\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">andreas bruns\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"eric p. prinssen\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">eric p. prinssen\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"philipp schoenenberger\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">philipp schoenenberger\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2424959\" class=\"user-id-2424959\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2424959/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"philipp janz\">philipp janz\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"roger redondo\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">roger redondo\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"barbara biemans&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">barbara biemans\u003csup>2\u003c/sup>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"henner knust\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">henner knust\u003csup>1\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2264913\" class=\"user-id-2264913\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2264913/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"andr&#xe;s olivares-morales\">andr&#x000e9;s olivares-morales\u003c/a>\u003csup>3\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/1172717\" class=\"user-id-1172717\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1172717/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"alessandro brigo\">alessandro brigo\u003c/a>\u003csup>3\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"jan michael schulz\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">jan michael schulz\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/157846\" class=\"user-id-157846\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/157846/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"daniel bertrand\">daniel bertrand\u003c/a>\u003csup>4\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"michael saxe&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">michael saxe\u003csup>2\u003c/sup>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2733790\" class=\"user-id-2733790\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2733790/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"eoin c. o&#x;connor\">eoin c. o&#x02019;connor\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2269471\" class=\"user-id-2269471\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2269471/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"maria-clemencia hernandez&#xa;\">maria-clemencia hernandez\u003c/a>\u003csup>2\u003c/sup>&#x0002a;\u003c/span>\u003c/div>\u003cul class=\"notes\">\u003cli>\u003cspan>\u003csup>1\u003c/sup>\u003c/span>medicinal chemistry, roche pharmaceutical research and early development, roche innovation center basel, basel, switzerland\u003c/li>\u003cli>\u003cspan>\u003csup>2\u003c/sup>\u003c/span>neuroscience and rare diseases, roche pharmaceutical research and early development, roche innovation center basel, basel, switzerland\u003c/li>\u003cli>\u003cspan>\u003csup>3\u003c/sup>\u003c/span>pharmaceutical sciences, roche pharmaceutical research and early development, roche innovation center basel, basel, switzerland\u003c/li>\u003cli>\u003cspan>\u003csup>4\u003c/sup>\u003c/span>hiqscreen s&#x000e0;rl, v&#x000e9;senaz, switzerland\u003c/li>\u003c/ul>\u003cp class=\"mb0\">\u003cb>background:\u003c/b> alterations in the gabaergic system contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder (asd) and angelman syndrome (as), particularly in cases involving large deletions in the 15q11&#x02013;13 region. positive modulation of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors may provide a novel therapeutic approach without the typical side effects associated with non-selective gaba\u003csub>a\u003c/sub> positive allosteric modulators such as diazepam.\u003c/p>\u003cp class=\"mb0\">\u003cb>methods:\u003c/b> alogabat was assessed for binding and functional activity at gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 receptors \u003cem>in vitro\u003c/em> and in electrophysiological studies using hippocampal slices. \u003cem>in vivo\u003c/em> studies in rodents included receptor occupancy (ro) using a selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 tracer (autoradiography), pharmacological mri, and electroencephalography (eeg). alogabat was evaluated for its effects on the repetitive behavior phenotype in btbr and contactin-associated protein-like 2 (cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup>) knockout mice, seizure models, cognitive performance in rats, and rotarod performance following combination treatment with diazepam.\u003c/p>\u003cp class=\"mb0\">\u003cb>results:\u003c/b> alogabat is a potent positive allosteric modulator of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors, with binding and functional selectivity. receptor occupancy studies provided direct proof of dose-dependent target engagement. functional circuit modulation was demonstrated by dose-dependent regional perfusion changes in pharmacological mri and changes in eeg theta- and beta-band power in rats. at &#x0003e;50% gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor occupancy, alogabat normalized elevated self-grooming behavior in both cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> and btbr mice and exhibited antiepileptic activity in rats. alogabat did not impair cognition in wildtype rats at gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor occupancy up to 75%, although impairment occurred at higher doses, probably due to increased activity at other receptor subtypes and/or saturation of &#x003b1;5 receptors. alogabat did not worsen diazepam-induced impairment on the rotarod test.\u003c/p>\u003cp class=\"mb0\">\u003cb>conclusion:\u003c/b> alogabat showed beneficial effects in mouse models relevant to neurodevelopmental disorders and anti-seizure activity at doses that did not produce cognitive, sedative, or motoric side effects.\u003c/p>\u003cdiv class=\"clear\">\u003c/div>\u003c/div>\u003cdiv class=\"journalfulltext\">\u003ca id=\"h2\" name=\"h2\">\u003c/a>\u003ch2>1 introduction\u003c/h2>\u003cp class=\"mb15\">alterations in the gabaergic system, the main inhibitory neurotransmitter system in the brain, may contribute to the pathophysiology of neurodevelopmental disorders (ndds), such as autism spectrum disorder (asd) and angelman syndrome (as). asd is a complex, heterogeneous ndd with both genetic and environmental factors (\u003ca href=\"#b7\">bourgeron, 2015\u003c/a>) contributing to aberrant changes in brain growth, neuronal development, and functional connectivity (\u003ca href=\"#b18\">dhossche et al., 2002\u003c/a>; \u003ca href=\"#b55\">pizzarelli and cherubini, 2011\u003c/a>; \u003ca href=\"#b8\">braat and kooy, 2015\u003c/a>; \u003ca href=\"#b58\">robertson et al., 2016\u003c/a>). asd is characterized by two core domains: impairments in social interaction and communication and the presence of repetitive or restricted behaviors, interests, or activities (\u003ca href=\"#b3\">american psychiatric association, 2008\u003c/a>). there are a range of comorbid conditions, including irritability, depression, anxiety, attention deficits, obsessive-compulsive symptoms, seizures, and sleep disruption. as is a rare genetic ndd with a prevalence of 1 in 12,000 to 20,000 births (\u003ca href=\"#b38\">luk and lo, 2016\u003c/a>; \u003ca href=\"#b44\">mertz et al., 2013\u003c/a>). individuals with as often present with autistic features, severe intellectual disability, microcephaly, speech impairment, bursts of laughter, sleep problems, movement disorders, and epilepsy (\u003ca href=\"#b12\">buiting, 2010\u003c/a>; \u003ca href=\"#b35\">kalsner and chamberlain, 2015\u003c/a>).\u003c/p>\u003cp class=\"mb15\">gaba\u003csub>a\u003c/sub> receptors are ligand-gated chloride channels. there are 19 genes encoding gaba\u003csub>a\u003c/sub> receptor subunits that assemble as pentamers, with the most common stoichiometry being two &#x003b1;, two &#x003b2;, and one &#x003b3; subunit. gaba\u003csub>a\u003c/sub> subunit combinations give rise to functional, circuit, and behavioral specificity (\u003ca href=\"#b65\">sieghart, 2006\u003c/a>; \u003ca href=\"#b73\">vithlani et al., 2011\u003c/a>). gaba\u003csub>a\u003c/sub> receptors that contain the &#x003b1;5 subunit (gaba\u003csub>a\u003c/sub>-&#x003b1;5) are of particular interest due to their restricted pattern of expression and unique physiological and pharmacological properties (\u003ca href=\"#b69\">sur et al., 1999\u003c/a>; \u003ca href=\"#b46\">mohler, 2011\u003c/a>). in humans, gaba\u003csub>a\u003c/sub> receptors containing the &#x003b1;5 subunit are preferentially localized in the hippocampus, prefrontal cortex, nucleus accumbens, amygdala, insular cortex, anterior cingulate, and cingulate cortex&#x02014;key regions believed to be involved in the neuropathology and pathophysiology of asd (\u003ca href=\"#b42\">mendez et al., 2013\u003c/a>; \u003ca href=\"#b48\">myers et al., 2017\u003c/a>). the \u003cem>gabra5\u003c/em> gene has been proposed as a candidate gene for asd (\u003ca href=\"#b15\">delong, 2007\u003c/a>; \u003ca href=\"#b45\">mesbah-oskui et al., 2017\u003c/a>; \u003ca href=\"#b74\">warrier et al., 2013\u003c/a>; \u003ca href=\"#b19\">di nanni et al., 2019\u003c/a>), suggesting decreased gabaergic inhibition in a subpopulation of autistic individuals. mutations involving the gaba\u003csub>a\u003c/sub> receptor subunit genes \u003cem>gabra5\u003c/em>, \u003cem>gabrb3\u003c/em>, and \u003cem>gabrg3\u003c/em> (encoding the &#x003b1;5, &#x003b2;3, and &#x003b3;3 subunits) found on chromosomal region 15q11&#x02013;q13 have been associated with ndds including as, epilepsy, and prader&#x02013;willi syndrome in addition to asd (\u003ca href=\"#b32\">hogart et al., 2010\u003c/a>; \u003ca href=\"#b61\">sanders, 2015\u003c/a>). as is predominantly caused by the loss of function of the maternally inherited \u003cem>ube3a\u003c/em> gene; however, approximately 75% of individuals with as carry a large deletion of the maternal 15q11&#x02013;q13 chromosomal region. clinical studies have shown that individuals with as who have large deletions (deletion as) exhibit more severe symptoms than those in whom \u003cem>ube3a\u003c/em> is the only gene affected, suggesting that the \u003cem>gabra5\u003c/em>, \u003cem>gabrb3\u003c/em>, and \u003cem>gabrg3\u003c/em> genes are relevant to the etiology of the disease.\u003c/p>\u003cp class=\"mb15\">imaging studies using pet and magnetic resonance spectroscopy have shown reduced gaba\u003csub>a\u003c/sub> receptor binding in the superior and medial frontal cortex (\u003ca href=\"#b47\">mori et al., 2012\u003c/a>) and reduced gaba levels in individuals with asd (\u003ca href=\"#b58\">robertson et al., 2016\u003c/a>; \u003ca href=\"#b28\">gaetz et al., 2014\u003c/a>; \u003ca href=\"#b59\">rojas et al., 2014\u003c/a>; \u003ca href=\"#b57\">puts et al., 2017\u003c/a>). postmortem studies have shown reduced numbers of inhibitory interneurons (\u003ca href=\"#b20\">dufour et al., 2023\u003c/a>), reduced expression of gaba\u003csub>a\u003c/sub> receptor subunits (\u003ca href=\"#b16\">delorey, 2005\u003c/a>; \u003ca href=\"#b1\">abrahams and geschwind, 2008\u003c/a>), and reduced levels of the gaba-synthesizing enzymes such as glutamic acid decarboxylase (gad) 65 and 67 (\u003ca href=\"#b21\">fatemi et al., 2002\u003c/a>). there is increasing evidence from genetic, environmental, and phenotypic rodent models relevant to asd indicating that gabaergic circuit dysfunctions contribute to autism-like phenotypes (\u003ca href=\"#b27\">fukuda et al., 2005\u003c/a>; \u003ca href=\"#b13\">chao et al., 2010\u003c/a>; \u003ca href=\"#b6\">banerjee et al., 2013\u003c/a>). such deficits may result from multiple causes, including a reduced number of gabaergic interneurons, altered interneuron function, impaired gaba\u003csub>a\u003c/sub> receptor trafficking to the membrane, reduced expression of gaba\u003csub>a\u003c/sub> receptor subunits, and reduced gaba uptake function of gat-1 in neurons (\u003ca href=\"#b49\">nakamura et al., 2016\u003c/a>; \u003ca href=\"#b50\">orefice et al., 2016\u003c/a>; \u003ca href=\"#b43\">mermer et al., 2021\u003c/a>). supportive evidence is provided by the observation of autism-like behaviors in both gaba\u003csub>a\u003c/sub>-&#x003b1;5 and &#x003b2;3 subunit knockout mice (\u003ca href=\"#b77\">zurek et al., 2016\u003c/a>; \u003ca href=\"#b17\">delorey et al., 2008\u003c/a>). regarding possible therapeutic approaches, enhancement of the gaba\u003csub>a\u003c/sub> receptor activity by non-selective benzodiazepines has been shown to ameliorate autism-like behavioral deficits in mouse models; however, due to sedation that is likely mediated by the activation of the gaba\u003csub>a\u003c/sub>-&#x003b1;1 subtype, very narrow therapeutic margins were observed (\u003ca href=\"#b30\">han et al., 2012\u003c/a>; \u003ca href=\"#b29\">han et al., 2014\u003c/a>; \u003ca href=\"#b37\">lim et al., 2017\u003c/a>). interestingly, a recent study showed that a gaba\u003csub>a\u003c/sub>-&#x003b1;5 positive allosteric modulator (pam), sh-053-2&#x02032;f-r-ch3, attenuated social and cognitive deficits in male rats exposed to valproic acid \u003cem>in utero\u003c/em>, a rat model relevant to autism (\u003ca href=\"#b68\">souza et al., 2024\u003c/a>).\u003c/p>\u003cp class=\"mb15\">the aim of the current study was to determine whether a selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 pam, alogabat (also known as ro7017773 or rg7816), would produce beneficial effects in animal models relevant to autism-like repetitive behavior&#x02014;specifically btbr mice (\u003ca href=\"#b40\">mcfarlane et al., 2008\u003c/a>) and contactin-associated protein-like 2 [cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup>] homozygous knockout mice (\u003ca href=\"#b51\">penagarikano et al., 2011\u003c/a>)&#x02014;and anti-seizure activity, without the typical side effects of non-selective gaba\u003csub>a\u003c/sub> pams, such as sedation and cognitive impairment. furthermore, target engagement was assessed by \u003cem>in vivo\u003c/em> receptor occupancy (ro) and pharmacological mri (phmri) in rodents, and an electroencephalography (eeg) study in rats was undertaken to identify a putative pharmacodynamic readout for future clinical trials.\u003c/p>\u003ca id=\"h3\" name=\"h3\">\u003c/a>\u003ch2>2 materials and methods\u003c/h2>\u003cp class=\"mb15\">further information for each method listed below can be found in the \u003ca href=\"#sm1\">supplementary material\u003c/a>.\u003c/p>\u003ca id=\"h3-1\" name=\"h3-1\">\u003c/a>\u003ch3 class=\"pt0\">2.1 materials\u003c/h3>\u003cp class=\"mb0\">alogabat [ro7017773; c\u003csub>21\u003c/sub>h\u003csub>23\u003c/sub>n\u003csub>5\u003c/sub>o\u003csub>4\u003c/sub>; 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl) methoxy)-n-(tetrahydropyran-4-yl)pyridazine-3-carboxamide (iupac name); molecular weight: 409.44&#x000a0;gmol\u003csup>&#x02212;1\u003c/sup>] was synthesized at f.hoffmann-la roche ag, switzerland [\u003ca href=\"#f1\">figure 1a\u003c/a>; see example 8 in \u003ca href=\"#b10\">buettelmann et al., 2018\u003c/a>]. the discovery of alogabat and the related chemical series will be disclosed in future publications. diazepam, l-655,708, [\u003csup>3\u003c/sup>h]flumazenil, [\u003csup>3\u003c/sup>h]l-655,708, and [\u003csup>3\u003c/sup>h]ro0154513 were synthesized at f.hoffmann-la roche ag, switzerland.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 1\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" name=\"figure1\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" alt=\"www.frontiersin.org\" id=\"f1\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 1\u003c/b>. \u003cem>in vitro\u003c/em> pharmacology of alogabat. \u003cb>(a)\u003c/b> chemical structure of alogabat (ro7017773; c21h23n5o4); 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl) methoxy)-n-(tetrahydropyran-4-yl)pyridazine-3-carboxamide (iupac name); molecular weight, 409.44&#x000a0;gmol\u003csup>&#x02212;1\u003c/sup>. \u003cb>(b)\u003c/b> concentration-response curves of alogabat in [\u003csup>3\u003c/sup>h]flumazenil competition-binding assays with membranes expressing different rat recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (\u003cem>n\u003c/em> &#x0003d; 10&#x02013;20/concentration). \u003cb>(c)\u003c/b> concentration-response curves of the effects of alogabat in hek293 cells expressing different rat recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (\u003cem>n\u003c/em> &#x0003d; 4&#x02013;5/concentration). data in the graphs are shown as the mean (symbols) &#x000b1; sem (error bars). error bars smaller than the symbol size are not shown. \u003cb>(d)\u003c/b> isoguvacine concentration-response curves obtained in the presence and absence of alogabat in rat hippocampal slices. the points represent the mean values &#x000b1; sem of three slices. the sigmoidal curves were fit through these points. \u003cb>(e)\u003c/b> the ppi of ps was measured in the absence (control) and presence of alogabat at 0.3&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 3 slices) and 1&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 6 slices). ps1 and ps2 are the responses induced by the first and second stimulus, respectively. the data are normalized to the amplitude of ps1 and presented as the mean &#x000b1; sem.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h3-2\" name=\"h3-2\">\u003c/a>\u003ch3 class=\"pt0\">2.2 \u003cem>in vitro\u003c/em> experiments\u003c/h3>\u003ca id=\"h7-2-1\" name=\"h7-2-1\">\u003c/a>\u003ch4>2.2.1 gaba\u003csub>a\u003c/sub> receptor radioligand binding assays\u003c/h4>\u003cp class=\"mb0\">the affinity of alogabat for rat and human gaba\u003csub>a\u003c/sub> receptors containing &#x003b1;5, &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits was measured by [\u003csup>3\u003c/sup>h]flumazenil competition-binding assays with membranes expressing different rat recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (\u003cem>n\u003c/em> &#x0003d; 10&#x02013;20/concentration) and for human &#x003b1;4 and &#x003b1;6 by [\u003csup>3\u003c/sup>h]ro0154513, as previously described (\u003ca href=\"#b4\">ballard et al., 2009\u003c/a>; \u003ca href=\"#b31\">hipp et al., 2021\u003c/a>).\u003c/p>\u003ca id=\"h7-2-2\" name=\"h7-2-2\">\u003c/a>\u003ch4>2.2.2 gaba\u003csub>a\u003c/sub> receptor electrophysiological studies\u003c/h4>\u003cp class=\"mb0\">alogabat was tested for functional activity on four different cloned rat and human gaba\u003csub>a\u003c/sub> receptor subtypes (\u003ca href=\"#b10\">buettelmann et al., 2018\u003c/a>), namely, &#x003b1;1&#x003b2;2&#x003b3;2, &#x003b1;2&#x003b2;3&#x003b3;2, &#x003b1;3&#x003b2;3&#x003b3;2, and &#x003b1;5&#x003b2;3&#x003b3;2. ion currents were induced by gaba concentrations that evoked approximately 20% of the maximal response (\u003cem>n\u003c/em> &#x0003d; 4&#x02013;5/concentration). the following concentrations of gaba were used: 1&#x000a0;&#x000b5;m for &#x003b1;1&#x003b2;2&#x003b3;2, 10&#x000a0;&#x000b5;m &#x003b1;2&#x003b2;3&#x003b3;2, 10&#x000a0;&#x000b5;m for &#x003b1;3&#x003b2;3&#x003b3;2, and 3&#x000a0;&#x000b5;m for &#x003b1;5&#x003b2;3&#x003b3;2 receptor subtype.\u003c/p>\u003cp class=\"mb0\">alogabat was also tested for functional activity on native gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors in rat hippocampal slices: modulation of isoguvacine-induced population spikes (\u003ca href=\"#b4\">ballard et al., 2009\u003c/a>) and paired-pulse inhibition (ppi) (\u003ca href=\"#b76\">xie and tietz, 1991\u003c/a>). population spikes (pss) were recorded every 30&#x000a0;s by the stimulation of the schaffer collaterals, and isoguvacine was applied consecutively and in increasing concentrations for at least 4&#x000a0;min to the slices (control). after the washout of isoguvacine, alogabat (300&#x000a0;nm) was added to the bath perfusion, and a new isoguvacine concentration-response curve was obtained (alogabat). the ps amplitudes were normalized to the control ps obtained before the first application of isoguvacine and were fitted individually for each slice (\u003cem>n\u003c/em> &#x0003d; 3 slices).\u003c/p>\u003cp class=\"mb0\">the ppi of ps was measured in the absence (control) and presence of alogabat at 0.3&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 3 slices from one animal) and 1&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 6 slices from two animals). the paired-pulse protocol consisted of two stimuli timely spaced by 20&#x000a0;ms, which were applied at the schaffer collaterals in rat hippocampal slices. we used a low number of animals based on our experience with the assay, which is highly robust and reproducible, and in alignment with our commitment to reducing the number of animals used.\u003c/p>\u003ca id=\"h7-2-3\" name=\"h7-2-3\">\u003c/a>\u003ch4>2.2.3 selectivity screening\u003c/h4>\u003cp class=\"mb0\">the selectivity of alogabat (10&#x000a0;&#x000b5;m) over more than 70 receptors was assessed by radioligand binding studies conducted using eurofins cerep sa (celle l&#x000e9;vescault, france), following the methods described on \u003ca href=\"http://www.eurofinsdiscoveryservices.com/\">www.eurofinsdiscoveryservices.com\u003c/a>.\u003c/p>\u003ca id=\"h3-3\" name=\"h3-3\">\u003c/a>\u003ch3 class=\"pt0\">2.3 \u003cem>in vivo\u003c/em> experiments\u003c/h3>\u003ca id=\"h7-3-1\" name=\"h7-3-1\">\u003c/a>\u003ch4>2.3.1 ethics approval\u003c/h4>\u003cp class=\"mb0\">experiments performed at f.hoffmann-la roche ag (basel, switzerland) complied with the swiss federal and cantonal laws on animal research and aaalac regulations and received prior approval from the cantonal veterinary office. the eeg study was conducted at brains online (ca, united states) in accordance with the guide for the care and use of laboratory animals (national research council 2011) after gaining approval from the institutional animal care and use committee. the pentylenetetrazole (ptz) and maximal electroshock (mes) tests were conducted at vivocore inc., canada, which is a facility licensed by the ontario ministry of agriculture, food, and rural affairs and accredited by the canadian council on animal care. all \u003cem>in vivo\u003c/em> studies are reported in compliance with the arrive guidelines (\u003ca href=\"#b52\">percie du sert et al., 2020\u003c/a>).\u003c/p>\u003ca id=\"h7-3-2\" name=\"h7-3-2\">\u003c/a>\u003ch4>2.3.2 animals\u003c/h4>\u003cp class=\"mb0\">all animals were group-housed in holding rooms at controlled temperature and humidity under a 12&#x000a0;h light/dark cycle and were allowed to acclimate for at least 7&#x000a0;days. twenty-six male wistar rats (charles river, germany; &#x0223c;160&#x000a0;g) and sixteen male cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (bred at roche basel; 18&#x02013;22&#x000a0;g) were used in receptor occupancy studies. thirty-two male fischer rats (charles river, germany) were assessed in mri experiments (&#x0223c;250&#x000a0;g). seventeen male wistar rats (envigo, united states) were assessed in eeg experiments. one hundred male btbr mice (bred in roche basel) were assessed in grooming and open-field tests (n &#x0003d; 60, &#x0223c;30&#x000a0;g) and for digging behavior (n &#x0003d; 40, &#x0223c;30&#x000a0;g). fifty-seven male cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (bred in roche basel; 5&#x02013;6&#x000a0;weeks) and wildtype littermates (n &#x0003d; 15) were assessed in grooming and open-field tests. one hundred male sprague&#x02013;dawley rats (charles river, canada) were used to evaluate antiepileptic effects in the ptz (70&#x02013;100&#x000a0;g, n &#x0003d; 40) and mes (&#x0003c;50&#x000a0;g n &#x0003d; 60) tests. forty-eight male sprague&#x02013;dawley rats (charles river, france) were used in the rotarod test (&#x0223c;170&#x02013;200&#x000a0;g). one hundred and forty-one male lister hooded (lh) rats (charles river, germany) were used in the cognition tests: 5-choice serial reaction time (5-csrt) task (n &#x0003d; 11, &#x0223c;400&#x000a0;g); continuous performance test (cpt; n &#x0003d; 11, &#x0223c;400&#x000a0;g); paired associates learning (pal) task (n &#x0003d; 12, &#x0223c;400&#x000a0;g); context fear conditioning (n &#x0003d; 67, &#x0223c;250&#x000a0;g); and morris water maze (n &#x0003d; 40, 350&#x02013;400&#x000a0;g).\u003c/p>\u003ca id=\"h7-3-3\" name=\"h7-3-3\">\u003c/a>\u003ch4>2.3.3 alogabat treatment\u003c/h4>\u003cp class=\"mb0\">alogabat was formulated in 2% hydroxypropyl cellulose in water (or 0.3% tween 80 in saline for \u003cem>in vivo\u003c/em> occupancy and grooming/digging experiments). the administration volume was 10&#x000a0;ml/kg (mice) and 5&#x000a0;ml/kg (rats). each dose was expressed as the weight of the base. alogabat was administered with a pre-treatment time of 30&#x000a0;min in mice and 60&#x000a0;min in rats (except for the eeg study), based on pharmacokinetic data indicating the time of maximal drug plasma concentration. treatment groups were assigned randomly. dose groups were provided as coded vials to allow blinded assessment during the conduct of each experiment. to minimize potential confounders regarding the time of day for behavioral testing, animals were split into separate cohorts (balanced for treatment groups) and tested during the same period.\u003c/p>\u003ca id=\"h7-3-4\" name=\"h7-3-4\">\u003c/a>\u003ch4>2.3.4 receptor occupancy studies\u003c/h4>\u003ch5>2.3.4.1 \u003cem>in vivo\u003c/em> occupancy in rats\u003c/h5>\u003cp class=\"mb0\">male wistar rats (n &#x0003d; 26, &#x0223c;160&#x000a0;g) were administered vehicle or alogabat (0.3, 1, 3, 10, 30, and 100&#x000a0;mg/kg, intraperitoneally [i.p.], n &#x0003d; 3/group) or the gaba\u003csub>a\u003c/sub>-&#x003b1;5 blocker l-655,708 at 10&#x000a0;mg/kg i.p. (n &#x0003d; 2). fifteen minutes later, the gaba\u003csub>a\u003c/sub>-&#x003b1;5 radioligand [\u003csup>3\u003c/sup>h]ro0154513 was administered intravenously (i.v.) to assess ro (\u003ca href=\"#b4\">ballard et al., 2009\u003c/a>; \u003ca href=\"#b31\">hipp et al., 2021\u003c/a>). non-specific binding was determined by pre-treatment with the established gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor blocker l-655,708 (10&#x000a0;mg/kg i.p.; n &#x0003d; 2).\u003c/p>\u003ch5>2.3.4.2 \u003cem>ex vivo\u003c/em> occupancy in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h5>\u003cp class=\"mb0\">cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (\u003ca href=\"#b51\">penagarikano et al., 2011\u003c/a>) (n &#x0003d; 16, 18&#x02013;22&#x000a0;g) were administered the vehicle or alogabat (30, 60, and 100&#x000a0;mg/kg) i.p. (n &#x0003d; 4/group), and ro was assessed in brain sections with the highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 radioligand, [\u003csup>3\u003c/sup>h]l-655,708, 30&#x000a0;min post-administration.\u003c/p>\u003ca id=\"h7-3-5\" name=\"h7-3-5\">\u003c/a>\u003ch4>2.3.5 pharmacological mri in rats\u003c/h4>\u003cp class=\"mb0\">male fischer rats (n &#x0003d; 32, &#x0223c;250&#x000a0;g) were administered vehicle or alogabat (3, 10, and 30&#x000a0;mg/kg) i.p. (n &#x0003d; 8/dose). phmri was performed under medetomidine sedation in a small-animal scanner (4.7t/40&#x000a0;cm; bruker biospin, germany), and blood perfusion was analyzed according to previously published procedures (\u003ca href=\"#b9\">bruns et al., 2009\u003c/a>). fifteen minutes after drug treatment, rats were initially anesthetized using isoflurane (4%) in the carrier gas composed of oxygen and air (1:5), supplied to the spontaneously breathing animals in an inhalation box. upon the induction of anesthesia, a subcutaneous (s.c.) bolus injection of 0.2&#x000a0;mg/kg (1&#x000a0;ml/kg) of medetomidine prepared from 1:5 diluted dormilan\u003csup>&#x000ae;\u003c/sup> was administered, and the animal was transferred onto a rat cradle for inserting an s.c. catheter and starting continuous infusion of 1:10 diluted dormilan\u003csup>&#x000ae;\u003c/sup> (medetomidine) at a dose of 0.1&#x000a0;mg/kg/h (1&#x000a0;ml/kg/h). the head was immobilized in a stereotaxic frame. respiratory rate, body temperature, and o\u003csub>2\u003c/sub> and co\u003csub>2\u003c/sub> levels in inhaled and exhaled air were continuously monitored using a powerlab data acquisition system (adinstruments, spechbach, germany). body temperature was maintained at 37&#x000b0;c with a feedback-regulated electric heating blanket. immediately after the last imaging assessment, rats were euthanized by decapitation under anesthesia, and plasma samples were collected at approximately 40&#x000a0;min post-administration of alogabat. images were processed and analyzed using in-house developed software written in idl (rsi, boulder, co, united states) and matlab (the mathworks inc., natick, ma, united states).\u003c/p>\u003ca id=\"h7-3-6\" name=\"h7-3-6\">\u003c/a>\u003ch4>2.3.6 eeg in rats\u003c/h4>\u003cp class=\"mb0\">male wistar rats (n &#x0003d; 17) were surgically prepared with wireless implanted transmitters to enable simultaneous recording of eeg, hippocampal (ca3) local field potential (lfp), and emg. rats were anesthetized using isoflurane (2%, 800&#x000a0;ml/min o2). bupivacaine/epinephrine was used for local analgesia, while finadyne or carprofen was used for peri-/post-operative analgesia. amoxicillin was used as an antibiotic. the animals were placed in a stereotaxic frame (kopf instruments, united states). a subcutaneous pocket was created near the dorsal flank, into which a transmitter (f50-eee, data sciences international, physio tel f50-eee small animal cns telemetry; three bipolar channels, biopotential lead, outer diameter 0.3&#x000a0;mm) was inserted. the transmitter included three bipolar channels: channel 1 (eeg): two screws in the left hemisphere (frontal: 11&#x000a0;mm anterior and 2.5&#x000a0;mm lateral to bregma; central: 3&#x000a0;mm anterior and 3.5&#x000a0;mm lateral to lambda); channel 2 (lfp): a single wire electrode targeting the ca3 region of the right hippocampus; and channel 3 (emg): electrodes placed in the neck muscle for recording emg activity, aiding in sleep stage classification.\u003c/p>\u003cp class=\"mb0\">after a 2-week recovery, rats were administered the vehicle or alogabat (10&#x000a0;mg/kg) using a cross-over design (1-week interval). if the setup allowed, the positive control diazepam (2&#x000a0;mg/kg) was assessed. all drugs were administered i.v. via an implanted cannula so that brain exposure was expected within a few minutes of administration. eeg spectral power was analyzed quantitatively up to 1&#x000a0;h post-administration. only animals with clean eeg recordings were included in the analysis. eeg data in the awake state were used for the analyses reported in this study. we first investigated the effects on power over predefined theta and beta power ranges, defined \u003cem>a priori\u003c/em> as 6&#x02013;10&#x000a0;hz and 20&#x02013;30&#x000a0;hz, respectively, based on previous studies with gabaa drugs (\u003ca href=\"#b72\">visser et al., 2003\u003c/a>; \u003ca href=\"#b71\">van lier et al., 2004\u003c/a>). then, we evaluated frequency-specific effects across the 2&#x02013;128&#x000a0;hz range.\u003c/p>\u003ca id=\"h7-3-7\" name=\"h7-3-7\">\u003c/a>\u003ch4>2.3.7 grooming behavior and open-field test in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h4>\u003cp class=\"mb0\">male btbr mice (n &#x0003d; 60, &#x0223c;30&#x000a0;g) were pre-treated with the vehicle or alogabat at 30, 60, 90, and 120&#x000a0;mg/kg i.p. (n &#x0003d; 12/dose). male cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (n &#x0003d; 57, 5&#x02013;6&#x000a0;weeks) and wildtype littermates (n &#x0003d; 15) received sub-chronic treatment (8&#x02013;10&#x000a0;days) with the vehicle or alogabat at 30, 60, and 100&#x000a0;mg/kg i.p. (n &#x0003d; 14&#x02013;15/dose). spontaneous locomotor activity was assessed in both groups of mice for 1&#x000a0;h in an open field (42 &#x000d7; 42 &#x000d7; 30.5&#x000a0;cm; 20 lux at the center of the arena) with a small amount of sawdust bedding. movement of the animal was detected by interruptions in an array of photobeams from horizontally located infrared sources placed around the open field, measured using a versamax system (accuscan instruments inc., columbus, oh, united states). activity was measured as the distance traveled (cm).\u003c/p>\u003cp class=\"mb0\">one week later, each mouse was placed into a type-ii cage (21.5 &#x000d7; 15.5 &#x000d7; 13.0&#x000a0;cm; 40 lux) for 5&#x000a0;min habituation, and then the cumulative time (s) spent grooming during 10&#x000a0;min was recorded manually by a blinded observer. distance traveled (cm) during the session was measured using a video tracking system (ethovision, noldus information technology, netherlands). plasma samples were collected from btbr mice 1&#x000a0;week after testing and 30&#x000a0;min after treatment (\u003cem>n\u003c/em> &#x0003d; 6/dose). plasma samples were collected from cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice 1&#x000a0;day later and 30&#x000a0;min after treatment (\u003cem>n\u003c/em> &#x0003d; 4/dose).\u003c/p>\u003ca id=\"h7-3-8\" name=\"h7-3-8\">\u003c/a>\u003ch4>2.3.8 digging behavior in btbr mice\u003c/h4>\u003cp class=\"mb0\">a separate group of male btbr mice (n &#x0003d; 40, &#x0223c;30&#x000a0;g) were pre-treated with vehicle or alogabat at 30, 60, and 100&#x000a0;mg/kg i.p. (n &#x0003d; 10/dose) and were placed into a small circular dish (d &#x0003d; 10&#x000a0;cm) filled with fresh thick sawdust located in the middle of a clean type-ii cage (21.5 &#x000d7; 15.5 &#x000d7; 13.0&#x000a0;cm; 40 lux). the cumulative time (s) spent digging over 5&#x000a0;min was recorded manually by a blinded observer. the distance traveled (cm) and speed were also measured in the arena, outside the dish (ethovision, noldus information technology, netherlands). plasma samples were collected immediately after the digging test, i.e., 35&#x02013;40&#x000a0;min post-administration (\u003cem>n\u003c/em> &#x0003d; 3/dose).\u003c/p>\u003ca id=\"h7-3-9\" name=\"h7-3-9\">\u003c/a>\u003ch4>2.3.9 evaluation of antiepileptic effects in rats\u003c/h4>\u003cp class=\"mb0\">vehicle or alogabat (5, 15, or 30&#x000a0;mg/kg) was administered p.o. (n &#x0003d; 8/dose) and assessed for seizures induced by (1) subcutaneous (s.c.) ptz and (2) the maximum electrical stimulus (mes) model in male sprague&#x02013;dawley rats (ptz: 70&#x02013;100&#x000a0;g, n &#x0003d; 40; mes: &#x0003c;50&#x000a0;g n &#x0003d; 60, charles river, canada). diazepam (synthesized at f.hoffmann-la roche ag) was included in each experiment as a positive control and administered at 3&#x000a0;mg/kg i.p., 30&#x000a0;min prior to testing. immediately following testing, a terminal blood sample was collected under anesthesia.\u003c/p>\u003ch5>2.3.9.1 pentylenetetrazole test\u003c/h5>\u003cp class=\"mb0\">following the designated pre-treatment time, ptz was administered at 75&#x000a0;mg/kg s.c. animals were transferred to a single cage and monitored closely for the onset of clonic seizure, and the percentage of each group showing seizures was recorded. protection was defined as the complete absence of clonic seizure, including forelimb clonus, over the 30&#x000a0;min observation period.\u003c/p>\u003ch5>2.3.9.2 maximal electroshock test\u003c/h5>\u003cp class=\"mb0\">following the designated pre-treatment time, rats received maximal electroshock (mes: 150&#x000a0;ma, 0.2&#x000a0;s duration, 60&#x000a0;hz) via corneal electrodes moistened with saline (shock simulator type 221; harvard apparatus). due to inconsistency in responses by rats to this type of stimuli, all test animals (n &#x0003d; 60) were subjected to two screening sessions on two separate days, and 40 rats were selected based on their reliability to have tonic seizures. drug testing was conducted on the third day, during which the rats received the standard maximal electroshock, and the presence or absence of a tonic seizure was recorded and expressed as the percentage of animals in each group that showed seizures. protection was defined as the absence of a full tonic seizure within 15&#x000a0;s of stimulus delivery.\u003c/p>\u003ca id=\"h7-3-10\" name=\"h7-3-10\">\u003c/a>\u003ch4>2.3.10 combination with diazepam on rotarod performance in rats\u003c/h4>\u003cp class=\"mb0\">forty-eight male sprague&#x02013;dawley rats (&#x0223c;170&#x02013;200&#x000a0;g) were pre-trained to the rotarod (47750 rota-rod ng, ugo basile) at 8&#x000a0;rpm for 120&#x000a0;s. one day later, rats were administered alogabat (or vehicle) p.o., 30&#x000a0;min prior to diazepam or vehicle i.p., and they were assessed on the rotarod 30&#x000a0;min later. each rat was given three attempts to remain on the rotarod, with a maximum duration of 120&#x000a0;s per attempt. treatment groups (n &#x0003d; 8/group) consisted of alogabat alone (30&#x000a0;mg/kg), diazepam alone (5&#x000a0;mg/kg), or alogabat at 3, 10, and 30&#x000a0;mg/kg in combination with diazepam (5&#x000a0;mg/kg). the maximum time (s) spent on the rotarod was recorded. after the completion of rotarod testing, animals were euthanized under isoflurane anesthesia for plasma sample collection at approximately 70&#x000a0;min post-administration of alogabat.\u003c/p>\u003ca id=\"h7-3-11\" name=\"h7-3-11\">\u003c/a>\u003ch4>2.3.11 cognition testing in rats\u003c/h4>\u003ch5>2.3.11.1 operant and touchscreen cognition tests\u003c/h5>\u003cp class=\"mb0\">separate groups of male lister hooded (lh) rats (&#x0223c;400&#x000a0;g) were pre-trained in the operant and touch screen tests, as described in \u003ca href=\"#sm1\">supplementary material\u003c/a>. the 5-csrt task (n &#x0003d; 11) is a test of attention. the primary parameter is the total percentage of correct responses. continuous performance test (cpt; n &#x0003d; 11) assesses sustained attention. the primary parameter is the discrimination sensitivity index (d prime), which is a ratio based on the rate at which rats make correct and incorrect responses. the paired associates learning (pal) task (n &#x0003d; 12) assesses visual&#x02013;spatial memory. the primary parameter is the total percentage of correct responses. a latin-squares design was used to assess the vehicle and doses of alogabat (3, 10, and 30&#x000a0;mg/kg p.o.). rats were tested twice weekly with at least a 2-day interval between test sessions. rats were trained between test days to maintain baseline performance.\u003c/p>\u003ch5>2.3.11.2 context fear conditioning\u003c/h5>\u003cp class=\"mb0\">two cohorts of male lh rats (&#x0223c;250&#x000a0;g; n &#x0003d; 67) were assessed for context fear conditioning (cfc) in two experiments: (1) vehicle or alogabat at 10 and 30&#x000a0;mg/kg (n &#x0003d; 9/dose); (2) vehicle or alogabat at 1, 3, and 10&#x000a0;mg/kg (n &#x0003d; 10/dose) administered p.o., 60&#x000a0;min prior to the acquisition session. rats were placed into a novel test chamber (45&#x000a0;cm &#x000d7; 45&#x000a0;cm &#x000d7; 46.5&#x000a0;cm) with a grid floor and clear plastic walls (tse-systems gmbh, germany). during the acquisition session, a 2-min habituation phase was followed by the delivery of a mild foot shock (0.8&#x000a0;ma for 1&#x000a0;s) applied through the grid floor. following a 1&#x000a0;min interval, a second foot shock was delivered. the animals remained in the chambers for a further 30&#x000a0;s. one day later, the animals were returned to the same test chamber for a 5-min period without any foot shock. rodents respond to danger in a species-specific manner by freezing, i.e., the animals will withhold all movement, except for respiration, to avoid detection. the amount of freezing behavior was measured by the computer as the time spent immobile (minimum threshold of 1&#x000a0;s) and was expressed as the percentage of time spent freezing during the 5-min session. following cfc, plasma samples were collected 1&#x02013;2&#x000a0;days later from rats pre-treated with the same dose at 60&#x000a0;min post-administration (\u003cem>n\u003c/em> &#x0003d; 4/dose).\u003c/p>\u003ch5>2.3.11.3 morris water maze\u003c/h5>\u003cp class=\"mb0\">male lh rats (350&#x02013;400&#x000a0;g) were pre-treated with vehicle or 10 or 30&#x000a0;mg/kg alogabat p.o. (n &#x0003d; 10/dose) once daily during cued acquisition (visible platform; three trials per day for 2&#x000a0;days), followed by a 2-day interval and then spatial acquisition (hidden platform; three trials per day for 4&#x000a0;days) in the morris water maze (mwm; computer tracking system hvs image ltd., united kingdom) (\u003ca href=\"#b5\">ballard et al., 2005\u003c/a>). twenty-four hours later, the platform was removed, and the rats were pre-treated with vehicle or alogabat and allowed to swim in the maze for 60&#x000a0;s (probe trial) to assess the retention/spatial memory of the platform position, expressed as the percentage of distance traveled in each quadrant. for the mwm, plasma samples were collected immediately after the last trial on the 12th day of treatment at approximately 70&#x000a0;min post-administration (\u003cem>n\u003c/em> &#x0003d; 4&#x02013;5/dose).\u003c/p>\u003ca id=\"h7-3-12\" name=\"h7-3-12\">\u003c/a>\u003ch4>2.3.12 plasma sampling and analysis\u003c/h4>\u003cp class=\"mb0\">rodents were deeply anesthetized with 5% isoflurane, and blood was collected following decapitation with a guillotine or via cardiac puncture (ptz and mes). during eeg experiments, blood was collected from a cannula in the right femoral artery. blood samples were centrifuged in edta-coated eppendorf tubes (4,000&#x000a0;rpm, 4&#x000b0;c, 5&#x000a0;min), and plasma was collected, immediately frozen, and stored at &#x02212;80&#x000b0;c. samples were analyzed for the concentration of alogabat using qualified liquid chromatography coupled to tandem mass spectrometry (lc-ms/ms) assays.\u003c/p>\u003ca id=\"h7-3-13\" name=\"h7-3-13\">\u003c/a>\u003ch4>2.3.13 statistical analysis\u003c/h4>\u003cp class=\"mb0\">sample sizes were determined based on historical data for each experiment within each laboratory.\u003c/p>\u003ch5>2.3.13.1 eeg\u003c/h5>\u003cp class=\"mb0\">linear mixed-effects models (lmms) were used since these can account for incomplete datasets, which was the case in this study. specific contrasts were derived and tested using t-tests within the model using satterthwaite approximation for degrees of freedom. models were derived for each compound individually: y &#x0223c; compound &#x0002b; (1&#x0007c;animal). the significance of differences in the peak frequency was assessed using random permutation tests (10,000).\u003c/p>\u003ch5>2.3.13.2 phmri\u003c/h5>\u003cp class=\"mb0\">analysis was performed with jmp (sas institute inc., cary, united states) and matlab (the mathworks inc., natick, ma, united states). global (whole-brain) absolute-perfusion values from the vehicle and the three dose groups were tested for a linear trend across the four doses using a one-way anova framework. the same analysis was applied roi-wise to the normalized-perfusion values. multiple testing across the single rois was accounted for by controlling the false discovery rate (fdr) at 10% using the benjamini&#x02013;hochberg approach. to also obtain an overall activation&#x02013;strength metric, normalized-perfusion values of each dose group were compared roi-wise to those of the vehicle group using welch&#x02019;s t-test without multiple-testing correction. the number of significantly modulated rois at each dose was then taken as a measure of &#x0201c;pattern strength.&#x0201d; the mean and the upper 95% confidence limit of the corresponding chance levels were estimated via random group-label permutations (100,000 runs per group). significance levels of the actual pattern strengths were determined based on the distributions obtained through the permutation procedure.\u003c/p>\u003ch5>2.3.13.3 behavior\u003c/h5>\u003cp class=\"mb0\">all statistical analyses were performed using prism (graphpad software). one-factor anova was used for between-group comparison (i.e., dose), with repeated measures for within-subject comparison (i.e., time bins and platform quadrants). dunnett&#x02019;s test was used for \u003cem>post hoc\u003c/em> comparisons. student&#x02019;s unpaired two-tailed t-test was used when two groups were compared. the chi-square test was used to compare the percentage of groups. rotarod data were analyzed using a non-parametric kruskal&#x02013;wallis test, followed by dunn&#x02019;s multiple comparison test. statistical significance was predetermined as \u003cem>p\u003c/em> &#x0003c; 0.05.\u003c/p>\u003ca id=\"h4\" name=\"h4\">\u003c/a>\u003ch2>3 results\u003c/h2>\u003ca id=\"h4-1\" name=\"h4-1\">\u003c/a>\u003ch3 class=\"pt0\">3.1 binding affinity for gaba\u003csub>a\u003c/sub> receptors containing &#x003b1;5 and other &#x003b1; subunits\u003c/h3>\u003cp class=\"mb0\">the aim of these radioligand binding studies was to determine the binding selectivity of alogabat at the rat and human gaba\u003csub>a\u003c/sub> receptors containing &#x003b1;5 compared to &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits. alogabat had a high affinity for gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 receptors in rats (ki 7.9&#x000a0;nm), with approximately 37-, 26-, and 18-fold selectivity compared to gaba\u003csub>a\u003c/sub> &#x003b1;1&#x003b2;3&#x003b3;2, &#x003b1;2&#x003b2;3&#x003b3;2, and &#x003b1;3&#x003b2;3&#x003b3;2, respectively (\u003ca href=\"#f1\">figure 1b\u003c/a>; see \u003ca href=\"#sm1\">supplementary table s1\u003c/a>). alogabat had a similar pharmacological profile in human recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (see \u003ca href=\"#sm1\">supplementary table s1\u003c/a>).\u003c/p>\u003ca id=\"h4-2\" name=\"h4-2\">\u003c/a>\u003ch3 class=\"pt0\">3.2 functional activity at recombinant and native gaba\u003csub>a\u003c/sub> receptors\u003c/h3>\u003cp class=\"mb0\">we undertook electrophysiological studies in hek293 cells and oocytes to assess the functional activity of alogabat on cloned rat and human gaba\u003csub>a\u003c/sub> receptor subtypes containing &#x003b1;5, &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits. alogabat enhanced gaba-evoked responses of rat and human &#x003b1;5-containing receptors by 167% (\u003ca href=\"#f1\">figure 1c\u003c/a>) and 72% (see \u003ca href=\"#sm1\">supplementary table s2\u003c/a>), respectively. the maximum amount of potentiation was slightly lower at human receptors. this may be due to the different expression systems used, i.e., hek293 cells for rat receptors and \u003cem>xenopus\u003c/em> oocytes for human receptors. at the highest concentrations tested, alogabat potentiated other receptor subtypes to a much lesser extent than &#x003b1;5-containing receptors. the potency of alogabat was comparable between gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors containing either &#x003b3;2 or &#x003b3;3 subunits, i.e., gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 and gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;3 receptors (see \u003ca href=\"#sm1\">supplementary figure s1\u003c/a>).\u003c/p>\u003cp class=\"mb0\">at native gaba\u003csub>a\u003c/sub> receptors in rat hippocampal slices, alogabat positively modulated gabaergic inhibition of ca1 pyramidal cells, as shown by a leftward shift of the concentration-dependent inhibition of the population spike by isoguvacine (\u003ca href=\"#f1\">figure 1d\u003c/a>) and enhanced paired-pulse inhibition of the population spike during field potential recordings (\u003ca href=\"#f1\">figure 1e\u003c/a>). together, these results confirm the binding selectivity of alogabat and demonstrate that alogabat is a functionally selective pam of gaba-evoked responses.\u003c/p>\u003ca id=\"h4-3\" name=\"h4-3\">\u003c/a>\u003ch3 class=\"pt0\">3.3 selectivity data\u003c/h3>\u003cp class=\"mb0\">we assessed alogabat in radioligand binding studies with more than 70 receptors and showed that alogabat at 10&#x000a0;&#x000b5;m had over 917-fold binding selectivity for the gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 receptor subtype against all other targets tested (see \u003ca href=\"#sm1\">supplementary table s3\u003c/a>).\u003c/p>\u003ca id=\"h4-4\" name=\"h4-4\">\u003c/a>\u003ch3 class=\"pt0\">3.4 receptor occupancy in wistar rats and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h3>\u003cp class=\"mb0\">the main objective of these studies was to visualize and quantify gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro by alogabat. alogabat decreased the specific binding of the gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor-specific radioligand [\u003csup>3\u003c/sup>h]ro0154513 in the hippocampus of rats in a dose-dependent manner. the highest dose of alogabat (100&#x000a0;mg/kg i.p.) reduced specific binding by 100%, i.e., to the same binding level as that of 10&#x000a0;mg/kg l-655,708 (\u003ca href=\"#f2\">figure 2a\u003c/a>). a total plasma concentration of 669&#x000a0;ng/ml and a total brain concentration of 208&#x000a0;ng/g were required to produce half-maximal gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro (ec\u003csub>50\u003c/sub>) in the hippocampus in rats. in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice, estimated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro based on the \u003cem>ex vivo\u003c/em> study with [\u003csup>3\u003c/sup>h]l-655,708 was 43%, 46%, and 71% at doses of 30, 60, and 100&#x000a0;mg/kg i.p., respectively (\u003ca href=\"#f2\">figure 2b\u003c/a>). in addition, the rat occupancy curve was used to calculate ro related to plasma exposure for all \u003cem>in vivo\u003c/em> experiments described in this manuscript below (also refer to \u003ca href=\"#sm1\">supplementary tables s4&#x02013;s5\u003c/a>).\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 2\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" name=\"figure2\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" alt=\"www.frontiersin.org\" id=\"f2\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 2\u003c/b>. receptor occupancy and phmri signature of alogabat following acute administration. \u003cb>(a)\u003c/b> concentration-dependent blockade of [\u003csup>3\u003c/sup>h]ro0154513 binding by alogabat in wistar rats: with increasing concentrations from the different doses (0.3&#x02013;100&#x000a0;mg/kg i.p., n &#x0003d; 3/dose) of alogabat (vehicle &#x0003d; without pre-treatment, n &#x0003d; 3). \u003cb>(b)\u003c/b> representative autoradiograms of alogabat \u003cem>ex vivo\u003c/em> occupancy in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice via \u003cem>in vitro\u003c/em> incubation of the highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor radioligand [\u003csup>3\u003c/sup>h]l-655,708 to sagittal brain sections. the cntnap2&#x02212;/&#x02212; mice were treated with vehicle and 30, 60, or 100&#x000a0;mg/kg i.p. alogabat (n &#x0003d; 4/dose). \u003cb>(c)\u003c/b> trend of normalized-perfusion response pattern strength increasing with dose, given as numbers (&#x000b1; 95% confidence intervals) of significantly (de-)activated regions of interest (rois) following the administration of alogabat (n &#x0003d; 8/dose) to fischer (f344) rats under medetomidine sedation. &#x0201c;chance level&#x0201d; &#x0003d; mean (black dotted line) and 95th percentile (gray dotted line) derived from the permutation test. significant deviations in the number of modulated rois from the chance level are denoted by &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 (uncorrected). ro is the calculated receptor occupancy for gaba\u003csub>a\u003c/sub>-&#x003b1;5 from measured plasma concentrations at each dose. \u003cb>(d)\u003c/b> sagittal schematic of rat brain showing rois with a significant dose-dependent modulation (linear trend of normalized perfusion). rois passing false discovery rate control at 10% are shown, with roi outlines indicating uncorrected significance level (no outline, \u003cem>p\u003c/em> &#x0003c; 0.05; dotted outline, \u003cem>p\u003c/em> &#x0003c; 0.01; and solid outline, \u003cem>p\u003c/em> &#x0003c; 0.001). roi abbreviations: acbsh, nucleus accumbens shell; amg, amygdala; drn, dorsal raphe nucleus; hpcfi, fimbria hippocampi; insc, insular cortex; lc, locus coeruleus; m1, primary motor cortex; mpfc/cg, medial prefrontal, cingulate cortex; pir, piriform (entorhinal) cortex; prh, perirhinal cortex; s1, primary somatosensory cortex; sn, substantia nigra; th, thalamus; vc, visual cortex.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h4-5\" name=\"h4-5\">\u003c/a>\u003ch3 class=\"pt0\">3.5 pharmacological mri signature in rats\u003c/h3>\u003cp class=\"mb0\">the purpose of this study was to evaluate the effects of alogabat on regional neural activity. blood perfusion, measured quantitatively by phmri, was taken as a proxy for neural activity. the administration of a single dose of alogabat at 3&#x02013;30&#x000a0;mg/kg i.p. in rats resulted in moderate but consistent and dose-dependent changes in neural activity patterns compared to treatment with the vehicle (\u003ca href=\"#f2\">figure 2c\u003c/a>). significant dose-dependent modulation of normalized perfusion by alogabat was observed in limbic brain regions, i.e., the nucleus accumbens (shell), amygdala, and hippocampus (fimbria); in several cortical brain regions, the thalamus and brainstem nuclei; and in the substantia nigra (\u003ca href=\"#f2\">figure 2d\u003c/a>). a linear dose effect was also observed on whole-brain absolute perfusion. alogabat target engagement in brain tissue ranged from 54% to 84% ro.\u003c/p>\u003ca id=\"h4-6\" name=\"h4-6\">\u003c/a>\u003ch3 class=\"pt0\">3.6 eeg signature in rats\u003c/h3>\u003cp class=\"mb0\">the aim of this study was to determine whether alogabat induces a characteristic eeg signature that could be used as a translational pharmacodynamic marker. as a first step and based on previous findings on the eeg effects of gaba\u003csub>a\u003c/sub> drugs (\u003ca href=\"#b71\">van lier et al., 2004\u003c/a>; \u003ca href=\"#b72\">visser et al., 2003\u003c/a>; \u003ca href=\"#b22\">friedman et al., 1992\u003c/a>), we investigated eeg spectral power change in the theta (6&#x02013;10&#x000a0;hz) and beta (20&#x02013;30&#x000a0;hz) frequency bands. alogabat, administered as 10&#x000a0;mg/kg i.v. (5&#x000a0;min infusion), significantly increased eeg beta-band activity by 21% &#x000b1; 11% relative to the baseline (mean &#x000b1; sd) and decreased theta-band activity by 32% &#x000b1; 19% (\u003ca href=\"#f3\">figures 3a,b\u003c/a>). frequency-resolved changes confirmed a decrease in theta power (approximately 6&#x02013;10&#x000a0;hz) and revealed broader beta and gamma modulation (approximately 20&#x02013;50&#x000a0;hz) (\u003ca href=\"#f3\">figures 3c&#x02013;e\u003c/a>). the calculated ro after the application of alogabat was 77%&#x02013;85% for gaba\u003csub>a\u003c/sub>-&#x003b1;5 (see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). the overall spectral pattern was qualitatively similar to that of diazepam; however, the peak frequency in the beta frequency range was higher for alogabat (32&#x000a0;hz for alogabat vs. 22.6&#x000a0;hz for diazepam; \u003cem>p\u003c/em> &#x0003d; 0.006, random permutation test), and its amplitude was greater for diazepam (142% &#x000b1; 44% increase for diazepam vs. 27% &#x000b1; 16% increase for alogabat; \u003cem>p\u003c/em> &#x0003c; 0.001). this is likely related to the high binding and functional selectivity of alogabat for &#x003b1;5-containing gaba\u003csub>a\u003c/sub> receptors compared to the non-selective profile of diazepam.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 3\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" name=\"figure3\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" alt=\"www.frontiersin.org\" id=\"f3\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 3\u003c/b>. pharmacodynamic effect of alogabat on eeg spectral power. \u003cb>(a,b)\u003c/b> modulations of vehicle (\u003cem>n\u003c/em> &#x0003d; 12), alogabat 10&#x000a0;mg/kg (\u003cem>n\u003c/em> &#x0003d; 9), and diazepam 2&#x000a0;mg/kg (\u003cem>n\u003c/em> &#x0003d; 7, positive control) in the beta (20&#x02013;30&#x000a0;hz) and theta (6&#x02013;10&#x000a0;hz) power. \u003cb>(c&#x02013;e)\u003c/b> effects of individual compounds and vehicle on the eeg power spectrum. each individual recording is displayed as a light gray line, and the group average and its 95% confidence intervals are shown as colored bands. for all panels, power averaged over 0.2&#x02013;1&#x000a0;h post dosing is shown relative to pre-dosing baseline average over &#x02212;1 to &#x02212;0.2&#x000a0;h before dosing. statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05 versus vehicle (linear mixed-effects models followed by t-tests).\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h4-7\" name=\"h4-7\">\u003c/a>\u003ch3 class=\"pt0\">3.7 repetitive behaviors in mouse models relevant to asd\u003c/h3>\u003cp class=\"mb0\">the inbred mouse strain btbr and the cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mouse show abnormalities in core asd behavioral domains, such as repetitive behaviors. self-grooming and digging are more elevated in the btbr mouse than in other strains, i.e., c57bl/6j (\u003ca href=\"#b40\">mcfarlane et al., 2008\u003c/a>), and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice show more elevated grooming than their wildtype littermates (\u003ca href=\"#b51\">penagarikano et al., 2011\u003c/a>). the aim of the following experiments was to determine whether alogabat has a specific effect on repetitive behaviors independent of potential effects on overall locomotor activity. we assessed the effects of subchronic treatment on cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice to exclude potential tolerance to the effects of alogabat.\u003c/p>\u003ca id=\"h8-7-1\" name=\"h8-7-1\">\u003c/a>\u003ch4>3.7.1 open field in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h4>\u003cp class=\"mb0\">in btbr mice, acute administration of alogabat (30&#x02013;120&#x000a0;mg/kg i.p.) had no effect on the total activity over 1&#x000a0;h measured in an open field [f(4,55) &#x0003d; 2.04], although during the first 10&#x000a0;min, alogabat at 90 and 120&#x000a0;mg/kg significantly reduced the distance traveled [f(4,55) &#x0003d; 9.623, \u003cem>p\u003c/em> &#x0003c; 0.001, \u003ca href=\"#f4\">figure 4a\u003c/a>]. there was also no effect of sub-chronic alogabat (30&#x02013;100&#x000a0;mg/kg i.p.) on the total activity over 1&#x000a0;h in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice [f(3,53) &#x0003d; 0.98]. during the first 5&#x000a0;min, 100&#x000a0;mg/kg reduced the distance traveled in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice to the same level as vehicle-treated wildtype mice (\u003ca href=\"#f4\">figure 4b\u003c/a>). alogabat did not induce a major impairment of locomotor activity in the open field.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 4\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" name=\"figure4\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" alt=\"www.frontiersin.org\" id=\"f4\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 4\u003c/b>. effect of alogabat on repetitive behaviors in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. \u003cb>(a)\u003c/b> alogabat was administered i.p. 30&#x000a0;min prior to the assessment of locomotor activity in an open-field test in btbr mice: distance traveled (cm) per 5&#x000a0;min time bin (\u003cem>line graph\u003c/em>) and in 1&#x000a0;h total (\u003cem>bar chart inset\u003c/em>). \u003cb>(b)\u003c/b> alogabat was administered i.p. once daily for 2&#x02013;3&#x000a0;days, and on the test day, it was administered 30&#x000a0;min prior to testing cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice in an open field: distance traveled (cm) per 5&#x000a0;min time bin (\u003cem>line graph\u003c/em>) and in 1&#x000a0;h total (\u003cem>bar chart insert\u003c/em>). in btbr mice, on a separate test day, alogabat was administered i.p. 30&#x000a0;min prior to the grooming test: \u003cb>(c)\u003c/b> duration (s) of grooming behavior and \u003cb>(e)\u003c/b> distance (cm) traveled during the 10&#x000a0;min period in the test chamber. in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice, alogabat was administered i.p. once daily for 8&#x02013;10&#x000a0;days, and on the test day, it was administered 30&#x000a0;min prior to the grooming test: \u003cb>(d)\u003c/b> duration (s) of grooming behavior and \u003cb>(f)\u003c/b> distance traveled during the 10&#x000a0;min period in the test chamber. data are presented as individual points (circles) and mean &#x000b1; sem (btbr: \u003cem>n\u003c/em> &#x0003d; 12/group; cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup>: \u003cem>n\u003c/em> &#x0003d; 14&#x02013;15/group). statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. vehicle (veh)-treated btbr or cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. &#x000a7;&#x000a7;&#x000a7;\u003cem>p\u003c/em> &#x0003c; 0.001 vehicle-treated wildtype (wt-v) mice vs. vehicle (v)-treated cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. alogabat was administered i.p. 30&#x000a0;min prior to the assessment of digging behavior in btbr mice: \u003cb>(g)\u003c/b> duration (s) of digging behavior, \u003cb>(h)\u003c/b> distance traveled (cm), and \u003cb>(i)\u003c/b> speed (cm/s) during the 5&#x000a0;min period in the test chamber. data are presented as individual points (circles) and mean &#x000b1; sem (\u003cem>n\u003c/em> &#x0003d; 12/group). statistics: &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01 and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. vehicle-treated btbr mice. ro is the calculated receptor occupancy for gaba\u003csub>a\u003c/sub>-&#x003b1;5 from the measured plasma concentrations at each dose.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h8-7-2\" name=\"h8-7-2\">\u003c/a>\u003ch4>3.7.2 grooming behavior in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h4>\u003cp class=\"mb0\">acute administration of alogabat in btbr mice dose-dependently attenuated grooming behavior at 60, 90, and 120&#x000a0;mg/kg i.p. [f(4,55) &#x0003d; 6.946, \u003cem>p\u003c/em> &#x0003d; 0.0001, \u003ca href=\"#f4\">figure 4c\u003c/a>] without reducing locomotor activity in the same test arena (\u003ca href=\"#f4\">figure 4e\u003c/a>). in contrast, doses of 60 and 90&#x000a0;mg/kg increased the distance traveled [f(4,55) &#x0003d; 3.454, \u003cem>p\u003c/em> &#x0003c; 0.05]. alogabat had a specific effect on grooming behavior at plasma concentrations corresponding to calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 45%&#x02013;70% (see \u003ca href=\"#sm1\">supplementary table s4\u003c/a>).\u003c/p>\u003cp class=\"mb0\">sub-chronic administration of alogabat in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice attenuated grooming behavior at 60 and 100&#x000a0;mg/kg i.p. [f(3,53) &#x0003d; 10.57, \u003cem>p\u003c/em> &#x0003c; 0.0001, \u003ca href=\"#f4\">figure 4d\u003c/a>], with no effect on locomotor activity measured in the same test arena [f(3,53) &#x0003d; 0.74, \u003ca href=\"#f4\">figure 4f\u003c/a>]. alogabat had a specific effect on repetitive grooming behavior at plasma concentrations that correspond with calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro of 52%&#x02013;79% (see \u003ca href=\"#sm1\">supplementary table s4\u003c/a>).\u003c/p>\u003ca id=\"h8-7-3\" name=\"h8-7-3\">\u003c/a>\u003ch4>3.7.3 digging behavior in btbr mice\u003c/h4>\u003cp class=\"mb0\">there was no effect of acute alogabat administration on digging behavior at doses up to 100&#x000a0;mg/kg i.p. [f(3,36) &#x0003d; 0.8, \u003ca href=\"#f4\">figure 4g\u003c/a>], corresponding to a calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro level of 67% (see \u003ca href=\"#sm1\">supplementary table s4\u003c/a>). alogabat at 100&#x000a0;mg/kg reduced the distance traveled [f(3,36) &#x0003d; 12.1, \u003cem>p\u003c/em> &#x0003c; 0.001, \u003ca href=\"#f4\">figure 4h\u003c/a>] and speed [f(3,36) &#x0003d; 11.5, \u003cem>p\u003c/em> &#x0003c; 0.001, \u003ca href=\"#f4\">figure 4i\u003c/a>] in the same arena.\u003c/p>\u003ca id=\"h4-8\" name=\"h4-8\">\u003c/a>\u003ch3 class=\"pt0\">3.8 anticonvulsant activity in rats\u003c/h3>\u003cp class=\"mb0\">the purpose of these experiments was to evaluate the antiepileptic properties of alogabat against seizures induced by ptz and the mes model. alogabat administered in combination with a convulsant dose of ptz completely blocked seizures at 15 and 30&#x000a0;mg/kg (\u003ca href=\"#f5\">figure 5a\u003c/a>), which corresponds to calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 71% and 77% (see \u003ca href=\"#sm1\">supplementary table s5\u003c/a>). meanwhile, in the mes test, alogabat at 5&#x000a0;mg/kg (57% ro, see \u003ca href=\"#sm1\">supplementary table s5\u003c/a>) showed a significant reduction in the percent of rats that had tonic seizures (\u003ca href=\"#f5\">figure 5b\u003c/a>); there was only a tendency for reduction at 15&#x000a0;mg/kg (\u003cem>p\u003c/em> &#x0003d; 0.1) and 30&#x000a0;mg/kg (\u003cem>p\u003c/em> &#x0003d; 0.06). the positive control, diazepam, significantly reduced the percentage of rats that had seizures in both the ptz and mes tests.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 5\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" name=\"figure5\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" alt=\"www.frontiersin.org\" id=\"f5\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 5\u003c/b>. evaluation of alogabat for effects on anticonvulsant, motor, and cognitive tests. alogabat was administered p.o. 60&#x000a0;min prior to the following behavior tests. assessment of potential anticonvulsant activity in \u003cb>(a)\u003c/b> ptz and \u003cb>(b)\u003c/b> mes tests in rats. diazepam (dzp) at 3&#x000a0;mg/kg i.p. was included as a positive control. data are presented as individual points (circles) and the percentage of rats per group showing seizures (\u003cem>n\u003c/em> &#x0003d; 8/group). \u003cb>(c)\u003c/b> time (s) spent on the rotarod at 16&#x000a0;rpm in rats administered alogabat alone (30&#x000a0;mg/kg, gray bar with black outline) or alogabat at 3, 10, and 30&#x000a0;mg/kg co-administered with diazepam at 5&#x000a0;mg/kg i.p. (gray bars with red outline) compared with vehicle (open bar) or diazepam (open bar with red outline). data are presented as individual points (circles) and median &#x000b1; interquartile range (n &#x0003d; 8/group). assessment of cognition in rats: \u003cb>(d)\u003c/b> attention in the 5-choice serial reaction time (5-csrt) task; \u003cb>(e)\u003c/b> sustained attention in the touchscreen continuous performance test (cpt); \u003cb>(f)\u003c/b> visual&#x02013;spatial memory in the touchscreen pal task. cfc at \u003cb>(g)\u003c/b> 10 and 30&#x000a0;mg/kg; \u003cb>(h)\u003c/b> 1, 3, and 10&#x000a0;mg/kg. spatial learning and memory in the mwm: alogabat was administered once daily for 11&#x000a0;days prior to the probe trial. \u003cb>(i)\u003c/b> percentage of distance traveled in all four quadrants: vehicle; 10&#x000a0;mg/kg; 30&#x000a0;mg/kg. data are presented as individual points (circles) and mean &#x000b1; sem for pal (\u003cem>n\u003c/em> &#x0003d; 12/dose; within-subjects), 5-csrt and cpt (\u003cem>n\u003c/em> &#x0003d; 11/dose, within-subjects), cfc (\u003cem>n\u003c/em> &#x0003d; 9&#x02013;10/group), and mwm (\u003cem>n\u003c/em> &#x0003d; 10/group). statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. vehicle (veh or 0)-treated rats; mwm statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. percentage of distance in the platform quadrant. ro is the calculated receptor occupancy of alogabat for gaba\u003csub>a\u003c/sub>-&#x003b1;5 from measured plasma concentrations at each dose.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h4-9\" name=\"h4-9\">\u003c/a>\u003ch3 class=\"pt0\">3.9 combination with diazepam on rotarod performance in rats\u003c/h3>\u003cp class=\"mb0\">classical benzodiazepines, such as diazepam, are known to induce sedation and ataxia, which can be measured by the rotarod task in rodents. the aim of this experiment was to determine whether alogabat affects rotarod performance when administered alone and, second, whether alogabat modulates the sedative/motor effect of diazepam on rotarod performance when given in combination. diazepam at 5&#x000a0;mg/kg i.p. significantly impaired rotarod performance. alogabat (3&#x02013;30&#x000a0;mg/kg p.o.) co-administered with diazepam did not worsen the effects of diazepam on rotarod performance (\u003ca href=\"#f5\">figure 5c\u003c/a>). alogabat administered alone at 30&#x000a0;mg/kg p.o. did not differ from vehicle-treated rats, corresponding to a calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro level of 88% (see \u003ca href=\"#sm1\">supplementary table s5\u003c/a>).\u003c/p>\u003ca id=\"h4-10\" name=\"h4-10\">\u003c/a>\u003ch3 class=\"pt0\">3.10 evaluation of cognition in rats\u003c/h3>\u003cp class=\"mb0\">since non-selective gaba\u003csub>a\u003c/sub> pams, such as diazepam, have been shown to impair cognition (\u003ca href=\"#b5\">ballard et al., 2005\u003c/a>), the aim of the following experiments was to study the potential effects of acute administration of alogabat on cognition in rats. this included attention in the 5-csrt task and associative (fear) memory in cfc. we also assessed visual&#x02013;spatial memory (pal task) and attention (cpt) in a touchscreen system, which provides a translational approach for assessing cognition (\u003ca href=\"#b34\">hvoslef-eide et al., 2016\u003c/a>). chronic treatment with alogabat was also assessed on spatial learning and memory in the mwm.\u003c/p>\u003cp class=\"mb0\">in the 5-csrt task, alogabat at 30&#x000a0;mg/kg induced a small but statistically significant reduction in percent correct (3%; within-subjects comparison; f(3,30) &#x0003d; 5.6, \u003cem>p\u003c/em> &#x0003c; 0.01; \u003ca href=\"#f5\">figure 5d\u003c/a>). however, alogabat did not impair attention in cpt (f(2,20) &#x0003d; 0.3; \u003ca href=\"#f5\">figure 5e\u003c/a>) or visual&#x02013;spatial memory in the pal task (f(2,22) &#x0003d; 2.6; \u003ca href=\"#f5\">figure 5f\u003c/a>).\u003c/p>\u003cp class=\"mb0\">in the cfc test, alogabat was administered before the acquisition session to determine whether there was an effect on learning the association between foot shock and the surrounding context. in the first experiment, alogabat impaired cfc at 10 and 30&#x000a0;mg/kg, corresponding to calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 75% and 81% (f(2,24) &#x0003d; 10.99, \u003cem>p\u003c/em> &#x0003c; 0.001; \u003ca href=\"#f5\">figure 5g\u003c/a>). a second experiment was undertaken to explore lower doses, and it showed that alogabat did not significantly impair cfc at 1, 3, and 10&#x000a0;mg/kg (f(3,36) &#x0003d; 0.9; \u003ca href=\"#f5\">figure 5h\u003c/a>), corresponding to the calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 35%, 56%, and 72%. this suggests that the dose of 10&#x000a0;mg/kg is approximately the threshold level for the impairment of cfc and is likely dependent on the level of ro achieved per subject.\u003c/p>\u003cp class=\"mb0\">in the mwm test, chronic administration of alogabat at 10 and 30&#x000a0;mg/kg did not significantly impair the acquisition of the hidden platform position (see \u003ca href=\"#sm1\">supplementary figure s2\u003c/a>). twenty-four hours later, the platform was removed, and the rats were allowed to swim in the maze for 60&#x000a0;s (probe trial) to assess memory-retention of the platform position. the groups receiving vehicle [f(3,27) &#x0003d; 8, \u003cem>p\u003c/em> &#x0003c; 0.001] and 10&#x000a0;mg/kg [f(3,27) &#x0003d; 7, \u003cem>p\u003c/em> &#x0003c; 0.01] had learned the spatial position of the platform, as shown by their preference for the platform quadrant (\u003ca href=\"#f5\">figure 5i\u003c/a>). however, rats that received 30&#x000a0;mg/kg alogabat showed impaired spatial memory of the platform position during the probe trial [f(3,27) &#x0003d; 3, p &#x0003d; 0.08; \u003ca href=\"#f5\">figure 5i\u003c/a>], and gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro was estimated to be 79%. in summary, alogabat impaired context and spatial memory at gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro above 70%.\u003c/p>\u003ca id=\"h5\" name=\"h5\">\u003c/a>\u003ch2>4 discussion\u003c/h2>\u003ca id=\"h5-1\" name=\"h5-1\">\u003c/a>\u003ch3 class=\"pt0\">4.1 \u003cem>in vitro\u003c/em> and \u003cem>in vivo\u003c/em> characterization of alogabat\u003c/h3>\u003cp class=\"mb0\">alogabat was shown to be a potent and functionally selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor pam \u003cem>in vitro\u003c/em>. the functional activity of alogabat was confirmed at native gaba\u003csub>a\u003c/sub> receptors in rat hippocampal slices. \u003cem>in vivo\u003c/em> binding experiments demonstrated dose-dependent target engagement of alogabat in rats and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. the highest specific binding was observed in the hippocampus, which is consistent with the known distribution of the gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor subtype in rodents (\u003ca href=\"#b54\">pirker et al., 2000\u003c/a>). phmri studies in rats demonstrated dose-dependent perfusion changes, indicating circuit modulation by alogabat. there were consistent changes in the neural activity pattern across dose groups, with modulation of neural activity in, among others, the medial prefrontal cortex, cingulate cortex, motor cortex, perirhinal cortex, nucleus accumbens shell, amygdala, hippocampus fimbria, and substantia nigra.\u003c/p>\u003ca id=\"h5-2\" name=\"h5-2\">\u003c/a>\u003ch3 class=\"pt0\">4.2 eeg signature\u003c/h3>\u003cp class=\"mb0\">acute administration of alogabat in rats induced an eeg signature characterized by a power decrease in theta and an increase in the beta frequency range, which was qualitatively similar to the eeg signature of non-selective gaba\u003csub>a\u003c/sub> pams such as diazepam (\u003ca href=\"#b71\">van lier et al., 2004\u003c/a>; \u003ca href=\"#b72\">visser et al., 2003\u003c/a>; \u003ca href=\"#b22\">friedman et al., 1992\u003c/a>). the lower magnitude of induced eeg beta-band power by alogabat compared to diazepam is likely attributed to its &#x003b1;5-selectivity, resulting in an overall lower magnitude of gaba\u003csub>a\u003c/sub> receptor modulation. this eeg signature of alogabat is qualitatively a mirror image of the eeg signature of basmisanil, a highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 negative allosteric modulator (nam), which we recently found to induce an increase in the theta power and a decrease in the beta-band eeg power in healthy volunteers (\u003ca href=\"#b31\">hipp et al., 2021\u003c/a>). furthermore, the eeg signature of alogabat is in agreement with the link between beta-band activity and single-nucleotide polymorphisms (snps) in gaba\u003csub>a\u003c/sub> receptor genes (\u003ca href=\"#b56\">porjesz et al., 2002\u003c/a>; \u003ca href=\"#b67\">smit et al., 2018\u003c/a>) and ndds (dup15q syndrome, as) involving gene copy number variations of \u003cem>gabrb3, gabra5\u003c/em>, and \u003cem>gabrg3\u003c/em> (\u003ca href=\"#b24\">frohlich et al., 2019a\u003c/a>; \u003ca href=\"#b25\">frohlich et al., 2019b\u003c/a>). gaba\u003csub>a\u003c/sub> receptor-related changes in beta-band activity are believed to reflect the modulation of recurrent excitatory&#x02013;inhibitory feedback loops in the cortical tissue (\u003ca href=\"#b75\">whittington et al., 2000\u003c/a>; \u003ca href=\"#b70\">traub and jefferys, 1999\u003c/a>). for the administered doses, the calculated receptor occupancies were in the range of 77%&#x02013;84% for &#x003b1;5-containing receptors and 22%&#x02013;34% for &#x003b1;1-containing receptors (with different pam effects (e\u003csub>max\u003c/sub>) at &#x003b1;5 vs. &#x003b1;1). thus, at the studied doses, alogabat has some effect on &#x003b1;1-containing receptors, and further work is needed to systematically study lower doses of alogabat, including those &#x0003c;70% ro without the impairment of cognition in wt rats, to confirm whether the modulation of &#x003b1;5-containing receptors alone is sufficient to induce the described eeg effect. nonetheless, eeg theta- and beta-band power are promising candidates for translational mechanistic biomarkers of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor function and could be used in the further development of alogabat.\u003c/p>\u003ca id=\"h5-3\" name=\"h5-3\">\u003c/a>\u003ch3 class=\"pt0\">4.3 behavioral effects of alogabat in animal models relevant to asd\u003c/h3>\u003cp class=\"mb0\">we assessed the effects of alogabat in two different mouse models relevant to asd, one phenotypic and one genetic. acute administration of alogabat significantly and dose-dependently attenuated excessive grooming, but not digging, behavior in btbr mice. sub-chronic administration of alogabat significantly attenuated elevated grooming behavior in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. efficacy in these different models was linked to gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro above 50%. despite initial findings of a transiently decreased activity in an open-field test, alogabat increased the activity of btbr mice and had no effect on the activity of cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice during the grooming test, supporting the specific effect of alogabat on repetitive grooming. we have tested additional compounds with similar properties, e.g., ro7015738, and have confirmed that gaba\u003csub>a\u003c/sub>-&#x003b1;5 pams reduce repetitive behaviors in these mouse models (\u003ca href=\"#b10\">buettelmann et al., 2018\u003c/a>). these results align well with recently published data showing that gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor deficiency causes autism-like behaviors in mice, including increased grooming and reduced social contacts (\u003ca href=\"#b77\">zurek et al., 2016\u003c/a>), and with sh-053-2&#x02032;f-r-ch3, a gaba\u003csub>a\u003c/sub>-&#x003b1;5 pam, which was recently shown to have positive effects on social and cognitive deficits in a rat model of autism (\u003ca href=\"#b68\">souza et al., 2024\u003c/a>). our data are valuable in providing information on the ro required for \u003cem>in vivo\u003c/em> effects on repetitive behavior. however, it should be noted that this effect may not directly translate to all individuals with asd as it is a heterogeneous disorder, whereas these mouse models exhibit specific genetic or phenotypic deficits.\u003c/p>\u003ca id=\"h5-4\" name=\"h5-4\">\u003c/a>\u003ch3 class=\"pt0\">4.4 anticonvulsant effects of alogabat\u003c/h3>\u003cp class=\"mb0\">it has been proposed that the reduction of gabaergic inhibitory activity results in hyperexcitability of minicolumn circuits, explaining some of the symptomatology observed in some ndds, including the high incidence of seizures and auditory&#x02013;tactile hypersensitivity (\u003ca href=\"#b60\">rubenstein and merzenich, 2003\u003c/a>; \u003ca href=\"#b26\">frye et al., 2016\u003c/a>). in the current study, we demonstrated that alogabat exhibits an anticonvulsant profile with activity comparable to the benzodiazepine drug class in acutely induced seizure models (electrical and chemical). alogabat had a small effect on seizures in the mes test, whereas in the ptz test, alogabat was shown to completely block seizures at calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro &#x0003e;70%. since ptz is a gaba\u003csub>a\u003c/sub> antagonist, this supports the assessment of alogabat for anticonvulsant activity in disorders where there is dysfunction of the gabaergic system. furthermore, in a separate eeg study, we observed that one out of eight rats had frequent spike-and-wave discharge (swd) activity, which was alleviated following treatment with alogabat (see \u003ca href=\"#sm1\">supplementary figures s3a&#x02013;s3c\u003c/a>; methods in \u003ca href=\"#sm1\">supplementary material\u003c/a>). to better understand the temporal dynamics of swd occurrence and the suppressing effect of alogabat, we performed a follow-up study on three additional rats that showed pronounced swd. both 3 and 10&#x000a0;mg/kg alogabat substantially reduced the number of swds within the first 3&#x000a0;h of recording, when the same rats showed increased swd numbers in the vehicle control condition (see \u003ca href=\"#sm1\">supplementary figures s3d&#x02013;s3f\u003c/a>), which corresponds to the calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro level of 30%&#x02013;46% (see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). from a circuit perspective, the consensus is that such epileptic activity is generated by dysregulated thalamocortical circuitry, with abnormal interactions between reticular thalamic neurons and thalamic relay cells acting as the trigger and cortical circuits serving as the generator (\u003ca href=\"#b66\">sitnikova et al., 2023\u003c/a>). considering that in rats, &#x003b1;5-subunit-containing gaba\u003csub>a\u003c/sub> receptors are enriched in the cortex and hippocampus (\u003ca href=\"#b64\">serwanski et al., 2006\u003c/a>; \u003ca href=\"#b33\">hu et al., 2019\u003c/a>), mediating dendritic inhibition on pyramidal neurons (\u003ca href=\"#b2\">ali and thomson, 2008\u003c/a>; \u003ca href=\"#b62\">schulz et al., 2018\u003c/a>), we hypothesize that alogabat could suppress swd generation by enhancing the inhibition of cortical pyramidal neurons. however, more systematic work is required to confirm that alogabat can prevent swd activity.\u003c/p>\u003ca id=\"h5-5\" name=\"h5-5\">\u003c/a>\u003ch3 class=\"pt0\">4.5 assessment of non-specific behavioral effects\u003c/h3>\u003cp class=\"mb0\">non-selective gaba\u003csub>a\u003c/sub> pams, such as diazepam and chlordiazepoxide, are effective anxiolytics in clinical use but have also been shown to impair cognition in rodents and humans. gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors are believed to play a major role in cognition since they are predominantly expressed in the hippocampus in rats, where they regulate nmdar-dependent synaptic plasticity underlying learning and memory processes (\u003ca href=\"#b62\">schulz et al., 2018\u003c/a>; \u003ca href=\"#b23\">fritschy et al., 1997\u003c/a>; \u003ca href=\"#b63\">schulz et al., 2019\u003c/a>; \u003ca href=\"#b14\">davenport et al., 2021\u003c/a>). moreover, it has been proposed that gaba\u003csub>a\u003c/sub> pams may induce memory impairment by modulating hippocampal function (\u003ca href=\"#b41\">mcnaughton and morris, 1987\u003c/a>). therefore, alogabat was evaluated in several rodent tests of cognition to determine whether a selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 pam would induce cognitive impairment following acute administration in rats. there was no effect of alogabat up to 70% gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro on cognition (visual&#x02013;spatial memory, attention, context fear conditioning, spatial learning, and memory). cognitive impairment was only observed at high doses (&#x0003e;70% ro) and supra-therapeutic levels of alogabat in associative (fear) learning (cfc) and spatial memory in the mwm in wildtype rats. the impairment at high doses is likely linked to the loss of selectivity toward gaba\u003csub>a\u003c/sub> &#x003b1;1, &#x003b1;2, and &#x003b1;3 receptor subtypes (&#x003b1;1 ro was calculated as 19%&#x02013;25% at these doses; see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). in addition to the loss of selectivity, we cannot exclude the possibility that these effects may be a consequence of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor saturation, i.e., excessive &#x003b1;5 activity in wildtype subjects may be detrimental. the cognitive impairment observed in wildtype rats may translate to healthy human subjects; however, our focus is on the effect of &#x003b1;5 pams in disease conditions with impaired gaba\u003csub>a\u003c/sub> signaling and impaired cognition, where our hypothesis is that an &#x003b1;5 pam would have beneficial effects.\u003c/p>\u003cp class=\"mb0\">alogabat had no effect on social approach/avoidance, the elevated plus maze, and the vogel conflict test in rats at ro levels up to 80% (see \u003ca href=\"#sm1\">supplementary figure s4\u003c/a> and methods in \u003ca href=\"#sm1\">supplementary material\u003c/a>), suggesting that alogabat does not exhibit an anxiolytic-like effect in rodents. this might be explained by the low expression of gaba\u003csub>a\u003c/sub>-&#x003b1;5 in the amygdala, a key node controlling anxiety-like behaviors. potential anxiolytic effects of alogabat in humans cannot be excluded as this receptor subtype is much more abundant in the human amygdala. since benzodiazepines, such as diazepam, are frequently used to treat anxiety and seizures in ndds, it was important to establish that alogabat at relevant therapeutic doses in mouse models did not worsen the sedative/motor-impairing effects of diazepam in the rotarod test. alogabat did not worsen diazepam-induced motor impairment; on the contrary, in combination, it reduced the motor impairments, which is more likely due to the more localized and precise inhibitory effect, counterbalancing the broader suppression of neuronal activity by diazepam, or due to lower intrinsic activity at &#x003b1;1 receptors compared to diazepam. we have previously shown that a gaba\u003csub>a\u003c/sub>-&#x003b1;5 nam, which binds at the benzodiazepine binding site of the receptor, does not decrease the anxiolytic activity of chlordiazepoxide (see \u003ca href=\"#sm1\">supplementary figure s5\u003c/a>); therefore, it is unlikely that alogabat will interfere with the anxiolytic effect of the classical benzodiazepines.\u003c/p>\u003ca id=\"h6\" name=\"h6\">\u003c/a>\u003ch2>5 conclusion\u003c/h2>\u003cp class=\"mb15\">multiple lines of evidence point to deficits in gabaergic signaling in epilepsy and ndds, such as asd and deletion as, with a prominent role attributed to gaba\u003csub>a\u003c/sub> receptors, including the gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor subtype. the current data for alogabat showed robust dose-dependent efficacy on repetitive behaviors in two disease-relevant mouse models and anti-seizure activity in the ptz rat model at gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro above 50%. our \u003cem>in vivo\u003c/em> occupancy measurements using the selective &#x003b1;5 tracer l-655,708 were highly valuable for understanding plasma and csf exposures (as a surrogate of free brain concentration) and their relationship to \u003cem>in vivo\u003c/em> effects. we observed that there was a 34-fold shift between the csf concentration of alogabat in the \u003cem>in vivo\u003c/em> occupancy study and that of alogabat \u003cem>in vitro\u003c/em> binding data (ki value). the receptor occupancy of alogabat correlates well with pd effects (\u003cem>in vivo\u003c/em> effects) and is consistent across the different studies/species (see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). this finding highlights the importance of using pet tracers in drug development.\u003c/p>\u003cp class=\"mb15\">our data suggest that gaba\u003csub>a\u003c/sub>-&#x003b1;5 pams may have potential benefits in individuals with autistic features and in conditions with clinical and nonclinical manifestations of cortical hyperexcitability and epilepsy. however, alogabat is unlikely to work across all ndds and should be utilized as a precision medicine to target a specific subgroup of the ndd population with deficient gaba\u003csub>a\u003c/sub> pathway signaling, or specifically gaba\u003csub>a\u003c/sub>-&#x003b1;5. interestingly, recent data suggest that gaba\u003csub>a\u003c/sub>-&#x003b1;5 pams may also have therapeutic potential in schizophrenia, alzheimer&#x02019;s disease, and depression (\u003ca href=\"#b53\">perez et al., 2023\u003c/a>; \u003ca href=\"#b39\">luscher et al., 2023\u003c/a>; \u003ca href=\"#b36\">koh et al., 2013\u003c/a>). with regard to the current status of alogabat, good-laboratory practice (glp) toxicology and safety pharmacology studies in rats and minipigs showed an overall benign safety profile, which supported its clinical investigations in phase-1 studies in healthy volunteers and phase-2 trials in asd and deletion as patients (nct03507569, nct03774576, nct03847987, nct04299464, nct05630066, and eudract&#x00023;2019-003524-20). the outcome of these studies, including pet, eeg, and effects on cognition, will be reported in the future.\u003c/p>\u003ca id=\"h7\" name=\"h7\">\u003c/a>\u003ch2>data availability statement\u003c/h2>\u003cp class=\"mb15\">the original contributions presented in the study are included in the article/\u003ca href=\"#sm1\">supplementary material\u003c/a>, further inquiries can be directed to the corresponding author.\u003c/p>\u003ca id=\"h8\" name=\"h8\">\u003c/a>\u003ch2>ethics statement\u003c/h2>\u003cp class=\"mb0\">experiments performed at f. hoffmann-la roche ag (basel, switzerland) complied with swiss federal and cantonal laws on animal research and aaalac regulations and received prior approval from the cantonal veterinary office. the eeg study was conducted at brains online (ca, united states) in accordance with the guide for the care and use of laboratory animals (national research council 2011) after receiving approval from the institutional animal care and use committee. the ptz and mes tests were conducted at vivocore inc., canada, which is a facility licensed by the ontario ministry of agriculture, food, and rural affairs and accredited by the canadian council on animal care. all \u003cem>in vivo\u003c/em> studies are reported in compliance with the arrive guidelines (\u003ca href=\"#b52\">percie du sert et al., 2020\u003c/a>). the study was conducted in accordance with the local legislation and institutional requirements.\u003c/p>\u003ca id=\"h9\" name=\"h9\">\u003c/a>\u003ch2>author contributions\u003c/h2>\u003cp class=\"mb0\">gc: supervision, writing - original draft, investigation, formal analysis. tmb: formal analysis, investigation, writing - review and editing, methodology. fk: formal analysis, writing - original draft, investigation, methodology. mh: writing - original draft, investigation, methodology, formal analysis. jfh: data curation, visualization, methodology, writing - original draft, formal analysis. pg: methodology, data curation, formal analysis, writing - original draft. tm: investigation, writing - original draft, formal analysis, methodology. bk: investigation, writing - original draft, methodology, formal analysis. anb: formal analysis, writing - original draft, data curation. epp: writing - original draft, methodology, investigation. ps: methodology, investigation, writing - original draft, formal analysis. pj: writing - original draft, formal analysis. rr: methodology, writing - original draft, investigation, formal analysis. bb: methodology, investigation, writing - original draft. hk: methodology, writing - original draft, investigation. ao-m: writing - original draft, formal analysis, methodology. alb: methodology, writing - original draft, investigation. jms: investigation, formal analysis, writing - original draft. db: methodology, writing - original draft, investigation. ms: writing - original draft, methodology, investigation. eco&#x00027;c: investigation, writing - original draft, methodology. m-ch: investigation, conceptualization, writing - review and editing, supervision, writing - original draft, methodology.\u003c/p>\u003ca id=\"h10\" name=\"h10\">\u003c/a>\u003ch2>funding\u003c/h2>\u003cp class=\"mb0\">the author(s) declare that financial support was received for the research and/or publication of this article. the funding was provided by f. hoffmann-la roche ag switzerland.\u003c/p>\u003ca id=\"h11\" name=\"h11\">\u003c/a>\u003ch2>acknowledgments\u003c/h2>\u003cp class=\"mb03\">the authors thank gregoire friz, maria karg, and judith lengyel (molecular biology and binding assays); v&#x000e9;ronique graf, rachel haab, and marie-claire pflimlin (\u003cem>in vitro\u003c/em> electrophysiology); brigitte algeyer, severine bandinelli, sean durkin, audrey genet, marie haman, martine maco, and roger wyler (behavioral pharmacology); and stephanie sch&#x000f6;ppenthau, s&#x000e9;bastien debilly, and thomas bielser (\u003cem>in vivo\u003c/em> phmri). the rat ptz and mes studies were carried out under the scientific guidance of dr guy higgins, intervivo solutions, and coordinated by leo silenieks at vivocore inc., ontario, canada. the rat eeg data acquisition was undertaken by brains on-line llc, south san francisco, united states, and the data analysis was undertaken by pg, vanessa keeney, and andr&#x000e9;s olivares at roche.\u003c/p>\u003ca id=\"h12\" name=\"h12\">\u003c/a>\u003ch2>conflict of interest\u003c/h2>\u003cp class=\"mb0\">authors gc, tmb, fk, mh, jfh, pg, tm, bk, ab, epp, ps, pj, rr, bb, hk, ao-m, ab, jms, ms, eco&#x00027;c, and m-ch were employed by f. hoffmann-la roche ag switzerland. all employees (former and current) may be eligible for stock and stock options. author db was employed by hiqscreen s&#x000e0;rl.\u003c/p>\u003ca id=\"h13\" name=\"h13\">\u003c/a>\u003ch2>generative ai statement\u003c/h2>\u003cp class=\"mb15\">the author(s) declare that no generative ai was used in the creation of this manuscript.\u003c/p>\u003ca id=\"h14\" name=\"h14\">\u003c/a>\u003ch2>publisher&#x02019;s note\u003c/h2>\u003cp class=\"mb15\">all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.\u003c/p>\u003ca id=\"h15\" name=\"h15\">\u003c/a>\u003ch2>supplementary material\u003c/h2>\u003cp class=\"mb15\" id=\"sm1\">the supplementary material for this article can be found online at: \u003ca href=\"https://www.frontiersin.org/articles/10.3389/fphar.2025.1626078/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fphar.2025.1626078/full&#x00023;supplementary-material\u003c/a>\u003c/p>\u003ca id=\"h16\" name=\"h16\">\u003c/a>\u003ch2>abbreviations\u003c/h2>\u003cp class=\"mb15\">as, angelman syndrome; asd, autism spectrum disorder; cfc, context fear conditioning; cntnap2, contactin-associated protein-like 2; cpt, continuous performance test; 5-csrt, 5-choice serial reaction time; eeg, electroencephalography; gaba, gamma-aminobutyric acid; gad, glutamic acid decarboxylase; i.p., intraperitoneally; i.v., intravenously; lfp, local field potential; mes, maximum electrical stimulus; mwm, morris water maze; ndds, neurodevelopmental disorders; pal, paired associates learning; pam, positive allosteric modulator; phmri, pharmacological magnetic resonance imaging; p.o, per os; ptz, pentylenetetrazole; ro, receptor occupancy; pet, positron emission tomography.\u003c/p>\u003ca id=\"h17\" name=\"h17\">\u003c/a>\u003ch2>references\u003c/h2>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b1\" id=\"b1\">\u003c/a>abrahams, b. s., and geschwind, d. h. (2008). advances in autism genetics: on the threshold of a new neurobiology. \u003cem>nat. rev. genet.\u003c/em> 9, 341&#x02013;355. doi:10.1038/nrg2346\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/18414403/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nrg2346\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=advances+in+autism+genetics:+on+the+threshold+of+a+new+neurobiology&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b2\" id=\"b2\">\u003c/a>ali, a. b., and thomson, a. m. (2008). synaptic alpha 5 subunit-containing gabaa receptors mediate ipsps elicited by dendrite-preferring cells in rat neocortex. \u003cem>cereb. cortex\u003c/em> 18, 1260&#x02013;1271. doi:10.1093/cercor/bhm160\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17951598/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1093/cercor/bhm160\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=synaptic+alpha+5+subunit-containing+gabaa+receptors+mediate+ipsps+elicited+by+dendrite-preferring+cells+in+rat+neocortex&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\" style=\"margin-bottom:0.5em;\">\u003cp class=\"referencescopy1\">\u003ca name=\"b3\" id=\"b3\">\u003c/a>american psychiatric association (2008). \u003cem>diagnostic and statistical manual of mental disorders\u003c/em>. 5th ed. washington: \u003cspan class=\"publisher-name\">american psychiatric association\u003c/span>. \u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=american+psychiatric+association+%2c+diagnostic+and+statistical+manual+of+mental+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b4\" id=\"b4\">\u003c/a>ballard, t. m., knoflach, f., prinssen, e., borroni, e., vivian, j. a., basile, j., et al. (2009). ro4938581, a novel cognitive enhancer acting at gabaa alpha5 subunit-containing receptors. \u003cem>psychopharmacol. berl.\u003c/em> 202, 207&#x02013;223. doi:10.1007/s00213-008-1357-7\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/18936916/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1007/s00213-008-1357-7\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=ro4938581%2c+a+novel+cognitive+enhancer+acting+at+gabaa+alpha5+subunit-containing+receptors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b5\" id=\"b5\">\u003c/a>ballard, t. m., woolley, m. l., prinssen, e., huwyler, j., porter, r., and spooren, w. (2005). the effect of the mglu5 receptor antagonist mpep in rodent tests of anxiety and cognition: a comparison. \u003cem>psychopharmacol. berl.\u003c/em> 179, 218&#x02013;229. doi:10.1007/s00213-005-2211-9\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/15739074/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1007/s00213-005-2211-9\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+effect+of+the+mglu5+receptor+antagonist+mpep+in+rodent+tests+of+anxiety+and+cognition:+a+comparison&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b6\" id=\"b6\">\u003c/a>banerjee, a., garcia-oscos, f., roychowdhury, s., galindo, l. c., hall, s., kilgard, m. p., et al. (2013). impairment of cortical gabaergic synaptic transmission in an environmental rat model of autism. \u003cem>int. j. neuropsychopharmacol.\u003c/em> 16, 1309&#x02013;1318. doi:10.1017/s1461145712001216\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23228615/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1017/s1461145712001216\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=impairment+of+cortical+gabaergic+synaptic+transmission+in+an+environmental+rat+model+of+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b7\" id=\"b7\">\u003c/a>bourgeron, t. (2015). from the genetic architecture to synaptic plasticity in autism spectrum disorder. \u003cem>nat. rev. neurosci.\u003c/em> 16, 551&#x02013;563. doi:10.1038/nrn3992\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26289574/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nrn3992\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=from+the+genetic+architecture+to+synaptic+plasticity+in+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b8\" id=\"b8\">\u003c/a>braat, s., and kooy, r. f. (2015). the gabaa receptor as a therapeutic target for neurodevelopmental disorders. \u003cem>neuron\u003c/em> 86, 1119&#x02013;1130. doi:10.1016/j.neuron.2015.03.042\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26050032/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuron.2015.03.042\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+gabaa+receptor+as+a+therapeutic+target+for+neurodevelopmental+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b9\" id=\"b9\">\u003c/a>bruns, a., kunnecke, b., risterucci, c., moreau, j. l., and von kienlin, m. (2009). validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological mri in rats. \u003cem>magn. reson med.\u003c/em> 61, 1451&#x02013;1458. doi:10.1002/mrm.21779\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/19358231/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/mrm.21779\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=validation+of+cerebral+blood+perfusion+imaging+as+a+modality+for+quantitative+pharmacological+mri+in+rats&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\" style=\"margin-bottom:0.5em;\">\u003cp class=\"referencescopy1\">\u003ca name=\"b10\" id=\"b10\">\u003c/a>buettelmann, b., cecere, g., fasching, b., groebke zbinden, k., hernandez, m.-c., knust, h., et al. (2018). \u003cem>preparation of new isoxazolyl ether derivatives as gabaa &#x003b1;5 receptor positive allosteric modulators (pams)\u003c/em>. \u003cspan class=\"publisher-name\">copyright &#x000a9; 2025 american chemical society acs\u003c/span>. available online at: \u003ca href=\"https://worldwide.espacent.com/patent/search/family/057530563/publication/wo2018104419a1?q=wo2018104419a1\">https://worldwide.espacent.com/patent/search/family/057530563/publication/wo2018104419a1?q&#x0003d;wo2018104419a1\u003c/a>\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=â buettelmannâ bcecereâ gfaschingâ bgroebke+zbindenâ khernandezâ m-cknustâ het+al+2018+preparation+of+new+isoxazolyl+ether+derivatives+as+gabaa+î±5+receptor+positive+allosteric+modulators+pams+copyright+â©+2025+american+chemical+society+acs+available+online+at:+https://worldwideespacentcom/patent/search/family/057530563/publication/wo2018104419a1?q=wo2018104419a1&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b12\" id=\"b12\">\u003c/a>buiting, k. (2010). prader-willi syndrome and angelman syndrome. \u003cem>am. j. med. genet. c semin. med. genet.\u003c/em> 154c, 365&#x02013;376. doi:10.1002/ajmg.c.30273\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/20803659/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/ajmg.c.30273\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=prader-willi+syndrome+and+angelman+syndrome&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b13\" id=\"b13\">\u003c/a>chao, h. t., chen, h., samaco, r. c., xue, m., chahrour, m., yoo, j., et al. (2010). dysfunction in gaba signalling mediates autism-like stereotypies and rett syndrome phenotypes. \u003cem>nature\u003c/em> 468, 263&#x02013;269. doi:10.1038/nature09582\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21068835/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nature09582\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=dysfunction+in+gaba+signalling+mediates+autism-like+stereotypies+and+rett+syndrome+phenotypes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b14\" id=\"b14\">\u003c/a>davenport, c. m., rajappa, r., katchan, l., taylor, c. r., tsai, m. c., smith, c. m., et al. (2021). relocation of an extrasynaptic gaba(a) receptor to inhibitory synapses freezes excitatory synaptic strength and preserves memory. \u003cem>neuron\u003c/em> 109, 123&#x02013;134 e4. doi:10.1016/j.neuron.2020.09.037\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/33096025/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuron.2020.09.037\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=relocation+of+an+extrasynaptic+gabaa+receptor+to+inhibitory+synapses+freezes+excitatory+synaptic+strength+and+preserves+memory&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b15\" id=\"b15\">\u003c/a>delong, r. (2007). gaba(a) receptor alpha5 subunit as a candidate gene for autism and bipolar disorder: a proposed endophenotype with parent-of-origin and gain-of-function features,with or without oculocutaneous albinism. \u003cem>autism\u003c/em> 11, 135&#x02013;147. doi:10.1177/1362361307075705\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17353214/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1177/1362361307075705\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa+receptor+alpha5+subunit+as+a+candidate+gene+for+autism+and+bipolar+disorder:+a+proposed+endophenotype+with+parent-of-origin+and+gain-of-function+features%2cwith+or+without+oculocutaneous+albinism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b16\" id=\"b16\">\u003c/a>delorey, t. m. (2005). gabrb3 gene deficient mice: a potential model of autism spectrum disorder. \u003cem>int. rev. neurobiol.\u003c/em> 71, 359&#x02013;382. doi:10.1016/s0074-7742(05)71015-1\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/16512358/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0074-7742(05)71015-1\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabrb3+gene+deficient+mice:+a+potential+model+of+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b17\" id=\"b17\">\u003c/a>delorey, t. m., sahbaie, p., hashemi, e., homanics, g. e., and clark, j. d. (2008). gabrb3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: a potential model of autism spectrum disorder. \u003cem>behav. brain res.\u003c/em> 187, 207&#x02013;220. doi:10.1016/j.bbr.2007.09.009\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17983671/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.bbr.2007.09.009\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabrb3+gene+deficient+mice+exhibit+impaired+social+and+exploratory+behaviors%2c+deficits+in+non-selective+attention+and+hypoplasia+of+cerebellar+vermal+lobules:+a+potential+model+of+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b18\" id=\"b18\">\u003c/a>dhossche, d., applegate, h., abraham, a., maertens, p., bland, l., bencsath, a., et al. (2002). elevated plasma gamma-aminobutyric acid (gaba) levels in autistic youngsters: stimulus for a gaba hypothesis of autism. \u003cem>med. sci. monit.\u003c/em> 8, pr1&#x02013;pr6.\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/12165753/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=elevated+plasma+gamma-aminobutyric+acid+gaba+levels+in+autistic+youngsters:+stimulus+for+a+gaba+hypothesis+of+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b19\" id=\"b19\">\u003c/a>di nanni, n., bersanelli, m., cupaioli, f. a., milanesi, l., mezzelani, a., and mosca, e. (2019). network-based integrative analysis of genomics, epigenomics and transcriptomics in autism spectrum disorders. \u003cem>int. j. mol. sci.\u003c/em> 20, 3363. doi:10.3390/ijms20133363\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/31323926/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.3390/ijms20133363\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=network-based+integrative+analysis+of+genomics%2c+epigenomics+and+transcriptomics+in+autism+spectrum+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b20\" id=\"b20\">\u003c/a>dufour, b. d., mcbride, e., bartley, t., juarez, p., and martinez-cerdeno, v. (2023). distinct patterns of gabaergic interneuron pathology in autism are associated with intellectual impairment and stereotypic behaviors. \u003cem>autism\u003c/em> 27, 1730&#x02013;1745. doi:10.1177/13623613231154053\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/36935610/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1177/13623613231154053\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=distinct+patterns+of+gabaergic+interneuron+pathology+in+autism+are+associated+with+intellectual+impairment+and+stereotypic+behaviors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b21\" id=\"b21\">\u003c/a>fatemi, s. h., halt, a. r., stary, j. m., kanodia, r., schulz, s. c., and realmuto, g. r. (2002). glutamic acid decarboxylase 65 and 67 kda proteins are reduced in autistic parietal and cerebellar cortices. \u003cem>biol. psychiatry\u003c/em> 52, 805&#x02013;810. doi:10.1016/s0006-3223(02)01430-0\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/12372652/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0006-3223(02)01430-0\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=glutamic+acid+decarboxylase+65+and+67+kda+proteins+are+reduced+in+autistic+parietal+and+cerebellar+cortices&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b22\" id=\"b22\">\u003c/a>friedman, h., greenblatt, d. j., peters, g. r., metzler, c. m., charlton, m. d., harmatz, j. s., et al. (1992). pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. \u003cem>clin. pharmacol. ther.\u003c/em> 52, 139&#x02013;150. doi:10.1038/clpt.1992.123\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/1505149/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/clpt.1992.123\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=pharmacokinetics+and+pharmacodynamics+of+oral+diazepam:+effect+of+dose%2c+plasma+concentration%2c+and+time&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b23\" id=\"b23\">\u003c/a>fritschy, j. m., benke, d., johnson, d. k., mohler, h., and rudolph, u. (1997). gabaa-receptor alpha-subunit is an essential prerequisite for receptor formation \u003cem>in vivo\u003c/em>. \u003cem>neuroscience\u003c/em> 81, 1043&#x02013;1053. doi:10.1016/s0306-4522(97)00244-3\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/9330366/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0306-4522(97)00244-3\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa-receptor+alpha-subunit+is+an+essential+prerequisite+for+receptor+formation+in+vivo&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b24\" id=\"b24\">\u003c/a>frohlich, j., miller, m. t., bird, l. m., garces, p., purtell, h., hoener, m. c., et al. (2019a). electrophysiological phenotype in angelman syndrome differs between genotypes. \u003cem>biol. psychiatry\u003c/em> 85, 752&#x02013;759. doi:10.1016/j.biopsych.2019.01.008\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/30826071/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.biopsych.2019.01.008\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=electrophysiological+phenotype+in+angelman+syndrome+differs+between+genotypes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b25\" id=\"b25\">\u003c/a>frohlich, j., reiter, l. t., saravanapandian, v., distefano, c., huberty, s., hyde, c., et al. (2019b). mechanisms underlying the eeg biomarker in dup15q syndrome. \u003cem>mol. autism\u003c/em> 10, 29. doi:10.1186/s13229-019-0280-6\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/31312421/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1186/s13229-019-0280-6\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=mechanisms+underlying+the+eeg+biomarker+in+dup15q+syndrome&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b26\" id=\"b26\">\u003c/a>frye, r. e., casanova, m. f., fatemi, s. h., folsom, t. d., reutiman, t. j., brown, g. l., et al. (2016). neuropathological mechanisms of seizures in autism spectrum disorder. \u003cem>front. neurosci.\u003c/em> 10, 192. doi:10.3389/fnins.2016.00192\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27242398/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.3389/fnins.2016.00192\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=neuropathological+mechanisms+of+seizures+in+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b27\" id=\"b27\">\u003c/a>fukuda, t., itoh, m., ichikawa, t., washiyama, k., and goto, y. (2005). delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of mecp2-deficient mice. \u003cem>j. neuropathol. exp. neurol.\u003c/em> 64, 537&#x02013;544. doi:10.1093/jnen/64.6.537\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/15977646/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1093/jnen/64.6.537\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=delayed+maturation+of+neuronal+architecture+and+synaptogenesis+in+cerebral+cortex+of+mecp2-deficient+mice&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b28\" id=\"b28\">\u003c/a>gaetz, w., bloy, l., wang, d. j., port, r. g., blaskey, l., levy, s. e., et al. (2014). gaba estimation in the brains of children on the autism spectrum: measurement precision and regional cortical variation. \u003cem>neuroimage\u003c/em> 86, 1&#x02013;9. doi:10.1016/j.neuroimage.2013.05.068\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23707581/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuroimage.2013.05.068\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gaba+estimation+in+the+brains+of+children+on+the+autism+spectrum:+measurement+precision+and+regional+cortical+variation&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b29\" id=\"b29\">\u003c/a>han, s., tai, c., jones, c. j., scheuer, t., and catterall, w. a. (2014). enhancement of inhibitory neurotransmission by gabaa receptors having &#x003b1;2,3-subunits ameliorates behavioral deficits in a mouse model of autism. \u003cem>neuron\u003c/em> 81, 1282&#x02013;1289. doi:10.1016/j.neuron.2014.01.016\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/24656250/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuron.2014.01.016\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=enhancement+of+inhibitory+neurotransmission+by+gabaa+receptors+having+î±2%2c3-subunits+ameliorates+behavioral+deficits+in+a+mouse+model+of+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b30\" id=\"b30\">\u003c/a>han, s., tai, c., westenbroek, r. e., yu, f. h., cheah, c. s., potter, g. b., et al. (2012). autistic-like behaviour in scn1a&#x0002b;/- mice and rescue by enhanced gaba-mediated neurotransmission. \u003cem>nature\u003c/em> 489, 385&#x02013;390. doi:10.1038/nature11356\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22914087/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nature11356\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=autistic-like+behaviour+in+scn1a+/-+mice+and+rescue+by+enhanced+gaba-mediated+neurotransmission&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b31\" id=\"b31\">\u003c/a>hipp, j. f., knoflach, f., comley, r., ballard, t. m., honer, m., trube, g., et al. (2021). basmisanil, a highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man. \u003cem>sci. rep.\u003c/em> 11, 7700. doi:10.1038/s41598-021-87307-7\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/33833333/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/s41598-021-87307-7\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=basmisanil%2c+a+highly+selective+gabaa-î±5+negative+allosteric+modulator:+preclinical+pharmacology+and+demonstration+of+functional+target+engagement+in+man&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b32\" id=\"b32\">\u003c/a>hogart, a., wu, d., lasalle, j. m., and schanen, n. c. (2010). the comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. \u003cem>neurobiol. dis.\u003c/em> 38, 181&#x02013;191. doi:10.1016/j.nbd.2008.08.011\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/18840528/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.nbd.2008.08.011\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+comorbidity+of+autism+with+the+genomic+disorders+of+chromosome+15q112-q13&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b33\" id=\"b33\">\u003c/a>hu, x., rocco, b. r., fee, c., and sibille, e. (2019). cell type-specific gene expression of alpha 5 subunit-containing gamma-aminobutyric acid subtype a receptors in human and mouse frontal cortex. \u003cem>mol. neuropsychiatry\u003c/em> 4, 204&#x02013;215. doi:10.1159/000495840\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/30815456/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1159/000495840\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=cell+type-specific+gene+expression+of+alpha+5+subunit-containing+gamma-aminobutyric+acid+subtype+a+receptors+in+human+and+mouse+frontal+cortex&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b34\" id=\"b34\">\u003c/a>hvoslef-eide, m., nilsson, s. r., saksida, l. m., and bussey, t. j. (2016). cognitive translation using the rodent touchscreen testing approach. \u003cem>curr. top. behav. neurosci.\u003c/em> 28, 423&#x02013;447. doi:10.1007/7854_2015_5007\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27305921/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1007/7854_2015_5007\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=cognitive+translation+using+the+rodent+touchscreen+testing+approach&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b35\" id=\"b35\">\u003c/a>kalsner, l., and chamberlain, s. j. (2015). prader-willi, angelman, and 15q11-q13 duplication syndromes. \u003cem>pediatr. clin. north am.\u003c/em> 62, 587&#x02013;606. doi:10.1016/j.pcl.2015.03.004\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26022164/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.pcl.2015.03.004\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=prader-willi%2c+angelman%2c+and+15q11-q13+duplication+syndromes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b36\" id=\"b36\">\u003c/a>koh, m. t., rosenzweig-lipson, s., and gallagher, m. (2013). selective gaba(a) &#x003b1;5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. \u003cem>neuropharmacology\u003c/em> 64, 145&#x02013;152. doi:10.1016/j.neuropharm.2012.06.023\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22732440/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2012.06.023\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=selective+gabaa+î±5+positive+allosteric+modulators+improve+cognitive+function+in+aged+rats+with+memory+impairment&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b37\" id=\"b37\">\u003c/a>lim, c. s., kim, h., yu, n. k., kang, s. j., kim, t., ko, h. g., et al. (2017). enhancing inhibitory synaptic function reverses spatial memory deficits in shank2 mutant mice. \u003cem>neuropharmacology\u003c/em> 112, 104&#x02013;112. doi:10.1016/j.neuropharm.2016.08.016\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27544825/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2016.08.016\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=enhancing+inhibitory+synaptic+function+reverses+spatial+memory+deficits+in+shank2+mutant+mice&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b38\" id=\"b38\">\u003c/a>luk, h. m., and lo, i. f. (2016). angelman syndrome in hong kong chinese: a 20 years&#x00027; experience. \u003cem>eur. j. med. genet.\u003c/em> 59, 315&#x02013;319. doi:10.1016/j.ejmg.2016.05.003\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27174604/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.ejmg.2016.05.003\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=angelman+syndrome+in+hong+kong+chinese:+a+20+years'+experience&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b39\" id=\"b39\">\u003c/a>luscher, b., maguire, j. l., rudolph, u., and sibille, e. (2023). gaba(a) receptors as targets for treating affective and cognitive symptoms of depression. \u003cem>trends pharmacol. sci.\u003c/em> 44, 586&#x02013;600. doi:10.1016/j.tips.2023.06.009\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/37543478/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.tips.2023.06.009\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa+receptors+as+targets+for+treating+affective+and+cognitive+symptoms+of+depression&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b40\" id=\"b40\">\u003c/a>mcfarlane, h. g., kusek, g. k., yang, m., phoenix, j. l., bolivar, v. j., and crawley, j. n. (2008). autism-like behavioral phenotypes in btbr t&#x0002b;tf/j mice. \u003cem>genes brain behav.\u003c/em> 7, 152&#x02013;163. doi:10.1111/j.1601-183x.2007.00330.x\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17559418/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1111/j.1601-183x.2007.00330.x\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=autism-like+behavioral+phenotypes+in+btbr+t+tf/j+mice&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b41\" id=\"b41\">\u003c/a>mcnaughton, n., and morris, r. g. (1987). chlordiazepoxide, an anxiolytic benzodiazepine, impairs place navigation in rats. \u003cem>behav. brain res.\u003c/em> 24, 39&#x02013;46. doi:10.1016/0166-4328(87)90034-9\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/3580114/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/0166-4328(87)90034-9\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=chlordiazepoxide%2c+an+anxiolytic+benzodiazepine%2c+impairs+place+navigation+in+rats&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b42\" id=\"b42\">\u003c/a>mendez, m. a., horder, j., myers, j., coghlan, s., stokes, p., erritzoe, d., et al. (2013). the brain gaba-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)c]ro15-4513 positron emission tomography study. \u003cem>neuropharmacology\u003c/em> 68, 195&#x02013;201. doi:10.1016/j.neuropharm.2012.04.008\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22546616/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2012.04.008\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+brain+gaba-benzodiazepine+receptor+alpha-5+subtype+in+autism+spectrum+disorder:+a+pilot+%5b11c%5dro15-4513+positron+emission+tomography+study&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b43\" id=\"b43\">\u003c/a>mermer, f., poliquin, s., rigsby, k., rastogi, a., shen, w., romero-morales, a., et al. (2021). common molecular mechanisms of slc6a1 variant-mediated neurodevelopmental disorders in astrocytes and neurons. \u003cem>brain\u003c/em> 144, 2499&#x02013;2512. doi:10.1093/brain/awab207\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/34028503/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1093/brain/awab207\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=common+molecular+mechanisms+of+slc6a1+variant-mediated+neurodevelopmental+disorders+in+astrocytes+and+neurons&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b44\" id=\"b44\">\u003c/a>mertz, l. g., christensen, r., vogel, i., hertz, j. m., nielsen, k. b., gronskov, k., et al. (2013). angelman syndrome in denmark. birth incidence, genetic findings, and age at diagnosis. \u003cem>am. j. med. genet. a\u003c/em> 161a, 2197&#x02013;2203. doi:10.1002/ajmg.a.36058\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23913711/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/ajmg.a.36058\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=angelman+syndrome+in+denmark+birth+incidence%2c+genetic+findings%2c+and+age+at+diagnosis&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b45\" id=\"b45\">\u003c/a>mesbah-oskui, l., penna, a., orser, b. a., and horner, r. l. (2017). reduced expression of &#x003b1;5gaba\u003csub>a\u003c/sub> receptors elicits autism-like alterations in eeg patterns and sleep-wake behavior. \u003cem>neurotoxicol teratol.\u003c/em> 61, 115&#x02013;122. doi:10.1016/j.ntt.2016.10.009\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27793660/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.ntt.2016.10.009\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=reduced+expression+of+î±5gabaa+receptors+elicits+autism-like+alterations+in+eeg+patterns+and+sleep-wake+behavior&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b46\" id=\"b46\">\u003c/a>mohler, h. (2011). the rise of a new gaba pharmacology. \u003cem>neuropharmacology\u003c/em> 60, 1042&#x02013;1049. doi:10.1016/j.neuropharm.2010.10.020\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21035473/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2010.10.020\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+rise+of+a+new+gaba+pharmacology&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b47\" id=\"b47\">\u003c/a>mori, t., mori, k., fujii, e., toda, y., miyazaki, m., harada, m., et al. (2012). evaluation of the gabaergic nervous system in autistic brain: (123)i-iomazenil spect study. \u003cem>brain dev.\u003c/em> 34, 648&#x02013;654. doi:10.1016/j.braindev.2011.10.007\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22099869/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.braindev.2011.10.007\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=evaluation+of+the+gabaergic+nervous+system+in+autistic+brain:+123i-iomazenil+spect+study&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b48\" id=\"b48\">\u003c/a>myers, j. f., comley, r. a., and gunn, r. n. (2017). quantification of [\u003csup>11\u003c/sup>c]ro15-4513 gaba\u003csub>a\u003c/sub>&#x003b1;5 specific binding and regional selectivity in humans. \u003cem>j. cereb. blood flow. metab.\u003c/em> 37, 2137&#x02013;2148. doi:10.1177/0271678x16661339\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27466376/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1177/0271678x16661339\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=quantification+of+%5b11c%5dro15-4513+gabaaî±5+specific+binding+and+regional+selectivity+in+humans&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b49\" id=\"b49\">\u003c/a>nakamura, t., arima-yoshida, f., sakaue, f., nasu-nishimura, y., takeda, y., matsuura, k., et al. (2016). px-rics-deficient mice mimic autism spectrum disorder in jacobsen syndrome through impaired gabaa receptor trafficking. \u003cem>nat. commun.\u003c/em> 7, 10861. doi:10.1038/ncomms10861\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26979507/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/ncomms10861\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=px-rics-deficient+mice+mimic+autism+spectrum+disorder+in+jacobsen+syndrome+through+impaired+gabaa+receptor+trafficking&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b50\" id=\"b50\">\u003c/a>orefice, l. l., zimmerman, a. l., chirila, a. m., sleboda, s. j., head, j. p., and ginty, d. d. (2016). peripheral mechanosensory neuron dysfunction underlies tactile and behavioral deficits in mouse models of asds. \u003cem>cell\u003c/em> 166, 299&#x02013;313. doi:10.1016/j.cell.2016.05.033\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27293187/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.cell.2016.05.033\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=peripheral+mechanosensory+neuron+dysfunction+underlies+tactile+and+behavioral+deficits+in+mouse+models+of+asds&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b51\" id=\"b51\">\u003c/a>penagarikano, o., abrahams, b. s., herman, e. i., winden, k. d., gdalyahu, a., dong, h., et al. (2011). absence of cntnap2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. \u003cem>cell\u003c/em> 147, 235&#x02013;246. doi:10.1016/j.cell.2011.08.040\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21962519/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.cell.2011.08.040\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=absence+of+cntnap2+leads+to+epilepsy%2c+neuronal+migration+abnormalities%2c+and+core+autism-related+deficits&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b52\" id=\"b52\">\u003c/a>percie du sert, n., hurst, v., ahluwalia, a., alam, s., avey, m. t., baker, m., et al. (2020). the arrive guidelines 2.0: updated guidelines for reporting animal research. \u003cem>plos biol.\u003c/em> 18, e3000410. doi:10.1371/journal.pbio.3000410\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/32663219/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1371/journal.pbio.3000410\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+arrive+guidelines+20:+updated+guidelines+for+reporting+animal+research&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b53\" id=\"b53\">\u003c/a>perez, s. m., mccoy, a. m., prevot, t. d., mian, m. y., carreno, f. r., frazer, a., et al. (2023). hippocampal &#x003b1;5-gaba(a) receptors modulate dopamine neuron activity in the rat ventral tegmental area. \u003cem>biol. psychiatry glob. open sci.\u003c/em> 3, 78&#x02013;86. doi:10.1016/j.bpsgos.2021.12.010\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/36712569/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.bpsgos.2021.12.010\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=hippocampal+î±5-gabaa+receptors+modulate+dopamine+neuron+activity+in+the+rat+ventral+tegmental+area&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b54\" id=\"b54\">\u003c/a>pirker, s., schwarzer, c., wieselthaler, a., sieghart, w., and sperk, g. (2000). gaba(a) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. \u003cem>neuroscience\u003c/em> 101, 815&#x02013;850. doi:10.1016/s0306-4522(00)00442-5\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/11113332/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0306-4522(00)00442-5\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa+receptors:+immunocytochemical+distribution+of+13+subunits+in+the+adult+rat+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b55\" id=\"b55\">\u003c/a>pizzarelli, r., and cherubini, e. (2011). alterations of gabaergic signaling in autism spectrum disorders. \u003cem>neural plast.\u003c/em> 2011, 297153. doi:10.1155/2011/297153\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21766041/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1155/2011/297153\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=alterations+of+gabaergic+signaling+in+autism+spectrum+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b56\" id=\"b56\">\u003c/a>porjesz, b., almasy, l., edenberg, h. j., wang, k., chorlian, d. b., foroud, t., et al. (2002). linkage disequilibrium between the beta frequency of the human eeg and a gabaa receptor gene locus. \u003cem>proc. natl. acad. sci. u. s. a.\u003c/em> 99, 3729&#x02013;3733. doi:10.1073/pnas.052716399\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/11891318/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1073/pnas.052716399\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=linkage+disequilibrium+between+the+beta+frequency+of+the+human+eeg+and+a+gabaa+receptor+gene+locus&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b57\" id=\"b57\">\u003c/a>puts, n. a. j., wodka, e. l., harris, a. d., crocetti, d., tommerdahl, m., mostofsky, s. h., et al. (2017). reduced gaba and altered somatosensory function in children with autism spectrum disorder. \u003cem>autism res.\u003c/em> 10, 608&#x02013;619. doi:10.1002/aur.1691\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27611990/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/aur.1691\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=reduced+gaba+and+altered+somatosensory+function+in+children+with+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b58\" id=\"b58\">\u003c/a>robertson, c. e., ratai, e. m., and kanwisher, n. (2016). reduced gabaergic action in the autistic brain. \u003cem>curr. biol.\u003c/em> 26, 80&#x02013;85. doi:10.1016/j.cub.2015.11.019\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26711497/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.cub.2015.11.019\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=reduced+gabaergic+action+in+the+autistic+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b59\" id=\"b59\">\u003c/a>rojas, d. c., singel, d., steinmetz, s., hepburn, s., and brown, m. s. (2014). decreased left perisylvian gaba concentration in children with autism and unaffected siblings. \u003cem>neuroimage\u003c/em> 86, 28&#x02013;34. doi:10.1016/j.neuroimage.2013.01.045\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23370056/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuroimage.2013.01.045\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=decreased+left+perisylvian+gaba+concentration+in+children+with+autism+and+unaffected+siblings&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b60\" id=\"b60\">\u003c/a>rubenstein, j. l., and merzenich, m. m. (2003). model of autism: increased ratio of excitation/inhibition in key neural systems. \u003cem>genes brain behav.\u003c/em> 2, 255&#x02013;267. doi:10.1034/j.1601-183x.2003.00037.x\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/14606691/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1034/j.1601-183x.2003.00037.x\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=model+of+autism:+increased+ratio+of+excitation/inhibition+in+key+neural+systems&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b61\" id=\"b61\">\u003c/a>sanders, s. j. (2015). first glimpses of the neurobiology of autism spectrum disorder. \u003cem>curr. opin. genet. dev.\u003c/em> 33, 80&#x02013;92. doi:10.1016/j.gde.2015.10.002\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26547130/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.gde.2015.10.002\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=first+glimpses+of+the+neurobiology+of+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b62\" id=\"b62\">\u003c/a>schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2018). dendrite-targeting interneurons control synaptic nmda-receptor activation \u003cem>via\u003c/em> nonlinear &#x003b1;5-gaba\u003csub>a\u003c/sub> receptors. \u003cem>nat. commun.\u003c/em> 9, 3576. doi:10.1038/s41467-018-06004-8\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/30177704/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/s41467-018-06004-8\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=dendrite-targeting+interneurons+control+synaptic+nmda-receptor+activation+via+nonlinear+î±5-gabaa+receptors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b63\" id=\"b63\">\u003c/a>schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2019). enhanced dendritic inhibition and impaired nmdar activation in a mouse model of down syndrome. \u003cem>j. neurosci.\u003c/em> 39, 5210&#x02013;5221. doi:10.1523/jneurosci.2723-18.2019\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/31000585/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1523/jneurosci.2723-18.2019\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=enhanced+dendritic+inhibition+and+impaired+nmdar+activation+in+a+mouse+model+of+down+syndrome&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b64\" id=\"b64\">\u003c/a>serwanski, d. r., miralles, c. p., christie, s. b., mehta, a. k., li, x., and de blas, a. l. (2006). synaptic and nonsynaptic localization of gabaa receptors containing the alpha5 subunit in the rat brain. \u003cem>j. comp. neurol.\u003c/em> 499, 458&#x02013;470. doi:10.1002/cne.21115\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/16998906/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/cne.21115\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=synaptic+and+nonsynaptic+localization+of+gabaa+receptors+containing+the+alpha5+subunit+in+the+rat+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b65\" id=\"b65\">\u003c/a>sieghart, w. (2006). structure, pharmacology, and function of gabaa receptor subtypes. \u003cem>adv. pharmacol.\u003c/em> 54, 231&#x02013;263. doi:10.1016/s1054-3589(06)54010-4\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17175817/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s1054-3589(06)54010-4\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=structure%2c+pharmacology%2c+and+function+of+gabaa+receptor+subtypes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b66\" id=\"b66\">\u003c/a>sitnikova, e., rutskova, e., and smirnov, k. (2023). alpha2-adrenergic receptors as a pharmacological target for spike-wave epilepsy. \u003cem>int. j. mol. sci.\u003c/em> 24, 1477. doi:10.3390/ijms24021477\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/36674992/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.3390/ijms24021477\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=alpha2-adrenergic+receptors+as+a+pharmacological+target+for+spike-wave+epilepsy&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b67\" id=\"b67\">\u003c/a>smit, d. j. a., wright, m. j., meyers, j. l., martin, n. g., ho, y. y. w., malone, s. m., et al. (2018). genome-wide association analysis links multiple psychiatric liability genes to oscillatory brain activity. \u003cem>hum. brain mapp.\u003c/em> 39, 4183&#x02013;4195. doi:10.1002/hbm.24238\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/29947131/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/hbm.24238\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=genome-wide+association+analysis+links+multiple+psychiatric+liability+genes+to+oscillatory+brain+activity&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b68\" id=\"b68\">\u003c/a>souza, a. j., freitas, i. s., sharmin, d., cook, j. m., guimaraes, f. s., and gomes, f. v. (2024). an alpha 5-gaba(a) receptor positive allosteric modulator attenuates social and cognitive deficits without changing dopamine system hyperactivity in rats exposed to valproic acid in utero. \u003cem>autism res.\u003c/em> 17, 1534&#x02013;1544. doi:10.1002/aur.3178\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/39169698/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/aur.3178\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=an+alpha+5-gabaa+receptor+positive+allosteric+modulator+attenuates+social+and+cognitive+deficits+without+changing+dopamine+system+hyperactivity+in+rats+exposed+to+valproic+acid+in+utero&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b69\" id=\"b69\">\u003c/a>sur, c., fresu, l., howell, o., mckernan, r. m., and atack, j. r. (1999). autoradiographic localization of alpha5 subunit-containing gabaa receptors in rat brain. \u003cem>brain res.\u003c/em> 822, 265&#x02013;270. doi:10.1016/s0006-8993(99)01152-x\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/10082908/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0006-8993(99)01152-x\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=autoradiographic+localization+of+alpha5+subunit-containing+gabaa+receptors+in+rat+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\" style=\"margin-bottom:0.5em;\">\u003cp class=\"referencescopy1\">\u003ca name=\"b70\" id=\"b70\">\u003c/a>traub, r. d. w. m., and jefferys, j. g. r. (1999). \u003cem>fast oscillations in cortical circuits\u003c/em>. \u003cspan class=\"publisher-name\">the mit press\u003c/span>. \u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=â traubâ r+d+w+mjefferysâ j+g+r+1999+fast+oscillations+in+cortical+circuits+the+mit+press&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b71\" id=\"b71\">\u003c/a>van lier, h., drinkenburg, w. h., van eeten, y. j., and coenen, a. m. (2004). effects of diazepam and zolpidem on eeg beta frequencies are behavior-specific in rats. \u003cem>neuropharmacology\u003c/em> 47, 163&#x02013;174. doi:10.1016/j.neuropharm.2004.03.017\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/15223295/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2004.03.017\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=effects+of+diazepam+and+zolpidem+on+eeg+beta+frequencies+are+behavior-specific+in+rats&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b72\" id=\"b72\">\u003c/a>visser, s. a., wolters, f. l., gubbens-stibbe, j. m., tukker, e., van der graaf, p. h., peletier, l. a., et al. (2003). mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of gabaa receptor modulators: in vitro-in vivo correlations. \u003cem>j. pharmacol. exp. ther.\u003c/em> 304, 88&#x02013;101. doi:10.1124/jpet.102.042341\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/12490579/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1124/jpet.102.042341\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=mechanism-based+pharmacokinetic/pharmacodynamic+modeling+of+the+electroencephalogram+effects+of+gabaa+receptor+modulators:+in+vitro-in+vivo+correlations&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b73\" id=\"b73\">\u003c/a>vithlani, m., terunuma, m., and moss, s. j. (2011). the dynamic modulation of gaba(a) receptor trafficking and its role in regulating the plasticity of inhibitory synapses. \u003cem>physiol. rev.\u003c/em> 91, 1009&#x02013;1022. doi:10.1152/physrev.00015.2010\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21742794/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1152/physrev.00015.2010\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+dynamic+modulation+of+gabaa+receptor+trafficking+and+its+role+in+regulating+the+plasticity+of+inhibitory+synapses&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b74\" id=\"b74\">\u003c/a>warrier, v., baron-cohen, s., and chakrabarti, b. (2013). genetic variation in gabrb3 is associated with asperger syndrome and multiple endophenotypes relevant to autism. \u003cem>mol. autism\u003c/em> 4, 48. doi:10.1186/2040-2392-4-48\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/24321478/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1186/2040-2392-4-48\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=genetic+variation+in+gabrb3+is+associated+with+asperger+syndrome+and+multiple+endophenotypes+relevant+to+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b75\" id=\"b75\">\u003c/a>whittington, m. a., traub, r. d., kopell, n., ermentrout, b., and buhl, e. h. (2000). inhibition-based rhythms: experimental and mathematical observations on network dynamics. \u003cem>int. j. psychophysiol.\u003c/em> 38, 315&#x02013;336. doi:10.1016/s0167-8760(00)00173-2\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/11102670/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0167-8760(00)00173-2\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=inhibition-based+rhythms:+experimental+and+mathematical+observations+on+network+dynamics&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b76\" id=\"b76\">\u003c/a>xie, x. h., and tietz, e. i. (1991). chronic benzodiazepine treatment of rats induces reduction of paired-pulse inhibition in ca1 region of \u003cem>in vitro\u003c/em> hippocampus. \u003cem>brain res.\u003c/em> 561, 69&#x02013;76. doi:10.1016/0006-8993(91)90750-p\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/1797351/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/0006-8993(91)90750-p\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=chronic+benzodiazepine+treatment+of+rats+induces+reduction+of+paired-pulse+inhibition+in+ca1+region+of+in+vitro+hippocampus&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b77\" id=\"b77\">\u003c/a>zurek, a. a., kemp, s. w., aga, z., walker, s., milenkovic, m., ramsey, a. j., et al. (2016). &#x003b1;5gabaa receptor deficiency causes autism-like behaviors. \u003cem>ann. clin. transl. neurol.\u003c/em> 3, 392&#x02013;398. doi:10.1002/acn3.303\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27231709/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/acn3.303\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=î±5gabaa+receptor+deficiency+causes+autism-like+behaviors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003c/div>\u003cdiv class=\"thinlinem20\">\u003c/div>\u003cdiv class=\"abstractsummary\">\u003cp>\u003cspan>keywords:\u003c/span> autism spectrum disorder, angelman syndrome, gaba\u003csub>a\u003c/sub>, gaba\u003csub>a\u003c/sub>-&#x003b1;5, positron emission tomography (pet), electroencephalography, pharmacological mri, biomarker\u003c/p>\u003cp>\u003cspan>citation:\u003c/span> cecere g, ballard tm, knoflach f, honer m, hipp jf, garces p, mueggler t, k&#x000fc;nnecke b, bruns a, prinssen ep, schoenenberger p, janz p, redondo r, biemans b, knust h, olivares-morales a, brigo a, schulz jm, bertrand d, saxe m, o&#x02019;connor ec and hernandez m-c (2025) preclinical pharmacology of alogabat: a novel gaba\u003csub>a\u003c/sub>-&#x003b1;5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gaba\u003csub>a\u003c/sub> signaling. \u003cem>front. pharmacol.\u003c/em> 16:1626078. doi: 10.3389/fphar.2025.1626078\u003c/p>\u003cp id=\"timestamps\">\u003cspan>received:\u003c/span> 09 may 2025; \u003cspan>accepted:\u003c/span> 18 june 2025;\u003cbr>\u003cspan>published:\u003c/span> 21 july 2025.\u003c/p>\u003cdiv>\u003cp>edited by:\u003c/p> \u003ca href=\"https://loop.frontiersin.org/people/52072/overview\">agenor limon\u003c/a>, university of texas medical branch at galveston, united states\u003c/div>\u003cdiv>\u003cp>reviewed by:\u003c/p> \u003ca href=\"https://loop.frontiersin.org/people/39673/overview\">hansen wang\u003c/a>, university of toronto, canada\u003cbr>\u003ca href=\"https://loop.frontiersin.org/people/1285968/overview\">junzhan jing\u003c/a>, baylor college of medicine, united states\u003cbr>\u003ca href=\"https://loop.frontiersin.org/people/1380630/overview\">azar omrani\u003c/a>, boehringer ingelheim, germany\u003c/div>\u003cp>\u003cspan>copyright\u003c/span> &#x000a9; 2025 cecere, ballard, knoflach, honer, hipp, garces, mueggler, k&#x000fc;nnecke, bruns, prinssen, schoenenberger, janz, redondo, biemans, knust, olivares-morales, brigo, schulz, bertrand, saxe, o&#x02019;connor and hernandez. this is an open-access article distributed under the terms of the \u003ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">creative commons attribution license (cc by).\u003c/a> the use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. no use, distribution or reproduction is permitted which does not comply with these terms.\u003c/p>\u003cp>\u003cspan>&#x0002a;correspondence:\u003c/span> maria-clemencia hernandez, \u003ca id=\"encmail\">bwfyawety2xlbwvuy2lhlmhlcm5hbmrlekbyb2nozs5jb20=\u003c/a>\u003c/p>\u003cp>\u003cspan>\u003csup>&#x02020;\u003c/sup>\u003c/span>these authors have contributed equally to this work\u003c/p>\u003cp>\u003cspan>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cb>present address:\u003c/b> theresa m. ballard, galwyn (uk) ltd., dartmouth, united kingdom\u003cbr>barbara biemans, b2discovery llc, riehen, switzerland\u003cbr>michael saxe, translational in vivo sciences, biogen, cambridge, ma, united states\u003c/p>\u003cdiv class=\"clear\">\u003c/div>\u003c/div>","\u003cul class=\"flyoutjournal\">\u003cli>\u003ca href=\"#h1\">abstract\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h2\">1 introduction\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h3\">2 materials and methods\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h4\">3 results\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h5\">4 discussion\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h6\">5 conclusion\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h7\">data availability statement\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h8\">ethics statement\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h9\">author contributions\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h10\">funding\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h11\">acknowledgments\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h12\">conflict of interest\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h13\">generative ai statement\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h14\">publisher&#x02019;s note\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h15\">supplementary material\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h16\">abbreviations\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h17\">references\u003c/a>\u003c/li>\u003c/ul>",[732,740,746,752],{"name":733,"fileserverpackageentryid":734,"fileserverid":735,"fileserverversionnumber":736,"type":737},"fphar-16-1626078.xml","fphar-16-1626078-r1/fphar-16-1626078.xml","1626078/xml",2,{"code":738,"name":739},"nlm_xml","xml",{"name":741,"fileserverpackageentryid":19,"fileserverid":742,"fileserverversionnumber":736,"type":743},"epub.epub","1626078/epub",{"code":744,"name":745},"epub","epub",{"name":747,"fileserverpackageentryid":19,"fileserverid":748,"fileserverversionnumber":736,"type":749},"publishers-proof.pdf","1626078/publishers-proof",{"code":750,"name":751},"pdf","pdf",{"name":753,"fileserverpackageentryid":19,"fileserverid":754,"fileserverversionnumber":370,"type":755},"supplementary file 1.docx","1626078/supplementary-file/1",{"code":756,"name":757},"supplementary_material","docx","v3",{"title":760,"link":761,"meta":765,"script":956},"frontiers | preclinical pharmacology of alogabat: a novel gabaa-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gabaa signaling",[762],{"rel":763,"href":764},"canonical","https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1626078/full",[766,769,772,774,777,781,784,788,791,794,797,799,801,803,805,807,810,813,815,818,820,822,825,828,831,834,837,841,845,848,851,854,856,859,861,864,866,869,871,874,876,879,881,884,886,889,891,894,896,899,901,904,906,909,911,914,916,919,922,925,927,930,932,935,938,941,943,946,948,951,953],{"hid":767,"property":767,"name":767,"content":768},"description","backgroundalterations in the gabaergic system contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder (asd) and...",{"hid":770,"property":770,"name":771,"content":760},"og:title","title",{"hid":773,"property":773,"name":767,"content":768},"og:description",{"hid":775,"name":775,"content":776},"keywords","biomarker,autism spectrum disorder,electroencephalography,positron emission tomography (pet),angelman syndrome,gabaa,gabaa-α5,pharmacological mri",{"hid":778,"property":778,"name":779,"content":780},"og:site_name","site_name","frontiers",{"hid":782,"property":782,"name":363,"content":783},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg",{"hid":785,"property":785,"name":786,"content":787},"og:type","type","article",{"hid":789,"property":789,"name":790,"content":764},"og:url","url",{"hid":792,"name":792,"content":793},"twitter:card","summary_large_image",{"hid":795,"name":795,"content":796},"citation_volume","16",{"hid":798,"name":798,"content":116},"citation_journal_title",{"hid":800,"name":800,"content":780},"citation_publisher",{"hid":802,"name":802,"content":713},"citation_journal_abbrev",{"hid":804,"name":804,"content":714},"citation_issn",{"hid":806,"name":806,"content":515},"citation_doi",{"hid":808,"name":808,"content":809},"citation_firstpage","1626078",{"hid":811,"name":811,"content":812},"citation_language","english",{"hid":814,"name":814,"content":516},"citation_title",{"hid":816,"name":816,"content":817},"citation_keywords","biomarker; autism spectrum disorder; electroencephalography; positron emission tomography (pet); angelman syndrome; gabaa; gabaa-α5; pharmacological mri",{"hid":819,"name":819,"content":521},"citation_abstract",{"hid":821,"name":821,"content":524},"citation_article_type",{"hid":823,"name":823,"content":824},"citation_pdf_url","https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1626078/pdf",{"hid":826,"name":826,"content":827},"citation_xml_url","https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1626078/xml",{"hid":829,"name":829,"content":830},"citation_fulltext_world_readable","yes",{"hid":832,"name":832,"content":833},"citation_online_date","2025/06/18",{"hid":835,"name":835,"content":836},"citation_publication_date","2025/07/21",{"hid":838,"name":839,"content":840},"citation_author_0","citation_author","cecere, giuseppe ",{"hid":842,"name":843,"content":844},"citation_author_institution_0","citation_author_institution","medicinal chemistry, switzerland",{"hid":846,"name":839,"content":847},"citation_author_1","ballard, theresa m. ",{"hid":849,"name":843,"content":850},"citation_author_institution_1","neuroscience and rare diseases, switzerland",{"hid":852,"name":839,"content":853},"citation_author_2","knoflach, frederic ",{"hid":855,"name":843,"content":850},"citation_author_institution_2",{"hid":857,"name":839,"content":858},"citation_author_3","honer, michael ",{"hid":860,"name":843,"content":850},"citation_author_institution_3",{"hid":862,"name":839,"content":863},"citation_author_4","hipp, joerg f. ",{"hid":865,"name":843,"content":850},"citation_author_institution_4",{"hid":867,"name":839,"content":868},"citation_author_5","garces, pilar ",{"hid":870,"name":843,"content":850},"citation_author_institution_5",{"hid":872,"name":839,"content":873},"citation_author_6","mueggler, thomas ",{"hid":875,"name":843,"content":850},"citation_author_institution_6",{"hid":877,"name":839,"content":878},"citation_author_7","künnecke, basil ",{"hid":880,"name":843,"content":850},"citation_author_institution_7",{"hid":882,"name":839,"content":883},"citation_author_8","bruns, andreas ",{"hid":885,"name":843,"content":850},"citation_author_institution_8",{"hid":887,"name":839,"content":888},"citation_author_9","prinssen, eric p. ",{"hid":890,"name":843,"content":850},"citation_author_institution_9",{"hid":892,"name":839,"content":893},"citation_author_10","schoenenberger, philipp ",{"hid":895,"name":843,"content":850},"citation_author_institution_10",{"hid":897,"name":839,"content":898},"citation_author_11","janz, philipp ",{"hid":900,"name":843,"content":850},"citation_author_institution_11",{"hid":902,"name":839,"content":903},"citation_author_12","redondo, roger ",{"hid":905,"name":843,"content":850},"citation_author_institution_12",{"hid":907,"name":839,"content":908},"citation_author_13","biemans, barbara ",{"hid":910,"name":843,"content":850},"citation_author_institution_13",{"hid":912,"name":839,"content":913},"citation_author_14","knust, henner ",{"hid":915,"name":843,"content":844},"citation_author_institution_14",{"hid":917,"name":839,"content":918},"citation_author_15","olivares-morales, andrés ",{"hid":920,"name":843,"content":921},"citation_author_institution_15","pharmaceutical sciences, switzerland",{"hid":923,"name":839,"content":924},"citation_author_16","brigo, alessandro ",{"hid":926,"name":843,"content":921},"citation_author_institution_16",{"hid":928,"name":839,"content":929},"citation_author_17","schulz, jan michael ",{"hid":931,"name":843,"content":850},"citation_author_institution_17",{"hid":933,"name":839,"content":934},"citation_author_18","bertrand, daniel ",{"hid":936,"name":843,"content":937},"citation_author_institution_18","hiqscreen sàrl, switzerland",{"hid":939,"name":839,"content":940},"citation_author_19","saxe, michael ",{"hid":942,"name":843,"content":850},"citation_author_institution_19",{"hid":944,"name":839,"content":945},"citation_author_20","o’connor, eoin c. ",{"hid":947,"name":843,"content":850},"citation_author_institution_20",{"hid":949,"name":839,"content":950},"citation_author_21","hernandez, maria-clemencia ",{"hid":952,"name":843,"content":850},"citation_author_institution_21",{"hid":954,"name":954,"content":955},"dc.identifier","doi:10.3389/fphar.2025.1626078",[957,960,962,964,966],{"src":958,"body":13,"type":959,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":961,"body":13,"type":959,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/mathjax.js?config=tex-mml-am_chtml",{"src":963,"body":13,"type":959,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":965,"body":13,"type":959,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fphar.2025.1626078?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":967,"body":13,"type":959,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articlehubslug":19,"articlehubpage":969,"articlehubarticleslist":970,"canjournalhasarticlehub":347,"articledoilist":971},{},[],[],{"title":19,"image":-1,"breadcrumbs":973,"linkscollection":974,"metricscollection":976},[],{"total":367,"items":975},[],{"total":367,"items":977},[]] window.__nuxt__={};window.__nuxt__.config={public:{isdevmode:false,appname:"article-pages-2024",baseurl:"https://www.frontiersin.org",domain:"frontiersin.org",loopurl:"https://loop.frontiersin.org",ssmaindomain:"frontiersin.org",contentfulurl:"https://graphql.contentful.com/content/v1/spaces",spaceid:1,spacename:"frontiers",livespaceid:1,tenantlogourl:"",frontiersgraphurl:"https://apollo-federation-gateway.frontiersin.org",registrationapiurl:"https://onboarding-ui.frontiersin.org",emaildigestapiurl:"https://api-email-digest.frontiersin.org",journalfilesapiurl:"https://files-journal-api.frontiersin.org",searchapiurl:"https://search-api.frontiersin.org",productionforumapiurl:"https://production-forum-api-v2.frontiersin.org",gtmserverurl:"https://tag-manager.frontiersin.org",gtmid:"gtm-m322fv2",gtmauth:"owvbwxfajr21yqv1fe1caq",gtmpreview:"env-1",figsharepluginurl:"https://widgets.figshare.com/static/figshare.js",figshareapiurl:"https://api.figshare.com/v2/collections/search",figsharetimeout:3000,crossmarkpublisheddate:"2015/08/24",googlerecaptchasitekey:"6ldg3i0uaaaaaoc4quh35ubhgjotehp_stxhgr_v",googlerecaptchakeyname:"frontiersrecaptchav2",faviconsize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantfavicon-frontiers.png",faviconsize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantfavicon-frontiers.png",faviconsize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantfavicon-frontiers.png",faviconsize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantfavicon-frontiers.png",faviconsize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantfavicon-frontiers.png",socialmediaimg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/guidelines-frontiers_logo_1200x628_1-91to1.png",linkedarticlecopytext:"'{\"articletypecopytext\":[{\"articletypeid\":0,\"originalarticlecopytext\":\"part of this article's content has been mentioned in:\",\"linkedarticlecopytext\":\"this article mentions parts of:\"},{\"articletypeid\":122,\"originalarticlecopytext\":\"parts of this article's content have been modified or rectified in:\",\"linkedarticlecopytext\":\"this article is an erratum on:\"},{\"articletypeid\":129,\"originalarticlecopytext\":\"parts of this article's content have been modified or rectified in:\",\"linkedarticlecopytext\":\"this article is an addendum to:\"},{\"articletypeid\":128,\"originalarticlecopytext\":\"a correction has been applied to this article in:\",\"linkedarticlecopytext\":\"this article is a correction to:\"},{\"articletypeid\":134,\"originalarticlecopytext\":\"a retraction of this article was approved in:\",\"linkedarticlecopytext\":\"this article is a retraction of:\"},{\"articletypeid\":29,\"originalarticlecopytext\":\"a commentary has been posted on this article:\",\"linkedarticlecopytext\":\"this article is a commentary on:\"},{\"articletypeid\":30,\"originalarticlecopytext\":\"a commentary has been posted on this article:\",\"linkedarticlecopytext\":\"this article is a commentary on:\"}],\"articleidcopytext\":[]}'\n",acceptedarticleexcludedjournalids:"'[2766,979]'\n",articletypeconfigurablelabel:"\u003c\u003carticle-type:uppercase>> article",settingsfeaturesswitchers:"'{\"displaytitlepilllabels\":true,\"displayrelatedarticlesbox\":true,\"showeditors\":true,\"showreviewers\":true,\"showloopimpactlink\":true,\"enablefigshare\":false,\"usexmlimages\":true}'\n",journalswitharticlehub:"'{\"strings\":[\"science\"]}'\n",terminologysettings:"'{\"terms\":[{\"sequencenumber\":1,\"key\":\"frontiers\",\"tenantterm\":\"frontiers\",\"frontiersdefaultterm\":\"frontiers\",\"category\":\"customer\"},{\"sequencenumber\":2,\"key\":\"submission_system\",\"tenantterm\":\"submission system\",\"frontiersdefaultterm\":\"submission system\",\"category\":\"product\"},{\"sequencenumber\":3,\"key\":\"public_pages\",\"tenantterm\":\"public pages\",\"frontiersdefaultterm\":\"public pages\",\"category\":\"product\"},{\"sequencenumber\":4,\"key\":\"my_frontiers\",\"tenantterm\":\"my frontiers\",\"frontiersdefaultterm\":\"my frontiers\",\"category\":\"product\"},{\"sequencenumber\":5,\"key\":\"digital_editorial_office\",\"tenantterm\":\"digital editorial office\",\"frontiersdefaultterm\":\"digital editorial office\",\"category\":\"product\"},{\"sequencenumber\":6,\"key\":\"deo\",\"tenantterm\":\"deo\",\"frontiersdefaultterm\":\"deo\",\"category\":\"product\"},{\"sequencenumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantterm\":\"digital editorial office for chiefs\",\"frontiersdefaultterm\":\"digital editorial office for chiefs\",\"category\":\"product\"},{\"sequencenumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantterm\":\"digital editorial office for eof\",\"frontiersdefaultterm\":\"digital editorial office for eof\",\"category\":\"product\"},{\"sequencenumber\":9,\"key\":\"editorial_office\",\"tenantterm\":\"editorial office\",\"frontiersdefaultterm\":\"editorial office\",\"category\":\"product\"},{\"sequencenumber\":10,\"key\":\"eof\",\"tenantterm\":\"eof\",\"frontiersdefaultterm\":\"eof\",\"category\":\"product\"},{\"sequencenumber\":11,\"key\":\"research_topic_management\",\"tenantterm\":\"research topic management\",\"frontiersdefaultterm\":\"research topic management\",\"category\":\"product\"},{\"sequencenumber\":12,\"key\":\"review_forum\",\"tenantterm\":\"review forum\",\"frontiersdefaultterm\":\"review forum\",\"category\":\"product\"},{\"sequencenumber\":13,\"key\":\"accounting_office\",\"tenantterm\":\"accounting office\",\"frontiersdefaultterm\":\"accounting office\",\"category\":\"product\"},{\"sequencenumber\":14,\"key\":\"aof\",\"tenantterm\":\"aof\",\"frontiersdefaultterm\":\"aof\",\"category\":\"product\"},{\"sequencenumber\":15,\"key\":\"publishing_office\",\"tenantterm\":\"publishing office\",\"frontiersdefaultterm\":\"publishing office\",\"category\":\"product\"},{\"sequencenumber\":16,\"key\":\"production_office\",\"tenantterm\":\"production office forum\",\"frontiersdefaultterm\":\"production office forum\",\"category\":\"product\"},{\"sequencenumber\":17,\"key\":\"pof\",\"tenantterm\":\"pof\",\"frontiersdefaultterm\":\"pof\",\"category\":\"product\"},{\"sequencenumber\":18,\"key\":\"book_office_forum\",\"tenantterm\":\"book office forum\",\"frontiersdefaultterm\":\"book office forum\",\"category\":\"product\"},{\"sequencenumber\":19,\"key\":\"bof\",\"tenantterm\":\"bof\",\"frontiersdefaultterm\":\"bof\",\"category\":\"product\"},{\"sequencenumber\":20,\"key\":\"aira\",\"tenantterm\":\"aira\",\"frontiersdefaultterm\":\"aira\",\"category\":\"product\"},{\"sequencenumber\":21,\"key\":\"editorial_board_management\",\"tenantterm\":\"editorial board management\",\"frontiersdefaultterm\":\"editorial board management\",\"category\":\"product\"},{\"sequencenumber\":22,\"key\":\"ebm\",\"tenantterm\":\"ebm\",\"frontiersdefaultterm\":\"ebm\",\"category\":\"product\"},{\"sequencenumber\":23,\"key\":\"domain\",\"tenantterm\":\"domain\",\"frontiersdefaultterm\":\"domain\",\"category\":\"taxonomy\"},{\"sequencenumber\":24,\"key\":\"journal\",\"tenantterm\":\"journal\",\"frontiersdefaultterm\":\"journal\",\"category\":\"taxonomy\"},{\"sequencenumber\":25,\"key\":\"section\",\"tenantterm\":\"section\",\"frontiersdefaultterm\":\"section\",\"category\":\"taxonomy\"},{\"sequencenumber\":26,\"key\":\"domains\",\"tenantterm\":\"domains\",\"frontiersdefaultterm\":\"domains\",\"category\":\"taxonomy\"},{\"sequencenumber\":27,\"key\":\"specialty_section\",\"tenantterm\":\"specialty section\",\"frontiersdefaultterm\":\"specialty section\",\"category\":\"taxonomy\"},{\"sequencenumber\":28,\"key\":\"specialty_journal\",\"tenantterm\":\"specialty journal\",\"frontiersdefaultterm\":\"specialty journal\",\"category\":\"taxonomy\"},{\"sequencenumber\":29,\"key\":\"journals\",\"tenantterm\":\"journals\",\"frontiersdefaultterm\":\"journals\",\"category\":\"taxonomy\"},{\"sequencenumber\":30,\"key\":\"sections\",\"tenantterm\":\"sections\",\"frontiersdefaultterm\":\"sections\",\"category\":\"taxonomy\"},{\"sequencenumber\":31,\"key\":\"specialty_sections\",\"tenantterm\":\"specialty sections\",\"frontiersdefaultterm\":\"specialty sections\",\"category\":\"taxonomy\"},{\"sequencenumber\":32,\"key\":\"specialty_journals\",\"tenantterm\":\"specialty journals\",\"frontiersdefaultterm\":\"specialty journals\",\"category\":\"taxonomy\"},{\"sequencenumber\":33,\"key\":\"manuscript\",\"tenantterm\":\"manuscript\",\"frontiersdefaultterm\":\"manuscript\",\"category\":\"core\"},{\"sequencenumber\":34,\"key\":\"manuscripts\",\"tenantterm\":\"manuscripts\",\"frontiersdefaultterm\":\"manuscripts\",\"category\":\"core\"},{\"sequencenumber\":35,\"key\":\"article\",\"tenantterm\":\"article\",\"frontiersdefaultterm\":\"article\",\"category\":\"core\"},{\"sequencenumber\":36,\"key\":\"articles\",\"tenantterm\":\"articles\",\"frontiersdefaultterm\":\"articles\",\"category\":\"core\"},{\"sequencenumber\":37,\"key\":\"article_type\",\"tenantterm\":\"article type\",\"frontiersdefaultterm\":\"article type\",\"category\":\"core\"},{\"sequencenumber\":38,\"key\":\"article_types\",\"tenantterm\":\"article types\",\"frontiersdefaultterm\":\"article types\",\"category\":\"core\"},{\"sequencenumber\":39,\"key\":\"author\",\"tenantterm\":\"author\",\"frontiersdefaultterm\":\"author\",\"category\":\"label (role)\"},{\"sequencenumber\":40,\"key\":\"authors\",\"tenantterm\":\"authors\",\"frontiersdefaultterm\":\"authors\",\"category\":\"label (role)\"},{\"sequencenumber\":41,\"key\":\"authoring\",\"tenantterm\":\"authoring\",\"frontiersdefaultterm\":\"authoring\",\"category\":\"core\"},{\"sequencenumber\":42,\"key\":\"authored\",\"tenantterm\":\"authored\",\"frontiersdefaultterm\":\"authored\",\"category\":\"core\"},{\"sequencenumber\":43,\"key\":\"accept\",\"tenantterm\":\"accept\",\"frontiersdefaultterm\":\"accept\",\"category\":\"process\"},{\"sequencenumber\":44,\"key\":\"accepted\",\"tenantterm\":\"accepted\",\"frontiersdefaultterm\":\"accepted\",\"category\":\"process\"},{\"sequencenumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantterm\":\"assistant field chief editor\",\"frontiersdefaultterm\":\"assistant field chief editor\",\"description\":\"an editorial role on a field journal that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantterm\":\"assistant specialty chief editor\",\"frontiersdefaultterm\":\"assistant specialty chief editor\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantterm\":\"assistant specialty chief editors\",\"frontiersdefaultterm\":\"assistant specialty chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":48,\"key\":\"associate_editor\",\"tenantterm\":\"associate editor\",\"frontiersdefaultterm\":\"associate editor\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":49,\"key\":\"specialty_chief_editor\",\"tenantterm\":\"specialty chief editor\",\"frontiersdefaultterm\":\"specialty chief editor\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":50,\"key\":\"specialty_chief_editors\",\"tenantterm\":\"specialty chief editors\",\"frontiersdefaultterm\":\"specialty chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":51,\"key\":\"chief_editor\",\"tenantterm\":\"chief editor\",\"frontiersdefaultterm\":\"chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":52,\"key\":\"chief_editors\",\"tenantterm\":\"chief editors\",\"frontiersdefaultterm\":\"chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":53,\"key\":\"call_for_participation\",\"tenantterm\":\"call for participation\",\"frontiersdefaultterm\":\"call for participation\",\"category\":\"process\"},{\"sequencenumber\":54,\"key\":\"citation\",\"tenantterm\":\"citation\",\"frontiersdefaultterm\":\"citation\",\"category\":\"misc.\"},{\"sequencenumber\":55,\"key\":\"citations\",\"tenantterm\":\"citations\",\"frontiersdefaultterm\":\"citations\",\"category\":\"misc.\"},{\"sequencenumber\":56,\"key\":\"contributor\",\"tenantterm\":\"contributor\",\"frontiersdefaultterm\":\"contributor\",\"category\":\"label (role)\"},{\"sequencenumber\":57,\"key\":\"contributors\",\"tenantterm\":\"contributors\",\"frontiersdefaultterm\":\"contributors\",\"category\":\"label (role)\"},{\"sequencenumber\":58,\"key\":\"corresponding_author\",\"tenantterm\":\"corresponding author\",\"frontiersdefaultterm\":\"corresponding author\",\"category\":\"label (role)\"},{\"sequencenumber\":59,\"key\":\"corresponding_authors\",\"tenantterm\":\"corresponding authors\",\"frontiersdefaultterm\":\"corresponding authors\",\"category\":\"label (role)\"},{\"sequencenumber\":60,\"key\":\"decline\",\"tenantterm\":\"decline\",\"frontiersdefaultterm\":\"decline\",\"category\":\"process\"},{\"sequencenumber\":61,\"key\":\"declined\",\"tenantterm\":\"declined\",\"frontiersdefaultterm\":\"declined\",\"category\":\"process\"},{\"sequencenumber\":62,\"key\":\"reject\",\"tenantterm\":\"reject\",\"frontiersdefaultterm\":\"reject\",\"category\":\"process\"},{\"sequencenumber\":63,\"key\":\"rejected\",\"tenantterm\":\"rejected\",\"frontiersdefaultterm\":\"rejected\",\"category\":\"process\"},{\"sequencenumber\":64,\"key\":\"publish\",\"tenantterm\":\"publish\",\"frontiersdefaultterm\":\"publish\",\"category\":\"core\"},{\"sequencenumber\":65,\"key\":\"published\",\"tenantterm\":\"published\",\"frontiersdefaultterm\":\"published\",\"category\":\"core\"},{\"sequencenumber\":66,\"key\":\"publication\",\"tenantterm\":\"publication\",\"frontiersdefaultterm\":\"publication\",\"category\":\"core\"},{\"sequencenumber\":67,\"key\":\"peer_review\",\"tenantterm\":\"peer review\",\"frontiersdefaultterm\":\"peer review\",\"category\":\"peer review process\"},{\"sequencenumber\":68,\"key\":\"peer_reviewed\",\"tenantterm\":\"peer reviewed\",\"frontiersdefaultterm\":\"peer reviewed\",\"category\":\"peer review process\"},{\"sequencenumber\":69,\"key\":\"initial_validation\",\"tenantterm\":\"initial validation\",\"frontiersdefaultterm\":\"initial validation\",\"category\":\"peer review process\"},{\"sequencenumber\":70,\"key\":\"editorial_assignment\",\"tenantterm\":\"editorial assignment\",\"frontiersdefaultterm\":\"editorial assignment\",\"category\":\"peer review process\"},{\"sequencenumber\":71,\"key\":\"independent_review\",\"tenantterm\":\"independent review\",\"frontiersdefaultterm\":\"independent review\",\"category\":\"peer review process\"},{\"sequencenumber\":72,\"key\":\"interactive_review\",\"tenantterm\":\"interactive review\",\"frontiersdefaultterm\":\"interactive review\",\"category\":\"peer review process\"},{\"sequencenumber\":73,\"key\":\"review\",\"tenantterm\":\"review\",\"frontiersdefaultterm\":\"review\",\"category\":\"peer review process\"},{\"sequencenumber\":74,\"key\":\"reviewing\",\"tenantterm\":\"reviewing\",\"frontiersdefaultterm\":\"reviewing\",\"category\":\"peer review process\"},{\"sequencenumber\":75,\"key\":\"reviewer\",\"tenantterm\":\"reviewer\",\"frontiersdefaultterm\":\"reviewer\",\"category\":\"label (role)\"},{\"sequencenumber\":76,\"key\":\"reviewers\",\"tenantterm\":\"reviewers\",\"frontiersdefaultterm\":\"reviewers\",\"category\":\"label (role)\"},{\"sequencenumber\":77,\"key\":\"review_finalized\",\"tenantterm\":\"review finalized\",\"frontiersdefaultterm\":\"review finalized\",\"category\":\"peer review process\"},{\"sequencenumber\":78,\"key\":\"final_decision\",\"tenantterm\":\"final decision\",\"frontiersdefaultterm\":\"final decision\",\"category\":\"peer review process\"},{\"sequencenumber\":79,\"key\":\"final_validation\",\"tenantterm\":\"final validation\",\"frontiersdefaultterm\":\"final validation\",\"category\":\"peer review process\"},{\"sequencenumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantterm\":\"recommend to accept manuscript\",\"frontiersdefaultterm\":\"accept manuscript\",\"category\":\"process\"},{\"sequencenumber\":81,\"key\":\"fee\",\"tenantterm\":\"fee\",\"frontiersdefaultterm\":\"fee\",\"category\":\"accounting\"},{\"sequencenumber\":82,\"key\":\"fees\",\"tenantterm\":\"fees\",\"frontiersdefaultterm\":\"fees\",\"category\":\"accounting\"},{\"sequencenumber\":83,\"key\":\"guest_associate_editor\",\"tenantterm\":\"guest associate editor\",\"frontiersdefaultterm\":\"guest associate editor\",\"category\":\"label (role)\"},{\"sequencenumber\":84,\"key\":\"guest_associate_editors\",\"tenantterm\":\"guest associate editors\",\"frontiersdefaultterm\":\"guest associate editors\",\"category\":\"label (role)\"},{\"sequencenumber\":85,\"key\":\"in_review\",\"tenantterm\":\"in review\",\"frontiersdefaultterm\":\"in review\",\"category\":\"peer review process\"},{\"sequencenumber\":86,\"key\":\"institutional_member\",\"tenantterm\":\"institutional partner\",\"frontiersdefaultterm\":\"institutional partner\",\"category\":\"accounting\"},{\"sequencenumber\":87,\"key\":\"institutional_membership\",\"tenantterm\":\"institutional partnership\",\"frontiersdefaultterm\":\"institutional partnership\",\"category\":\"accounting\"},{\"sequencenumber\":88,\"key\":\"article_processing_charge\",\"tenantterm\":\"article processing charge\",\"frontiersdefaultterm\":\"article processing charge\",\"category\":\"accounting\"},{\"sequencenumber\":89,\"key\":\"article_processing_charges\",\"tenantterm\":\"article processing charges\",\"frontiersdefaultterm\":\"article processing charges\",\"category\":\"accounting\"},{\"sequencenumber\":90,\"key\":\"apcs\",\"tenantterm\":\"apcs\",\"frontiersdefaultterm\":\"apcs\",\"category\":\"accounting\"},{\"sequencenumber\":91,\"key\":\"apc\",\"tenantterm\":\"apc\",\"frontiersdefaultterm\":\"apc\",\"category\":\"accounting\"},{\"sequencenumber\":92,\"key\":\"received\",\"tenantterm\":\"received\",\"frontiersdefaultterm\":\"received\",\"description\":\"date manuscript was received on.\",\"category\":\"core\"},{\"sequencenumber\":93,\"key\":\"transferred\",\"tenantterm\":\"transferred\",\"frontiersdefaultterm\":\"transferred\",\"category\":\"core\"},{\"sequencenumber\":94,\"key\":\"transfer\",\"tenantterm\":\"transfer\",\"frontiersdefaultterm\":\"transfer\",\"category\":\"core\"},{\"sequencenumber\":95,\"key\":\"research_topic\",\"tenantterm\":\"research topic\",\"frontiersdefaultterm\":\"research topic\",\"category\":\"core\"},{\"sequencenumber\":96,\"key\":\"research_topics\",\"tenantterm\":\"research topics\",\"frontiersdefaultterm\":\"research topics\",\"category\":\"core\"},{\"sequencenumber\":97,\"key\":\"topic_editor\",\"tenantterm\":\"topic editor\",\"frontiersdefaultterm\":\"topic editor\",\"category\":\"label (role)\"},{\"sequencenumber\":98,\"key\":\"review_editor\",\"tenantterm\":\"community reviewer\",\"frontiersdefaultterm\":\"review editor\",\"category\":\"label (role)\"},{\"sequencenumber\":99,\"key\":\"title\",\"tenantterm\":\"title\",\"frontiersdefaultterm\":\"title\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":100,\"key\":\"running_title\",\"tenantterm\":\"running title\",\"frontiersdefaultterm\":\"running title\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":101,\"key\":\"submit\",\"tenantterm\":\"submit\",\"frontiersdefaultterm\":\"submit\",\"category\":\"process\"},{\"sequencenumber\":102,\"key\":\"submitted\",\"tenantterm\":\"submitted\",\"frontiersdefaultterm\":\"submitted\",\"category\":\"process\"},{\"sequencenumber\":103,\"key\":\"submitting\",\"tenantterm\":\"submitting\",\"frontiersdefaultterm\":\"submitting\",\"category\":\"process\"},{\"sequencenumber\":104,\"key\":\"t_e\",\"tenantterm\":\"te\",\"frontiersdefaultterm\":\"te\",\"category\":\"label (role)\"},{\"sequencenumber\":105,\"key\":\"topic\",\"tenantterm\":\"topic\",\"frontiersdefaultterm\":\"topic\",\"category\":\"process\"},{\"sequencenumber\":106,\"key\":\"topic_summary\",\"tenantterm\":\"topic summary\",\"frontiersdefaultterm\":\"topic summary\",\"category\":\"process\"},{\"sequencenumber\":107,\"key\":\"figure\",\"tenantterm\":\"figure\",\"frontiersdefaultterm\":\"figure\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":108,\"key\":\"figures\",\"tenantterm\":\"figures\",\"frontiersdefaultterm\":\"figures\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":109,\"key\":\"editorial_file\",\"tenantterm\":\"editorial file\",\"frontiersdefaultterm\":\"editorial file\",\"category\":\"core\"},{\"sequencenumber\":110,\"key\":\"editorial_files\",\"tenantterm\":\"editorial files\",\"frontiersdefaultterm\":\"editorial files\",\"category\":\"core\"},{\"sequencenumber\":111,\"key\":\"e_book\",\"tenantterm\":\"e-book\",\"frontiersdefaultterm\":\"e-book\",\"category\":\"core\"},{\"sequencenumber\":112,\"key\":\"organization\",\"tenantterm\":\"organization\",\"frontiersdefaultterm\":\"organization\",\"category\":\"core\"},{\"sequencenumber\":113,\"key\":\"institution\",\"tenantterm\":\"institution\",\"frontiersdefaultterm\":\"institution\",\"category\":\"core\"},{\"sequencenumber\":114,\"key\":\"reference\",\"tenantterm\":\"reference\",\"frontiersdefaultterm\":\"reference\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":115,\"key\":\"references\",\"tenantterm\":\"references\",\"frontiersdefaultterm\":\"references\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":116,\"key\":\"sce\",\"tenantterm\":\"sce\",\"frontiersdefaultterm\":\"sce\",\"description\":\"abbreviation for specialty chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":117,\"key\":\"submission\",\"tenantterm\":\"submission\",\"frontiersdefaultterm\":\"submission\",\"category\":\"process\"},{\"sequencenumber\":118,\"key\":\"submissions\",\"tenantterm\":\"submissions\",\"frontiersdefaultterm\":\"submissions\",\"category\":\"process\"},{\"sequencenumber\":119,\"key\":\"editing\",\"tenantterm\":\"editing\",\"frontiersdefaultterm\":\"editing\",\"category\":\"process\"},{\"sequencenumber\":120,\"key\":\"in_preparation\",\"tenantterm\":\"in preparation\",\"frontiersdefaultterm\":\"in preparation\",\"category\":\"process\"},{\"sequencenumber\":121,\"key\":\"country_region\",\"tenantterm\":\"country/region\",\"frontiersdefaultterm\":\"country/region\",\"description\":\"because of political issues, some of the country listings are actually classified as `regions` and we need to include this. however other clients may not want to do this.\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":122,\"key\":\"countries_regions\",\"tenantterm\":\"countries/regions\",\"frontiersdefaultterm\":\"countries/regions\",\"description\":\"because of political issues, some of the country listings are actually classified as `regions` and we need to include this. however other clients may not want to do this.\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":123,\"key\":\"specialty\",\"tenantterm\":\"specialty\",\"frontiersdefaultterm\":\"specialty\",\"category\":\"core\"},{\"sequencenumber\":124,\"key\":\"specialties\",\"tenantterm\":\"specialties\",\"frontiersdefaultterm\":\"specialties\",\"category\":\"core\"},{\"sequencenumber\":125,\"key\":\"associate_editors\",\"tenantterm\":\"associate editors\",\"frontiersdefaultterm\":\"associate editors\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":126,\"key\":\"reviewed\",\"tenantterm\":\"reviewed\",\"frontiersdefaultterm\":\"reviewed\",\"category\":\"peer review process\"},{\"sequencenumber\":127,\"key\":\"institutional_members\",\"tenantterm\":\"institutional partners\",\"frontiersdefaultterm\":\"institutional partners\",\"category\":\"accounting\"},{\"sequencenumber\":128,\"key\":\"institutional_memberships\",\"tenantterm\":\"institutional partnerships\",\"frontiersdefaultterm\":\"institutional partnerships\",\"category\":\"accounting\"},{\"sequencenumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantterm\":\"assistant field chief editors\",\"frontiersdefaultterm\":\"assistant field chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":130,\"key\":\"publications\",\"tenantterm\":\"publications\",\"frontiersdefaultterm\":\"publications\",\"category\":\"process\"},{\"sequencenumber\":131,\"key\":\"ae_accepted\",\"tenantterm\":\"recommended acceptance\",\"frontiersdefaultterm\":\"accepted\",\"category\":\"process\"},{\"sequencenumber\":132,\"key\":\"field_journal\",\"tenantterm\":\"field journal\",\"frontiersdefaultterm\":\"field journal\",\"category\":\"taxonomy\"},{\"sequencenumber\":133,\"key\":\"field_journals\",\"tenantterm\":\"field journals\",\"frontiersdefaultterm\":\"field journals\",\"category\":\"taxonomy\"},{\"sequencenumber\":134,\"key\":\"program_manager\",\"tenantterm\":\"program manager\",\"frontiersdefaultterm\":\"program manager\",\"category\":\"label (role)\"},{\"sequencenumber\":135,\"key\":\"journal_manager\",\"tenantterm\":\"journal manager\",\"frontiersdefaultterm\":\"journal manager\",\"category\":\"label (role)\"},{\"sequencenumber\":136,\"key\":\"journal_specialist\",\"tenantterm\":\"journal specialist\",\"frontiersdefaultterm\":\"journal specialist\",\"category\":\"label (role)\"},{\"sequencenumber\":137,\"key\":\"program_managers\",\"tenantterm\":\"program managers\",\"frontiersdefaultterm\":\"program managers\",\"category\":\"label (role)\"},{\"sequencenumber\":138,\"key\":\"journal_managers\",\"tenantterm\":\"journal managers\",\"frontiersdefaultterm\":\"journal managers\",\"category\":\"label (role)\"},{\"sequencenumber\":139,\"key\":\"journal_specialists\",\"tenantterm\":\"journal specialists\",\"frontiersdefaultterm\":\"journal specialists\",\"category\":\"label (role)\"},{\"sequencenumber\":140,\"key\":\"cover_letter\",\"tenantterm\":\"manuscript contribution to the field\",\"frontiersdefaultterm\":\"manuscript contribution to the field\",\"category\":\"process\"},{\"sequencenumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantterm\":\"recommended to accept manuscript\",\"frontiersdefaultterm\":\"accepted manuscript\",\"category\":\"process\"},{\"sequencenumber\":142,\"key\":\"recommend_for_rejection\",\"tenantterm\":\"recommend for rejection\",\"frontiersdefaultterm\":\"recommend for rejection\",\"category\":\"process\"},{\"sequencenumber\":143,\"key\":\"recommended_for_rejection\",\"tenantterm\":\"recommended for rejection\",\"frontiersdefaultterm\":\"recommended for rejection\",\"category\":\"process\"},{\"sequencenumber\":144,\"key\":\"ae\",\"tenantterm\":\"ae\",\"frontiersdefaultterm\":\"ae\",\"description\":\"associate editor - board member\",\"category\":\"label (role)\"},{\"sequencenumber\":145,\"key\":\"re\",\"tenantterm\":\"re\",\"frontiersdefaultterm\":\"re\",\"description\":\"review editor\",\"category\":\"label (role)\"},{\"sequencenumber\":146,\"key\":\"rev\",\"tenantterm\":\"rev\",\"frontiersdefaultterm\":\"rev\",\"description\":\"reviewer\",\"category\":\"label (role)\"},{\"sequencenumber\":147,\"key\":\"aut\",\"tenantterm\":\"aut\",\"frontiersdefaultterm\":\"aut\",\"description\":\"author\",\"category\":\"label (role)\"},{\"sequencenumber\":148,\"key\":\"coraut\",\"tenantterm\":\"coraut\",\"frontiersdefaultterm\":\"coraut\",\"description\":\"corresponding author\",\"category\":\"label (role)\"},{\"sequencenumber\":149,\"key\":\"saut\",\"tenantterm\":\"saut\",\"frontiersdefaultterm\":\"saut\",\"description\":\"submitting author\",\"category\":\"label (role)\"},{\"sequencenumber\":150,\"key\":\"coaut\",\"tenantterm\":\"coaut\",\"frontiersdefaultterm\":\"coaut\",\"description\":\"co-author\",\"category\":\"label (role)\"},{\"sequencenumber\":151,\"key\":\"tsof\",\"tenantterm\":\"tsof\",\"frontiersdefaultterm\":\"tsof\",\"description\":\"typesetter\",\"category\":\"label (role)\"},{\"sequencenumber\":152,\"key\":\"typesetting_office\",\"tenantterm\":\"typesetting office\",\"frontiersdefaultterm\":\"typesetting office\",\"category\":\"product\"},{\"sequencenumber\":153,\"key\":\"config\",\"tenantterm\":\"config\",\"frontiersdefaultterm\":\"config\",\"description\":\"configuration office role\",\"category\":\"label (role)\"},{\"sequencenumber\":154,\"key\":\"jm\",\"tenantterm\":\"jm\",\"frontiersdefaultterm\":\"jm\",\"description\":\"journal manager\",\"category\":\"label (role)\"},{\"sequencenumber\":155,\"key\":\"rte\",\"tenantterm\":\"rte\",\"frontiersdefaultterm\":\"rte\",\"description\":\"research topic editor\",\"category\":\"label (role)\"},{\"sequencenumber\":156,\"key\":\"organizations\",\"tenantterm\":\"organizations\",\"frontiersdefaultterm\":\"organizations\",\"category\":\"core\"},{\"sequencenumber\":157,\"key\":\"publishing\",\"tenantterm\":\"publishing\",\"frontiersdefaultterm\":\"publishing\",\"category\":\"core\"},{\"sequencenumber\":158,\"key\":\"acceptance\",\"tenantterm\":\"acceptance\",\"frontiersdefaultterm\":\"acceptance\",\"category\":\"process\"},{\"sequencenumber\":159,\"key\":\"preferred_associate_editor\",\"tenantterm\":\"preferred associate editor\",\"frontiersdefaultterm\":\"preferred associate editor\",\"category\":\"label (role)\"},{\"sequencenumber\":160,\"key\":\"topic_editors\",\"tenantterm\":\"topic editors\",\"frontiersdefaultterm\":\"topic editors\",\"category\":\"label (role)\"},{\"sequencenumber\":161,\"key\":\"institutions\",\"tenantterm\":\"institutions\",\"frontiersdefaultterm\":\"institutions\",\"category\":\"core\"},{\"sequencenumber\":162,\"key\":\"author(s)\",\"tenantterm\":\"author(s)\",\"frontiersdefaultterm\":\"author(s)\",\"category\":\"label (role)\"},{\"sequencenumber\":163,\"key\":\"figure(s)\",\"tenantterm\":\"figure(s)\",\"frontiersdefaultterm\":\"figure(s)\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":164,\"key\":\"co-authors\",\"tenantterm\":\"co-authors\",\"frontiersdefaultterm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"label (role)\"},{\"sequencenumber\":165,\"key\":\"editorial_board_members\",\"tenantterm\":\"editorial board members\",\"frontiersdefaultterm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"label (role)\"},{\"sequencenumber\":166,\"key\":\"editorial_board\",\"tenantterm\":\"editorial board\",\"frontiersdefaultterm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"product\"},{\"sequencenumber\":167,\"key\":\"co-authorship\",\"tenantterm\":\"co-authorship\",\"frontiersdefaultterm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"misc.\"},{\"sequencenumber\":168,\"key\":\"role_id_1\",\"tenantterm\":\"registration office\",\"frontiersdefaultterm\":\"registration office\",\"category\":\"user role\"},{\"sequencenumber\":169,\"key\":\"role_id_2\",\"tenantterm\":\"editorial office\",\"frontiersdefaultterm\":\"editorial office\",\"category\":\"user role\"},{\"sequencenumber\":170,\"key\":\"role_id_7\",\"tenantterm\":\"field chief editor\",\"frontiersdefaultterm\":\"field chief editor\",\"category\":\"user role\"},{\"sequencenumber\":171,\"key\":\"role_id_8\",\"tenantterm\":\"assistant field chief editor\",\"frontiersdefaultterm\":\"assistant field chief editor\",\"category\":\"user role\"},{\"sequencenumber\":172,\"key\":\"role_id_9\",\"tenantterm\":\"specialty chief editor\",\"frontiersdefaultterm\":\"specialty chief editor\",\"category\":\"user role\"},{\"sequencenumber\":173,\"key\":\"role_id_10\",\"tenantterm\":\"assistant specialty chief editor\",\"frontiersdefaultterm\":\"assistant specialty chief editor\",\"category\":\"user role\"},{\"sequencenumber\":174,\"key\":\"role_id_11\",\"tenantterm\":\"associate editor\",\"frontiersdefaultterm\":\"associate editor\",\"category\":\"user role\"},{\"sequencenumber\":175,\"key\":\"role_id_12\",\"tenantterm\":\"guest associate editor\",\"frontiersdefaultterm\":\"guest associate editor\",\"category\":\"user role\"},{\"sequencenumber\":176,\"key\":\"role_id_13\",\"tenantterm\":\"review editor\",\"frontiersdefaultterm\":\"review editor\",\"category\":\"user role\"},{\"sequencenumber\":177,\"key\":\"role_id_14\",\"tenantterm\":\"reviewer\",\"frontiersdefaultterm\":\"reviewer\",\"category\":\"user role\"},{\"sequencenumber\":178,\"key\":\"role_id_15\",\"tenantterm\":\"author\",\"frontiersdefaultterm\":\"author\",\"category\":\"user role\"},{\"sequencenumber\":179,\"key\":\"role_id_16\",\"tenantterm\":\"corresponding author\",\"frontiersdefaultterm\":\"corresponding author\",\"category\":\"user role\"},{\"sequencenumber\":180,\"key\":\"role_id_17\",\"tenantterm\":\"submitting author\",\"frontiersdefaultterm\":\"submitting author\",\"category\":\"user role\"},{\"sequencenumber\":181,\"key\":\"role_id_18\",\"tenantterm\":\"co-author\",\"frontiersdefaultterm\":\"co-author\",\"category\":\"user role\"},{\"sequencenumber\":182,\"key\":\"role_id_20\",\"tenantterm\":\"production office\",\"frontiersdefaultterm\":\"production office\",\"category\":\"user role\"},{\"sequencenumber\":183,\"key\":\"role_id_22\",\"tenantterm\":\"typesetting office (typesetter)\",\"frontiersdefaultterm\":\"typesetting office (typesetter)\",\"category\":\"user role\"},{\"sequencenumber\":184,\"key\":\"role_id_24\",\"tenantterm\":\"registered user\",\"frontiersdefaultterm\":\"registered user\",\"category\":\"user role\"},{\"sequencenumber\":185,\"key\":\"role_id_35\",\"tenantterm\":\"job office\",\"frontiersdefaultterm\":\"job office\",\"category\":\"user role\"},{\"sequencenumber\":186,\"key\":\"role_id_41\",\"tenantterm\":\"special event administrator\",\"frontiersdefaultterm\":\"special event administrator\",\"category\":\"user role\"},{\"sequencenumber\":187,\"key\":\"role_id_42\",\"tenantterm\":\"special event reviewer\",\"frontiersdefaultterm\":\"special event reviewer\",\"category\":\"user role\"},{\"sequencenumber\":188,\"key\":\"role_id_43\",\"tenantterm\":\"submit abstract\",\"frontiersdefaultterm\":\"submit abstract\",\"category\":\"user role\"},{\"sequencenumber\":189,\"key\":\"role_id_52\",\"tenantterm\":\"events office\",\"frontiersdefaultterm\":\"events office\",\"category\":\"user role\"},{\"sequencenumber\":190,\"key\":\"role_id_53\",\"tenantterm\":\"event administrator\",\"frontiersdefaultterm\":\"event administrator\",\"category\":\"user role\"},{\"sequencenumber\":191,\"key\":\"role_id_89\",\"tenantterm\":\"content management office\",\"frontiersdefaultterm\":\"content management office\",\"category\":\"user role\"},{\"sequencenumber\":192,\"key\":\"role_id_98\",\"tenantterm\":\"accounting office\",\"frontiersdefaultterm\":\"accounting office\",\"category\":\"user role\"},{\"sequencenumber\":193,\"key\":\"role_id_99\",\"tenantterm\":\"projects\",\"frontiersdefaultterm\":\"projects\",\"category\":\"user role\"},{\"sequencenumber\":194,\"key\":\"role_id_103\",\"tenantterm\":\"configuration office\",\"frontiersdefaultterm\":\"configuration office\",\"category\":\"user role\"},{\"sequencenumber\":195,\"key\":\"role_id_104\",\"tenantterm\":\"beta user\",\"frontiersdefaultterm\":\"beta user\",\"category\":\"user role\"},{\"sequencenumber\":196,\"key\":\"role_id_106\",\"tenantterm\":\"wfconf\",\"frontiersdefaultterm\":\"wfconf\",\"category\":\"user role\"},{\"sequencenumber\":197,\"key\":\"role_id_107\",\"tenantterm\":\"rt management beta user\",\"frontiersdefaultterm\":\"rt management beta user\",\"category\":\"user role\"},{\"sequencenumber\":198,\"key\":\"role_id_108\",\"tenantterm\":\"deo beta user\",\"frontiersdefaultterm\":\"deo beta user\",\"category\":\"user role\"},{\"sequencenumber\":199,\"key\":\"role_id_109\",\"tenantterm\":\"search beta user\",\"frontiersdefaultterm\":\"search beta user\",\"category\":\"user role\"},{\"sequencenumber\":200,\"key\":\"role_id_110\",\"tenantterm\":\"journal manager\",\"frontiersdefaultterm\":\"journal manager\",\"category\":\"user role\"},{\"sequencenumber\":201,\"key\":\"role_id_111\",\"tenantterm\":\"myfrontiers beta user\",\"frontiersdefaultterm\":\"myfrontiers beta user\",\"category\":\"user role\"},{\"sequencenumber\":202,\"key\":\"role_id_21\",\"tenantterm\":\"copy editor\",\"frontiersdefaultterm\":\"copy editor\",\"category\":\"user role\"},{\"sequencenumber\":203,\"key\":\"role_id_1_abr\",\"tenantterm\":\"rof\",\"frontiersdefaultterm\":\"rof\",\"category\":\"user role\"},{\"sequencenumber\":204,\"key\":\"role_id_2_abr\",\"tenantterm\":\"eof\",\"frontiersdefaultterm\":\"eof\",\"category\":\"user role\"},{\"sequencenumber\":205,\"key\":\"role_id_7_abr\",\"tenantterm\":\"fce\",\"frontiersdefaultterm\":\"fce\",\"category\":\"user role\"},{\"sequencenumber\":206,\"key\":\"role_id_8_abr\",\"tenantterm\":\"afce\",\"frontiersdefaultterm\":\"afce\",\"category\":\"user role\"},{\"sequencenumber\":207,\"key\":\"role_id_9_abr\",\"tenantterm\":\"sce\",\"frontiersdefaultterm\":\"sce\",\"category\":\"user role\"},{\"sequencenumber\":208,\"key\":\"role_id_10_abr\",\"tenantterm\":\"asce\",\"frontiersdefaultterm\":\"asce\",\"category\":\"user role\"},{\"sequencenumber\":209,\"key\":\"role_id_11_abr\",\"tenantterm\":\"ae\",\"frontiersdefaultterm\":\"ae\",\"category\":\"user role\"},{\"sequencenumber\":210,\"key\":\"role_id_12_abr\",\"tenantterm\":\"gae\",\"frontiersdefaultterm\":\"gae\",\"category\":\"user role\"},{\"sequencenumber\":211,\"key\":\"role_id_13_abr\",\"tenantterm\":\"re\",\"frontiersdefaultterm\":\"re\",\"category\":\"user role\"},{\"sequencenumber\":212,\"key\":\"role_id_14_abr\",\"tenantterm\":\"rev\",\"frontiersdefaultterm\":\"rev\",\"category\":\"user role\"},{\"sequencenumber\":213,\"key\":\"role_id_15_abr\",\"tenantterm\":\"aut\",\"frontiersdefaultterm\":\"aut\",\"category\":\"user role\"},{\"sequencenumber\":214,\"key\":\"role_id_16_abr\",\"tenantterm\":\"coraut\",\"frontiersdefaultterm\":\"coraut\",\"category\":\"user role\"},{\"sequencenumber\":215,\"key\":\"role_id_17_abr\",\"tenantterm\":\"saut\",\"frontiersdefaultterm\":\"saut\",\"category\":\"user role\"},{\"sequencenumber\":216,\"key\":\"role_id_18_abr\",\"tenantterm\":\"coaut\",\"frontiersdefaultterm\":\"coaut\",\"category\":\"user role\"},{\"sequencenumber\":217,\"key\":\"role_id_20_abr\",\"tenantterm\":\"pof\",\"frontiersdefaultterm\":\"pof\",\"category\":\"user role\"},{\"sequencenumber\":218,\"key\":\"role_id_22_abr\",\"tenantterm\":\"tsof\",\"frontiersdefaultterm\":\"tsof\",\"category\":\"user role\"},{\"sequencenumber\":219,\"key\":\"role_id_24_abr\",\"tenantterm\":\"ru\",\"frontiersdefaultterm\":\"ru\",\"category\":\"user role\"},{\"sequencenumber\":220,\"key\":\"role_id_35_abr\",\"tenantterm\":\"jof\",\"frontiersdefaultterm\":\"jof\",\"category\":\"user role\"},{\"sequencenumber\":221,\"key\":\"role_id_41_abr\",\"tenantterm\":\"se-adm\",\"frontiersdefaultterm\":\"se-adm\",\"category\":\"user role\"},{\"sequencenumber\":222,\"key\":\"role_id_42_abr\",\"tenantterm\":\"se-rev\",\"frontiersdefaultterm\":\"se-rev\",\"category\":\"user role\"},{\"sequencenumber\":223,\"key\":\"role_id_43_abr\",\"tenantterm\":\"se-aut\",\"frontiersdefaultterm\":\"se-aut\",\"category\":\"user role\"},{\"sequencenumber\":224,\"key\":\"role_id_52_abr\",\"tenantterm\":\"evof\",\"frontiersdefaultterm\":\"evof\",\"category\":\"user role\"},{\"sequencenumber\":225,\"key\":\"role_id_53_abr\",\"tenantterm\":\"ev-adm\",\"frontiersdefaultterm\":\"ev-adm\",\"category\":\"user role\"},{\"sequencenumber\":226,\"key\":\"role_id_89_abr\",\"tenantterm\":\"comof\",\"frontiersdefaultterm\":\"comof\",\"category\":\"user role\"},{\"sequencenumber\":227,\"key\":\"role_id_98_abr\",\"tenantterm\":\"aof\",\"frontiersdefaultterm\":\"aof\",\"category\":\"user role\"},{\"sequencenumber\":228,\"key\":\"role_id_99_abr\",\"tenantterm\":\"projects\",\"frontiersdefaultterm\":\"projects\",\"category\":\"user role\"},{\"sequencenumber\":229,\"key\":\"role_id_103_abr\",\"tenantterm\":\"config\",\"frontiersdefaultterm\":\"config\",\"category\":\"user role\"},{\"sequencenumber\":230,\"key\":\"role_id_104_abr\",\"tenantterm\":\"beta\",\"frontiersdefaultterm\":\"beta\",\"category\":\"user role\"},{\"sequencenumber\":231,\"key\":\"role_id_106_abr\",\"tenantterm\":\"wfconf\",\"frontiersdefaultterm\":\"wfconf\",\"category\":\"user role\"},{\"sequencenumber\":232,\"key\":\"role_id_107_abr\",\"tenantterm\":\"rtbeta\",\"frontiersdefaultterm\":\"rtbeta\",\"category\":\"user role\"},{\"sequencenumber\":233,\"key\":\"role_id_108_abr\",\"tenantterm\":\"deobeta\",\"frontiersdefaultterm\":\"deobeta\",\"category\":\"user role\"},{\"sequencenumber\":234,\"key\":\"role_id_109_abr\",\"tenantterm\":\"searchbeta\",\"frontiersdefaultterm\":\"searchbeta\",\"category\":\"user role\"},{\"sequencenumber\":235,\"key\":\"role_id_110_abr\",\"tenantterm\":\"jm\",\"frontiersdefaultterm\":\"jm\",\"category\":\"user role\"},{\"sequencenumber\":236,\"key\":\"role_id_111_abr\",\"tenantterm\":\"mfbeta\",\"frontiersdefaultterm\":\"mfbeta\",\"category\":\"user role\"},{\"sequencenumber\":237,\"key\":\"role_id_21_abr\",\"tenantterm\":\"coped\",\"frontiersdefaultterm\":\"coped\",\"category\":\"user role\"},{\"sequencenumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantterm\":\"editorial board\",\"frontiersdefaultterm\":\"editorial board\",\"description\":\"this is the label for the review editorial board\",\"category\":\"label\"},{\"sequencenumber\":239,\"key\":\"field_chief_editor\",\"tenantterm\":\"field chief editor\",\"frontiersdefaultterm\":\"field chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":240,\"key\":\"field_chief_editors\",\"tenantterm\":\"field chief editors\",\"frontiersdefaultterm\":\"field chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":241,\"key\":\"editor\",\"tenantterm\":\"editor\",\"frontiersdefaultterm\":\"editor\",\"category\":\"label (role)\"},{\"sequencenumber\":242,\"key\":\"editors\",\"tenantterm\":\"editors\",\"frontiersdefaultterm\":\"editors\",\"category\":\"label (role)\"},{\"sequencenumber\":243,\"key\":\"board\",\"tenantterm\":\"board\",\"frontiersdefaultterm\":\"board\",\"category\":\"label\"},{\"sequencenumber\":244,\"key\":\"boards\",\"tenantterm\":\"boards\",\"frontiersdefaultterm\":\"boards\",\"category\":\"label\"},{\"sequencenumber\":245,\"key\":\"article_collection\",\"tenantterm\":\"article collection\",\"frontiersdefaultterm\":\"article collection\",\"category\":\"label\"},{\"sequencenumber\":246,\"key\":\"article_collections\",\"tenantterm\":\"article collections\",\"frontiersdefaultterm\":\"article collections\",\"category\":\"label\"},{\"sequencenumber\":247,\"key\":\"handling_editor\",\"tenantterm\":\"handling editor\",\"frontiersdefaultterm\":\"associate editor\",\"description\":\"this terminology key is for the person assigned to edit a manuscript. it is a label for the temporary handling editor assignment.\",\"category\":\"label (role)\"},{\"sequencenumber\":248,\"key\":\"handling_editors\",\"tenantterm\":\"handling editors\",\"frontiersdefaultterm\":\"associate editors\",\"description\":\"this terminology key is for the person assigned to edit a manuscript. it is a label for the temporary handling editor assignment.\",\"category\":\"label (role)\"},{\"sequencenumber\":249,\"key\":\"ae_accept\",\"tenantterm\":\"recommend acceptance\",\"frontiersdefaultterm\":\"accept\",\"category\":\"process\"},{\"sequencenumber\":250,\"key\":\"rtm\",\"tenantterm\":\"rtm\",\"frontiersdefaultterm\":\"rtm\",\"category\":\"product\"},{\"sequencenumber\":251,\"key\":\"frontiers_media_sa\",\"tenantterm\":\"frontiers media s.a\",\"frontiersdefaultterm\":\"frontiers media s.a\",\"category\":\"customer\"},{\"sequencenumber\":252,\"key\":\"review_editors\",\"tenantterm\":\"community reviewers\",\"frontiersdefaultterm\":\"review editors\",\"category\":\"label (role)\"},{\"sequencenumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantterm\":\"chief editor\",\"frontiersdefaultterm\":\"chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantterm\":\"chief editors\",\"frontiersdefaultterm\":\"chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":255,\"key\":\"call_for_papers\",\"tenantterm\":\"call for papers\",\"frontiersdefaultterm\":\"call for papers\",\"category\":\"label\"},{\"sequencenumber\":256,\"key\":\"calls_for_papers\",\"tenantterm\":\"calls for papers\",\"frontiersdefaultterm\":\"calls for papers\",\"category\":\"label\"},{\"sequencenumber\":257,\"key\":\"supervising_editor\",\"tenantterm\":\"supervising editor\",\"frontiersdefaultterm\":\"supervising editor\",\"description\":\"a chief or assistant chief editor who is assigned to a manuscript to supervise.\",\"category\":\"role\",\"externalkey\":\"supervising_editor\"},{\"sequencenumber\":258,\"key\":\"supervising_editors\",\"tenantterm\":\"supervising editors\",\"frontiersdefaultterm\":\"supervising editors\",\"description\":\"a chief or assistant chief editor who is assigned to a manuscript to supervise.\",\"category\":\"role\",\"externalkey\":\"supervising_editors\"},{\"sequencenumber\":259,\"key\":\"reviewer_endorse\",\"tenantterm\":\"endorse\",\"frontiersdefaultterm\":\"endorse\",\"category\":\"label\"},{\"sequencenumber\":260,\"key\":\"reviewer_endorsed\",\"tenantterm\":\"endorsed\",\"frontiersdefaultterm\":\"endorsed\",\"category\":\"label\"},{\"sequencenumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantterm\":\"endorse publication\",\"frontiersdefaultterm\":\"endorse publication\",\"category\":\"label\"},{\"sequencenumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantterm\":\"endorsed publication\",\"frontiersdefaultterm\":\"endorsed publication\",\"category\":\"label\"},{\"sequencenumber\":263,\"key\":\"editor_role\",\"tenantterm\":\"editor role\",\"frontiersdefaultterm\":\"editor role\",\"category\":\"label\"},{\"sequencenumber\":264,\"key\":\"editor_roles\",\"tenantterm\":\"editor roles\",\"frontiersdefaultterm\":\"editor roles\",\"category\":\"label\"},{\"sequencenumber\":265,\"key\":\"editorial_role\",\"tenantterm\":\"editorial role\",\"frontiersdefaultterm\":\"editorial role\",\"category\":\"label\"},{\"sequencenumber\":266,\"key\":\"editorial_roles\",\"tenantterm\":\"editorial roles\",\"frontiersdefaultterm\":\"editorial roles\",\"category\":\"label\"},{\"sequencenumber\":267,\"key\":\"call_for_paper\",\"tenantterm\":\"call for paper\",\"frontiersdefaultterm\":\"call for paper\",\"category\":\"label\"},{\"sequencenumber\":268,\"key\":\"research_topic_abstract\",\"tenantterm\":\"manuscript summary\",\"frontiersdefaultterm\":\"manuscript summary\",\"category\":\"process\"},{\"sequencenumber\":269,\"key\":\"research_topic_abstracts\",\"tenantterm\":\"manuscript summaries\",\"frontiersdefaultterm\":\"manuscript summaries\",\"category\":\"process\"},{\"sequencenumber\":270,\"key\":\"submissions_team_manager\",\"tenantterm\":\"journal manager\",\"frontiersdefaultterm\":\"content manager\",\"category\":\"process\"},{\"sequencenumber\":271,\"key\":\"submissions_team\",\"tenantterm\":\"journal team\",\"frontiersdefaultterm\":\"content team\",\"category\":\"process\"},{\"sequencenumber\":272,\"key\":\"topic_coordinator\",\"tenantterm\":\"topic coordinator\",\"frontiersdefaultterm\":\"topic coordinator\",\"category\":\"process\"},{\"sequencenumber\":273,\"key\":\"topic_coordinators\",\"tenantterm\":\"topic coordinators\",\"frontiersdefaultterm\":\"topic coordinators\",\"category\":\"process\"},{\"sequencenumber\":274,\"key\":\"frontiers_journal_team\",\"tenantterm\":\"frontiers journal team\",\"frontiersdefaultterm\":\"frontiers journal team\",\"category\":\"label (role)\"},{\"sequencenumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantterm\":\"rt:ic submission\",\"frontiersdefaultterm\":\"rt:ic submission\",\"category\":\"label (role)\"},{\"sequencenumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantterm\":\"rt:ic submission participant\",\"frontiersdefaultterm\":\"rt:ic submission participant\",\"category\":\"label (role)\"}]}'\n",impactgtmid:"gtm-njf2ml9b",impactgtmauth:"fyo-7nodm9w37qgfms03sa",impactgtmpreview:"env-1",impactgooglemapsapikey:"aizasyctehx2eu8pwfi86gw9fi00ftcykk6ifr8",qualtricsv4tov3:"'{\"enabled\":true,\"interceptid\":\"si_er0e2ze69oz8yn4\",\"projectid\":\"zn_cloy77jhkpc8gai\",\"brandid\":\"frontiersin\"}'\n",qualtricsumux:"'{\"enabled\":false,\"interceptid\":\"si_89fphy3etxqbwtu\",\"projectid\":\"zn_cloy77jhkpc8gai\",\"brandid\":\"frontiersin\"}'\n",qualtricscontinuousbrand:"'{\"enabled\":true,\"interceptid\":\"si_9zut94ut81fcrh4\",\"projectid\":\"zn_cloy77jhkpc8gai\",\"brandid\":\"frontiersin\"}'\n",defaultarticletemplate:"v3"},app:{baseurl:"/",buildid:"f2d5b6d8-d01c-4534-90b9-d659f10f17ca",buildassetsdir:"ap-2024/_nuxt",cdnurl:""}}## Discussion
4.1 in vitro and in vivo characterization of alogabat alogabat was shown to be a potent and functionally selective gaba a -&#x003b1;5 receptor pam in vitro . the functional activity of alogabat was confirmed at native gaba a receptors in rat hippocampal slices. in vivo binding experiments demonstrated dose-dependent target engagement of alogabat in rats and cntnap2 &#x02212;/&#x02212; mice. the highest specific binding was observed in the hippocampus, which is consistent with the known distribution of the gaba a -&#x003b1;5 receptor subtype in rodents ( pirker et al., 2000 ). phmri studies in rats demonstrated dose-dependent perfusion changes, indicating circuit modulation by alogabat. there were consistent changes in the neural activity pattern across dose groups, with modulation of neural activity in, among others, the medial prefrontal cortex, cingulate cortex, motor cortex, perirhinal cortex, nucleus accumbens shell, amygdala, hippocampus fimbria, and substantia nigra. 4.2 eeg signature acute administration of alogabat in rats induced an eeg signature characterized by a power decrease in theta and an increase in the beta frequency range, which was qualitatively similar to the eeg signature of non-selective gaba a pams such as diazepam ( van lier et al., 2004 ; visser et al., 2003 ; friedman et al., 1992 ). the lower magnitude of induced eeg beta-band power by alogabat compared to diazepam is likely attributed to its &#x003b1;5-selectivity, resulting in an overall lower magnitude of gaba a receptor modulation. this eeg signature of alogabat is qualitatively a mirror image of the eeg signature of basmisanil, a highly selective gaba a -&#x003b1;5 negative allosteric modulator (nam), which we recently found to induce an increase in the theta power and a decrease in the beta-band eeg power in healthy volunteers ( hipp et al., 2021 ). furthermore, the eeg signature of alogabat is in agreement with the link between beta-band activity and single-nucleotide polymorphisms (snps) in gaba a receptor genes ( porjesz et al., 2002 ; smit et al., 2018 ) and ndds (dup15q syndrome, as) involving gene copy number variations of gabrb3, gabra5 , and gabrg3 ( frohlich et al., 2019a ; frohlich et al., 2019b ). gaba a receptor-related changes in beta-band activity are believed to reflect the modulation of recurrent excitatory&#x02013;inhibitory feedback loops in the cortical tissue ( whittington et al., 2000 ; traub and jefferys, 1999 ). for the administered doses, the calculated receptor occupancies were in the range of 77%&#x02013;84% for &#x003b1;5-containing receptors and 22%&#x02013;34% for &#x003b1;1-containing receptors (with different pam effects (e max ) at &#x003b1;5 vs. &#x003b1;1). thus, at the studied doses, alogabat has some effect on &#x003b1;1-containing receptors, and further work is needed to systematically study lower doses of alogabat, including those &#x0003c;70% ro without the impairment of cognition in wt rats, to confirm whether the modulation of &#x003b1;5-containing receptors alone is sufficient to induce the described eeg effect. nonetheless, eeg theta- and beta-band power are promising candidates for translational mechanistic biomarkers of gaba a -&#x003b1;5 receptor function and could be used in the further development of alogabat. 4.3 behavioral effects of alogabat in animal models relevant to asd we assessed the effects of alogabat in two different mouse models relevant to asd, one phenotypic and one genetic. acute administration of alogabat significantly and dose-dependently attenuated excessive grooming, but not digging, behavior in btbr mice. sub-chronic administration of alogabat significantly attenuated elevated grooming behavior in cntnap2 &#x02212;/&#x02212; mice. efficacy in these different models was linked to gaba a -&#x003b1;5 ro above 50%. despite initial findings of a transiently decreased activity in an open-field test, alogabat increased the activity of btbr mice and had no effect on the activity of cntnap2 &#x02212;/&#x02212; mice during the grooming test, supporting the specific effect of alogabat on repetitive grooming. we have tested additional compounds with similar properties, e.g., ro7015738, and have confirmed that gaba a -&#x003b1;5 pams reduce repetitive behaviors in these mouse models ( buettelmann et al., 2018 ). these results align well with recently published data showing that gaba a -&#x003b1;5 receptor deficiency causes autism-like behaviors in mice, including increased grooming and reduced social contacts ( zurek et al., 2016 ), and with sh-053-2&#x02032;f-r-ch3, a gaba a -&#x003b1;5 pam, which was recently shown to have positive effects on social and cognitive deficits in a rat model of autism ( souza et al., 2024 ). our data are valuable in providing information on the ro required for in vivo effects on repetitive behavior. however, it should be noted that this effect may not directly translate to all individuals with asd as it is a heterogeneous disorder, whereas these mouse models exhibit specific genetic or phenotypic deficits. 4.4 anticonvulsant effects of alogabat it has been proposed that the reduction of gabaergic inhibitory activity results in hyperexcitability of minicolumn circuits, explaining some of the symptomatology observed in some ndds, including the high incidence of seizures and auditory&#x02013;tactile hypersensitivity ( rubenstein and merzenich, 2003 ; frye et al., 2016 ). in the current study, we demonstrated that alogabat exhibits an anticonvulsant profile with activity comparable to the benzodiazepine drug class in acutely induced seizure models (electrical and chemical). alogabat had a small effect on seizures in the mes test, whereas in the ptz test, alogabat was shown to completely block seizures at calculated gaba a -&#x003b1;5 ro &#x0003e;70%. since ptz is a gaba a antagonist, this supports the assessment of alogabat for anticonvulsant activity in disorders where there is dysfunction of the gabaergic system. furthermore, in a separate eeg study, we observed that one out of eight rats had frequent spike-and-wave discharge (swd) activity, which was alleviated following treatment with alogabat (see supplementary figures s3a&#x02013;s3c ; methods in supplementary material ). to better understand the temporal dynamics of swd occurrence and the suppressing effect of alogabat, we performed a follow-up study on three additional rats that showed pronounced swd. both 3 and 10&#x000a0;mg/kg alogabat substantially reduced the number of swds within the first 3&#x000a0;h of recording, when the same rats showed increased swd numbers in the vehicle control condition (see supplementary figures s3d&#x02013;s3f ), which corresponds to the calculated gaba a -&#x003b1;5 ro level of 30%&#x02013;46% (see supplementary table s6 ). from a circuit perspective, the consensus is that such epileptic activity is generated by dysregulated thalamocortical circuitry, with abnormal interactions between reticular thalamic neurons and thalamic relay cells acting as the trigger and cortical circuits serving as the generator ( sitnikova et al., 2023 ). considering that in rats, &#x003b1;5-subunit-containing gaba a receptors are enriched in the cortex and hippocampus ( serwanski et al., 2006 ; hu et al., 2019 ), mediating dendritic inhibition on pyramidal neurons ( ali and thomson, 2008 ; schulz et al., 2018 ), we hypothesize that alogabat could suppress swd generation by enhancing the inhibition of cortical pyramidal neurons. however, more systematic work is required to confirm that alogabat can prevent swd activity. 4.5 assessment of non-specific behavioral effects non-selective gaba a pams, such as diazepam and chlordiazepoxide, are effective anxiolytics in clinical use but have also been shown to impair cognition in rodents and humans. gaba a -&#x003b1;5 receptors are believed to play a major role in cognition since they are predominantly expressed in the hippocampus in rats, where they regulate nmdar-dependent synaptic plasticity underlying learning and memory processes ( schulz et al., 2018 ; fritschy et al., 1997 ; schulz et al., 2019 ; davenport et al., 2021 ). moreover, it has been proposed that gaba a pams may induce memory impairment by modulating hippocampal function ( mcnaughton and morris, 1987 ). therefore, alogabat was evaluated in several rodent tests of cognition to determine whether a selective gaba a -&#x003b1;5 pam would induce cognitive impairment following acute administration in rats. there was no effect of alogabat up to 70% gaba a -&#x003b1;5 ro on cognition (visual&#x02013;spatial memory, attention, context fear conditioning, spatial learning, and memory). cognitive impairment was only observed at high doses (&#x0003e;70% ro) and supra-therapeutic levels of alogabat in associative (fear) learning (cfc) and spatial memory in the mwm in wildtype rats. the impairment at high doses is likely linked to the loss of selectivity toward gaba a &#x003b1;1, &#x003b1;2, and &#x003b1;3 receptor subtypes (&#x003b1;1 ro was calculated as 19%&#x02013;25% at these doses; see supplementary table s6 ). in addition to the loss of selectivity, we cannot exclude the possibility that these effects may be a consequence of gaba a -&#x003b1;5 receptor saturation, i.e., excessive &#x003b1;5 activity in wildtype subjects may be detrimental. the cognitive impairment observed in wildtype rats may translate to healthy human subjects; however, our focus is on the effect of &#x003b1;5 pams in disease conditions with impaired gaba a signaling and impaired cognition, where our hypothesis is that an &#x003b1;5 pam would have beneficial effects. alogabat had no effect on social approach/avoidance, the elevated plus maze, and the vogel conflict test in rats at ro levels up to 80% (see supplementary figure s4 and methods in supplementary material ), suggesting that alogabat does not exhibit an anxiolytic-like effect in rodents. this might be explained by the low expression of gaba a -&#x003b1;5 in the amygdala, a key node controlling anxiety-like behaviors. potential anxiolytic effects of alogabat in humans cannot be excluded as this receptor subtype is much more abundant in the human amygdala. since benzodiazepines, such as diazepam, are frequently used to treat anxiety and seizures in ndds, it was important to establish that alogabat at relevant therapeutic doses in mouse models did not worsen the sedative/motor-impairing effects of diazepam in the rotarod test. alogabat did not worsen diazepam-induced motor impairment; on the contrary, in combination, it reduced the motor impairments, which is more likely due to the more localized and precise inhibitory effect, counterbalancing the broader suppression of neuronal activity by diazepam, or due to lower intrinsic activity at &#x003b1;1 receptors compared to diazepam. we have previously shown that a gaba a -&#x003b1;5 nam, which binds at the benzodiazepine binding site of the receptor, does not decrease the anxiolytic activity of chlordiazepoxide (see supplementary figure s5 ); therefore, it is unlikely that alogabat will interfere with the anxiolytic effect of the classical benzodiazepines. 5 conclusion multiple lines of evidence point to deficits in gabaergic signaling in epilepsy and ndds, such as asd and deletion as, with a prominent role attributed to gaba a receptors, including the gaba a -&#x003b1;5 receptor subtype. the current data for alogabat showed robust dose-dependent efficacy on repetitive behaviors in two disease-relevant mouse models and anti-seizure activity in the ptz rat model at gaba a -&#x003b1;5 ro above 50%. our in vivo occupancy measurements using the selective &#x003b1;5 tracer l-655,708 were highly valuable for understanding plasma and csf exposures (as a surrogate of free brain concentration) and their relationship to in vivo effects. we observed that there was a 34-fold shift between the csf concentration of alogabat in the in vivo occupancy study and that of alogabat in vitro binding data (ki value). the receptor occupancy of alogabat correlates well with pd effects ( in vivo effects) and is consistent across the different studies/species (see supplementary table s6 ). this finding highlights the importance of using pet tracers in drug development. our data suggest that gaba a -&#x003b1;5 pams may have potential benefits in individuals with autistic features and in conditions with clinical and nonclinical manifestations of cortical hyperexcitability and epilepsy. however, alogabat is unlikely to work across all ndds and should be utilized as a precision medicine to target a specific subgroup of the ndd population with deficient gaba a pathway signaling, or specifically gaba a -&#x003b1;5. interestingly, recent data suggest that gaba a -&#x003b1;5 pams may also have therapeutic potential in schizophrenia, alzheimer&#x02019;s disease, and depression ( perez et al., 2023 ; luscher et al., 2023 ; koh et al., 2013 ). with regard to the current status of alogabat, good-laboratory practice (glp) toxicology and safety pharmacology studies in rats and minipigs showed an overall benign safety profile, which supported its clinical investigations in phase-1 studies in healthy volunteers and phase-2 trials in asd and deletion as patients (nct03507569, nct03774576, nct03847987, nct04299464, nct05630066, and eudract&#x00023;2019-003524-20). the outcome of these studies, including pet, eeg, and effects on cognition, will be reported in the future. data availability statement the original contributions presented in the study are included in the article/ supplementary material , further inquiries can be directed to the corresponding author. ethics statement experiments performed at f. hoffmann-la roche ag (basel, switzerland) complied with swiss federal and cantonal laws on animal research and aaalac regulations and received prior approval from the cantonal veterinary office. the eeg study was conducted at brains online (ca, united states) in accordance with the guide for the care and use of laboratory animals (national research council 2011) after receiving approval from the institutional animal care and use committee. the ptz and mes tests were conducted at vivocore inc., canada, which is a facility licensed by the ontario ministry of agriculture, food, and rural affairs and accredited by the canadian council on animal care. all in vivo studies are reported in compliance with the arrive guidelines ( percie du sert et al., 2020 ). the study was conducted in accordance with the local legislation and institutional requirements. author contributions gc: supervision, writing - original draft, investigation, formal analysis. tmb: formal analysis, investigation, writing - review and editing, methodology. fk: formal analysis, writing - original draft, investigation, methodology. mh: writing - original draft, investigation, methodology, formal analysis. jfh: data curation, visualization, methodology, writing - original draft, formal analysis. pg: methodology, data curation, formal analysis, writing - original draft. tm: investigation, writing - original draft, formal analysis, methodology. bk: investigation, writing - original draft, methodology, formal analysis. anb: formal analysis, writing - original draft, data curation. epp: writing - original draft, methodology, investigation. ps: methodology, investigation, writing - original draft, formal analysis. pj: writing - original draft, formal analysis. rr: methodology, writing - original draft, investigation, formal analysis. bb: methodology, investigation, writing - original draft. hk: methodology, writing - original draft, investigation. ao-m: writing - original draft, formal analysis, methodology. alb: methodology, writing - original draft, investigation. jms: investigation, formal analysis, writing - original draft. db: methodology, writing - original draft, investigation. ms: writing - original draft, methodology, investigation. eco&#x00027;c: investigation, writing - original draft, methodology. m-ch: investigation, conceptualization, writing - review and editing, supervision, writing - original draft, methodology. funding the author(s) declare that financial support was received for the research and/or publication of this article. the funding was provided by f. hoffmann-la roche ag switzerland. acknowledgments the authors thank gregoire friz, maria karg, and judith lengyel (molecular biology and binding assays); v&#x000e9;ronique graf, rachel haab, and marie-claire pflimlin ( in vitro electrophysiology); brigitte algeyer, severine bandinelli, sean durkin, audrey genet, marie haman, martine maco, and roger wyler (behavioral pharmacology); and stephanie sch&#x000f6;ppenthau, s&#x000e9;bastien debilly, and thomas bielser ( in vivo phmri). the rat ptz and mes studies were carried out under the scientific guidance of dr guy higgins, intervivo solutions, and coordinated by leo silenieks at vivocore inc., ontario, canada. the rat eeg data acquisition was undertaken by brains on-line llc, south san francisco, united states, and the data analysis was undertaken by pg, vanessa keeney, and andr&#x000e9;s olivares at roche. conflict of interest authors gc, tmb, fk, mh, jfh, pg, tm, bk, ab, epp, ps, pj, rr, bb, hk, ao-m, ab, jms, ms, eco&#x00027;c, and m-ch were employed by f. hoffmann-la roche ag switzerland. all employees (former and current) may be eligible for stock and stock options. author db was employed by hiqscreen s&#x000e0;rl. generative ai statement the author(s) declare that no generative ai was used in the creation of this manuscript. publisher&#x02019;s note all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. supplementary material the supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2025.1626078/full&#x00023;supplementary-material abbreviations as, angelman syndrome; asd, autism spectrum disorder; cfc, context fear conditioning; cntnap2, contactin-associated protein-like 2; cpt, continuous performance test; 5-csrt, 5-choice serial reaction time; eeg, electroencephalography; gaba, gamma-aminobutyric acid; gad, glutamic acid decarboxylase; i.p., intraperitoneally; i.v., intravenously; lfp, local field potential; mes, maximum electrical stimulus; mwm, morris water maze; ndds, neurodevelopmental disorders; pal, paired associates learning; pam, positive allosteric modulator; phmri, pharmacological magnetic resonance imaging; p.o, per os; ptz, pentylenetetrazole; ro, receptor occupancy; pet, positron emission tomography. references abrahams, b. s., and geschwind, d. h. (2008). advances in autism genetics: on the threshold of a new neurobiology. nat. rev. genet. 9, 341&#x02013;355. doi:10.1038/nrg2346 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar ali, a. b., and thomson, a. m. (2008). synaptic alpha 5 subunit-containing gabaa receptors mediate ipsps elicited by dendrite-preferring cells in rat neocortex. cereb. cortex 18, 1260&#x02013;1271. doi:10.1093/cercor/bhm160 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar american psychiatric association (2008). diagnostic and statistical manual of mental disorders . 5th ed. washington: american psychiatric association . google scholar ballard, t. m., knoflach, f., prinssen, e., borroni, e., vivian, j. a., basile, j., et al. (2009). ro4938581, a novel cognitive enhancer acting at gabaa alpha5 subunit-containing receptors. psychopharmacol. berl. 202, 207&#x02013;223. doi:10.1007/s00213-008-1357-7 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar ballard, t. m., woolley, m. l., prinssen, e., huwyler, j., porter, r., and spooren, w. (2005). the effect of the mglu5 receptor antagonist mpep in rodent tests of anxiety and cognition: a comparison. psychopharmacol. berl. 179, 218&#x02013;229. doi:10.1007/s00213-005-2211-9 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar banerjee, a., garcia-oscos, f., roychowdhury, s., galindo, l. c., hall, s., kilgard, m. p., et al. (2013). impairment of cortical gabaergic synaptic transmission in an environmental rat model of autism. int. j. neuropsychopharmacol. 16, 1309&#x02013;1318. doi:10.1017/s1461145712001216 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar bourgeron, t. (2015). from the genetic architecture to synaptic plasticity in autism spectrum disorder. nat. rev. neurosci. 16, 551&#x02013;563. doi:10.1038/nrn3992 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar braat, s., and kooy, r. f. (2015). the gabaa receptor as a therapeutic target for neurodevelopmental disorders. neuron 86, 1119&#x02013;1130. doi:10.1016/j.neuron.2015.03.042 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar bruns, a., kunnecke, b., risterucci, c., moreau, j. l., and von kienlin, m. (2009). validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological mri in rats. magn. reson med. 61, 1451&#x02013;1458. doi:10.1002/mrm.21779 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar buettelmann, b., cecere, g., fasching, b., groebke zbinden, k., hernandez, m.-c., knust, h., et al. (2018). preparation of new isoxazolyl ether derivatives as gabaa &#x003b1;5 receptor positive allosteric modulators (pams) . copyright &#x000a9; 2025 american chemical society acs . available online at: https://worldwide.espacent.com/patent/search/family/057530563/publication/wo2018104419a1?q&#x0003d;wo2018104419a1 google scholar buiting, k. (2010). prader-willi syndrome and angelman syndrome. am. j. med. genet. c semin. med. genet. 154c, 365&#x02013;376. doi:10.1002/ajmg.c.30273 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar chao, h. t., chen, h., samaco, r. c., xue, m., chahrour, m., yoo, j., et al. (2010). dysfunction in gaba signalling mediates autism-like stereotypies and rett syndrome phenotypes. nature 468, 263&#x02013;269. doi:10.1038/nature09582 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar davenport, c. m., rajappa, r., katchan, l., taylor, c. r., tsai, m. c., smith, c. m., et al. (2021). relocation of an extrasynaptic gaba(a) receptor to inhibitory synapses freezes excitatory synaptic strength and preserves memory. neuron 109, 123&#x02013;134 e4. doi:10.1016/j.neuron.2020.09.037 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar delong, r. (2007). gaba(a) receptor alpha5 subunit as a candidate gene for autism and bipolar disorder: a proposed endophenotype with parent-of-origin and gain-of-function features,with or without oculocutaneous albinism. autism 11, 135&#x02013;147. doi:10.1177/1362361307075705 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar delorey, t. m. (2005). gabrb3 gene deficient mice: a potential model of autism spectrum disorder. int. rev. neurobiol. 71, 359&#x02013;382. doi:10.1016/s0074-7742(05)71015-1 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar delorey, t. m., sahbaie, p., hashemi, e., homanics, g. e., and clark, j. d. (2008). gabrb3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: a potential model of autism spectrum disorder. behav. brain res. 187, 207&#x02013;220. doi:10.1016/j.bbr.2007.09.009 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar dhossche, d., applegate, h., abraham, a., maertens, p., bland, l., bencsath, a., et al. (2002). elevated plasma gamma-aminobutyric acid (gaba) levels in autistic youngsters: stimulus for a gaba hypothesis of autism. med. sci. monit. 8, pr1&#x02013;pr6. pubmed abstract &#x0007c; google scholar di nanni, n., bersanelli, m., cupaioli, f. a., milanesi, l., mezzelani, a., and mosca, e. (2019). network-based integrative analysis of genomics, epigenomics and transcriptomics in autism spectrum disorders. int. j. mol. sci. 20, 3363. doi:10.3390/ijms20133363 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar dufour, b. d., mcbride, e., bartley, t., juarez, p., and martinez-cerdeno, v. (2023). distinct patterns of gabaergic interneuron pathology in autism are associated with intellectual impairment and stereotypic behaviors. autism 27, 1730&#x02013;1745. doi:10.1177/13623613231154053 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar fatemi, s. h., halt, a. r., stary, j. m., kanodia, r., schulz, s. c., and realmuto, g. r. (2002). glutamic acid decarboxylase 65 and 67 kda proteins are reduced in autistic parietal and cerebellar cortices. biol. psychiatry 52, 805&#x02013;810. doi:10.1016/s0006-3223(02)01430-0 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar friedman, h., greenblatt, d. j., peters, g. r., metzler, c. m., charlton, m. d., harmatz, j. s., et al. (1992). pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. clin. pharmacol. ther. 52, 139&#x02013;150. doi:10.1038/clpt.1992.123 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar fritschy, j. m., benke, d., johnson, d. k., mohler, h., and rudolph, u. (1997). gabaa-receptor alpha-subunit is an essential prerequisite for receptor formation in vivo . neuroscience 81, 1043&#x02013;1053. doi:10.1016/s0306-4522(97)00244-3 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar frohlich, j., miller, m. t., bird, l. m., garces, p., purtell, h., hoener, m. c., et al. (2019a). electrophysiological phenotype in angelman syndrome differs between genotypes. biol. psychiatry 85, 752&#x02013;759. doi:10.1016/j.biopsych.2019.01.008 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar frohlich, j., reiter, l. t., saravanapandian, v., distefano, c., huberty, s., hyde, c., et al. (2019b). mechanisms underlying the eeg biomarker in dup15q syndrome. mol. autism 10, 29. doi:10.1186/s13229-019-0280-6 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar frye, r. e., casanova, m. f., fatemi, s. h., folsom, t. d., reutiman, t. j., brown, g. l., et al. (2016). neuropathological mechanisms of seizures in autism spectrum disorder. front. neurosci. 10, 192. doi:10.3389/fnins.2016.00192 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar fukuda, t., itoh, m., ichikawa, t., washiyama, k., and goto, y. (2005). delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of mecp2-deficient mice. j. neuropathol. exp. neurol. 64, 537&#x02013;544. doi:10.1093/jnen/64.6.537 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar gaetz, w., bloy, l., wang, d. j., port, r. g., blaskey, l., levy, s. e., et al. (2014). gaba estimation in the brains of children on the autism spectrum: measurement precision and regional cortical variation. neuroimage 86, 1&#x02013;9. doi:10.1016/j.neuroimage.2013.05.068 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar han, s., tai, c., jones, c. j., scheuer, t., and catterall, w. a. (2014). enhancement of inhibitory neurotransmission by gabaa receptors having &#x003b1;2,3-subunits ameliorates behavioral deficits in a mouse model of autism. neuron 81, 1282&#x02013;1289. doi:10.1016/j.neuron.2014.01.016 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar han, s., tai, c., westenbroek, r. e., yu, f. h., cheah, c. s., potter, g. b., et al. (2012). autistic-like behaviour in scn1a&#x0002b;/- mice and rescue by enhanced gaba-mediated neurotransmission. nature 489, 385&#x02013;390. doi:10.1038/nature11356 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar hipp, j. f., knoflach, f., comley, r., ballard, t. m., honer, m., trube, g., et al. (2021). basmisanil, a highly selective gaba a -&#x003b1;5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man. sci. rep. 11, 7700. doi:10.1038/s41598-021-87307-7 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar hogart, a., wu, d., lasalle, j. m., and schanen, n. c. (2010). the comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. neurobiol. dis. 38, 181&#x02013;191. doi:10.1016/j.nbd.2008.08.011 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar hu, x., rocco, b. r., fee, c., and sibille, e. (2019). cell type-specific gene expression of alpha 5 subunit-containing gamma-aminobutyric acid subtype a receptors in human and mouse frontal cortex. mol. neuropsychiatry 4, 204&#x02013;215. doi:10.1159/000495840 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar hvoslef-eide, m., nilsson, s. r., saksida, l. m., and bussey, t. j. (2016). cognitive translation using the rodent touchscreen testing approach. curr. top. behav. neurosci. 28, 423&#x02013;447. doi:10.1007/7854_2015_5007 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar kalsner, l., and chamberlain, s. j. (2015). prader-willi, angelman, and 15q11-q13 duplication syndromes. pediatr. clin. north am. 62, 587&#x02013;606. doi:10.1016/j.pcl.2015.03.004 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar koh, m. t., rosenzweig-lipson, s., and gallagher, m. (2013). selective gaba(a) &#x003b1;5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. neuropharmacology 64, 145&#x02013;152. doi:10.1016/j.neuropharm.2012.06.023 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar lim, c. s., kim, h., yu, n. k., kang, s. j., kim, t., ko, h. g., et al. (2017). enhancing inhibitory synaptic function reverses spatial memory deficits in shank2 mutant mice. neuropharmacology 112, 104&#x02013;112. doi:10.1016/j.neuropharm.2016.08.016 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar luk, h. m., and lo, i. f. (2016). angelman syndrome in hong kong chinese: a 20 years&#x00027; experience. eur. j. med. genet. 59, 315&#x02013;319. doi:10.1016/j.ejmg.2016.05.003 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar luscher, b., maguire, j. l., rudolph, u., and sibille, e. (2023). gaba(a) receptors as targets for treating affective and cognitive symptoms of depression. trends pharmacol. sci. 44, 586&#x02013;600. doi:10.1016/j.tips.2023.06.009 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mcfarlane, h. g., kusek, g. k., yang, m., phoenix, j. l., bolivar, v. j., and crawley, j. n. (2008). autism-like behavioral phenotypes in btbr t&#x0002b;tf/j mice. genes brain behav. 7, 152&#x02013;163. doi:10.1111/j.1601-183x.2007.00330.x pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mcnaughton, n., and morris, r. g. (1987). chlordiazepoxide, an anxiolytic benzodiazepine, impairs place navigation in rats. behav. brain res. 24, 39&#x02013;46. doi:10.1016/0166-4328(87)90034-9 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mendez, m. a., horder, j., myers, j., coghlan, s., stokes, p., erritzoe, d., et al. (2013). the brain gaba-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)c]ro15-4513 positron emission tomography study. neuropharmacology 68, 195&#x02013;201. doi:10.1016/j.neuropharm.2012.04.008 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mermer, f., poliquin, s., rigsby, k., rastogi, a., shen, w., romero-morales, a., et al. (2021). common molecular mechanisms of slc6a1 variant-mediated neurodevelopmental disorders in astrocytes and neurons. brain 144, 2499&#x02013;2512. doi:10.1093/brain/awab207 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mertz, l. g., christensen, r., vogel, i., hertz, j. m., nielsen, k. b., gronskov, k., et al. (2013). angelman syndrome in denmark. birth incidence, genetic findings, and age at diagnosis. am. j. med. genet. a 161a, 2197&#x02013;2203. doi:10.1002/ajmg.a.36058 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mesbah-oskui, l., penna, a., orser, b. a., and horner, r. l. (2017). reduced expression of &#x003b1;5gaba a receptors elicits autism-like alterations in eeg patterns and sleep-wake behavior. neurotoxicol teratol. 61, 115&#x02013;122. doi:10.1016/j.ntt.2016.10.009 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mohler, h. (2011). the rise of a new gaba pharmacology. neuropharmacology 60, 1042&#x02013;1049. doi:10.1016/j.neuropharm.2010.10.020 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar mori, t., mori, k., fujii, e., toda, y., miyazaki, m., harada, m., et al. (2012). evaluation of the gabaergic nervous system in autistic brain: (123)i-iomazenil spect study. brain dev. 34, 648&#x02013;654. doi:10.1016/j.braindev.2011.10.007 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar myers, j. f., comley, r. a., and gunn, r. n. (2017). quantification of [ 11 c]ro15-4513 gaba a &#x003b1;5 specific binding and regional selectivity in humans. j. cereb. blood flow. metab. 37, 2137&#x02013;2148. doi:10.1177/0271678x16661339 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar nakamura, t., arima-yoshida, f., sakaue, f., nasu-nishimura, y., takeda, y., matsuura, k., et al. (2016). px-rics-deficient mice mimic autism spectrum disorder in jacobsen syndrome through impaired gabaa receptor trafficking. nat. commun. 7, 10861. doi:10.1038/ncomms10861 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar orefice, l. l., zimmerman, a. l., chirila, a. m., sleboda, s. j., head, j. p., and ginty, d. d. (2016). peripheral mechanosensory neuron dysfunction underlies tactile and behavioral deficits in mouse models of asds. cell 166, 299&#x02013;313. doi:10.1016/j.cell.2016.05.033 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar penagarikano, o., abrahams, b. s., herman, e. i., winden, k. d., gdalyahu, a., dong, h., et al. (2011). absence of cntnap2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. cell 147, 235&#x02013;246. doi:10.1016/j.cell.2011.08.040 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar percie du sert, n., hurst, v., ahluwalia, a., alam, s., avey, m. t., baker, m., et al. (2020). the arrive guidelines 2.0: updated guidelines for reporting animal research. plos biol. 18, e3000410. doi:10.1371/journal.pbio.3000410 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar perez, s. m., mccoy, a. m., prevot, t. d., mian, m. y., carreno, f. r., frazer, a., et al. (2023). hippocampal &#x003b1;5-gaba(a) receptors modulate dopamine neuron activity in the rat ventral tegmental area. biol. psychiatry glob. open sci. 3, 78&#x02013;86. doi:10.1016/j.bpsgos.2021.12.010 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar pirker, s., schwarzer, c., wieselthaler, a., sieghart, w., and sperk, g. (2000). gaba(a) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. neuroscience 101, 815&#x02013;850. doi:10.1016/s0306-4522(00)00442-5 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar pizzarelli, r., and cherubini, e. (2011). alterations of gabaergic signaling in autism spectrum disorders. neural plast. 2011, 297153. doi:10.1155/2011/297153 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar porjesz, b., almasy, l., edenberg, h. j., wang, k., chorlian, d. b., foroud, t., et al. (2002). linkage disequilibrium between the beta frequency of the human eeg and a gabaa receptor gene locus. proc. natl. acad. sci. u. s. a. 99, 3729&#x02013;3733. doi:10.1073/pnas.052716399 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar puts, n. a. j., wodka, e. l., harris, a. d., crocetti, d., tommerdahl, m., mostofsky, s. h., et al. (2017). reduced gaba and altered somatosensory function in children with autism spectrum disorder. autism res. 10, 608&#x02013;619. doi:10.1002/aur.1691 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar robertson, c. e., ratai, e. m., and kanwisher, n. (2016). reduced gabaergic action in the autistic brain. curr. biol. 26, 80&#x02013;85. doi:10.1016/j.cub.2015.11.019 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar rojas, d. c., singel, d., steinmetz, s., hepburn, s., and brown, m. s. (2014). decreased left perisylvian gaba concentration in children with autism and unaffected siblings. neuroimage 86, 28&#x02013;34. doi:10.1016/j.neuroimage.2013.01.045 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar rubenstein, j. l., and merzenich, m. m. (2003). model of autism: increased ratio of excitation/inhibition in key neural systems. genes brain behav. 2, 255&#x02013;267. doi:10.1034/j.1601-183x.2003.00037.x pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar sanders, s. j. (2015). first glimpses of the neurobiology of autism spectrum disorder. curr. opin. genet. dev. 33, 80&#x02013;92. doi:10.1016/j.gde.2015.10.002 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2018). dendrite-targeting interneurons control synaptic nmda-receptor activation via nonlinear &#x003b1;5-gaba a receptors. nat. commun. 9, 3576. doi:10.1038/s41467-018-06004-8 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2019). enhanced dendritic inhibition and impaired nmdar activation in a mouse model of down syndrome. j. neurosci. 39, 5210&#x02013;5221. doi:10.1523/jneurosci.2723-18.2019 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar serwanski, d. r., miralles, c. p., christie, s. b., mehta, a. k., li, x., and de blas, a. l. (2006). synaptic and nonsynaptic localization of gabaa receptors containing the alpha5 subunit in the rat brain. j. comp. neurol. 499, 458&#x02013;470. doi:10.1002/cne.21115 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar sieghart, w. (2006). structure, pharmacology, and function of gabaa receptor subtypes. adv. pharmacol. 54, 231&#x02013;263. doi:10.1016/s1054-3589(06)54010-4 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar sitnikova, e., rutskova, e., and smirnov, k. (2023). alpha2-adrenergic receptors as a pharmacological target for spike-wave epilepsy. int. j. mol. sci. 24, 1477. doi:10.3390/ijms24021477 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar smit, d. j. a., wright, m. j., meyers, j. l., martin, n. g., ho, y. y. w., malone, s. m., et al. (2018). genome-wide association analysis links multiple psychiatric liability genes to oscillatory brain activity. hum. brain mapp. 39, 4183&#x02013;4195. doi:10.1002/hbm.24238 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar souza, a. j., freitas, i. s., sharmin, d., cook, j. m., guimaraes, f. s., and gomes, f. v. (2024). an alpha 5-gaba(a) receptor positive allosteric modulator attenuates social and cognitive deficits without changing dopamine system hyperactivity in rats exposed to valproic acid in utero. autism res. 17, 1534&#x02013;1544. doi:10.1002/aur.3178 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar sur, c., fresu, l., howell, o., mckernan, r. m., and atack, j. r. (1999). autoradiographic localization of alpha5 subunit-containing gabaa receptors in rat brain. brain res. 822, 265&#x02013;270. doi:10.1016/s0006-8993(99)01152-x pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar traub, r. d. w. m., and jefferys, j. g. r. (1999). fast oscillations in cortical circuits . the mit press . google scholar van lier, h., drinkenburg, w. h., van eeten, y. j., and coenen, a. m. (2004). effects of diazepam and zolpidem on eeg beta frequencies are behavior-specific in rats. neuropharmacology 47, 163&#x02013;174. doi:10.1016/j.neuropharm.2004.03.017 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar visser, s. a., wolters, f. l., gubbens-stibbe, j. m., tukker, e., van der graaf, p. h., peletier, l. a., et al. (2003). mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of gabaa receptor modulators: in vitro-in vivo correlations. j. pharmacol. exp. ther. 304, 88&#x02013;101. doi:10.1124/jpet.102.042341 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar vithlani, m., terunuma, m., and moss, s. j. (2011). the dynamic modulation of gaba(a) receptor trafficking and its role in regulating the plasticity of inhibitory synapses. physiol. rev. 91, 1009&#x02013;1022. doi:10.1152/physrev.00015.2010 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar warrier, v., baron-cohen, s., and chakrabarti, b. (2013). genetic variation in gabrb3 is associated with asperger syndrome and multiple endophenotypes relevant to autism. mol. autism 4, 48. doi:10.1186/2040-2392-4-48 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar whittington, m. a., traub, r. d., kopell, n., ermentrout, b., and buhl, e. h. (2000). inhibition-based rhythms: experimental and mathematical observations on network dynamics. int. j. psychophysiol. 38, 315&#x02013;336. doi:10.1016/s0167-8760(00)00173-2 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar xie, x. h., and tietz, e. i. (1991). chronic benzodiazepine treatment of rats induces reduction of paired-pulse inhibition in ca1 region of in vitro hippocampus. brain res. 561, 69&#x02013;76. doi:10.1016/0006-8993(91)90750-p pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar zurek, a. a., kemp, s. w., aga, z., walker, s., milenkovic, m., ramsey, a. j., et al. (2016). &#x003b1;5gabaa receptor deficiency causes autism-like behaviors. ann. clin. transl. neurol. 3, 392&#x02013;398. doi:10.1002/acn3.303 pubmed abstract &#x0007c; crossref full text &#x0007c; google scholar keywords: autism spectrum disorder, angelman syndrome, gaba a , gaba a -&#x003b1;5, positron emission tomography (pet), electroencephalography, pharmacological mri, biomarker citation: cecere g, ballard tm, knoflach f, honer m, hipp jf, garces p, mueggler t, k&#x000fc;nnecke b, bruns a, prinssen ep, schoenenberger p, janz p, redondo r, biemans b, knust h, olivares-morales a, brigo a, schulz jm, bertrand d, saxe m, o&#x02019;connor ec and hernandez m-c (2025) preclinical pharmacology of alogabat: a novel gaba a -&#x003b1;5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gaba a signaling. front. pharmacol. 16:1626078. doi: 10.3389/fphar.2025.1626078 received: 09 may 2025; accepted: 18 june 2025; published: 21 july 2025. edited by: agenor limon , university of texas medical branch at galveston, united states reviewed by: hansen wang , university of toronto, canada junzhan jing , baylor college of medicine, united states azar omrani , boehringer ingelheim, germany copyright &#x000a9; 2025 cecere, ballard, knoflach, honer, hipp, garces, mueggler, k&#x000fc;nnecke, bruns, prinssen, schoenenberger, janz, redondo, biemans, knust, olivares-morales, brigo, schulz, bertrand, saxe, o&#x02019;connor and hernandez. this is an open-access article distributed under the terms of the creative commons attribution license (cc by). the use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. no use, distribution or reproduction is permitted which does not comply with these terms. &#x0002a;correspondence: maria-clemencia hernandez, bwfyawety2xlbwvuy2lhlmhlcm5hbmrlekbyb2nozs5jb20= &#x02020; these authors have contributed equally to this work &#x02021; present address: theresa m. ballard, galwyn (uk) ltd., dartmouth, united kingdom barbara biemans, b2discovery llc, riehen, switzerland michael saxe, translational in vivo sciences, biogen, cambridge, ma, united states disclaimer: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. download article download pdf readcube epub xml share on export citation endnote reference manager simple text file bibtex 2,218 total views 442 downloads citation numbers are available from dimensions view article impact view altmetric score share on edited by a l agenor limon reviewed by j j junzhan jing a o azar omrani h w hansen wang table of contents abstract 1 introduction 2 materials and methods 3 results 4 discussion 5 conclusion data availability statement ethics statement author contributions funding acknowledgments conflict of interest generative ai statement publisher&#x02019;s note supplementary material abbreviations references export citation endnote reference manager simple text file bibtex check for updates frontiers&#39; impact articles published with frontiers have received 12 million total citations your research is the real superpower - learn how we maximise its impact through our leading community journals explore our impact metrics supplementary material download article download download pdf readcube epub xml guidelines author guidelines services for authors policies and publication ethics editor guidelines fee policy explore articles research topics journals how we publish outreach frontiers forum frontiers policy labs frontiers for young minds frontiers planet prize connect help center emails and alerts contact us submit career opportunities follow us © 2025 frontiers media s.a. all rights reserved privacy policy | terms and conditions [["shallowreactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverrendered":13,"path":14,"pinia":15},["shallowreactive",3],{},["reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","frontiers articles","https://article-pages-2024.frontiersin.org/",["set"],["shallowreactive",12],{},true,"/journals/pharmacology/articles/10.3389/fphar.2025.1626078/full",["reactive",16],{"main":17,"user":511,"article":512,"articlehub":968,"mainheader":972},{"ibar":18,"footer":264,"newslettercomponent":-1,"snackbaritem":346,"toggleshowsnackbar":347,"contentfuljournal":348,"graphjournal":412,"settingsfeaturesswitchers":416,"templatetogglebanner":417,"tenantconfig":476},{"tenantlogo":19,"journallogo":19,"aboutus":20,"submiturl":113,"showsubmitbutton":13,"journal":114,"sectionterm":195,"aboutjournal":196,"mainlinks":245,"journallinks":252,"helpcenterlink":261},"",[21,38,47,71,87],{"title":22,"links":23},"who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"arialabel":28},"mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"arialabel":28},"history","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"arialabel":28},"leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"arialabel":28},"awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"impact and progress",[41,44],{"text":42,"url":43,"target":27,"arialabel":28},"frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"arialabel":28},"our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"arialabel":28},"how we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"arialabel":28},"open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"arialabel":28},"peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"arialabel":28},"research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"arialabel":28},"research topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"arialabel":28},"fair² data management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"arialabel":28},"fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"services",[74,78,81,84],{"text":75,"url":76,"target":77,"arialabel":28},"societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"arialabel":28},"national consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"arialabel":28},"institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"arialabel":28},"collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"more from frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"arialabel":93},"frontiers forum","https://forum.frontiersin.org/","this link will take you to the frontiers forum website",{"text":95,"url":96,"target":27,"arialabel":28},"frontiers planet prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"arialabel":100},"press office","https://pressoffice.frontiersin.org/","this link will take you to the frontiers press office website",{"text":102,"url":103,"target":27,"arialabel":104},"sustainability","https://www.frontiersin.org/about/sustainability","link to information about frontiers' sustainability",{"text":106,"url":107,"target":77,"arialabel":108},"career opportunities","https://careers.frontiersin.org/","this link will take you to the frontiers careers website",{"text":110,"url":111,"target":27,"arialabel":112},"contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=1&fieldid=62&specialtyid=0&entitytype=2&entityid=176",{"id":115,"name":116,"slug":117,"sections":118},176,"frontiers in pharmacology","pharmacology",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191],{"id":120,"name":121,"slug":122},182,"cardiovascular and smooth muscle pharmacology","cardiovascular-and-smooth-muscle-pharmacology",{"id":124,"name":125,"slug":126},199,"drug metabolism and transport","drug-metabolism-and-transport",{"id":128,"name":129,"slug":130},202,"drugs outcomes research and policies","drugs-outcomes-research-and-policies",{"id":132,"name":133,"slug":134},184,"ethnopharmacology","ethnopharmacology",{"id":136,"name":137,"slug":138},183,"experimental pharmacology and drug discovery","experimental-pharmacology-and-drug-discovery",{"id":140,"name":141,"slug":142},186,"gastrointestinal and hepatic pharmacology","gastrointestinal-and-hepatic-pharmacology",{"id":144,"name":145,"slug":146},188,"inflammation pharmacology","inflammation-pharmacology",{"id":148,"name":149,"slug":150},178,"integrative and regenerative pharmacology","integrative-and-regenerative-pharmacology",{"id":152,"name":153,"slug":154},26,"neuropharmacology","neuropharmacology",{"id":156,"name":157,"slug":158},196,"obstetric and pediatric pharmacology","obstetric-and-pediatric-pharmacology",{"id":160,"name":161,"slug":162},2186,"pharmacoepidemiology","pharmacoepidemiology",{"id":164,"name":165,"slug":166},198,"pharmacogenetics and pharmacogenomics","pharmacogenetics-and-pharmacogenomics",{"id":168,"name":169,"slug":170},192,"pharmacology of anti-cancer drugs","pharmacology-of-anti-cancer-drugs",{"id":172,"name":173,"slug":174},2216,"pharmacology of infectious diseases","pharmacology-of-infectious-diseases",{"id":176,"name":177,"slug":178},179,"pharmacology of ion channels and channelopathies","pharmacology-of-ion-channels-and-channelopathies",{"id":180,"name":181,"slug":182},195,"predictive toxicology","predictive-toxicology",{"id":184,"name":185,"slug":186},1357,"renal pharmacology","renal-pharmacology",{"id":188,"name":189,"slug":190},190,"respiratory pharmacology","respiratory-pharmacology",{"id":192,"name":193,"slug":194},1251,"translational pharmacology","translational-pharmacology","sections",[197,221],{"title":198,"links":199},"scope",[200,203,206,209,212,215,218],{"text":201,"url":202,"target":27,"arialabel":28},"field chief editors","https://www.frontiersin.org/journals/pharmacology/about#about-editors",{"text":204,"url":205,"target":27,"arialabel":28},"mission & scope","https://www.frontiersin.org/journals/pharmacology/about#about-scope",{"text":207,"url":208,"target":27,"arialabel":28},"facts","https://www.frontiersin.org/journals/pharmacology/about#about-facts",{"text":210,"url":211,"target":27,"arialabel":28},"journal sections","https://www.frontiersin.org/journals/pharmacology/about#about-submission",{"text":213,"url":214,"target":27,"arialabel":28},"open access statement","https://www.frontiersin.org/journals/pharmacology/about#about-open",{"text":216,"url":217,"target":27,"arialabel":28},"copyright statement","https://www.frontiersin.org/journals/pharmacology/about#copyright-statement",{"text":219,"url":220,"target":27,"arialabel":28},"quality","https://www.frontiersin.org/journals/pharmacology/about#about-quality",{"title":222,"links":223},"for authors",[224,227,230,233,236,239,242],{"text":225,"url":226,"target":27,"arialabel":28},"why submit?","https://www.frontiersin.org/journals/pharmacology/for-authors/why-submit",{"text":228,"url":229,"target":27,"arialabel":28},"article types","https://www.frontiersin.org/journals/pharmacology/for-authors/article-types",{"text":231,"url":232,"target":27,"arialabel":28},"author guidelines","https://www.frontiersin.org/journals/pharmacology/for-authors/author-guidelines",{"text":234,"url":235,"target":27,"arialabel":28},"editor guidelines","https://www.frontiersin.org/journals/pharmacology/for-authors/editor-guidelines",{"text":237,"url":238,"target":27,"arialabel":28},"publishing fees","https://www.frontiersin.org/journals/pharmacology/for-authors/publishing-fees",{"text":240,"url":241,"target":27,"arialabel":28},"submission checklist","https://www.frontiersin.org/journals/pharmacology/for-authors/submission-checklist",{"text":243,"url":244,"target":27,"arialabel":28},"contact editorial office","https://www.frontiersin.org/journals/pharmacology/for-authors/contact-editorial-office",[246,249],{"text":247,"url":248,"target":27,"arialabel":28},"all journals","https://www.frontiersin.org/journals",{"text":250,"url":251,"target":27,"arialabel":28},"all articles","https://www.frontiersin.org/articles",[253,256,258],{"text":254,"url":255,"target":27,"arialabel":28},"articles","articles",{"text":63,"url":257,"target":27,"arialabel":28},"research-topics",{"text":259,"url":260,"target":27,"arialabel":28},"editorial board","editors",{"text":262,"url":263,"target":77,"arialabel":262},"help center","https://helpcenter.frontiersin.org",{"blocks":265,"sociallinks":319,"copyright":343,"termsandconditionsurl":344,"privacypolicyurl":345},[266,280,290,304],{"title":267,"links":268},"guidelines",[269,271,274,277,279],{"text":231,"url":270,"target":27,"arialabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":272,"url":273,"target":27,"arialabel":28},"services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":275,"url":276,"target":27,"arialabel":28},"policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":234,"url":278,"target":27,"arialabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"arialabel":28},{"title":281,"links":282},"explore",[283,284,287,289],{"text":254,"url":251,"target":27,"arialabel":28},{"text":285,"url":286,"target":27,"arialabel":28},"research topics ","https://www.frontiersin.org/research-topics",{"text":288,"url":248,"target":27,"arialabel":28},"journals",{"text":51,"url":52,"target":27,"arialabel":28},{"title":291,"links":292},"outreach",[293,296,299,303],{"text":294,"url":92,"target":77,"arialabel":295},"frontiers forum ","frontiers forum website",{"text":297,"url":298,"target":77,"arialabel":28},"frontiers policy labs ","https://policylabs.frontiersin.org/",{"text":300,"url":301,"target":77,"arialabel":302},"frontiers for young minds","https://kids.frontiersin.org/","frontiers for young minds journal",{"text":95,"url":96,"target":27,"arialabel":28},{"title":305,"links":306},"connect",[307,308,312,315,318],{"text":262,"url":263,"target":77,"arialabel":262},{"text":309,"url":310,"target":77,"arialabel":311},"emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","subscribe to frontiers emails",{"text":313,"url":111,"target":27,"arialabel":314},"contact us ","subscribe to newsletter",{"text":316,"url":317,"target":27,"arialabel":28},"submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"arialabel":28},[320,328,333,338],{"link":321,"type":324,"color":325,"icon":326,"size":327,"hiddentext":13},{"text":322,"url":323,"target":77,"arialabel":322},"frontiers facebook","https://www.facebook.com/frontiersin","link","grey","facebook","medium",{"link":329,"type":324,"color":325,"icon":332,"size":327,"hiddentext":13},{"text":330,"url":331,"target":77,"arialabel":28},"frontiers twitter","https://twitter.com/frontiersin","twitter",{"link":334,"type":324,"color":325,"icon":337,"size":327,"hiddentext":13},{"text":335,"url":336,"target":77,"arialabel":28},"frontiers linkedin","https://www.linkedin.com/company/frontiers","linkedin",{"link":339,"type":324,"color":325,"icon":342,"size":327,"hiddentext":13},{"text":340,"url":341,"target":77,"arialabel":28},"frontiers instagram","https://www.instagram.com/frontiersin_","instagram","frontiers media s.a. all rights reserved","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":349,"identifier":115,"name":116,"slug":117,"banner":350,"description":405,"mission":406,"palette":407,"impactfactor":408,"citescore":409,"citations":410,"showtagline":28,"twitter":411},"journal",[351],{"id":352,"src":353,"name":354,"tags":355,"type":363,"width":364,"height":365,"idhash":366,"archive":367,"brandid":368,"limited":367,"filesize":369,"ispublic":370,"original":371,"copyright":372,"extension":373,"thumbnails":375,"datecreated":383,"description":384,"orientation":385,"usercreated":386,"watermarked":367,"datemodified":383,"datepublished":387,"ecsarchivefiles":388,"propertyoptions":389,"property_channel":394,"property_sub-type":396,"property_asset_type":398,"activeoriginalfocuspoint":400,"property_office_department":403},"754e12a9-443f-4ea8-ab01e0811e45131d","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/webimage-9d720582-24ad-4d2e-9205ab9d241919da.jpg","fphar_main visual_purple_website",[356,357,358,359,360,361,362],"pain","medical","pharmaceutical","antibiotic","concept","capsule","treatment","image",5844,3896,"79b643019a2651e0",0,"22c10171-81b3-4da6-99342f272a32e8bb",8675243,1,"https://brand.frontiersin.org/m/79b643019a2651e0/original/fphar_main-visual_purple_website.jpeg","copyright (c) 2017 marian weyo/shutterstock. no use without permission.",[374],"jpeg",{"mini":376,"thul":377,"webimage":353,"guidelines":378,"websitejpg_xl":379,"websitewebp_l":380,"websitewebp_m":381,"websitewebp_xl":382},"https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/mini-97eef455-249b-43bd-9d8f02fee86046d3.jpg","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/thul-b2dbd910-1ddf-4ed3-b1500df973953144.jpg","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/guidelines-fphar_main visual_purple_website.png","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitejpg_xl-fphar_main visual_purple_website.jpg","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitewebp_l-fphar_main visual_purple_website.webp","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitewebp_m-fphar_main visual_purple_website.webp","https://d2csxpduxe849s.cloudfront.net/media/e32629c6-9347-4f84-81feaef7bfa342b3/754e12a9-443f-4ea8-ab01e0811e45131d/f3882bde-513e-4d16-8db695504865e7b8/websitewebp_xl-fphar_main visual_purple_website.webp","2022-06-27t10:00:45z","pills tablets capsule or medicament freely laid on glass background.","landscape","caroline sutter","2022-06-27t09:27:09z",[],[390,391,392,393],"414fb2d4-2283-43fd-be14e534eca67928","6c18119b-14bd-4951-b437696f4357bd33","7c692885-db25-4858-b1fb4ff47b241e9b","d88c0047-ec30-4506-a7df28a4d765e1cf",[395],"frontiersin_org",[397],"main_visual",[399],"photography",{"x":401,"y":402},2922,1948,[404],"publishing","the world's most cited pharmacology and pharmacy journal, advancing global pharmacological discoveries to prevent and treat human disease.","\u003cp>frontiers in pharmacology is an interdisciplinary journal that publishes research on the interactions between drugs and living beings to prevent and cure human disease.\u003c/p>\n\n\u003cp>led by field chief editor heike wulff (university of california, davis, us), frontiers in pharmacology explores basic and clinical pharmacology, medicinal chemistry, pharmacy, and toxicology to clarify the fundamental processes of disease treatment and drug effects. indexed in pubmed central (pmc), scopus, web of science (scie), and the doaj, the journal welcomes academic, industrial, and clinical work focused on pharmacology.\u003c/p>\n\n\u003cp>topics include, but are not limited to:\u003c/p>\n\u003cul>\n \u003cli>cardiovascular and smooth muscle pharmacology\u003c/li>\n \u003cli>drug metabolism and transport\u003c/li>\n \u003cli>drugs outcomes research and policies\u003c/li>\n \u003cli>elsi in science and genetics\u003c/li>\n \u003cli>ethnopharmacology\u003c/li>\n \u003cli>experimental pharmacology and drug discovery\u003c/li>\n \u003cli>gastrointestinal and hepatic pharmacology\u003c/li>\n \u003cli>inflammation pharmacology\u003c/li>\n \u003cli>integrative and regenerative pharmacology\u003c/li>\n \u003cli>neuropharmacology\u003c/li>\n \u003cli>obstetric and pediatric pharmacology\u003c/li>\n \u003cli>pharmacoepidemiology\u003c/li>\n \u003cli>pharmacogenetics and pharmacogenomics\u003c/li>\n \u003cli>pharmacology of anti-cancer drugs\u003c/li>\n \u003cli>pharmacology of infectious diseases\u003c/li>\n \u003cli>pharmacology of ion channels and channelopathies\u003c/li>\n \u003cli>predictive toxicology\u003c/li>\n \u003cli>renal pharmacology\u003c/li>\n \u003cli>respiratory pharmacology\u003c/li>\n \u003cli>translational pharmacology.\u003c/li>\n\u003c/ul>\n\n\u003cp>all submissions to the journal involving natural products, including plant extracts or preparations, must adhere to \u003ci>'the four pillars of ethnopharmacology'\u003c/i> to be considered for peer review, regardless of the specialty section, as a baseline standard for sample characterization. these are a set of mandatory guidelines designed to maintain the scientific, cultural, and ethical integrity of the journal, and describe what the leading journals in the field consider as the basic aspects of good research (full conphymp statement available \u003ca href=\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.953205/full\" target=\"_blank\">here\u003c/a>, conphymp statement overview \u003ca href=\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1338710/full\" target=\"_blank\">here\u003c/a>, and ga-tool \u003ca href=\"https://ga-online.org/best-practice/\" target=\"_blank\">here\u003c/a>). please refer to the \u003ca href=\"https://assets.ctfassets.net/41vi7p4898pd/63dcrrxgncg4b1stfayeh8/1b87b9a742b0610ace5b19fd11f62359/four_pillars_ethnopharmacology_2025.pdf\" target=\"_blank\">full version\u003c/a> of these guidelines before submitting a manuscript to the journal.\u003c/p> \n\u003cp>to be considered for publication in frontiers in pharmacology, studies incorporating complementary or alternative medicine must be based on a set of data linked to local or traditional uses that can be evaluated pharmacologically. a clear and plausible set of pharmacological data must be generated in these studies. similarly, the journal endorses protocols including a minimum of 2 cell-lines in vitro as an evidential basis to demonstrate proposed anti-cancer effects in all relevant studies submitted to all specialty sections in the journal.\u003c/p>\n\u003cp>isolated data mining studies using disproportionality analyses of databases containing spontaneously reported adverse events, frequently lead to misinterpretation due to various reporting biases, lack of structured control, and insufficient demographic details. presenting such analyses in isolation typically does not yield clinically actionable safety findings without the broader context of a comprehensive signal evaluation. to ensure rigor and relevance, all submissions to the journal must be complemented by a proper systematic review and/or thorough analyses of reported cases, and adhere to the readus-pv guidelines (\u003ca href=\"https://www.equator-network.org/reporting-guidelines/the-reporting-of-a-disproportionality-analysis-for-drug-safety-signal-detection-using-individual-case-safety-reports-in-pharmacovigilance-readus-pv-development-and-statement/\" target=\"_blank\">the reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance\u003c/a>). authors are expected to ensure compliance with the corresponding \u003ca href=\"https://readus-statement.org/wp-content/uploads/2024/03/readus-checklist.pdf\" target=\"_blank\">checklist\u003c/a> before proceeding with submission to the journal. full publication of the readus-pv guidelines is available \u003ca href=\"https://pmc.ncbi.nlm.nih.gov/articles/pmc11116242/pdf/40264_2024_article_1421.pdf\" target=\"_blank\">here\u003c/a>.\u003c/p>\n\n\u003cp>frontiers’ journals require that manuscripts primarily comprising computational studies of public data, such as nhanes or mendelian randomization studies, must include appropriate validation. please refer to the \u003ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology:~:text=complaints%20and%20allegations.-,standards%20for%20research%20methodology,-experiments\">frontiers standards for research methodology policy\u003c/a>, for more information. manuscripts not adhering to these standards will not be considered.\u003cp>\n\n\u003cp>further unique criteria for the conception and review of submissions may apply, where appropriate, for individual specialty sections.\u003c/p>\n\n\u003cp>the journal welcomes submissions that support and advance the \u003ca href=\"https://www.globalgoals.org/goals/\" target=\"_blank\">un sustainable development goals\u003c/a> (sdgs), notably the \u003ca href=\"https://www.globalgoals.org/goals/3-good-health-and-well-being/\" target=\"_blank\">sdg 3: good health and well-being\u003c/a>.\u003c/p>\n\n\u003cp>manuscripts that focus solely on clinical trials, patient management, or conventional therapies without a focus on pharmacological research are not suitable for publication in this journal. additionally, studies that are purely statistical or predictive in nature, without providing novel insights into pharmacological mechanisms or drug development, are not within the scope of this journal.\u003c/p>\n\n\u003cp>frontiers in pharmacology is committed to advancing developments in the field of pharmacological discoveries by allowing unrestricted access to articles and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.\u003c/p>\n\n\u003cb>\u003cp>ethics information\u003c/p>\u003c/b>\n\u003cp>research involving human subjects should comply with the ethical guidelines outlined in the \u003ca href= https://www.wma.net/policies-post/wma-declaration-of-helsinki/” target=”_blank”>world medical association’s declaration of helsinki\u003c/a>.\u003c/p>\n\u003cp>similarly, authors are required to specify the institutional and national standards adhered to for the care and use of laboratory animals. transparent and accurate reporting of animal studies is required, with references to guidelines such as \u003ca href=\"https://arriveguidelines.org/arrive-guidelines\" target=\"_blank\">arrive\u003c/a> and \u003ca href=\"https://nc3rs.org.uk/sites/default/files/2022-01/the%20improve%20guidelines%20%28poster%29.pdf\" target=\"_blank\"> improve\u003c/a>.\u003c/p>\n\u003cp>extended information on research ethics can be found under the frontiers policies and publication ethics page.\u003c/p>","purple","5.6","6.3","531663","@frontpharmacol",{"id":115,"name":116,"slug":117,"abbreviation":413,"isonline":13,"isopenforsubmissions":13,"citescore":414,"impactfactor":415},"fphar",8.9,4.8,{"displaytitlepilllabels":13,"displayrelatedarticlesbox":13,"showeditors":13,"showreviewers":13,"showloopimpactlink":13,"enablefigshare":347,"usexmlimages":13},{"ispublic":13,"allowcompanyusers":347,"whitelistemails":418,"enablealljournals":13,"whitelistjournals":440},[419,420,421,422,423,424,425,426,427,424,428,429,430,431,432,433,434,435,436,437,438,439],"y2fybg9zlmxvcmnhqgzyb250awvyc2lulm9yzw==","zgfuawvslmx1ekbmcm9udgllcnnpbi5vcmc=","bgf1cmeudgvuyubmcm9udgllcnnpbi5vcmc=","cmfmywvslnjpyw5jag9aznjvbnrpzxjzaw4ub3jn","amftzxmuc21hbgxib25lqgzyb250awvyc2lulm9yzw==","znjhbi5tb3jlbm9aznjvbnrpzxjzaw4ub3jn","c2ftdwvslmzlcm5hbmrlekbmcm9udgllcnnpbi5vcmc=","ymfyymfyys5jyxjjyw5naxvaznjvbnrpzxjzaw4ub3jn","axzhbi5zyw50yw1hcmlhqgzyb250awvyc2lulm9yzw==","ahvllnryyw5aznjvbnrpzxjzaw4ub3jn","z29uy2fsby52yxjnyxnaznjvbnrpzxjzaw4ub3jn","bhvjawuuc2vubkbmcm9udgllcnnpbi5vcmc=","bg9ybi5mcmfzzxjaznjvbnrpzxjzaw4ub3jn","zwxzys5jyxjyb25aznjvbnrpzxjzaw4ub3jn","bwfhcnrlbi52yw5kawpja0bmcm9udgllcnnpbi5vcmc=","ymluzgh1lmtyaxnobmfuqgzyb250awvyc2lulm9yzw==","bwf0dghldy5hdhr3yxrlcnnaznjvbnrpzxjzaw4ub3jn","z2l1bglhlnzhbhnly2noaubmcm9udgllcnnpbi5vcmc=","zmfiawfulmrlbgxhbw9ydgvaznjvbnrpzxjzaw4ub3jn","dmlqyxlhbi5wcebwaxrzb2x1dglvbnmuy29t","z3vpbgxhdw1llnnldxjhdebmcm9udgllcnnpbi5vcmc=",[441,442,443,444,445,446,370,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,115,469,470,471,472,473,474,475],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,451,141,1335,2655,1238,604,698,1547,1440,403,1239,755,2136,609,1534,{"spaceid":370,"name":370,"availablejournalpages":477,"announcement":481},[255,260,257,478,479,480],"volumes","about","community-reviewers",{"__typename":482,"sys":483,"preheader":42,"title":485,"description":486,"image":487,"link":509},"announcement",{"id":484},"5ittnttqgazppgh6rx0alm","articles published with frontiers have received 12 million total citations","your research is the real superpower - learn how we maximise its impact through our leading community journals",[488],{"archive":367,"brandid":368,"copyright":28,"datecreated":489,"datemodified":490,"datepublished":491,"description":28,"extension":492,"filesize":494,"height":495,"id":496,"ispublic":367,"limited":367,"name":497,"orientation":385,"original":28,"thumbnails":498,"type":363,"watermarked":367,"width":505,"videopreviewurls":506,"tags":507,"textmetaproperties":508,"src":499},"2025-06-18t12:58:01z","2025-06-18t14:15:34z","2025-06-18t12:57:32z",[493],"png",1365026,920,"7c5269c4-3c83-4591-951a74d15b95daea","impact metrics banner for article pages",{"webimage":499,"thul":500,"mini":501,"websitewebp_l":502,"websitewebp_m":503,"guidelines":504},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/websitewebp_l/impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/websitewebp_m/impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/guidelines/impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":510,"url":43,"target":27,"arialabel":28},"explore our impact metrics",{"loggeduserinfo":-1},{"currentarticle":513,"ispreviewpage":347,"hassupplementaldata":347,"showcrossmarkwidget":13,"articletemplate":758,"currentarticlepagemetainfo":759,"xmlparsedarticlecontent":-1,"xmlparsingerror":-1},{"id":514,"doi":515,"title":516,"acceptancedate":517,"receptiondate":518,"publicationdate":519,"lastmodifieddate":520,"ispublished":13,"abstract":521,"researchtopic":28,"articletype":522,"stage":525,"keywords":527,"authors":536,"editors":682,"reviewers":690,"journal":712,"section":719,"impactmetrics":721,"volume":724,"articlevolume":725,"relatedarticles":726,"ispublishedv2":13,"contents":727,"files":731},1626078,"10.3389/fphar.2025.1626078","preclinical pharmacology of alogabat: a novel gabaa-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gabaa signaling","2025-06-18t08:27:15.000z","2025-05-09t23:15:40.000z","2025-07-21t00:00:00.000z","2025-10-21t02:34:53.269z","backgroundalterations in the gabaergic system contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder (asd) and angelman syndrome (as), particularly in cases involving large deletions in the 15q11–13 region. positive modulation of gabaa-α5 receptors may provide a novel therapeutic approach without the typical side effects associated with non-selective gabaa positive allosteric modulators such as diazepam.methodsalogabat was assessed for binding and functional activity at gabaa-α5β3γ2 receptors in vitro and in electrophysiological studies using hippocampal slices. in vivo studies in rodents included receptor occupancy (ro) using a selective gabaa-α5 tracer (autoradiography), pharmacological mri, and electroencephalography (eeg). alogabat was evaluated for its effects on the repetitive behavior phenotype in btbr and contactin-associated protein-like 2 (cntnap2−/−) knockout mice, seizure models, cognitive performance in rats, and rotarod performance following combination treatment with diazepam.resultsalogabat is a potent positive allosteric modulator of gabaa-α5 receptors, with binding and functional selectivity. receptor occupancy studies provided direct proof of dose-dependent target engagement. functional circuit modulation was demonstrated by dose-dependent regional perfusion changes in pharmacological mri and changes in eeg theta- and beta-band power in rats. at >50% gabaa-α5 receptor occupancy, alogabat normalized elevated self-grooming behavior in both cntnap2−/− and btbr mice and exhibited antiepileptic activity in rats. alogabat did not impair cognition in wildtype rats at gabaa-α5 receptor occupancy up to 75%, although impairment occurred at higher doses, probably due to increased activity at other receptor subtypes and/or saturation of α5 receptors. alogabat did not worsen diazepam-induced impairment on the rotarod test.conclusionalogabat showed beneficial effects in mouse models relevant to neurodevelopmental disorders and anti-seizure activity at doses that did not produce cognitive, sedative, or motoric side effects.",{"id":523,"name":524},24,"original research",{"id":526,"name":19},18,[528,529,530,531,532,533,534,535],"biomarker","autism spectrum disorder","electroencephalography","positron emission tomography (pet)","angelman syndrome","gabaa","gabaa-α5","pharmacological mri",[537,546,554,560,566,573,580,587,594,600,606,612,617,623,629,635,643,650,656,664,668,675],{"id":538,"firstname":539,"middlename":19,"lastname":540,"givennames":541,"iscorresponding":347,"isprofilepublic":13,"userid":538,"email":-1,"affiliations":542},3088634,"giuseppe","cecere","giuseppe ",[543],{"organizationname":544,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"medicinal chemistry","switzerland",{"id":547,"firstname":548,"middlename":19,"lastname":549,"givennames":550,"iscorresponding":347,"isprofilepublic":13,"userid":547,"email":-1,"affiliations":551},3064665,"theresa m.","ballard","theresa m. ",[552],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"neuroscience and rare diseases",{"id":367,"firstname":555,"middlename":19,"lastname":556,"givennames":557,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":558},"frederic","knoflach","frederic ",[559],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":561,"middlename":19,"lastname":562,"givennames":563,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":564},"michael","honer","michael ",[565],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":567,"firstname":568,"middlename":19,"lastname":569,"givennames":570,"iscorresponding":347,"isprofilepublic":13,"userid":567,"email":-1,"affiliations":571},81732,"joerg f.","hipp","joerg f. ",[572],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":574,"firstname":575,"middlename":19,"lastname":576,"givennames":577,"iscorresponding":347,"isprofilepublic":13,"userid":574,"email":-1,"affiliations":578},2412410,"pilar","garces","pilar ",[579],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":581,"firstname":582,"middlename":19,"lastname":583,"givennames":584,"iscorresponding":347,"isprofilepublic":13,"userid":581,"email":-1,"affiliations":585},13967,"thomas","mueggler","thomas ",[586],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":588,"firstname":589,"middlename":19,"lastname":590,"givennames":591,"iscorresponding":347,"isprofilepublic":13,"userid":588,"email":-1,"affiliations":592},577428,"basil","künnecke","basil ",[593],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":595,"middlename":19,"lastname":596,"givennames":597,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":598},"andreas","bruns","andreas ",[599],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":601,"middlename":19,"lastname":602,"givennames":603,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":604},"eric p.","prinssen","eric p. ",[605],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":607,"middlename":19,"lastname":608,"givennames":609,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":610},"philipp","schoenenberger","philipp ",[611],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":613,"firstname":607,"middlename":19,"lastname":614,"givennames":609,"iscorresponding":347,"isprofilepublic":13,"userid":613,"email":-1,"affiliations":615},2424959,"janz",[616],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":618,"middlename":19,"lastname":619,"givennames":620,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":621},"roger","redondo","roger ",[622],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":624,"middlename":19,"lastname":625,"givennames":626,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":627},"barbara","biemans","barbara ",[628],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":630,"middlename":19,"lastname":631,"givennames":632,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":633},"henner","knust","henner ",[634],{"organizationname":544,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":636,"firstname":637,"middlename":19,"lastname":638,"givennames":639,"iscorresponding":347,"isprofilepublic":13,"userid":636,"email":-1,"affiliations":640},2264913,"andrés","olivares-morales","andrés ",[641],{"organizationname":642,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"pharmaceutical sciences",{"id":644,"firstname":645,"middlename":19,"lastname":646,"givennames":647,"iscorresponding":347,"isprofilepublic":13,"userid":644,"email":-1,"affiliations":648},1172717,"alessandro","brigo","alessandro ",[649],{"organizationname":642,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":367,"firstname":651,"middlename":19,"lastname":652,"givennames":653,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":654},"jan michael","schulz","jan michael ",[655],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":657,"firstname":658,"middlename":19,"lastname":659,"givennames":660,"iscorresponding":347,"isprofilepublic":13,"userid":657,"email":-1,"affiliations":661},157846,"daniel","bertrand","daniel ",[662],{"organizationname":663,"countryname":545,"cityname":19,"statename":19,"zipcode":19},"hiqscreen sàrl",{"id":367,"firstname":561,"middlename":19,"lastname":665,"givennames":563,"iscorresponding":347,"isprofilepublic":347,"userid":367,"email":-1,"affiliations":666},"saxe",[667],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":669,"firstname":670,"middlename":19,"lastname":671,"givennames":672,"iscorresponding":347,"isprofilepublic":13,"userid":669,"email":-1,"affiliations":673},2733790,"eoin c.","o’connor","eoin c. ",[674],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},{"id":676,"firstname":677,"middlename":19,"lastname":678,"givennames":679,"iscorresponding":347,"isprofilepublic":13,"userid":676,"email":-1,"affiliations":680},2269471,"maria-clemencia","hernandez","maria-clemencia ",[681],{"organizationname":553,"countryname":545,"cityname":19,"statename":19,"zipcode":19},[683],{"id":684,"firstname":685,"middlename":19,"lastname":686,"givennames":687,"iscorresponding":347,"isprofilepublic":13,"userid":684,"email":-1,"affiliations":688},52072,"agenor","limon","agenor ",[689],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},[691,698,705],{"id":692,"firstname":693,"middlename":19,"lastname":694,"givennames":695,"iscorresponding":347,"isprofilepublic":13,"userid":692,"email":-1,"affiliations":696},1285968,"junzhan","jing","junzhan ",[697],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},{"id":699,"firstname":700,"middlename":19,"lastname":701,"givennames":702,"iscorresponding":347,"isprofilepublic":13,"userid":699,"email":-1,"affiliations":703},1380630,"azar","omrani","azar ",[704],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},{"id":706,"firstname":707,"middlename":19,"lastname":708,"givennames":709,"iscorresponding":347,"isprofilepublic":13,"userid":706,"email":-1,"affiliations":710},39673,"hansen","wang","hansen ",[711],{"organizationname":19,"countryname":19,"cityname":19,"statename":19,"zipcode":19},{"id":115,"slug":117,"name":116,"shortname":713,"electronicissn":714,"field":715,"specialtyid":28,"journalsectionpaths":717},"front. pharmacol.","1663-9812",{"id":716,"domainid":370},62,[718],{"section":719},{"id":152,"name":153,"slug":154,"specialtyid":720},762,{"views":722,"downloads":723,"citations":367},2218,442,16,"volume 16 - 2025",[],{"titlehtml":728,"fulltexthtml":729,"menuhtml":730},"preclinical pharmacology of alogabat: a novel gaba\u003csub>a\u003c/sub>-&#x003b1;5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gaba\u003csub>a\u003c/sub> signaling","\u003cdiv class=\"journalabstract\">\u003ca id=\"h1\" name=\"h1\">\u003c/a>\u003cdiv class=\"authors\">\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/3088634\" class=\"user-id-3088634\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/3088634/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"giuseppe cecere&#x;\">giuseppe cecere\u003c/a>\u003csup>1\u003c/sup>\u003csup>&#x02020;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/3064665\" class=\"user-id-3064665\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/3064665/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"theresa m. ballard&#x;&#x;\">theresa m. ballard\u003c/a>\u003csup>2\u003c/sup>\u003csup>&#x02020;\u003c/sup>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"frederic knoflach&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">frederic knoflach\u003csup>2\u003c/sup>\u003csup>&#x02020;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"michael honer\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">michael honer\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/81732\" class=\"user-id-81732\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/81732/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"joerg f. hipp\">joerg f. hipp\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2412410\" class=\"user-id-2412410\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2412410/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"pilar garces\">pilar garces\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/13967\" class=\"user-id-13967\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/13967/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"thomas mueggler\">thomas mueggler\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/577428\" class=\"user-id-577428\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/577428/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"basil k&#xfc;nnecke\">basil k&#x000fc;nnecke\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"andreas bruns\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">andreas bruns\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"eric p. prinssen\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">eric p. prinssen\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"philipp schoenenberger\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">philipp schoenenberger\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2424959\" class=\"user-id-2424959\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2424959/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"philipp janz\">philipp janz\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"roger redondo\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">roger redondo\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"barbara biemans&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">barbara biemans\u003csup>2\u003c/sup>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"henner knust\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">henner knust\u003csup>1\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2264913\" class=\"user-id-2264913\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2264913/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"andr&#xe;s olivares-morales\">andr&#x000e9;s olivares-morales\u003c/a>\u003csup>3\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/1172717\" class=\"user-id-1172717\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1172717/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"alessandro brigo\">alessandro brigo\u003c/a>\u003csup>3\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"jan michael schulz\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">jan michael schulz\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/157846\" class=\"user-id-157846\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/157846/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"daniel bertrand\">daniel bertrand\u003c/a>\u003csup>4\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"michael saxe&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">michael saxe\u003csup>2\u003c/sup>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2733790\" class=\"user-id-2733790\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2733790/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"eoin c. o&#x;connor\">eoin c. o&#x02019;connor\u003c/a>\u003csup>2\u003c/sup>\u003c/span>\u003cspan class=\"author-wrapper notranslate\">\u003ca href=\"https://loop.frontiersin.org/people/2269471\" class=\"user-id-2269471\">\u003cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2269471/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"maria-clemencia hernandez&#xa;\">maria-clemencia hernandez\u003c/a>\u003csup>2\u003c/sup>&#x0002a;\u003c/span>\u003c/div>\u003cul class=\"notes\">\u003cli>\u003cspan>\u003csup>1\u003c/sup>\u003c/span>medicinal chemistry, roche pharmaceutical research and early development, roche innovation center basel, basel, switzerland\u003c/li>\u003cli>\u003cspan>\u003csup>2\u003c/sup>\u003c/span>neuroscience and rare diseases, roche pharmaceutical research and early development, roche innovation center basel, basel, switzerland\u003c/li>\u003cli>\u003cspan>\u003csup>3\u003c/sup>\u003c/span>pharmaceutical sciences, roche pharmaceutical research and early development, roche innovation center basel, basel, switzerland\u003c/li>\u003cli>\u003cspan>\u003csup>4\u003c/sup>\u003c/span>hiqscreen s&#x000e0;rl, v&#x000e9;senaz, switzerland\u003c/li>\u003c/ul>\u003cp class=\"mb0\">\u003cb>background:\u003c/b> alterations in the gabaergic system contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder (asd) and angelman syndrome (as), particularly in cases involving large deletions in the 15q11&#x02013;13 region. positive modulation of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors may provide a novel therapeutic approach without the typical side effects associated with non-selective gaba\u003csub>a\u003c/sub> positive allosteric modulators such as diazepam.\u003c/p>\u003cp class=\"mb0\">\u003cb>methods:\u003c/b> alogabat was assessed for binding and functional activity at gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 receptors \u003cem>in vitro\u003c/em> and in electrophysiological studies using hippocampal slices. \u003cem>in vivo\u003c/em> studies in rodents included receptor occupancy (ro) using a selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 tracer (autoradiography), pharmacological mri, and electroencephalography (eeg). alogabat was evaluated for its effects on the repetitive behavior phenotype in btbr and contactin-associated protein-like 2 (cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup>) knockout mice, seizure models, cognitive performance in rats, and rotarod performance following combination treatment with diazepam.\u003c/p>\u003cp class=\"mb0\">\u003cb>results:\u003c/b> alogabat is a potent positive allosteric modulator of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors, with binding and functional selectivity. receptor occupancy studies provided direct proof of dose-dependent target engagement. functional circuit modulation was demonstrated by dose-dependent regional perfusion changes in pharmacological mri and changes in eeg theta- and beta-band power in rats. at &#x0003e;50% gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor occupancy, alogabat normalized elevated self-grooming behavior in both cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> and btbr mice and exhibited antiepileptic activity in rats. alogabat did not impair cognition in wildtype rats at gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor occupancy up to 75%, although impairment occurred at higher doses, probably due to increased activity at other receptor subtypes and/or saturation of &#x003b1;5 receptors. alogabat did not worsen diazepam-induced impairment on the rotarod test.\u003c/p>\u003cp class=\"mb0\">\u003cb>conclusion:\u003c/b> alogabat showed beneficial effects in mouse models relevant to neurodevelopmental disorders and anti-seizure activity at doses that did not produce cognitive, sedative, or motoric side effects.\u003c/p>\u003cdiv class=\"clear\">\u003c/div>\u003c/div>\u003cdiv class=\"journalfulltext\">\u003ca id=\"h2\" name=\"h2\">\u003c/a>\u003ch2>1 introduction\u003c/h2>\u003cp class=\"mb15\">alterations in the gabaergic system, the main inhibitory neurotransmitter system in the brain, may contribute to the pathophysiology of neurodevelopmental disorders (ndds), such as autism spectrum disorder (asd) and angelman syndrome (as). asd is a complex, heterogeneous ndd with both genetic and environmental factors (\u003ca href=\"#b7\">bourgeron, 2015\u003c/a>) contributing to aberrant changes in brain growth, neuronal development, and functional connectivity (\u003ca href=\"#b18\">dhossche et al., 2002\u003c/a>; \u003ca href=\"#b55\">pizzarelli and cherubini, 2011\u003c/a>; \u003ca href=\"#b8\">braat and kooy, 2015\u003c/a>; \u003ca href=\"#b58\">robertson et al., 2016\u003c/a>). asd is characterized by two core domains: impairments in social interaction and communication and the presence of repetitive or restricted behaviors, interests, or activities (\u003ca href=\"#b3\">american psychiatric association, 2008\u003c/a>). there are a range of comorbid conditions, including irritability, depression, anxiety, attention deficits, obsessive-compulsive symptoms, seizures, and sleep disruption. as is a rare genetic ndd with a prevalence of 1 in 12,000 to 20,000 births (\u003ca href=\"#b38\">luk and lo, 2016\u003c/a>; \u003ca href=\"#b44\">mertz et al., 2013\u003c/a>). individuals with as often present with autistic features, severe intellectual disability, microcephaly, speech impairment, bursts of laughter, sleep problems, movement disorders, and epilepsy (\u003ca href=\"#b12\">buiting, 2010\u003c/a>; \u003ca href=\"#b35\">kalsner and chamberlain, 2015\u003c/a>).\u003c/p>\u003cp class=\"mb15\">gaba\u003csub>a\u003c/sub> receptors are ligand-gated chloride channels. there are 19 genes encoding gaba\u003csub>a\u003c/sub> receptor subunits that assemble as pentamers, with the most common stoichiometry being two &#x003b1;, two &#x003b2;, and one &#x003b3; subunit. gaba\u003csub>a\u003c/sub> subunit combinations give rise to functional, circuit, and behavioral specificity (\u003ca href=\"#b65\">sieghart, 2006\u003c/a>; \u003ca href=\"#b73\">vithlani et al., 2011\u003c/a>). gaba\u003csub>a\u003c/sub> receptors that contain the &#x003b1;5 subunit (gaba\u003csub>a\u003c/sub>-&#x003b1;5) are of particular interest due to their restricted pattern of expression and unique physiological and pharmacological properties (\u003ca href=\"#b69\">sur et al., 1999\u003c/a>; \u003ca href=\"#b46\">mohler, 2011\u003c/a>). in humans, gaba\u003csub>a\u003c/sub> receptors containing the &#x003b1;5 subunit are preferentially localized in the hippocampus, prefrontal cortex, nucleus accumbens, amygdala, insular cortex, anterior cingulate, and cingulate cortex&#x02014;key regions believed to be involved in the neuropathology and pathophysiology of asd (\u003ca href=\"#b42\">mendez et al., 2013\u003c/a>; \u003ca href=\"#b48\">myers et al., 2017\u003c/a>). the \u003cem>gabra5\u003c/em> gene has been proposed as a candidate gene for asd (\u003ca href=\"#b15\">delong, 2007\u003c/a>; \u003ca href=\"#b45\">mesbah-oskui et al., 2017\u003c/a>; \u003ca href=\"#b74\">warrier et al., 2013\u003c/a>; \u003ca href=\"#b19\">di nanni et al., 2019\u003c/a>), suggesting decreased gabaergic inhibition in a subpopulation of autistic individuals. mutations involving the gaba\u003csub>a\u003c/sub> receptor subunit genes \u003cem>gabra5\u003c/em>, \u003cem>gabrb3\u003c/em>, and \u003cem>gabrg3\u003c/em> (encoding the &#x003b1;5, &#x003b2;3, and &#x003b3;3 subunits) found on chromosomal region 15q11&#x02013;q13 have been associated with ndds including as, epilepsy, and prader&#x02013;willi syndrome in addition to asd (\u003ca href=\"#b32\">hogart et al., 2010\u003c/a>; \u003ca href=\"#b61\">sanders, 2015\u003c/a>). as is predominantly caused by the loss of function of the maternally inherited \u003cem>ube3a\u003c/em> gene; however, approximately 75% of individuals with as carry a large deletion of the maternal 15q11&#x02013;q13 chromosomal region. clinical studies have shown that individuals with as who have large deletions (deletion as) exhibit more severe symptoms than those in whom \u003cem>ube3a\u003c/em> is the only gene affected, suggesting that the \u003cem>gabra5\u003c/em>, \u003cem>gabrb3\u003c/em>, and \u003cem>gabrg3\u003c/em> genes are relevant to the etiology of the disease.\u003c/p>\u003cp class=\"mb15\">imaging studies using pet and magnetic resonance spectroscopy have shown reduced gaba\u003csub>a\u003c/sub> receptor binding in the superior and medial frontal cortex (\u003ca href=\"#b47\">mori et al., 2012\u003c/a>) and reduced gaba levels in individuals with asd (\u003ca href=\"#b58\">robertson et al., 2016\u003c/a>; \u003ca href=\"#b28\">gaetz et al., 2014\u003c/a>; \u003ca href=\"#b59\">rojas et al., 2014\u003c/a>; \u003ca href=\"#b57\">puts et al., 2017\u003c/a>). postmortem studies have shown reduced numbers of inhibitory interneurons (\u003ca href=\"#b20\">dufour et al., 2023\u003c/a>), reduced expression of gaba\u003csub>a\u003c/sub> receptor subunits (\u003ca href=\"#b16\">delorey, 2005\u003c/a>; \u003ca href=\"#b1\">abrahams and geschwind, 2008\u003c/a>), and reduced levels of the gaba-synthesizing enzymes such as glutamic acid decarboxylase (gad) 65 and 67 (\u003ca href=\"#b21\">fatemi et al., 2002\u003c/a>). there is increasing evidence from genetic, environmental, and phenotypic rodent models relevant to asd indicating that gabaergic circuit dysfunctions contribute to autism-like phenotypes (\u003ca href=\"#b27\">fukuda et al., 2005\u003c/a>; \u003ca href=\"#b13\">chao et al., 2010\u003c/a>; \u003ca href=\"#b6\">banerjee et al., 2013\u003c/a>). such deficits may result from multiple causes, including a reduced number of gabaergic interneurons, altered interneuron function, impaired gaba\u003csub>a\u003c/sub> receptor trafficking to the membrane, reduced expression of gaba\u003csub>a\u003c/sub> receptor subunits, and reduced gaba uptake function of gat-1 in neurons (\u003ca href=\"#b49\">nakamura et al., 2016\u003c/a>; \u003ca href=\"#b50\">orefice et al., 2016\u003c/a>; \u003ca href=\"#b43\">mermer et al., 2021\u003c/a>). supportive evidence is provided by the observation of autism-like behaviors in both gaba\u003csub>a\u003c/sub>-&#x003b1;5 and &#x003b2;3 subunit knockout mice (\u003ca href=\"#b77\">zurek et al., 2016\u003c/a>; \u003ca href=\"#b17\">delorey et al., 2008\u003c/a>). regarding possible therapeutic approaches, enhancement of the gaba\u003csub>a\u003c/sub> receptor activity by non-selective benzodiazepines has been shown to ameliorate autism-like behavioral deficits in mouse models; however, due to sedation that is likely mediated by the activation of the gaba\u003csub>a\u003c/sub>-&#x003b1;1 subtype, very narrow therapeutic margins were observed (\u003ca href=\"#b30\">han et al., 2012\u003c/a>; \u003ca href=\"#b29\">han et al., 2014\u003c/a>; \u003ca href=\"#b37\">lim et al., 2017\u003c/a>). interestingly, a recent study showed that a gaba\u003csub>a\u003c/sub>-&#x003b1;5 positive allosteric modulator (pam), sh-053-2&#x02032;f-r-ch3, attenuated social and cognitive deficits in male rats exposed to valproic acid \u003cem>in utero\u003c/em>, a rat model relevant to autism (\u003ca href=\"#b68\">souza et al., 2024\u003c/a>).\u003c/p>\u003cp class=\"mb15\">the aim of the current study was to determine whether a selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 pam, alogabat (also known as ro7017773 or rg7816), would produce beneficial effects in animal models relevant to autism-like repetitive behavior&#x02014;specifically btbr mice (\u003ca href=\"#b40\">mcfarlane et al., 2008\u003c/a>) and contactin-associated protein-like 2 [cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup>] homozygous knockout mice (\u003ca href=\"#b51\">penagarikano et al., 2011\u003c/a>)&#x02014;and anti-seizure activity, without the typical side effects of non-selective gaba\u003csub>a\u003c/sub> pams, such as sedation and cognitive impairment. furthermore, target engagement was assessed by \u003cem>in vivo\u003c/em> receptor occupancy (ro) and pharmacological mri (phmri) in rodents, and an electroencephalography (eeg) study in rats was undertaken to identify a putative pharmacodynamic readout for future clinical trials.\u003c/p>\u003ca id=\"h3\" name=\"h3\">\u003c/a>\u003ch2>2 materials and methods\u003c/h2>\u003cp class=\"mb15\">further information for each method listed below can be found in the \u003ca href=\"#sm1\">supplementary material\u003c/a>.\u003c/p>\u003ca id=\"h3-1\" name=\"h3-1\">\u003c/a>\u003ch3 class=\"pt0\">2.1 materials\u003c/h3>\u003cp class=\"mb0\">alogabat [ro7017773; c\u003csub>21\u003c/sub>h\u003csub>23\u003c/sub>n\u003csub>5\u003c/sub>o\u003csub>4\u003c/sub>; 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl) methoxy)-n-(tetrahydropyran-4-yl)pyridazine-3-carboxamide (iupac name); molecular weight: 409.44&#x000a0;gmol\u003csup>&#x02212;1\u003c/sup>] was synthesized at f.hoffmann-la roche ag, switzerland [\u003ca href=\"#f1\">figure 1a\u003c/a>; see example 8 in \u003ca href=\"#b10\">buettelmann et al., 2018\u003c/a>]. the discovery of alogabat and the related chemical series will be disclosed in future publications. diazepam, l-655,708, [\u003csup>3\u003c/sup>h]flumazenil, [\u003csup>3\u003c/sup>h]l-655,708, and [\u003csup>3\u003c/sup>h]ro0154513 were synthesized at f.hoffmann-la roche ag, switzerland.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 1\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" name=\"figure1\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg\" alt=\"www.frontiersin.org\" id=\"f1\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 1\u003c/b>. \u003cem>in vitro\u003c/em> pharmacology of alogabat. \u003cb>(a)\u003c/b> chemical structure of alogabat (ro7017773; c21h23n5o4); 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl) methoxy)-n-(tetrahydropyran-4-yl)pyridazine-3-carboxamide (iupac name); molecular weight, 409.44&#x000a0;gmol\u003csup>&#x02212;1\u003c/sup>. \u003cb>(b)\u003c/b> concentration-response curves of alogabat in [\u003csup>3\u003c/sup>h]flumazenil competition-binding assays with membranes expressing different rat recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (\u003cem>n\u003c/em> &#x0003d; 10&#x02013;20/concentration). \u003cb>(c)\u003c/b> concentration-response curves of the effects of alogabat in hek293 cells expressing different rat recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (\u003cem>n\u003c/em> &#x0003d; 4&#x02013;5/concentration). data in the graphs are shown as the mean (symbols) &#x000b1; sem (error bars). error bars smaller than the symbol size are not shown. \u003cb>(d)\u003c/b> isoguvacine concentration-response curves obtained in the presence and absence of alogabat in rat hippocampal slices. the points represent the mean values &#x000b1; sem of three slices. the sigmoidal curves were fit through these points. \u003cb>(e)\u003c/b> the ppi of ps was measured in the absence (control) and presence of alogabat at 0.3&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 3 slices) and 1&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 6 slices). ps1 and ps2 are the responses induced by the first and second stimulus, respectively. the data are normalized to the amplitude of ps1 and presented as the mean &#x000b1; sem.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h3-2\" name=\"h3-2\">\u003c/a>\u003ch3 class=\"pt0\">2.2 \u003cem>in vitro\u003c/em> experiments\u003c/h3>\u003ca id=\"h7-2-1\" name=\"h7-2-1\">\u003c/a>\u003ch4>2.2.1 gaba\u003csub>a\u003c/sub> receptor radioligand binding assays\u003c/h4>\u003cp class=\"mb0\">the affinity of alogabat for rat and human gaba\u003csub>a\u003c/sub> receptors containing &#x003b1;5, &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits was measured by [\u003csup>3\u003c/sup>h]flumazenil competition-binding assays with membranes expressing different rat recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (\u003cem>n\u003c/em> &#x0003d; 10&#x02013;20/concentration) and for human &#x003b1;4 and &#x003b1;6 by [\u003csup>3\u003c/sup>h]ro0154513, as previously described (\u003ca href=\"#b4\">ballard et al., 2009\u003c/a>; \u003ca href=\"#b31\">hipp et al., 2021\u003c/a>).\u003c/p>\u003ca id=\"h7-2-2\" name=\"h7-2-2\">\u003c/a>\u003ch4>2.2.2 gaba\u003csub>a\u003c/sub> receptor electrophysiological studies\u003c/h4>\u003cp class=\"mb0\">alogabat was tested for functional activity on four different cloned rat and human gaba\u003csub>a\u003c/sub> receptor subtypes (\u003ca href=\"#b10\">buettelmann et al., 2018\u003c/a>), namely, &#x003b1;1&#x003b2;2&#x003b3;2, &#x003b1;2&#x003b2;3&#x003b3;2, &#x003b1;3&#x003b2;3&#x003b3;2, and &#x003b1;5&#x003b2;3&#x003b3;2. ion currents were induced by gaba concentrations that evoked approximately 20% of the maximal response (\u003cem>n\u003c/em> &#x0003d; 4&#x02013;5/concentration). the following concentrations of gaba were used: 1&#x000a0;&#x000b5;m for &#x003b1;1&#x003b2;2&#x003b3;2, 10&#x000a0;&#x000b5;m &#x003b1;2&#x003b2;3&#x003b3;2, 10&#x000a0;&#x000b5;m for &#x003b1;3&#x003b2;3&#x003b3;2, and 3&#x000a0;&#x000b5;m for &#x003b1;5&#x003b2;3&#x003b3;2 receptor subtype.\u003c/p>\u003cp class=\"mb0\">alogabat was also tested for functional activity on native gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors in rat hippocampal slices: modulation of isoguvacine-induced population spikes (\u003ca href=\"#b4\">ballard et al., 2009\u003c/a>) and paired-pulse inhibition (ppi) (\u003ca href=\"#b76\">xie and tietz, 1991\u003c/a>). population spikes (pss) were recorded every 30&#x000a0;s by the stimulation of the schaffer collaterals, and isoguvacine was applied consecutively and in increasing concentrations for at least 4&#x000a0;min to the slices (control). after the washout of isoguvacine, alogabat (300&#x000a0;nm) was added to the bath perfusion, and a new isoguvacine concentration-response curve was obtained (alogabat). the ps amplitudes were normalized to the control ps obtained before the first application of isoguvacine and were fitted individually for each slice (\u003cem>n\u003c/em> &#x0003d; 3 slices).\u003c/p>\u003cp class=\"mb0\">the ppi of ps was measured in the absence (control) and presence of alogabat at 0.3&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 3 slices from one animal) and 1&#x000a0;&#x000b5;m (\u003cem>n\u003c/em> &#x0003d; 6 slices from two animals). the paired-pulse protocol consisted of two stimuli timely spaced by 20&#x000a0;ms, which were applied at the schaffer collaterals in rat hippocampal slices. we used a low number of animals based on our experience with the assay, which is highly robust and reproducible, and in alignment with our commitment to reducing the number of animals used.\u003c/p>\u003ca id=\"h7-2-3\" name=\"h7-2-3\">\u003c/a>\u003ch4>2.2.3 selectivity screening\u003c/h4>\u003cp class=\"mb0\">the selectivity of alogabat (10&#x000a0;&#x000b5;m) over more than 70 receptors was assessed by radioligand binding studies conducted using eurofins cerep sa (celle l&#x000e9;vescault, france), following the methods described on \u003ca href=\"http://www.eurofinsdiscoveryservices.com/\">www.eurofinsdiscoveryservices.com\u003c/a>.\u003c/p>\u003ca id=\"h3-3\" name=\"h3-3\">\u003c/a>\u003ch3 class=\"pt0\">2.3 \u003cem>in vivo\u003c/em> experiments\u003c/h3>\u003ca id=\"h7-3-1\" name=\"h7-3-1\">\u003c/a>\u003ch4>2.3.1 ethics approval\u003c/h4>\u003cp class=\"mb0\">experiments performed at f.hoffmann-la roche ag (basel, switzerland) complied with the swiss federal and cantonal laws on animal research and aaalac regulations and received prior approval from the cantonal veterinary office. the eeg study was conducted at brains online (ca, united states) in accordance with the guide for the care and use of laboratory animals (national research council 2011) after gaining approval from the institutional animal care and use committee. the pentylenetetrazole (ptz) and maximal electroshock (mes) tests were conducted at vivocore inc., canada, which is a facility licensed by the ontario ministry of agriculture, food, and rural affairs and accredited by the canadian council on animal care. all \u003cem>in vivo\u003c/em> studies are reported in compliance with the arrive guidelines (\u003ca href=\"#b52\">percie du sert et al., 2020\u003c/a>).\u003c/p>\u003ca id=\"h7-3-2\" name=\"h7-3-2\">\u003c/a>\u003ch4>2.3.2 animals\u003c/h4>\u003cp class=\"mb0\">all animals were group-housed in holding rooms at controlled temperature and humidity under a 12&#x000a0;h light/dark cycle and were allowed to acclimate for at least 7&#x000a0;days. twenty-six male wistar rats (charles river, germany; &#x0223c;160&#x000a0;g) and sixteen male cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (bred at roche basel; 18&#x02013;22&#x000a0;g) were used in receptor occupancy studies. thirty-two male fischer rats (charles river, germany) were assessed in mri experiments (&#x0223c;250&#x000a0;g). seventeen male wistar rats (envigo, united states) were assessed in eeg experiments. one hundred male btbr mice (bred in roche basel) were assessed in grooming and open-field tests (n &#x0003d; 60, &#x0223c;30&#x000a0;g) and for digging behavior (n &#x0003d; 40, &#x0223c;30&#x000a0;g). fifty-seven male cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (bred in roche basel; 5&#x02013;6&#x000a0;weeks) and wildtype littermates (n &#x0003d; 15) were assessed in grooming and open-field tests. one hundred male sprague&#x02013;dawley rats (charles river, canada) were used to evaluate antiepileptic effects in the ptz (70&#x02013;100&#x000a0;g, n &#x0003d; 40) and mes (&#x0003c;50&#x000a0;g n &#x0003d; 60) tests. forty-eight male sprague&#x02013;dawley rats (charles river, france) were used in the rotarod test (&#x0223c;170&#x02013;200&#x000a0;g). one hundred and forty-one male lister hooded (lh) rats (charles river, germany) were used in the cognition tests: 5-choice serial reaction time (5-csrt) task (n &#x0003d; 11, &#x0223c;400&#x000a0;g); continuous performance test (cpt; n &#x0003d; 11, &#x0223c;400&#x000a0;g); paired associates learning (pal) task (n &#x0003d; 12, &#x0223c;400&#x000a0;g); context fear conditioning (n &#x0003d; 67, &#x0223c;250&#x000a0;g); and morris water maze (n &#x0003d; 40, 350&#x02013;400&#x000a0;g).\u003c/p>\u003ca id=\"h7-3-3\" name=\"h7-3-3\">\u003c/a>\u003ch4>2.3.3 alogabat treatment\u003c/h4>\u003cp class=\"mb0\">alogabat was formulated in 2% hydroxypropyl cellulose in water (or 0.3% tween 80 in saline for \u003cem>in vivo\u003c/em> occupancy and grooming/digging experiments). the administration volume was 10&#x000a0;ml/kg (mice) and 5&#x000a0;ml/kg (rats). each dose was expressed as the weight of the base. alogabat was administered with a pre-treatment time of 30&#x000a0;min in mice and 60&#x000a0;min in rats (except for the eeg study), based on pharmacokinetic data indicating the time of maximal drug plasma concentration. treatment groups were assigned randomly. dose groups were provided as coded vials to allow blinded assessment during the conduct of each experiment. to minimize potential confounders regarding the time of day for behavioral testing, animals were split into separate cohorts (balanced for treatment groups) and tested during the same period.\u003c/p>\u003ca id=\"h7-3-4\" name=\"h7-3-4\">\u003c/a>\u003ch4>2.3.4 receptor occupancy studies\u003c/h4>\u003ch5>2.3.4.1 \u003cem>in vivo\u003c/em> occupancy in rats\u003c/h5>\u003cp class=\"mb0\">male wistar rats (n &#x0003d; 26, &#x0223c;160&#x000a0;g) were administered vehicle or alogabat (0.3, 1, 3, 10, 30, and 100&#x000a0;mg/kg, intraperitoneally [i.p.], n &#x0003d; 3/group) or the gaba\u003csub>a\u003c/sub>-&#x003b1;5 blocker l-655,708 at 10&#x000a0;mg/kg i.p. (n &#x0003d; 2). fifteen minutes later, the gaba\u003csub>a\u003c/sub>-&#x003b1;5 radioligand [\u003csup>3\u003c/sup>h]ro0154513 was administered intravenously (i.v.) to assess ro (\u003ca href=\"#b4\">ballard et al., 2009\u003c/a>; \u003ca href=\"#b31\">hipp et al., 2021\u003c/a>). non-specific binding was determined by pre-treatment with the established gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor blocker l-655,708 (10&#x000a0;mg/kg i.p.; n &#x0003d; 2).\u003c/p>\u003ch5>2.3.4.2 \u003cem>ex vivo\u003c/em> occupancy in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h5>\u003cp class=\"mb0\">cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (\u003ca href=\"#b51\">penagarikano et al., 2011\u003c/a>) (n &#x0003d; 16, 18&#x02013;22&#x000a0;g) were administered the vehicle or alogabat (30, 60, and 100&#x000a0;mg/kg) i.p. (n &#x0003d; 4/group), and ro was assessed in brain sections with the highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 radioligand, [\u003csup>3\u003c/sup>h]l-655,708, 30&#x000a0;min post-administration.\u003c/p>\u003ca id=\"h7-3-5\" name=\"h7-3-5\">\u003c/a>\u003ch4>2.3.5 pharmacological mri in rats\u003c/h4>\u003cp class=\"mb0\">male fischer rats (n &#x0003d; 32, &#x0223c;250&#x000a0;g) were administered vehicle or alogabat (3, 10, and 30&#x000a0;mg/kg) i.p. (n &#x0003d; 8/dose). phmri was performed under medetomidine sedation in a small-animal scanner (4.7t/40&#x000a0;cm; bruker biospin, germany), and blood perfusion was analyzed according to previously published procedures (\u003ca href=\"#b9\">bruns et al., 2009\u003c/a>). fifteen minutes after drug treatment, rats were initially anesthetized using isoflurane (4%) in the carrier gas composed of oxygen and air (1:5), supplied to the spontaneously breathing animals in an inhalation box. upon the induction of anesthesia, a subcutaneous (s.c.) bolus injection of 0.2&#x000a0;mg/kg (1&#x000a0;ml/kg) of medetomidine prepared from 1:5 diluted dormilan\u003csup>&#x000ae;\u003c/sup> was administered, and the animal was transferred onto a rat cradle for inserting an s.c. catheter and starting continuous infusion of 1:10 diluted dormilan\u003csup>&#x000ae;\u003c/sup> (medetomidine) at a dose of 0.1&#x000a0;mg/kg/h (1&#x000a0;ml/kg/h). the head was immobilized in a stereotaxic frame. respiratory rate, body temperature, and o\u003csub>2\u003c/sub> and co\u003csub>2\u003c/sub> levels in inhaled and exhaled air were continuously monitored using a powerlab data acquisition system (adinstruments, spechbach, germany). body temperature was maintained at 37&#x000b0;c with a feedback-regulated electric heating blanket. immediately after the last imaging assessment, rats were euthanized by decapitation under anesthesia, and plasma samples were collected at approximately 40&#x000a0;min post-administration of alogabat. images were processed and analyzed using in-house developed software written in idl (rsi, boulder, co, united states) and matlab (the mathworks inc., natick, ma, united states).\u003c/p>\u003ca id=\"h7-3-6\" name=\"h7-3-6\">\u003c/a>\u003ch4>2.3.6 eeg in rats\u003c/h4>\u003cp class=\"mb0\">male wistar rats (n &#x0003d; 17) were surgically prepared with wireless implanted transmitters to enable simultaneous recording of eeg, hippocampal (ca3) local field potential (lfp), and emg. rats were anesthetized using isoflurane (2%, 800&#x000a0;ml/min o2). bupivacaine/epinephrine was used for local analgesia, while finadyne or carprofen was used for peri-/post-operative analgesia. amoxicillin was used as an antibiotic. the animals were placed in a stereotaxic frame (kopf instruments, united states). a subcutaneous pocket was created near the dorsal flank, into which a transmitter (f50-eee, data sciences international, physio tel f50-eee small animal cns telemetry; three bipolar channels, biopotential lead, outer diameter 0.3&#x000a0;mm) was inserted. the transmitter included three bipolar channels: channel 1 (eeg): two screws in the left hemisphere (frontal: 11&#x000a0;mm anterior and 2.5&#x000a0;mm lateral to bregma; central: 3&#x000a0;mm anterior and 3.5&#x000a0;mm lateral to lambda); channel 2 (lfp): a single wire electrode targeting the ca3 region of the right hippocampus; and channel 3 (emg): electrodes placed in the neck muscle for recording emg activity, aiding in sleep stage classification.\u003c/p>\u003cp class=\"mb0\">after a 2-week recovery, rats were administered the vehicle or alogabat (10&#x000a0;mg/kg) using a cross-over design (1-week interval). if the setup allowed, the positive control diazepam (2&#x000a0;mg/kg) was assessed. all drugs were administered i.v. via an implanted cannula so that brain exposure was expected within a few minutes of administration. eeg spectral power was analyzed quantitatively up to 1&#x000a0;h post-administration. only animals with clean eeg recordings were included in the analysis. eeg data in the awake state were used for the analyses reported in this study. we first investigated the effects on power over predefined theta and beta power ranges, defined \u003cem>a priori\u003c/em> as 6&#x02013;10&#x000a0;hz and 20&#x02013;30&#x000a0;hz, respectively, based on previous studies with gabaa drugs (\u003ca href=\"#b72\">visser et al., 2003\u003c/a>; \u003ca href=\"#b71\">van lier et al., 2004\u003c/a>). then, we evaluated frequency-specific effects across the 2&#x02013;128&#x000a0;hz range.\u003c/p>\u003ca id=\"h7-3-7\" name=\"h7-3-7\">\u003c/a>\u003ch4>2.3.7 grooming behavior and open-field test in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h4>\u003cp class=\"mb0\">male btbr mice (n &#x0003d; 60, &#x0223c;30&#x000a0;g) were pre-treated with the vehicle or alogabat at 30, 60, 90, and 120&#x000a0;mg/kg i.p. (n &#x0003d; 12/dose). male cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice (n &#x0003d; 57, 5&#x02013;6&#x000a0;weeks) and wildtype littermates (n &#x0003d; 15) received sub-chronic treatment (8&#x02013;10&#x000a0;days) with the vehicle or alogabat at 30, 60, and 100&#x000a0;mg/kg i.p. (n &#x0003d; 14&#x02013;15/dose). spontaneous locomotor activity was assessed in both groups of mice for 1&#x000a0;h in an open field (42 &#x000d7; 42 &#x000d7; 30.5&#x000a0;cm; 20 lux at the center of the arena) with a small amount of sawdust bedding. movement of the animal was detected by interruptions in an array of photobeams from horizontally located infrared sources placed around the open field, measured using a versamax system (accuscan instruments inc., columbus, oh, united states). activity was measured as the distance traveled (cm).\u003c/p>\u003cp class=\"mb0\">one week later, each mouse was placed into a type-ii cage (21.5 &#x000d7; 15.5 &#x000d7; 13.0&#x000a0;cm; 40 lux) for 5&#x000a0;min habituation, and then the cumulative time (s) spent grooming during 10&#x000a0;min was recorded manually by a blinded observer. distance traveled (cm) during the session was measured using a video tracking system (ethovision, noldus information technology, netherlands). plasma samples were collected from btbr mice 1&#x000a0;week after testing and 30&#x000a0;min after treatment (\u003cem>n\u003c/em> &#x0003d; 6/dose). plasma samples were collected from cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice 1&#x000a0;day later and 30&#x000a0;min after treatment (\u003cem>n\u003c/em> &#x0003d; 4/dose).\u003c/p>\u003ca id=\"h7-3-8\" name=\"h7-3-8\">\u003c/a>\u003ch4>2.3.8 digging behavior in btbr mice\u003c/h4>\u003cp class=\"mb0\">a separate group of male btbr mice (n &#x0003d; 40, &#x0223c;30&#x000a0;g) were pre-treated with vehicle or alogabat at 30, 60, and 100&#x000a0;mg/kg i.p. (n &#x0003d; 10/dose) and were placed into a small circular dish (d &#x0003d; 10&#x000a0;cm) filled with fresh thick sawdust located in the middle of a clean type-ii cage (21.5 &#x000d7; 15.5 &#x000d7; 13.0&#x000a0;cm; 40 lux). the cumulative time (s) spent digging over 5&#x000a0;min was recorded manually by a blinded observer. the distance traveled (cm) and speed were also measured in the arena, outside the dish (ethovision, noldus information technology, netherlands). plasma samples were collected immediately after the digging test, i.e., 35&#x02013;40&#x000a0;min post-administration (\u003cem>n\u003c/em> &#x0003d; 3/dose).\u003c/p>\u003ca id=\"h7-3-9\" name=\"h7-3-9\">\u003c/a>\u003ch4>2.3.9 evaluation of antiepileptic effects in rats\u003c/h4>\u003cp class=\"mb0\">vehicle or alogabat (5, 15, or 30&#x000a0;mg/kg) was administered p.o. (n &#x0003d; 8/dose) and assessed for seizures induced by (1) subcutaneous (s.c.) ptz and (2) the maximum electrical stimulus (mes) model in male sprague&#x02013;dawley rats (ptz: 70&#x02013;100&#x000a0;g, n &#x0003d; 40; mes: &#x0003c;50&#x000a0;g n &#x0003d; 60, charles river, canada). diazepam (synthesized at f.hoffmann-la roche ag) was included in each experiment as a positive control and administered at 3&#x000a0;mg/kg i.p., 30&#x000a0;min prior to testing. immediately following testing, a terminal blood sample was collected under anesthesia.\u003c/p>\u003ch5>2.3.9.1 pentylenetetrazole test\u003c/h5>\u003cp class=\"mb0\">following the designated pre-treatment time, ptz was administered at 75&#x000a0;mg/kg s.c. animals were transferred to a single cage and monitored closely for the onset of clonic seizure, and the percentage of each group showing seizures was recorded. protection was defined as the complete absence of clonic seizure, including forelimb clonus, over the 30&#x000a0;min observation period.\u003c/p>\u003ch5>2.3.9.2 maximal electroshock test\u003c/h5>\u003cp class=\"mb0\">following the designated pre-treatment time, rats received maximal electroshock (mes: 150&#x000a0;ma, 0.2&#x000a0;s duration, 60&#x000a0;hz) via corneal electrodes moistened with saline (shock simulator type 221; harvard apparatus). due to inconsistency in responses by rats to this type of stimuli, all test animals (n &#x0003d; 60) were subjected to two screening sessions on two separate days, and 40 rats were selected based on their reliability to have tonic seizures. drug testing was conducted on the third day, during which the rats received the standard maximal electroshock, and the presence or absence of a tonic seizure was recorded and expressed as the percentage of animals in each group that showed seizures. protection was defined as the absence of a full tonic seizure within 15&#x000a0;s of stimulus delivery.\u003c/p>\u003ca id=\"h7-3-10\" name=\"h7-3-10\">\u003c/a>\u003ch4>2.3.10 combination with diazepam on rotarod performance in rats\u003c/h4>\u003cp class=\"mb0\">forty-eight male sprague&#x02013;dawley rats (&#x0223c;170&#x02013;200&#x000a0;g) were pre-trained to the rotarod (47750 rota-rod ng, ugo basile) at 8&#x000a0;rpm for 120&#x000a0;s. one day later, rats were administered alogabat (or vehicle) p.o., 30&#x000a0;min prior to diazepam or vehicle i.p., and they were assessed on the rotarod 30&#x000a0;min later. each rat was given three attempts to remain on the rotarod, with a maximum duration of 120&#x000a0;s per attempt. treatment groups (n &#x0003d; 8/group) consisted of alogabat alone (30&#x000a0;mg/kg), diazepam alone (5&#x000a0;mg/kg), or alogabat at 3, 10, and 30&#x000a0;mg/kg in combination with diazepam (5&#x000a0;mg/kg). the maximum time (s) spent on the rotarod was recorded. after the completion of rotarod testing, animals were euthanized under isoflurane anesthesia for plasma sample collection at approximately 70&#x000a0;min post-administration of alogabat.\u003c/p>\u003ca id=\"h7-3-11\" name=\"h7-3-11\">\u003c/a>\u003ch4>2.3.11 cognition testing in rats\u003c/h4>\u003ch5>2.3.11.1 operant and touchscreen cognition tests\u003c/h5>\u003cp class=\"mb0\">separate groups of male lister hooded (lh) rats (&#x0223c;400&#x000a0;g) were pre-trained in the operant and touch screen tests, as described in \u003ca href=\"#sm1\">supplementary material\u003c/a>. the 5-csrt task (n &#x0003d; 11) is a test of attention. the primary parameter is the total percentage of correct responses. continuous performance test (cpt; n &#x0003d; 11) assesses sustained attention. the primary parameter is the discrimination sensitivity index (d prime), which is a ratio based on the rate at which rats make correct and incorrect responses. the paired associates learning (pal) task (n &#x0003d; 12) assesses visual&#x02013;spatial memory. the primary parameter is the total percentage of correct responses. a latin-squares design was used to assess the vehicle and doses of alogabat (3, 10, and 30&#x000a0;mg/kg p.o.). rats were tested twice weekly with at least a 2-day interval between test sessions. rats were trained between test days to maintain baseline performance.\u003c/p>\u003ch5>2.3.11.2 context fear conditioning\u003c/h5>\u003cp class=\"mb0\">two cohorts of male lh rats (&#x0223c;250&#x000a0;g; n &#x0003d; 67) were assessed for context fear conditioning (cfc) in two experiments: (1) vehicle or alogabat at 10 and 30&#x000a0;mg/kg (n &#x0003d; 9/dose); (2) vehicle or alogabat at 1, 3, and 10&#x000a0;mg/kg (n &#x0003d; 10/dose) administered p.o., 60&#x000a0;min prior to the acquisition session. rats were placed into a novel test chamber (45&#x000a0;cm &#x000d7; 45&#x000a0;cm &#x000d7; 46.5&#x000a0;cm) with a grid floor and clear plastic walls (tse-systems gmbh, germany). during the acquisition session, a 2-min habituation phase was followed by the delivery of a mild foot shock (0.8&#x000a0;ma for 1&#x000a0;s) applied through the grid floor. following a 1&#x000a0;min interval, a second foot shock was delivered. the animals remained in the chambers for a further 30&#x000a0;s. one day later, the animals were returned to the same test chamber for a 5-min period without any foot shock. rodents respond to danger in a species-specific manner by freezing, i.e., the animals will withhold all movement, except for respiration, to avoid detection. the amount of freezing behavior was measured by the computer as the time spent immobile (minimum threshold of 1&#x000a0;s) and was expressed as the percentage of time spent freezing during the 5-min session. following cfc, plasma samples were collected 1&#x02013;2&#x000a0;days later from rats pre-treated with the same dose at 60&#x000a0;min post-administration (\u003cem>n\u003c/em> &#x0003d; 4/dose).\u003c/p>\u003ch5>2.3.11.3 morris water maze\u003c/h5>\u003cp class=\"mb0\">male lh rats (350&#x02013;400&#x000a0;g) were pre-treated with vehicle or 10 or 30&#x000a0;mg/kg alogabat p.o. (n &#x0003d; 10/dose) once daily during cued acquisition (visible platform; three trials per day for 2&#x000a0;days), followed by a 2-day interval and then spatial acquisition (hidden platform; three trials per day for 4&#x000a0;days) in the morris water maze (mwm; computer tracking system hvs image ltd., united kingdom) (\u003ca href=\"#b5\">ballard et al., 2005\u003c/a>). twenty-four hours later, the platform was removed, and the rats were pre-treated with vehicle or alogabat and allowed to swim in the maze for 60&#x000a0;s (probe trial) to assess the retention/spatial memory of the platform position, expressed as the percentage of distance traveled in each quadrant. for the mwm, plasma samples were collected immediately after the last trial on the 12th day of treatment at approximately 70&#x000a0;min post-administration (\u003cem>n\u003c/em> &#x0003d; 4&#x02013;5/dose).\u003c/p>\u003ca id=\"h7-3-12\" name=\"h7-3-12\">\u003c/a>\u003ch4>2.3.12 plasma sampling and analysis\u003c/h4>\u003cp class=\"mb0\">rodents were deeply anesthetized with 5% isoflurane, and blood was collected following decapitation with a guillotine or via cardiac puncture (ptz and mes). during eeg experiments, blood was collected from a cannula in the right femoral artery. blood samples were centrifuged in edta-coated eppendorf tubes (4,000&#x000a0;rpm, 4&#x000b0;c, 5&#x000a0;min), and plasma was collected, immediately frozen, and stored at &#x02212;80&#x000b0;c. samples were analyzed for the concentration of alogabat using qualified liquid chromatography coupled to tandem mass spectrometry (lc-ms/ms) assays.\u003c/p>\u003ca id=\"h7-3-13\" name=\"h7-3-13\">\u003c/a>\u003ch4>2.3.13 statistical analysis\u003c/h4>\u003cp class=\"mb0\">sample sizes were determined based on historical data for each experiment within each laboratory.\u003c/p>\u003ch5>2.3.13.1 eeg\u003c/h5>\u003cp class=\"mb0\">linear mixed-effects models (lmms) were used since these can account for incomplete datasets, which was the case in this study. specific contrasts were derived and tested using t-tests within the model using satterthwaite approximation for degrees of freedom. models were derived for each compound individually: y &#x0223c; compound &#x0002b; (1&#x0007c;animal). the significance of differences in the peak frequency was assessed using random permutation tests (10,000).\u003c/p>\u003ch5>2.3.13.2 phmri\u003c/h5>\u003cp class=\"mb0\">analysis was performed with jmp (sas institute inc., cary, united states) and matlab (the mathworks inc., natick, ma, united states). global (whole-brain) absolute-perfusion values from the vehicle and the three dose groups were tested for a linear trend across the four doses using a one-way anova framework. the same analysis was applied roi-wise to the normalized-perfusion values. multiple testing across the single rois was accounted for by controlling the false discovery rate (fdr) at 10% using the benjamini&#x02013;hochberg approach. to also obtain an overall activation&#x02013;strength metric, normalized-perfusion values of each dose group were compared roi-wise to those of the vehicle group using welch&#x02019;s t-test without multiple-testing correction. the number of significantly modulated rois at each dose was then taken as a measure of &#x0201c;pattern strength.&#x0201d; the mean and the upper 95% confidence limit of the corresponding chance levels were estimated via random group-label permutations (100,000 runs per group). significance levels of the actual pattern strengths were determined based on the distributions obtained through the permutation procedure.\u003c/p>\u003ch5>2.3.13.3 behavior\u003c/h5>\u003cp class=\"mb0\">all statistical analyses were performed using prism (graphpad software). one-factor anova was used for between-group comparison (i.e., dose), with repeated measures for within-subject comparison (i.e., time bins and platform quadrants). dunnett&#x02019;s test was used for \u003cem>post hoc\u003c/em> comparisons. student&#x02019;s unpaired two-tailed t-test was used when two groups were compared. the chi-square test was used to compare the percentage of groups. rotarod data were analyzed using a non-parametric kruskal&#x02013;wallis test, followed by dunn&#x02019;s multiple comparison test. statistical significance was predetermined as \u003cem>p\u003c/em> &#x0003c; 0.05.\u003c/p>\u003ca id=\"h4\" name=\"h4\">\u003c/a>\u003ch2>3 results\u003c/h2>\u003ca id=\"h4-1\" name=\"h4-1\">\u003c/a>\u003ch3 class=\"pt0\">3.1 binding affinity for gaba\u003csub>a\u003c/sub> receptors containing &#x003b1;5 and other &#x003b1; subunits\u003c/h3>\u003cp class=\"mb0\">the aim of these radioligand binding studies was to determine the binding selectivity of alogabat at the rat and human gaba\u003csub>a\u003c/sub> receptors containing &#x003b1;5 compared to &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits. alogabat had a high affinity for gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 receptors in rats (ki 7.9&#x000a0;nm), with approximately 37-, 26-, and 18-fold selectivity compared to gaba\u003csub>a\u003c/sub> &#x003b1;1&#x003b2;3&#x003b3;2, &#x003b1;2&#x003b2;3&#x003b3;2, and &#x003b1;3&#x003b2;3&#x003b3;2, respectively (\u003ca href=\"#f1\">figure 1b\u003c/a>; see \u003ca href=\"#sm1\">supplementary table s1\u003c/a>). alogabat had a similar pharmacological profile in human recombinant gaba\u003csub>a\u003c/sub> receptor subtypes (see \u003ca href=\"#sm1\">supplementary table s1\u003c/a>).\u003c/p>\u003ca id=\"h4-2\" name=\"h4-2\">\u003c/a>\u003ch3 class=\"pt0\">3.2 functional activity at recombinant and native gaba\u003csub>a\u003c/sub> receptors\u003c/h3>\u003cp class=\"mb0\">we undertook electrophysiological studies in hek293 cells and oocytes to assess the functional activity of alogabat on cloned rat and human gaba\u003csub>a\u003c/sub> receptor subtypes containing &#x003b1;5, &#x003b1;1, &#x003b1;2, and &#x003b1;3 subunits. alogabat enhanced gaba-evoked responses of rat and human &#x003b1;5-containing receptors by 167% (\u003ca href=\"#f1\">figure 1c\u003c/a>) and 72% (see \u003ca href=\"#sm1\">supplementary table s2\u003c/a>), respectively. the maximum amount of potentiation was slightly lower at human receptors. this may be due to the different expression systems used, i.e., hek293 cells for rat receptors and \u003cem>xenopus\u003c/em> oocytes for human receptors. at the highest concentrations tested, alogabat potentiated other receptor subtypes to a much lesser extent than &#x003b1;5-containing receptors. the potency of alogabat was comparable between gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors containing either &#x003b3;2 or &#x003b3;3 subunits, i.e., gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 and gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;3 receptors (see \u003ca href=\"#sm1\">supplementary figure s1\u003c/a>).\u003c/p>\u003cp class=\"mb0\">at native gaba\u003csub>a\u003c/sub> receptors in rat hippocampal slices, alogabat positively modulated gabaergic inhibition of ca1 pyramidal cells, as shown by a leftward shift of the concentration-dependent inhibition of the population spike by isoguvacine (\u003ca href=\"#f1\">figure 1d\u003c/a>) and enhanced paired-pulse inhibition of the population spike during field potential recordings (\u003ca href=\"#f1\">figure 1e\u003c/a>). together, these results confirm the binding selectivity of alogabat and demonstrate that alogabat is a functionally selective pam of gaba-evoked responses.\u003c/p>\u003ca id=\"h4-3\" name=\"h4-3\">\u003c/a>\u003ch3 class=\"pt0\">3.3 selectivity data\u003c/h3>\u003cp class=\"mb0\">we assessed alogabat in radioligand binding studies with more than 70 receptors and showed that alogabat at 10&#x000a0;&#x000b5;m had over 917-fold binding selectivity for the gaba\u003csub>a\u003c/sub>-&#x003b1;5&#x003b2;3&#x003b3;2 receptor subtype against all other targets tested (see \u003ca href=\"#sm1\">supplementary table s3\u003c/a>).\u003c/p>\u003ca id=\"h4-4\" name=\"h4-4\">\u003c/a>\u003ch3 class=\"pt0\">3.4 receptor occupancy in wistar rats and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h3>\u003cp class=\"mb0\">the main objective of these studies was to visualize and quantify gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro by alogabat. alogabat decreased the specific binding of the gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor-specific radioligand [\u003csup>3\u003c/sup>h]ro0154513 in the hippocampus of rats in a dose-dependent manner. the highest dose of alogabat (100&#x000a0;mg/kg i.p.) reduced specific binding by 100%, i.e., to the same binding level as that of 10&#x000a0;mg/kg l-655,708 (\u003ca href=\"#f2\">figure 2a\u003c/a>). a total plasma concentration of 669&#x000a0;ng/ml and a total brain concentration of 208&#x000a0;ng/g were required to produce half-maximal gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro (ec\u003csub>50\u003c/sub>) in the hippocampus in rats. in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice, estimated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro based on the \u003cem>ex vivo\u003c/em> study with [\u003csup>3\u003c/sup>h]l-655,708 was 43%, 46%, and 71% at doses of 30, 60, and 100&#x000a0;mg/kg i.p., respectively (\u003ca href=\"#f2\">figure 2b\u003c/a>). in addition, the rat occupancy curve was used to calculate ro related to plasma exposure for all \u003cem>in vivo\u003c/em> experiments described in this manuscript below (also refer to \u003ca href=\"#sm1\">supplementary tables s4&#x02013;s5\u003c/a>).\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 2\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" name=\"figure2\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g002.jpg\" alt=\"www.frontiersin.org\" id=\"f2\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 2\u003c/b>. receptor occupancy and phmri signature of alogabat following acute administration. \u003cb>(a)\u003c/b> concentration-dependent blockade of [\u003csup>3\u003c/sup>h]ro0154513 binding by alogabat in wistar rats: with increasing concentrations from the different doses (0.3&#x02013;100&#x000a0;mg/kg i.p., n &#x0003d; 3/dose) of alogabat (vehicle &#x0003d; without pre-treatment, n &#x0003d; 3). \u003cb>(b)\u003c/b> representative autoradiograms of alogabat \u003cem>ex vivo\u003c/em> occupancy in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice via \u003cem>in vitro\u003c/em> incubation of the highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor radioligand [\u003csup>3\u003c/sup>h]l-655,708 to sagittal brain sections. the cntnap2&#x02212;/&#x02212; mice were treated with vehicle and 30, 60, or 100&#x000a0;mg/kg i.p. alogabat (n &#x0003d; 4/dose). \u003cb>(c)\u003c/b> trend of normalized-perfusion response pattern strength increasing with dose, given as numbers (&#x000b1; 95% confidence intervals) of significantly (de-)activated regions of interest (rois) following the administration of alogabat (n &#x0003d; 8/dose) to fischer (f344) rats under medetomidine sedation. &#x0201c;chance level&#x0201d; &#x0003d; mean (black dotted line) and 95th percentile (gray dotted line) derived from the permutation test. significant deviations in the number of modulated rois from the chance level are denoted by &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 (uncorrected). ro is the calculated receptor occupancy for gaba\u003csub>a\u003c/sub>-&#x003b1;5 from measured plasma concentrations at each dose. \u003cb>(d)\u003c/b> sagittal schematic of rat brain showing rois with a significant dose-dependent modulation (linear trend of normalized perfusion). rois passing false discovery rate control at 10% are shown, with roi outlines indicating uncorrected significance level (no outline, \u003cem>p\u003c/em> &#x0003c; 0.05; dotted outline, \u003cem>p\u003c/em> &#x0003c; 0.01; and solid outline, \u003cem>p\u003c/em> &#x0003c; 0.001). roi abbreviations: acbsh, nucleus accumbens shell; amg, amygdala; drn, dorsal raphe nucleus; hpcfi, fimbria hippocampi; insc, insular cortex; lc, locus coeruleus; m1, primary motor cortex; mpfc/cg, medial prefrontal, cingulate cortex; pir, piriform (entorhinal) cortex; prh, perirhinal cortex; s1, primary somatosensory cortex; sn, substantia nigra; th, thalamus; vc, visual cortex.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h4-5\" name=\"h4-5\">\u003c/a>\u003ch3 class=\"pt0\">3.5 pharmacological mri signature in rats\u003c/h3>\u003cp class=\"mb0\">the purpose of this study was to evaluate the effects of alogabat on regional neural activity. blood perfusion, measured quantitatively by phmri, was taken as a proxy for neural activity. the administration of a single dose of alogabat at 3&#x02013;30&#x000a0;mg/kg i.p. in rats resulted in moderate but consistent and dose-dependent changes in neural activity patterns compared to treatment with the vehicle (\u003ca href=\"#f2\">figure 2c\u003c/a>). significant dose-dependent modulation of normalized perfusion by alogabat was observed in limbic brain regions, i.e., the nucleus accumbens (shell), amygdala, and hippocampus (fimbria); in several cortical brain regions, the thalamus and brainstem nuclei; and in the substantia nigra (\u003ca href=\"#f2\">figure 2d\u003c/a>). a linear dose effect was also observed on whole-brain absolute perfusion. alogabat target engagement in brain tissue ranged from 54% to 84% ro.\u003c/p>\u003ca id=\"h4-6\" name=\"h4-6\">\u003c/a>\u003ch3 class=\"pt0\">3.6 eeg signature in rats\u003c/h3>\u003cp class=\"mb0\">the aim of this study was to determine whether alogabat induces a characteristic eeg signature that could be used as a translational pharmacodynamic marker. as a first step and based on previous findings on the eeg effects of gaba\u003csub>a\u003c/sub> drugs (\u003ca href=\"#b71\">van lier et al., 2004\u003c/a>; \u003ca href=\"#b72\">visser et al., 2003\u003c/a>; \u003ca href=\"#b22\">friedman et al., 1992\u003c/a>), we investigated eeg spectral power change in the theta (6&#x02013;10&#x000a0;hz) and beta (20&#x02013;30&#x000a0;hz) frequency bands. alogabat, administered as 10&#x000a0;mg/kg i.v. (5&#x000a0;min infusion), significantly increased eeg beta-band activity by 21% &#x000b1; 11% relative to the baseline (mean &#x000b1; sd) and decreased theta-band activity by 32% &#x000b1; 19% (\u003ca href=\"#f3\">figures 3a,b\u003c/a>). frequency-resolved changes confirmed a decrease in theta power (approximately 6&#x02013;10&#x000a0;hz) and revealed broader beta and gamma modulation (approximately 20&#x02013;50&#x000a0;hz) (\u003ca href=\"#f3\">figures 3c&#x02013;e\u003c/a>). the calculated ro after the application of alogabat was 77%&#x02013;85% for gaba\u003csub>a\u003c/sub>-&#x003b1;5 (see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). the overall spectral pattern was qualitatively similar to that of diazepam; however, the peak frequency in the beta frequency range was higher for alogabat (32&#x000a0;hz for alogabat vs. 22.6&#x000a0;hz for diazepam; \u003cem>p\u003c/em> &#x0003d; 0.006, random permutation test), and its amplitude was greater for diazepam (142% &#x000b1; 44% increase for diazepam vs. 27% &#x000b1; 16% increase for alogabat; \u003cem>p\u003c/em> &#x0003c; 0.001). this is likely related to the high binding and functional selectivity of alogabat for &#x003b1;5-containing gaba\u003csub>a\u003c/sub> receptors compared to the non-selective profile of diazepam.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 3\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" name=\"figure3\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g003.jpg\" alt=\"www.frontiersin.org\" id=\"f3\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 3\u003c/b>. pharmacodynamic effect of alogabat on eeg spectral power. \u003cb>(a,b)\u003c/b> modulations of vehicle (\u003cem>n\u003c/em> &#x0003d; 12), alogabat 10&#x000a0;mg/kg (\u003cem>n\u003c/em> &#x0003d; 9), and diazepam 2&#x000a0;mg/kg (\u003cem>n\u003c/em> &#x0003d; 7, positive control) in the beta (20&#x02013;30&#x000a0;hz) and theta (6&#x02013;10&#x000a0;hz) power. \u003cb>(c&#x02013;e)\u003c/b> effects of individual compounds and vehicle on the eeg power spectrum. each individual recording is displayed as a light gray line, and the group average and its 95% confidence intervals are shown as colored bands. for all panels, power averaged over 0.2&#x02013;1&#x000a0;h post dosing is shown relative to pre-dosing baseline average over &#x02212;1 to &#x02212;0.2&#x000a0;h before dosing. statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05 versus vehicle (linear mixed-effects models followed by t-tests).\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h4-7\" name=\"h4-7\">\u003c/a>\u003ch3 class=\"pt0\">3.7 repetitive behaviors in mouse models relevant to asd\u003c/h3>\u003cp class=\"mb0\">the inbred mouse strain btbr and the cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mouse show abnormalities in core asd behavioral domains, such as repetitive behaviors. self-grooming and digging are more elevated in the btbr mouse than in other strains, i.e., c57bl/6j (\u003ca href=\"#b40\">mcfarlane et al., 2008\u003c/a>), and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice show more elevated grooming than their wildtype littermates (\u003ca href=\"#b51\">penagarikano et al., 2011\u003c/a>). the aim of the following experiments was to determine whether alogabat has a specific effect on repetitive behaviors independent of potential effects on overall locomotor activity. we assessed the effects of subchronic treatment on cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice to exclude potential tolerance to the effects of alogabat.\u003c/p>\u003ca id=\"h8-7-1\" name=\"h8-7-1\">\u003c/a>\u003ch4>3.7.1 open field in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h4>\u003cp class=\"mb0\">in btbr mice, acute administration of alogabat (30&#x02013;120&#x000a0;mg/kg i.p.) had no effect on the total activity over 1&#x000a0;h measured in an open field [f(4,55) &#x0003d; 2.04], although during the first 10&#x000a0;min, alogabat at 90 and 120&#x000a0;mg/kg significantly reduced the distance traveled [f(4,55) &#x0003d; 9.623, \u003cem>p\u003c/em> &#x0003c; 0.001, \u003ca href=\"#f4\">figure 4a\u003c/a>]. there was also no effect of sub-chronic alogabat (30&#x02013;100&#x000a0;mg/kg i.p.) on the total activity over 1&#x000a0;h in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice [f(3,53) &#x0003d; 0.98]. during the first 5&#x000a0;min, 100&#x000a0;mg/kg reduced the distance traveled in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice to the same level as vehicle-treated wildtype mice (\u003ca href=\"#f4\">figure 4b\u003c/a>). alogabat did not induce a major impairment of locomotor activity in the open field.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 4\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" name=\"figure4\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g004.jpg\" alt=\"www.frontiersin.org\" id=\"f4\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 4\u003c/b>. effect of alogabat on repetitive behaviors in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. \u003cb>(a)\u003c/b> alogabat was administered i.p. 30&#x000a0;min prior to the assessment of locomotor activity in an open-field test in btbr mice: distance traveled (cm) per 5&#x000a0;min time bin (\u003cem>line graph\u003c/em>) and in 1&#x000a0;h total (\u003cem>bar chart inset\u003c/em>). \u003cb>(b)\u003c/b> alogabat was administered i.p. once daily for 2&#x02013;3&#x000a0;days, and on the test day, it was administered 30&#x000a0;min prior to testing cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice in an open field: distance traveled (cm) per 5&#x000a0;min time bin (\u003cem>line graph\u003c/em>) and in 1&#x000a0;h total (\u003cem>bar chart insert\u003c/em>). in btbr mice, on a separate test day, alogabat was administered i.p. 30&#x000a0;min prior to the grooming test: \u003cb>(c)\u003c/b> duration (s) of grooming behavior and \u003cb>(e)\u003c/b> distance (cm) traveled during the 10&#x000a0;min period in the test chamber. in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice, alogabat was administered i.p. once daily for 8&#x02013;10&#x000a0;days, and on the test day, it was administered 30&#x000a0;min prior to the grooming test: \u003cb>(d)\u003c/b> duration (s) of grooming behavior and \u003cb>(f)\u003c/b> distance traveled during the 10&#x000a0;min period in the test chamber. data are presented as individual points (circles) and mean &#x000b1; sem (btbr: \u003cem>n\u003c/em> &#x0003d; 12/group; cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup>: \u003cem>n\u003c/em> &#x0003d; 14&#x02013;15/group). statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. vehicle (veh)-treated btbr or cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. &#x000a7;&#x000a7;&#x000a7;\u003cem>p\u003c/em> &#x0003c; 0.001 vehicle-treated wildtype (wt-v) mice vs. vehicle (v)-treated cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. alogabat was administered i.p. 30&#x000a0;min prior to the assessment of digging behavior in btbr mice: \u003cb>(g)\u003c/b> duration (s) of digging behavior, \u003cb>(h)\u003c/b> distance traveled (cm), and \u003cb>(i)\u003c/b> speed (cm/s) during the 5&#x000a0;min period in the test chamber. data are presented as individual points (circles) and mean &#x000b1; sem (\u003cem>n\u003c/em> &#x0003d; 12/group). statistics: &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01 and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. vehicle-treated btbr mice. ro is the calculated receptor occupancy for gaba\u003csub>a\u003c/sub>-&#x003b1;5 from the measured plasma concentrations at each dose.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h8-7-2\" name=\"h8-7-2\">\u003c/a>\u003ch4>3.7.2 grooming behavior in btbr and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice\u003c/h4>\u003cp class=\"mb0\">acute administration of alogabat in btbr mice dose-dependently attenuated grooming behavior at 60, 90, and 120&#x000a0;mg/kg i.p. [f(4,55) &#x0003d; 6.946, \u003cem>p\u003c/em> &#x0003d; 0.0001, \u003ca href=\"#f4\">figure 4c\u003c/a>] without reducing locomotor activity in the same test arena (\u003ca href=\"#f4\">figure 4e\u003c/a>). in contrast, doses of 60 and 90&#x000a0;mg/kg increased the distance traveled [f(4,55) &#x0003d; 3.454, \u003cem>p\u003c/em> &#x0003c; 0.05]. alogabat had a specific effect on grooming behavior at plasma concentrations corresponding to calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 45%&#x02013;70% (see \u003ca href=\"#sm1\">supplementary table s4\u003c/a>).\u003c/p>\u003cp class=\"mb0\">sub-chronic administration of alogabat in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice attenuated grooming behavior at 60 and 100&#x000a0;mg/kg i.p. [f(3,53) &#x0003d; 10.57, \u003cem>p\u003c/em> &#x0003c; 0.0001, \u003ca href=\"#f4\">figure 4d\u003c/a>], with no effect on locomotor activity measured in the same test arena [f(3,53) &#x0003d; 0.74, \u003ca href=\"#f4\">figure 4f\u003c/a>]. alogabat had a specific effect on repetitive grooming behavior at plasma concentrations that correspond with calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro of 52%&#x02013;79% (see \u003ca href=\"#sm1\">supplementary table s4\u003c/a>).\u003c/p>\u003ca id=\"h8-7-3\" name=\"h8-7-3\">\u003c/a>\u003ch4>3.7.3 digging behavior in btbr mice\u003c/h4>\u003cp class=\"mb0\">there was no effect of acute alogabat administration on digging behavior at doses up to 100&#x000a0;mg/kg i.p. [f(3,36) &#x0003d; 0.8, \u003ca href=\"#f4\">figure 4g\u003c/a>], corresponding to a calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro level of 67% (see \u003ca href=\"#sm1\">supplementary table s4\u003c/a>). alogabat at 100&#x000a0;mg/kg reduced the distance traveled [f(3,36) &#x0003d; 12.1, \u003cem>p\u003c/em> &#x0003c; 0.001, \u003ca href=\"#f4\">figure 4h\u003c/a>] and speed [f(3,36) &#x0003d; 11.5, \u003cem>p\u003c/em> &#x0003c; 0.001, \u003ca href=\"#f4\">figure 4i\u003c/a>] in the same arena.\u003c/p>\u003ca id=\"h4-8\" name=\"h4-8\">\u003c/a>\u003ch3 class=\"pt0\">3.8 anticonvulsant activity in rats\u003c/h3>\u003cp class=\"mb0\">the purpose of these experiments was to evaluate the antiepileptic properties of alogabat against seizures induced by ptz and the mes model. alogabat administered in combination with a convulsant dose of ptz completely blocked seizures at 15 and 30&#x000a0;mg/kg (\u003ca href=\"#f5\">figure 5a\u003c/a>), which corresponds to calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 71% and 77% (see \u003ca href=\"#sm1\">supplementary table s5\u003c/a>). meanwhile, in the mes test, alogabat at 5&#x000a0;mg/kg (57% ro, see \u003ca href=\"#sm1\">supplementary table s5\u003c/a>) showed a significant reduction in the percent of rats that had tonic seizures (\u003ca href=\"#f5\">figure 5b\u003c/a>); there was only a tendency for reduction at 15&#x000a0;mg/kg (\u003cem>p\u003c/em> &#x0003d; 0.1) and 30&#x000a0;mg/kg (\u003cem>p\u003c/em> &#x0003d; 0.06). the positive control, diazepam, significantly reduced the percentage of rats that had seizures in both the ptz and mes tests.\u003c/p>\u003cdiv class=\"dottedline\">\u003c/div>\u003cdiv class=\"imageheaders\">figure 5\u003c/div>\u003cdiv class=\"figuredesc\">\u003ca href=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" name=\"figure5\" target=\"_blank\">\n \u003cpicture>\n \u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"(max-width: 563px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"(max-width: 1024px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"(max-width: 1441px)\">\u003csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"\">\u003csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" media=\"\"> \u003cimg src=\"https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g005.jpg\" alt=\"www.frontiersin.org\" id=\"f5\" loading=\"lazy\">\n \u003c/picture>\n\u003c/a>\u003cp>\u003cb>figure 5\u003c/b>. evaluation of alogabat for effects on anticonvulsant, motor, and cognitive tests. alogabat was administered p.o. 60&#x000a0;min prior to the following behavior tests. assessment of potential anticonvulsant activity in \u003cb>(a)\u003c/b> ptz and \u003cb>(b)\u003c/b> mes tests in rats. diazepam (dzp) at 3&#x000a0;mg/kg i.p. was included as a positive control. data are presented as individual points (circles) and the percentage of rats per group showing seizures (\u003cem>n\u003c/em> &#x0003d; 8/group). \u003cb>(c)\u003c/b> time (s) spent on the rotarod at 16&#x000a0;rpm in rats administered alogabat alone (30&#x000a0;mg/kg, gray bar with black outline) or alogabat at 3, 10, and 30&#x000a0;mg/kg co-administered with diazepam at 5&#x000a0;mg/kg i.p. (gray bars with red outline) compared with vehicle (open bar) or diazepam (open bar with red outline). data are presented as individual points (circles) and median &#x000b1; interquartile range (n &#x0003d; 8/group). assessment of cognition in rats: \u003cb>(d)\u003c/b> attention in the 5-choice serial reaction time (5-csrt) task; \u003cb>(e)\u003c/b> sustained attention in the touchscreen continuous performance test (cpt); \u003cb>(f)\u003c/b> visual&#x02013;spatial memory in the touchscreen pal task. cfc at \u003cb>(g)\u003c/b> 10 and 30&#x000a0;mg/kg; \u003cb>(h)\u003c/b> 1, 3, and 10&#x000a0;mg/kg. spatial learning and memory in the mwm: alogabat was administered once daily for 11&#x000a0;days prior to the probe trial. \u003cb>(i)\u003c/b> percentage of distance traveled in all four quadrants: vehicle; 10&#x000a0;mg/kg; 30&#x000a0;mg/kg. data are presented as individual points (circles) and mean &#x000b1; sem for pal (\u003cem>n\u003c/em> &#x0003d; 12/dose; within-subjects), 5-csrt and cpt (\u003cem>n\u003c/em> &#x0003d; 11/dose, within-subjects), cfc (\u003cem>n\u003c/em> &#x0003d; 9&#x02013;10/group), and mwm (\u003cem>n\u003c/em> &#x0003d; 10/group). statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. vehicle (veh or 0)-treated rats; mwm statistics: &#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.05, &#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.01, and &#x0002a;&#x0002a;&#x0002a;\u003cem>p\u003c/em> &#x0003c; 0.001 vs. percentage of distance in the platform quadrant. ro is the calculated receptor occupancy of alogabat for gaba\u003csub>a\u003c/sub>-&#x003b1;5 from measured plasma concentrations at each dose.\u003c/p>\u003c/div>\u003cdiv class=\"clear\">\u003c/div>\u003cdiv class=\"dottedline\">\u003c/div>\u003ca id=\"h4-9\" name=\"h4-9\">\u003c/a>\u003ch3 class=\"pt0\">3.9 combination with diazepam on rotarod performance in rats\u003c/h3>\u003cp class=\"mb0\">classical benzodiazepines, such as diazepam, are known to induce sedation and ataxia, which can be measured by the rotarod task in rodents. the aim of this experiment was to determine whether alogabat affects rotarod performance when administered alone and, second, whether alogabat modulates the sedative/motor effect of diazepam on rotarod performance when given in combination. diazepam at 5&#x000a0;mg/kg i.p. significantly impaired rotarod performance. alogabat (3&#x02013;30&#x000a0;mg/kg p.o.) co-administered with diazepam did not worsen the effects of diazepam on rotarod performance (\u003ca href=\"#f5\">figure 5c\u003c/a>). alogabat administered alone at 30&#x000a0;mg/kg p.o. did not differ from vehicle-treated rats, corresponding to a calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro level of 88% (see \u003ca href=\"#sm1\">supplementary table s5\u003c/a>).\u003c/p>\u003ca id=\"h4-10\" name=\"h4-10\">\u003c/a>\u003ch3 class=\"pt0\">3.10 evaluation of cognition in rats\u003c/h3>\u003cp class=\"mb0\">since non-selective gaba\u003csub>a\u003c/sub> pams, such as diazepam, have been shown to impair cognition (\u003ca href=\"#b5\">ballard et al., 2005\u003c/a>), the aim of the following experiments was to study the potential effects of acute administration of alogabat on cognition in rats. this included attention in the 5-csrt task and associative (fear) memory in cfc. we also assessed visual&#x02013;spatial memory (pal task) and attention (cpt) in a touchscreen system, which provides a translational approach for assessing cognition (\u003ca href=\"#b34\">hvoslef-eide et al., 2016\u003c/a>). chronic treatment with alogabat was also assessed on spatial learning and memory in the mwm.\u003c/p>\u003cp class=\"mb0\">in the 5-csrt task, alogabat at 30&#x000a0;mg/kg induced a small but statistically significant reduction in percent correct (3%; within-subjects comparison; f(3,30) &#x0003d; 5.6, \u003cem>p\u003c/em> &#x0003c; 0.01; \u003ca href=\"#f5\">figure 5d\u003c/a>). however, alogabat did not impair attention in cpt (f(2,20) &#x0003d; 0.3; \u003ca href=\"#f5\">figure 5e\u003c/a>) or visual&#x02013;spatial memory in the pal task (f(2,22) &#x0003d; 2.6; \u003ca href=\"#f5\">figure 5f\u003c/a>).\u003c/p>\u003cp class=\"mb0\">in the cfc test, alogabat was administered before the acquisition session to determine whether there was an effect on learning the association between foot shock and the surrounding context. in the first experiment, alogabat impaired cfc at 10 and 30&#x000a0;mg/kg, corresponding to calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 75% and 81% (f(2,24) &#x0003d; 10.99, \u003cem>p\u003c/em> &#x0003c; 0.001; \u003ca href=\"#f5\">figure 5g\u003c/a>). a second experiment was undertaken to explore lower doses, and it showed that alogabat did not significantly impair cfc at 1, 3, and 10&#x000a0;mg/kg (f(3,36) &#x0003d; 0.9; \u003ca href=\"#f5\">figure 5h\u003c/a>), corresponding to the calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro levels of 35%, 56%, and 72%. this suggests that the dose of 10&#x000a0;mg/kg is approximately the threshold level for the impairment of cfc and is likely dependent on the level of ro achieved per subject.\u003c/p>\u003cp class=\"mb0\">in the mwm test, chronic administration of alogabat at 10 and 30&#x000a0;mg/kg did not significantly impair the acquisition of the hidden platform position (see \u003ca href=\"#sm1\">supplementary figure s2\u003c/a>). twenty-four hours later, the platform was removed, and the rats were allowed to swim in the maze for 60&#x000a0;s (probe trial) to assess memory-retention of the platform position. the groups receiving vehicle [f(3,27) &#x0003d; 8, \u003cem>p\u003c/em> &#x0003c; 0.001] and 10&#x000a0;mg/kg [f(3,27) &#x0003d; 7, \u003cem>p\u003c/em> &#x0003c; 0.01] had learned the spatial position of the platform, as shown by their preference for the platform quadrant (\u003ca href=\"#f5\">figure 5i\u003c/a>). however, rats that received 30&#x000a0;mg/kg alogabat showed impaired spatial memory of the platform position during the probe trial [f(3,27) &#x0003d; 3, p &#x0003d; 0.08; \u003ca href=\"#f5\">figure 5i\u003c/a>], and gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro was estimated to be 79%. in summary, alogabat impaired context and spatial memory at gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro above 70%.\u003c/p>\u003ca id=\"h5\" name=\"h5\">\u003c/a>\u003ch2>4 discussion\u003c/h2>\u003ca id=\"h5-1\" name=\"h5-1\">\u003c/a>\u003ch3 class=\"pt0\">4.1 \u003cem>in vitro\u003c/em> and \u003cem>in vivo\u003c/em> characterization of alogabat\u003c/h3>\u003cp class=\"mb0\">alogabat was shown to be a potent and functionally selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor pam \u003cem>in vitro\u003c/em>. the functional activity of alogabat was confirmed at native gaba\u003csub>a\u003c/sub> receptors in rat hippocampal slices. \u003cem>in vivo\u003c/em> binding experiments demonstrated dose-dependent target engagement of alogabat in rats and cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. the highest specific binding was observed in the hippocampus, which is consistent with the known distribution of the gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor subtype in rodents (\u003ca href=\"#b54\">pirker et al., 2000\u003c/a>). phmri studies in rats demonstrated dose-dependent perfusion changes, indicating circuit modulation by alogabat. there were consistent changes in the neural activity pattern across dose groups, with modulation of neural activity in, among others, the medial prefrontal cortex, cingulate cortex, motor cortex, perirhinal cortex, nucleus accumbens shell, amygdala, hippocampus fimbria, and substantia nigra.\u003c/p>\u003ca id=\"h5-2\" name=\"h5-2\">\u003c/a>\u003ch3 class=\"pt0\">4.2 eeg signature\u003c/h3>\u003cp class=\"mb0\">acute administration of alogabat in rats induced an eeg signature characterized by a power decrease in theta and an increase in the beta frequency range, which was qualitatively similar to the eeg signature of non-selective gaba\u003csub>a\u003c/sub> pams such as diazepam (\u003ca href=\"#b71\">van lier et al., 2004\u003c/a>; \u003ca href=\"#b72\">visser et al., 2003\u003c/a>; \u003ca href=\"#b22\">friedman et al., 1992\u003c/a>). the lower magnitude of induced eeg beta-band power by alogabat compared to diazepam is likely attributed to its &#x003b1;5-selectivity, resulting in an overall lower magnitude of gaba\u003csub>a\u003c/sub> receptor modulation. this eeg signature of alogabat is qualitatively a mirror image of the eeg signature of basmisanil, a highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 negative allosteric modulator (nam), which we recently found to induce an increase in the theta power and a decrease in the beta-band eeg power in healthy volunteers (\u003ca href=\"#b31\">hipp et al., 2021\u003c/a>). furthermore, the eeg signature of alogabat is in agreement with the link between beta-band activity and single-nucleotide polymorphisms (snps) in gaba\u003csub>a\u003c/sub> receptor genes (\u003ca href=\"#b56\">porjesz et al., 2002\u003c/a>; \u003ca href=\"#b67\">smit et al., 2018\u003c/a>) and ndds (dup15q syndrome, as) involving gene copy number variations of \u003cem>gabrb3, gabra5\u003c/em>, and \u003cem>gabrg3\u003c/em> (\u003ca href=\"#b24\">frohlich et al., 2019a\u003c/a>; \u003ca href=\"#b25\">frohlich et al., 2019b\u003c/a>). gaba\u003csub>a\u003c/sub> receptor-related changes in beta-band activity are believed to reflect the modulation of recurrent excitatory&#x02013;inhibitory feedback loops in the cortical tissue (\u003ca href=\"#b75\">whittington et al., 2000\u003c/a>; \u003ca href=\"#b70\">traub and jefferys, 1999\u003c/a>). for the administered doses, the calculated receptor occupancies were in the range of 77%&#x02013;84% for &#x003b1;5-containing receptors and 22%&#x02013;34% for &#x003b1;1-containing receptors (with different pam effects (e\u003csub>max\u003c/sub>) at &#x003b1;5 vs. &#x003b1;1). thus, at the studied doses, alogabat has some effect on &#x003b1;1-containing receptors, and further work is needed to systematically study lower doses of alogabat, including those &#x0003c;70% ro without the impairment of cognition in wt rats, to confirm whether the modulation of &#x003b1;5-containing receptors alone is sufficient to induce the described eeg effect. nonetheless, eeg theta- and beta-band power are promising candidates for translational mechanistic biomarkers of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor function and could be used in the further development of alogabat.\u003c/p>\u003ca id=\"h5-3\" name=\"h5-3\">\u003c/a>\u003ch3 class=\"pt0\">4.3 behavioral effects of alogabat in animal models relevant to asd\u003c/h3>\u003cp class=\"mb0\">we assessed the effects of alogabat in two different mouse models relevant to asd, one phenotypic and one genetic. acute administration of alogabat significantly and dose-dependently attenuated excessive grooming, but not digging, behavior in btbr mice. sub-chronic administration of alogabat significantly attenuated elevated grooming behavior in cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice. efficacy in these different models was linked to gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro above 50%. despite initial findings of a transiently decreased activity in an open-field test, alogabat increased the activity of btbr mice and had no effect on the activity of cntnap2\u003csup>&#x02212;/&#x02212;\u003c/sup> mice during the grooming test, supporting the specific effect of alogabat on repetitive grooming. we have tested additional compounds with similar properties, e.g., ro7015738, and have confirmed that gaba\u003csub>a\u003c/sub>-&#x003b1;5 pams reduce repetitive behaviors in these mouse models (\u003ca href=\"#b10\">buettelmann et al., 2018\u003c/a>). these results align well with recently published data showing that gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor deficiency causes autism-like behaviors in mice, including increased grooming and reduced social contacts (\u003ca href=\"#b77\">zurek et al., 2016\u003c/a>), and with sh-053-2&#x02032;f-r-ch3, a gaba\u003csub>a\u003c/sub>-&#x003b1;5 pam, which was recently shown to have positive effects on social and cognitive deficits in a rat model of autism (\u003ca href=\"#b68\">souza et al., 2024\u003c/a>). our data are valuable in providing information on the ro required for \u003cem>in vivo\u003c/em> effects on repetitive behavior. however, it should be noted that this effect may not directly translate to all individuals with asd as it is a heterogeneous disorder, whereas these mouse models exhibit specific genetic or phenotypic deficits.\u003c/p>\u003ca id=\"h5-4\" name=\"h5-4\">\u003c/a>\u003ch3 class=\"pt0\">4.4 anticonvulsant effects of alogabat\u003c/h3>\u003cp class=\"mb0\">it has been proposed that the reduction of gabaergic inhibitory activity results in hyperexcitability of minicolumn circuits, explaining some of the symptomatology observed in some ndds, including the high incidence of seizures and auditory&#x02013;tactile hypersensitivity (\u003ca href=\"#b60\">rubenstein and merzenich, 2003\u003c/a>; \u003ca href=\"#b26\">frye et al., 2016\u003c/a>). in the current study, we demonstrated that alogabat exhibits an anticonvulsant profile with activity comparable to the benzodiazepine drug class in acutely induced seizure models (electrical and chemical). alogabat had a small effect on seizures in the mes test, whereas in the ptz test, alogabat was shown to completely block seizures at calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro &#x0003e;70%. since ptz is a gaba\u003csub>a\u003c/sub> antagonist, this supports the assessment of alogabat for anticonvulsant activity in disorders where there is dysfunction of the gabaergic system. furthermore, in a separate eeg study, we observed that one out of eight rats had frequent spike-and-wave discharge (swd) activity, which was alleviated following treatment with alogabat (see \u003ca href=\"#sm1\">supplementary figures s3a&#x02013;s3c\u003c/a>; methods in \u003ca href=\"#sm1\">supplementary material\u003c/a>). to better understand the temporal dynamics of swd occurrence and the suppressing effect of alogabat, we performed a follow-up study on three additional rats that showed pronounced swd. both 3 and 10&#x000a0;mg/kg alogabat substantially reduced the number of swds within the first 3&#x000a0;h of recording, when the same rats showed increased swd numbers in the vehicle control condition (see \u003ca href=\"#sm1\">supplementary figures s3d&#x02013;s3f\u003c/a>), which corresponds to the calculated gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro level of 30%&#x02013;46% (see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). from a circuit perspective, the consensus is that such epileptic activity is generated by dysregulated thalamocortical circuitry, with abnormal interactions between reticular thalamic neurons and thalamic relay cells acting as the trigger and cortical circuits serving as the generator (\u003ca href=\"#b66\">sitnikova et al., 2023\u003c/a>). considering that in rats, &#x003b1;5-subunit-containing gaba\u003csub>a\u003c/sub> receptors are enriched in the cortex and hippocampus (\u003ca href=\"#b64\">serwanski et al., 2006\u003c/a>; \u003ca href=\"#b33\">hu et al., 2019\u003c/a>), mediating dendritic inhibition on pyramidal neurons (\u003ca href=\"#b2\">ali and thomson, 2008\u003c/a>; \u003ca href=\"#b62\">schulz et al., 2018\u003c/a>), we hypothesize that alogabat could suppress swd generation by enhancing the inhibition of cortical pyramidal neurons. however, more systematic work is required to confirm that alogabat can prevent swd activity.\u003c/p>\u003ca id=\"h5-5\" name=\"h5-5\">\u003c/a>\u003ch3 class=\"pt0\">4.5 assessment of non-specific behavioral effects\u003c/h3>\u003cp class=\"mb0\">non-selective gaba\u003csub>a\u003c/sub> pams, such as diazepam and chlordiazepoxide, are effective anxiolytics in clinical use but have also been shown to impair cognition in rodents and humans. gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptors are believed to play a major role in cognition since they are predominantly expressed in the hippocampus in rats, where they regulate nmdar-dependent synaptic plasticity underlying learning and memory processes (\u003ca href=\"#b62\">schulz et al., 2018\u003c/a>; \u003ca href=\"#b23\">fritschy et al., 1997\u003c/a>; \u003ca href=\"#b63\">schulz et al., 2019\u003c/a>; \u003ca href=\"#b14\">davenport et al., 2021\u003c/a>). moreover, it has been proposed that gaba\u003csub>a\u003c/sub> pams may induce memory impairment by modulating hippocampal function (\u003ca href=\"#b41\">mcnaughton and morris, 1987\u003c/a>). therefore, alogabat was evaluated in several rodent tests of cognition to determine whether a selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 pam would induce cognitive impairment following acute administration in rats. there was no effect of alogabat up to 70% gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro on cognition (visual&#x02013;spatial memory, attention, context fear conditioning, spatial learning, and memory). cognitive impairment was only observed at high doses (&#x0003e;70% ro) and supra-therapeutic levels of alogabat in associative (fear) learning (cfc) and spatial memory in the mwm in wildtype rats. the impairment at high doses is likely linked to the loss of selectivity toward gaba\u003csub>a\u003c/sub> &#x003b1;1, &#x003b1;2, and &#x003b1;3 receptor subtypes (&#x003b1;1 ro was calculated as 19%&#x02013;25% at these doses; see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). in addition to the loss of selectivity, we cannot exclude the possibility that these effects may be a consequence of gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor saturation, i.e., excessive &#x003b1;5 activity in wildtype subjects may be detrimental. the cognitive impairment observed in wildtype rats may translate to healthy human subjects; however, our focus is on the effect of &#x003b1;5 pams in disease conditions with impaired gaba\u003csub>a\u003c/sub> signaling and impaired cognition, where our hypothesis is that an &#x003b1;5 pam would have beneficial effects.\u003c/p>\u003cp class=\"mb0\">alogabat had no effect on social approach/avoidance, the elevated plus maze, and the vogel conflict test in rats at ro levels up to 80% (see \u003ca href=\"#sm1\">supplementary figure s4\u003c/a> and methods in \u003ca href=\"#sm1\">supplementary material\u003c/a>), suggesting that alogabat does not exhibit an anxiolytic-like effect in rodents. this might be explained by the low expression of gaba\u003csub>a\u003c/sub>-&#x003b1;5 in the amygdala, a key node controlling anxiety-like behaviors. potential anxiolytic effects of alogabat in humans cannot be excluded as this receptor subtype is much more abundant in the human amygdala. since benzodiazepines, such as diazepam, are frequently used to treat anxiety and seizures in ndds, it was important to establish that alogabat at relevant therapeutic doses in mouse models did not worsen the sedative/motor-impairing effects of diazepam in the rotarod test. alogabat did not worsen diazepam-induced motor impairment; on the contrary, in combination, it reduced the motor impairments, which is more likely due to the more localized and precise inhibitory effect, counterbalancing the broader suppression of neuronal activity by diazepam, or due to lower intrinsic activity at &#x003b1;1 receptors compared to diazepam. we have previously shown that a gaba\u003csub>a\u003c/sub>-&#x003b1;5 nam, which binds at the benzodiazepine binding site of the receptor, does not decrease the anxiolytic activity of chlordiazepoxide (see \u003ca href=\"#sm1\">supplementary figure s5\u003c/a>); therefore, it is unlikely that alogabat will interfere with the anxiolytic effect of the classical benzodiazepines.\u003c/p>\u003ca id=\"h6\" name=\"h6\">\u003c/a>\u003ch2>5 conclusion\u003c/h2>\u003cp class=\"mb15\">multiple lines of evidence point to deficits in gabaergic signaling in epilepsy and ndds, such as asd and deletion as, with a prominent role attributed to gaba\u003csub>a\u003c/sub> receptors, including the gaba\u003csub>a\u003c/sub>-&#x003b1;5 receptor subtype. the current data for alogabat showed robust dose-dependent efficacy on repetitive behaviors in two disease-relevant mouse models and anti-seizure activity in the ptz rat model at gaba\u003csub>a\u003c/sub>-&#x003b1;5 ro above 50%. our \u003cem>in vivo\u003c/em> occupancy measurements using the selective &#x003b1;5 tracer l-655,708 were highly valuable for understanding plasma and csf exposures (as a surrogate of free brain concentration) and their relationship to \u003cem>in vivo\u003c/em> effects. we observed that there was a 34-fold shift between the csf concentration of alogabat in the \u003cem>in vivo\u003c/em> occupancy study and that of alogabat \u003cem>in vitro\u003c/em> binding data (ki value). the receptor occupancy of alogabat correlates well with pd effects (\u003cem>in vivo\u003c/em> effects) and is consistent across the different studies/species (see \u003ca href=\"#sm1\">supplementary table s6\u003c/a>). this finding highlights the importance of using pet tracers in drug development.\u003c/p>\u003cp class=\"mb15\">our data suggest that gaba\u003csub>a\u003c/sub>-&#x003b1;5 pams may have potential benefits in individuals with autistic features and in conditions with clinical and nonclinical manifestations of cortical hyperexcitability and epilepsy. however, alogabat is unlikely to work across all ndds and should be utilized as a precision medicine to target a specific subgroup of the ndd population with deficient gaba\u003csub>a\u003c/sub> pathway signaling, or specifically gaba\u003csub>a\u003c/sub>-&#x003b1;5. interestingly, recent data suggest that gaba\u003csub>a\u003c/sub>-&#x003b1;5 pams may also have therapeutic potential in schizophrenia, alzheimer&#x02019;s disease, and depression (\u003ca href=\"#b53\">perez et al., 2023\u003c/a>; \u003ca href=\"#b39\">luscher et al., 2023\u003c/a>; \u003ca href=\"#b36\">koh et al., 2013\u003c/a>). with regard to the current status of alogabat, good-laboratory practice (glp) toxicology and safety pharmacology studies in rats and minipigs showed an overall benign safety profile, which supported its clinical investigations in phase-1 studies in healthy volunteers and phase-2 trials in asd and deletion as patients (nct03507569, nct03774576, nct03847987, nct04299464, nct05630066, and eudract&#x00023;2019-003524-20). the outcome of these studies, including pet, eeg, and effects on cognition, will be reported in the future.\u003c/p>\u003ca id=\"h7\" name=\"h7\">\u003c/a>\u003ch2>data availability statement\u003c/h2>\u003cp class=\"mb15\">the original contributions presented in the study are included in the article/\u003ca href=\"#sm1\">supplementary material\u003c/a>, further inquiries can be directed to the corresponding author.\u003c/p>\u003ca id=\"h8\" name=\"h8\">\u003c/a>\u003ch2>ethics statement\u003c/h2>\u003cp class=\"mb0\">experiments performed at f. hoffmann-la roche ag (basel, switzerland) complied with swiss federal and cantonal laws on animal research and aaalac regulations and received prior approval from the cantonal veterinary office. the eeg study was conducted at brains online (ca, united states) in accordance with the guide for the care and use of laboratory animals (national research council 2011) after receiving approval from the institutional animal care and use committee. the ptz and mes tests were conducted at vivocore inc., canada, which is a facility licensed by the ontario ministry of agriculture, food, and rural affairs and accredited by the canadian council on animal care. all \u003cem>in vivo\u003c/em> studies are reported in compliance with the arrive guidelines (\u003ca href=\"#b52\">percie du sert et al., 2020\u003c/a>). the study was conducted in accordance with the local legislation and institutional requirements.\u003c/p>\u003ca id=\"h9\" name=\"h9\">\u003c/a>\u003ch2>author contributions\u003c/h2>\u003cp class=\"mb0\">gc: supervision, writing - original draft, investigation, formal analysis. tmb: formal analysis, investigation, writing - review and editing, methodology. fk: formal analysis, writing - original draft, investigation, methodology. mh: writing - original draft, investigation, methodology, formal analysis. jfh: data curation, visualization, methodology, writing - original draft, formal analysis. pg: methodology, data curation, formal analysis, writing - original draft. tm: investigation, writing - original draft, formal analysis, methodology. bk: investigation, writing - original draft, methodology, formal analysis. anb: formal analysis, writing - original draft, data curation. epp: writing - original draft, methodology, investigation. ps: methodology, investigation, writing - original draft, formal analysis. pj: writing - original draft, formal analysis. rr: methodology, writing - original draft, investigation, formal analysis. bb: methodology, investigation, writing - original draft. hk: methodology, writing - original draft, investigation. ao-m: writing - original draft, formal analysis, methodology. alb: methodology, writing - original draft, investigation. jms: investigation, formal analysis, writing - original draft. db: methodology, writing - original draft, investigation. ms: writing - original draft, methodology, investigation. eco&#x00027;c: investigation, writing - original draft, methodology. m-ch: investigation, conceptualization, writing - review and editing, supervision, writing - original draft, methodology.\u003c/p>\u003ca id=\"h10\" name=\"h10\">\u003c/a>\u003ch2>funding\u003c/h2>\u003cp class=\"mb0\">the author(s) declare that financial support was received for the research and/or publication of this article. the funding was provided by f. hoffmann-la roche ag switzerland.\u003c/p>\u003ca id=\"h11\" name=\"h11\">\u003c/a>\u003ch2>acknowledgments\u003c/h2>\u003cp class=\"mb03\">the authors thank gregoire friz, maria karg, and judith lengyel (molecular biology and binding assays); v&#x000e9;ronique graf, rachel haab, and marie-claire pflimlin (\u003cem>in vitro\u003c/em> electrophysiology); brigitte algeyer, severine bandinelli, sean durkin, audrey genet, marie haman, martine maco, and roger wyler (behavioral pharmacology); and stephanie sch&#x000f6;ppenthau, s&#x000e9;bastien debilly, and thomas bielser (\u003cem>in vivo\u003c/em> phmri). the rat ptz and mes studies were carried out under the scientific guidance of dr guy higgins, intervivo solutions, and coordinated by leo silenieks at vivocore inc., ontario, canada. the rat eeg data acquisition was undertaken by brains on-line llc, south san francisco, united states, and the data analysis was undertaken by pg, vanessa keeney, and andr&#x000e9;s olivares at roche.\u003c/p>\u003ca id=\"h12\" name=\"h12\">\u003c/a>\u003ch2>conflict of interest\u003c/h2>\u003cp class=\"mb0\">authors gc, tmb, fk, mh, jfh, pg, tm, bk, ab, epp, ps, pj, rr, bb, hk, ao-m, ab, jms, ms, eco&#x00027;c, and m-ch were employed by f. hoffmann-la roche ag switzerland. all employees (former and current) may be eligible for stock and stock options. author db was employed by hiqscreen s&#x000e0;rl.\u003c/p>\u003ca id=\"h13\" name=\"h13\">\u003c/a>\u003ch2>generative ai statement\u003c/h2>\u003cp class=\"mb15\">the author(s) declare that no generative ai was used in the creation of this manuscript.\u003c/p>\u003ca id=\"h14\" name=\"h14\">\u003c/a>\u003ch2>publisher&#x02019;s note\u003c/h2>\u003cp class=\"mb15\">all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.\u003c/p>\u003ca id=\"h15\" name=\"h15\">\u003c/a>\u003ch2>supplementary material\u003c/h2>\u003cp class=\"mb15\" id=\"sm1\">the supplementary material for this article can be found online at: \u003ca href=\"https://www.frontiersin.org/articles/10.3389/fphar.2025.1626078/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fphar.2025.1626078/full&#x00023;supplementary-material\u003c/a>\u003c/p>\u003ca id=\"h16\" name=\"h16\">\u003c/a>\u003ch2>abbreviations\u003c/h2>\u003cp class=\"mb15\">as, angelman syndrome; asd, autism spectrum disorder; cfc, context fear conditioning; cntnap2, contactin-associated protein-like 2; cpt, continuous performance test; 5-csrt, 5-choice serial reaction time; eeg, electroencephalography; gaba, gamma-aminobutyric acid; gad, glutamic acid decarboxylase; i.p., intraperitoneally; i.v., intravenously; lfp, local field potential; mes, maximum electrical stimulus; mwm, morris water maze; ndds, neurodevelopmental disorders; pal, paired associates learning; pam, positive allosteric modulator; phmri, pharmacological magnetic resonance imaging; p.o, per os; ptz, pentylenetetrazole; ro, receptor occupancy; pet, positron emission tomography.\u003c/p>\u003ca id=\"h17\" name=\"h17\">\u003c/a>\u003ch2>references\u003c/h2>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b1\" id=\"b1\">\u003c/a>abrahams, b. s., and geschwind, d. h. (2008). advances in autism genetics: on the threshold of a new neurobiology. \u003cem>nat. rev. genet.\u003c/em> 9, 341&#x02013;355. doi:10.1038/nrg2346\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/18414403/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nrg2346\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=advances+in+autism+genetics:+on+the+threshold+of+a+new+neurobiology&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b2\" id=\"b2\">\u003c/a>ali, a. b., and thomson, a. m. (2008). synaptic alpha 5 subunit-containing gabaa receptors mediate ipsps elicited by dendrite-preferring cells in rat neocortex. \u003cem>cereb. cortex\u003c/em> 18, 1260&#x02013;1271. doi:10.1093/cercor/bhm160\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17951598/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1093/cercor/bhm160\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=synaptic+alpha+5+subunit-containing+gabaa+receptors+mediate+ipsps+elicited+by+dendrite-preferring+cells+in+rat+neocortex&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\" style=\"margin-bottom:0.5em;\">\u003cp class=\"referencescopy1\">\u003ca name=\"b3\" id=\"b3\">\u003c/a>american psychiatric association (2008). \u003cem>diagnostic and statistical manual of mental disorders\u003c/em>. 5th ed. washington: \u003cspan class=\"publisher-name\">american psychiatric association\u003c/span>. \u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=american+psychiatric+association+%2c+diagnostic+and+statistical+manual+of+mental+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b4\" id=\"b4\">\u003c/a>ballard, t. m., knoflach, f., prinssen, e., borroni, e., vivian, j. a., basile, j., et al. (2009). ro4938581, a novel cognitive enhancer acting at gabaa alpha5 subunit-containing receptors. \u003cem>psychopharmacol. berl.\u003c/em> 202, 207&#x02013;223. doi:10.1007/s00213-008-1357-7\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/18936916/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1007/s00213-008-1357-7\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=ro4938581%2c+a+novel+cognitive+enhancer+acting+at+gabaa+alpha5+subunit-containing+receptors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b5\" id=\"b5\">\u003c/a>ballard, t. m., woolley, m. l., prinssen, e., huwyler, j., porter, r., and spooren, w. (2005). the effect of the mglu5 receptor antagonist mpep in rodent tests of anxiety and cognition: a comparison. \u003cem>psychopharmacol. berl.\u003c/em> 179, 218&#x02013;229. doi:10.1007/s00213-005-2211-9\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/15739074/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1007/s00213-005-2211-9\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+effect+of+the+mglu5+receptor+antagonist+mpep+in+rodent+tests+of+anxiety+and+cognition:+a+comparison&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b6\" id=\"b6\">\u003c/a>banerjee, a., garcia-oscos, f., roychowdhury, s., galindo, l. c., hall, s., kilgard, m. p., et al. (2013). impairment of cortical gabaergic synaptic transmission in an environmental rat model of autism. \u003cem>int. j. neuropsychopharmacol.\u003c/em> 16, 1309&#x02013;1318. doi:10.1017/s1461145712001216\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23228615/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1017/s1461145712001216\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=impairment+of+cortical+gabaergic+synaptic+transmission+in+an+environmental+rat+model+of+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b7\" id=\"b7\">\u003c/a>bourgeron, t. (2015). from the genetic architecture to synaptic plasticity in autism spectrum disorder. \u003cem>nat. rev. neurosci.\u003c/em> 16, 551&#x02013;563. doi:10.1038/nrn3992\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26289574/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nrn3992\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=from+the+genetic+architecture+to+synaptic+plasticity+in+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b8\" id=\"b8\">\u003c/a>braat, s., and kooy, r. f. (2015). the gabaa receptor as a therapeutic target for neurodevelopmental disorders. \u003cem>neuron\u003c/em> 86, 1119&#x02013;1130. doi:10.1016/j.neuron.2015.03.042\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26050032/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuron.2015.03.042\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+gabaa+receptor+as+a+therapeutic+target+for+neurodevelopmental+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b9\" id=\"b9\">\u003c/a>bruns, a., kunnecke, b., risterucci, c., moreau, j. l., and von kienlin, m. (2009). validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological mri in rats. \u003cem>magn. reson med.\u003c/em> 61, 1451&#x02013;1458. doi:10.1002/mrm.21779\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/19358231/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/mrm.21779\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=validation+of+cerebral+blood+perfusion+imaging+as+a+modality+for+quantitative+pharmacological+mri+in+rats&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\" style=\"margin-bottom:0.5em;\">\u003cp class=\"referencescopy1\">\u003ca name=\"b10\" id=\"b10\">\u003c/a>buettelmann, b., cecere, g., fasching, b., groebke zbinden, k., hernandez, m.-c., knust, h., et al. (2018). \u003cem>preparation of new isoxazolyl ether derivatives as gabaa &#x003b1;5 receptor positive allosteric modulators (pams)\u003c/em>. \u003cspan class=\"publisher-name\">copyright &#x000a9; 2025 american chemical society acs\u003c/span>. available online at: \u003ca href=\"https://worldwide.espacent.com/patent/search/family/057530563/publication/wo2018104419a1?q=wo2018104419a1\">https://worldwide.espacent.com/patent/search/family/057530563/publication/wo2018104419a1?q&#x0003d;wo2018104419a1\u003c/a>\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=â buettelmannâ bcecereâ gfaschingâ bgroebke+zbindenâ khernandezâ m-cknustâ het+al+2018+preparation+of+new+isoxazolyl+ether+derivatives+as+gabaa+î±5+receptor+positive+allosteric+modulators+pams+copyright+â©+2025+american+chemical+society+acs+available+online+at:+https://worldwideespacentcom/patent/search/family/057530563/publication/wo2018104419a1?q=wo2018104419a1&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b12\" id=\"b12\">\u003c/a>buiting, k. (2010). prader-willi syndrome and angelman syndrome. \u003cem>am. j. med. genet. c semin. med. genet.\u003c/em> 154c, 365&#x02013;376. doi:10.1002/ajmg.c.30273\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/20803659/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/ajmg.c.30273\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=prader-willi+syndrome+and+angelman+syndrome&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b13\" id=\"b13\">\u003c/a>chao, h. t., chen, h., samaco, r. c., xue, m., chahrour, m., yoo, j., et al. (2010). dysfunction in gaba signalling mediates autism-like stereotypies and rett syndrome phenotypes. \u003cem>nature\u003c/em> 468, 263&#x02013;269. doi:10.1038/nature09582\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21068835/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nature09582\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=dysfunction+in+gaba+signalling+mediates+autism-like+stereotypies+and+rett+syndrome+phenotypes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b14\" id=\"b14\">\u003c/a>davenport, c. m., rajappa, r., katchan, l., taylor, c. r., tsai, m. c., smith, c. m., et al. (2021). relocation of an extrasynaptic gaba(a) receptor to inhibitory synapses freezes excitatory synaptic strength and preserves memory. \u003cem>neuron\u003c/em> 109, 123&#x02013;134 e4. doi:10.1016/j.neuron.2020.09.037\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/33096025/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuron.2020.09.037\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=relocation+of+an+extrasynaptic+gabaa+receptor+to+inhibitory+synapses+freezes+excitatory+synaptic+strength+and+preserves+memory&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b15\" id=\"b15\">\u003c/a>delong, r. (2007). gaba(a) receptor alpha5 subunit as a candidate gene for autism and bipolar disorder: a proposed endophenotype with parent-of-origin and gain-of-function features,with or without oculocutaneous albinism. \u003cem>autism\u003c/em> 11, 135&#x02013;147. doi:10.1177/1362361307075705\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17353214/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1177/1362361307075705\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa+receptor+alpha5+subunit+as+a+candidate+gene+for+autism+and+bipolar+disorder:+a+proposed+endophenotype+with+parent-of-origin+and+gain-of-function+features%2cwith+or+without+oculocutaneous+albinism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b16\" id=\"b16\">\u003c/a>delorey, t. m. (2005). gabrb3 gene deficient mice: a potential model of autism spectrum disorder. \u003cem>int. rev. neurobiol.\u003c/em> 71, 359&#x02013;382. doi:10.1016/s0074-7742(05)71015-1\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/16512358/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0074-7742(05)71015-1\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabrb3+gene+deficient+mice:+a+potential+model+of+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b17\" id=\"b17\">\u003c/a>delorey, t. m., sahbaie, p., hashemi, e., homanics, g. e., and clark, j. d. (2008). gabrb3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: a potential model of autism spectrum disorder. \u003cem>behav. brain res.\u003c/em> 187, 207&#x02013;220. doi:10.1016/j.bbr.2007.09.009\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17983671/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.bbr.2007.09.009\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabrb3+gene+deficient+mice+exhibit+impaired+social+and+exploratory+behaviors%2c+deficits+in+non-selective+attention+and+hypoplasia+of+cerebellar+vermal+lobules:+a+potential+model+of+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b18\" id=\"b18\">\u003c/a>dhossche, d., applegate, h., abraham, a., maertens, p., bland, l., bencsath, a., et al. (2002). elevated plasma gamma-aminobutyric acid (gaba) levels in autistic youngsters: stimulus for a gaba hypothesis of autism. \u003cem>med. sci. monit.\u003c/em> 8, pr1&#x02013;pr6.\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/12165753/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=elevated+plasma+gamma-aminobutyric+acid+gaba+levels+in+autistic+youngsters:+stimulus+for+a+gaba+hypothesis+of+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b19\" id=\"b19\">\u003c/a>di nanni, n., bersanelli, m., cupaioli, f. a., milanesi, l., mezzelani, a., and mosca, e. (2019). network-based integrative analysis of genomics, epigenomics and transcriptomics in autism spectrum disorders. \u003cem>int. j. mol. sci.\u003c/em> 20, 3363. doi:10.3390/ijms20133363\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/31323926/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.3390/ijms20133363\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=network-based+integrative+analysis+of+genomics%2c+epigenomics+and+transcriptomics+in+autism+spectrum+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b20\" id=\"b20\">\u003c/a>dufour, b. d., mcbride, e., bartley, t., juarez, p., and martinez-cerdeno, v. (2023). distinct patterns of gabaergic interneuron pathology in autism are associated with intellectual impairment and stereotypic behaviors. \u003cem>autism\u003c/em> 27, 1730&#x02013;1745. doi:10.1177/13623613231154053\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/36935610/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1177/13623613231154053\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=distinct+patterns+of+gabaergic+interneuron+pathology+in+autism+are+associated+with+intellectual+impairment+and+stereotypic+behaviors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b21\" id=\"b21\">\u003c/a>fatemi, s. h., halt, a. r., stary, j. m., kanodia, r., schulz, s. c., and realmuto, g. r. (2002). glutamic acid decarboxylase 65 and 67 kda proteins are reduced in autistic parietal and cerebellar cortices. \u003cem>biol. psychiatry\u003c/em> 52, 805&#x02013;810. doi:10.1016/s0006-3223(02)01430-0\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/12372652/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0006-3223(02)01430-0\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=glutamic+acid+decarboxylase+65+and+67+kda+proteins+are+reduced+in+autistic+parietal+and+cerebellar+cortices&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b22\" id=\"b22\">\u003c/a>friedman, h., greenblatt, d. j., peters, g. r., metzler, c. m., charlton, m. d., harmatz, j. s., et al. (1992). pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. \u003cem>clin. pharmacol. ther.\u003c/em> 52, 139&#x02013;150. doi:10.1038/clpt.1992.123\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/1505149/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/clpt.1992.123\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=pharmacokinetics+and+pharmacodynamics+of+oral+diazepam:+effect+of+dose%2c+plasma+concentration%2c+and+time&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b23\" id=\"b23\">\u003c/a>fritschy, j. m., benke, d., johnson, d. k., mohler, h., and rudolph, u. (1997). gabaa-receptor alpha-subunit is an essential prerequisite for receptor formation \u003cem>in vivo\u003c/em>. \u003cem>neuroscience\u003c/em> 81, 1043&#x02013;1053. doi:10.1016/s0306-4522(97)00244-3\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/9330366/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0306-4522(97)00244-3\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa-receptor+alpha-subunit+is+an+essential+prerequisite+for+receptor+formation+in+vivo&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b24\" id=\"b24\">\u003c/a>frohlich, j., miller, m. t., bird, l. m., garces, p., purtell, h., hoener, m. c., et al. (2019a). electrophysiological phenotype in angelman syndrome differs between genotypes. \u003cem>biol. psychiatry\u003c/em> 85, 752&#x02013;759. doi:10.1016/j.biopsych.2019.01.008\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/30826071/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.biopsych.2019.01.008\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=electrophysiological+phenotype+in+angelman+syndrome+differs+between+genotypes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b25\" id=\"b25\">\u003c/a>frohlich, j., reiter, l. t., saravanapandian, v., distefano, c., huberty, s., hyde, c., et al. (2019b). mechanisms underlying the eeg biomarker in dup15q syndrome. \u003cem>mol. autism\u003c/em> 10, 29. doi:10.1186/s13229-019-0280-6\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/31312421/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1186/s13229-019-0280-6\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=mechanisms+underlying+the+eeg+biomarker+in+dup15q+syndrome&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b26\" id=\"b26\">\u003c/a>frye, r. e., casanova, m. f., fatemi, s. h., folsom, t. d., reutiman, t. j., brown, g. l., et al. (2016). neuropathological mechanisms of seizures in autism spectrum disorder. \u003cem>front. neurosci.\u003c/em> 10, 192. doi:10.3389/fnins.2016.00192\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27242398/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.3389/fnins.2016.00192\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=neuropathological+mechanisms+of+seizures+in+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b27\" id=\"b27\">\u003c/a>fukuda, t., itoh, m., ichikawa, t., washiyama, k., and goto, y. (2005). delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of mecp2-deficient mice. \u003cem>j. neuropathol. exp. neurol.\u003c/em> 64, 537&#x02013;544. doi:10.1093/jnen/64.6.537\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/15977646/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1093/jnen/64.6.537\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=delayed+maturation+of+neuronal+architecture+and+synaptogenesis+in+cerebral+cortex+of+mecp2-deficient+mice&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b28\" id=\"b28\">\u003c/a>gaetz, w., bloy, l., wang, d. j., port, r. g., blaskey, l., levy, s. e., et al. (2014). gaba estimation in the brains of children on the autism spectrum: measurement precision and regional cortical variation. \u003cem>neuroimage\u003c/em> 86, 1&#x02013;9. doi:10.1016/j.neuroimage.2013.05.068\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23707581/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuroimage.2013.05.068\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gaba+estimation+in+the+brains+of+children+on+the+autism+spectrum:+measurement+precision+and+regional+cortical+variation&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b29\" id=\"b29\">\u003c/a>han, s., tai, c., jones, c. j., scheuer, t., and catterall, w. a. (2014). enhancement of inhibitory neurotransmission by gabaa receptors having &#x003b1;2,3-subunits ameliorates behavioral deficits in a mouse model of autism. \u003cem>neuron\u003c/em> 81, 1282&#x02013;1289. doi:10.1016/j.neuron.2014.01.016\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/24656250/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuron.2014.01.016\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=enhancement+of+inhibitory+neurotransmission+by+gabaa+receptors+having+î±2%2c3-subunits+ameliorates+behavioral+deficits+in+a+mouse+model+of+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b30\" id=\"b30\">\u003c/a>han, s., tai, c., westenbroek, r. e., yu, f. h., cheah, c. s., potter, g. b., et al. (2012). autistic-like behaviour in scn1a&#x0002b;/- mice and rescue by enhanced gaba-mediated neurotransmission. \u003cem>nature\u003c/em> 489, 385&#x02013;390. doi:10.1038/nature11356\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22914087/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/nature11356\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=autistic-like+behaviour+in+scn1a+/-+mice+and+rescue+by+enhanced+gaba-mediated+neurotransmission&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b31\" id=\"b31\">\u003c/a>hipp, j. f., knoflach, f., comley, r., ballard, t. m., honer, m., trube, g., et al. (2021). basmisanil, a highly selective gaba\u003csub>a\u003c/sub>-&#x003b1;5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man. \u003cem>sci. rep.\u003c/em> 11, 7700. doi:10.1038/s41598-021-87307-7\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/33833333/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/s41598-021-87307-7\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=basmisanil%2c+a+highly+selective+gabaa-î±5+negative+allosteric+modulator:+preclinical+pharmacology+and+demonstration+of+functional+target+engagement+in+man&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b32\" id=\"b32\">\u003c/a>hogart, a., wu, d., lasalle, j. m., and schanen, n. c. (2010). the comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. \u003cem>neurobiol. dis.\u003c/em> 38, 181&#x02013;191. doi:10.1016/j.nbd.2008.08.011\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/18840528/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.nbd.2008.08.011\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+comorbidity+of+autism+with+the+genomic+disorders+of+chromosome+15q112-q13&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b33\" id=\"b33\">\u003c/a>hu, x., rocco, b. r., fee, c., and sibille, e. (2019). cell type-specific gene expression of alpha 5 subunit-containing gamma-aminobutyric acid subtype a receptors in human and mouse frontal cortex. \u003cem>mol. neuropsychiatry\u003c/em> 4, 204&#x02013;215. doi:10.1159/000495840\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/30815456/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1159/000495840\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=cell+type-specific+gene+expression+of+alpha+5+subunit-containing+gamma-aminobutyric+acid+subtype+a+receptors+in+human+and+mouse+frontal+cortex&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b34\" id=\"b34\">\u003c/a>hvoslef-eide, m., nilsson, s. r., saksida, l. m., and bussey, t. j. (2016). cognitive translation using the rodent touchscreen testing approach. \u003cem>curr. top. behav. neurosci.\u003c/em> 28, 423&#x02013;447. doi:10.1007/7854_2015_5007\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27305921/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1007/7854_2015_5007\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=cognitive+translation+using+the+rodent+touchscreen+testing+approach&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b35\" id=\"b35\">\u003c/a>kalsner, l., and chamberlain, s. j. (2015). prader-willi, angelman, and 15q11-q13 duplication syndromes. \u003cem>pediatr. clin. north am.\u003c/em> 62, 587&#x02013;606. doi:10.1016/j.pcl.2015.03.004\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26022164/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.pcl.2015.03.004\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=prader-willi%2c+angelman%2c+and+15q11-q13+duplication+syndromes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b36\" id=\"b36\">\u003c/a>koh, m. t., rosenzweig-lipson, s., and gallagher, m. (2013). selective gaba(a) &#x003b1;5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. \u003cem>neuropharmacology\u003c/em> 64, 145&#x02013;152. doi:10.1016/j.neuropharm.2012.06.023\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22732440/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2012.06.023\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=selective+gabaa+î±5+positive+allosteric+modulators+improve+cognitive+function+in+aged+rats+with+memory+impairment&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b37\" id=\"b37\">\u003c/a>lim, c. s., kim, h., yu, n. k., kang, s. j., kim, t., ko, h. g., et al. (2017). enhancing inhibitory synaptic function reverses spatial memory deficits in shank2 mutant mice. \u003cem>neuropharmacology\u003c/em> 112, 104&#x02013;112. doi:10.1016/j.neuropharm.2016.08.016\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27544825/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2016.08.016\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=enhancing+inhibitory+synaptic+function+reverses+spatial+memory+deficits+in+shank2+mutant+mice&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b38\" id=\"b38\">\u003c/a>luk, h. m., and lo, i. f. (2016). angelman syndrome in hong kong chinese: a 20 years&#x00027; experience. \u003cem>eur. j. med. genet.\u003c/em> 59, 315&#x02013;319. doi:10.1016/j.ejmg.2016.05.003\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27174604/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.ejmg.2016.05.003\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=angelman+syndrome+in+hong+kong+chinese:+a+20+years'+experience&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b39\" id=\"b39\">\u003c/a>luscher, b., maguire, j. l., rudolph, u., and sibille, e. (2023). gaba(a) receptors as targets for treating affective and cognitive symptoms of depression. \u003cem>trends pharmacol. sci.\u003c/em> 44, 586&#x02013;600. doi:10.1016/j.tips.2023.06.009\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/37543478/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.tips.2023.06.009\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa+receptors+as+targets+for+treating+affective+and+cognitive+symptoms+of+depression&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b40\" id=\"b40\">\u003c/a>mcfarlane, h. g., kusek, g. k., yang, m., phoenix, j. l., bolivar, v. j., and crawley, j. n. (2008). autism-like behavioral phenotypes in btbr t&#x0002b;tf/j mice. \u003cem>genes brain behav.\u003c/em> 7, 152&#x02013;163. doi:10.1111/j.1601-183x.2007.00330.x\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17559418/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1111/j.1601-183x.2007.00330.x\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=autism-like+behavioral+phenotypes+in+btbr+t+tf/j+mice&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b41\" id=\"b41\">\u003c/a>mcnaughton, n., and morris, r. g. (1987). chlordiazepoxide, an anxiolytic benzodiazepine, impairs place navigation in rats. \u003cem>behav. brain res.\u003c/em> 24, 39&#x02013;46. doi:10.1016/0166-4328(87)90034-9\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/3580114/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/0166-4328(87)90034-9\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=chlordiazepoxide%2c+an+anxiolytic+benzodiazepine%2c+impairs+place+navigation+in+rats&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b42\" id=\"b42\">\u003c/a>mendez, m. a., horder, j., myers, j., coghlan, s., stokes, p., erritzoe, d., et al. (2013). the brain gaba-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)c]ro15-4513 positron emission tomography study. \u003cem>neuropharmacology\u003c/em> 68, 195&#x02013;201. doi:10.1016/j.neuropharm.2012.04.008\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22546616/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2012.04.008\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+brain+gaba-benzodiazepine+receptor+alpha-5+subtype+in+autism+spectrum+disorder:+a+pilot+%5b11c%5dro15-4513+positron+emission+tomography+study&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b43\" id=\"b43\">\u003c/a>mermer, f., poliquin, s., rigsby, k., rastogi, a., shen, w., romero-morales, a., et al. (2021). common molecular mechanisms of slc6a1 variant-mediated neurodevelopmental disorders in astrocytes and neurons. \u003cem>brain\u003c/em> 144, 2499&#x02013;2512. doi:10.1093/brain/awab207\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/34028503/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1093/brain/awab207\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=common+molecular+mechanisms+of+slc6a1+variant-mediated+neurodevelopmental+disorders+in+astrocytes+and+neurons&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b44\" id=\"b44\">\u003c/a>mertz, l. g., christensen, r., vogel, i., hertz, j. m., nielsen, k. b., gronskov, k., et al. (2013). angelman syndrome in denmark. birth incidence, genetic findings, and age at diagnosis. \u003cem>am. j. med. genet. a\u003c/em> 161a, 2197&#x02013;2203. doi:10.1002/ajmg.a.36058\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23913711/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/ajmg.a.36058\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=angelman+syndrome+in+denmark+birth+incidence%2c+genetic+findings%2c+and+age+at+diagnosis&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b45\" id=\"b45\">\u003c/a>mesbah-oskui, l., penna, a., orser, b. a., and horner, r. l. (2017). reduced expression of &#x003b1;5gaba\u003csub>a\u003c/sub> receptors elicits autism-like alterations in eeg patterns and sleep-wake behavior. \u003cem>neurotoxicol teratol.\u003c/em> 61, 115&#x02013;122. doi:10.1016/j.ntt.2016.10.009\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27793660/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.ntt.2016.10.009\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=reduced+expression+of+î±5gabaa+receptors+elicits+autism-like+alterations+in+eeg+patterns+and+sleep-wake+behavior&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b46\" id=\"b46\">\u003c/a>mohler, h. (2011). the rise of a new gaba pharmacology. \u003cem>neuropharmacology\u003c/em> 60, 1042&#x02013;1049. doi:10.1016/j.neuropharm.2010.10.020\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21035473/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2010.10.020\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+rise+of+a+new+gaba+pharmacology&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b47\" id=\"b47\">\u003c/a>mori, t., mori, k., fujii, e., toda, y., miyazaki, m., harada, m., et al. (2012). evaluation of the gabaergic nervous system in autistic brain: (123)i-iomazenil spect study. \u003cem>brain dev.\u003c/em> 34, 648&#x02013;654. doi:10.1016/j.braindev.2011.10.007\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/22099869/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.braindev.2011.10.007\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=evaluation+of+the+gabaergic+nervous+system+in+autistic+brain:+123i-iomazenil+spect+study&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b48\" id=\"b48\">\u003c/a>myers, j. f., comley, r. a., and gunn, r. n. (2017). quantification of [\u003csup>11\u003c/sup>c]ro15-4513 gaba\u003csub>a\u003c/sub>&#x003b1;5 specific binding and regional selectivity in humans. \u003cem>j. cereb. blood flow. metab.\u003c/em> 37, 2137&#x02013;2148. doi:10.1177/0271678x16661339\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27466376/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1177/0271678x16661339\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=quantification+of+%5b11c%5dro15-4513+gabaaî±5+specific+binding+and+regional+selectivity+in+humans&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b49\" id=\"b49\">\u003c/a>nakamura, t., arima-yoshida, f., sakaue, f., nasu-nishimura, y., takeda, y., matsuura, k., et al. (2016). px-rics-deficient mice mimic autism spectrum disorder in jacobsen syndrome through impaired gabaa receptor trafficking. \u003cem>nat. commun.\u003c/em> 7, 10861. doi:10.1038/ncomms10861\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26979507/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/ncomms10861\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=px-rics-deficient+mice+mimic+autism+spectrum+disorder+in+jacobsen+syndrome+through+impaired+gabaa+receptor+trafficking&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b50\" id=\"b50\">\u003c/a>orefice, l. l., zimmerman, a. l., chirila, a. m., sleboda, s. j., head, j. p., and ginty, d. d. (2016). peripheral mechanosensory neuron dysfunction underlies tactile and behavioral deficits in mouse models of asds. \u003cem>cell\u003c/em> 166, 299&#x02013;313. doi:10.1016/j.cell.2016.05.033\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27293187/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.cell.2016.05.033\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=peripheral+mechanosensory+neuron+dysfunction+underlies+tactile+and+behavioral+deficits+in+mouse+models+of+asds&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b51\" id=\"b51\">\u003c/a>penagarikano, o., abrahams, b. s., herman, e. i., winden, k. d., gdalyahu, a., dong, h., et al. (2011). absence of cntnap2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. \u003cem>cell\u003c/em> 147, 235&#x02013;246. doi:10.1016/j.cell.2011.08.040\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21962519/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.cell.2011.08.040\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=absence+of+cntnap2+leads+to+epilepsy%2c+neuronal+migration+abnormalities%2c+and+core+autism-related+deficits&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b52\" id=\"b52\">\u003c/a>percie du sert, n., hurst, v., ahluwalia, a., alam, s., avey, m. t., baker, m., et al. (2020). the arrive guidelines 2.0: updated guidelines for reporting animal research. \u003cem>plos biol.\u003c/em> 18, e3000410. doi:10.1371/journal.pbio.3000410\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/32663219/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1371/journal.pbio.3000410\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+arrive+guidelines+20:+updated+guidelines+for+reporting+animal+research&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b53\" id=\"b53\">\u003c/a>perez, s. m., mccoy, a. m., prevot, t. d., mian, m. y., carreno, f. r., frazer, a., et al. (2023). hippocampal &#x003b1;5-gaba(a) receptors modulate dopamine neuron activity in the rat ventral tegmental area. \u003cem>biol. psychiatry glob. open sci.\u003c/em> 3, 78&#x02013;86. doi:10.1016/j.bpsgos.2021.12.010\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/36712569/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.bpsgos.2021.12.010\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=hippocampal+î±5-gabaa+receptors+modulate+dopamine+neuron+activity+in+the+rat+ventral+tegmental+area&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b54\" id=\"b54\">\u003c/a>pirker, s., schwarzer, c., wieselthaler, a., sieghart, w., and sperk, g. (2000). gaba(a) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. \u003cem>neuroscience\u003c/em> 101, 815&#x02013;850. doi:10.1016/s0306-4522(00)00442-5\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/11113332/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0306-4522(00)00442-5\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=gabaa+receptors:+immunocytochemical+distribution+of+13+subunits+in+the+adult+rat+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b55\" id=\"b55\">\u003c/a>pizzarelli, r., and cherubini, e. (2011). alterations of gabaergic signaling in autism spectrum disorders. \u003cem>neural plast.\u003c/em> 2011, 297153. doi:10.1155/2011/297153\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21766041/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1155/2011/297153\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=alterations+of+gabaergic+signaling+in+autism+spectrum+disorders&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b56\" id=\"b56\">\u003c/a>porjesz, b., almasy, l., edenberg, h. j., wang, k., chorlian, d. b., foroud, t., et al. (2002). linkage disequilibrium between the beta frequency of the human eeg and a gabaa receptor gene locus. \u003cem>proc. natl. acad. sci. u. s. a.\u003c/em> 99, 3729&#x02013;3733. doi:10.1073/pnas.052716399\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/11891318/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1073/pnas.052716399\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=linkage+disequilibrium+between+the+beta+frequency+of+the+human+eeg+and+a+gabaa+receptor+gene+locus&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b57\" id=\"b57\">\u003c/a>puts, n. a. j., wodka, e. l., harris, a. d., crocetti, d., tommerdahl, m., mostofsky, s. h., et al. (2017). reduced gaba and altered somatosensory function in children with autism spectrum disorder. \u003cem>autism res.\u003c/em> 10, 608&#x02013;619. doi:10.1002/aur.1691\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27611990/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/aur.1691\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=reduced+gaba+and+altered+somatosensory+function+in+children+with+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b58\" id=\"b58\">\u003c/a>robertson, c. e., ratai, e. m., and kanwisher, n. (2016). reduced gabaergic action in the autistic brain. \u003cem>curr. biol.\u003c/em> 26, 80&#x02013;85. doi:10.1016/j.cub.2015.11.019\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26711497/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.cub.2015.11.019\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=reduced+gabaergic+action+in+the+autistic+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b59\" id=\"b59\">\u003c/a>rojas, d. c., singel, d., steinmetz, s., hepburn, s., and brown, m. s. (2014). decreased left perisylvian gaba concentration in children with autism and unaffected siblings. \u003cem>neuroimage\u003c/em> 86, 28&#x02013;34. doi:10.1016/j.neuroimage.2013.01.045\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/23370056/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuroimage.2013.01.045\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=decreased+left+perisylvian+gaba+concentration+in+children+with+autism+and+unaffected+siblings&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b60\" id=\"b60\">\u003c/a>rubenstein, j. l., and merzenich, m. m. (2003). model of autism: increased ratio of excitation/inhibition in key neural systems. \u003cem>genes brain behav.\u003c/em> 2, 255&#x02013;267. doi:10.1034/j.1601-183x.2003.00037.x\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/14606691/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1034/j.1601-183x.2003.00037.x\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=model+of+autism:+increased+ratio+of+excitation/inhibition+in+key+neural+systems&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b61\" id=\"b61\">\u003c/a>sanders, s. j. (2015). first glimpses of the neurobiology of autism spectrum disorder. \u003cem>curr. opin. genet. dev.\u003c/em> 33, 80&#x02013;92. doi:10.1016/j.gde.2015.10.002\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/26547130/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.gde.2015.10.002\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=first+glimpses+of+the+neurobiology+of+autism+spectrum+disorder&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b62\" id=\"b62\">\u003c/a>schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2018). dendrite-targeting interneurons control synaptic nmda-receptor activation \u003cem>via\u003c/em> nonlinear &#x003b1;5-gaba\u003csub>a\u003c/sub> receptors. \u003cem>nat. commun.\u003c/em> 9, 3576. doi:10.1038/s41467-018-06004-8\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/30177704/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1038/s41467-018-06004-8\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=dendrite-targeting+interneurons+control+synaptic+nmda-receptor+activation+via+nonlinear+î±5-gabaa+receptors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b63\" id=\"b63\">\u003c/a>schulz, j. m., knoflach, f., hernandez, m. c., and bischofberger, j. (2019). enhanced dendritic inhibition and impaired nmdar activation in a mouse model of down syndrome. \u003cem>j. neurosci.\u003c/em> 39, 5210&#x02013;5221. doi:10.1523/jneurosci.2723-18.2019\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/31000585/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1523/jneurosci.2723-18.2019\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=enhanced+dendritic+inhibition+and+impaired+nmdar+activation+in+a+mouse+model+of+down+syndrome&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b64\" id=\"b64\">\u003c/a>serwanski, d. r., miralles, c. p., christie, s. b., mehta, a. k., li, x., and de blas, a. l. (2006). synaptic and nonsynaptic localization of gabaa receptors containing the alpha5 subunit in the rat brain. \u003cem>j. comp. neurol.\u003c/em> 499, 458&#x02013;470. doi:10.1002/cne.21115\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/16998906/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/cne.21115\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=synaptic+and+nonsynaptic+localization+of+gabaa+receptors+containing+the+alpha5+subunit+in+the+rat+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b65\" id=\"b65\">\u003c/a>sieghart, w. (2006). structure, pharmacology, and function of gabaa receptor subtypes. \u003cem>adv. pharmacol.\u003c/em> 54, 231&#x02013;263. doi:10.1016/s1054-3589(06)54010-4\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/17175817/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s1054-3589(06)54010-4\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=structure%2c+pharmacology%2c+and+function+of+gabaa+receptor+subtypes&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b66\" id=\"b66\">\u003c/a>sitnikova, e., rutskova, e., and smirnov, k. (2023). alpha2-adrenergic receptors as a pharmacological target for spike-wave epilepsy. \u003cem>int. j. mol. sci.\u003c/em> 24, 1477. doi:10.3390/ijms24021477\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/36674992/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.3390/ijms24021477\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=alpha2-adrenergic+receptors+as+a+pharmacological+target+for+spike-wave+epilepsy&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b67\" id=\"b67\">\u003c/a>smit, d. j. a., wright, m. j., meyers, j. l., martin, n. g., ho, y. y. w., malone, s. m., et al. (2018). genome-wide association analysis links multiple psychiatric liability genes to oscillatory brain activity. \u003cem>hum. brain mapp.\u003c/em> 39, 4183&#x02013;4195. doi:10.1002/hbm.24238\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/29947131/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/hbm.24238\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=genome-wide+association+analysis+links+multiple+psychiatric+liability+genes+to+oscillatory+brain+activity&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b68\" id=\"b68\">\u003c/a>souza, a. j., freitas, i. s., sharmin, d., cook, j. m., guimaraes, f. s., and gomes, f. v. (2024). an alpha 5-gaba(a) receptor positive allosteric modulator attenuates social and cognitive deficits without changing dopamine system hyperactivity in rats exposed to valproic acid in utero. \u003cem>autism res.\u003c/em> 17, 1534&#x02013;1544. doi:10.1002/aur.3178\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/39169698/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/aur.3178\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=an+alpha+5-gabaa+receptor+positive+allosteric+modulator+attenuates+social+and+cognitive+deficits+without+changing+dopamine+system+hyperactivity+in+rats+exposed+to+valproic+acid+in+utero&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b69\" id=\"b69\">\u003c/a>sur, c., fresu, l., howell, o., mckernan, r. m., and atack, j. r. (1999). autoradiographic localization of alpha5 subunit-containing gabaa receptors in rat brain. \u003cem>brain res.\u003c/em> 822, 265&#x02013;270. doi:10.1016/s0006-8993(99)01152-x\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/10082908/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0006-8993(99)01152-x\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=autoradiographic+localization+of+alpha5+subunit-containing+gabaa+receptors+in+rat+brain&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\" style=\"margin-bottom:0.5em;\">\u003cp class=\"referencescopy1\">\u003ca name=\"b70\" id=\"b70\">\u003c/a>traub, r. d. w. m., and jefferys, j. g. r. (1999). \u003cem>fast oscillations in cortical circuits\u003c/em>. \u003cspan class=\"publisher-name\">the mit press\u003c/span>. \u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=â traubâ r+d+w+mjefferysâ j+g+r+1999+fast+oscillations+in+cortical+circuits+the+mit+press&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b71\" id=\"b71\">\u003c/a>van lier, h., drinkenburg, w. h., van eeten, y. j., and coenen, a. m. (2004). effects of diazepam and zolpidem on eeg beta frequencies are behavior-specific in rats. \u003cem>neuropharmacology\u003c/em> 47, 163&#x02013;174. doi:10.1016/j.neuropharm.2004.03.017\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/15223295/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/j.neuropharm.2004.03.017\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=effects+of+diazepam+and+zolpidem+on+eeg+beta+frequencies+are+behavior-specific+in+rats&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b72\" id=\"b72\">\u003c/a>visser, s. a., wolters, f. l., gubbens-stibbe, j. m., tukker, e., van der graaf, p. h., peletier, l. a., et al. (2003). mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of gabaa receptor modulators: in vitro-in vivo correlations. \u003cem>j. pharmacol. exp. ther.\u003c/em> 304, 88&#x02013;101. doi:10.1124/jpet.102.042341\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/12490579/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1124/jpet.102.042341\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=mechanism-based+pharmacokinetic/pharmacodynamic+modeling+of+the+electroencephalogram+effects+of+gabaa+receptor+modulators:+in+vitro-in+vivo+correlations&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b73\" id=\"b73\">\u003c/a>vithlani, m., terunuma, m., and moss, s. j. (2011). the dynamic modulation of gaba(a) receptor trafficking and its role in regulating the plasticity of inhibitory synapses. \u003cem>physiol. rev.\u003c/em> 91, 1009&#x02013;1022. doi:10.1152/physrev.00015.2010\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/21742794/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1152/physrev.00015.2010\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=the+dynamic+modulation+of+gabaa+receptor+trafficking+and+its+role+in+regulating+the+plasticity+of+inhibitory+synapses&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b74\" id=\"b74\">\u003c/a>warrier, v., baron-cohen, s., and chakrabarti, b. (2013). genetic variation in gabrb3 is associated with asperger syndrome and multiple endophenotypes relevant to autism. \u003cem>mol. autism\u003c/em> 4, 48. doi:10.1186/2040-2392-4-48\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/24321478/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1186/2040-2392-4-48\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=genetic+variation+in+gabrb3+is+associated+with+asperger+syndrome+and+multiple+endophenotypes+relevant+to+autism&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b75\" id=\"b75\">\u003c/a>whittington, m. a., traub, r. d., kopell, n., ermentrout, b., and buhl, e. h. (2000). inhibition-based rhythms: experimental and mathematical observations on network dynamics. \u003cem>int. j. psychophysiol.\u003c/em> 38, 315&#x02013;336. doi:10.1016/s0167-8760(00)00173-2\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/11102670/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/s0167-8760(00)00173-2\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=inhibition-based+rhythms:+experimental+and+mathematical+observations+on+network+dynamics&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b76\" id=\"b76\">\u003c/a>xie, x. h., and tietz, e. i. (1991). chronic benzodiazepine treatment of rats induces reduction of paired-pulse inhibition in ca1 region of \u003cem>in vitro\u003c/em> hippocampus. \u003cem>brain res.\u003c/em> 561, 69&#x02013;76. doi:10.1016/0006-8993(91)90750-p\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/1797351/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1016/0006-8993(91)90750-p\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=chronic+benzodiazepine+treatment+of+rats+induces+reduction+of+paired-pulse+inhibition+in+ca1+region+of+in+vitro+hippocampus&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003cdiv class=\"references\">\u003cp class=\"referencescopy1\">\u003ca name=\"b77\" id=\"b77\">\u003c/a>zurek, a. a., kemp, s. w., aga, z., walker, s., milenkovic, m., ramsey, a. j., et al. (2016). &#x003b1;5gabaa receptor deficiency causes autism-like behaviors. \u003cem>ann. clin. transl. neurol.\u003c/em> 3, 392&#x02013;398. doi:10.1002/acn3.303\u003c/p>\u003cp class=\"referencescopy2\">\u003ca href=\"https://pubmed.ncbi.nlm.nih.gov/27231709/\">pubmed abstract\u003c/a> &#x0007c; \u003ca href=\"https://doi.org/10.1002/acn3.303\">crossref full text\u003c/a> &#x0007c; \u003ca href=\"https://scholar.google.com/scholar?hl=en&amp;as_sdt=0%2c5&amp;q=î±5gabaa+receptor+deficiency+causes+autism-like+behaviors&amp;btng=\">google scholar\u003c/a>\u003c/p>\u003c/div>\u003c/div>\u003cdiv class=\"thinlinem20\">\u003c/div>\u003cdiv class=\"abstractsummary\">\u003cp>\u003cspan>keywords:\u003c/span> autism spectrum disorder, angelman syndrome, gaba\u003csub>a\u003c/sub>, gaba\u003csub>a\u003c/sub>-&#x003b1;5, positron emission tomography (pet), electroencephalography, pharmacological mri, biomarker\u003c/p>\u003cp>\u003cspan>citation:\u003c/span> cecere g, ballard tm, knoflach f, honer m, hipp jf, garces p, mueggler t, k&#x000fc;nnecke b, bruns a, prinssen ep, schoenenberger p, janz p, redondo r, biemans b, knust h, olivares-morales a, brigo a, schulz jm, bertrand d, saxe m, o&#x02019;connor ec and hernandez m-c (2025) preclinical pharmacology of alogabat: a novel gaba\u003csub>a\u003c/sub>-&#x003b1;5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gaba\u003csub>a\u003c/sub> signaling. \u003cem>front. pharmacol.\u003c/em> 16:1626078. doi: 10.3389/fphar.2025.1626078\u003c/p>\u003cp id=\"timestamps\">\u003cspan>received:\u003c/span> 09 may 2025; \u003cspan>accepted:\u003c/span> 18 june 2025;\u003cbr>\u003cspan>published:\u003c/span> 21 july 2025.\u003c/p>\u003cdiv>\u003cp>edited by:\u003c/p> \u003ca href=\"https://loop.frontiersin.org/people/52072/overview\">agenor limon\u003c/a>, university of texas medical branch at galveston, united states\u003c/div>\u003cdiv>\u003cp>reviewed by:\u003c/p> \u003ca href=\"https://loop.frontiersin.org/people/39673/overview\">hansen wang\u003c/a>, university of toronto, canada\u003cbr>\u003ca href=\"https://loop.frontiersin.org/people/1285968/overview\">junzhan jing\u003c/a>, baylor college of medicine, united states\u003cbr>\u003ca href=\"https://loop.frontiersin.org/people/1380630/overview\">azar omrani\u003c/a>, boehringer ingelheim, germany\u003c/div>\u003cp>\u003cspan>copyright\u003c/span> &#x000a9; 2025 cecere, ballard, knoflach, honer, hipp, garces, mueggler, k&#x000fc;nnecke, bruns, prinssen, schoenenberger, janz, redondo, biemans, knust, olivares-morales, brigo, schulz, bertrand, saxe, o&#x02019;connor and hernandez. this is an open-access article distributed under the terms of the \u003ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">creative commons attribution license (cc by).\u003c/a> the use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. no use, distribution or reproduction is permitted which does not comply with these terms.\u003c/p>\u003cp>\u003cspan>&#x0002a;correspondence:\u003c/span> maria-clemencia hernandez, \u003ca id=\"encmail\">bwfyawety2xlbwvuy2lhlmhlcm5hbmrlekbyb2nozs5jb20=\u003c/a>\u003c/p>\u003cp>\u003cspan>\u003csup>&#x02020;\u003c/sup>\u003c/span>these authors have contributed equally to this work\u003c/p>\u003cp>\u003cspan>\u003csup>&#x02021;\u003c/sup>\u003c/span>\u003cb>present address:\u003c/b> theresa m. ballard, galwyn (uk) ltd., dartmouth, united kingdom\u003cbr>barbara biemans, b2discovery llc, riehen, switzerland\u003cbr>michael saxe, translational in vivo sciences, biogen, cambridge, ma, united states\u003c/p>\u003cdiv class=\"clear\">\u003c/div>\u003c/div>","\u003cul class=\"flyoutjournal\">\u003cli>\u003ca href=\"#h1\">abstract\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h2\">1 introduction\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h3\">2 materials and methods\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h4\">3 results\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h5\">4 discussion\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h6\">5 conclusion\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h7\">data availability statement\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h8\">ethics statement\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h9\">author contributions\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h10\">funding\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h11\">acknowledgments\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h12\">conflict of interest\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h13\">generative ai statement\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h14\">publisher&#x02019;s note\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h15\">supplementary material\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h16\">abbreviations\u003c/a>\u003c/li>\u003cli>\u003ca href=\"#h17\">references\u003c/a>\u003c/li>\u003c/ul>",[732,740,746,752],{"name":733,"fileserverpackageentryid":734,"fileserverid":735,"fileserverversionnumber":736,"type":737},"fphar-16-1626078.xml","fphar-16-1626078-r1/fphar-16-1626078.xml","1626078/xml",2,{"code":738,"name":739},"nlm_xml","xml",{"name":741,"fileserverpackageentryid":19,"fileserverid":742,"fileserverversionnumber":736,"type":743},"epub.epub","1626078/epub",{"code":744,"name":745},"epub","epub",{"name":747,"fileserverpackageentryid":19,"fileserverid":748,"fileserverversionnumber":736,"type":749},"publishers-proof.pdf","1626078/publishers-proof",{"code":750,"name":751},"pdf","pdf",{"name":753,"fileserverpackageentryid":19,"fileserverid":754,"fileserverversionnumber":370,"type":755},"supplementary file 1.docx","1626078/supplementary-file/1",{"code":756,"name":757},"supplementary_material","docx","v3",{"title":760,"link":761,"meta":765,"script":956},"frontiers | preclinical pharmacology of alogabat: a novel gabaa-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired gabaa signaling",[762],{"rel":763,"href":764},"canonical","https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1626078/full",[766,769,772,774,777,781,784,788,791,794,797,799,801,803,805,807,810,813,815,818,820,822,825,828,831,834,837,841,845,848,851,854,856,859,861,864,866,869,871,874,876,879,881,884,886,889,891,894,896,899,901,904,906,909,911,914,916,919,922,925,927,930,932,935,938,941,943,946,948,951,953],{"hid":767,"property":767,"name":767,"content":768},"description","backgroundalterations in the gabaergic system contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder (asd) and...",{"hid":770,"property":770,"name":771,"content":760},"og:title","title",{"hid":773,"property":773,"name":767,"content":768},"og:description",{"hid":775,"name":775,"content":776},"keywords","biomarker,autism spectrum disorder,electroencephalography,positron emission tomography (pet),angelman syndrome,gabaa,gabaa-α5,pharmacological mri",{"hid":778,"property":778,"name":779,"content":780},"og:site_name","site_name","frontiers",{"hid":782,"property":782,"name":363,"content":783},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/articles/1626078/fphar-16-1626078-html-r1/image_m/fphar-16-1626078-g001.jpg",{"hid":785,"property":785,"name":786,"content":787},"og:type","type","article",{"hid":789,"property":789,"name":790,"content":764},"og:url","url",{"hid":792,"name":792,"content":793},"twitter:card","summary_large_image",{"hid":795,"name":795,"content":796},"citation_volume","16",{"hid":798,"name":798,"content":116},"citation_journal_title",{"hid":800,"name":800,"content":780},"citation_publisher",{"hid":802,"name":802,"content":713},"citation_journal_abbrev",{"hid":804,"name":804,"content":714},"citation_issn",{"hid":806,"name":806,"content":515},"citation_doi",{"hid":808,"name":808,"content":809},"citation_firstpage","1626078",{"hid":811,"name":811,"content":812},"citation_language","english",{"hid":814,"name":814,"content":516},"citation_title",{"hid":816,"name":816,"content":817},"citation_keywords","biomarker; autism spectrum disorder; electroencephalography; positron emission tomography (pet); angelman syndrome; gabaa; gabaa-α5; pharmacological mri",{"hid":819,"name":819,"content":521},"citation_abstract",{"hid":821,"name":821,"content":524},"citation_article_type",{"hid":823,"name":823,"content":824},"citation_pdf_url","https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1626078/pdf",{"hid":826,"name":826,"content":827},"citation_xml_url","https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1626078/xml",{"hid":829,"name":829,"content":830},"citation_fulltext_world_readable","yes",{"hid":832,"name":832,"content":833},"citation_online_date","2025/06/18",{"hid":835,"name":835,"content":836},"citation_publication_date","2025/07/21",{"hid":838,"name":839,"content":840},"citation_author_0","citation_author","cecere, giuseppe ",{"hid":842,"name":843,"content":844},"citation_author_institution_0","citation_author_institution","medicinal chemistry, switzerland",{"hid":846,"name":839,"content":847},"citation_author_1","ballard, theresa m. ",{"hid":849,"name":843,"content":850},"citation_author_institution_1","neuroscience and rare diseases, switzerland",{"hid":852,"name":839,"content":853},"citation_author_2","knoflach, frederic ",{"hid":855,"name":843,"content":850},"citation_author_institution_2",{"hid":857,"name":839,"content":858},"citation_author_3","honer, michael ",{"hid":860,"name":843,"content":850},"citation_author_institution_3",{"hid":862,"name":839,"content":863},"citation_author_4","hipp, joerg f. ",{"hid":865,"name":843,"content":850},"citation_author_institution_4",{"hid":867,"name":839,"content":868},"citation_author_5","garces, pilar ",{"hid":870,"name":843,"content":850},"citation_author_institution_5",{"hid":872,"name":839,"content":873},"citation_author_6","mueggler, thomas ",{"hid":875,"name":843,"content":850},"citation_author_institution_6",{"hid":877,"name":839,"content":878},"citation_author_7","künnecke, basil ",{"hid":880,"name":843,"content":850},"citation_author_institution_7",{"hid":882,"name":839,"content":883},"citation_author_8","bruns, andreas ",{"hid":885,"name":843,"content":850},"citation_author_institution_8",{"hid":887,"name":839,"content":888},"citation_author_9","prinssen, eric p. ",{"hid":890,"name":843,"content":850},"citation_author_institution_9",{"hid":892,"name":839,"content":893},"citation_author_10","schoenenberger, philipp ",{"hid":895,"name":843,"content":850},"citation_author_institution_10",{"hid":897,"name":839,"content":898},"citation_author_11","janz, philipp ",{"hid":900,"name":843,"content":850},"citation_author_institution_11",{"hid":902,"name":839,"content":903},"citation_author_12","redondo, roger ",{"hid":905,"name":843,"content":850},"citation_author_institution_12",{"hid":907,"name":839,"content":908},"citation_author_13","biemans, barbara ",{"hid":910,"name":843,"content":850},"citation_author_institution_13",{"hid":912,"name":839,"content":913},"citation_author_14","knust, henner ",{"hid":915,"name":843,"content":844},"citation_author_institution_14",{"hid":917,"name":839,"content":918},"citation_author_15","olivares-morales, andrés ",{"hid":920,"name":843,"content":921},"citation_author_institution_15","pharmaceutical sciences, switzerland",{"hid":923,"name":839,"content":924},"citation_author_16","brigo, alessandro ",{"hid":926,"name":843,"content":921},"citation_author_institution_16",{"hid":928,"name":839,"content":929},"citation_author_17","schulz, jan michael ",{"hid":931,"name":843,"content":850},"citation_author_institution_17",{"hid":933,"name":839,"content":934},"citation_author_18","bertrand, daniel ",{"hid":936,"name":843,"content":937},"citation_author_institution_18","hiqscreen sàrl, switzerland",{"hid":939,"name":839,"content":940},"citation_author_19","saxe, michael ",{"hid":942,"name":843,"content":850},"citation_author_institution_19",{"hid":944,"name":839,"content":945},"citation_author_20","o’connor, eoin c. ",{"hid":947,"name":843,"content":850},"citation_author_institution_20",{"hid":949,"name":839,"content":950},"citation_author_21","hernandez, maria-clemencia ",{"hid":952,"name":843,"content":850},"citation_author_institution_21",{"hid":954,"name":954,"content":955},"dc.identifier","doi:10.3389/fphar.2025.1626078",[957,960,962,964,966],{"src":958,"body":13,"type":959,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":961,"body":13,"type":959,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/mathjax.js?config=tex-mml-am_chtml",{"src":963,"body":13,"type":959,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":965,"body":13,"type":959,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fphar.2025.1626078?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":967,"body":13,"type":959,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articlehubslug":19,"articlehubpage":969,"articlehubarticleslist":970,"canjournalhasarticlehub":347,"articledoilist":971},{},[],[],{"title":19,"image":-1,"breadcrumbs":973,"linkscollection":974,"metricscollection":976},[],{"total":367,"items":975},[],{"total":367,"items":977},[]] window.__nuxt__={};window.__nuxt__.config={public:{isdevmode:false,appname:"article-pages-2024",baseurl:"https://www.frontiersin.org",domain:"frontiersin.org",loopurl:"https://loop.frontiersin.org",ssmaindomain:"frontiersin.org",contentfulurl:"https://graphql.contentful.com/content/v1/spaces",spaceid:1,spacename:"frontiers",livespaceid:1,tenantlogourl:"",frontiersgraphurl:"https://apollo-federation-gateway.frontiersin.org",registrationapiurl:"https://onboarding-ui.frontiersin.org",emaildigestapiurl:"https://api-email-digest.frontiersin.org",journalfilesapiurl:"https://files-journal-api.frontiersin.org",searchapiurl:"https://search-api.frontiersin.org",productionforumapiurl:"https://production-forum-api-v2.frontiersin.org",gtmserverurl:"https://tag-manager.frontiersin.org",gtmid:"gtm-m322fv2",gtmauth:"owvbwxfajr21yqv1fe1caq",gtmpreview:"env-1",figsharepluginurl:"https://widgets.figshare.com/static/figshare.js",figshareapiurl:"https://api.figshare.com/v2/collections/search",figsharetimeout:3000,crossmarkpublisheddate:"2015/08/24",googlerecaptchasitekey:"6ldg3i0uaaaaaoc4quh35ubhgjotehp_stxhgr_v",googlerecaptchakeyname:"frontiersrecaptchav2",faviconsize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantfavicon-frontiers.png",faviconsize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantfavicon-frontiers.png",faviconsize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantfavicon-frontiers.png",faviconsize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantfavicon-frontiers.png",faviconsize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantfavicon-frontiers.png",socialmediaimg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/guidelines-frontiers_logo_1200x628_1-91to1.png",linkedarticlecopytext:"'{\"articletypecopytext\":[{\"articletypeid\":0,\"originalarticlecopytext\":\"part of this article's content has been mentioned in:\",\"linkedarticlecopytext\":\"this article mentions parts of:\"},{\"articletypeid\":122,\"originalarticlecopytext\":\"parts of this article's content have been modified or rectified in:\",\"linkedarticlecopytext\":\"this article is an erratum on:\"},{\"articletypeid\":129,\"originalarticlecopytext\":\"parts of this article's content have been modified or rectified in:\",\"linkedarticlecopytext\":\"this article is an addendum to:\"},{\"articletypeid\":128,\"originalarticlecopytext\":\"a correction has been applied to this article in:\",\"linkedarticlecopytext\":\"this article is a correction to:\"},{\"articletypeid\":134,\"originalarticlecopytext\":\"a retraction of this article was approved in:\",\"linkedarticlecopytext\":\"this article is a retraction of:\"},{\"articletypeid\":29,\"originalarticlecopytext\":\"a commentary has been posted on this article:\",\"linkedarticlecopytext\":\"this article is a commentary on:\"},{\"articletypeid\":30,\"originalarticlecopytext\":\"a commentary has been posted on this article:\",\"linkedarticlecopytext\":\"this article is a commentary on:\"}],\"articleidcopytext\":[]}'\n",acceptedarticleexcludedjournalids:"'[2766,979]'\n",articletypeconfigurablelabel:"\u003c\u003carticle-type:uppercase>> article",settingsfeaturesswitchers:"'{\"displaytitlepilllabels\":true,\"displayrelatedarticlesbox\":true,\"showeditors\":true,\"showreviewers\":true,\"showloopimpactlink\":true,\"enablefigshare\":false,\"usexmlimages\":true}'\n",journalswitharticlehub:"'{\"strings\":[\"science\"]}'\n",terminologysettings:"'{\"terms\":[{\"sequencenumber\":1,\"key\":\"frontiers\",\"tenantterm\":\"frontiers\",\"frontiersdefaultterm\":\"frontiers\",\"category\":\"customer\"},{\"sequencenumber\":2,\"key\":\"submission_system\",\"tenantterm\":\"submission system\",\"frontiersdefaultterm\":\"submission system\",\"category\":\"product\"},{\"sequencenumber\":3,\"key\":\"public_pages\",\"tenantterm\":\"public pages\",\"frontiersdefaultterm\":\"public pages\",\"category\":\"product\"},{\"sequencenumber\":4,\"key\":\"my_frontiers\",\"tenantterm\":\"my frontiers\",\"frontiersdefaultterm\":\"my frontiers\",\"category\":\"product\"},{\"sequencenumber\":5,\"key\":\"digital_editorial_office\",\"tenantterm\":\"digital editorial office\",\"frontiersdefaultterm\":\"digital editorial office\",\"category\":\"product\"},{\"sequencenumber\":6,\"key\":\"deo\",\"tenantterm\":\"deo\",\"frontiersdefaultterm\":\"deo\",\"category\":\"product\"},{\"sequencenumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantterm\":\"digital editorial office for chiefs\",\"frontiersdefaultterm\":\"digital editorial office for chiefs\",\"category\":\"product\"},{\"sequencenumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantterm\":\"digital editorial office for eof\",\"frontiersdefaultterm\":\"digital editorial office for eof\",\"category\":\"product\"},{\"sequencenumber\":9,\"key\":\"editorial_office\",\"tenantterm\":\"editorial office\",\"frontiersdefaultterm\":\"editorial office\",\"category\":\"product\"},{\"sequencenumber\":10,\"key\":\"eof\",\"tenantterm\":\"eof\",\"frontiersdefaultterm\":\"eof\",\"category\":\"product\"},{\"sequencenumber\":11,\"key\":\"research_topic_management\",\"tenantterm\":\"research topic management\",\"frontiersdefaultterm\":\"research topic management\",\"category\":\"product\"},{\"sequencenumber\":12,\"key\":\"review_forum\",\"tenantterm\":\"review forum\",\"frontiersdefaultterm\":\"review forum\",\"category\":\"product\"},{\"sequencenumber\":13,\"key\":\"accounting_office\",\"tenantterm\":\"accounting office\",\"frontiersdefaultterm\":\"accounting office\",\"category\":\"product\"},{\"sequencenumber\":14,\"key\":\"aof\",\"tenantterm\":\"aof\",\"frontiersdefaultterm\":\"aof\",\"category\":\"product\"},{\"sequencenumber\":15,\"key\":\"publishing_office\",\"tenantterm\":\"publishing office\",\"frontiersdefaultterm\":\"publishing office\",\"category\":\"product\"},{\"sequencenumber\":16,\"key\":\"production_office\",\"tenantterm\":\"production office forum\",\"frontiersdefaultterm\":\"production office forum\",\"category\":\"product\"},{\"sequencenumber\":17,\"key\":\"pof\",\"tenantterm\":\"pof\",\"frontiersdefaultterm\":\"pof\",\"category\":\"product\"},{\"sequencenumber\":18,\"key\":\"book_office_forum\",\"tenantterm\":\"book office forum\",\"frontiersdefaultterm\":\"book office forum\",\"category\":\"product\"},{\"sequencenumber\":19,\"key\":\"bof\",\"tenantterm\":\"bof\",\"frontiersdefaultterm\":\"bof\",\"category\":\"product\"},{\"sequencenumber\":20,\"key\":\"aira\",\"tenantterm\":\"aira\",\"frontiersdefaultterm\":\"aira\",\"category\":\"product\"},{\"sequencenumber\":21,\"key\":\"editorial_board_management\",\"tenantterm\":\"editorial board management\",\"frontiersdefaultterm\":\"editorial board management\",\"category\":\"product\"},{\"sequencenumber\":22,\"key\":\"ebm\",\"tenantterm\":\"ebm\",\"frontiersdefaultterm\":\"ebm\",\"category\":\"product\"},{\"sequencenumber\":23,\"key\":\"domain\",\"tenantterm\":\"domain\",\"frontiersdefaultterm\":\"domain\",\"category\":\"taxonomy\"},{\"sequencenumber\":24,\"key\":\"journal\",\"tenantterm\":\"journal\",\"frontiersdefaultterm\":\"journal\",\"category\":\"taxonomy\"},{\"sequencenumber\":25,\"key\":\"section\",\"tenantterm\":\"section\",\"frontiersdefaultterm\":\"section\",\"category\":\"taxonomy\"},{\"sequencenumber\":26,\"key\":\"domains\",\"tenantterm\":\"domains\",\"frontiersdefaultterm\":\"domains\",\"category\":\"taxonomy\"},{\"sequencenumber\":27,\"key\":\"specialty_section\",\"tenantterm\":\"specialty section\",\"frontiersdefaultterm\":\"specialty section\",\"category\":\"taxonomy\"},{\"sequencenumber\":28,\"key\":\"specialty_journal\",\"tenantterm\":\"specialty journal\",\"frontiersdefaultterm\":\"specialty journal\",\"category\":\"taxonomy\"},{\"sequencenumber\":29,\"key\":\"journals\",\"tenantterm\":\"journals\",\"frontiersdefaultterm\":\"journals\",\"category\":\"taxonomy\"},{\"sequencenumber\":30,\"key\":\"sections\",\"tenantterm\":\"sections\",\"frontiersdefaultterm\":\"sections\",\"category\":\"taxonomy\"},{\"sequencenumber\":31,\"key\":\"specialty_sections\",\"tenantterm\":\"specialty sections\",\"frontiersdefaultterm\":\"specialty sections\",\"category\":\"taxonomy\"},{\"sequencenumber\":32,\"key\":\"specialty_journals\",\"tenantterm\":\"specialty journals\",\"frontiersdefaultterm\":\"specialty journals\",\"category\":\"taxonomy\"},{\"sequencenumber\":33,\"key\":\"manuscript\",\"tenantterm\":\"manuscript\",\"frontiersdefaultterm\":\"manuscript\",\"category\":\"core\"},{\"sequencenumber\":34,\"key\":\"manuscripts\",\"tenantterm\":\"manuscripts\",\"frontiersdefaultterm\":\"manuscripts\",\"category\":\"core\"},{\"sequencenumber\":35,\"key\":\"article\",\"tenantterm\":\"article\",\"frontiersdefaultterm\":\"article\",\"category\":\"core\"},{\"sequencenumber\":36,\"key\":\"articles\",\"tenantterm\":\"articles\",\"frontiersdefaultterm\":\"articles\",\"category\":\"core\"},{\"sequencenumber\":37,\"key\":\"article_type\",\"tenantterm\":\"article type\",\"frontiersdefaultterm\":\"article type\",\"category\":\"core\"},{\"sequencenumber\":38,\"key\":\"article_types\",\"tenantterm\":\"article types\",\"frontiersdefaultterm\":\"article types\",\"category\":\"core\"},{\"sequencenumber\":39,\"key\":\"author\",\"tenantterm\":\"author\",\"frontiersdefaultterm\":\"author\",\"category\":\"label (role)\"},{\"sequencenumber\":40,\"key\":\"authors\",\"tenantterm\":\"authors\",\"frontiersdefaultterm\":\"authors\",\"category\":\"label (role)\"},{\"sequencenumber\":41,\"key\":\"authoring\",\"tenantterm\":\"authoring\",\"frontiersdefaultterm\":\"authoring\",\"category\":\"core\"},{\"sequencenumber\":42,\"key\":\"authored\",\"tenantterm\":\"authored\",\"frontiersdefaultterm\":\"authored\",\"category\":\"core\"},{\"sequencenumber\":43,\"key\":\"accept\",\"tenantterm\":\"accept\",\"frontiersdefaultterm\":\"accept\",\"category\":\"process\"},{\"sequencenumber\":44,\"key\":\"accepted\",\"tenantterm\":\"accepted\",\"frontiersdefaultterm\":\"accepted\",\"category\":\"process\"},{\"sequencenumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantterm\":\"assistant field chief editor\",\"frontiersdefaultterm\":\"assistant field chief editor\",\"description\":\"an editorial role on a field journal that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantterm\":\"assistant specialty chief editor\",\"frontiersdefaultterm\":\"assistant specialty chief editor\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantterm\":\"assistant specialty chief editors\",\"frontiersdefaultterm\":\"assistant specialty chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":48,\"key\":\"associate_editor\",\"tenantterm\":\"associate editor\",\"frontiersdefaultterm\":\"associate editor\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":49,\"key\":\"specialty_chief_editor\",\"tenantterm\":\"specialty chief editor\",\"frontiersdefaultterm\":\"specialty chief editor\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":50,\"key\":\"specialty_chief_editors\",\"tenantterm\":\"specialty chief editors\",\"frontiersdefaultterm\":\"specialty chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":51,\"key\":\"chief_editor\",\"tenantterm\":\"chief editor\",\"frontiersdefaultterm\":\"chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":52,\"key\":\"chief_editors\",\"tenantterm\":\"chief editors\",\"frontiersdefaultterm\":\"chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":53,\"key\":\"call_for_participation\",\"tenantterm\":\"call for participation\",\"frontiersdefaultterm\":\"call for participation\",\"category\":\"process\"},{\"sequencenumber\":54,\"key\":\"citation\",\"tenantterm\":\"citation\",\"frontiersdefaultterm\":\"citation\",\"category\":\"misc.\"},{\"sequencenumber\":55,\"key\":\"citations\",\"tenantterm\":\"citations\",\"frontiersdefaultterm\":\"citations\",\"category\":\"misc.\"},{\"sequencenumber\":56,\"key\":\"contributor\",\"tenantterm\":\"contributor\",\"frontiersdefaultterm\":\"contributor\",\"category\":\"label (role)\"},{\"sequencenumber\":57,\"key\":\"contributors\",\"tenantterm\":\"contributors\",\"frontiersdefaultterm\":\"contributors\",\"category\":\"label (role)\"},{\"sequencenumber\":58,\"key\":\"corresponding_author\",\"tenantterm\":\"corresponding author\",\"frontiersdefaultterm\":\"corresponding author\",\"category\":\"label (role)\"},{\"sequencenumber\":59,\"key\":\"corresponding_authors\",\"tenantterm\":\"corresponding authors\",\"frontiersdefaultterm\":\"corresponding authors\",\"category\":\"label (role)\"},{\"sequencenumber\":60,\"key\":\"decline\",\"tenantterm\":\"decline\",\"frontiersdefaultterm\":\"decline\",\"category\":\"process\"},{\"sequencenumber\":61,\"key\":\"declined\",\"tenantterm\":\"declined\",\"frontiersdefaultterm\":\"declined\",\"category\":\"process\"},{\"sequencenumber\":62,\"key\":\"reject\",\"tenantterm\":\"reject\",\"frontiersdefaultterm\":\"reject\",\"category\":\"process\"},{\"sequencenumber\":63,\"key\":\"rejected\",\"tenantterm\":\"rejected\",\"frontiersdefaultterm\":\"rejected\",\"category\":\"process\"},{\"sequencenumber\":64,\"key\":\"publish\",\"tenantterm\":\"publish\",\"frontiersdefaultterm\":\"publish\",\"category\":\"core\"},{\"sequencenumber\":65,\"key\":\"published\",\"tenantterm\":\"published\",\"frontiersdefaultterm\":\"published\",\"category\":\"core\"},{\"sequencenumber\":66,\"key\":\"publication\",\"tenantterm\":\"publication\",\"frontiersdefaultterm\":\"publication\",\"category\":\"core\"},{\"sequencenumber\":67,\"key\":\"peer_review\",\"tenantterm\":\"peer review\",\"frontiersdefaultterm\":\"peer review\",\"category\":\"peer review process\"},{\"sequencenumber\":68,\"key\":\"peer_reviewed\",\"tenantterm\":\"peer reviewed\",\"frontiersdefaultterm\":\"peer reviewed\",\"category\":\"peer review process\"},{\"sequencenumber\":69,\"key\":\"initial_validation\",\"tenantterm\":\"initial validation\",\"frontiersdefaultterm\":\"initial validation\",\"category\":\"peer review process\"},{\"sequencenumber\":70,\"key\":\"editorial_assignment\",\"tenantterm\":\"editorial assignment\",\"frontiersdefaultterm\":\"editorial assignment\",\"category\":\"peer review process\"},{\"sequencenumber\":71,\"key\":\"independent_review\",\"tenantterm\":\"independent review\",\"frontiersdefaultterm\":\"independent review\",\"category\":\"peer review process\"},{\"sequencenumber\":72,\"key\":\"interactive_review\",\"tenantterm\":\"interactive review\",\"frontiersdefaultterm\":\"interactive review\",\"category\":\"peer review process\"},{\"sequencenumber\":73,\"key\":\"review\",\"tenantterm\":\"review\",\"frontiersdefaultterm\":\"review\",\"category\":\"peer review process\"},{\"sequencenumber\":74,\"key\":\"reviewing\",\"tenantterm\":\"reviewing\",\"frontiersdefaultterm\":\"reviewing\",\"category\":\"peer review process\"},{\"sequencenumber\":75,\"key\":\"reviewer\",\"tenantterm\":\"reviewer\",\"frontiersdefaultterm\":\"reviewer\",\"category\":\"label (role)\"},{\"sequencenumber\":76,\"key\":\"reviewers\",\"tenantterm\":\"reviewers\",\"frontiersdefaultterm\":\"reviewers\",\"category\":\"label (role)\"},{\"sequencenumber\":77,\"key\":\"review_finalized\",\"tenantterm\":\"review finalized\",\"frontiersdefaultterm\":\"review finalized\",\"category\":\"peer review process\"},{\"sequencenumber\":78,\"key\":\"final_decision\",\"tenantterm\":\"final decision\",\"frontiersdefaultterm\":\"final decision\",\"category\":\"peer review process\"},{\"sequencenumber\":79,\"key\":\"final_validation\",\"tenantterm\":\"final validation\",\"frontiersdefaultterm\":\"final validation\",\"category\":\"peer review process\"},{\"sequencenumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantterm\":\"recommend to accept manuscript\",\"frontiersdefaultterm\":\"accept manuscript\",\"category\":\"process\"},{\"sequencenumber\":81,\"key\":\"fee\",\"tenantterm\":\"fee\",\"frontiersdefaultterm\":\"fee\",\"category\":\"accounting\"},{\"sequencenumber\":82,\"key\":\"fees\",\"tenantterm\":\"fees\",\"frontiersdefaultterm\":\"fees\",\"category\":\"accounting\"},{\"sequencenumber\":83,\"key\":\"guest_associate_editor\",\"tenantterm\":\"guest associate editor\",\"frontiersdefaultterm\":\"guest associate editor\",\"category\":\"label (role)\"},{\"sequencenumber\":84,\"key\":\"guest_associate_editors\",\"tenantterm\":\"guest associate editors\",\"frontiersdefaultterm\":\"guest associate editors\",\"category\":\"label (role)\"},{\"sequencenumber\":85,\"key\":\"in_review\",\"tenantterm\":\"in review\",\"frontiersdefaultterm\":\"in review\",\"category\":\"peer review process\"},{\"sequencenumber\":86,\"key\":\"institutional_member\",\"tenantterm\":\"institutional partner\",\"frontiersdefaultterm\":\"institutional partner\",\"category\":\"accounting\"},{\"sequencenumber\":87,\"key\":\"institutional_membership\",\"tenantterm\":\"institutional partnership\",\"frontiersdefaultterm\":\"institutional partnership\",\"category\":\"accounting\"},{\"sequencenumber\":88,\"key\":\"article_processing_charge\",\"tenantterm\":\"article processing charge\",\"frontiersdefaultterm\":\"article processing charge\",\"category\":\"accounting\"},{\"sequencenumber\":89,\"key\":\"article_processing_charges\",\"tenantterm\":\"article processing charges\",\"frontiersdefaultterm\":\"article processing charges\",\"category\":\"accounting\"},{\"sequencenumber\":90,\"key\":\"apcs\",\"tenantterm\":\"apcs\",\"frontiersdefaultterm\":\"apcs\",\"category\":\"accounting\"},{\"sequencenumber\":91,\"key\":\"apc\",\"tenantterm\":\"apc\",\"frontiersdefaultterm\":\"apc\",\"category\":\"accounting\"},{\"sequencenumber\":92,\"key\":\"received\",\"tenantterm\":\"received\",\"frontiersdefaultterm\":\"received\",\"description\":\"date manuscript was received on.\",\"category\":\"core\"},{\"sequencenumber\":93,\"key\":\"transferred\",\"tenantterm\":\"transferred\",\"frontiersdefaultterm\":\"transferred\",\"category\":\"core\"},{\"sequencenumber\":94,\"key\":\"transfer\",\"tenantterm\":\"transfer\",\"frontiersdefaultterm\":\"transfer\",\"category\":\"core\"},{\"sequencenumber\":95,\"key\":\"research_topic\",\"tenantterm\":\"research topic\",\"frontiersdefaultterm\":\"research topic\",\"category\":\"core\"},{\"sequencenumber\":96,\"key\":\"research_topics\",\"tenantterm\":\"research topics\",\"frontiersdefaultterm\":\"research topics\",\"category\":\"core\"},{\"sequencenumber\":97,\"key\":\"topic_editor\",\"tenantterm\":\"topic editor\",\"frontiersdefaultterm\":\"topic editor\",\"category\":\"label (role)\"},{\"sequencenumber\":98,\"key\":\"review_editor\",\"tenantterm\":\"community reviewer\",\"frontiersdefaultterm\":\"review editor\",\"category\":\"label (role)\"},{\"sequencenumber\":99,\"key\":\"title\",\"tenantterm\":\"title\",\"frontiersdefaultterm\":\"title\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":100,\"key\":\"running_title\",\"tenantterm\":\"running title\",\"frontiersdefaultterm\":\"running title\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":101,\"key\":\"submit\",\"tenantterm\":\"submit\",\"frontiersdefaultterm\":\"submit\",\"category\":\"process\"},{\"sequencenumber\":102,\"key\":\"submitted\",\"tenantterm\":\"submitted\",\"frontiersdefaultterm\":\"submitted\",\"category\":\"process\"},{\"sequencenumber\":103,\"key\":\"submitting\",\"tenantterm\":\"submitting\",\"frontiersdefaultterm\":\"submitting\",\"category\":\"process\"},{\"sequencenumber\":104,\"key\":\"t_e\",\"tenantterm\":\"te\",\"frontiersdefaultterm\":\"te\",\"category\":\"label (role)\"},{\"sequencenumber\":105,\"key\":\"topic\",\"tenantterm\":\"topic\",\"frontiersdefaultterm\":\"topic\",\"category\":\"process\"},{\"sequencenumber\":106,\"key\":\"topic_summary\",\"tenantterm\":\"topic summary\",\"frontiersdefaultterm\":\"topic summary\",\"category\":\"process\"},{\"sequencenumber\":107,\"key\":\"figure\",\"tenantterm\":\"figure\",\"frontiersdefaultterm\":\"figure\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":108,\"key\":\"figures\",\"tenantterm\":\"figures\",\"frontiersdefaultterm\":\"figures\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":109,\"key\":\"editorial_file\",\"tenantterm\":\"editorial file\",\"frontiersdefaultterm\":\"editorial file\",\"category\":\"core\"},{\"sequencenumber\":110,\"key\":\"editorial_files\",\"tenantterm\":\"editorial files\",\"frontiersdefaultterm\":\"editorial files\",\"category\":\"core\"},{\"sequencenumber\":111,\"key\":\"e_book\",\"tenantterm\":\"e-book\",\"frontiersdefaultterm\":\"e-book\",\"category\":\"core\"},{\"sequencenumber\":112,\"key\":\"organization\",\"tenantterm\":\"organization\",\"frontiersdefaultterm\":\"organization\",\"category\":\"core\"},{\"sequencenumber\":113,\"key\":\"institution\",\"tenantterm\":\"institution\",\"frontiersdefaultterm\":\"institution\",\"category\":\"core\"},{\"sequencenumber\":114,\"key\":\"reference\",\"tenantterm\":\"reference\",\"frontiersdefaultterm\":\"reference\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":115,\"key\":\"references\",\"tenantterm\":\"references\",\"frontiersdefaultterm\":\"references\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":116,\"key\":\"sce\",\"tenantterm\":\"sce\",\"frontiersdefaultterm\":\"sce\",\"description\":\"abbreviation for specialty chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":117,\"key\":\"submission\",\"tenantterm\":\"submission\",\"frontiersdefaultterm\":\"submission\",\"category\":\"process\"},{\"sequencenumber\":118,\"key\":\"submissions\",\"tenantterm\":\"submissions\",\"frontiersdefaultterm\":\"submissions\",\"category\":\"process\"},{\"sequencenumber\":119,\"key\":\"editing\",\"tenantterm\":\"editing\",\"frontiersdefaultterm\":\"editing\",\"category\":\"process\"},{\"sequencenumber\":120,\"key\":\"in_preparation\",\"tenantterm\":\"in preparation\",\"frontiersdefaultterm\":\"in preparation\",\"category\":\"process\"},{\"sequencenumber\":121,\"key\":\"country_region\",\"tenantterm\":\"country/region\",\"frontiersdefaultterm\":\"country/region\",\"description\":\"because of political issues, some of the country listings are actually classified as `regions` and we need to include this. however other clients may not want to do this.\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":122,\"key\":\"countries_regions\",\"tenantterm\":\"countries/regions\",\"frontiersdefaultterm\":\"countries/regions\",\"description\":\"because of political issues, some of the country listings are actually classified as `regions` and we need to include this. however other clients may not want to do this.\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":123,\"key\":\"specialty\",\"tenantterm\":\"specialty\",\"frontiersdefaultterm\":\"specialty\",\"category\":\"core\"},{\"sequencenumber\":124,\"key\":\"specialties\",\"tenantterm\":\"specialties\",\"frontiersdefaultterm\":\"specialties\",\"category\":\"core\"},{\"sequencenumber\":125,\"key\":\"associate_editors\",\"tenantterm\":\"associate editors\",\"frontiersdefaultterm\":\"associate editors\",\"description\":\"an editorial role on a specialty that a registered user may hold. this gives them rights to different functionality and parts of the platform\",\"category\":\"label (role)\"},{\"sequencenumber\":126,\"key\":\"reviewed\",\"tenantterm\":\"reviewed\",\"frontiersdefaultterm\":\"reviewed\",\"category\":\"peer review process\"},{\"sequencenumber\":127,\"key\":\"institutional_members\",\"tenantterm\":\"institutional partners\",\"frontiersdefaultterm\":\"institutional partners\",\"category\":\"accounting\"},{\"sequencenumber\":128,\"key\":\"institutional_memberships\",\"tenantterm\":\"institutional partnerships\",\"frontiersdefaultterm\":\"institutional partnerships\",\"category\":\"accounting\"},{\"sequencenumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantterm\":\"assistant field chief editors\",\"frontiersdefaultterm\":\"assistant field chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":130,\"key\":\"publications\",\"tenantterm\":\"publications\",\"frontiersdefaultterm\":\"publications\",\"category\":\"process\"},{\"sequencenumber\":131,\"key\":\"ae_accepted\",\"tenantterm\":\"recommended acceptance\",\"frontiersdefaultterm\":\"accepted\",\"category\":\"process\"},{\"sequencenumber\":132,\"key\":\"field_journal\",\"tenantterm\":\"field journal\",\"frontiersdefaultterm\":\"field journal\",\"category\":\"taxonomy\"},{\"sequencenumber\":133,\"key\":\"field_journals\",\"tenantterm\":\"field journals\",\"frontiersdefaultterm\":\"field journals\",\"category\":\"taxonomy\"},{\"sequencenumber\":134,\"key\":\"program_manager\",\"tenantterm\":\"program manager\",\"frontiersdefaultterm\":\"program manager\",\"category\":\"label (role)\"},{\"sequencenumber\":135,\"key\":\"journal_manager\",\"tenantterm\":\"journal manager\",\"frontiersdefaultterm\":\"journal manager\",\"category\":\"label (role)\"},{\"sequencenumber\":136,\"key\":\"journal_specialist\",\"tenantterm\":\"journal specialist\",\"frontiersdefaultterm\":\"journal specialist\",\"category\":\"label (role)\"},{\"sequencenumber\":137,\"key\":\"program_managers\",\"tenantterm\":\"program managers\",\"frontiersdefaultterm\":\"program managers\",\"category\":\"label (role)\"},{\"sequencenumber\":138,\"key\":\"journal_managers\",\"tenantterm\":\"journal managers\",\"frontiersdefaultterm\":\"journal managers\",\"category\":\"label (role)\"},{\"sequencenumber\":139,\"key\":\"journal_specialists\",\"tenantterm\":\"journal specialists\",\"frontiersdefaultterm\":\"journal specialists\",\"category\":\"label (role)\"},{\"sequencenumber\":140,\"key\":\"cover_letter\",\"tenantterm\":\"manuscript contribution to the field\",\"frontiersdefaultterm\":\"manuscript contribution to the field\",\"category\":\"process\"},{\"sequencenumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantterm\":\"recommended to accept manuscript\",\"frontiersdefaultterm\":\"accepted manuscript\",\"category\":\"process\"},{\"sequencenumber\":142,\"key\":\"recommend_for_rejection\",\"tenantterm\":\"recommend for rejection\",\"frontiersdefaultterm\":\"recommend for rejection\",\"category\":\"process\"},{\"sequencenumber\":143,\"key\":\"recommended_for_rejection\",\"tenantterm\":\"recommended for rejection\",\"frontiersdefaultterm\":\"recommended for rejection\",\"category\":\"process\"},{\"sequencenumber\":144,\"key\":\"ae\",\"tenantterm\":\"ae\",\"frontiersdefaultterm\":\"ae\",\"description\":\"associate editor - board member\",\"category\":\"label (role)\"},{\"sequencenumber\":145,\"key\":\"re\",\"tenantterm\":\"re\",\"frontiersdefaultterm\":\"re\",\"description\":\"review editor\",\"category\":\"label (role)\"},{\"sequencenumber\":146,\"key\":\"rev\",\"tenantterm\":\"rev\",\"frontiersdefaultterm\":\"rev\",\"description\":\"reviewer\",\"category\":\"label (role)\"},{\"sequencenumber\":147,\"key\":\"aut\",\"tenantterm\":\"aut\",\"frontiersdefaultterm\":\"aut\",\"description\":\"author\",\"category\":\"label (role)\"},{\"sequencenumber\":148,\"key\":\"coraut\",\"tenantterm\":\"coraut\",\"frontiersdefaultterm\":\"coraut\",\"description\":\"corresponding author\",\"category\":\"label (role)\"},{\"sequencenumber\":149,\"key\":\"saut\",\"tenantterm\":\"saut\",\"frontiersdefaultterm\":\"saut\",\"description\":\"submitting author\",\"category\":\"label (role)\"},{\"sequencenumber\":150,\"key\":\"coaut\",\"tenantterm\":\"coaut\",\"frontiersdefaultterm\":\"coaut\",\"description\":\"co-author\",\"category\":\"label (role)\"},{\"sequencenumber\":151,\"key\":\"tsof\",\"tenantterm\":\"tsof\",\"frontiersdefaultterm\":\"tsof\",\"description\":\"typesetter\",\"category\":\"label (role)\"},{\"sequencenumber\":152,\"key\":\"typesetting_office\",\"tenantterm\":\"typesetting office\",\"frontiersdefaultterm\":\"typesetting office\",\"category\":\"product\"},{\"sequencenumber\":153,\"key\":\"config\",\"tenantterm\":\"config\",\"frontiersdefaultterm\":\"config\",\"description\":\"configuration office role\",\"category\":\"label (role)\"},{\"sequencenumber\":154,\"key\":\"jm\",\"tenantterm\":\"jm\",\"frontiersdefaultterm\":\"jm\",\"description\":\"journal manager\",\"category\":\"label (role)\"},{\"sequencenumber\":155,\"key\":\"rte\",\"tenantterm\":\"rte\",\"frontiersdefaultterm\":\"rte\",\"description\":\"research topic editor\",\"category\":\"label (role)\"},{\"sequencenumber\":156,\"key\":\"organizations\",\"tenantterm\":\"organizations\",\"frontiersdefaultterm\":\"organizations\",\"category\":\"core\"},{\"sequencenumber\":157,\"key\":\"publishing\",\"tenantterm\":\"publishing\",\"frontiersdefaultterm\":\"publishing\",\"category\":\"core\"},{\"sequencenumber\":158,\"key\":\"acceptance\",\"tenantterm\":\"acceptance\",\"frontiersdefaultterm\":\"acceptance\",\"category\":\"process\"},{\"sequencenumber\":159,\"key\":\"preferred_associate_editor\",\"tenantterm\":\"preferred associate editor\",\"frontiersdefaultterm\":\"preferred associate editor\",\"category\":\"label (role)\"},{\"sequencenumber\":160,\"key\":\"topic_editors\",\"tenantterm\":\"topic editors\",\"frontiersdefaultterm\":\"topic editors\",\"category\":\"label (role)\"},{\"sequencenumber\":161,\"key\":\"institutions\",\"tenantterm\":\"institutions\",\"frontiersdefaultterm\":\"institutions\",\"category\":\"core\"},{\"sequencenumber\":162,\"key\":\"author(s)\",\"tenantterm\":\"author(s)\",\"frontiersdefaultterm\":\"author(s)\",\"category\":\"label (role)\"},{\"sequencenumber\":163,\"key\":\"figure(s)\",\"tenantterm\":\"figure(s)\",\"frontiersdefaultterm\":\"figure(s)\",\"category\":\"manuscript metadata\"},{\"sequencenumber\":164,\"key\":\"co-authors\",\"tenantterm\":\"co-authors\",\"frontiersdefaultterm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"label (role)\"},{\"sequencenumber\":165,\"key\":\"editorial_board_members\",\"tenantterm\":\"editorial board members\",\"frontiersdefaultterm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"label (role)\"},{\"sequencenumber\":166,\"key\":\"editorial_board\",\"tenantterm\":\"editorial board\",\"frontiersdefaultterm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"product\"},{\"sequencenumber\":167,\"key\":\"co-authorship\",\"tenantterm\":\"co-authorship\",\"frontiersdefaultterm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"misc.\"},{\"sequencenumber\":168,\"key\":\"role_id_1\",\"tenantterm\":\"registration office\",\"frontiersdefaultterm\":\"registration office\",\"category\":\"user role\"},{\"sequencenumber\":169,\"key\":\"role_id_2\",\"tenantterm\":\"editorial office\",\"frontiersdefaultterm\":\"editorial office\",\"category\":\"user role\"},{\"sequencenumber\":170,\"key\":\"role_id_7\",\"tenantterm\":\"field chief editor\",\"frontiersdefaultterm\":\"field chief editor\",\"category\":\"user role\"},{\"sequencenumber\":171,\"key\":\"role_id_8\",\"tenantterm\":\"assistant field chief editor\",\"frontiersdefaultterm\":\"assistant field chief editor\",\"category\":\"user role\"},{\"sequencenumber\":172,\"key\":\"role_id_9\",\"tenantterm\":\"specialty chief editor\",\"frontiersdefaultterm\":\"specialty chief editor\",\"category\":\"user role\"},{\"sequencenumber\":173,\"key\":\"role_id_10\",\"tenantterm\":\"assistant specialty chief editor\",\"frontiersdefaultterm\":\"assistant specialty chief editor\",\"category\":\"user role\"},{\"sequencenumber\":174,\"key\":\"role_id_11\",\"tenantterm\":\"associate editor\",\"frontiersdefaultterm\":\"associate editor\",\"category\":\"user role\"},{\"sequencenumber\":175,\"key\":\"role_id_12\",\"tenantterm\":\"guest associate editor\",\"frontiersdefaultterm\":\"guest associate editor\",\"category\":\"user role\"},{\"sequencenumber\":176,\"key\":\"role_id_13\",\"tenantterm\":\"review editor\",\"frontiersdefaultterm\":\"review editor\",\"category\":\"user role\"},{\"sequencenumber\":177,\"key\":\"role_id_14\",\"tenantterm\":\"reviewer\",\"frontiersdefaultterm\":\"reviewer\",\"category\":\"user role\"},{\"sequencenumber\":178,\"key\":\"role_id_15\",\"tenantterm\":\"author\",\"frontiersdefaultterm\":\"author\",\"category\":\"user role\"},{\"sequencenumber\":179,\"key\":\"role_id_16\",\"tenantterm\":\"corresponding author\",\"frontiersdefaultterm\":\"corresponding author\",\"category\":\"user role\"},{\"sequencenumber\":180,\"key\":\"role_id_17\",\"tenantterm\":\"submitting author\",\"frontiersdefaultterm\":\"submitting author\",\"category\":\"user role\"},{\"sequencenumber\":181,\"key\":\"role_id_18\",\"tenantterm\":\"co-author\",\"frontiersdefaultterm\":\"co-author\",\"category\":\"user role\"},{\"sequencenumber\":182,\"key\":\"role_id_20\",\"tenantterm\":\"production office\",\"frontiersdefaultterm\":\"production office\",\"category\":\"user role\"},{\"sequencenumber\":183,\"key\":\"role_id_22\",\"tenantterm\":\"typesetting office (typesetter)\",\"frontiersdefaultterm\":\"typesetting office (typesetter)\",\"category\":\"user role\"},{\"sequencenumber\":184,\"key\":\"role_id_24\",\"tenantterm\":\"registered user\",\"frontiersdefaultterm\":\"registered user\",\"category\":\"user role\"},{\"sequencenumber\":185,\"key\":\"role_id_35\",\"tenantterm\":\"job office\",\"frontiersdefaultterm\":\"job office\",\"category\":\"user role\"},{\"sequencenumber\":186,\"key\":\"role_id_41\",\"tenantterm\":\"special event administrator\",\"frontiersdefaultterm\":\"special event administrator\",\"category\":\"user role\"},{\"sequencenumber\":187,\"key\":\"role_id_42\",\"tenantterm\":\"special event reviewer\",\"frontiersdefaultterm\":\"special event reviewer\",\"category\":\"user role\"},{\"sequencenumber\":188,\"key\":\"role_id_43\",\"tenantterm\":\"submit abstract\",\"frontiersdefaultterm\":\"submit abstract\",\"category\":\"user role\"},{\"sequencenumber\":189,\"key\":\"role_id_52\",\"tenantterm\":\"events office\",\"frontiersdefaultterm\":\"events office\",\"category\":\"user role\"},{\"sequencenumber\":190,\"key\":\"role_id_53\",\"tenantterm\":\"event administrator\",\"frontiersdefaultterm\":\"event administrator\",\"category\":\"user role\"},{\"sequencenumber\":191,\"key\":\"role_id_89\",\"tenantterm\":\"content management office\",\"frontiersdefaultterm\":\"content management office\",\"category\":\"user role\"},{\"sequencenumber\":192,\"key\":\"role_id_98\",\"tenantterm\":\"accounting office\",\"frontiersdefaultterm\":\"accounting office\",\"category\":\"user role\"},{\"sequencenumber\":193,\"key\":\"role_id_99\",\"tenantterm\":\"projects\",\"frontiersdefaultterm\":\"projects\",\"category\":\"user role\"},{\"sequencenumber\":194,\"key\":\"role_id_103\",\"tenantterm\":\"configuration office\",\"frontiersdefaultterm\":\"configuration office\",\"category\":\"user role\"},{\"sequencenumber\":195,\"key\":\"role_id_104\",\"tenantterm\":\"beta user\",\"frontiersdefaultterm\":\"beta user\",\"category\":\"user role\"},{\"sequencenumber\":196,\"key\":\"role_id_106\",\"tenantterm\":\"wfconf\",\"frontiersdefaultterm\":\"wfconf\",\"category\":\"user role\"},{\"sequencenumber\":197,\"key\":\"role_id_107\",\"tenantterm\":\"rt management beta user\",\"frontiersdefaultterm\":\"rt management beta user\",\"category\":\"user role\"},{\"sequencenumber\":198,\"key\":\"role_id_108\",\"tenantterm\":\"deo beta user\",\"frontiersdefaultterm\":\"deo beta user\",\"category\":\"user role\"},{\"sequencenumber\":199,\"key\":\"role_id_109\",\"tenantterm\":\"search beta user\",\"frontiersdefaultterm\":\"search beta user\",\"category\":\"user role\"},{\"sequencenumber\":200,\"key\":\"role_id_110\",\"tenantterm\":\"journal manager\",\"frontiersdefaultterm\":\"journal manager\",\"category\":\"user role\"},{\"sequencenumber\":201,\"key\":\"role_id_111\",\"tenantterm\":\"myfrontiers beta user\",\"frontiersdefaultterm\":\"myfrontiers beta user\",\"category\":\"user role\"},{\"sequencenumber\":202,\"key\":\"role_id_21\",\"tenantterm\":\"copy editor\",\"frontiersdefaultterm\":\"copy editor\",\"category\":\"user role\"},{\"sequencenumber\":203,\"key\":\"role_id_1_abr\",\"tenantterm\":\"rof\",\"frontiersdefaultterm\":\"rof\",\"category\":\"user role\"},{\"sequencenumber\":204,\"key\":\"role_id_2_abr\",\"tenantterm\":\"eof\",\"frontiersdefaultterm\":\"eof\",\"category\":\"user role\"},{\"sequencenumber\":205,\"key\":\"role_id_7_abr\",\"tenantterm\":\"fce\",\"frontiersdefaultterm\":\"fce\",\"category\":\"user role\"},{\"sequencenumber\":206,\"key\":\"role_id_8_abr\",\"tenantterm\":\"afce\",\"frontiersdefaultterm\":\"afce\",\"category\":\"user role\"},{\"sequencenumber\":207,\"key\":\"role_id_9_abr\",\"tenantterm\":\"sce\",\"frontiersdefaultterm\":\"sce\",\"category\":\"user role\"},{\"sequencenumber\":208,\"key\":\"role_id_10_abr\",\"tenantterm\":\"asce\",\"frontiersdefaultterm\":\"asce\",\"category\":\"user role\"},{\"sequencenumber\":209,\"key\":\"role_id_11_abr\",\"tenantterm\":\"ae\",\"frontiersdefaultterm\":\"ae\",\"category\":\"user role\"},{\"sequencenumber\":210,\"key\":\"role_id_12_abr\",\"tenantterm\":\"gae\",\"frontiersdefaultterm\":\"gae\",\"category\":\"user role\"},{\"sequencenumber\":211,\"key\":\"role_id_13_abr\",\"tenantterm\":\"re\",\"frontiersdefaultterm\":\"re\",\"category\":\"user role\"},{\"sequencenumber\":212,\"key\":\"role_id_14_abr\",\"tenantterm\":\"rev\",\"frontiersdefaultterm\":\"rev\",\"category\":\"user role\"},{\"sequencenumber\":213,\"key\":\"role_id_15_abr\",\"tenantterm\":\"aut\",\"frontiersdefaultterm\":\"aut\",\"category\":\"user role\"},{\"sequencenumber\":214,\"key\":\"role_id_16_abr\",\"tenantterm\":\"coraut\",\"frontiersdefaultterm\":\"coraut\",\"category\":\"user role\"},{\"sequencenumber\":215,\"key\":\"role_id_17_abr\",\"tenantterm\":\"saut\",\"frontiersdefaultterm\":\"saut\",\"category\":\"user role\"},{\"sequencenumber\":216,\"key\":\"role_id_18_abr\",\"tenantterm\":\"coaut\",\"frontiersdefaultterm\":\"coaut\",\"category\":\"user role\"},{\"sequencenumber\":217,\"key\":\"role_id_20_abr\",\"tenantterm\":\"pof\",\"frontiersdefaultterm\":\"pof\",\"category\":\"user role\"},{\"sequencenumber\":218,\"key\":\"role_id_22_abr\",\"tenantterm\":\"tsof\",\"frontiersdefaultterm\":\"tsof\",\"category\":\"user role\"},{\"sequencenumber\":219,\"key\":\"role_id_24_abr\",\"tenantterm\":\"ru\",\"frontiersdefaultterm\":\"ru\",\"category\":\"user role\"},{\"sequencenumber\":220,\"key\":\"role_id_35_abr\",\"tenantterm\":\"jof\",\"frontiersdefaultterm\":\"jof\",\"category\":\"user role\"},{\"sequencenumber\":221,\"key\":\"role_id_41_abr\",\"tenantterm\":\"se-adm\",\"frontiersdefaultterm\":\"se-adm\",\"category\":\"user role\"},{\"sequencenumber\":222,\"key\":\"role_id_42_abr\",\"tenantterm\":\"se-rev\",\"frontiersdefaultterm\":\"se-rev\",\"category\":\"user role\"},{\"sequencenumber\":223,\"key\":\"role_id_43_abr\",\"tenantterm\":\"se-aut\",\"frontiersdefaultterm\":\"se-aut\",\"category\":\"user role\"},{\"sequencenumber\":224,\"key\":\"role_id_52_abr\",\"tenantterm\":\"evof\",\"frontiersdefaultterm\":\"evof\",\"category\":\"user role\"},{\"sequencenumber\":225,\"key\":\"role_id_53_abr\",\"tenantterm\":\"ev-adm\",\"frontiersdefaultterm\":\"ev-adm\",\"category\":\"user role\"},{\"sequencenumber\":226,\"key\":\"role_id_89_abr\",\"tenantterm\":\"comof\",\"frontiersdefaultterm\":\"comof\",\"category\":\"user role\"},{\"sequencenumber\":227,\"key\":\"role_id_98_abr\",\"tenantterm\":\"aof\",\"frontiersdefaultterm\":\"aof\",\"category\":\"user role\"},{\"sequencenumber\":228,\"key\":\"role_id_99_abr\",\"tenantterm\":\"projects\",\"frontiersdefaultterm\":\"projects\",\"category\":\"user role\"},{\"sequencenumber\":229,\"key\":\"role_id_103_abr\",\"tenantterm\":\"config\",\"frontiersdefaultterm\":\"config\",\"category\":\"user role\"},{\"sequencenumber\":230,\"key\":\"role_id_104_abr\",\"tenantterm\":\"beta\",\"frontiersdefaultterm\":\"beta\",\"category\":\"user role\"},{\"sequencenumber\":231,\"key\":\"role_id_106_abr\",\"tenantterm\":\"wfconf\",\"frontiersdefaultterm\":\"wfconf\",\"category\":\"user role\"},{\"sequencenumber\":232,\"key\":\"role_id_107_abr\",\"tenantterm\":\"rtbeta\",\"frontiersdefaultterm\":\"rtbeta\",\"category\":\"user role\"},{\"sequencenumber\":233,\"key\":\"role_id_108_abr\",\"tenantterm\":\"deobeta\",\"frontiersdefaultterm\":\"deobeta\",\"category\":\"user role\"},{\"sequencenumber\":234,\"key\":\"role_id_109_abr\",\"tenantterm\":\"searchbeta\",\"frontiersdefaultterm\":\"searchbeta\",\"category\":\"user role\"},{\"sequencenumber\":235,\"key\":\"role_id_110_abr\",\"tenantterm\":\"jm\",\"frontiersdefaultterm\":\"jm\",\"category\":\"user role\"},{\"sequencenumber\":236,\"key\":\"role_id_111_abr\",\"tenantterm\":\"mfbeta\",\"frontiersdefaultterm\":\"mfbeta\",\"category\":\"user role\"},{\"sequencenumber\":237,\"key\":\"role_id_21_abr\",\"tenantterm\":\"coped\",\"frontiersdefaultterm\":\"coped\",\"category\":\"user role\"},{\"sequencenumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantterm\":\"editorial board\",\"frontiersdefaultterm\":\"editorial board\",\"description\":\"this is the label for the review editorial board\",\"category\":\"label\"},{\"sequencenumber\":239,\"key\":\"field_chief_editor\",\"tenantterm\":\"field chief editor\",\"frontiersdefaultterm\":\"field chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":240,\"key\":\"field_chief_editors\",\"tenantterm\":\"field chief editors\",\"frontiersdefaultterm\":\"field chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":241,\"key\":\"editor\",\"tenantterm\":\"editor\",\"frontiersdefaultterm\":\"editor\",\"category\":\"label (role)\"},{\"sequencenumber\":242,\"key\":\"editors\",\"tenantterm\":\"editors\",\"frontiersdefaultterm\":\"editors\",\"category\":\"label (role)\"},{\"sequencenumber\":243,\"key\":\"board\",\"tenantterm\":\"board\",\"frontiersdefaultterm\":\"board\",\"category\":\"label\"},{\"sequencenumber\":244,\"key\":\"boards\",\"tenantterm\":\"boards\",\"frontiersdefaultterm\":\"boards\",\"category\":\"label\"},{\"sequencenumber\":245,\"key\":\"article_collection\",\"tenantterm\":\"article collection\",\"frontiersdefaultterm\":\"article collection\",\"category\":\"label\"},{\"sequencenumber\":246,\"key\":\"article_collections\",\"tenantterm\":\"article collections\",\"frontiersdefaultterm\":\"article collections\",\"category\":\"label\"},{\"sequencenumber\":247,\"key\":\"handling_editor\",\"tenantterm\":\"handling editor\",\"frontiersdefaultterm\":\"associate editor\",\"description\":\"this terminology key is for the person assigned to edit a manuscript. it is a label for the temporary handling editor assignment.\",\"category\":\"label (role)\"},{\"sequencenumber\":248,\"key\":\"handling_editors\",\"tenantterm\":\"handling editors\",\"frontiersdefaultterm\":\"associate editors\",\"description\":\"this terminology key is for the person assigned to edit a manuscript. it is a label for the temporary handling editor assignment.\",\"category\":\"label (role)\"},{\"sequencenumber\":249,\"key\":\"ae_accept\",\"tenantterm\":\"recommend acceptance\",\"frontiersdefaultterm\":\"accept\",\"category\":\"process\"},{\"sequencenumber\":250,\"key\":\"rtm\",\"tenantterm\":\"rtm\",\"frontiersdefaultterm\":\"rtm\",\"category\":\"product\"},{\"sequencenumber\":251,\"key\":\"frontiers_media_sa\",\"tenantterm\":\"frontiers media s.a\",\"frontiersdefaultterm\":\"frontiers media s.a\",\"category\":\"customer\"},{\"sequencenumber\":252,\"key\":\"review_editors\",\"tenantterm\":\"community reviewers\",\"frontiersdefaultterm\":\"review editors\",\"category\":\"label (role)\"},{\"sequencenumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantterm\":\"chief editor\",\"frontiersdefaultterm\":\"chief editor\",\"category\":\"label (role)\"},{\"sequencenumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantterm\":\"chief editors\",\"frontiersdefaultterm\":\"chief editors\",\"category\":\"label (role)\"},{\"sequencenumber\":255,\"key\":\"call_for_papers\",\"tenantterm\":\"call for papers\",\"frontiersdefaultterm\":\"call for papers\",\"category\":\"label\"},{\"sequencenumber\":256,\"key\":\"calls_for_papers\",\"tenantterm\":\"calls for papers\",\"frontiersdefaultterm\":\"calls for papers\",\"category\":\"label\"},{\"sequencenumber\":257,\"key\":\"supervising_editor\",\"tenantterm\":\"supervising editor\",\"frontiersdefaultterm\":\"supervising editor\",\"description\":\"a chief or assistant chief editor who is assigned to a manuscript to supervise.\",\"category\":\"role\",\"externalkey\":\"supervising_editor\"},{\"sequencenumber\":258,\"key\":\"supervising_editors\",\"tenantterm\":\"supervising editors\",\"frontiersdefaultterm\":\"supervising editors\",\"description\":\"a chief or assistant chief editor who is assigned to a manuscript to supervise.\",\"category\":\"role\",\"externalkey\":\"supervising_editors\"},{\"sequencenumber\":259,\"key\":\"reviewer_endorse\",\"tenantterm\":\"endorse\",\"frontiersdefaultterm\":\"endorse\",\"category\":\"label\"},{\"sequencenumber\":260,\"key\":\"reviewer_endorsed\",\"tenantterm\":\"endorsed\",\"frontiersdefaultterm\":\"endorsed\",\"category\":\"label\"},{\"sequencenumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantterm\":\"endorse publication\",\"frontiersdefaultterm\":\"endorse publication\",\"category\":\"label\"},{\"sequencenumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantterm\":\"endorsed publication\",\"frontiersdefaultterm\":\"endorsed publication\",\"category\":\"label\"},{\"sequencenumber\":263,\"key\":\"editor_role\",\"tenantterm\":\"editor role\",\"frontiersdefaultterm\":\"editor role\",\"category\":\"label\"},{\"sequencenumber\":264,\"key\":\"editor_roles\",\"tenantterm\":\"editor roles\",\"frontiersdefaultterm\":\"editor roles\",\"category\":\"label\"},{\"sequencenumber\":265,\"key\":\"editorial_role\",\"tenantterm\":\"editorial role\",\"frontiersdefaultterm\":\"editorial role\",\"category\":\"label\"},{\"sequencenumber\":266,\"key\":\"editorial_roles\",\"tenantterm\":\"editorial roles\",\"frontiersdefaultterm\":\"editorial roles\",\"category\":\"label\"},{\"sequencenumber\":267,\"key\":\"call_for_paper\",\"tenantterm\":\"call for paper\",\"frontiersdefaultterm\":\"call for paper\",\"category\":\"label\"},{\"sequencenumber\":268,\"key\":\"research_topic_abstract\",\"tenantterm\":\"manuscript summary\",\"frontiersdefaultterm\":\"manuscript summary\",\"category\":\"process\"},{\"sequencenumber\":269,\"key\":\"research_topic_abstracts\",\"tenantterm\":\"manuscript summaries\",\"frontiersdefaultterm\":\"manuscript summaries\",\"category\":\"process\"},{\"sequencenumber\":270,\"key\":\"submissions_team_manager\",\"tenantterm\":\"journal manager\",\"frontiersdefaultterm\":\"content manager\",\"category\":\"process\"},{\"sequencenumber\":271,\"key\":\"submissions_team\",\"tenantterm\":\"journal team\",\"frontiersdefaultterm\":\"content team\",\"category\":\"process\"},{\"sequencenumber\":272,\"key\":\"topic_coordinator\",\"tenantterm\":\"topic coordinator\",\"frontiersdefaultterm\":\"topic coordinator\",\"category\":\"process\"},{\"sequencenumber\":273,\"key\":\"topic_coordinators\",\"tenantterm\":\"topic coordinators\",\"frontiersdefaultterm\":\"topic coordinators\",\"category\":\"process\"},{\"sequencenumber\":274,\"key\":\"frontiers_journal_team\",\"tenantterm\":\"frontiers journal team\",\"frontiersdefaultterm\":\"frontiers journal team\",\"category\":\"label (role)\"},{\"sequencenumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantterm\":\"rt:ic submission\",\"frontiersdefaultterm\":\"rt:ic submission\",\"category\":\"label (role)\"},{\"sequencenumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantterm\":\"rt:ic submission participant\",\"frontiersdefaultterm\":\"rt:ic submission participant\",\"category\":\"label (role)\"}]}'\n",impactgtmid:"gtm-njf2ml9b",impactgtmauth:"fyo-7nodm9w37qgfms03sa",impactgtmpreview:"env-1",impactgooglemapsapikey:"aizasyctehx2eu8pwfi86gw9fi00ftcykk6ifr8",qualtricsv4tov3:"'{\"enabled\":true,\"interceptid\":\"si_er0e2ze69oz8yn4\",\"projectid\":\"zn_cloy77jhkpc8gai\",\"brandid\":\"frontiersin\"}'\n",qualtricsumux:"'{\"enabled\":false,\"interceptid\":\"si_89fphy3etxqbwtu\",\"projectid\":\"zn_cloy77jhkpc8gai\",\"brandid\":\"frontiersin\"}'\n",qualtricscontinuousbrand:"'{\"enabled\":true,\"interceptid\":\"si_9zut94ut81fcrh4\",\"projectid\":\"zn_cloy77jhkpc8gai\",\"brandid\":\"frontiersin\"}'\n",defaultarticletemplate:"v3"},app:{baseurl:"/",buildid:"f2d5b6d8-d01c-4534-90b9-d659f10f17ca",buildassetsdir:"ap-2024/_nuxt",cdnurl:""}}## Scraping Notes- Successfully scraped from DOI.org